Clustering O 0 7.533084863098338e-05
of O 0 2.742822289292235e-06
missense O 0 0.0004911578726023436
mutations O 0 5.337240145308897e-05
in O 0 2.815932248267927e-06
the O 0 3.902660682797432e-05
ataxia B-Disease 1 0.998958945274353
- I-Disease 0 0.03599635884165764
telangiectasia I-Disease 1 0.8059934973716736
gene O 0 9.77984382188879e-06
in O 0 6.156394078971061e-07
a O 0 1.0850498256331775e-05
sporadic B-Disease 0 0.006112097762525082
T I-Disease 1 0.9969071745872498
- I-Disease 0 0.026037348434329033
cell I-Disease 0 0.05298220366239548
leukaemia I-Disease 1 0.9950202703475952
. O 0 7.316513074329123e-05

Ataxia B-Disease 1 0.9965305924415588
- I-Disease 1 0.7721759676933289
telangiectasia I-Disease 1 0.9879728555679321
( O 0 7.64795477152802e-05
A B-Disease 0 0.00906651932746172
- I-Disease 0 0.006249610800296068
T I-Disease 1 0.5551790595054626
) O 0 2.5565233841007284e-07
is O 0 1.6547483028261922e-07
a O 0 2.327630681975279e-06
recessive B-Disease 0 0.3144533038139343
multi I-Disease 1 0.5525141358375549
- I-Disease 1 0.6242225766181946
system I-Disease 0 0.06767202168703079
disorder I-Disease 1 0.999536395072937
caused O 0 0.005819462705403566
by O 0 4.3619419898277556e-07
mutations O 0 1.7965373899642145e-06
in O 0 5.002345204729863e-08
the O 0 1.342990856301185e-07
ATM O 0 1.4931501937098801e-05
gene O 0 3.2390651085734135e-06
at O 0 1.9753595097427024e-06
11q22 O 0 0.00013943863450549543
- O 0 2.4286106054205447e-05
q23 O 0 4.297530176700093e-05
( O 0 2.8397992082318524e-06
ref O 0 0.0005335216992534697
. O 0 1.8029258797014336e-07
3 O 0 1.017402269098966e-06
) O 0 1.5221520470731775e-06
. O 0 6.078468231862644e-06

The O 0 3.295434726169333e-05
risk O 0 0.001349004334770143
of O 0 1.727978997223545e-05
cancer B-Disease 1 0.9979333877563477
, O 0 2.956361186079448e-06
especially O 0 7.754007128824014e-06
lymphoid B-Disease 0 0.0726633220911026
neoplasias I-Disease 0 0.01140789594501257
, O 0 1.0324832828700892e-06
is O 0 1.7078584733098978e-06
substantially O 0 0.00022745353635400534
elevated O 0 0.009717163629829884
in O 0 5.678734851244371e-06
A B-Disease 1 0.8135801553726196
- I-Disease 1 0.9914836287498474
T I-Disease 1 0.9991880059242249
patients O 0 0.006529476959258318
and O 0 3.027018635748391e-07
has O 0 5.549503612201079e-07
long O 0 5.866516858077375e-06
been O 0 6.900648372720752e-07
associated O 0 7.207923772512004e-06
with O 0 1.409035667165881e-05
chromosomal O 1 0.9896670579910278
instability O 1 0.954133927822113
. O 0 0.0001513931929366663

By O 0 1.761209568940103e-05
analysing O 0 0.0007239338592626154
tumour B-Disease 1 0.9978247880935669
DNA O 0 0.00023670544032938778
from O 0 2.2244079445954412e-05
patients O 0 0.003214229829609394
with O 0 4.597486167767784e-06
sporadic B-Disease 0 0.007955444045364857
T I-Disease 1 0.99033522605896
- I-Disease 0 0.000970156688708812
cell I-Disease 0 0.0010003690840676427
prolymphocytic I-Disease 0 0.17216069996356964
leukaemia I-Disease 1 0.9958242177963257
( O 0 0.00018217056640423834
T B-Disease 1 0.885820746421814
- I-Disease 0 7.815446588210762e-05
PLL I-Disease 0 0.0018788359593600035
) O 0 2.767887963273097e-07
, O 0 8.553553243473289e-08
a O 0 1.4313650353869889e-06
rare O 0 6.222364027053118e-05
clonal B-Disease 0 0.042539630085229874
malignancy I-Disease 1 0.8802792429924011
with O 0 1.9158909481120645e-07
similarities O 0 1.5901953247521305e-06
to O 0 1.1805455102376072e-07
a O 0 5.668659923685482e-06
mature B-Disease 0 0.0009705237462185323
T I-Disease 1 0.987542986869812
- I-Disease 0 0.0005214738775976002
cell I-Disease 0 0.0009450578945688903
leukaemia I-Disease 1 0.9860936403274536
seen O 0 7.762419954815414e-06
in O 0 1.224921220455144e-06
A B-Disease 0 0.0012018741108477116
- I-Disease 0 0.0014688705559819937
T I-Disease 0 0.209040567278862
, O 0 4.1398269701176105e-08
we O 0 6.62688881547524e-09
demonstrate O 0 3.079534494077052e-08
a O 0 1.9177219812149815e-08
high O 0 7.41282519811648e-08
frequency O 0 3.97269133145528e-08
of O 0 4.8835964605586923e-08
ATM O 0 0.00011356656614225358
mutations O 0 2.6532308766036294e-05
in O 0 7.193290002760477e-06
T B-Disease 1 0.9677004218101501
- I-Disease 0 0.0005916130030527711
PLL I-Disease 0 0.04167184606194496
. O 0 3.133813152089715e-05

In O 0 2.8988433768972754e-06
marked O 0 3.3541252832947066e-06
contrast O 0 8.072153150351369e-07
to O 0 2.710303270703207e-08
the O 0 7.998620077387386e-08
ATM O 0 1.045465705828974e-05
mutation O 0 2.6566551696305396e-06
pattern O 0 2.5879221539071295e-06
in O 0 3.20532024034037e-07
A B-Disease 0 0.0012621297501027584
- I-Disease 0 0.0013899382902309299
T I-Disease 0 0.32295292615890503
, O 0 2.001996612932544e-08
the O 0 7.3833161806646785e-09
most O 0 1.0186634646913717e-08
frequent O 0 3.06190287346908e-07
nucleotide O 0 5.60732587473467e-07
changes O 0 4.349654432189709e-07
in O 0 3.946011588595866e-07
this O 0 2.851572162398952e-06
leukaemia B-Disease 1 0.9924812316894531
were O 0 7.201862899819389e-06
missense O 0 0.0014292810810729861
mutations O 0 0.00037291241460479796
. O 0 2.8596916308742948e-05

These O 0 5.867282766303106e-07
clustered O 0 3.764925850191503e-06
in O 0 9.016069668632554e-08
the O 0 4.544820342289313e-08
region O 0 7.960873915635602e-08
corresponding O 0 3.584040797477428e-08
to O 0 5.314018558522093e-09
the O 0 2.0546270462773464e-08
kinase O 0 1.3830280067850254e-06
domain O 0 1.1608105410232383e-07
, O 0 2.0352617369212567e-08
which O 0 8.813830554288415e-09
is O 0 9.653032151391017e-09
highly O 0 1.488311482944482e-07
conserved O 0 3.47083158658279e-07
in O 0 1.7071877778107591e-07
ATM O 0 7.900502532720566e-05
- O 0 2.2095016447565285e-06
related O 0 2.649666726028954e-07
proteins O 0 1.5129663211155275e-07
in O 0 1.2643452862448612e-07
mouse O 0 1.1637967872957233e-05
, O 0 1.7386589945544983e-07
yeast O 0 7.181219189078547e-06
and O 0 5.797477911073656e-07
Drosophila O 0 3.571566776372492e-05
. O 0 1.2933778634760529e-05

The O 0 3.517694494803436e-06
resulting O 0 2.843489528459031e-05
amino O 0 1.0914936865447089e-05
- O 0 2.151077933376655e-05
acid O 0 2.324548586329911e-05
substitutions O 0 1.6896345869099605e-06
are O 0 5.0906663773275795e-08
predicted O 0 1.3230113609097316e-06
to O 0 2.106012786384781e-08
interfere O 0 6.002848067510058e-07
with O 0 9.596622874141758e-08
ATP O 0 5.988844350213185e-05
binding O 0 9.166997756437922e-07
or O 0 8.270595799331204e-07
substrate O 0 4.2771647713379934e-05
recognition O 0 1.72549880517181e-05
. O 0 1.6801506717456505e-05

Two O 0 3.857279295971239e-07
of O 0 3.5098562989333004e-07
seventeen O 0 5.544449595618062e-05
mutated O 0 0.003809340763837099
T B-Disease 1 0.564734697341919
- I-Disease 0 6.728818698320538e-05
PLL I-Disease 0 0.0010001718765124679
samples O 0 7.29802479781938e-07
had O 0 3.978971108153928e-07
a O 0 5.249732453194156e-07
previously O 0 3.962509254051838e-06
reported O 0 7.482467481167987e-05
A B-Disease 0 0.0029122584965080023
- I-Disease 0 0.004330566618591547
T I-Disease 1 0.9422165751457214
allele O 0 9.25741478567943e-05
. O 0 1.425814571121009e-05

In O 0 3.4057493394357152e-06
contrast O 0 1.0646388545865193e-05
, O 0 3.9868641010798456e-07
no O 0 4.711070005214424e-07
mutations O 0 2.0892505290248664e-06
were O 0 4.3823977335932796e-08
detected O 0 1.6426866977781174e-06
in O 0 1.5178216017375235e-08
the O 0 5.8957660087344266e-08
p53 O 0 2.253144430142129e-06
gene O 0 6.13946724570269e-07
, O 0 6.402759566981331e-08
suggesting O 0 1.8081343569065211e-06
that O 0 1.4419762806028302e-07
this O 0 3.5939506233262364e-06
tumour B-Disease 1 0.9991942048072815
suppressor O 0 0.0006853469531051815
is O 0 1.4651884328031883e-07
not O 0 7.335789575790841e-08
frequently O 0 7.724557349320094e-07
altered O 0 1.2109566341678146e-05
in O 0 9.755760856933193e-07
this O 0 7.041342087177327e-06
leukaemia B-Disease 1 0.9963357448577881
. O 0 6.985430809436366e-05

Occasional O 0 0.0002232134429505095
missense O 0 0.0007002131314948201
mutations O 0 2.8033471608068794e-05
in O 0 8.800679438536463e-07
ATM O 0 4.026124588563107e-05
were O 0 1.9513079507760267e-07
also O 0 1.758090348857877e-07
found O 0 1.0251599178445758e-06
in O 0 1.3099493116897065e-06
tumour B-Disease 1 0.9966603517532349
DNA O 0 1.6023546777432784e-05
from O 0 3.3231422094104346e-06
patients O 0 0.0006625691894441843
with O 0 1.5661000816180604e-06
B B-Disease 0 0.0021725015249103308
- I-Disease 0 0.00018587557133287191
cell I-Disease 0 0.00013876310549676418
non I-Disease 0 6.98311414453201e-05
- I-Disease 0 0.005304007790982723
Hodgkins I-Disease 1 0.9971030354499817
lymphomas I-Disease 1 0.5876396894454956
( O 0 3.68853761756327e-06
B B-Disease 0 2.9959384846733883e-05
- I-Disease 0 2.6633117613528157e-06
NHL I-Disease 0 1.5060519444887177e-06
) O 0 2.7160215410049204e-08
and O 0 1.241664993045788e-08
a O 0 4.1704112163643003e-07
B B-Disease 0 3.3352138416375965e-05
- I-Disease 0 8.05722356744809e-06
NHL I-Disease 0 2.32311685977038e-05
cell O 0 3.304778510937467e-05
line O 0 2.1723548343288712e-05
. O 0 1.2647806215682067e-05

The O 0 8.201835726140416e-07
evidence O 0 4.400490070111118e-07
of O 0 2.7348654896286462e-08
a O 0 2.941289096725086e-07
significant O 0 2.504752671939059e-07
proportion O 0 2.143624016071044e-07
of O 0 5.364246291605923e-08
loss O 0 6.972806295379996e-05
- O 0 1.9264271031715907e-06
of O 0 3.4983798968823976e-08
- O 0 9.061684522748692e-07
function O 0 6.334735047630602e-08
mutations O 0 1.8425539849431516e-07
and O 0 5.229337851631044e-09
a O 0 3.463609132836609e-08
complete O 0 1.0689871032809606e-07
absence O 0 2.0246380927346763e-07
of O 0 4.2711394421246496e-09
the O 0 2.2940442434560282e-08
normal O 0 1.9827663777505222e-07
copy O 0 2.176519586782888e-07
of O 0 8.581590549283646e-09
ATM O 0 3.4258582672919147e-06
in O 0 1.7862490153675026e-08
the O 0 3.9666719686692886e-08
majority O 0 1.9924962657569267e-07
of O 0 4.1444181420047244e-07
mutated O 0 0.0053126332350075245
tumours B-Disease 1 0.9904282093048096
establishes O 0 0.00013535043399315327
somatic O 0 3.920774906873703e-05
inactivation O 0 6.403569568647072e-05
of O 0 1.3892098138512665e-08
this O 0 5.621724952220575e-08
gene O 0 5.308207278176269e-07
in O 0 5.1724601490832356e-08
the O 0 5.732471777264436e-07
pathogenesis O 0 0.0017397328047081828
of O 0 1.2583034276758553e-06
sporadic B-Disease 0 0.005318426992744207
T I-Disease 1 0.9944663643836975
- I-Disease 0 0.00045357138151302934
PLL I-Disease 0 0.00452024070546031
and O 0 2.439293211864424e-07
suggests O 0 1.6556510900045396e-06
that O 0 1.0021060603548904e-07
ATM O 0 1.7108470274251886e-05
acts O 0 1.0651774573489092e-06
as O 0 1.6107483133964706e-06
a O 0 0.00015863438602536917
tumour B-Disease 1 0.9985324144363403
suppressor O 0 0.045256055891513824
. O 0 3.083420233451761e-05

As O 0 1.2795762813766487e-06
constitutional O 0 2.9381758395174984e-06
DNA O 0 7.964646101754624e-06
was O 0 5.786585575151548e-07
not O 0 1.1368521235510798e-08
available O 0 1.5072826542450457e-08
, O 0 1.955847750423345e-08
a O 0 7.125607908164966e-07
putative O 0 0.0002038669481407851
hereditary O 0 0.1605055183172226
predisposition O 0 0.3805781304836273
to O 0 1.348966088698944e-05
T B-Disease 1 0.9900299310684204
- I-Disease 0 0.0001071717997547239
PLL I-Disease 0 0.0028241551481187344
will O 0 1.6789805101780075e-07
require O 0 5.373298108679592e-07
further O 0 4.5778503476867627e-07
investigation O 0 9.617742762202397e-06
. O 0 2.1328357888705796e-06
. O 0 6.470246717071859e-06

Myotonic B-Disease 1 0.9955819249153137
dystrophy I-Disease 1 0.9969550371170044
protein O 0 0.0001296279951930046
kinase O 0 7.875011215219274e-05
is O 0 2.1630404489769717e-07
involved O 0 6.586931533547613e-08
in O 0 1.017193707042452e-08
the O 0 1.1040859781985546e-08
modulation O 0 2.4348682359232043e-07
of O 0 2.9625875086480846e-08
the O 0 5.323303753357322e-07
Ca2 O 0 0.00026521793915890157
+ O 0 0.00031019648304209113
homeostasis O 0 0.017300713807344437
in O 0 2.7139478333992884e-05
skeletal O 1 0.9958368539810181
muscle O 1 0.9847680926322937
cells O 0 0.0044602337293326855
. O 0 5.9633701312122867e-05

Myotonic B-Disease 1 0.9985952973365784
dystrophy I-Disease 1 0.9994878768920898
( O 0 0.01775515079498291
DM B-Disease 1 0.9978454113006592
) O 0 5.945447355770739e-06
, O 0 8.428733622167783e-07
the O 0 1.015205953081022e-06
most O 0 9.585995940142311e-06
prevalent O 1 0.8146185874938965
muscular B-Disease 1 0.9996920824050903
disorder I-Disease 1 0.9997350573539734
in O 0 2.428624611638952e-05
adults O 0 0.00041975226486101747
, O 0 1.212267989103566e-06
is O 0 1.0161406862607691e-06
caused O 0 0.00015378145326394588
by O 0 1.9895684033599537e-07
( O 0 9.031574563778122e-07
CTG O 0 0.00024047199985943735
) O 0 2.2353792417106888e-07
n O 0 1.430641759725404e-06
- O 0 8.408276812588156e-07
repeat O 0 4.02643451025142e-07
expansion O 0 7.304779359174063e-08
in O 0 2.067761073476504e-09
a O 0 7.960931469597199e-09
gene O 0 3.0483978008533086e-08
encoding O 0 2.7269896563097973e-08
a O 0 6.271569930049736e-08
protein O 0 7.772403023409424e-07
kinase O 0 1.0043992006103508e-05
( O 0 1.901885752886301e-06
DM B-Disease 0 0.47222208976745605
protein O 0 4.6882669266778976e-06
kinase O 0 1.5379666365333833e-05
; O 0 6.016862243996002e-07
DMPK O 0 0.000123453646665439
) O 0 7.96546117953767e-08
and O 0 2.5383650736898744e-08
involves O 0 4.494802681165311e-07
changes O 0 7.533466828135715e-07
in O 0 5.848412456543883e-07
cytoarchitecture O 0 0.00022140075452625751
and O 0 1.586714120094257e-06
ion O 0 0.00045978929847478867
homeostasis O 0 0.15849804878234863
. O 0 7.117113273125142e-05

To O 0 6.131994609859248e-07
obtain O 0 9.773081046660081e-07
clues O 0 1.41304542466969e-06
to O 0 2.6310276624030848e-08
the O 0 6.034532162857431e-08
normal O 0 4.727262989945302e-07
biological O 0 4.29964359227597e-07
role O 0 8.939970541632647e-08
of O 0 6.404592056696856e-08
DMPK O 0 0.0004866356321144849
in O 0 3.955551619583275e-07
cellular O 0 2.2321835785987787e-05
ion O 0 0.0001384909264743328
homeostasis O 0 0.008877336047589779
, O 0 1.5319923818424286e-07
we O 0 1.4203322074024527e-08
have O 0 1.3208962812427671e-08
compared O 0 2.2819955347586074e-07
the O 0 1.3043008095792175e-07
resting O 0 3.8273396057775244e-05
[ O 0 1.2464231076592114e-05
Ca2 O 0 9.322314872406423e-05
+ O 0 4.179411553195678e-05
] O 0 3.083801175307599e-06
i O 0 1.2143607364123454e-07
, O 0 5.50441425772874e-09
the O 0 4.099015349368074e-09
amplitude O 0 1.3585352576228615e-07
and O 0 3.090449496312431e-08
shape O 0 1.1278953024884686e-06
of O 0 2.462366808231309e-07
depolarization O 0 0.0036002814304083586
- O 0 0.0002204488409915939
induced O 0 0.0010058245388790965
Ca2 O 0 0.0003673767205327749
+ O 0 7.447805546689779e-05
transients O 0 2.691978261282202e-05
, O 0 2.678282839951862e-08
and O 0 3.98132193879519e-09
the O 0 1.0570001762744141e-08
content O 0 2.1423586460400657e-08
of O 0 4.800891417744424e-08
ATP O 0 0.00015153213462326676
- O 0 2.864748239517212e-06
driven O 0 1.2234969517521677e-06
ion O 0 1.7906970242620446e-05
pumps O 0 3.6066219763597474e-05
in O 0 9.095295467886899e-07
cultured O 0 0.00040526152588427067
skeletal O 1 0.9703288078308105
muscle O 0 0.02430175058543682
cells O 0 5.5385721680067945e-06
of O 0 1.4867227093873225e-07
wild O 0 8.315610102727078e-06
- O 0 2.4869086701073684e-05
type O 0 7.201430435088696e-06
and O 0 4.6465675040963106e-07
DMPK O 0 0.005565761588513851
[ O 0 0.00016003119526430964
- O 0 0.00021695531904697418
/ O 0 0.0003670011064969003
- O 0 4.742027522297576e-05
] O 0 5.86319001740776e-05
knockout O 0 0.001255482085980475
mice O 0 0.0013120638905093074
. O 0 1.4746798115083948e-05

In O 0 1.629325379326474e-05
vitro O 0 0.00014231429668143392
- O 0 0.00011207656643819064
differentiated O 0 0.00015512856771238148
DMPK O 0 0.014717435464262962
[ O 0 0.0004887517425231636
- O 0 0.0003069407830480486
/ O 0 0.00015733452164568007
- O 0 1.0486931387276854e-05
] O 0 6.15698445471935e-06
myotubes O 0 2.910097646235954e-05
exhibit O 0 1.7849500864031143e-06
a O 0 7.471868457287201e-07
higher O 0 4.608992639987264e-06
resting O 0 0.00013470140402205288
[ O 0 2.253263482998591e-05
Ca2 O 0 0.0001694269012659788
+ O 0 5.218006481300108e-05
] O 0 5.856304142071167e-06
i O 0 1.9512020799083984e-07
than O 0 1.5075414694365463e-08
do O 0 4.369344352994631e-08
wild O 0 1.3894702988181962e-06
- O 0 7.89581099525094e-06
type O 0 5.8483396969677415e-06
myotubes O 0 2.7721547667169943e-05
because O 0 6.8098415795248e-08
of O 0 5.0003778895302275e-09
an O 0 5.4720292297361084e-08
altered O 0 1.1828281003545271e-06
open O 0 1.767152468801214e-07
probability O 0 2.8499622217736942e-08
of O 0 5.1671946721398854e-08
voltage O 0 2.7679016056936234e-05
- O 0 1.531001180410385e-05
dependent O 0 4.520372840488562e-06
l O 0 0.00028829186339862645
- O 0 8.078475730144419e-06
type O 0 4.650859409593977e-06
Ca2 O 0 1.5080502635100856e-05
+ O 0 9.80565801000921e-06
and O 0 2.6395656504973886e-07
Na O 0 0.00017600582214072347
+ O 0 1.6649260942358524e-05
channels O 0 4.577296749630477e-06
. O 0 8.513157808920369e-06

The O 0 2.4066617697826587e-05
mutant O 0 0.0004463247023522854
myotubes O 0 0.001120051834732294
exhibit O 0 1.0240469237032812e-05
smaller O 0 1.2823934412153903e-06
and O 0 2.772318055122014e-07
slower O 0 2.086027234327048e-05
Ca2 O 0 0.00010351380478823557
+ O 0 1.4553051187249366e-05
responses O 0 8.488136131745705e-07
upon O 0 4.4079246208639233e-07
triggering O 0 4.5153188693802804e-05
by O 0 4.4795856979362725e-07
acetylcholine O 0 0.0005527038010768592
or O 0 9.034590107148688e-07
high O 0 4.747575985675212e-06
external O 0 1.2410419913067017e-05
K O 0 0.0002340844803256914
+ O 0 0.00018294395704288036
. O 0 1.006764159683371e-05

In O 0 1.6059813106039655e-06
addition O 0 1.3168848909117514e-06
, O 0 1.819136628000706e-07
we O 0 2.5600211728260547e-08
observed O 0 1.2756282785630901e-07
that O 0 2.5075053144973936e-08
these O 0 8.32620088431213e-08
Ca2 O 0 0.000113726629933808
+ O 0 0.00011403894313843921
transients O 0 0.00030715216416865587
partially O 0 2.4637891328893602e-05
result O 0 4.3630112145365274e-07
from O 0 4.20533261547007e-08
an O 0 2.6581144396686796e-08
influx O 0 2.830201992765069e-07
of O 0 2.0289206759116496e-08
extracellular O 0 3.709633347170893e-06
Ca2 O 0 1.2249107385287061e-05
+ O 0 2.572991888882825e-06
through O 0 7.37556433705322e-08
the O 0 3.145932794268447e-07
l O 0 0.0005793648306280375
- O 0 1.3459746696753427e-05
type O 0 1.0769776963570621e-05
Ca2 O 0 8.469255408272147e-05
+ O 0 3.891210872097872e-05
channel O 0 1.4115360499999952e-05
. O 0 8.41771634441102e-06

Neither O 0 1.714195059321355e-05
the O 0 3.0058805577937164e-07
content O 0 3.1708364645055553e-07
nor O 0 5.588848352999776e-07
the O 0 2.6936005426136944e-08
activity O 0 1.7705330890294135e-07
of O 0 1.1138011757338973e-07
Na O 0 0.0003376477397978306
+ O 0 4.9392678192816675e-05
/ O 0 1.9551636796677485e-05
K O 0 1.931394581333734e-05
+ O 0 1.980437446036376e-05
ATPase O 0 7.62913259677589e-05
and O 0 9.668640359450364e-07
sarcoplasmic O 0 0.008198000490665436
reticulum O 0 0.0026510488241910934
Ca2 O 0 0.0007575791096314788
+ O 0 0.0003629037528298795
- O 0 5.567215703194961e-05
ATPase O 0 8.305776282213628e-05
are O 0 1.8733807394255564e-07
affected O 0 4.162287950748578e-06
by O 0 2.4034559373831144e-06
DMPK O 0 0.02294744923710823
absence O 0 0.00023463818070013076
. O 0 3.617469337768853e-05

In O 0 1.895763261927641e-06
conclusion O 0 2.5369042759848526e-06
, O 0 1.8544922397722985e-07
our O 0 7.131196610998813e-08
data O 0 1.5863282953887392e-07
suggest O 0 6.512191248475574e-07
that O 0 8.91823930260216e-08
DMPK O 0 0.00012323337432462722
is O 0 1.0038852593652337e-07
involved O 0 1.1114838116554893e-07
in O 0 4.4880437144456664e-08
modulating O 0 7.073973392834887e-06
the O 0 3.754781729981005e-08
initial O 0 2.2739749283573474e-07
events O 0 2.5893385213748843e-08
of O 0 5.026389615636617e-08
excitation O 0 7.063926750561222e-05
- O 0 0.00012155915464973077
contraction O 0 0.0003163467044942081
coupling O 0 0.00016962540394160897
in O 0 6.387723988154903e-05
skeletal O 1 0.9965699911117554
muscle O 1 0.9638407826423645
. O 0 1.0491922694200184e-05
. O 0 2.794322972476948e-05

Constitutional O 0 0.0006796495290473104
RB1 O 1 0.9740005731582642
- O 0 0.0007258086116053164
gene O 0 9.933291585184634e-05
mutations O 0 0.00012076197890564799
in O 0 1.0636503247951623e-05
patients O 0 0.0344984270632267
with O 0 9.810718438529875e-06
isolated O 0 0.002730914857238531
unilateral B-Disease 0 0.0036628630477935076
retinoblastoma I-Disease 1 0.9856129288673401
. O 0 0.0001880495110526681

In O 0 1.3796457096759696e-05
most O 0 1.2089270057913382e-05
patients O 0 0.008872085250914097
with O 0 4.925589564663824e-06
isolated O 0 0.000781786919105798
unilateral B-Disease 0 0.0009671213338151574
retinoblastoma I-Disease 1 0.9905389547348022
, O 0 2.55297236435581e-05
tumor B-Disease 0 0.4370860159397125
development O 0 9.243327667718404e-07
is O 0 1.3342511806513357e-07
initiated O 0 1.2036280168103985e-06
by O 0 8.26284036747893e-08
somatic O 0 5.561950729315868e-06
inactivation O 0 3.124306022073142e-05
of O 0 8.54269011085762e-09
both O 0 1.583800290916315e-08
alleles O 0 2.7100608690489025e-07
of O 0 8.197678624810578e-08
the O 0 8.140686077240389e-06
RB1 O 1 0.9701818823814392
gene O 0 0.00011198213178431615
. O 0 3.4626194974407554e-05

However O 0 4.303443802200491e-06
, O 0 2.841506727691012e-07
some O 0 5.0831758358071966e-08
of O 0 8.408166962681207e-08
these O 0 6.716859388689045e-07
patients O 0 0.007415481377393007
can O 0 1.967056050489191e-06
transmit O 0 0.00038061171653680503
retinoblastoma B-Disease 1 0.9381749629974365
predisposition O 0 0.006146623287349939
to O 0 3.669219950097613e-07
their O 0 4.755592044602963e-07
offspring O 0 0.00014783705410081893
. O 0 2.2696949599776417e-05

To O 0 5.689987574442057e-07
determine O 0 3.1408126233145595e-07
the O 0 3.740600007517969e-08
frequency O 0 1.2246556480022264e-07
and O 0 2.9266821854889713e-08
nature O 0 2.0275248857615225e-07
of O 0 6.384016870697451e-08
constitutional O 0 1.6405279893660918e-05
RB1 O 1 0.9837363362312317
- O 0 5.8034238463733345e-05
gene O 0 8.898044143279549e-06
mutations O 0 1.77451493073022e-05
in O 0 2.566421471783542e-06
patients O 0 0.004775426350533962
with O 0 3.880504664266482e-06
isolated O 0 0.00024348785518668592
unilateral B-Disease 0 0.00018585004727356136
retinoblastoma I-Disease 0 0.051920995116233826
, O 0 3.091982989644748e-07
we O 0 5.8407650271874445e-08
analyzed O 0 1.4673058785774629e-06
DNA O 0 6.092513558542123e-06
from O 0 3.7163115393923363e-06
peripheral O 0 0.05265997350215912
blood O 0 0.015232892706990242
and O 0 5.321341177477734e-06
from O 0 0.0002651451213750988
tumor B-Disease 1 0.9987238049507141
tissue O 1 0.9063636660575867
. O 0 7.243480649776757e-05

The O 0 1.4283377822721377e-06
analysis O 0 2.3867155505286064e-06
of O 0 2.642454774104408e-06
tumors B-Disease 1 0.9957648515701294
from O 0 1.6390828250223421e-06
54 O 0 5.952964329480892e-06
( O 0 3.45815749369649e-07
71 O 0 9.993400453822687e-07
% O 0 3.060433684254349e-08
) O 0 2.0340005235652825e-08
of O 0 1.8710696991774967e-08
76 O 0 1.0508596460567787e-05
informative O 0 1.156583948613843e-05
patients O 0 0.001512683229520917
showed O 0 1.4154288692225236e-05
loss O 0 1.4275220564741176e-05
of O 0 2.3998546794246067e-07
constitutional O 0 3.6102868762100115e-05
heterozygosity O 0 0.30316662788391113
( O 0 0.00028409375227056444
LOH O 1 0.9872620701789856
) O 0 2.9363916382862953e-06
at O 0 1.1257900041528046e-05
intragenic O 0 0.0011921994155272841
loci O 0 0.00024947550264187157
. O 0 3.9154841942945495e-05

Three O 0 1.0669800758478232e-06
of O 0 1.940200036187889e-06
13 O 0 9.717042848933488e-05
uninformative O 1 0.7819596529006958
patients O 0 0.11998151242733002
had O 0 1.6199041056097485e-05
constitutional O 0 4.8837566282600164e-05
deletions O 0 0.0007840855396352708
. O 0 6.329453026410192e-05

For O 0 1.045577732838865e-06
39 O 0 6.281701644184068e-06
randomly O 0 2.7961939395027002e-06
selected O 0 9.823666005104315e-06
tumors B-Disease 1 0.9942809343338013
, O 0 1.8480989183444763e-06
SSCP O 0 0.003492987947538495
, O 0 2.7944929570367094e-06
hetero O 0 0.0009189918637275696
- O 0 9.21366699913051e-06
duplex O 0 2.6228608476230875e-05
analysis O 0 6.636808080884293e-08
, O 0 2.6561885135834018e-08
sequencing O 0 1.7813300701163826e-07
, O 0 2.84661041405343e-08
and O 0 2.2633166452123987e-08
Southern O 0 3.481459600607195e-07
blot O 0 9.760929060576018e-06
analysis O 0 1.15641618947393e-07
were O 0 2.0077822071584706e-08
used O 0 5.790361612412198e-08
to O 0 9.308624271398003e-08
identify O 0 3.3379469641658943e-06
mutations O 0 4.449407060747035e-05
. O 0 1.791631439118646e-05

Mutations O 0 0.0001120346860261634
were O 0 1.0626927178236656e-06
detected O 0 1.1856983292091172e-05
in O 0 1.0654797222287016e-07
21 O 0 5.034949026594404e-07
( O 0 2.0446432813514548e-07
91 O 0 1.1947887514907052e-06
% O 0 9.897173924855451e-08
) O 0 9.047629134784074e-08
of O 0 2.566088710409531e-07
23 O 0 0.0004730108194053173
tumors B-Disease 1 0.9985716342926025
with O 0 0.00016966050316113979
LOH O 1 0.9953135251998901
. O 0 6.274890620261431e-05

In O 0 1.5027466133687994e-06
6 O 0 2.7594510356721003e-06
( O 0 3.689962113639922e-07
38 O 0 3.620580173446797e-07
% O 0 1.5024355093373742e-07
) O 0 9.324190841653035e-08
of O 0 2.669923730991286e-07
16 O 0 0.00015659857308492064
tumors B-Disease 1 0.998977780342102
without O 0 5.759714258601889e-05
LOH O 1 0.9943352341651917
, O 0 1.4264983860812208e-07
one O 0 9.600577044466263e-08
mutation O 0 5.832276201545028e-06
was O 0 1.8622384914124268e-06
detected O 0 3.970267698605312e-06
, O 0 1.7095624471608062e-08
and O 0 7.873588891982308e-09
in O 0 1.4591932107066441e-08
9 O 0 1.2237403268500202e-07
( O 0 2.7993310780516367e-08
56 O 0 5.380056578019321e-08
% O 0 2.360170547888174e-08
) O 0 1.8935983447931903e-08
of O 0 6.309821287686646e-08
the O 0 1.4370205462910235e-05
tumors B-Disease 1 0.9989439845085144
without O 0 0.00012648267147596925
LOH O 1 0.9959151148796082
, O 0 3.2883681910789164e-07
both O 0 2.367813749515335e-07
mutations O 0 4.675051059166435e-06
were O 0 3.5231062156526605e-07
found O 0 4.805930984730367e-06
. O 0 1.4479873243544716e-05

Thus O 0 2.500456957932329e-06
, O 0 1.6077774489531294e-07
a O 0 6.12641741781772e-08
total O 0 2.2074695849028103e-08
of O 0 1.203086696932587e-08
45 O 0 4.995880544811371e-07
mutations O 0 1.5382671563202166e-06
were O 0 9.193475136726192e-08
identified O 0 2.133714815499843e-06
in O 0 2.8701354040094884e-06
tumors B-Disease 1 0.9953393936157227
of O 0 2.26105271394772e-06
36 O 0 0.0007812361582182348
patients O 0 0.42512211203575134
. O 0 4.752666427521035e-05

Thirty O 0 2.026865513471421e-05
- O 0 2.2669646568829194e-06
nine O 0 3.8409510239034717e-08
of O 0 1.1522732101809652e-08
the O 0 2.0297844116612396e-07
mutations O 0 2.5022841327881906e-06
- O 0 6.130661631686962e-07
including O 0 2.4979200929919898e-08
34 O 0 1.7295697318786551e-07
small O 0 1.2032019469643274e-07
mutations O 0 1.069659560926084e-06
, O 0 8.727798217478266e-08
2 O 0 3.177393068654055e-07
large O 0 1.1171898677275749e-06
structural O 0 0.00024565975763835013
alterations O 0 0.00011108376202173531
, O 0 2.614856668969878e-07
and O 0 3.228846026104293e-07
hypermethylation O 0 0.006253609899431467
in O 0 2.892039447033312e-06
3 O 0 0.0002846159040927887
tumors O 1 0.9991457462310791
- O 0 6.750104148522951e-06
were O 0 3.262217163069181e-08
not O 0 3.022783090500525e-08
detected O 0 1.0583497669358621e-06
in O 0 1.0645996972868943e-08
the O 0 1.1119693965611077e-07
corresponding O 0 1.0286707947670948e-05
peripheral O 0 0.04139086604118347
blood O 0 0.01948942430317402
DNA O 0 0.00032473259489052
. O 0 3.302393452031538e-05

In O 0 2.3933916963869706e-06
6 O 0 3.1424563076143386e-06
( O 0 4.0428801639791345e-07
17 O 0 2.8234299520590866e-07
% O 0 5.023274596283045e-08
) O 0 9.083175989132997e-09
of O 0 2.7928126478116155e-09
the O 0 9.978547410582905e-08
36 O 0 2.9476930194505258e-06
patients O 0 0.00010423995991004631
, O 0 9.397948730338612e-08
a O 0 6.205968929862138e-07
mutation O 0 1.1953247849305626e-05
was O 0 9.204192679135303e-07
detected O 0 1.2967391285201302e-06
in O 0 1.1662049992366974e-08
constitutional O 0 8.88952200739368e-08
DNA O 0 3.171952300817793e-07
, O 0 9.018439328656314e-09
and O 0 1.56071477963593e-09
1 O 0 5.730917074231456e-09
of O 0 2.430759593607945e-09
these O 0 9.891433450093245e-09
mutations O 0 8.411773819716473e-07
is O 0 4.060979108544416e-08
known O 0 8.710684795687484e-08
to O 0 1.465899224228906e-08
be O 0 4.09958822444878e-08
associated O 0 9.125182600655535e-07
with O 0 1.5402914641526877e-06
reduced O 0 0.0002874561178032309
expressivity O 0 0.07809166610240936
. O 0 0.00010728529741754755

The O 0 9.004123739941861e-07
presence O 0 4.922565608467266e-07
of O 0 2.174253665998549e-08
a O 0 3.538389705681766e-07
constitutional O 0 1.2641248758882284e-06
mutation O 0 7.681856004637666e-06
was O 0 8.099304409370234e-07
not O 0 1.7897036741487682e-08
associated O 0 1.304866827922524e-07
with O 0 1.572332486432515e-08
an O 0 9.96819835563656e-08
early O 0 1.7935980167749221e-06
age O 0 2.8627588108065538e-05
at O 0 4.950538641423918e-05
treatment O 0 0.012831906788051128
. O 0 7.467078103218228e-05

In O 0 1.1566303328436334e-05
1 O 0 2.317297548870556e-05
patient O 0 0.0011810400756075978
, O 0 2.5722606551425997e-06
somatic O 0 0.00017343198123853654
mosaicism O 0 0.04759582504630089
was O 0 3.033994516954408e-06
demonstrated O 0 6.433953103623935e-07
by O 0 3.040355522898608e-08
molecular O 0 2.6785440354615275e-07
analysis O 0 2.380029506809933e-08
of O 0 2.0564739244832708e-08
DNA O 0 3.202000925739412e-06
and O 0 2.4806996634652023e-07
RNA O 0 2.4213702999986708e-05
from O 0 1.1872313734784257e-05
peripheral O 0 0.20490479469299316
blood O 0 0.04990021139383316
. O 0 6.856637628516182e-05

In O 0 1.3533703167922795e-05
2 O 0 4.530851583695039e-05
patients O 0 0.0007701397989876568
without O 0 9.566009566697176e-07
a O 0 4.456126589502674e-06
detectable O 0 0.0005639465525746346
mutation O 0 5.937800233368762e-05
in O 0 4.566562438412802e-06
peripheral O 1 0.5361522436141968
blood O 0 0.08084003627300262
, O 0 4.957795681548305e-06
mosaicism O 0 0.15505507588386536
was O 0 6.86437761032721e-06
suggested O 0 2.571929371697479e-06
because O 0 1.538179219551239e-07
1 O 0 1.0645860015756625e-07
of O 0 1.0523075388846337e-07
the O 0 8.436329153482802e-06
patients O 1 0.87343829870224
showed O 0 0.18529155850410461
multifocal O 1 0.999450147151947
tumors B-Disease 1 0.9993963241577148
and O 0 3.2885188261388976e-07
the O 0 2.795724753923423e-07
other O 0 1.1968137414442026e-07
later O 0 4.215156423015287e-06
developed O 0 4.050331699545495e-05
bilateral B-Disease 0 0.00033123031607829034
retinoblastoma I-Disease 1 0.9181010723114014
. O 0 5.524146763491444e-05

In O 0 1.20114202672994e-06
conclusion O 0 1.890727503450762e-06
, O 0 2.0685673973730445e-07
our O 0 6.867717416980668e-08
results O 0 3.611889383137168e-07
emphasize O 0 5.833817340317182e-07
that O 0 5.207641962101661e-08
the O 0 1.8396674761333998e-07
manifestation O 0 2.7858191970153712e-05
and O 0 5.746757665292535e-07
transmissibility O 0 0.00011748573160730302
of O 0 2.192715982118898e-07
retinoblastoma B-Disease 0 0.007432817947119474
depend O 0 2.9282799118846015e-07
on O 0 4.1069682765737525e-08
the O 0 2.58188173063445e-08
nature O 0 6.982857314596913e-08
of O 0 3.1737688033217637e-09
the O 0 1.3004846977082707e-08
first O 0 4.674916098679205e-08
mutation O 0 4.402723163821065e-07
, O 0 7.790932343709756e-09
its O 0 5.979807760070344e-09
time O 0 1.0576112430271678e-08
in O 0 1.22223529075427e-08
development O 0 3.534254489068189e-08
, O 0 5.873539876688483e-09
and O 0 1.5333211367263289e-09
the O 0 3.827047567739328e-09
number O 0 2.5291475580502265e-09
and O 0 8.303296716860586e-09
types O 0 7.195932738568445e-08
of O 0 3.755089750256957e-08
cells O 0 8.285853255074471e-06
that O 0 9.783735066548616e-08
are O 0 4.291270272460679e-08
affected O 0 3.0035389499971643e-06
. O 0 1.045467001858924e-06
. O 0 6.398477125912905e-06

Hereditary B-Disease 1 0.9927496910095215
deficiency I-Disease 1 0.9978725910186768
of I-Disease 0 3.054859121220943e-07
the I-Disease 0 3.7020666354692366e-07
fifth I-Disease 0 1.7365689473081147e-06
component I-Disease 0 1.1020913461834425e-06
of I-Disease 0 5.3351861595274386e-08
complement I-Disease 0 2.847555379048572e-06
in O 0 1.5594218893966172e-06
man O 0 4.621121843229048e-05
. O 0 1.1166743206558749e-05

I O 0 0.0028520526830106974
. O 0 0.0003125591902062297

Clinical O 0 0.002129300031810999
, O 0 8.908809832064435e-06
immunochemical O 0 0.0023019711952656507
, O 0 1.8288827732249047e-06
and O 0 1.2414919865477714e-06
family O 0 1.8338660083827563e-05
studies O 0 1.5194273146335036e-05
. O 0 1.5584417269565165e-05

The O 0 2.276306076964829e-06
first O 0 2.4593539365014294e-06
recognized O 0 5.27490828972077e-06
human O 0 7.235160410345998e-06
kindred O 0 0.002878837985917926
with O 0 5.279441029415466e-05
hereditary B-Disease 1 0.9982738494873047
deficiency I-Disease 1 0.9996340274810791
of I-Disease 0 1.045331927684856e-07
the I-Disease 0 9.881763674002286e-08
fifth I-Disease 0 5.591034550889162e-07
component I-Disease 0 1.890468439569304e-07
of I-Disease 0 3.3519267361725724e-08
complement I-Disease 0 2.001734628720442e-06
( O 0 2.7107303139928263e-06
C5 O 0 0.0014587658224627376
) O 0 9.236648566002259e-07
is O 0 5.598429311248765e-07
described O 0 3.43563842761796e-05
. O 0 1.1326702406222466e-05

The O 0 6.311889137577964e-06
proband O 0 0.00016791382222436368
, O 0 3.812136810665834e-07
a O 0 7.389158440673782e-07
20 O 0 2.34078424909967e-06
- O 0 1.327634890913032e-05
year O 0 1.5957737105054548e-06
- O 0 1.1441827155067585e-05
old O 0 3.876665505231358e-05
black O 0 0.0001455048768548295
female O 0 0.00029726384673267603
with O 0 0.13851360976696014
systemic B-Disease 1 0.999925971031189
lupus I-Disease 1 0.9999397993087769
erythematosus I-Disease 1 0.9998112320899963
since O 0 0.0005324325175024569
age O 0 0.00020435662008821964
11 O 0 1.2371647244435735e-05
, O 0 3.531459014993743e-06
lacked O 0 0.0022945604287087917
serum O 1 0.8835994601249695
hemolytic O 1 0.9971495270729065
complement O 0 7.324405942199519e-06
activity O 0 2.9649334010173334e-06
, O 0 7.818943572601711e-07
even O 0 2.195389015469118e-06
during O 0 5.4050968174124137e-05
remission O 0 0.22598135471343994
. O 0 3.682319220388308e-05

C5 O 0 0.34956276416778564
was O 0 0.0002786349505186081
undetectable O 0 0.0036382866092026234
in O 0 1.5168989193625748e-06
her O 0 9.777102604857646e-06
serum O 0 0.0008814468747004867
by O 0 5.273763576951751e-07
both O 0 1.552662411086203e-06
immunodiffusion O 0 0.005668354220688343
and O 0 2.3238169887918048e-05
hemolytic O 1 0.9980717897415161
assays O 0 0.0014879204099997878
. O 0 7.582207035738975e-05

Other O 0 3.7256262430673814e-07
complement O 0 1.6388046333304374e-06
components O 0 1.5423421473315102e-06
were O 0 2.0129861866280407e-07
normal O 0 3.113588945780066e-06
during O 0 1.184539905807469e-05
remission O 0 0.04472929239273071
of O 0 8.014027116587386e-06
lupus O 1 0.9996194839477539
, O 0 1.6719831137379515e-06
but O 0 1.1572485618671635e-06
C1 O 0 0.02441728301346302
, O 0 7.590206223540008e-07
C4 O 0 0.0008333898731507361
, O 0 9.258351951757504e-07
C2 O 0 0.004266510251909494
, O 0 5.464383434627962e-07
and O 0 7.546805704805593e-07
C3 O 0 0.0916290208697319
levels O 0 0.0001478765334468335
fell O 0 0.0007252896903082728
during O 0 0.00011785612878156826
exacerbations O 1 0.8447710871696472
. O 0 8.749482367420569e-05

A O 0 4.611336044035852e-05
younger O 0 3.813451621681452e-05
half O 0 6.475160262198187e-06
- O 0 3.0349663575179875e-05
sister O 0 1.1093769899161998e-05
, O 0 3.383769069387199e-07
who O 0 5.77910725496622e-07
had O 0 2.7449418666947167e-06
no O 0 1.205261651193723e-05
underlying O 1 0.6907356977462769
disease O 1 0.9995179176330566
, O 0 5.937407081546553e-07
was O 0 1.5094079799382598e-06
also O 0 1.8241085797399137e-07
found O 0 4.199817738026468e-07
to O 0 4.2982250647582987e-07
lack O 0 0.0001207502355100587
immunochemically O 0 0.03891877830028534
detectable O 0 0.0412871390581131
C5 O 0 0.24142800271511078
. O 0 0.000102697653346695

By O 0 0.0005086738965474069
hemolytic O 1 0.996310293674469
assay O 0 0.00035772795672528446
, O 0 2.945324240499758e-06
she O 0 3.791177277889801e-06
exhibited O 0 2.6401476134196855e-06
1 O 0 2.723206478094653e-07
- O 0 2.1577947961759492e-07
2 O 0 1.0887386103775043e-08
% O 0 6.518302342328752e-09
of O 0 3.5591809499635474e-09
the O 0 8.998580369734555e-08
normal O 0 3.9530427784484345e-06
serum O 0 0.0005400195950642228
C5 O 0 0.00022616614296566695
level O 0 3.9718361222185194e-07
and O 0 2.7114252176829723e-08
normal O 0 3.3175490443682065e-07
concentrations O 0 4.1248799220738874e-07
of O 0 9.15839848403266e-09
other O 0 2.869626314350171e-08
complement O 0 1.721557168821164e-06
components O 0 1.4766570529900491e-05
. O 0 1.3387736544245854e-05

C5 O 0 0.020637651905417442
levels O 0 9.876664989860728e-06
of O 0 1.1680553768655955e-07
other O 0 8.234976434096097e-08
family O 0 1.0871220865737996e-06
members O 0 2.9695009118313465e-08
were O 0 1.694531626128537e-08
either O 0 5.126073787664609e-08
normal O 0 3.1024157465253666e-07
or O 0 6.276093245105585e-08
approximately O 0 8.468086321045121e-08
half O 0 2.86858750087049e-07
- O 0 1.3788519481749972e-06
normal O 0 3.304041626961407e-07
, O 0 4.1196386746378266e-08
consistent O 0 4.0641720033818274e-07
with O 0 2.2054334181120794e-07
autosomal O 0 0.009350393898785114
codominant O 0 0.0014186010230332613
inheritance O 0 1.4401513908524066e-05
of O 0 2.2225019336019614e-07
the O 0 3.2645129977026954e-06
gene O 0 0.0001634749787626788
determining O 0 0.0009197819163091481
C5 B-Disease 1 0.9983059167861938
deficiency I-Disease 1 0.9996821880340576
. O 0 0.00022102428192738444

Normal O 0 0.05784652754664421
hemolytic O 1 0.9970533847808838
titers O 0 0.27071401476860046
were O 0 2.8850865874119336e-06
restored O 0 1.460701423638966e-05
to O 0 3.5981716450805834e-07
both O 0 1.742041149555007e-06
homozygous O 0 0.001283537596464157
C5 B-Disease 1 0.996086597442627
- I-Disease 0 0.23651818931102753
deficient I-Disease 1 0.9962195754051208
( O 0 2.0542021957226098e-05
C5D B-Disease 0 0.32497063279151917
) O 0 2.5560141239111545e-06
sera O 0 9.510950621915981e-05
by O 0 1.1748209516326824e-07
addition O 0 2.858117795767612e-07
of O 0 1.9349508306731877e-07
highly O 0 1.7848644347395748e-05
purified O 0 0.00017559701518621296
human O 0 4.796993744093925e-05
C5 O 0 0.15967345237731934
. O 0 3.861176810460165e-05

In O 0 4.4437183532863855e-06
specific O 0 1.3028606190346181e-05
C5 O 0 0.33357587456703186
titrations O 0 0.006485749501734972
, O 0 7.393394412247289e-07
however O 0 4.917254159408913e-07
, O 0 7.213193242705529e-08
it O 0 2.4362609707395677e-08
was O 0 1.899067711974567e-07
noted O 0 1.2279957672944875e-07
that O 0 5.689280158094334e-09
when O 0 4.0478173701785636e-08
limited O 0 5.163559180232369e-08
amounts O 0 1.485988434524188e-07
of O 0 6.565908705624679e-08
C5 O 0 0.00024906150065362453
were O 0 3.0299986519821687e-08
assayed O 0 5.979970296721149e-07
in O 0 1.5007278975076588e-08
the O 0 1.8937898360604777e-08
presence O 0 8.525586281393771e-08
of O 0 2.960057265966043e-08
low O 0 6.666904027952114e-06
dilutions O 0 7.50182953197509e-05
of O 0 2.091713611207524e-07
either O 0 1.324011100223288e-05
C5D B-Disease 1 0.9834929704666138
serum O 0 0.0031344706658273935
, O 0 2.869730906240875e-07
curving O 0 6.601076620427193e-06
rather O 0 1.3790516106837458e-07
than O 0 8.903504067347967e-08
linear O 0 9.887228770821821e-06
dose O 0 0.001099323621019721
- O 0 2.0732431948999874e-05
response O 0 8.576012646699382e-07
plots O 0 2.996658281517739e-07
were O 0 3.970252393514784e-08
consistently O 0 5.492727837008715e-07
obtained O 0 1.7878177516195137e-07
, O 0 9.183975890891816e-08
suggesting O 0 1.9187850739399437e-06
some O 0 1.5292131649857765e-07
inhibitory O 0 2.0842493540840223e-05
effect O 0 2.2422220354201272e-05
. O 0 1.8615159206092358e-05

Further O 0 8.899444765120279e-06
studies O 0 3.3139201605081325e-06
suggested O 0 5.627503469440853e-06
that O 0 3.156143861815508e-07
low O 0 1.3406965990725439e-05
dilutions O 0 0.00025727981119416654
of O 0 3.0855517252348363e-06
C5D B-Disease 1 0.9919288158416748
serum O 0 0.006049009971320629
contain O 0 2.962395456052036e-06
a O 0 1.1533053339007893e-06
factor O 0 1.6286601294268621e-06
( O 0 2.051041150252786e-07
or O 0 6.540160057966204e-08
factors O 0 1.2865825738117564e-07
) O 0 5.5727014114381745e-08
interfering O 0 2.9131444989616284e-07
at O 0 5.375820322228719e-08
some O 0 1.0657455362661494e-08
step O 0 2.712654350034427e-07
in O 0 8.591486988507313e-08
the O 0 1.0751475656434195e-06
hemolytic O 1 0.997142493724823
assay O 0 1.5921581507427618e-05
of O 0 3.2770600455478416e-07
C5 O 0 0.00348519254475832
, O 0 7.275814795093538e-08
rather O 0 4.41376286630657e-08
than O 0 3.424576178190364e-08
a O 0 7.792256724314939e-07
true O 0 7.345573067141231e-06
C5 O 0 0.01149506215006113
inhibitor O 0 0.0009819919941946864
or O 0 1.574388261360582e-05
inactivator O 0 0.0054362160153687
. O 0 2.8538535843836144e-05

Of O 0 2.8103038403060054e-06
clinical O 0 9.834930096985772e-05
interest O 0 3.9908584881231945e-07
are O 0 2.2397147247943394e-08
( O 0 8.922339844730232e-08
a O 0 4.9866081042182486e-08
) O 0 3.5178512547417995e-08
the O 0 3.825998362572136e-08
documentation O 0 1.677487034612568e-06
of O 0 1.6838066585478373e-06
membranous O 1 0.9970209002494812
glomerulonephritis B-Disease 1 0.9995394945144653
, O 0 0.0018627403769642115
vasculitis B-Disease 1 0.9996102452278137
, O 0 0.00019432448607403785
and O 0 0.0004959475481882691
arthritis B-Disease 1 0.9999566078186035
in O 0 9.557948033034336e-07
an O 0 6.505194960482186e-07
individual O 0 1.054786707754829e-06
lacking O 0 0.0001886421669041738
C5 O 0 0.005000927019864321
( O 0 3.351856889821647e-07
and O 0 2.661107245671701e-08
its O 0 5.7104504236349385e-08
biologic O 0 2.885392495954875e-05
functions O 0 1.4530697001191584e-07
) O 0 1.0593277011139435e-07
, O 0 1.6835652871804996e-08
and O 0 1.4695637595707467e-08
( O 0 1.124306763244931e-07
b O 0 7.179036742854805e-07
) O 0 3.780421664600908e-08
a O 0 2.3427109852036665e-07
remarkable O 0 4.831660589843523e-06
propensity O 0 0.0001277773262700066
to O 0 4.707886546384543e-06
bacterial B-Disease 1 0.9991119503974915
infections I-Disease 1 0.9982268214225769
in O 0 4.5256339831212244e-07
the O 0 9.457501164433779e-07
proband O 0 0.0004613720520865172
, O 0 1.2067066279541905e-07
even O 0 1.0849785780919774e-07
during O 0 2.521520059417526e-07
periods O 0 6.339122364806826e-07
of O 0 5.937792835197797e-08
low O 0 1.2340068678895477e-05
- O 0 5.898414656257955e-06
dose O 0 1.147625152952969e-05
or O 0 1.853021416309275e-07
alternate O 0 1.5616781183780404e-06
- O 0 5.010706081520766e-05
day O 0 2.1265042960294522e-05
corticosteroid O 0 0.3135964870452881
therapy O 0 0.01637444645166397
. O 0 4.809887468582019e-05

Other O 0 8.829471767057839e-07
observations O 0 1.82882013177732e-06
indicate O 0 4.1866919673339e-06
that O 0 3.686068907882145e-07
the O 0 9.412476060788322e-07
C5D B-Disease 0 0.012269165366888046
state O 0 2.0165485636880476e-07
is O 0 6.403151076028735e-08
compatible O 0 4.845887815463357e-07
with O 0 1.2655468140110315e-07
normal O 0 3.482374040686409e-06
coagulation O 0 0.0001316826237598434
function O 0 1.5188443569513765e-07
and O 0 2.9207544827158927e-08
the O 0 5.089472310260135e-08
capacity O 0 3.2269434768750216e-07
to O 0 8.552818542284513e-08
mount O 0 2.6257137506036088e-05
a O 0 3.925227065337822e-05
neutrophilic O 1 0.967467725276947
leukocytosis O 1 0.9808628559112549
during O 0 0.013024167157709599
pyogenic B-Disease 1 0.9942997694015503
infection I-Disease 1 0.9963101744651794
. O 0 2.1906767869950272e-05
. O 0 5.1639159210026264e-05

Susceptibility O 1 0.6753910779953003
to O 0 0.00781938061118126
ankylosing B-Disease 1 0.999708354473114
spondylitis I-Disease 1 0.9998434782028198
in O 0 2.5598275897209533e-05
twins O 0 0.0003381054266355932
: O 0 3.149336862406926e-07
the O 0 3.589952157767584e-08
role O 0 1.0846495257510469e-07
of O 0 2.716114799738989e-08
genes O 0 1.6209203295147745e-06
, O 0 9.552608162266552e-07
HLA O 0 0.008964919485151768
, O 0 1.0914170189835204e-07
and O 0 8.324406053361599e-08
the O 0 9.477094522480911e-07
environment O 0 2.1013154764659703e-05
. O 0 1.131370481743943e-05

OBJECTIVE O 0 7.241269486257806e-06
To O 0 1.496015897828329e-07
determine O 0 2.4029233713918074e-07
the O 0 1.5466135039332585e-07
relative O 0 2.3869340566307073e-06
effects O 0 8.712413546163589e-06
of O 0 1.3103837659400597e-07
genetic O 0 5.0399867177475244e-05
and O 0 6.247131523196003e-07
environmental O 0 2.3534455976914614e-05
factors O 0 2.119813188983244e-06
in O 0 6.608199782931479e-06
susceptibility O 0 0.21666988730430603
to O 0 0.0016796825220808387
ankylosing B-Disease 1 0.9998977184295654
spondylitis I-Disease 1 0.999889612197876
( O 0 0.0008045246941037476
AS B-Disease 0 0.0003938366426154971
) O 0 2.357796620344743e-05
. O 0 2.0193932869005948e-05

METHODS O 0 4.655783413909376e-05
Twins O 0 0.000158969487529248
with O 0 9.897577228912269e-07
AS B-Disease 0 2.393378053966444e-06
were O 0 9.700656278255337e-08
identified O 0 3.613487820075534e-07
from O 0 2.170620234664966e-07
the O 0 1.0876934766201884e-06
Royal O 0 0.0005158460699021816
National O 0 0.00100477144587785
Hospital O 1 0.9619358777999878
for O 0 0.0011016740463674068
Rheumatic B-Disease 1 0.9998427629470825
Diseases I-Disease 1 0.9991920590400696
database O 0 0.00602829409763217
. O 0 0.00022247742163017392

Clinical O 0 0.0016106931725516915
and O 0 7.619210464326898e-06
radiographic O 0 0.006945916451513767
examinations O 0 3.950183963752352e-05
were O 0 3.9127652939896507e-07
performed O 0 2.370638640059042e-06
to O 0 4.213385693674354e-07
establish O 0 1.661456008150708e-05
diagnoses O 0 0.42495009303092957
, O 0 9.847377441474237e-06
and O 0 0.00010621908586472273
disease O 1 0.9997441172599792
severity O 1 0.8738572001457214
was O 0 5.372854957386153e-06
assessed O 0 2.4492192096658982e-06
using O 0 6.435204369381609e-08
a O 0 3.10215511944989e-07
combination O 0 1.5818958445379394e-06
of O 0 8.39160065879696e-08
validated O 0 1.0017685781349428e-05
scoring O 0 3.166356691508554e-06
systems O 0 0.00012844910088460892
. O 0 2.665632746357005e-05

HLA O 0 0.03188483789563179
typing O 0 0.000290868803858757
for O 0 1.9609036826295778e-05
HLA O 0 0.13780799508094788
- O 0 9.390488412464038e-05
B27 O 0 0.00018109353550244123
, O 0 5.556861651712097e-06
HLA O 0 0.02335340529680252
- O 0 2.0945488358847797e-05
B60 O 0 3.536488293320872e-05
, O 0 3.800919614604936e-07
and O 0 1.1950999123655492e-06
HLA O 0 0.40440070629119873
- O 0 0.00022558533237315714
DR1 O 0 0.0063398159109056
was O 0 4.993994480173569e-07
performed O 0 2.1176946063405921e-07
by O 0 6.456646417518641e-08
polymerase O 0 3.896547241311055e-06
chain O 0 3.7010111100244103e-06
reaction O 0 5.820735395900556e-07
with O 0 2.1935521843374772e-08
sequence O 0 4.507139408360672e-07
- O 0 9.270146961171122e-07
specific O 0 5.190179308556253e-08
primers O 0 2.5946314963221084e-06
, O 0 9.401445311141288e-08
and O 0 1.6575882000324782e-07
zygosity O 0 0.00016153471369761974
was O 0 3.0741525733901653e-06
assessed O 0 5.514501935977023e-06
using O 0 1.3996816505823517e-06
microsatellite O 0 0.003650534898042679
markers O 0 0.0007970036822371185
. O 0 4.640040060621686e-05

Genetic O 0 0.00013864405627828091
and O 0 1.312343897552637e-06
environmental O 0 5.691578735422809e-06
variance O 0 9.637635685066925e-07
components O 0 1.2109900353607372e-06
were O 0 5.7533167563406096e-08
assessed O 0 8.168621548065857e-07
with O 0 3.2205480948732657e-08
the O 0 1.0978098430314276e-07
program O 0 9.637313951316173e-07
Mx O 0 5.545517706195824e-05
, O 0 6.9375851730058e-09
using O 0 4.992039226436873e-09
data O 0 1.9508329174300343e-08
from O 0 8.277711849302705e-09
this O 0 5.021796756210506e-09
and O 0 8.735971057660663e-09
previous O 0 6.903018601178701e-08
studies O 0 1.1856533177478923e-07
of O 0 6.86708858665952e-08
twins O 0 6.235218461370096e-05
with O 0 1.922970795931178e-06
AS B-Disease 0 7.713440572842956e-05
. O 0 1.0991231647494715e-05

RESULTS O 0 1.4390201613423415e-05
Six O 0 4.4225103579265124e-07
of O 0 1.7220119730154693e-07
8 O 0 8.34560069051804e-06
monozygotic O 0 0.0019125891849398613
( O 0 2.7676800527842715e-05
MZ O 1 0.6332806944847107
) O 0 4.445231297722785e-06
twin O 0 0.00023021963716018945
pairs O 0 5.169177893549204e-05
were O 0 1.6553003661101684e-05
disease O 1 0.9971638321876526
concordant O 0 0.001808005734346807
, O 0 3.507296639781998e-07
compared O 0 5.703624310626765e-07
with O 0 2.921617969775525e-08
4 O 0 9.256430644200009e-08
of O 0 2.7197177843163445e-08
15 O 0 7.39934819193877e-07
B27 O 0 4.062919833813794e-05
- O 0 4.1515008888382e-06
positive O 0 5.73241720758233e-07
dizygotic O 0 0.00013264520384836942
( O 0 3.869891315844143e-06
DZ O 0 0.00174744485411793
) O 0 8.567592431063531e-07
twin O 0 1.4274321983975824e-05
pairs O 0 1.1780739441746846e-06
( O 0 2.9232523957034573e-07
27 O 0 3.0811216333859193e-07
% O 0 5.7896439642490805e-08
) O 0 1.4922022728569573e-08
and O 0 3.000963255672673e-09
4 O 0 1.5719155754823078e-08
of O 0 4.052604918314273e-09
32 O 0 6.293079195529572e-07
DZ O 0 0.0005845908308401704
twin O 0 1.0574564839771483e-05
pairs O 0 8.168614158421406e-07
overall O 0 6.716077791679709e-07
( O 0 1.6964114024631272e-07
12 O 0 1.3334778259377345e-07
. O 0 3.611227583633081e-08
5 O 0 1.8920863453786296e-07
% O 0 3.436243218857271e-07
) O 0 9.103521847464435e-07
. O 0 3.7763934415124822e-06

Nonsignificant O 0 0.004091248847544193
increases O 0 3.2499687222298235e-05
in O 0 2.279409443417535e-07
similarity O 0 1.5136331512621837e-06
with O 0 2.1276989059515472e-07
regard O 0 1.2677769518631976e-06
to O 0 2.707518831357447e-07
age O 0 0.00032801119959913194
at O 0 0.0014206193154677749
disease O 1 0.9995586276054382
onset O 1 0.9881891012191772
and O 0 1.1185636594746029e-07
all O 0 2.22900933266601e-08
of O 0 2.5253899593735696e-07
the O 0 0.00016013943240977824
disease O 1 0.9994893074035645
severity O 0 0.1543080359697342
scores O 0 1.219290879816981e-05
assessed O 0 2.378941462666262e-05
were O 0 8.122300414470374e-07
noted O 0 2.937817043857649e-05
in O 0 4.100915975868702e-05
disease O 1 0.998881995677948
- O 0 0.002878202823922038
concordant O 0 0.22185003757476807
MZ O 1 0.9874233603477478
twins O 0 0.0020617179106920958
compared O 0 9.136505104834214e-05
with O 0 3.0229039111873135e-05
concordant O 1 0.7209503650665283
DZ O 1 0.9749797582626343
twins O 0 0.03282267600297928
. O 0 0.00020050533930771053

HLA O 1 0.930101752281189
- O 0 0.0005504389991983771
B27 O 0 0.0003348309837747365
and O 0 1.0259403779855347e-06
B60 O 0 7.134999032132328e-05
were O 0 3.216423749563546e-07
associated O 0 1.4905373291185242e-06
with O 0 7.222636213555234e-07
the O 0 1.255031384062022e-05
disease O 1 0.9971740245819092
in O 0 3.417673326566728e-07
probands O 0 0.00023188884370028973
, O 0 5.644933409598707e-08
and O 0 1.267776195135184e-08
the O 0 1.1672425159758859e-07
rate O 0 1.8142937960874406e-06
of O 0 1.353097104583867e-06
disease O 1 0.9978654980659485
concordance O 0 0.0002850664022844285
was O 0 2.4794493583613075e-05
significantly O 0 1.5243109373841435e-05
increased O 0 1.416192844772013e-06
among O 0 5.271566010378592e-07
DZ O 0 0.005132467485964298
twin O 0 3.456097692833282e-05
pairs O 0 1.253684786206577e-06
in O 0 6.455143619632508e-08
which O 0 7.178879712910202e-08
the O 0 5.92756236983405e-07
co O 0 6.199761992320418e-05
- O 0 1.5503437680308707e-05
twin O 0 1.1301615813863464e-05
was O 0 3.955943839173415e-07
positive O 0 9.719769167304548e-08
for O 0 3.455980746025489e-08
both O 0 3.367222802808101e-07
B27 O 0 0.000208452926017344
and O 0 6.970640697545605e-06
DR1 O 1 0.7992936372756958
. O 0 4.292811718187295e-05

Additive O 0 0.0005873456248082221
genetic O 0 0.0003277698706369847
effects O 0 7.6904303568881e-05
were O 0 2.395076137418073e-07
estimated O 0 2.9595275918836705e-07
to O 0 1.8077908947589094e-08
contribute O 0 1.6922521695050818e-07
97 O 0 2.672101686584938e-07
% O 0 2.214567196290318e-08
of O 0 3.733577003117716e-09
the O 0 6.368486538121942e-08
population O 0 1.2708538577044237e-07
variance O 0 3.164726422255626e-06
. O 0 7.329912477871403e-06

CONCLUSION O 0 0.00020581911667250097
Susceptibility O 0 0.00045866190339438617
to O 0 1.0308037872164277e-06
AS B-Disease 0 7.630321306351107e-06
is O 0 4.848864705309097e-07
largely O 0 5.73167369566363e-07
genetically O 0 2.859922005882254e-06
determined O 0 4.5178722984928754e-07
, O 0 2.6717417611621386e-08
and O 0 1.4629971012425358e-08
the O 0 1.1669308719319815e-07
environmental O 0 6.164352271298412e-06
trigger O 0 5.85724956181366e-05
for O 0 6.484105483650637e-07
the O 0 3.7061661714687943e-05
disease O 1 0.9990434050559998
is O 0 6.327498795144493e-06
probably O 0 6.052954267943278e-05
ubiquitous O 0 0.000419088639318943
. O 0 2.7054411475546658e-05

HLA O 1 0.6412646770477295
- O 0 7.631286280229688e-05
B27 O 0 2.3834878447814845e-05
accounts O 0 1.4298353789854445e-07
for O 0 1.1196988225492532e-08
a O 0 6.070561653359619e-08
minority O 0 5.6842825557623655e-08
of O 0 1.2957134920554836e-08
the O 0 3.1005285450191877e-07
overall O 0 1.8905124306911603e-05
genetic O 0 9.651697473600507e-05
susceptibility O 0 0.0009192466386593878
to O 0 1.4932107887943857e-06
AS B-Disease 0 0.0001025400051730685
. O 0 3.0935370887164026e-05

Cell O 0 0.0008751178393140435
cycle O 0 0.00033673824509605765
- O 0 3.745477442862466e-05
dependent O 0 4.127305601286935e-06
colocalization O 0 7.804967026459053e-05
of O 0 3.382646411864698e-07
BARD1 O 0 0.0015358872478827834
and O 0 5.497376491803152e-07
BRCA1 O 0 7.555790216429159e-05
proteins O 0 5.357222221391567e-07
in O 0 1.5954299215081846e-07
discrete O 0 3.88053422284429e-06
nuclear O 0 6.667359411949292e-05
domains O 0 5.512579809874296e-05
. O 0 2.6724799681687728e-05

Germ O 0 0.38973745703697205
- O 0 5.719811815652065e-05
line O 0 4.242301201884402e-06
mutations O 0 1.6578077293161186e-06
of O 0 6.265341312428063e-08
the O 0 2.0693362330348464e-06
BRCA1 O 0 0.0014936968218535185
gene O 0 1.5856803656788543e-05
predispose O 0 0.00012719091319013387
women O 0 2.081558022837271e-06
to O 0 1.1356989944033558e-06
early O 0 0.00018875912064686418
- O 0 0.11462314426898956
onset O 1 0.9987427592277527
breast B-Disease 1 0.9993274211883545
and I-Disease 0 0.076267309486866
ovarian I-Disease 1 0.9999557733535767
cancer I-Disease 1 0.9997045397758484
by O 0 1.03219383618125e-06
compromising O 0 3.001142613356933e-05
the O 0 4.740752785892255e-07
genes O 0 3.845434093818767e-06
presumptive O 0 0.01112117525190115
function O 0 3.5742216368817026e-06
as O 0 2.5610577267798362e-06
a O 0 0.00015500187873840332
tumor B-Disease 1 0.9928538203239441
suppressor O 0 0.023661036044359207
. O 0 4.703807280748151e-05

Although O 0 4.766384790855227e-06
the O 0 6.784838433304685e-07
biochemical O 0 2.162303644581698e-05
properties O 0 2.1356365778046893e-06
of O 0 8.220058020924625e-07
BRCA1 O 0 0.003864442929625511
polypeptides O 0 1.5262688975781202e-05
are O 0 5.2860496424500525e-08
not O 0 2.9219634711807885e-08
understood O 0 2.0809139300581592e-07
, O 0 1.220425360770605e-08
their O 0 6.110147943161337e-09
expression O 0 2.4964680278571905e-07
pattern O 0 1.0891269539570203e-06
and O 0 3.5080887528238236e-08
subcellular O 0 2.5229107905033743e-06
localization O 0 4.950736638420494e-06
suggest O 0 7.599687705805991e-07
a O 0 1.767083261938751e-07
role O 0 4.6989637780825433e-07
in O 0 4.159900868216937e-07
cell O 0 0.00014478919911198318
- O 0 3.150236079818569e-05
cycle O 0 2.939711521321442e-05
regulation O 0 4.4016043830197304e-05
. O 0 2.1555688363150693e-05

When O 0 0.00012065700138919055
resting O 0 0.004599134437739849
cells O 0 4.973634713678621e-05
are O 0 2.1539543126891658e-07
induced O 0 0.00018626038217917085
to O 0 1.58948580519791e-07
proliferate O 0 1.0261898751195986e-05
, O 0 3.463953035520717e-08
the O 0 4.433277922544221e-08
steady O 0 1.2875758557129302e-06
- O 0 3.063593965180189e-07
state O 0 3.194687181462541e-08
levels O 0 1.3621949790376675e-07
of O 0 1.7168231281061708e-08
BRCA1 O 0 2.2615815396420658e-05
increase O 0 2.516436836685898e-07
in O 0 4.8895614668253984e-08
late O 0 1.904250666484586e-06
G1 O 0 0.0002351210277993232
and O 0 1.2588872166929832e-08
reach O 0 2.364604334559317e-08
a O 0 6.538240171494181e-08
maximum O 0 3.652838245216117e-07
during O 0 5.909799256187398e-06
S O 0 0.0002931435592472553
phase O 0 5.870127279195003e-05
. O 0 1.4496383300866e-05

Moreover O 0 8.387637353735045e-05
, O 0 1.9155634163325885e-06
in O 0 1.8454079508956056e-06
S O 0 0.00023928475275170058
phase O 0 2.9431590519379824e-05
cells O 0 1.6091262295958586e-05
, O 0 5.554872473112482e-07
BRCA1 O 0 5.4824300605105236e-05
polypeptides O 0 2.2460219497588696e-06
are O 0 3.774643531073707e-08
hyperphosphorylated O 0 2.150130421796348e-05
and O 0 5.111789391776256e-08
accumulate O 0 2.2964534309721785e-06
into O 0 1.3837890833201527e-07
discrete O 0 2.493287411198253e-06
subnuclear O 0 0.0011435600463300943
foci O 0 0.0005977536784484982
termed O 0 0.0010381770553067327
" O 0 2.336755278520286e-05
BRCA1 O 0 0.005995900370180607
nuclear O 0 0.00019839727610815316
dots O 0 0.00031602176022715867
. O 0 2.99388229905162e-05

" O 0 0.0002316020691068843
BRCA1 O 0 0.018448783084750175
associates O 0 0.00040910954703576863
in O 0 1.1589183941396186e-06
vivo O 0 1.824740320444107e-05
with O 0 5.198204462431022e-07
a O 0 6.2419421738013625e-06
structurally O 0 0.0019440369214862585
related O 0 4.3666026613209397e-05
protein O 0 0.00012844774755649269
termed O 0 0.0062581272795796394
BARD1 O 1 0.6785202622413635
. O 0 9.484694601269439e-05

Here O 0 3.085554681092617e-06
we O 0 7.308291571916925e-08
show O 0 7.795424750156599e-08
that O 0 1.2772004787109381e-08
the O 0 2.5879804965711628e-08
steady O 0 2.992745066876523e-06
- O 0 5.453804305943777e-07
state O 0 4.443996104441794e-08
levels O 0 2.839578030489065e-07
of O 0 6.508229688506617e-08
BARD1 O 0 0.0004497059853747487
, O 0 8.822664909757805e-08
unlike O 0 2.110190848725324e-07
those O 0 2.1443741005100492e-08
of O 0 1.0023832430761104e-07
BRCA1 O 0 0.0011236534919589758
, O 0 1.893324395041418e-07
remain O 0 2.5381723389727995e-07
relatively O 0 4.879234438703861e-07
constant O 0 1.8976172668772051e-06
during O 0 9.23514107853407e-06
cell O 0 0.00039490265771746635
cycle O 0 0.0006225876277312636
progression O 0 0.022201145067811012
. O 0 3.613889930420555e-05

However O 0 2.9367050956352614e-05
, O 0 6.57769305689726e-06
immunostaining O 0 0.0018468580674380064
revealed O 0 8.227240323321894e-05
that O 0 1.4240126802178565e-06
BARD1 O 0 0.0025614311452955008
resides O 0 1.539102231618017e-05
within O 0 9.182011808661628e-07
BRCA1 O 0 0.0005659139715135098
nuclear O 0 1.4236991773941554e-05
dots O 0 5.226052962825634e-06
during O 0 9.842033250606619e-07
S O 0 2.1192523490753956e-05
phase O 0 5.066875701231766e-07
of O 0 2.202355631197861e-08
the O 0 2.651446209256392e-07
cell O 0 1.0326376468583476e-05
cycle O 0 3.899610419466626e-06
, O 0 5.349206944060825e-08
but O 0 1.4665312519923646e-08
not O 0 1.0592727583969008e-08
during O 0 1.7579579036919313e-07
the O 0 4.0917299770626414e-07
G1 O 0 0.010129312053322792
phase O 0 5.502380008692853e-05
. O 0 1.8432165234116837e-05

Nevertheless O 0 0.00022321876895148307
, O 0 9.186810530081857e-06
BARD1 O 0 0.0012891041114926338
polypeptides O 0 1.3212990779720712e-05
are O 0 3.945747550915257e-08
found O 0 7.773806487421098e-08
exclusively O 0 3.63285792559509e-08
in O 0 9.77638059396213e-09
the O 0 1.3052857461559597e-08
nuclear O 0 1.507282121337994e-07
fractions O 0 3.389013158994203e-08
of O 0 1.3391381337157782e-08
both O 0 1.7280727604429558e-07
G1 O 0 0.01228985283523798
- O 0 5.794178832729813e-06
and O 0 2.494050193035946e-07
S O 0 0.00021951465168967843
- O 0 1.6775040421634912e-05
phase O 0 1.604366843821481e-05
cells O 0 5.956606401014142e-05
. O 0 1.2301752576604486e-05

Therefore O 0 1.3589174159278627e-05
, O 0 2.4065980142040644e-06
progression O 0 6.770352774765342e-05
to O 0 3.9379364125124994e-07
S O 0 0.00010007621312979609
phase O 0 2.4903954454202903e-06
is O 0 7.805244450764803e-08
accompanied O 0 5.226797838986386e-07
by O 0 1.8447266825205588e-08
the O 0 2.6135770880841847e-08
aggregation O 0 1.5241507753671613e-06
of O 0 9.39140818445594e-08
nuclear O 0 2.2738024199497886e-05
BARD1 O 0 0.00043710102909244597
polypeptides O 0 1.786066422937438e-05
into O 0 5.7906872825697064e-06
BRCA1 O 0 0.00393370445817709
nuclear O 0 0.00016513910668436438
dots O 0 0.0003458553983364254
. O 0 2.661116923263762e-05

This O 0 8.079939107119571e-06
cell O 0 0.0001538992510177195
cycle O 0 0.00010483826918061823
- O 0 1.7985199519898742e-05
dependent O 0 2.3257866814674344e-06
colocalization O 0 2.1252390070003457e-05
of O 0 1.530140991690132e-07
BARD1 O 0 0.0015505390474572778
and O 0 6.392052682713256e-07
BRCA1 O 0 0.0001720218569971621
indicates O 0 1.2306646794968401e-06
a O 0 1.348265072920185e-07
role O 0 3.6651877621807216e-07
for O 0 4.016378909454943e-07
BARD1 O 0 0.002200754825025797
in O 0 5.287333351589041e-06
BRCA1 O 0 0.1062111034989357
- O 0 0.0005748969269916415
mediated O 0 0.005459158681333065
tumor B-Disease 1 0.9905089139938354
suppression O 0 0.013367896899580956
. O 0 0.00010277828550897539

Ethnic O 0 9.845161002886016e-06
differences O 0 1.3925059647590388e-05
in O 0 1.4322525885290815e-06
the O 0 3.7226679978630273e-06
HFE O 0 0.013229082338511944
codon O 0 7.025836384855211e-05
282 O 0 0.0002591552911326289
( O 0 6.015665712766349e-05
Cys O 0 0.4189769923686981
/ O 0 0.0029708712827414274
Tyr O 0 0.006257170345634222
) O 0 6.329967618512455e-06
polymorphism O 0 7.812242984073237e-05
. O 0 3.6990833905292675e-05

Recent O 0 4.755884947371669e-05
studies O 0 7.081167495925911e-06
have O 0 8.482746238769323e-07
shown O 0 1.3698758266400546e-05
that O 0 5.163275636732578e-05
hereditary B-Disease 1 0.9991945624351501
hemochromatosis I-Disease 1 0.9999194145202637
( O 0 0.0070626819506287575
HH B-Disease 1 0.9986913800239563
) O 0 1.211188646266237e-06
is O 0 2.0032958047977445e-07
likely O 0 4.935793640470365e-07
to O 0 3.399909687118452e-08
be O 0 4.5514564561699444e-08
caused O 0 6.701837719447212e-06
by O 0 4.9914515187765574e-08
homozygosity O 0 1.4694744095322676e-05
for O 0 4.1730523037131206e-08
a O 0 5.741345603382797e-07
Cys282Tyr O 0 0.00010853893763851374
mutation O 0 2.856999572031782e-06
in O 0 1.4327100927857828e-07
the O 0 7.572991194138012e-07
HFE O 0 0.006468253210186958
gene O 0 8.258337402367033e-06
located O 0 3.2168361485673813e-06
4 O 0 9.552695701131597e-06
. O 0 6.263552222662838e-06

5 O 0 6.443846359616145e-05
Mb O 0 0.003945320378988981
telomeric O 0 0.007603648584336042
to O 0 1.750032060954254e-05
HLA O 1 0.8976294994354248
- O 0 0.00018523121252655983
A O 0 3.182117870892398e-05
. O 0 2.225734351668507e-05

Population O 0 5.692614877261803e-07
studies O 0 2.0084991092517157e-07
of O 0 8.094569459160539e-09
this O 0 2.5184288432456015e-08
polymorphism O 0 1.011312861010083e-06
are O 0 6.809086183778845e-09
facilitated O 0 3.7801521557412343e-07
by O 0 1.962690276968715e-08
the O 0 3.5227593286890624e-08
fact O 0 1.1062955707075162e-07
that O 0 2.2615173733697702e-08
the O 0 2.1355826618218998e-07
Cys282Tyr O 0 0.0001760896120686084
mutation O 0 1.2050789337081369e-05
creates O 0 6.438417585741263e-06
a O 0 4.4090443225286435e-06
Rsal O 0 0.0012683202512562275
restriction O 0 5.6967419368447736e-05
site O 0 5.13720115122851e-05
. O 0 1.4975594240240753e-05

We O 0 5.139319796398922e-07
have O 0 5.4135004035060774e-08
studied O 0 2.8165479193376086e-07
the O 0 1.559949964757834e-07
codon O 0 5.918157512496691e-06
282 O 0 4.15792856074404e-05
( O 0 8.421377970080357e-06
Cys O 0 0.06449829041957855
/ O 0 0.0005948897451162338
Tyr O 0 0.0009109149104915559
) O 0 4.784063207807776e-07
polymorphism O 0 8.679602956362942e-07
in O 0 3.938041004403203e-08
different O 0 2.158312994993139e-08
ethnic O 0 3.5075410664830997e-07
groups O 0 1.6034317695812206e-06
. O 0 1.2035330655635335e-05

In O 0 1.5028583675302798e-06
agreement O 0 1.1058626796511817e-06
with O 0 8.434830789383341e-08
previous O 0 3.1521554433311394e-07
observations O 0 4.2409598677295435e-07
the O 0 8.110874887279351e-07
Tyr O 0 0.004090487957000732
allele O 0 9.929666703101248e-06
appeared O 0 1.484991230427113e-06
to O 0 3.53197684432871e-08
be O 0 4.17874694846887e-08
rare O 0 3.281906174379401e-06
or O 0 5.253253334558394e-07
absent O 0 2.8884762286907062e-05
in O 0 8.224574798987305e-07
Asiatic O 0 0.0002526302414480597
( O 0 6.778067245249986e-07
Indian O 0 8.777745392762881e-07
, O 0 2.1672404670880496e-07
Chinese O 0 9.771049462869996e-07
) O 0 1.0180427807426895e-06
populations O 0 7.224025011964841e-06
. O 0 9.432124898012262e-06

The O 0 1.280283072446764e-06
highest O 0 3.5932721402787138e-06
allele O 0 1.3807928098685807e-06
frequency O 0 2.992192094097845e-07
( O 0 1.0780865977721987e-07
7 O 0 1.4723391927873308e-07
. O 0 1.7122546935866012e-08
5 O 0 5.575327577389544e-08
% O 0 7.933998347198212e-08
) O 0 1.0146170126290599e-07
was O 0 3.4027749507004046e-07
found O 0 3.791423921484238e-07
in O 0 8.404829259234248e-07
Swedes O 0 6.550679245265201e-05
. O 0 1.78582631633617e-05

Saamis O 0 0.0008265709620900452
( O 0 3.002315906996955e-06
2 O 0 1.113415123654704e-06
% O 0 4.0442989757139003e-07
) O 0 2.0741143202940293e-07
and O 0 4.1554034879709434e-08
Mordvinians O 0 1.7775126252672635e-05
( O 0 1.1908524299997225e-07
1 O 0 6.467973889812129e-08
. O 0 8.24493628925893e-09
8 O 0 6.459232793076808e-08
% O 0 8.002374585203142e-08
) O 0 7.849750005561873e-08
had O 0 1.288065618609835e-07
significantly O 0 4.002094442512316e-07
lower O 0 1.942331238069528e-07
frequencies O 0 2.5256975177967433e-08
of O 0 5.1066930240040165e-08
the O 0 2.11164956454013e-06
Tyr O 0 0.008691082708537579
allele O 0 0.0001180073813884519
. O 0 3.652521991170943e-05

Comparisons O 0 4.660120794142131e-06
with O 0 3.0315771937239333e-07
allele O 0 2.160965323128039e-06
frequencies O 0 2.0472265305215842e-07
based O 0 2.393916247456218e-07
on O 0 1.267131551685452e-06
prevalence O 0 0.0029235926922410727
estimates O 0 5.955354936304502e-06
of O 0 1.0359234465795453e-06
HH B-Disease 1 0.9973401427268982
showed O 0 3.2490704597876174e-06
some O 0 2.5574248496695873e-08
disagreements O 0 1.0265295031786081e-06
with O 0 5.839350336600546e-08
the O 0 1.763717847325097e-07
RFLP O 0 5.362718729884364e-05
data O 0 6.295948651313665e-07
, O 0 2.6116589424418635e-07
particularly O 0 8.4414517687037e-07
in O 0 1.1934416761505418e-06
Finns O 0 0.00023251627862919122
. O 0 2.1014458980062045e-05

The O 0 1.0597035725368187e-05
newly O 0 4.411184636410326e-05
described O 0 0.00011203489702893421
HFE O 0 0.048264309763908386
marker O 0 1.2758908269461244e-05
provides O 0 5.691148885489383e-07
a O 0 1.94761383909281e-07
new O 0 5.831470062389599e-08
approach O 0 8.272301954548311e-08
to O 0 1.394000737064971e-08
the O 0 5.543336456526049e-08
screening O 0 1.331588464381639e-06
of O 0 2.6756870852295833e-07
HH B-Disease 1 0.9594489336013794
as O 0 5.6831662931244864e-08
well O 0 1.790847470317658e-08
as O 0 9.127705702383082e-09
studies O 0 1.2263427606740152e-08
of O 0 2.3566246731832052e-09
the O 0 4.399684172540219e-08
relationship O 0 9.768003792487434e-07
between O 0 6.411705726350192e-07
the O 0 9.372040949529037e-06
HFE O 1 0.9780740737915039
Tyr O 0 0.06510353833436966
allele O 0 5.24243587278761e-05
and O 0 2.0217682958900696e-06
different O 0 1.2964391316927504e-05
disorders O 1 0.9988721013069153
including O 0 0.01577792316675186
cancer B-Disease 1 0.9985483288764954

Autosomal B-Disease 1 0.9857071042060852
dominant I-Disease 1 0.9769015908241272
neurohypophyseal I-Disease 1 0.9969725608825684
diabetes I-Disease 1 0.9997850060462952
insipidus I-Disease 1 0.9963002800941467
associated O 0 5.2809464250458404e-05
with O 0 8.224205885198899e-07
a O 0 5.053121185483178e-06
missense O 0 0.00010754125833045691
mutation O 0 1.4182880477164872e-05
encoding O 0 1.5156022527662572e-05
Gly23 O 0 0.012389128096401691
- O 0 0.000529525219462812
- O 0 9.823260916164145e-05
> O 0 0.0001556893257657066
Val O 0 0.0006160928169265389
in O 0 4.624768735084217e-06
neurophysin O 0 0.009494224563241005
II O 0 0.08297315984964371
. O 0 4.528587669483386e-05

Autosomal B-Disease 1 0.9861541390419006
dominant I-Disease 1 0.9467363953590393
neurohypophyseal I-Disease 1 0.9973698854446411
diabetes I-Disease 1 0.9998028874397278
insipidus I-Disease 1 0.9978345036506653
( O 0 0.00023539020912721753
ADNDI B-Disease 0 0.3112422525882721
) O 0 1.4650680896011181e-05
is O 0 1.54346926137805e-05
an O 0 0.001178054721094668
inherited B-Disease 1 0.9997634291648865
disease I-Disease 1 0.9999215602874756
caused O 1 0.9396630525588989
by O 0 5.725563823943958e-05
progressive O 1 0.5225111842155457
degeneration O 1 0.9980746507644653
of O 0 4.860884246227215e-07
the O 0 3.028340415767161e-06
magnocellular O 0 0.005973924417048693
neurons O 0 1.0940699212369509e-05
of O 0 8.331490874979863e-08
the O 0 6.976239887990232e-07
hypothalamus O 0 5.414609404397197e-05
leading O 0 1.2331682910371455e-06
to O 0 7.181933625588499e-08
decreased O 0 5.896788934478536e-06
ability O 0 1.2133455129514914e-07
to O 0 1.7482051362094353e-08
produce O 0 2.021888576564379e-07
the O 0 3.394665100131533e-07
hormone O 0 0.00011898204684257507
arginine O 0 5.129231794853695e-05
vasopressin O 0 0.00043752952478826046
( O 0 1.2847503057855647e-05
AVP O 0 0.008855788968503475
) O 0 9.696503184386529e-06
. O 0 2.2388223442249e-05

Affected O 0 0.00019632336625363678
individuals O 0 1.6134265479195165e-06
are O 0 2.2621497919317335e-07
not O 0 9.179901780953514e-07
symptomatic O 0 0.09589992463588715
at O 0 1.2139109458075836e-05
birth O 0 9.841458813752979e-05
, O 0 1.0370463314757217e-06
but O 0 1.5568289200018626e-06
usually O 0 2.4353994376724586e-05
develop O 0 0.008514217101037502
diabetes B-Disease 1 0.9994097948074341
insipidus I-Disease 1 0.9908500909805298
at O 0 1.5563236956950277e-05
1 O 0 1.0150046364287846e-05
- O 0 1.5057251403050032e-05
6 O 0 4.306481969251763e-06
yr O 0 0.0004326929338276386
of O 0 2.9177485316722596e-07
age O 0 4.8654506827006117e-05
. O 0 1.850845364970155e-05

The O 0 3.928988917323295e-06
genetic O 0 1.7727254089550115e-05
locus O 0 1.1472213373053819e-05
of O 0 1.0009196103055729e-06
the O 0 6.03348744334653e-05
disease O 1 0.9981111288070679
is O 0 1.6053626268330845e-06
the O 0 3.750262521862169e-06
AVP O 0 0.2464766502380371
- O 0 0.00018558354349806905
neurophysin O 0 0.0007201534463092685
II O 0 0.0017004519468173385
( O 0 2.4267365006380714e-06
NPII O 0 0.00017919312813319266
) O 0 2.024891045948607e-07
gene O 0 7.497479828089126e-07
, O 0 5.4736577936864705e-08
and O 0 8.95126532896029e-08
mutations O 0 5.0994453886232805e-06
that O 0 3.887828654569603e-07
cause O 0 0.0006150839035399258
ADNDI B-Disease 0 0.01410583220422268
have O 0 7.602842089227124e-08
been O 0 4.085739746528816e-08
found O 0 3.222490008170098e-08
in O 0 4.168396294801369e-09
both O 0 2.49284037856512e-09
the O 0 1.758572487631227e-08
signal O 0 2.8089405645914667e-07
peptide O 0 4.3540785554796457e-07
of O 0 1.5220861016018716e-08
the O 0 7.387869231934019e-07
prepro O 0 0.0013590292073786259
- O 0 0.00011203040776308626
AVP O 0 0.007111408282071352
- O 0 4.5417527871904895e-05
NPII O 0 0.0002876787621062249
precursor O 0 1.0583432413113769e-05
and O 0 2.3616482280885975e-07
within O 0 2.2965980406297604e-06
NPII O 0 0.011137425899505615
itself O 0 5.836357377120294e-05
. O 0 2.0055787899764255e-05

An O 0 3.0700964998686686e-05
affected O 0 9.793386561796069e-05
girl O 0 0.00012031853839289397
who O 0 7.051233978927485e-07
presented O 0 1.1445802101661684e-06
at O 0 3.375621133727691e-07
9 O 0 6.556447829098033e-07
months O 0 3.134086057343666e-07
of O 0 2.938562992937932e-08
age O 0 5.892336957913358e-06
and O 0 2.451775458212069e-07
her O 0 5.576843705057399e-06
similarly O 0 3.46844935847912e-05
affected O 0 1.86106153705623e-05
younger O 0 2.9973904020152986e-05
brother O 0 1.6687714378349483e-05
and O 0 1.202082557938411e-07
father O 0 1.6042546349126496e-06
were O 0 2.1616088474729622e-08
all O 0 4.5234402890059755e-09
found O 0 4.4520302111550336e-08
to O 0 7.325146711423258e-09
have O 0 9.915611443034322e-09
a O 0 1.7728849854847795e-07
novel O 0 2.522561771911569e-06
missense O 0 4.037297185277566e-05
mutation O 0 9.827957910601981e-06
( O 0 2.389646624578745e-06
G1758 O 0 0.00028725311858579516
- O 0 6.933149415999651e-05
- O 0 1.2343693015282042e-05
> O 0 1.4616516637033783e-05
T O 0 1.861917189671658e-05
) O 0 6.407289809828853e-09
encoding O 0 6.809631081239331e-09
the O 0 7.25216109387361e-09
amino O 0 3.2206560263148276e-07
acid O 0 1.638670619286131e-05
substitution O 0 1.0639729225658812e-05
Gly23 O 0 0.0022449176758527756
- O 0 0.00016901256458368152
- O 0 3.5352979466551915e-05
> O 0 7.783049659337848e-05
Val O 0 0.00012282290845178068
within O 0 2.289578105774126e-06
NPII O 0 0.008592274971306324
. O 0 4.2192456021439284e-05

The O 0 9.246102308679838e-06
mutation O 0 7.879309123381972e-05
was O 0 7.081856438162504e-06
confirmed O 0 4.159149284532759e-06
by O 0 3.5653732766149915e-07
restriction O 0 1.5692750821472146e-05
endonuclease O 0 0.0006277322536334395
analysis O 0 1.3086633771308698e-05
. O 0 1.9213364794268273e-05

A O 0 0.0003083486808463931
T1 O 0 0.1649969220161438
- O 0 1.3783976100967266e-05
weighted O 0 8.863260063662892e-07
magnetic O 0 2.711446313696797e-06
resonance O 0 4.761573109135497e-06
imaging O 0 1.1261025065323338e-05
of O 0 2.0407159695423616e-07
the O 0 5.079239599581342e-06
fathers O 0 0.0002524352166801691
pituitary O 1 0.9645236730575562
gland O 0 0.11739163100719452
demonstrates O 0 0.0001581378310220316
an O 0 2.015205245697871e-05
attenuated O 0 0.04675648733973503
posterior O 0 0.33446505665779114
pituitary O 1 0.9735375642776489
bright O 0 0.007235613185912371
spot O 0 0.0002011671313084662
. O 0 3.801650382229127e-05

This O 0 4.396594704303425e-06
mutation O 0 7.419522444251925e-05
may O 0 1.766649802448228e-06
be O 0 2.543706045798899e-08
valuable O 0 8.889928437838535e-08
for O 0 3.272799631304224e-08
developing O 0 7.720742019046156e-07
models O 0 8.365789199160645e-07
of O 0 8.80058678376372e-07
dominantly B-Disease 1 0.9495996832847595
inherited I-Disease 1 0.9988898634910583
neurodegeneration I-Disease 1 0.9995437264442444
, O 0 3.5532957554096356e-07
as O 0 5.379082068657226e-08
the O 0 4.719740331893263e-08
early O 0 4.151166308474785e-07
age O 0 1.5178727608144982e-06
of O 0 3.111233297659055e-07
onset O 1 0.99561607837677
of O 0 2.5073961296584457e-05
symptoms O 1 0.9993215799331665
suggests O 0 5.2904881158610806e-05
that O 0 1.864431595777205e-07
this O 0 3.734391498255718e-07
mutation O 0 2.731951099121943e-05
may O 0 9.8881798749062e-07
be O 0 3.810072257692809e-08
particularly O 0 2.756426340511098e-07
deleterious O 0 7.023582838883158e-06
to O 0 8.364546744132895e-08
the O 0 1.008656340673042e-06
magnocellular O 0 0.062005214393138885
neuron O 0 0.06604310125112534
. O 0 5.839322511747014e-06
. O 0 1.5927793356240727e-05

Frequent O 0 0.0004379416350275278
inactivation O 0 0.0031685293652117252
of O 0 1.9971274014096707e-05
PTEN O 1 0.9749325513839722
/ O 0 0.03100358135998249
MMAC1 O 0 0.2398148626089096
in O 0 0.00018758964142762125
primary O 1 0.9008806943893433
prostate B-Disease 1 0.9999217987060547
cancer I-Disease 1 0.9996059536933899
. O 0 0.0007516557816416025

Sporadic B-Disease 1 0.9824601411819458
prostate I-Disease 1 0.9998168349266052
carcinoma I-Disease 1 0.999854326248169
is O 0 3.051730573133682e-06
the O 0 4.949756089445145e-07
most O 0 5.429714065030566e-07
common O 0 2.903377935581375e-05
male B-Disease 0 0.0008112306240946054
cancer I-Disease 1 0.9751538634300232
in O 0 9.098976505583778e-08
the O 0 8.892031644336384e-08
Western O 0 2.688312292775663e-07
world O 0 1.1136057764815632e-07
, O 0 2.0535184219738767e-08
yet O 0 2.2706629465574224e-08
many O 0 8.95856777649584e-10
of O 0 2.250775121837023e-09
the O 0 3.346126575820563e-08
major O 0 5.763640729128383e-07
genetic O 0 1.64869777563581e-06
events O 0 7.781758171176989e-08
involved O 0 1.4769322831398313e-07
in O 0 3.3530074716736635e-08
the O 0 1.5938648800783994e-07
progression O 0 6.409679190255702e-05
of O 0 1.645805838279557e-07
this O 0 2.0810123260162072e-06
often O 0 0.0003784782311413437
fatal O 1 0.9994332194328308
cancer B-Disease 1 0.9994357228279114
remain O 0 2.964498207802535e-06
to O 0 2.8722143952109036e-07
be O 0 1.109515551434015e-06
elucidated O 0 0.0006298258085735142
. O 0 1.0919642591034062e-05

Numerous O 0 0.00014285363431554288
cytogenetic O 0 0.010946296155452728
and O 0 8.80078187037725e-06
allelotype O 0 0.001836217357777059
studies O 0 6.612071047129575e-06
have O 0 1.3698123666472384e-06
reported O 0 1.1454404557298403e-05
frequent O 0 1.0818559530889615e-05
loss O 0 3.970407851738855e-05
of O 0 7.358645461863489e-07
heterozygosity O 0 0.00199334230273962
on O 0 7.354348326771287e-06
chromosomal O 0 0.037205591797828674
arm O 0 0.13302047550678253
10q O 0 0.011966824531555176
in O 0 0.000194486667169258
sporadic B-Disease 1 0.9893954396247864
prostate I-Disease 1 0.9999334812164307
cancer I-Disease 1 0.9995947480201721
. O 0 0.000488677469547838

Deletion O 0 0.0003421913424972445
mapping O 0 2.783989293675404e-05
studies O 0 4.046893991471734e-06
have O 0 3.972813544805831e-07
unambiguously O 0 1.3915660019847564e-05
identified O 0 6.979926752137544e-07
a O 0 2.1467458566348796e-07
region O 0 1.5767207628414326e-07
of O 0 4.588974533703549e-08
chromosome O 0 1.4278189155447762e-05
10q23 O 0 1.567223262100015e-05
to O 0 1.580948172374974e-08
be O 0 1.1964230495209449e-08
the O 0 6.068547264703739e-08
minimal O 0 2.4111766379064647e-06
area O 0 9.312670385952515e-07
of O 0 5.59623003937304e-07
loss O 0 0.0021100351586937904
. O 0 3.6253466532798484e-05

A O 0 8.841539965942502e-05
new O 0 9.638636402087286e-05
tumor B-Disease 1 0.8856874704360962
suppressor O 0 0.0012928979704156518
gene O 0 4.0894068661145866e-05
, O 0 9.130430953518953e-06
PTEN O 1 0.7991488575935364
/ O 0 0.0033182173501700163
MMAC1 O 0 0.006201183423399925
, O 0 1.009514789984678e-06
was O 0 2.61939680967771e-06
isolated O 0 9.874329407466576e-06
recently O 0 1.2520872587629128e-06
at O 0 1.2197834564631194e-07
this O 0 1.5710163836502034e-08
region O 0 7.14423862291369e-08
of O 0 2.5090937327831853e-08
chromosome O 0 1.4280408322520088e-05
10q23 O 0 2.3172931832959875e-05
and O 0 3.559345529424718e-08
found O 0 8.318010458197023e-08
to O 0 1.4478955812080585e-08
be O 0 3.943527815408743e-08
inactivated O 0 3.7692441310355207e-06
by O 0 1.875654760397083e-07
mutation O 0 8.227490980061702e-06
in O 0 2.553088279455551e-06
three O 0 0.00037807392072863877
prostate B-Disease 1 0.9999188184738159
cancer I-Disease 1 0.9997400641441345
cell O 0 0.12048506736755371
lines O 0 0.0006217728368937969
. O 0 5.0596881919773296e-05

We O 0 3.294548878329806e-05
screened O 0 0.0011993037769570947
80 O 0 0.004404357168823481
prostate B-Disease 1 0.9994625449180603
tumors I-Disease 1 0.9977756142616272
by O 0 1.0753260539786424e-06
microsatellite O 0 0.0002470662584528327
analysis O 0 1.107723505811009e-06
and O 0 3.2763102808530675e-07
found O 0 1.6813436332085985e-06
chromosome O 0 1.5742592950118706e-05
10q23 O 0 1.5776573491166346e-05
to O 0 6.53767884273293e-08
be O 0 5.3420901480194516e-08
deleted O 0 4.565230028674705e-06
in O 0 2.5770805223146453e-07
23 O 0 6.08063646723167e-06
cases O 0 1.8824885046342388e-05
. O 0 1.5160981092776638e-05

We O 0 3.346120820424403e-07
then O 0 1.369497226733074e-07
proceeded O 0 1.3640593010677549e-07
with O 0 5.796613411490625e-09
sequence O 0 2.1540234484973553e-08
analysis O 0 1.2329426368751228e-08
of O 0 1.3944900345563838e-08
the O 0 3.324735473597684e-07
entire O 0 1.861925920820795e-05
PTEN O 0 0.395796537399292
/ O 0 0.0003799033584073186
MMAC1 O 0 0.0008292304119095206
coding O 0 1.776692624844145e-05
region O 0 4.2490486862334365e-07
and O 0 4.14128003001224e-08
tested O 0 9.083679515242693e-07
for O 0 2.0636210962265977e-08
homozygous O 0 2.3291072466236074e-06
deletion O 0 5.531007900572149e-06
with O 0 9.829504676872602e-08
new O 0 4.2854628645727644e-07
intragenic O 0 0.00025933203869499266
markers O 0 6.9057705331943e-06
in O 0 5.19233829265886e-08
these O 0 1.9111711324626413e-08
23 O 0 5.158942713023862e-07
cases O 0 6.441639470722293e-07
with O 0 4.840640599468315e-07
10q23 O 0 0.00036245715455152094
loss O 0 0.00017870920419227332
of O 0 2.970588411699282e-06
heterozygosity O 0 0.06787979602813721
. O 0 9.618291369406506e-05

The O 0 8.760592891121632e-07
identification O 0 2.7156647774972953e-07
of O 0 1.6702726313155836e-08
the O 0 1.2826622253214737e-07
second O 0 5.698709060197871e-07
mutational O 0 9.089517698157579e-05
event O 0 7.182206900324672e-07
in O 0 5.173012596060289e-08
10 O 0 9.432464054270895e-08
( O 0 1.4661320335562777e-07
43 O 0 6.091311774980568e-07
% O 0 1.1847359928651713e-06
) O 0 9.976460205507465e-06
tumors B-Disease 1 0.9899307489395142
establishes O 0 0.0015114623820409179
PTEN O 1 0.9438126683235168
/ O 0 0.00040181740769185126
MMAC1 O 0 0.0001630708429729566
as O 0 7.994166395519642e-08
a O 0 2.108480998685991e-07
main O 0 4.766693564306479e-07
inactivation O 0 4.775982233695686e-05
target O 0 2.647999792770861e-07
of O 0 3.1939262612468156e-07
10q O 0 0.0007186548318713903
loss O 0 0.0019106342224404216
in O 0 8.250676182797179e-05
sporadic B-Disease 1 0.9912375211715698
prostate I-Disease 1 0.9999613761901855
cancer I-Disease 1 0.9996883869171143
. O 0 4.898869156022556e-05
. O 0 6.50956790195778e-05

Risk O 0 0.002954663010314107
reversals O 0 0.0004900990752503276
in O 0 3.5687889976543374e-06
predictive O 0 0.00014534263755194843
testing O 0 0.0008124230662360787
for O 0 0.0009529378148727119
Huntington B-Disease 1 0.9994012117385864
disease I-Disease 1 0.9996737241744995
. O 0 0.0005153489182703197

The O 0 1.5849990404603886e-06
first O 0 1.2307750694162678e-06
predictive O 0 2.4257546101580374e-05
testing O 0 0.00011026218271581456
for O 0 8.989441266749054e-05
Huntington B-Disease 1 0.999371349811554
disease I-Disease 1 0.9997598528862
( O 0 1.8687142073758878e-05
HD B-Disease 0 0.00020572789071593434
) O 0 1.1716030456909721e-07
was O 0 7.05255303046215e-08
based O 0 6.5482841371533596e-09
on O 0 5.18462606180492e-09
analysis O 0 1.2673458726908393e-08
of O 0 1.6235343736070718e-08
linked O 0 4.054172222822672e-06
polymorphic O 0 8.343723493453581e-06
DNA O 0 2.1986722913425183e-06
markers O 0 1.2960566664332873e-06
to O 0 1.5810597275844884e-08
estimate O 0 1.65651030670233e-07
the O 0 2.3545501548483116e-08
likelihood O 0 5.961879310234508e-07
of O 0 1.955948647491823e-08
inheriting O 0 5.7044177083298564e-05
the O 0 2.518025894460152e-07
mutation O 0 1.2960595995537005e-05
for O 0 1.6775029507698491e-06
HD B-Disease 0 0.0015782882692292333
. O 0 1.6077181498985738e-05

Limits O 0 1.1166828244313365e-06
to O 0 3.263007286591346e-08
accuracy O 0 1.1511423281262978e-07
included O 0 5.365106048316193e-08
recombination O 0 8.257725880866928e-07
between O 0 6.0998452511285e-08
the O 0 9.41878326443657e-08
DNA O 0 2.1756468413514085e-06
markers O 0 1.96020459952706e-06
and O 0 2.664063103452463e-08
the O 0 1.5740705805455946e-07
mutation O 0 7.024560545687564e-06
, O 0 1.8167889948017546e-07
pedigree O 0 2.8319285775069147e-05
structure O 0 2.007155899264035e-06
, O 0 3.492712608021975e-08
and O 0 1.3898856288108163e-08
whether O 0 2.877546201318637e-08
DNA O 0 3.88417475960523e-07
samples O 0 1.2921886138883565e-07
were O 0 1.4188810126825047e-08
available O 0 2.9674456669681604e-08
from O 0 1.324047218531632e-07
family O 0 3.838757947960403e-06
members O 0 1.2000429023828474e-06
. O 0 9.337597475678194e-06

With O 0 2.971773938043043e-07
direct O 0 2.1661038829279278e-07
tests O 0 4.83218116187345e-07
for O 0 2.2638564800558925e-08
the O 0 1.72966878153602e-07
HD B-Disease 0 0.00014757114695385098
mutation O 0 2.2225622160476632e-06
, O 0 2.5452298046957367e-08
we O 0 6.485834536107404e-09
have O 0 2.3322366260458693e-09
assessed O 0 5.565521021821951e-08
the O 0 4.837472200591719e-09
accuracy O 0 2.753729866356025e-08
of O 0 7.256063305760563e-09
results O 0 1.2355762635252177e-07
obtained O 0 9.1387541090171e-08
by O 0 6.675325892047113e-08
linkage O 0 4.100083515368169e-06
approaches O 0 2.0873416417543922e-07
when O 0 1.5199370295704284e-07
requested O 0 1.4803052295064845e-07
to O 0 9.77682823588566e-09
do O 0 1.266724769521943e-08
so O 0 1.0260342797607791e-08
by O 0 1.693675422131946e-08
the O 0 9.186113203440982e-08
test O 0 1.2334811572145554e-06
individuals O 0 8.931565957936982e-07
. O 0 5.0726175686577335e-06

For O 0 6.244498536034371e-07
six O 0 5.742495545746351e-07
such O 0 8.010284346937624e-08
individuals O 0 1.1813519051884214e-07
, O 0 9.423077784731504e-08
there O 0 8.35568059187608e-08
was O 0 4.121525591926911e-07
significant O 0 2.401644962901628e-07
disparity O 0 1.5088213331182487e-05
between O 0 1.8487143904621917e-07
the O 0 7.262586905198987e-07
tests O 0 1.3823337212670594e-05
. O 0 7.934896530059632e-06

Three O 0 9.05624176539277e-07
went O 0 2.596232889118255e-06
from O 0 8.615499496045231e-07
a O 0 3.854720034723869e-06
decreased O 0 0.0004266765608917922
risk O 0 6.726386345690116e-06
to O 0 2.333901960582807e-08
an O 0 1.8208010033049504e-07
increased O 0 2.0623401724151336e-06
risk O 0 5.131237230671104e-06
, O 0 2.1920255832696967e-08
while O 0 1.3774894114249037e-08
in O 0 9.03924313178095e-09
another O 0 5.2349790280459274e-08
three O 0 5.196429953002735e-08
the O 0 9.634676416681032e-07
risk O 0 0.00035351928090676665
was O 0 2.734789995884057e-05
decreased O 0 0.0004212247731629759
. O 0 1.3971350199426524e-05

Knowledge O 0 1.0279646858180058e-06
of O 0 1.4735289255440875e-07
the O 0 3.303216260519548e-07
potential O 0 6.07696847509942e-07
reasons O 0 1.3985285818307602e-07
for O 0 1.0862225785501778e-08
these O 0 7.223088793750776e-09
changes O 0 1.0517577209157025e-07
in O 0 3.308960216941159e-08
results O 0 1.6063199836935382e-07
and O 0 3.0673064088659885e-08
impact O 0 2.4918676899687853e-07
of O 0 1.5261617747341916e-08
these O 0 1.445062736138425e-07
risk O 0 7.387054210994393e-05
reversals O 0 6.026161281624809e-05
on O 0 3.3142097777272284e-07
both O 0 5.20608296028513e-07
patients O 0 0.0004904951201751828
and O 0 4.78336943388058e-08
the O 0 9.90359438901578e-08
counseling O 0 4.116169748158427e-06
team O 0 4.537180942065788e-08
can O 0 5.797918145589165e-09
assist O 0 2.748236127558812e-08
in O 0 5.836285232874161e-09
the O 0 8.711528387550516e-09
development O 0 3.092637257395836e-08
of O 0 5.054767715506614e-09
strategies O 0 2.7711919869943813e-07
for O 0 2.8171998067705317e-08
the O 0 3.67399934475543e-07
prevention O 0 8.156823605531827e-05
and O 0 3.60844580882258e-08
, O 0 2.2962678869475894e-08
where O 0 3.2138959937810796e-08
necessary O 0 4.716707380225671e-08
, O 0 6.613518621634285e-08
management O 0 5.605289175036887e-07
of O 0 2.3669509019441648e-08
a O 0 1.5064110812090803e-06
risk O 0 3.7572041037492454e-05
reversal O 0 1.4217941497918218e-05
in O 0 6.66102977220362e-08
any O 0 1.0215259038659497e-07
predictive O 0 5.240681275608949e-06
testing O 0 1.041219184116926e-05
program O 0 6.3410179791389965e-06
. O 0 2.7142198177898536e-06
. O 0 1.4918279703124426e-05

A O 0 1.968606375157833e-05
novel O 0 1.4491904039459769e-05
common O 0 9.057504030351993e-06
missense O 0 0.00014489014574792236
mutation O 0 2.384181243542116e-05
G301C O 0 3.382717113709077e-05
in O 0 2.3328611575834657e-07
the O 0 7.208158763205574e-07
N O 0 4.24059180659242e-05
- O 0 1.711046206764877e-05
acetylgalactosamine O 0 0.00013251497875899076
- O 0 9.28271583688911e-06
6 O 0 4.397714292281307e-06
- O 0 3.158168328809552e-05
sulfate O 0 0.002436844864860177
sulfatase O 0 0.014989014714956284
gene O 0 3.01324762403965e-05
in O 0 1.0130251212103758e-05
mucopolysaccharidosis B-Disease 0 0.05244770646095276
IVA I-Disease 1 0.9595746397972107
. O 0 9.530824172543362e-05

Mucopolysaccharidosis B-Disease 0 0.20785003900527954
IVA I-Disease 1 0.9585275053977966
( O 0 0.0001785225176718086
MPS B-Disease 0 0.023227673023939133
IVA I-Disease 1 0.9788070321083069
) O 0 4.9554982979316264e-06
is O 0 2.3161076114774914e-06
an O 0 2.2360483853844926e-05
autosomal B-Disease 1 0.9947050213813782
recessive I-Disease 1 0.9981133937835693
lysosomal I-Disease 1 0.9993797540664673
storage I-Disease 1 0.9988435506820679
disorder I-Disease 1 0.9998296499252319
caused O 1 0.5249262452125549
by O 0 7.494794317608466e-06
a O 0 0.00014778293552808464
genetic B-Disease 0 0.49827268719673157
defect I-Disease 1 0.9886475205421448
in O 0 2.3688487544859527e-06
N O 0 0.00024851333000697196
- O 0 2.4819762984407134e-05
acetylgalactosamine O 0 0.00019504789088387042
- O 0 1.2563331438286696e-05
6 O 0 8.185745173250325e-06
- O 0 8.274928404716775e-05
sulfate O 0 0.007842699065804482
sulfatase O 0 0.08072593808174133
( O 0 1.1289216672594193e-05
GALNS O 0 0.004344295244663954
) O 0 1.1339932825649157e-05
. O 0 1.7922671759151854e-05

In O 0 2.3246313958225073e-06
previous O 0 3.153787019982701e-06
studies O 0 1.1073898349422961e-06
, O 0 1.2528010984169669e-07
we O 0 1.6948710879205464e-08
have O 0 8.99466456871778e-09
found O 0 3.168176121448596e-08
two O 0 1.9906419623794136e-08
common O 0 1.3629789918923052e-06
mutations O 0 6.296918400039431e-06
in O 0 9.527061592962127e-07
Caucasians O 0 0.0001734928518999368
and O 0 5.05098796566017e-07
Japanese O 0 2.2025920770829543e-05
, O 0 1.451367893423594e-06
respectively O 0 1.1270542927377392e-05
. O 0 2.1498597561731003e-05

To O 0 2.257698270113906e-06
characterize O 0 6.0424288676586e-05
the O 0 1.6967168221526663e-06
mutational O 0 0.000543412403203547
spectrum O 0 6.928899438207736e-06
in O 0 1.031141536600444e-07
various O 0 3.4146555805136813e-08
ethnic O 0 1.2250878000941157e-07
groups O 0 8.474436441474609e-08
, O 0 1.1977614633451594e-07
mutations O 0 1.0278323543388979e-06
in O 0 5.670724689821327e-08
the O 0 4.068298551374028e-07
GALNS O 0 0.0009944385383278131
gene O 0 1.4607751836592797e-05
in O 0 2.8983374704694143e-06
Colombian O 0 0.00018242084479425102
MPS B-Disease 0 0.35516420006752014
IVA I-Disease 1 0.9985731840133667
patients O 0 0.1924014538526535
were O 0 1.2157320270489436e-06
investigated O 0 2.9260960218380205e-05
, O 0 3.4994818065570144e-07
and O 0 3.60523387143985e-07
genetic O 0 1.222298033098923e-05
backgrounds O 0 8.465920586786524e-07
were O 0 1.0974120101536755e-07
extensively O 0 8.050089377320546e-07
analyzed O 0 3.0420497409977543e-07
to O 0 1.8524483280657478e-08
identify O 0 1.7952734765458445e-07
racial O 0 4.1292921082458633e-07
origin O 0 4.7351047527399714e-08
, O 0 2.8189305112391594e-08
based O 0 2.181281644197952e-08
on O 0 2.9615989660669584e-08
mitochondrial O 0 1.4955508049752098e-06
DNA O 0 3.384961246410967e-06
( O 0 7.100184120645281e-07
mtDNA O 0 5.544707619264955e-06
) O 0 1.010352775665524e-06
lineages O 0 2.6716363208834082e-05
. O 0 1.5989080566214398e-05

Three O 0 4.68516464025015e-06
novel O 0 7.876183371990919e-05
missense O 0 0.00144524360075593
mutations O 0 0.00012643056106753647
never O 0 7.871743946452625e-06
identified O 0 8.872698344930541e-07
previously O 0 4.2777088538059616e-07
in O 0 3.255684077885235e-08
other O 0 1.658406389992706e-08
populations O 0 9.211167650846619e-08
and O 0 1.7412002506489443e-08
found O 0 7.797937939812982e-08
in O 0 1.6772192523717422e-08
16 O 0 4.566909339587255e-08
out O 0 5.916310108489142e-09
of O 0 2.1683934647853675e-08
19 O 0 2.2480965071736136e-06
Colombian O 0 1.168897779280087e-05
MPS B-Disease 0 0.0005738536710850894
IVA I-Disease 1 0.5588315725326538
unrelated O 0 3.485104025457986e-05
alleles O 0 9.285035957873333e-06
account O 0 1.3537891163650784e-06
for O 0 1.2370363720037858e-06
84 O 0 0.00016302915173582733
. O 0 2.535449675633572e-05

2 O 0 1.8028655404123128e-06
% O 0 1.367737780810785e-07
of O 0 1.8937321044631972e-08
the O 0 1.318760780577577e-07
alleles O 0 1.3595491736850818e-06
in O 0 2.2643794750365487e-07
this O 0 2.1403025129984599e-07
study O 0 6.194466550368816e-06
. O 0 1.2446985238057096e-05

The O 0 9.714553016237915e-06
G301C O 0 0.00012795315706171095
and O 0 1.3835873460266157e-06
S162F O 0 7.162177644204348e-05
mutations O 0 4.509643076744396e-06
account O 0 5.110785536999174e-07
for O 0 6.553934213116008e-07
68 O 0 8.0771220382303e-05
. O 0 1.739521394483745e-05

4 O 0 1.5144810276979115e-05
% O 0 4.304125468479469e-06
and O 0 1.1770833907576161e-06
10 O 0 8.839279871608596e-06
. O 0 1.6175838027265854e-05

5 O 0 3.2609036679787096e-06
% O 0 4.233847619161679e-07
of O 0 6.329831592211121e-08
mutations O 0 3.8107664295239374e-06
, O 0 6.891218617965933e-08
respectively O 0 2.3397859649776365e-07
, O 0 2.1123730320482537e-08
whereas O 0 6.188970758103096e-08
the O 0 1.558989914940412e-08
remaining O 0 9.256748256802894e-08
F69V O 0 0.00011623436148511246
is O 0 3.230927703157249e-08
limited O 0 2.9588491656795668e-08
to O 0 5.035166950051462e-09
a O 0 1.902221811178606e-07
single O 0 7.928973673188011e-07
allele O 0 2.2171969249029644e-05
. O 0 9.677612069936004e-06

The O 0 1.4010548511578236e-05
skewed O 0 0.00015622675709892064
prevalence O 0 0.0005515633965842426
of O 0 3.2946400096989237e-07
G301C O 0 8.879485540091991e-05
in O 0 2.388682389664609e-07
only O 0 2.7191632057110837e-07
Colombian O 0 1.3531173863157164e-05
patients O 0 0.00018101101159118116
and O 0 6.695140797319254e-08
haplotype O 0 2.2174761397764087e-05
analysis O 0 1.1712635483718259e-07
by O 0 5.480562847992587e-08
restriction O 0 1.7208807321367203e-06
fragment O 0 3.63551748705504e-06
length O 0 1.3032106380705955e-06
polymorphisms O 0 2.0419163320184452e-06
in O 0 5.294464955341027e-08
the O 0 2.6155797172577877e-07
GALNS O 0 0.0007479245541617274
gene O 0 1.7161802361442824e-06
suggest O 0 6.467357138717489e-07
that O 0 6.204879809956765e-08
G301C O 0 1.844655162130948e-05
originated O 0 1.1867273315147031e-06
from O 0 2.7715884698409354e-07
a O 0 1.467125343879161e-06
common O 0 5.41424651601119e-06
ancestor O 0 6.434555689338595e-05
. O 0 2.508934267098084e-05

Investigation O 0 6.377095360221574e-06
of O 0 9.071354156731104e-08
the O 0 2.0323062699389993e-07
genetic O 0 2.5544325126247713e-06
background O 0 1.781773590892044e-07
by O 0 2.049359082434421e-08
means O 0 2.67484185911826e-08
of O 0 9.826464086870601e-09
mtDNA O 0 1.2643057516470435e-06
lineages O 0 1.753008632476849e-06
indicate O 0 1.253519826605043e-06
that O 0 2.6667217767339935e-08
all O 0 2.572596002892169e-08
our O 0 3.3817397593338683e-07
patients O 0 0.00013346860941965133
are O 0 1.2415750205718723e-08
probably O 0 2.0447174620130681e-07
of O 0 3.195930631250121e-08
native O 0 1.4389282796400948e-06
American O 0 5.070353836345021e-06
descent O 0 0.0003428070922382176

Low O 0 1.8173406715504825e-05
frequency O 0 2.696453748285421e-06
of O 0 1.6690868278601556e-06
BRCA1 O 0 0.0024999789893627167
germline O 0 0.0014086763840168715
mutations O 0 2.8693895728792995e-05
in O 0 4.6422101149801165e-06
45 O 0 0.00021377825760282576
German O 1 0.9031696319580078
breast B-Disease 1 0.9996953010559082
/ I-Disease 1 0.9988527297973633
ovarian I-Disease 1 0.9999376535415649
cancer I-Disease 1 0.999697208404541
families O 0 0.00040690242894925177
. O 0 0.00010372278484283015

In O 0 8.437017413598369e-07
this O 0 2.228246955837676e-07
study O 0 7.402015853585908e-07
we O 0 1.788410770586779e-07
investigated O 0 2.8121348805143498e-05
45 O 0 5.18498127348721e-05
German O 0 0.4574468433856964
breast B-Disease 1 0.9995471835136414
/ I-Disease 1 0.998843789100647
ovarian I-Disease 1 0.9999531507492065
cancer I-Disease 1 0.9994651675224304
families O 0 3.5402770208747825e-06
for O 0 9.835399623625563e-07
germline O 0 0.001953300554305315
mutations O 0 1.6713467630324885e-05
in O 0 7.060776283651649e-07
the O 0 4.640749011741718e-06
BRCA1 O 0 0.010179342702031136
gene O 0 0.0001382362679578364
. O 0 3.2823558285599574e-05

We O 0 2.320493877050467e-06
identified O 0 3.110983016085811e-06
four O 0 9.397443818670581e-07
germline O 0 0.000562203349545598
mutations O 0 1.6820600649225526e-05
in O 0 2.0881132059002994e-06
three O 0 7.309999637072906e-05
breast B-Disease 1 0.9995408058166504
cancer I-Disease 1 0.9988810420036316
families O 0 1.2778872360286186e-06
and O 0 2.0480429441249726e-07
in O 0 3.47901436725806e-06
one O 0 0.00019924713706132025
breast B-Disease 1 0.9997918009757996
- I-Disease 1 0.999180018901825
ovarian I-Disease 1 0.9999791383743286
cancer I-Disease 1 0.9999237060546875
family O 0 2.4566308638895862e-05
. O 0 9.260845246217286e-08
among O 0 1.7929940199223893e-08
these O 0 6.316984269005843e-09
were O 0 1.7963587950475812e-08
one O 0 7.187661310581461e-08
frameshift O 0 0.00021286928677000105
mutation O 0 2.007448983931681e-06
, O 0 4.526341967903136e-08
one O 0 5.156236682068993e-08
nonsense O 0 6.6329371293250006e-06
mutation O 0 8.556078796573274e-07
, O 0 1.4555157079598757e-08
one O 0 1.5554316945554092e-08
novel O 0 3.9383496641676174e-07
splice O 0 1.0005578587879427e-05
site O 0 1.8820886680259719e-06
mutation O 0 2.2455894850281766e-06
, O 0 8.794556549673871e-08
and O 0 7.105833788045857e-08
one O 0 5.66585924843821e-07
missense O 0 0.0004271757206879556
mutation O 0 0.00026103993877768517
. O 0 2.9921695386292413e-05

The O 0 1.3693077562493272e-05
missense O 0 0.00038164592115208507
mutation O 0 4.166323196841404e-05
was O 0 2.9877717224735534e-06
also O 0 2.4958157496257627e-07
found O 0 4.2605319094946026e-07
in O 0 3.235105623389245e-07
2 O 0 3.919344635505695e-06
. O 0 3.911394742317498e-06

8 O 0 1.4006230912855244e-06
% O 0 1.2401649485127564e-07
of O 0 1.5591593793828906e-08
the O 0 8.32836093422884e-08
general O 0 3.356706486101757e-07
population O 0 5.754337806251897e-08
, O 0 5.812803038907077e-08
suggesting O 0 2.5801596166274976e-06
that O 0 5.4413678896025885e-08
it O 0 1.3481803762260824e-07
is O 0 1.041605742102547e-06
not O 0 1.0292909792042337e-05
disease O 1 0.9965440630912781
associated O 0 9.902195597533137e-05
. O 0 3.061153620365076e-05

The O 0 6.005567229294684e-06
average O 0 1.6525022147106938e-05
age O 0 6.690402369713411e-05
of O 0 3.446795744821429e-05
disease O 1 0.9996813535690308
onset O 1 0.9985748529434204
in O 0 2.3377301658911165e-06
those O 0 7.671025628042116e-07
families O 0 6.04692240813165e-06
harbouring O 0 0.06683071702718735
causative O 0 0.0012317781802266836
mutations O 0 4.0017788705881685e-05
was O 0 3.63429398930748e-06
between O 0 1.8443522549205227e-06
32 O 0 1.4078469575906638e-05
. O 0 1.1572999937925488e-05

3 O 0 3.2805906812427565e-05
and O 0 4.16405873693293e-06
37 O 0 4.229219484841451e-05
. O 0 3.1070132536115125e-05

4 O 0 2.4922484954004176e-05
years O 0 2.9377106329775415e-06
, O 0 3.3184539915964706e-07
whereas O 0 9.957336715160636e-07
the O 0 2.338570226356751e-07
family O 0 4.05794708058238e-06
harbouring O 0 0.0002909029135480523
the O 0 4.444513308499154e-07
missense O 0 4.719898061011918e-05
mutation O 0 6.7185392254032195e-06
had O 0 2.340140810019875e-07
an O 0 6.405031882650292e-08
average O 0 3.82067554483001e-07
age O 0 7.917714697214251e-07
of O 0 2.0222645957801433e-07
onset O 0 0.3658181130886078
of O 0 9.96038579614833e-07
51 O 0 0.00011236409045523033
. O 0 2.3932681870064698e-05

2 O 0 0.00012713442265521735
years O 0 0.00013702876458410174
. O 0 4.911977157462388e-05

These O 0 1.1199314258192317e-06
findings O 0 8.931369848141912e-06
show O 0 1.4097570328885922e-06
that O 0 3.3135648891402525e-07
BRCA1 O 0 0.0003155111917294562
is O 0 2.0141557399711019e-07
implicated O 0 8.568837984057609e-06
in O 0 1.0888324908364666e-07
a O 0 2.1333188726657681e-07
small O 0 4.1577430920369807e-07
fraction O 0 4.736862138088327e-06
of O 0 4.123719918425195e-05
breast B-Disease 1 0.999765932559967
/ I-Disease 1 0.9992929697036743
ovarian I-Disease 1 0.9999611377716064
cancer I-Disease 1 0.9998034834861755
families O 0 8.046703442232683e-06
suggesting O 0 7.262730377988191e-06
the O 0 1.1233979080316203e-07
involvement O 0 8.384295142604969e-07
of O 0 7.873381946410518e-08
another O 0 3.0512533157889266e-06
susceptibility O 0 0.0006944107008166611
gene O 0 5.823609171784483e-05
( O 0 1.643855830479879e-05
s O 0 0.0008898510714061558
) O 0 3.174443554598838e-05

Paternal O 0 0.028562219813466072
transmission O 0 0.33294007182121277
of O 0 0.017575468868017197
congenital B-Disease 1 0.9998579025268555
myotonic I-Disease 1 0.99977046251297
dystrophy I-Disease 1 0.9997712969779968
. O 0 0.016956282779574394

We O 0 3.88427406505798e-06
report O 0 5.244591193331871e-06
a O 0 4.057657406519866e-06
rare O 0 6.41953301965259e-05
case O 0 1.924017306009773e-05
of O 0 1.6587200661888346e-05
paternally O 1 0.9833061099052429
transmitted O 1 0.9945976734161377
congenital B-Disease 1 0.999854564666748
myotonic I-Disease 1 0.9998443126678467
dystrophy I-Disease 1 0.9998857975006104
( O 1 0.8033503890037537
DM B-Disease 1 0.9988523721694946
) O 0 0.00018978057778440416
. O 0 9.538953599985689e-05

The O 0 7.917784387245774e-06
proband O 0 0.0002067555469693616
is O 0 7.979783163136744e-07
a O 0 1.5949353837640956e-06
23 O 0 6.907792339916341e-06
year O 0 6.3769375628908165e-06
old O 0 0.0001505315158283338
, O 0 2.2629881641478278e-05
mentally B-Disease 1 0.9948821067810059
retarded I-Disease 1 0.9945021867752075
male O 0 0.01864701136946678
who O 0 0.04949631169438362
suffers O 1 0.9996768236160278
severe O 1 0.9997116923332214
muscular B-Disease 1 0.9995629191398621
weakness I-Disease 1 0.9977840781211853
. O 0 0.001109579112380743

He O 0 8.684992644703016e-05
presented O 0 0.00010929680138360709
with O 0 0.00029623715090565383
respiratory O 1 0.9993835687637329
and O 0 1.5671903383918107e-05
feeding O 0 0.0018624337390065193
difficulties O 0 0.0020195923279970884
at O 0 6.988830136833712e-05
birth O 0 0.0020580433774739504
. O 0 7.86816599429585e-05

His O 0 8.865787094691768e-05
two O 0 5.4876189096830785e-05
sibs O 1 0.9881201982498169
suffer O 1 0.9890952706336975
from O 0 0.0003876638365909457
childhood O 1 0.9923784732818604
onset O 1 0.9987484216690063
DM B-Disease 1 0.9989917874336243
. O 0 0.0012308323057368398

Their O 0 1.0485504162716097e-06
late O 0 1.4316012311610393e-05
father O 0 4.045651621709112e-06
had O 0 3.3629129347900744e-07
the O 0 8.1449528011035e-08
adult O 0 2.2067765712563414e-06
type O 0 7.362600626947824e-06
of O 0 1.053219762070512e-06
DM B-Disease 1 0.9983161687850952
, O 0 4.2148283796450414e-07
with O 0 7.688207119826984e-07
onset O 0 0.4736001193523407
around O 0 9.642176337365527e-07
30 O 0 2.889414872697671e-06
years O 0 8.287354830827098e-06
. O 0 1.183151198347332e-05

Only O 0 2.922627686530177e-07
six O 0 1.9083378788309346e-07
other O 0 2.3066936805093974e-08
cases O 0 4.2807982936210465e-07
of O 0 1.7109985606111877e-07
paternal O 0 0.0010701657738536596
transmission O 0 0.012237505987286568
of O 0 0.0003858395211864263
congenital B-Disease 1 0.9999639987945557
DM I-Disease 1 0.9997561573982239
have O 0 1.149673516920302e-05
been O 0 7.767263014102355e-06
reported O 0 0.00011755186278605834
recently O 0 0.00014450699381995946
. O 0 1.9422033801674843e-05

We O 0 7.76172953464993e-07
review O 0 1.5992412727428018e-06
the O 0 4.2970609115400293e-07
sex O 0 4.284925580577692e-06
related O 0 9.157682143268175e-06
effects O 0 9.433038940187544e-05
on O 0 4.639067810785491e-06
transmission O 0 0.007099540438503027
of O 0 0.00024171143013518304
congenital B-Disease 1 0.9998754262924194
DM I-Disease 1 0.9993645548820496
. O 0 0.0008340162457898259

Decreased O 0 0.0013681380078196526
fertility O 0 0.0002610685769468546
of O 0 2.0301445147197228e-07
males O 0 5.379566573537886e-06
with O 0 2.3734824026178103e-06
adult O 0 0.0007126445998437703
onset O 1 0.9989921450614929
DM B-Disease 1 0.9992386102676392
and O 0 7.498087484236748e-07
contraction O 0 5.0538288633106276e-05
of O 0 3.6073519282808775e-08
the O 0 3.185518266946019e-07
repeat O 0 1.0560475857346319e-05
upon O 0 5.149161097506294e-07
male O 0 7.49443688619067e-06
transmission O 0 1.0233166904072277e-05
contribute O 0 2.3928021164465463e-07
to O 0 9.233978914835461e-09
the O 0 3.50320092934453e-08
almost O 0 3.021308145889634e-07
absent O 0 5.307504579832312e-06
occurrence O 0 3.1908316486806143e-06
of O 0 3.1900449926069996e-07
paternal O 0 0.0015010007191449404
transmission O 0 0.008973161689937115
of O 0 0.0005674597923643887
congenital B-Disease 1 0.9998327493667603
DM I-Disease 1 0.9992076754570007
. O 0 0.0010284289019182324

Also O 0 2.1691810161428293e-06
the O 0 4.314126158533327e-07
fathers O 0 1.4018604588272865e-06
of O 0 1.7523690587495366e-07
the O 0 6.727271738782292e-06
reported O 0 0.0010102743981406093
congenitally O 0 0.28615471720695496
affected O 0 4.303681998862885e-05
children O 0 2.6558168428891804e-06
showed O 0 2.320015937584685e-06
, O 0 6.36342250004418e-08
on O 0 6.367903182535883e-08
average O 0 7.734125233582745e-07
, O 0 2.0356466734483547e-07
shorter O 0 2.5129953428404406e-05
CTG O 0 0.002048908732831478
repeat O 0 3.373336585354991e-05
lengths O 0 2.8788399504264817e-05
and O 0 7.841061346880451e-07
hence O 0 3.437883788137697e-05
less O 0 0.0003120435285381973
severe O 1 0.9991151690483093
clinical O 1 0.99483323097229
symptoms O 1 0.9984380602836609
than O 0 7.470949299204221e-07
the O 0 1.4666161405330058e-06
mothers O 0 6.476898852270097e-05
of O 0 1.174298290607112e-06
children O 0 0.0003211633302271366
with O 0 0.009627390652894974
congenital B-Disease 1 0.9998753070831299
DM I-Disease 1 0.9994006156921387
. O 0 0.0012436859542503953

We O 0 1.40815541271877e-06
conclude O 0 1.276539569516899e-05
that O 0 7.138802970985125e-07
paternal O 0 0.00023542970302514732
transmission O 0 0.001337666530162096
of O 0 0.00011498763342387974
congenital B-Disease 1 0.9999551773071289
DM I-Disease 1 0.999810516834259
is O 0 5.531377155421069e-06
rare O 0 2.35908773902338e-05
and O 0 2.223481345708933e-07
preferentially O 0 5.685958512913203e-06
occurs O 0 4.06412846132298e-06
with O 0 1.3850619779987028e-06
onset O 1 0.7333617806434631
of O 0 3.800488002525526e-06
DM B-Disease 1 0.9978824257850647
past O 0 1.195502250084246e-06
30 O 0 6.078290084587934e-07
years O 0 4.1169687392539345e-07
in O 0 6.127633156438606e-08
the O 0 3.1319228810389177e-07
father O 0 1.544504084449727e-05
. O 0 2.3378015612252057e-06
. O 0 1.1191553312528413e-05

The O 0 6.345783913275227e-05
RB1 O 0 0.25227734446525574
gene O 0 3.168542752973735e-05
mutation O 0 1.8547571016824804e-05
in O 0 7.121233238649438e-07
a O 0 3.2362647743866546e-06
child O 0 0.00024387726443819702
with O 0 7.060465577524155e-05
ectopic B-Disease 1 0.994922935962677
intracranial I-Disease 1 0.9986845850944519
retinoblastoma I-Disease 1 0.9935025572776794
. O 0 0.00048125183093361557

The O 0 5.860288365511224e-05
RB1 O 0 0.48950397968292236
gene O 0 0.00010299039422534406
mutation O 0 6.352806667564437e-05
was O 0 6.407196906366153e-06
investigated O 0 1.2772812624461949e-05
in O 0 2.6125235308427364e-07
a O 0 1.67387531746499e-06
child O 0 5.741321001551114e-05
with O 0 1.6245452570728958e-05
ectopic B-Disease 1 0.991716206073761
intracranial I-Disease 1 0.9981460571289062
retinoblastoma I-Disease 0 0.018061185255646706
using O 0 5.042267048338545e-07
DNA O 0 1.3350777408049908e-06
obtained O 0 1.5383112383915432e-07
from O 0 7.339106389281369e-08
both O 0 6.550560271989525e-08
the O 0 1.6139127865244518e-06
pineal B-Disease 0 0.012789513915777206
and I-Disease 0 1.090911973733455e-05
retinal I-Disease 1 0.994918167591095
tumours I-Disease 1 0.9947330951690674
of O 0 2.9211498713266337e-06
the O 0 5.010037057218142e-05
patient O 0 0.2550157308578491
. O 0 4.833366256207228e-05

A O 0 3.949290839955211e-05
nonsense O 0 0.0001027804464683868
mutation O 0 9.845996828516945e-06
in O 0 2.329224173536204e-07
exon O 0 1.277027877222281e-05
17 O 0 5.857432370248716e-07
( O 0 1.3367704809752468e-07
codon O 0 5.099441864331311e-07
556 O 0 1.8241623820358654e-06
) O 0 2.7051076045836453e-08
of O 0 1.2159455664573215e-08
the O 0 7.104877681740618e-07
RB1 O 0 0.20140428841114044
gene O 0 4.923105279885931e-06
was O 0 6.639327239099657e-07
found O 0 8.906408055509019e-08
to O 0 1.3843693302817428e-08
be O 0 7.463071050040071e-09
present O 0 1.3202418358559953e-07
homozygously O 0 1.536289528303314e-05
in O 0 4.071294057439445e-08
both O 0 6.356981430144515e-08
the O 0 8.497061685375229e-07
retinal B-Disease 0 0.27349573373794556
and I-Disease 0 2.47651632889756e-06
the I-Disease 0 4.799020098289475e-05
pineal I-Disease 1 0.9706301689147949
tumours I-Disease 1 0.9960158467292786
. O 0 0.00014542996359523386

The O 0 9.838664709604927e-07
same O 0 6.409504749171901e-07
mutation O 0 6.249274974834407e-06
was O 0 6.483078891506011e-07
present O 0 3.4679200666687393e-07
heterozygously O 0 2.0987459720345214e-05
in O 0 1.628530732489253e-08
the O 0 1.536085214581817e-08
DNA O 0 2.133786978220087e-07
from O 0 1.8838395732245772e-08
the O 0 2.010269106733631e-08
constitutional O 0 1.8506743515445123e-07
cells O 0 5.327834173840529e-07
of O 0 1.535279636755149e-08
the O 0 5.658072836922656e-07
patient O 0 0.00024284077517222613
, O 0 1.1719450299096934e-07
proving O 0 2.8749843750119908e-06
it O 0 1.605780042268634e-08
to O 0 4.74414241224963e-09
be O 0 6.938312591131535e-09
of O 0 6.367235272364269e-08
germline O 0 0.0003204855020157993
origin O 0 5.716586201742757e-06
. O 0 1.6574045730521902e-05

The O 0 3.6325404835224617e-06
initial O 0 3.209384885849431e-05
mutation O 0 2.854011472663842e-05
was O 0 1.6178023543034215e-06
shown O 0 2.7035042649004026e-07
to O 0 1.7813157171531202e-08
have O 0 1.5215258386547248e-08
occurred O 0 5.526476911654754e-07
in O 0 7.191501794068245e-08
the O 0 4.783935310115339e-07
paternally O 0 0.0007628828752785921
derived O 0 6.787166785215959e-05
RB1 O 1 0.9586130380630493
allele O 0 0.00028180022491142154
. O 0 3.497085708659142e-05

The O 0 4.170969987171702e-06
mutation O 0 1.2414692719175946e-05
is O 0 1.2458431797313096e-07
in O 0 2.793000675183066e-08
an O 0 2.6730925029028185e-08
area O 0 2.425097278546673e-08
of O 0 1.886384159988097e-09
the O 0 1.1967014934555209e-08
gene O 0 8.531132777989114e-08
that O 0 4.533286190877561e-09
encodes O 0 5.258405977315306e-08
the O 0 2.8305141341888884e-08
protein O 0 9.068177178050973e-07
- O 0 1.204590375891712e-06
binding O 0 2.252847082218068e-07
region O 0 1.9080430035955942e-07
known O 0 1.6668393243435276e-07
as O 0 3.426686845386939e-08
the O 0 1.5491319516058866e-07
pocket O 0 9.644632518757135e-05
region O 0 2.4686212896085635e-07
and O 0 3.103794199432741e-08
has O 0 8.148666097440582e-08
been O 0 1.120423505085455e-07
detected O 0 3.450933490967145e-06
in O 0 3.27105240671699e-08
other O 0 2.081631578221277e-08
cases O 0 6.918717190274037e-07
of O 0 6.979713589316816e-07
retinoblastoma B-Disease 1 0.8842467069625854
. O 0 1.1201430424989667e-05
. O 0 2.0333007341832854e-05

Low O 0 6.81075980537571e-05
levels O 0 5.463911747938255e-06
of O 0 1.703872953839891e-07
beta O 0 2.729313200688921e-05
hexosaminidase O 0 0.00023242871975526214
A O 0 1.7181126850118744e-06
in O 0 4.092674430467014e-07
healthy O 0 3.3965654438361526e-05
individuals O 0 6.908721275067364e-07
with O 0 6.7869300437450875e-06
apparent O 0 0.4810720384120941
deficiency O 1 0.9994527697563171
of O 0 4.091827747743082e-07
this O 0 1.793608248590317e-06
enzyme O 0 0.00041501002851873636
. O 0 3.0398387025343254e-05

Appreciable O 0 0.0016346205957233906
beta O 0 0.00032043480314314365
hexosaminidase O 0 0.0005811536684632301
A O 0 6.402005055861082e-06
( O 0 1.396677475895558e-06
hex O 0 8.141027137753554e-06
A O 0 1.2674662457357044e-06
) O 0 2.938221825843357e-07
activity O 0 5.130445970280562e-07
has O 0 4.41662649564023e-07
been O 0 7.142303957152762e-07
detected O 0 2.6152431018999778e-05
in O 0 2.456878519296879e-06
cultured O 0 0.0030848428141325712
skin O 1 0.9955702424049377
fibroblasts O 0 0.046179067343473434
and O 0 0.00030774922925047576
melanoma B-Disease 1 0.9996774196624756
tissue O 0 0.31611520051956177
from O 0 9.44316889217589e-06
healthy O 0 0.00019099353812634945
individuals O 0 6.15539022419398e-07
previously O 0 6.146705800347263e-06
reported O 0 2.1401023332145996e-05
as O 0 1.0942409289782518e-06
having O 0 6.50909569230862e-05
deficiency B-Disease 1 0.9990930557250977
of I-Disease 0 7.483786390594105e-08
hex I-Disease 0 1.946018892340362e-05
A I-Disease 0 1.034113211062504e-06
activity O 0 2.570958201886242e-07
indistinguishable O 0 1.3351032066566404e-06
from O 0 6.63527686128873e-08
that O 0 6.547736575157614e-08
of O 0 3.9855945033195894e-07
patients O 0 0.34119072556495667
with O 0 0.0013923196820542216
Tay B-Disease 1 0.999423623085022
- I-Disease 1 0.9952160120010376
Sachs I-Disease 1 0.998775064945221
disease I-Disease 1 0.9987906813621521
( O 0 0.0002339644415769726
TSD B-Disease 1 0.9844735860824585
) O 0 3.0912317015463486e-05
. O 0 4.971553062205203e-05

Identification O 0 7.349559837166453e-06
and O 0 3.385344200523832e-07
quantitation O 0 5.983791561448015e-05
of O 0 3.8960314441283117e-07
hex O 0 5.231573959463276e-05
A O 0 2.571036702647689e-06
, O 0 1.6468703734062728e-07
amounting O 0 1.8675204955798108e-06
to O 0 1.9994975275494653e-07
3 O 0 4.411875124787912e-06
. O 0 7.110292244760785e-06

5 O 0 3.73098228010349e-05
% O 0 2.79358519037487e-05
- O 0 0.00022466278460342437
6 O 0 3.215686228941195e-05
. O 0 2.0907173166051507e-05

9 O 0 5.029136445955373e-06
% O 0 1.9362909142728313e-07
of O 0 2.6523510499032454e-08
total O 0 3.759121511848207e-07
beta O 0 1.7321564882877283e-05
hexosaminidase O 0 0.0001880444906419143
activity O 0 7.976314009283669e-07
, O 0 5.560247728908507e-08
has O 0 5.209867381950062e-08
been O 0 3.052068819897613e-08
obtained O 0 1.366142186043362e-07
by O 0 4.796397661266383e-07
cellulose O 0 0.0007479495252482593
acetate O 0 0.0008424097904935479
gel O 0 0.0011639533331617713
electrophoresis O 0 0.0002028633316513151
, O 0 2.2211042960407212e-06
DEAE O 0 0.001053109299391508
- O 0 2.9828759579686448e-05
cellulose O 0 0.0001405520597472787
ion O 0 4.278919368516654e-05
- O 0 9.018492164614145e-06
exchange O 0 1.5076471981956274e-06
chromatography O 0 0.00016022038471419364
, O 0 2.0016163944092114e-06
radial O 0 0.0009393512737005949
immunodiffusion O 0 0.0018551737302914262
, O 0 1.4998229289631126e-06
and O 0 2.2794777123635868e-06
radioimmunoassay O 0 0.004144080448895693
. O 0 5.2351570047903806e-05

Previous O 0 2.9848564736312255e-05
family O 0 1.909141064970754e-05
studies O 0 3.2436958008474903e-06
suggested O 0 2.5637891667429358e-06
that O 0 5.081944465246124e-08
these O 0 2.1846126685431955e-08
individuals O 0 2.1771943181647657e-07
may O 0 8.001517244338174e-07
be O 0 5.545832593156774e-08
compound O 0 6.014887730998453e-06
heterozygotes O 0 2.034489625657443e-05
for O 0 2.8406875074438176e-08
the O 0 1.610833066933992e-07
common O 0 2.4451769604638685e-06
mutant O 0 0.00012482321471907198
TSD B-Disease 0 0.11654650419950485
gene O 0 2.527900960558327e-06
and O 0 1.503461817264906e-07
a O 0 9.793234312382992e-07
rare O 0 1.3996555026096758e-05
( O 0 1.364306740470056e-06
allelic O 0 0.00011166799231432378
) O 0 2.5476206246821675e-06
mutant O 0 6.535130523843691e-05
gene O 0 5.288591637508944e-05
. O 0 1.5793491911608726e-05

Thus O 0 3.342801846883958e-06
, O 0 3.563517338989186e-07
the O 0 2.3307663354898978e-07
postulated O 0 1.4202560123521835e-05
rate O 0 3.916904915968189e-06
mutant O 0 1.1670932508422993e-05
gene O 0 1.9786909888352966e-06
appears O 0 6.380802801686514e-07
to O 0 6.094388993460598e-09
code O 0 1.2972715346393215e-08
for O 0 1.6826368076650056e-09
the O 0 3.332018216894994e-09
expression O 0 2.3862659404016995e-08
of O 0 8.881603008603633e-09
low O 0 7.578474310321326e-07
amounts O 0 4.863583171754726e-07
of O 0 1.1582041992141967e-07
hex O 0 8.007868018466979e-05
A O 0 2.2935335437068716e-05
. O 0 1.3516266335500404e-05

Heterozygotes O 0 0.0006034772959537804
for O 0 2.2985655050433706e-06
the O 0 1.916747578434297e-06
rare O 0 0.00011550832277862355
mutant O 0 0.0002487826277501881
may O 0 3.095900638072635e-06
be O 0 4.731213820718949e-08
indistinguishable O 0 2.7332912395650055e-06
from O 0 3.3942410482268315e-07
heterozygotes O 0 4.054834062117152e-05
for O 0 1.2099874879822892e-07
the O 0 1.3104890967952088e-06
common O 0 4.8504451115150005e-05
TSD B-Disease 1 0.9842560887336731
mutant O 0 0.0013850219547748566
. O 0 3.711974204634316e-05

However O 0 5.248944034974556e-06
, O 0 5.213605049902981e-07
direct O 0 4.6698366418240767e-07
visualization O 0 9.122352821577806e-06
and O 0 2.1747644041170133e-07
quantitation O 0 3.7783065636176616e-05
of O 0 1.0508253467378381e-07
hex O 0 1.9314682504045777e-05
A O 0 6.74384295962227e-07
by O 0 6.388304996107763e-08
the O 0 1.8731842033048451e-07
methods O 0 9.68725657912728e-07
described O 0 2.318128645129036e-05
may O 0 9.216558282787446e-06
prevent O 0 3.587244646041654e-05
false O 0 2.1896012185607105e-05
- O 0 5.974600207991898e-05
positive O 0 1.075445379683515e-05
prenatal O 0 0.009997813031077385
diagnosis O 0 0.04754211753606796
of O 0 2.8977929105167277e-06
TSD B-Disease 1 0.9899144172668457
in O 0 3.3243595680687577e-06
fetuses O 0 0.00015472545055672526
having O 0 7.074216341607098e-07
the O 0 3.1462568017559533e-07
incomplete O 0 2.5902880224748515e-05
hex B-Disease 0 0.00031849651713855565
A I-Disease 0 0.0003064326592721045
deficiency I-Disease 1 0.9988991022109985
of O 0 9.940118417262056e-08
the O 0 6.012737685523462e-07
type O 0 4.562206595437601e-05
described O 0 2.6502530090510845e-06
in O 0 7.16106072218281e-08
the O 0 1.912240179535729e-07
four O 0 1.2316637594267377e-06
healthy O 0 0.0001925191463669762
individuals O 0 3.0182578484527767e-05

The O 0 0.00016833224799484015
tumor B-Disease 1 0.9138075709342957
suppressor O 0 0.0025713692884892225
gene O 0 9.64114660746418e-05
Smad4 O 0 0.014614989049732685
/ O 0 0.0008065396687015891
Dpc4 O 0 0.00016288962797261775
is O 0 1.5048962609398586e-07
required O 0 3.484362878225511e-07
for O 0 1.089177317226131e-07
gastrulation O 0 0.000412242254242301
and O 0 7.488912245889878e-08
later O 0 2.2449459891049628e-07
for O 0 7.352430486662342e-08
anterior O 0 0.00039536936674267054
development O 0 4.086987530627084e-07
of O 0 1.048971043360325e-07
the O 0 2.307007434865227e-06
mouse O 0 0.0003286468854639679
embryo O 0 0.0002760841744020581
. O 0 2.5389290385646746e-05

Mutations O 0 6.663126987405121e-05
in O 0 1.8607703395900899e-06
the O 0 1.2653693374886643e-05
SMAD4 O 1 0.6060915589332581
/ O 0 0.02141059748828411
DPC4 O 0 0.3129061758518219
tumor B-Disease 1 0.804222583770752
suppressor O 0 0.00015217078907880932
gene O 0 1.5324235391744878e-06
, O 0 4.578090440077176e-08
a O 0 1.0674671813148962e-07
key O 0 1.5311218248825753e-07
signal O 0 7.516445066357846e-07
transducer O 0 9.483491339778993e-06
in O 0 1.2577643815347983e-07
most O 0 5.873699251424114e-07
TGFbeta O 0 0.00178415363188833
- O 0 3.256099080317654e-05
related O 0 1.3650264918396715e-06
pathways O 0 4.469635769055458e-06
, O 0 2.0405012790547516e-08
are O 0 1.6263881352784892e-09
involved O 0 3.016770122599155e-08
in O 0 3.167402695680721e-08
50 O 0 2.05471792469325e-07
% O 0 8.690677191225404e-07
of O 0 6.68758048050222e-06
pancreatic B-Disease 1 0.9993672966957092
cancers I-Disease 1 0.9981391429901123
. O 0 0.0001470641727792099

Homozygous O 0 0.004586181603372097
Smad4 O 0 0.1320677399635315
mutant O 0 0.023702414706349373
mice O 0 0.09350107610225677
die O 0 0.003471993375569582
before O 0 3.7600711948471144e-06
day O 0 3.4892484563897597e-06
7 O 0 9.010514077090193e-06
. O 0 7.001860922173364e-06

5 O 0 3.1687752198195085e-05
of O 0 9.268323992728256e-06
embryogenesis O 0 0.008633543737232685
. O 0 0.0002858908264897764

Mutant O 0 0.00018223414372187108
embryos O 0 1.5384361176984385e-05
have O 0 3.6330942521090037e-07
reduced O 0 6.196800768520916e-06
size O 0 1.6474546100653242e-06
, O 0 1.4736680498117494e-07
fail O 0 3.2589916827419074e-06
to O 0 6.846646982694438e-08
gastrulate O 0 4.679495032178238e-05
or O 0 2.5149853399852873e-07
express O 0 1.0440023743285565e-06
a O 0 1.2224193142174045e-06
mesodermal O 0 0.0005023680860176682
marker O 0 2.2786889530834742e-05
, O 0 2.958424261123582e-07
and O 0 2.3554984807105939e-07
show O 0 5.7382212617085315e-06
abnormal O 0 0.0016269120387732983
visceral O 0 0.003985293675214052
endoderm O 0 0.1861240714788437
development O 0 0.0001327733916696161
. O 0 5.601403972832486e-05

Growth B-Disease 1 0.6668570637702942
retardation I-Disease 1 0.9922103881835938
of O 0 2.974571316372021e-06
the O 0 6.558798486366868e-05
Smad4 O 1 0.7568349242210388
- O 0 0.006233787164092064
deficient O 0 0.032803975045681
embryos O 0 7.30019337424892e-06
results O 0 2.4456433038722025e-06
from O 0 1.2517517689047963e-06
reduced O 0 4.000516128144227e-05
cell O 0 0.00013542946544475853
proliferation O 0 9.190716809825972e-05
rather O 0 2.5533313419146e-07
than O 0 2.60287208675436e-07
increased O 0 1.0921705325017683e-05
apoptosis O 0 0.00037052432890050113
. O 0 1.5476949556614272e-05

Aggregation O 0 5.575333852902986e-05
of O 0 3.1946315175446216e-06
mutant O 0 0.0004336720157880336
Smad4 O 0 0.010276629589498043
ES O 0 0.0006297252839431167
cells O 0 6.010231572872726e-06
with O 0 3.860444053316314e-07
wild O 0 1.3635532013722695e-05
- O 0 5.819284706376493e-05
type O 0 5.193239849177189e-05
tetraploid O 0 0.00027612681151367724
morulae O 0 0.0033624540083110332
rescues O 0 0.0011236554710194468
the O 0 4.817861918127164e-05
gastrulation B-Disease 1 0.968010663986206
defect I-Disease 1 0.9814957976341248
. O 0 0.00014832122542429715

These O 0 1.2303725043238956e-06
results O 0 4.6976115299912635e-06
indicate O 0 5.678502475348068e-06
that O 0 3.7111584560989286e-07
Smad4 O 0 9.655729809310287e-05
is O 0 1.0096903224621201e-07
initially O 0 2.5590651375750895e-07
required O 0 2.867798620798112e-08
for O 0 3.756778443886333e-09
the O 0 7.743628849254947e-09
differentiation O 0 1.5960857524532912e-07
of O 0 1.6444339223653515e-08
the O 0 2.553107094627194e-07
visceral O 0 0.00015715998597443104
endoderm O 0 0.001191912218928337
and O 0 1.394397486365051e-07
that O 0 1.0244879433685128e-07
the O 0 1.1256590823904844e-06
gastrulation B-Disease 0 0.10246659070253372
defect I-Disease 0 0.037002235651016235
in O 0 4.4608111693378305e-07
the O 0 1.2281169574634987e-06
epiblast O 0 0.007984594441950321
is O 0 3.259102072661335e-07
secondary O 0 2.0701750145235565e-06
and O 0 3.114263904535619e-07
non O 0 5.961048373137601e-06
- O 0 1.849913678597659e-05
cell O 0 2.1620004190481268e-05
autonomous O 0 3.3418043585697887e-06
. O 0 9.440323083254043e-06

Rescued O 0 0.009515142999589443
embryos O 0 0.0006769458414055407
show O 0 0.0004473299195524305
severe O 1 0.994076132774353
anterior O 1 0.8735063076019287
truncations O 0 0.0046572317369282246
, O 0 2.147596887880354e-06
indicating O 0 5.272122052701889e-06
a O 0 1.3615871807814983e-07
second O 0 8.396691697498682e-08
important O 0 3.5484795546381065e-08
role O 0 2.5575985773684806e-07
for O 0 2.5132757741630485e-07
Smad4 O 0 0.0003485961351543665
in O 0 3.7906784200458787e-06
anterior O 0 0.25082939863204956
patterning O 0 0.009304077364504337
during O 0 0.000257472216617316
embryogenesis O 0 0.025386279448866844
. O 0 0.00010744213795987889

Prevalence O 0 0.0023739889729768038
of O 0 2.4518903956050053e-06
p16 O 0 0.0005935284425504506
and O 0 4.654444637708366e-06
CDK4 O 0 0.013796020299196243
germline O 0 0.003225098131224513
mutations O 0 7.229734910652041e-05
in O 0 7.41590338293463e-06
48 O 0 0.004337555728852749
melanoma B-Disease 1 0.9995096921920776
- O 0 0.00689729256555438
prone O 0 0.0058503905311226845
families O 0 5.184449491935084e-06
in O 0 2.0967474938515807e-06
France O 0 5.34041719220113e-05
. O 0 1.871872882475145e-05

The O 0 0.00017225886404048651
French O 0 0.00785104464739561
Familial B-Disease 1 0.9888507723808289
Melanoma I-Disease 1 0.998507559299469
Study O 0 0.00032520011882297695
Group O 0 0.00010983676475007087
. O 0 8.833534229779616e-05

Germline O 0 0.004184838384389877
mutations O 0 2.3445878468919545e-05
in O 0 3.965560608776286e-07
the O 0 6.271283155001584e-07
p16 O 0 9.050079097505659e-05
and O 0 3.596501017000264e-07
CDK4 O 0 0.000886486261151731
genes O 0 7.867914746384486e-07
have O 0 2.052249747919177e-08
been O 0 4.3828656259847776e-08
reported O 0 2.4513593643860077e-07
in O 0 8.669178264142374e-09
a O 0 1.4590114005841315e-07
subset O 0 1.5264024568750756e-06
of O 0 2.218475174231571e-06
melanoma B-Disease 1 0.9996143579483032
pedigrees O 0 0.00038038031198084354
, O 0 4.2419350165801006e-07
but O 0 1.4321172159270645e-07
their O 0 1.1974690039551206e-07
prevalence O 0 0.0013487820979207754
is O 0 1.4418964155993308e-07
not O 0 1.0526748894790217e-07
well O 0 4.0279093127537635e-07
known O 0 5.674003659805749e-06
. O 0 9.922982826537918e-06

We O 0 1.3099031548335915e-06
searched O 0 3.1809875054022996e-06
for O 0 1.1069288063936256e-07
such O 0 3.018917595909443e-07
germline O 0 0.0003163702494930476
mutations O 0 8.314396836794913e-06
in O 0 9.069639190784073e-07
48 O 0 4.481613723328337e-05
French O 0 0.00834742933511734
melanoma B-Disease 1 0.9997984766960144
- O 0 0.00140088377520442
prone O 0 0.0003022463642992079
families O 0 1.880935371900705e-07
selected O 0 2.5377309142982085e-08
according O 0 3.888376909344515e-08
to O 0 5.527623692103134e-09
two O 0 8.011808994012881e-09
major O 0 2.836324881627661e-07
criteria O 0 1.5614368464866857e-07
families O 0 5.7825921828680293e-08
with O 0 2.1621737289478915e-08
at O 0 1.2551114991765644e-07
least O 0 2.5409857329350416e-08
three O 0 2.2882669981072468e-08
affected O 0 4.049926189964026e-07
members O 0 2.078041561048849e-08
( O 0 7.626283604622586e-08
n O 0 5.623225547424227e-07
= O 0 9.269978704651294e-07
20 O 0 7.279021474460023e-08
) O 0 2.509639429604249e-08
or O 0 2.0517722632007462e-08
families O 0 3.065879283781214e-08
with O 0 9.344270246458564e-09
two O 0 1.3611218818709858e-08
affected O 0 2.1379258896558895e-07
members O 0 1.2251388348261116e-08
, O 0 4.738969217044087e-09
one O 0 1.751675582362111e-09
of O 0 2.9848428173551156e-09
them O 0 6.8054246682436315e-09
affected O 0 1.2673693561282562e-07
before O 0 2.2553058087737554e-08
the O 0 8.102555071332063e-09
age O 0 6.91639527872212e-08
of O 0 3.68108166171055e-09
50 O 0 4.496586214486342e-08
( O 0 6.863317736360841e-08
n O 0 3.9936224993653013e-07
= O 0 7.388862286461517e-07
28 O 0 1.7424700615720212e-07
) O 0 3.4832126516448625e-08
, O 0 9.279973234299632e-09
and O 0 7.1243011490196295e-09
one O 0 2.269307763924644e-08
additional O 0 6.327018695628794e-07
minor O 0 0.0001480955397710204
criterion O 0 0.0005237559671513736
. O 0 3.0470888304989785e-05

Sixteen O 0 1.5812329365871847e-05
different O 0 1.3397612974586082e-06
p16 O 0 0.0013072335859760642
germline O 0 0.0031664154957979918
mutations O 0 1.2150621842010878e-05
were O 0 1.2941900706664455e-07
found O 0 3.231501182199281e-07
in O 0 5.228073618468443e-08
21 O 0 3.1646192155676545e-07
families O 0 4.947141363231822e-08
, O 0 2.0865131844516327e-08
while O 0 4.579461432285825e-08
one O 0 2.492366775186383e-07
germline O 0 0.00023229513317346573
mutation O 0 1.5161733244895004e-05
, O 0 3.9423329667442886e-07
Arg24His O 0 0.00010381203173892573
, O 0 2.4157677103175956e-07
was O 0 1.15220154839335e-06
detected O 0 2.9475440896931104e-06
in O 0 9.673458833958648e-08
the O 0 1.0700136954255868e-06
CDK4 O 0 0.004160510841757059
gene O 0 6.229102291399613e-05
. O 0 2.096933349093888e-05

The O 0 5.973586212348891e-07
frequency O 0 2.9236369414320507e-07
of O 0 9.249741594885563e-08
p16 O 0 4.5310502173379064e-05
gene O 0 1.7541658507980173e-06
mutation O 0 1.2816207117793965e-06
in O 0 1.2801784521343507e-08
our O 0 1.0075987155744315e-08
sample O 0 3.879946319784722e-08
( O 0 6.663228901970797e-08
44 O 0 1.2493374867972307e-07
% O 0 5.311123274509555e-08
) O 0 3.048269903160872e-08
is O 0 7.174318916725042e-09
among O 0 7.983619099150019e-09
the O 0 3.3700235491096464e-08
highest O 0 1.1686476000249968e-06
rates O 0 9.279142432205845e-07
yet O 0 2.4122545028149034e-07
reported O 0 5.260071702650748e-07
and O 0 1.50455701231067e-08
the O 0 5.916798784255661e-08
CDK4 O 0 8.868840814102441e-05
mutation O 0 4.0242309751192806e-07
is O 0 1.1422708112718283e-08
the O 0 1.5934933372818705e-08
second O 0 2.9739794626948424e-07
mutation O 0 7.682646355533507e-06
detected O 0 4.110513600608101e-06
in O 0 6.30648884225593e-08
this O 0 1.7196259705087868e-07
gene O 0 1.6217943993979134e-05
worldwide O 0 1.4343288967211265e-05
. O 0 1.420544595021056e-05

In O 0 3.917278263543267e-06
summary O 0 3.580181783036096e-06
, O 0 2.8410190111571865e-07
our O 0 6.786709150219394e-08
results O 0 3.74684844928197e-07
show O 0 2.886672234581056e-07
frequent O 0 5.470974429044873e-07
involvement O 0 4.791642709278676e-07
of O 0 2.1739177569202184e-08
the O 0 4.7512537548755063e-07
p16 O 0 0.00015621424245182425
gene O 0 1.557859286549501e-05
in O 0 6.218509042810183e-06
familial B-Disease 1 0.9970454573631287
melanoma I-Disease 1 0.9995455145835876
and O 0 3.927101772660535e-07
confirm O 0 1.157250835603918e-06
the O 0 2.4565913747665036e-08
role O 0 4.990252477909962e-08
of O 0 1.841601182661634e-08
the O 0 2.7393352297622187e-07
CDK4 O 0 0.0003163702494930476
gene O 0 2.2338670078170253e-06
as O 0 7.297704769371194e-07
a O 0 7.997505599632859e-05
melanoma B-Disease 1 0.9994741082191467
- O 0 0.00038199624395929277
predisposing O 0 0.0002404399128863588
gene O 0 1.9477029127301648e-05
. O 0 2.6605903258314356e-06
. O 0 1.0607015610730741e-05

Progression O 0 0.00045514298835769296
of O 0 2.033296368608717e-06
somatic O 0 0.00021348902373574674
CTG O 0 0.01838732697069645
repeat O 0 0.0001372284459648654
length O 0 1.462196814827621e-05
heterogeneity O 0 3.817789183813147e-05
in O 0 1.2616415006050374e-06
the O 0 7.897150680946652e-06
blood O 0 0.17529989778995514
cells O 0 0.001525392639450729
of O 0 0.000512261816766113
myotonic B-Disease 1 0.9997754693031311
dystrophy I-Disease 1 0.999902606010437
patients O 1 0.996235191822052
. O 0 0.0006311230827122927

The O 0 7.627644663443789e-06
genetic O 0 4.931186413159594e-05
basis O 0 4.650202754419297e-06
of O 0 0.0001301217416767031
myotonic B-Disease 1 0.9996095299720764
dystrophy I-Disease 1 0.99983811378479
( O 0 0.013181095011532307
DM B-Disease 1 0.9986028075218201
) O 0 8.909421467251377e-07
is O 0 3.913615387318714e-08
the O 0 1.871273269671292e-08
expansion O 0 1.9843761833726603e-07
of O 0 3.8905803023681074e-08
an O 0 1.240498932020273e-06
unstable O 0 0.00228845770470798
CTG O 0 0.001515972544439137
repeat O 0 6.2378248912864365e-06
in O 0 3.6241516454538214e-08
the O 0 6.519423578765782e-08
34 O 0 3.74153529492105e-07
UTR O 0 9.494386176811531e-06
of O 0 4.91497544885533e-08
the O 0 1.2458413038984872e-06
DM B-Disease 1 0.6621041297912598
protein O 0 5.644089014822384e-06
kinase O 0 1.2900690308015328e-05
gene O 0 2.9412399271677714e-06
on O 0 8.415271963713167e-07
chromosome O 0 4.510055805440061e-05
19 O 0 1.8679604181670584e-05
. O 0 1.1090490261267405e-05

One O 0 1.1788085174657681e-07
of O 0 3.046008956175683e-08
the O 0 9.03500563254056e-08
principal O 0 2.0605577333299152e-07
features O 0 9.638907272346842e-08
of O 0 5.562347737964046e-08
the O 0 3.2766965887276456e-06
DM B-Disease 1 0.9978729486465454
mutation O 0 1.2168698958703317e-05
is O 0 7.111569289008912e-08
an O 0 1.6259274104868382e-07
extraordinarily O 0 1.4005034245201387e-05
high O 0 8.228803949350549e-07
level O 0 2.6382645046396647e-07
of O 0 9.618960916668584e-08
somatic O 0 0.0001384952774969861
mosaicism O 0 0.04745640605688095
, O 0 4.628857936950226e-07
due O 0 1.628737777537026e-06
to O 0 2.0636132802565044e-08
an O 0 7.843090088499594e-08
extremely O 0 1.967346861420083e-06
high O 0 1.0382773325545713e-06
degree O 0 4.6930074404372135e-07
of O 0 8.38566478478242e-08
somatic O 0 3.8828144170111045e-05
instability O 0 1.0534704415476881e-05
both O 0 2.5719433693893734e-08
within O 0 6.331437418793939e-08
and O 0 5.438079142550123e-08
between O 0 4.914281817036681e-07
different O 0 4.2991268855985254e-07
tissues O 0 0.0017656241543591022
. O 0 3.0943279853090644e-05

This O 0 1.5111194443306886e-05
instability O 0 0.000506119686178863
appears O 0 1.3159659829398151e-05
to O 0 6.510092021017044e-08
be O 0 1.9482969904061065e-08
biased O 0 2.376328751552137e-07
towards O 0 3.804966652865005e-08
further O 0 2.623711203852963e-08
expansion O 0 9.290408797824057e-08
and O 0 7.776309374207813e-09
continuous O 0 1.35968747372317e-07
throughout O 0 2.035871382588539e-08
the O 0 1.0120402293978259e-08
life O 0 3.504163359480117e-08
of O 0 3.235187229222447e-09
an O 0 2.0811672385434576e-08
individual O 0 1.791691417452057e-08
, O 0 1.933175752810712e-08
features O 0 1.0155540763889803e-07
that O 0 2.425383982540552e-08
could O 0 4.6493596528307535e-08
be O 0 8.738887835590958e-09
associated O 0 9.560011449138983e-08
with O 0 2.6472767089558147e-08
the O 0 1.324061145169253e-07
progressive O 0 1.7333693904220127e-05
nature O 0 2.2323913526633987e-06
of O 0 1.1188234338987968e-06
the O 0 0.000420401047449559
disease O 1 0.9980736970901489
. O 0 0.00014296661538537592

Although O 0 9.375143235956784e-06
increasing O 0 3.121631152680493e-06
measured O 0 3.942200237361249e-06
allele O 0 2.3379365302389488e-05
size O 0 7.5793582254846115e-06
between O 0 5.975448857498122e-06
patients O 0 0.0035192316863685846
clearly O 0 1.8738896869763266e-06
correlates O 0 3.5908640256820945e-06
with O 0 1.1321126436314444e-07
an O 0 3.8491106124638463e-07
increased O 0 1.3791905075777322e-05
severity O 0 0.031113071367144585
of O 0 2.3207439880934544e-06
symptoms O 1 0.9773876070976257
and O 0 5.876612974020645e-08
an O 0 6.879661640368795e-08
earlier O 0 6.037928983460006e-07
age O 0 1.274417513741355e-06
of O 0 1.1359844620528747e-07
onset O 1 0.9320634007453918
, O 0 6.891783499440862e-08
this O 0 1.4270096215796002e-08
correlation O 0 1.7155539921986929e-07
is O 0 1.5238843076303965e-08
not O 0 2.848167701685611e-09
precise O 0 1.59029003299338e-08
and O 0 1.222969814307362e-08
measured O 0 3.1975346814760996e-07
allele O 0 1.4622169146605302e-06
length O 0 7.941354169815895e-07
cannot O 0 1.2017477502013207e-07
be O 0 2.712696289819405e-09
used O 0 5.739536845794646e-09
as O 0 4.055442648365215e-09
an O 0 1.082318057399334e-08
accurate O 0 1.3580222457676427e-07
predictor O 0 3.899182502209442e-06
of O 0 1.0013437901079669e-07
age O 0 1.639120455365628e-05
of O 0 3.743491106433794e-06
onset O 1 0.996061384677887
. O 0 0.00010718242992879823

In O 0 5.571409360527468e-07
order O 0 2.512206833671371e-07
to O 0 5.755907395155191e-08
further O 0 2.613981564536516e-07
characterize O 0 9.005642823467497e-06
the O 0 1.1433080544520635e-06
dynamics O 0 8.228542719734833e-05
of O 0 9.683621101430617e-06
DM B-Disease 1 0.9973118305206299
CTG O 0 0.4781634211540222
repeat O 0 0.0016282473225146532
somatic O 0 0.00037455130950547755
instability O 0 0.00027114892145618796
, O 0 2.5360333211210673e-07
we O 0 3.851059560133763e-08
have O 0 1.2951231198599089e-08
studied O 0 1.2756574108152563e-07
repeat O 0 2.2219687707547564e-06
length O 0 4.080444853116205e-07
changes O 0 1.6673942582201562e-07
over O 0 1.2449999076125096e-07
time O 0 4.0355533315050707e-07
in O 0 7.772176104481332e-06
111 O 0 0.172323539853096
myotonic B-Disease 1 0.9997625946998596
dystrophy I-Disease 1 0.9998862743377686
patients O 1 0.9355860948562622
with O 0 6.966082310100319e-06
varying O 0 0.00020963688439223915
clinical O 0 0.09531909227371216
severity O 0 0.42201969027519226
and O 0 3.4322449664614396e-06
CTG O 0 0.010841046459972858
repeat O 0 1.5063455975905526e-05
size O 0 3.035859208466718e-07
over O 0 1.8671874713049874e-08
time O 0 1.192338405786586e-08
intervals O 0 7.468556617595823e-08
of O 0 3.201677856168317e-08
1 O 0 1.6441820207546698e-06
- O 0 5.09711117047118e-06
7 O 0 1.3621396419694065e-06
years O 0 1.9763733689615037e-06
. O 0 3.705097014972125e-06

We O 0 1.0754470167739782e-06
have O 0 1.0385749504848718e-07
found O 0 1.5202820691229135e-07
a O 0 7.984093741697507e-08
direct O 0 1.0189184251885308e-07
progression O 0 6.058889084670227e-06
of O 0 1.512310632278968e-08
the O 0 7.543575719637374e-08
size O 0 6.363932811837003e-07
heterogeneity O 0 3.019665655301651e-06
over O 0 7.009037261695994e-08
time O 0 4.689079702302479e-08
related O 0 2.8164376431050187e-07
to O 0 8.411262797380914e-08
initial O 0 6.074064003769308e-06
CTG O 0 0.001792929950170219
repeat O 0 1.2884694115200546e-05
size O 0 4.928173780172074e-07
and O 0 1.6507062383652737e-08
the O 0 1.5996448610167135e-08
time O 0 2.323654690883359e-08
interval O 0 2.809259456171276e-07
and O 0 2.028231982365014e-08
always O 0 4.5080419397436344e-08
biased O 0 3.319884740449197e-07
towards O 0 1.9598329004111292e-07
further O 0 8.315121249324875e-07
expansion O 0 1.954568870132789e-05
. O 0 8.357699698535725e-06

Attempts O 0 3.41454961017007e-06
to O 0 2.4069188953035336e-07
mathematically O 0 1.9046918851017836e-06
model O 0 9.870307167147985e-07
the O 0 2.7085519604952424e-07
dynamics O 0 2.1747906430391595e-05
have O 0 1.2754628642142052e-07
proved O 0 2.0160171061434085e-06
only O 0 8.169301679572527e-08
partially O 0 1.5793793863849714e-05
successful O 0 6.655835136371024e-07
suggesting O 0 1.3779304026684258e-06
that O 0 3.397751058287213e-08
individual O 0 3.982797380785996e-08
specific O 0 1.967315768069966e-07
genetic O 0 2.5096756871789694e-05
and O 0 7.135876103347982e-07
/ O 0 0.00021886240574531257
or O 0 5.302322847455798e-07
environmental O 0 2.443440735078184e-06
factors O 0 1.2454344755497004e-07
also O 0 2.226621376166804e-08
play O 0 2.0917211074333864e-08
a O 0 2.228618853905573e-07
role O 0 6.190434760355856e-07
in O 0 1.3436446124615031e-06
somatic O 0 0.00036436767550185323
mosaicism O 0 0.3483513295650482
. O 0 7.20433581591351e-06
. O 0 3.2687396014807746e-05

Aspartylglucosaminuria B-Disease 0 0.29305657744407654
among O 0 1.5221551620925311e-05
Palestinian O 0 6.487815699074417e-05
Arabs O 0 6.573344580829144e-05
. O 0 3.976966763730161e-05

Aspartylglucosaminuria B-Disease 1 0.9425249695777893
( O 0 0.0008688722155056894
AGU B-Disease 1 0.9908677339553833
) O 0 4.110423560632626e-06
is O 0 1.4729446320416173e-06
a O 0 1.4679673768114299e-05
rare O 0 0.002451906679198146
disorder B-Disease 1 0.9968611001968384
of I-Disease 0 3.376275799382711e-06
glycoprotein I-Disease 1 0.9448981285095215
metabolism I-Disease 0 0.1982879340648651
caused O 0 0.004901255015283823
by O 0 2.7494427286001155e-06
the O 0 1.2307349606999196e-05
deficiency B-Disease 1 0.9986546039581299
of I-Disease 0 2.954896842766175e-07
the I-Disease 0 4.8245519792544656e-06
lysosomal I-Disease 1 0.8299123644828796
enzyme I-Disease 0 0.0006280637462623417
aspartylglucosaminidase I-Disease 0 0.005654199980199337
( O 0 2.3227314159157686e-05
AGA O 0 0.010773533955216408
) O 0 6.443091933761025e-06
. O 0 1.5697900380473584e-05

AGU B-Disease 1 0.989657461643219
is O 0 6.676871271338314e-05
inherited O 0 0.02970568835735321
as O 0 1.8095799987349892e-06
an O 0 9.761190085555427e-06
autosomal O 1 0.9953073859214783
recessive O 1 0.9951828122138977
trait O 0 0.0025746659375727177
and O 0 3.6741604958479e-07
occurs O 0 1.1798875902968575e-06
with O 0 3.794096059550611e-08
a O 0 1.4622054322899203e-07
high O 0 2.6434074129610963e-07
frequency O 0 7.228025111771785e-08
in O 0 2.7951964298722487e-08
Finland O 0 2.932108316144877e-07
because O 0 5.8224014054530926e-08
of O 0 3.1311042647530485e-08
a O 0 2.6415932552481536e-06
founder O 0 6.224453682079911e-05
effect O 0 2.0244255210855044e-05
. O 0 1.761165913194418e-05

While O 0 2.0105844669160433e-05
very O 0 1.626061202841811e-05
few O 0 3.6270241253077984e-05
patients O 0 0.05806536599993706
with O 0 3.457151979091577e-05
AGU B-Disease 1 0.9974823594093323
have O 0 9.613987685952452e-07
been O 0 8.825843451631954e-07
reported O 0 2.712610239541391e-06
from O 0 2.0253970944850153e-07
non O 0 1.356587063128245e-06
- O 0 3.479910674286657e-06
Finnish O 0 4.784524207934737e-06
origin O 0 4.070712407155952e-07
, O 0 1.5634303736078436e-06
we O 0 5.5215054999280255e-06
diagnosed O 1 0.9985972046852112
the O 0 4.319594518165104e-05
disorder O 1 0.998913049697876
in O 0 3.9488490983785596e-06
8 O 0 7.909367559477687e-05
patients O 0 0.0018500826554372907
originating O 0 2.612252046674257e-06
from O 0 4.400095576784224e-07
3 O 0 1.4222672461983166e-06
unrelated O 0 1.1312215974612627e-05
families O 0 2.5920272150870005e-07
, O 0 3.549650884338007e-08
all O 0 5.670289127124306e-09
Palestinian O 0 2.759835524557275e-07
Arabs O 0 1.6824297688344814e-07
from O 0 5.334819874747154e-08
the O 0 4.63998723887471e-08
region O 0 2.647868200256198e-07
of O 0 1.819848023387749e-07
Jerusalem O 0 3.406364703550935e-05
. O 0 1.76705088961171e-05

The O 0 0.00016259323456324637
clinical O 0 0.0527537502348423
diagnosis O 1 0.984858512878418
of O 0 3.6126009945292026e-05
AGU B-Disease 1 0.9991406202316284
is O 0 2.878188524846337e-06
often O 0 6.050956358194526e-07
difficult O 0 7.843835874155047e-07
, O 0 4.180899537686855e-08
in O 0 1.0618802726014565e-08
particular O 0 1.6727081941780853e-08
early O 0 6.690188314451007e-08
in O 0 1.4954389726540285e-08
the O 0 4.682876664219293e-08
course O 0 9.566803100824472e-07
of O 0 1.7341746172405692e-07
the O 0 1.1916347830265295e-05
disease O 1 0.9965141415596008
, O 0 8.286639996413214e-08
and O 0 9.703946091121907e-09
most O 0 1.6352913689843263e-08
of O 0 4.06401667873979e-08
the O 0 5.856711595697561e-06
patients O 0 0.09000463038682938
are O 0 1.2145221717219101e-06
diagnosed O 1 0.9992026686668396
after O 0 1.2181739066363662e-06
the O 0 1.0201415534538683e-07
age O 0 9.665247944212751e-07
of O 0 5.334240071874774e-08
5 O 0 3.4704451081779553e-06
years O 0 5.339805284165777e-06
. O 0 6.468981609941693e-06

However O 0 3.054146873182617e-05
, O 0 2.2292490484687733e-06
since O 0 7.032067969703348e-06
these O 0 9.03949398889381e-07
patients O 0 0.0021474200766533613
excrete O 0 0.00023249388323165476
early O 0 1.4179713616613299e-06
large O 0 6.530437985929893e-07
amounts O 0 4.37565773836468e-07
of O 0 9.354330643418507e-08
aspartylglucosamine O 0 0.0003482189495116472
in O 0 4.989995545656711e-07
urine O 0 1.465281911805505e-05
, O 0 1.8829922510121833e-07
biochemical O 0 1.0064847629109863e-05
screening O 0 2.3291718207474332e-06
is O 0 4.8936573904256875e-08
easy O 0 3.5190464586776216e-07
by O 0 2.692037242013612e-07
urine O 0 6.03306143602822e-05
chromatography O 0 0.0008567356853745878
. O 0 2.3019922537059756e-06
. O 0 7.398441539407941e-06

Detection O 0 4.5270673581399024e-05
of O 0 9.311133908340707e-07
heterozygous O 0 4.008585892734118e-05
carriers O 0 2.1655516320606694e-05
of O 0 1.200949668600515e-06
the O 0 0.00010054549056803808
ataxia B-Disease 1 0.9993284940719604
- I-Disease 0 0.10931967198848724
telangiectasia I-Disease 1 0.9042736887931824
( O 0 2.4213363758462947e-06
ATM O 0 2.3451670131180435e-05
) O 0 3.2217775469689514e-07
gene O 0 1.4052094456928899e-06
by O 0 9.328563805865997e-07
G2 O 0 0.02675122395157814
phase O 0 7.38901217118837e-05
chromosomal O 0 0.001993550918996334
radiosensitivity O 0 0.0022425970528274775
of O 0 9.109739039558917e-06
peripheral O 1 0.9909173846244812
blood O 1 0.9898411631584167
lymphocytes O 1 0.9186340570449829
. O 0 8.50642318255268e-05

In O 0 0.0007367819198407233
ataxia B-Disease 1 0.9973747730255127
- I-Disease 1 0.5374889969825745
telangiectasia I-Disease 1 0.9897622466087341
( O 0 0.00011658469156827778
A B-Disease 0 0.18372848629951477
- I-Disease 1 0.5568402409553528
T I-Disease 1 0.997748076915741
) O 0 5.025842710892903e-06
patients O 0 0.00016748001507949084
, O 0 1.051811935326441e-07
mutations O 0 3.995672273049422e-07
in O 0 1.583824449369331e-08
a O 0 7.722216111005764e-08
single O 0 9.447912674431791e-08
gene O 0 3.142089042285079e-07
, O 0 3.1504598041465215e-08
ATM O 0 7.551559974672273e-06
, O 0 7.25309163840393e-08
result O 0 6.363314355439798e-07
in O 0 9.209750828631513e-07
an O 0 0.00012008082558168098
autosomal B-Disease 1 0.9998055100440979
recessive I-Disease 1 0.9998570680618286
syndrome I-Disease 1 0.9999850988388062
that O 0 3.575844857550692e-06
embraces O 0 2.531398058636114e-05
a O 0 8.314820547639101e-07
variety O 0 3.2821489526213554e-07
of O 0 2.169428228171455e-07
clinical O 0 0.00022038833412807435
features O 0 8.971056558948476e-06
and O 0 2.643841298777261e-06
manifests O 0 0.0023873026948422194
extreme O 0 0.0002118025440722704
radiosensitivity O 0 0.0006937610451132059
and O 0 3.1978336778593075e-07
a O 0 6.107575813985022e-07
strong O 0 4.982024620403536e-06
pre O 0 0.00043421846930868924
- O 0 9.84134676400572e-05
disposition O 0 0.00011613930109888315
to O 0 6.674538326478796e-06
malignancy B-Disease 1 0.9838244915008545
. O 0 5.759615305578336e-05

Heterozygotes O 0 0.00035297407885082066
for O 0 4.136469158311229e-07
the O 0 1.15408420242602e-06
ATM O 0 5.029328531236388e-05
gene O 0 1.9125807284581242e-06
have O 0 4.0507675436174395e-08
no O 0 1.3665253106864839e-07
clinical O 0 2.2210833776625805e-06
expression O 0 1.771200146549745e-07
of O 0 3.419538074922457e-07
A B-Disease 0 0.14276671409606934
- I-Disease 0 0.4684551954269409
T I-Disease 1 0.9974169731140137
but O 0 1.2941706017954857e-06
may O 0 7.376263511105208e-06
be O 0 2.7002495244232705e-06
cancer B-Disease 1 0.9920749664306641
prone O 0 0.00015160349721554667
with O 0 1.327078678059479e-07
a O 0 1.1436679869802902e-06
moderate O 0 1.7461879906477407e-05
increase O 0 1.9935275759053184e-06
in O 0 3.466762734660733e-07
in O 0 1.1154024832649156e-06
vitro O 0 0.00012711380259133875
radiosensitivity O 0 0.004361518658697605
. O 0 3.7279591197147965e-05

We O 0 1.9820756733679445e-06
performed O 0 2.5910360363923246e-06
a O 0 2.6396289740659995e-06
blind O 0 4.795753920916468e-05
chromosomal O 0 3.634998211055063e-05
analysis O 0 1.4597187600884354e-06
on O 0 2.9443945095408708e-06
G2 O 1 0.7326532006263733
- O 0 3.0542865715688094e-05
phase O 0 1.3837120604875963e-05
lymphocytes O 0 0.00012800062540918589
from O 0 3.0143030471663224e-07
7 O 0 3.4816432616935344e-06
unrelated O 0 0.00024578344891779125
A B-Disease 0 0.08731260150671005
- I-Disease 1 0.6065937280654907
T I-Disease 1 0.9984270334243774
patients O 0 0.0003575356677174568
, O 0 1.6878487940630293e-07
13 O 0 1.7396885141351959e-06
obligate O 0 2.9376686143223196e-05
A B-Disease 0 0.003513968549668789
- I-Disease 0 0.011907905340194702
T I-Disease 1 0.988257110118866
heterozygotes O 0 0.00015404094301629812
( O 0 3.106151780229993e-07
parents O 0 1.5445057499618997e-07
of O 0 2.4667144771228777e-08
the O 0 1.2923342183057684e-06
patients O 0 0.00042063614819198847
) O 0 1.1115982090359466e-07
, O 0 1.613113731480098e-08
and O 0 8.274838592114975e-09
14 O 0 6.25337790438607e-08
normal O 0 2.862023791294632e-07
controls O 0 3.6923455581927556e-07
following O 0 4.607040580140165e-07
X O 0 3.663653478724882e-05
- O 0 3.860344804706983e-06
irradiation O 0 3.227699153285357e-06
with O 0 1.3877854598831618e-07
1 O 0 1.1476527106424328e-06
Gy O 0 5.438569496618584e-05
in O 0 1.3094051176665289e-08
order O 0 8.538243001510182e-09
to O 0 3.995136221845996e-09
evaluate O 0 9.674491963096443e-08
this O 0 1.2417100236916667e-08
cytogenetic O 0 7.869447472330648e-06
method O 0 5.166081251672949e-08
as O 0 2.424875233941748e-08
a O 0 8.444344246072433e-08
tool O 0 5.291335583024193e-07
for O 0 1.9099759995810928e-08
detection O 0 2.575336111476645e-06
of O 0 3.503839707263978e-07
ATM O 0 0.001066500786691904
carriers O 0 0.0003459279250819236
. O 0 1.4920613466529176e-05

Both O 0 4.4892185542266816e-05
A B-Disease 0 0.030885916203260422
- I-Disease 0 0.3037054240703583
T I-Disease 1 0.9948150515556335
homozygotes O 0 0.003888253355398774
and O 0 2.5560166250215843e-06
heterozygotes O 0 0.00191551074385643
showed O 0 4.8757250624476e-05
significantly O 0 2.443031371512916e-05
increased O 0 2.5003234895848436e-06
levels O 0 7.513895525335101e-06
of O 0 1.7233443259101477e-06
radiation O 1 0.7242248058319092
- O 0 0.0014835295733064413
induced O 0 0.0736505463719368
chromatid O 0 0.46465784311294556
damage O 0 0.0042930953204631805
relative O 0 2.837105739672552e-06
to O 0 5.588412221868566e-08
that O 0 3.699807038515246e-08
of O 0 5.984477269294075e-08
normal O 0 9.907323146762792e-06
controls O 0 2.6950712708639912e-05
. O 0 1.38935683935415e-05

These O 0 4.5072596321915626e-07
results O 0 1.1584168078115908e-06
show O 0 4.088781224709237e-07
that O 0 6.742337887999383e-08
the O 0 3.5227733974352304e-07
G2 O 0 0.030245551839470863
- O 0 6.432568625314161e-06
phase O 0 3.531469246809138e-06
chromosomal O 0 6.730062887072563e-05
radiosensitivity O 0 7.504905079258606e-05
assay O 0 1.4778227068745764e-06
can O 0 1.2637878299415206e-08
be O 0 1.4865143560527372e-09
used O 0 1.7972352495121413e-09
for O 0 2.3469357568473015e-09
the O 0 2.288319400634009e-08
detection O 0 1.313091161136981e-06
of O 0 2.0679203771578614e-07
A B-Disease 0 0.01971067301928997
- I-Disease 0 0.06625574082136154
T I-Disease 1 0.9921985268592834
heterozygotes O 0 0.0034142141230404377
. O 0 2.1507785277208313e-05

In O 0 1.8984209191330592e-06
combination O 0 1.2561906260089017e-05
with O 0 4.393370147681708e-07
molecular O 0 1.4277031368692406e-05
genetic O 0 1.4534244655806106e-05
analyses O 0 1.795775119717291e-06
, O 0 8.67799982984252e-08
this O 0 3.720981212040897e-08
test O 0 2.951370845494239e-07
may O 0 3.551187788275456e-08
be O 0 7.234529086908026e-10
of O 0 4.1622769120230885e-10
value O 0 4.817767518261462e-09
in O 0 1.0564580321670292e-08
studies O 0 8.013829955189067e-08
of O 0 8.407877771787753e-08
familial B-Disease 0 0.01226169615983963
and I-Disease 0 1.2717537174466997e-06
sporadic I-Disease 0 0.0008673934498801827
cancers I-Disease 1 0.5379977226257324
aimed O 0 9.581311815054505e-07
at O 0 2.8573819577104587e-07
determination O 0 1.3421637845567602e-07
of O 0 4.41324710109825e-09
the O 0 5.313605910828301e-08
potential O 0 2.554149602929101e-07
involvement O 0 5.614833753497805e-07
of O 0 1.1688331369441585e-07
ATM O 0 0.0003046948986593634
mutations O 0 5.808273999718949e-05
in O 0 1.0682461834221613e-05
tumor B-Disease 1 0.9987866282463074
risk O 0 0.0006297382060438395
or O 0 1.968014885278535e-06
development O 0 3.862694029521663e-06
. O 0 2.025628191404394e-06
. O 0 9.060467164090369e-06

Ataxia B-Disease 1 0.9977442026138306
- I-Disease 1 0.881626546382904
telangiectasia I-Disease 1 0.975779116153717
: O 0 3.6268775147618726e-06
identification O 0 6.850800673419144e-07
and O 0 7.185784056673583e-08
detection O 0 1.6607510815447313e-06
of O 0 5.786564116760928e-08
founder O 0 3.1634401238989085e-05
- O 0 4.7945595724741e-06
effect O 0 4.835348477172374e-07
mutations O 0 4.160797288932372e-07
in O 0 1.5592128477237566e-08
the O 0 7.187058770341537e-08
ATM O 0 1.1655416528810747e-05
gene O 0 1.395151798533334e-06
in O 0 1.369335365097868e-07
ethnic O 0 1.0845808446902083e-06
populations O 0 1.6263775250990875e-05
. O 0 1.9072776922257617e-05

To O 0 7.598730462632375e-07
facilitate O 0 7.35347498448391e-07
the O 0 2.053362493370514e-07
evaluation O 0 1.430180645911605e-06
of O 0 1.8750984054349829e-07
ATM O 0 0.00020950539328623563
heterozygotes O 0 0.00018560992612037808
for O 0 2.2815648037521896e-07
susceptibility O 0 0.0001645900192670524
to O 0 3.3185045822392567e-07
other O 0 1.9474334749247646e-06
diseases O 1 0.9983773231506348
, O 0 8.327771752192348e-07
such O 0 1.7751210634742165e-06
as O 0 0.0006219275528565049
breast B-Disease 1 0.9997628331184387
cancer I-Disease 1 0.9992813467979431
, O 0 2.373769234509382e-07
we O 0 1.499560475792805e-08
have O 0 8.497155867814854e-09
attempted O 0 1.159261771022102e-07
to O 0 9.020676650095538e-09
define O 0 9.252741506315942e-08
the O 0 2.6890678128665968e-08
most O 0 3.557309469215397e-08
common O 0 2.162213377232547e-07
mutations O 0 3.892986057962844e-07
and O 0 6.677972397284293e-09
their O 0 9.581182958129375e-09
frequencies O 0 4.2671763367252424e-07
in O 0 6.73714566801209e-06
ataxia B-Disease 1 0.9986771941184998
- I-Disease 0 0.04282557964324951
telangiectasia I-Disease 1 0.99048912525177
( O 0 2.1491545339813456e-05
A B-Disease 0 0.0035418907646089792
- I-Disease 0 0.004229751881211996
T I-Disease 1 0.7603235840797424
) O 0 9.50898936480371e-07
homozygotes O 0 5.322794459061697e-05
from O 0 2.936882594894996e-07
10 O 0 4.828026476388914e-07
ethnic O 0 6.045211762284453e-07
populations O 0 9.61880596150877e-06
. O 0 8.223859367717523e-06

Both O 0 2.5681304123281734e-06
genomic O 0 4.956598422722891e-05
mutations O 0 1.2062379937560763e-05
and O 0 1.39453575798143e-07
their O 0 1.0268687589132242e-07
effects O 0 1.067169796442613e-05
on O 0 5.566932372857991e-07
cDNA O 0 2.181819945690222e-05
were O 0 2.0165900878055254e-06
characterized O 0 0.0012575507862493396
. O 0 4.143437399761751e-05

Protein O 0 3.894105975632556e-05
- O 0 2.0369147023302503e-05
truncation O 0 1.0186430699832272e-05
testing O 0 4.4552498934535834e-07
of O 0 1.3523287378802706e-08
the O 0 6.797565532679073e-08
entire O 0 8.13383451259142e-07
ATM O 0 1.0820097486430313e-05
cDNA O 0 7.4903637141687796e-06
detected O 0 1.0287983059242833e-05
92 O 0 2.5400418053322937e-06
( O 0 2.234543785561982e-07
66 O 0 1.6117563745865482e-06
% O 0 1.8825791414656123e-07
) O 0 2.886826564463263e-07
truncating O 0 3.90049499401357e-05
mutations O 0 3.5337332064955262e-06
in O 0 2.990306313677138e-07
140 O 0 5.726718882215209e-06
mutant O 0 7.145048584789038e-05
alleles O 0 5.792945739813149e-05
screened O 0 0.00025578931672498584
. O 0 2.8593371098395437e-05

The O 0 1.301798693020828e-05
haplotyping O 0 0.0007245505694299936
of O 0 3.0172013794071972e-06
patients O 0 0.003836930263787508
with O 0 3.782391502227256e-07
identical O 0 1.960580084414687e-05
mutations O 0 6.001364818075672e-05
indicates O 0 5.9849048739124555e-06
that O 0 1.653258507872124e-08
almost O 0 9.064760497778934e-09
all O 0 8.105101589883645e-10
of O 0 2.0364023800567566e-09
these O 0 3.776218449047519e-09
represent O 0 3.3805882537762955e-08
common O 0 2.5873643494378484e-07
ancestry O 0 9.933795581673621e-07
and O 0 7.152474523763885e-08
that O 0 6.322181889117928e-08
very O 0 3.214969979126181e-07
few O 0 8.334271228704893e-07
spontaneously O 0 7.479286432499066e-05
recurring O 0 0.001259815413504839
ATM O 0 0.0031581842340528965
mutations O 0 0.0002449162711855024
exist O 0 1.2027963748550974e-05
. O 0 2.0679039153037593e-05

Assays O 0 8.128706394927576e-05
requiring O 0 1.8410644770483486e-05
minimal O 0 9.797992788662668e-06
amounts O 0 5.665394837706117e-07
of O 0 4.9342407493213614e-08
genomic O 0 5.264987521513831e-06
DNA O 0 2.428843572488404e-06
were O 0 3.0953930973964816e-08
designed O 0 2.8551045261338004e-07
to O 0 1.2225851442337898e-08
allow O 0 9.652484322941746e-08
rapid O 0 6.760850283171749e-06
screening O 0 1.4776621810597135e-06
for O 0 6.323206491742894e-08
common O 0 1.5604125565005234e-06
ethnic O 0 1.9940086986025563e-06
mutations O 0 0.00022962073853705078
. O 0 2.9790098778903484e-05

These O 0 2.0941718048561597e-06
rapid O 0 0.00011677894508466125
assays O 0 1.7861073501990177e-05
detected O 0 3.723060217453167e-05
mutations O 0 2.7294463507132605e-06
in O 0 9.234334896746077e-08
76 O 0 2.849753172995406e-06
% O 0 1.1718533698967804e-07
of O 0 6.511917405305212e-08
Costa O 0 1.103708018490579e-05
Rican O 0 1.6534449969185516e-05
patients O 0 0.0001445516390958801
( O 0 1.683525994167212e-07
3 O 0 8.140324325722759e-08
) O 0 1.748898981190905e-08
, O 0 3.7379095374490134e-09
50 O 0 9.70929647792218e-09
% O 0 1.673094374154971e-08
of O 0 2.7866738250281742e-08
Norwegian O 0 1.975960549316369e-05
patients O 0 0.00015320874808821827
( O 0 1.8224601205929503e-07
1 O 0 7.492312903423226e-08
) O 0 1.8513356181415475e-08
, O 0 4.7003325676087115e-09
25 O 0 2.2744513827888113e-08
% O 0 2.104434670968658e-08
of O 0 4.76434856011565e-08
Polish O 0 0.00036360532976686954
patients O 0 0.00036137274582870305
( O 0 2.148251212474861e-07
4 O 0 1.3647697016949678e-07
) O 0 2.8942134022713617e-08
, O 0 6.1296647757558276e-09
and O 0 4.711031564852419e-09
14 O 0 4.427759847658308e-08
% O 0 3.362222855685104e-08
of O 0 5.296061189596912e-08
Italian O 0 0.00010978355567203835
patients O 0 0.0005869664601050317
( O 0 3.428877732858382e-07
1 O 0 1.6816244396977709e-07
) O 0 3.138572424177255e-08
, O 0 7.619679109893696e-09
as O 0 7.10087277866478e-09
well O 0 1.191985976589649e-08
as O 0 2.899733431149798e-08
in O 0 1.0829896268660377e-07
patients O 0 1.848799001891166e-05
of O 0 1.1459963644711024e-07
Amish O 0 0.00014680456661153585
/ O 0 9.712095925351605e-05
Mennonite O 0 2.3574481019750237e-05
and O 0 2.7419383741289494e-07
Irish O 0 8.737741154618561e-06
English O 0 3.398322633074713e-06
backgrounds O 0 1.8751676179817878e-05
. O 0 2.256471816508565e-05

Additional O 0 9.997662345995195e-06
mutations O 0 1.9653592971735634e-05
were O 0 2.923279964761605e-07
observed O 0 8.548787491235998e-07
in O 0 2.5778572876333783e-07
Japanese O 0 2.625343995532603e-06
, O 0 1.6106334044252435e-07
Utah O 0 2.9453326533257496e-06
Mormon O 0 1.0937881143036066e-06
, O 0 2.044623812480495e-07
and O 0 2.6637005134944047e-07
African O 0 6.366134130075807e-06
American O 0 2.2609561710851267e-05
patients O 0 0.033838968724012375
. O 0 5.0046837714035064e-05

These O 0 4.239625468471786e-07
assays O 0 3.4324807529628742e-06
should O 0 1.1785353137838683e-07
facilitate O 0 3.588453125757951e-07
screening O 0 2.1253615614114096e-06
for O 0 4.940333724334778e-07
A B-Disease 0 0.0029085639398545027
- I-Disease 0 0.017946431413292885
T I-Disease 1 0.9843016266822815
heterozygotes O 0 5.313888323144056e-05
in O 0 9.493597019627487e-08
the O 0 1.9095958236903243e-07
populations O 0 1.082214794223546e-06
studied O 0 3.889467279805103e-06
. O 0 1.7825531131165917e-06
. O 0 8.22884885565145e-06

The O 0 0.00013035534357186407
von B-Disease 0 0.04772088676691055
Hippel I-Disease 1 0.7544251084327698
- I-Disease 0 0.009470193646848202
Lindau I-Disease 1 0.940887451171875
tumor I-Disease 1 0.9180192351341248
suppressor O 0 0.00023136545496527106
gene O 0 1.0330288660043152e-06
is O 0 4.722684820990253e-08
required O 0 1.0304612629852272e-07
for O 0 4.962536337416168e-08
cell O 0 1.3945884347776882e-05
cycle O 0 8.90847877599299e-06
exit O 0 2.4623985154903494e-05
upon O 0 5.735884769819677e-06
serum O 0 0.008033465594053268
withdrawal O 0 0.00023719681485090405
. O 0 2.5325693059130572e-05

The O 0 5.886484359507449e-06
inactivation O 0 0.00023355433950200677
of O 0 5.762590831182024e-07
the O 0 1.7360756828566082e-05
von B-Disease 0 0.02415201999247074
Hippel I-Disease 0 0.457372784614563
- I-Disease 0 0.002864264650270343
Lindau I-Disease 0 0.1052313894033432
( I-Disease 0 0.00012286927085369825
VHL I-Disease 1 0.9829793572425842
) I-Disease 0 0.0001709205098450184
tumor I-Disease 1 0.9899771213531494
suppressor O 0 0.045005545020103455
gene O 0 0.0006505342898890376
predisposes O 0 0.11502785235643387
affected O 0 2.3947499357745983e-05
individuals O 0 4.879983634964447e-07
to O 0 3.1964128766048816e-07
the O 0 1.3020680853514932e-05
human O 0 0.013967683538794518
VHL B-Disease 1 0.9997242093086243
cancer I-Disease 1 0.9999380111694336
syndrome I-Disease 1 0.9999229907989502
and O 0 2.289848907821579e-06
is O 0 1.2936561688547954e-06
associated O 0 1.3852371012035292e-05
with O 0 1.387675274600042e-05
sporadic B-Disease 1 0.654559314250946
renal I-Disease 1 0.9999008178710938
cell I-Disease 1 0.9968516230583191
carcinomas I-Disease 1 0.9994230270385742
( O 0 0.0024161634501069784
RCC B-Disease 1 0.9984400868415833
) O 0 1.583529774507042e-05
and O 0 1.0067458788398653e-05
brain B-Disease 1 0.9537145495414734
hemangioblastomas I-Disease 0 0.08311854302883148
. O 0 9.065582707989961e-05

VHL O 1 0.9457302093505859
- O 0 0.0008052273187786341
negative O 0 0.00010411509720142931
786 O 0 0.0035037363413721323
- O 0 0.00023577002866659313
0 O 0 4.1900708311004564e-05
RCC B-Disease 1 0.9893274307250977
cells O 0 1.5017183613963425e-05
are O 0 1.7393124096543033e-07
tumorigenic O 0 0.00018755136989057064
in O 0 1.76833725618053e-06
nude O 0 0.0007012645364739001
mice O 0 5.455430073197931e-05
which O 0 3.5959278221753266e-08
is O 0 6.686845921421991e-08
suppressed O 0 3.0351291115948698e-06
by O 0 5.8020251714197e-08
the O 0 3.185250818660279e-07
reintroduction O 0 6.038172432454303e-05
of O 0 5.29284761796589e-06
VHL B-Disease 1 0.9719559550285339
. O 0 0.00011673252447508276

Remarkably O 0 0.00031125792884267867
, O 0 9.599860959497164e-07
this O 0 1.7324620671388402e-07
occurs O 0 1.2675847074206104e-06
without O 0 3.3058947224162694e-07
affecting O 0 1.6180769080165192e-06
the O 0 9.422520008683932e-08
growth O 0 1.6973804122244474e-06
rate O 0 4.137648943469685e-07
and O 0 6.38927915019849e-08
cell O 0 2.7602986847341526e-06
cycle O 0 2.3626218990102643e-06
profile O 0 3.407064070870547e-07
of O 0 1.7494960147246275e-08
these O 0 5.1790742361390585e-08
cells O 0 9.047799721884076e-06
in O 0 3.4594469866533473e-07
culture O 0 5.821040303999325e-06
. O 0 1.042191797751002e-05

The O 0 1.513340430392418e-05
786 O 0 0.0009293379844166338
- O 0 3.2047573768068105e-05
0 O 0 1.8953943481392344e-06
cell O 0 1.1497700143081602e-05
line O 0 1.981996319955215e-06
, O 0 1.4129670944384998e-07
like O 0 7.87826138548553e-07
many O 0 9.439534665034444e-07
cancer B-Disease 1 0.9972620010375977
cells O 0 1.5487683413084596e-05
, O 0 1.08390089792465e-07
fails O 0 2.5693407224025577e-06
to O 0 3.7503369298974576e-08
exit O 0 1.861609916886664e-06
the O 0 1.401816120960575e-07
cell O 0 1.11348099380848e-05
cycle O 0 1.1941067896259483e-05
upon O 0 5.586436145676998e-06
serum O 0 0.013799251057207584
withdrawal O 0 0.0001992786565097049
. O 0 2.7778232833952643e-05

Here O 0 2.6654361136024818e-06
, O 0 1.6979133476979769e-07
it O 0 2.797857945324722e-08
is O 0 2.8330960688549567e-08
shown O 0 4.9913943200863287e-08
that O 0 4.741166126365215e-09
reintroduction O 0 3.864555253585422e-07
of O 0 5.883316500643332e-09
the O 0 1.4014057114764e-07
wild O 0 4.268643351679202e-06
- O 0 1.7359367120661773e-05
type O 0 1.621078627067618e-05
VHL B-Disease 0 0.008632229641079903
gene O 0 2.2224012354854494e-06
restores O 0 8.566892574890517e-06
the O 0 1.0072051281895256e-07
ability O 0 4.803814022125152e-07
of O 0 1.7017290474541369e-06
VHL O 1 0.9939416646957397
- O 0 0.008900306187570095
negative O 0 0.001416928949765861
RCC B-Disease 1 0.9991427659988403
cancer I-Disease 1 0.9959943294525146
cells O 0 3.982524049206404e-06
to O 0 4.8774708716337045e-08
exit O 0 2.0241470792825567e-06
the O 0 1.2346326627721282e-07
cell O 0 4.03674494009465e-06
cycle O 0 3.189392600688734e-06
and O 0 1.7056319734365388e-07
enter O 0 6.891046723467298e-06
G0 O 0 0.06945660710334778
/ O 0 0.0003484759945422411
quiescence O 0 0.0008923073182813823
in O 0 3.7909387629042612e-06
low O 0 0.0003122345369774848
serum O 0 0.022510411217808723
. O 0 4.9563575885258615e-05

Both O 0 5.640200834022835e-05
VHL O 1 0.9040656089782715
- O 0 8.63014065544121e-05
positive O 0 4.091162736585829e-06
and O 0 3.892836502927821e-06
VHL O 1 0.9802240133285522
- O 0 0.0003140634507872164
negative O 0 4.0839393477654085e-05
RCC B-Disease 1 0.9800251722335815
cells O 0 1.10699165816186e-05
exit O 0 9.79724427452311e-06
the O 0 5.456936378323007e-07
cell O 0 1.920296017487999e-05
cycle O 0 7.520053713960806e-06
by O 0 3.2963058060886397e-07
contact O 0 1.1000481208611745e-05
inhibition O 0 0.00024284447135869414
. O 0 2.614008917589672e-05

The O 0 2.0448398572625592e-05
cyclin O 0 0.0024005358573049307
- O 0 3.5483084502629936e-05
dependent O 0 7.963355528772809e-06
kinase O 0 6.125351501395926e-05
inhibitor O 0 0.00011858448124257848
, O 0 1.0058419093184057e-06
p27 O 0 0.00034757782123051584
, O 0 3.4353845990153786e-07
accumulates O 0 2.182935713790357e-05
upon O 0 1.7337839608444483e-06
serum O 0 0.0006605430971831083
withdrawal O 0 1.7368505496051512e-06
, O 0 1.4627516087273307e-08
only O 0 2.5330484376695495e-09
in O 0 8.98249208347579e-09
the O 0 3.065879283781214e-08
presence O 0 1.0374186842909694e-07
of O 0 7.361804676975225e-08
VHL B-Disease 0 0.06344474852085114
, O 0 4.137222120448314e-08
as O 0 8.672088824823732e-09
a O 0 3.7715345513333887e-08
result O 0 4.970844358354043e-08
of O 0 4.9067399032765024e-09
the O 0 6.712927813623537e-08
stabilization O 0 2.271283847221639e-06
of O 0 3.363050282700897e-08
the O 0 6.25553752797714e-07
protein O 0 2.0369650883367285e-05
. O 0 7.3352262006665114e-06

We O 0 8.873442993717617e-07
propose O 0 3.291965413154685e-06
that O 0 8.561469400092392e-08
the O 0 1.7914288719111937e-07
loss O 0 5.2791760936088394e-06
of O 0 1.5319588442253007e-07
wild O 0 1.590126339579001e-05
- O 0 5.111799328005873e-05
type O 0 7.188411836978048e-05
VHL B-Disease 0 0.03745558112859726
gene O 0 1.7444067452743184e-06
results O 0 2.313709188683788e-07
in O 0 4.30153797026378e-08
a O 0 2.835456598404562e-07
specific O 0 4.2222711726935813e-07
cellular O 0 0.00021273332822602242
defect O 0 0.1289345771074295
in O 0 4.788312708114972e-06
serum O 0 0.024264315143227577
- O 0 2.0506065993686207e-05
dependent O 0 1.6577982933085877e-06
growth O 0 1.6112122693812125e-06
control O 0 4.605419690051349e-07
, O 0 5.96044138490015e-08
which O 0 7.817088487627188e-08
may O 0 3.6858230032521533e-06
initiate O 0 0.00011362863733666018
tumor B-Disease 1 0.9883735775947571
formation O 0 0.001308382605202496
. O 0 4.185973375570029e-05

This O 0 1.3378588619161746e-06
is O 0 2.1678349639842054e-06
corrected O 0 5.816122211399488e-05
by O 0 1.372582971725933e-07
the O 0 2.170665851508602e-07
reintroduction O 0 7.882628779043444e-06
of O 0 1.4910563095327234e-07
wild O 0 2.4620250769658014e-05
- O 0 0.00029192669899202883
type O 0 0.0003926821518689394
VHL B-Disease 1 0.964218258857727
, O 0 2.840964043571148e-06
implicating O 0 0.011873865500092506
VHL B-Disease 0 0.3865180015563965
as O 0 2.100857869891115e-07
the O 0 3.470249225756561e-07
first O 0 3.0673818400828168e-06
tumor B-Disease 1 0.8980256915092468
suppressor O 0 5.994917592033744e-05
involved O 0 1.590833846876194e-07
in O 0 1.2084706568771253e-08
the O 0 1.7660548579101487e-08
regulation O 0 3.9943844853951305e-07
of O 0 2.3559426409747175e-08
cell O 0 1.0353622201364487e-05
cycle O 0 5.060364401288098e-06
exit O 0 4.248645382176619e-06
, O 0 3.303757267758556e-08
which O 0 1.0222447777152865e-08
is O 0 1.8216047337205055e-08
consistent O 0 7.543748381522164e-08
with O 0 2.4262538644848064e-08
its O 0 1.0856969367978309e-07
gatekeeper O 0 5.234213676885702e-05
function O 0 6.316655003502092e-07
in O 0 9.866844266070984e-07
the O 0 2.7233385480940342e-05
kidney O 1 0.9986513257026672
. O 0 1.2205961866129655e-05
. O 0 3.757504964596592e-05

Piebaldism B-Disease 1 0.9603642821311951
with O 0 0.00047310462105087936
deafness B-Disease 1 0.9993374943733215
: O 0 5.737274477723986e-06
molecular O 0 1.5048522982397117e-05
evidence O 0 3.0436042379733408e-06
for O 0 7.943626201267762e-07
an O 0 1.9601146050263196e-05
expanded O 0 0.019766760990023613
syndrome O 1 0.9995154142379761
. O 0 7.626957085449249e-05

In O 0 1.577856323820015e-06
a O 0 2.2367150904756272e-06
South O 0 2.76740479421278e-06
African O 0 2.4594103251729393e-06
girl O 0 2.538643457228318e-05
of O 0 1.0721046237449627e-06
Xhosa O 0 0.1355644166469574
stock O 0 0.0006444543832913041
with O 0 8.363931556232274e-05
severe O 1 0.9977606534957886
piebaldism B-Disease 1 0.975284218788147
and O 0 0.00036559367435984313
profound O 1 0.9908270239830017
congenital O 1 0.9999450445175171
sensorineural B-Disease 1 0.9998810291290283
deafness I-Disease 1 0.9998883008956909
we O 0 5.357101599656744e-06
identified O 0 4.0065378925646655e-06
a O 0 5.939536436017079e-07
novel O 0 1.2904191635243478e-06
missense O 0 7.866513442422729e-06
substitution O 0 6.361809141708363e-07
at O 0 2.310150506446007e-07
a O 0 1.3417337640930782e-07
highly O 0 1.4362778699705814e-07
conserved O 0 2.401191636636213e-07
residue O 0 1.1780267641370301e-06
in O 0 1.241949210140092e-08
the O 0 2.7934161650478018e-08
intracellular O 0 2.375678832322592e-06
kinase O 0 1.5822745353943901e-06
domain O 0 8.521895722424233e-08
of O 0 2.7970948224265157e-08
the O 0 2.4405458134424407e-06
KIT O 0 0.012081981636583805
proto O 0 0.007538984529674053
- O 0 0.00022760081628803164
oncogene O 0 0.0005876370705664158
, O 0 2.70197801910399e-06
R796G O 0 0.0003822651051450521
. O 0 1.9904344298993237e-05

Though O 0 0.00033230127883143723
auditory B-Disease 0 0.022102823480963707
anomalies I-Disease 0 0.00846471544355154
have O 0 4.101614194951253e-07
been O 0 4.734729941446858e-07
observed O 0 7.4965430485463e-07
in O 0 4.4071174443161e-07
mice O 0 4.678303957916796e-05
with O 0 4.361455410162307e-07
dominant O 0 8.680389146320522e-05
white O 0 0.0009361953707411885
spotting O 0 0.002914859913289547
( O 0 1.4890547390677966e-05
W O 0 0.03427088260650635
) O 0 3.859060200284148e-07
due O 0 1.3785797818854917e-06
to O 0 2.5305490680693765e-07
KIT O 0 0.05523151159286499
mutations O 0 0.0002711621345952153
, O 0 1.5353976777987555e-05
deafness B-Disease 1 0.9993870258331299
is O 0 5.66448704830691e-07
not O 0 1.2162128371073777e-07
typical O 0 7.95330652181292e-06
in O 0 9.33287083171308e-07
human O 0 2.022634907916654e-05
piebaldism B-Disease 0 0.00659426162019372
. O 0 4.3776934035122395e-05

Thus O 0 8.964744665718172e-06
, O 0 1.5424789125972893e-06
the O 0 1.616220060896012e-06
occurrence O 0 6.920492887729779e-05
of O 0 1.024579341901699e-05
sensorineural B-Disease 1 0.999309778213501
deafness I-Disease 1 0.9998012185096741
in O 0 4.983944563718978e-06
this O 0 2.1142691366549116e-06
patient O 0 0.0011556277750059962
extends O 0 1.5003097360022366e-05
considerably O 0 4.163657649769448e-06
the O 0 5.12678752784268e-08
phenotypic O 0 1.3920524679633672e-06
range O 0 2.954341766780999e-07
of O 0 1.334089603233224e-07
piebaldism B-Disease 0 0.0004984309198334813
due O 0 5.5219743444467895e-06
to O 0 2.8725676770591235e-07
KIT O 0 0.0007217842503450811
gene O 0 8.012468242668547e-06
mutation O 0 5.823806077387417e-06
in O 0 2.1082719570131303e-07
humans O 0 1.4952371429899358e-06
and O 0 2.4277497345792654e-07
tightens O 0 0.0002665249048732221
the O 0 4.243533169301372e-07
clinical O 0 1.9817785869236104e-05
similarity O 0 2.9337886644498212e-06
between O 0 8.91689353466063e-07
piebaldism B-Disease 0 0.00019944329687859863
and O 0 1.1943258471092122e-07
the O 0 1.4305746276477294e-07
various O 0 1.5969048661190755e-07
forms O 0 2.3643040549359284e-05
of O 0 0.0004511482547968626
Waardenburg B-Disease 1 0.9996320009231567
syndrome I-Disease 1 0.9998297691345215
. O 0 7.584007835248485e-05
. O 0 7.338271825574338e-05

Cycloheximide O 0 0.0008603855967521667
facilitates O 0 1.054568201652728e-05
the O 0 2.5308435169790755e-07
identification O 0 2.8379210448292724e-07
of O 0 9.012080681713996e-08
aberrant O 0 5.7211371313314885e-05
transcripts O 0 4.7295898184529506e-06
resulting O 0 2.5108611225732602e-06
from O 0 1.4417507543385e-07
a O 0 2.4406614329564036e-07
novel O 0 1.3056961734037031e-06
splice O 0 3.0318480639834888e-05
- O 0 3.951196049456485e-06
site O 0 9.001341823022813e-07
mutation O 0 2.8915264920215122e-06
in O 0 3.7164568311709445e-07
COL17A1 O 0 0.0009740679524838924
in O 0 8.841723797559098e-07
a O 0 1.554484697408043e-05
patient O 0 0.008057682774960995
with O 0 7.712344086030498e-05
generalized O 1 0.9759209156036377
atrophic B-Disease 1 0.998618483543396
benign I-Disease 1 0.9984332919120789
epidermolysis I-Disease 1 0.9977220892906189
bullosa I-Disease 1 0.9950332641601562
. O 0 0.001394417486153543

Patients O 1 0.7676767706871033
with O 0 0.000419088639318943
generalized O 1 0.9847160577774048
atrophic B-Disease 1 0.9991316199302673
benign I-Disease 1 0.9989744424819946
epidermolysis I-Disease 1 0.9985170960426331
bullosa I-Disease 1 0.996457040309906
often O 0 5.1502636779332533e-05
show O 0 1.9198545487597585e-05
decreased O 0 6.251548620639369e-05
expression O 0 1.7150709936686326e-06
of O 0 1.0749998864412191e-06
type O 0 0.19039547443389893
XVII O 1 0.9976696372032166
collagen O 0 0.08148519694805145
, O 0 5.43778241990367e-07
a O 0 1.2688570905083907e-06
transmembrane O 0 8.975240052677691e-05
hemidesmosomal O 0 9.113602573052049e-05
protein O 0 2.5716597065184033e-06
encoded O 0 1.3305411812325474e-06
by O 0 2.908086116804043e-06
COL17A1 O 0 0.029779719188809395
. O 0 4.1635590605437756e-05

This O 0 1.756186293278006e-06
report O 0 2.44295142692863e-06
documents O 0 8.609561632511031e-07
a O 0 8.434056439909909e-07
novel O 0 4.007883035228588e-06
splice O 0 4.597382212523371e-05
- O 0 7.796741556376219e-06
site O 0 1.7286113234149525e-06
mutation O 0 4.625425845006248e-06
in O 0 4.106647963908472e-07
COL17A1 O 0 0.0012777146184816957
in O 0 1.0418600595585303e-06
a O 0 1.0485981874808203e-05
patient O 0 0.005592122208327055
with O 0 2.8402429961715825e-05
generalized O 1 0.9540543556213379
atrophic B-Disease 1 0.9991992115974426
benign I-Disease 1 0.9992498755455017
epidermolysis I-Disease 1 0.999117910861969
bullosa I-Disease 1 0.9972038269042969
, O 0 2.112636593665229e-06
and O 0 1.6524458601452352e-07
applies O 0 4.845130092689942e-07
a O 0 1.614767484170443e-07
new O 0 8.192738221168838e-08
methodology O 0 2.554071727445262e-07
to O 0 1.2906522073308224e-08
define O 0 1.6255614809779217e-07
and O 0 4.06730471524952e-08
characterize O 0 2.812296088450239e-06
the O 0 1.2600527554695873e-07
resulting O 0 6.6316720221948344e-06
mRNA O 0 6.6636621340876445e-06
splice O 0 9.519924788037315e-05
variants O 0 3.849797212751582e-05
. O 0 7.822262887202669e-06

Mutational O 0 0.0004170870815869421
analysis O 0 1.836864043980313e-06
of O 0 1.346290559922636e-06
COL17A1 O 0 0.012307467870414257
identified O 0 1.5113342669792473e-05
a O 0 1.1379918760212604e-05
maternally O 0 0.0043916525319218636
inherited O 0 0.3332173228263855
G O 0 0.002110221888870001
- O 0 2.3699340090388432e-05
to O 0 3.731343838353496e-07
- O 0 3.559842298272997e-05
T O 0 0.0006000531720928848
transversion O 0 6.818602287239628e-06
at O 0 1.1694420010144313e-07
the O 0 5.413644643681437e-08
- O 0 1.484220746306164e-07
1 O 0 1.1596550386627769e-08
position O 0 1.2164976581630071e-08
of O 0 1.1316253711868285e-08
exon O 0 3.280174860265106e-05
32 O 0 6.720807959936792e-06
. O 0 8.482734301651362e-06

This O 0 4.552604423224693e-06
acceptor O 0 0.00014725250366609544
splice O 0 0.00026638314011506736
- O 0 2.174296969315037e-05
site O 0 1.883377876765735e-06
mutation O 0 1.8821802996171755e-06
led O 0 1.573395138620981e-07
to O 0 1.4112885082795401e-08
the O 0 4.3371279900839e-08
formation O 0 1.5176035503827734e-06
of O 0 6.83988616856368e-08
aberrant O 0 4.3252744944766164e-05
transcripts O 0 4.185905254416866e-06
present O 0 7.852787575757247e-07
at O 0 3.668327735795174e-06
extremely O 0 5.739186599384993e-05
low O 0 5.3178580856183544e-05
levels O 0 5.277095624478534e-05
. O 0 1.1959644325543195e-05

Based O 0 5.526178483705735e-06
on O 0 1.3260568039186182e-06
our O 0 5.218002456786053e-07
recent O 0 1.0620351531542838e-06
finding O 0 1.6134788438648684e-06
that O 0 1.035345690070244e-06
cycloheximide O 0 0.0011881962418556213
stabilized O 0 0.0019537601619958878
mutant O 0 7.235928205773234e-05
COL17A1 O 0 0.0008129008929245174
transcripts O 0 7.403071322187316e-06
in O 0 4.7187052132358076e-07
keratinocytes O 0 5.537447577808052e-05
homozygous O 0 2.6125112526642624e-06
for O 0 5.5995091230442995e-08
a O 0 1.2136561053921469e-06
frameshift O 0 0.0015258189523592591
mutation O 0 4.510894541454036e-06
, O 0 3.22443867162292e-08
the O 0 3.292836225909923e-08
effects O 0 5.17191779181303e-07
of O 0 1.6507158306922065e-08
the O 0 2.5726066610332055e-07
splice O 0 3.987729360233061e-05
- O 0 1.7935346932063112e-06
site O 0 2.0726550076233252e-07
mutation O 0 2.536773422434635e-07
on O 0 1.329251819726096e-08
splicing O 0 2.4922240982050425e-07
of O 0 5.4736368326757656e-08
COL17A1 O 0 0.0001375635911244899
transcripts O 0 1.349563376606966e-06
were O 0 3.896157707572456e-08
determined O 0 1.381673939704342e-07
using O 0 8.984894606101079e-08
reverse O 0 7.551920134574175e-06
transcriptase O 0 5.120180867379531e-05
polymerase O 0 1.1575925782381091e-05
chain O 0 4.000303306384012e-06
reaction O 0 4.050150437251432e-07
of O 0 9.870193551364537e-09
total O 0 4.887575144607581e-08
RNA O 0 1.5800775372554199e-06
from O 0 3.762525011552498e-07
keratinocytes O 0 6.124148785602301e-05
incubated O 0 1.0483231562830042e-05
for O 0 5.082802658762375e-07
2 O 0 7.66721768741263e-06
. O 0 8.377634003409185e-06

5 O 0 1.7650669178692624e-05
h O 0 2.3963490093592554e-05
in O 0 1.239980491618553e-07
the O 0 9.095349184917723e-08
presence O 0 4.008993244042358e-07
or O 0 1.0257588911599669e-07
absence O 0 7.416473408738966e-07
of O 0 5.399722979859689e-08
10 O 0 1.6232174857577775e-06
microg O 0 0.00046082749031484127
cycloheximide O 0 0.00032273356919176877
per O 0 7.4332720032543875e-06
ml O 0 0.0016343320021405816
. O 0 3.304444544482976e-05

Using O 0 1.483520577494346e-06
this O 0 3.0576453013964056e-07
approach O 0 1.3805229173158295e-06
, O 0 3.4457661968190223e-07
an O 0 6.585863161490124e-07
abnormally O 0 0.0015372128691524267
spliced O 0 5.8088502555619925e-05
transcript O 0 8.552116923965514e-05
was O 0 1.4942505686121876e-06
identified O 0 1.551654378317835e-07
that O 0 4.961199451258835e-09
contains O 0 2.411591459861029e-08
an O 0 8.547530683244986e-09
extra O 0 2.9110880817029283e-08
264 O 0 2.24492467282289e-07
bases O 0 1.4538424686350027e-08
upstream O 0 2.4048677005339414e-07
from O 0 3.664564829364281e-08
exon O 0 2.3848087948863395e-06
32 O 0 1.7735158053255873e-07
, O 0 3.588288421951802e-08
resulting O 0 7.119562610569119e-07
in O 0 7.79936613071186e-08
a O 0 1.086375846170995e-06
premature O 0 0.0002606828056741506
termination O 0 5.3595027566188946e-05
codon O 0 8.744476872379892e-06
27 O 0 5.2541427066898905e-06
bp O 0 1.4746924534847494e-05
downstream O 0 3.116099151156959e-06
from O 0 1.7988520539802266e-07
the O 0 4.525728911630722e-07
cryptic O 0 0.0002363743697060272
splice O 0 0.00034725258592516184
site O 0 4.554473707685247e-05
. O 0 3.103708877461031e-05

Three O 0 5.005237539990048e-07
other O 0 2.50428456638474e-07
splice O 0 3.9338836359092966e-05
variants O 0 2.4561288682889426e-06
, O 0 3.2466864752223046e-08
including O 0 1.019269824098501e-08
one O 0 1.0793762328376033e-08
derived O 0 3.118641345167816e-08
from O 0 1.9735992395908397e-08
the O 0 2.4532296194479386e-08
skipping O 0 1.0755854873423232e-06
of O 0 2.0383268406476418e-08
exon O 0 9.386075362272095e-06
32 O 0 4.452951998246135e-07
, O 0 5.17444362913011e-08
were O 0 3.009620641591937e-08
also O 0 1.5162784450239997e-07
identified O 0 3.145127720927121e-06
. O 0 5.0703347369562835e-06

These O 0 1.1739657566067763e-06
results O 0 3.216078312107129e-06
indicate O 0 2.282148898302694e-06
the O 0 2.611888305636967e-07
usefulness O 0 8.042753506742883e-06
of O 0 5.654102892549417e-07
cycloheximide O 0 0.012373163364827633
treatment O 0 0.0003965619544032961
in O 0 1.4299786244009738e-07
evaluating O 0 6.173526685415709e-07
the O 0 1.4414153781672212e-07
abnormal O 0 6.6072675508621614e-06
processing O 0 9.295743552684144e-08
of O 0 1.3971150458758075e-08
mRNA O 0 5.902674615754222e-07
due O 0 6.468516176028061e-07
to O 0 7.970400162093938e-08
splice O 0 3.3080705179600045e-05
- O 0 1.5357389202108607e-05
site O 0 2.3410029825754464e-06
mutations O 0 3.94104654333205e-06
, O 0 1.4552303184700577e-07
because O 0 5.427622227216489e-07
( O 0 4.1118991589428333e-07
i O 0 4.074751700500201e-07
) O 0 6.391790208226666e-08
aberrant O 0 6.009554908814607e-06
splicing O 0 1.693516082923452e-06
often O 0 3.7516755924116296e-07
generates O 0 1.5932312180666486e-06
a O 0 3.923028089047875e-06
premature O 0 0.001278393785469234
termination O 0 0.00014071929035708308
codon O 0 5.4276410992315505e-06
, O 0 3.248551649903675e-07
( O 0 8.708490213393816e-07
ii O 0 2.7178666641702875e-05
) O 0 1.8158641523768893e-07
transcripts O 0 2.451665977787343e-06
with O 0 6.587760026377509e-07
premature O 0 0.0016505151288583875
termination O 0 0.0003030461957678199
codons O 0 8.890274330042303e-06
can O 0 2.2121446363598807e-07
occur O 0 6.702238692923856e-07
at O 0 1.1003186273228494e-06
low O 0 1.7386273611919023e-05
or O 0 3.4299675917282e-06
undetectable O 0 0.005168846342712641
levels O 0 4.6214663598220795e-06
due O 0 1.023658228405111e-06
to O 0 1.006406336045984e-07
nonsense O 0 8.357125807378907e-06
- O 0 1.0722660590545274e-06
mediated O 0 1.4429408565774793e-06
mRNA O 0 5.226702910476888e-07
decay O 0 4.836113930650754e-06
, O 0 7.042405059110024e-08
and O 0 4.106036044504435e-08
( O 0 3.218442543584388e-07
iii O 0 1.3101282092975453e-05
) O 0 4.520897789461742e-08
the O 0 2.8378064342859943e-08
levels O 0 9.076685358877512e-08
of O 0 2.8172360000411345e-09
these O 0 9.827645364168802e-09
transcripts O 0 1.0321761010345654e-06
can O 0 2.9474319873656896e-08
be O 0 2.941142263068741e-08
increased O 0 4.4407087784748e-07
by O 0 9.634987918616389e-07
cycloheximide O 0 0.0014973566867411137
. O 0 1.4727601410413627e-05

A O 0 4.220142727717757e-05
deletion O 0 0.0002220906608272344
mutation O 0 2.7030862838728353e-05
in O 0 8.074262609625293e-07
COL17A1 O 0 0.00030021765269339085
in O 0 1.2816326488973573e-07
five O 0 4.4691316247735813e-07
Austrian O 0 0.00014553844812326133
families O 0 3.7301558677427238e-06
with O 0 1.5846115275053307e-05
generalized O 1 0.9280053377151489
atrophic B-Disease 1 0.998843789100647
benign I-Disease 1 0.9976733326911926
epidermolysis I-Disease 1 0.9963420033454895
bullosa I-Disease 1 0.9870979189872742
represents O 0 1.283638266613707e-05
propagation O 0 3.625462795753265e-06
of O 0 2.774010852135689e-07
an O 0 2.4114801817631815e-06
ancestral O 0 0.0001687919138930738
allele O 0 0.00020205564214847982
. O 0 4.371251998236403e-05

Patients O 1 0.9521253705024719
with O 0 0.00045116417459212244
generalized O 1 0.980176568031311
atrophic B-Disease 1 0.9986671209335327
benign I-Disease 1 0.9986433386802673
epidermolysis I-Disease 1 0.9982055425643921
bullosa I-Disease 1 0.9950043559074402
, O 0 4.485058070713421e-06
a O 0 2.1974669834889937e-06
usually O 0 1.5400373740703799e-06
nonlethal O 0 3.928079968318343e-05
form O 0 4.067490408488084e-06
of O 0 1.3648581443703733e-05
junctional B-Disease 1 0.9929667711257935
epidermolysis I-Disease 1 0.995465099811554
bullosa I-Disease 1 0.9897159934043884
, O 0 1.190922466776101e-05
have O 0 4.412451289681485e-06
generalized O 0 0.0012576183071359992
blistering B-Disease 0 0.49480345845222473
, O 0 0.0008655070560052991
nail B-Disease 1 0.9973424077033997
dystrophy I-Disease 1 0.9993252754211426
, O 0 0.0018073923420161009
patchy B-Disease 1 0.9976995587348938
alopecia I-Disease 1 0.9997017979621887
, O 0 0.00011798532796092331
and O 0 0.0002516882959753275
dental B-Disease 1 0.9982958436012268
abnormalities I-Disease 1 0.9959079027175903
. O 0 0.00045726815005764365

Skin B-Disease 1 0.9978176355361938
fragility I-Disease 1 0.76857590675354
in O 0 1.3326225598575547e-06
most O 0 3.2404261673946166e-07
cases O 0 1.794939635146875e-06
is O 0 1.5888083737536363e-07
due O 0 7.461337077074859e-07
to O 0 2.6762759119947077e-08
mutations O 0 4.987036277270818e-07
in O 0 3.192323916323403e-08
the O 0 9.672443468389247e-08
gene O 0 2.9424802505673142e-06
encoding O 0 1.0860653674171772e-05
type O 0 0.008914003148674965
XVII O 1 0.996004045009613
collagen O 1 0.9417116045951843
( O 0 7.481254579033703e-05
COL17A1 O 0 0.03656216710805893
) O 0 1.2586498996824957e-05
. O 0 3.269309672759846e-05

Recently O 0 0.00012547838559839875
, O 0 1.0837164836630109e-06
we O 0 2.2189142612205615e-07
reported O 0 2.9452849048539065e-06
five O 0 4.5136516746424604e-07
Austrian O 0 5.3729101637145504e-05
families O 0 3.515213620630675e-06
with O 0 3.087289587710984e-05
generalized O 1 0.9175416231155396
atrophic B-Disease 1 0.998945415019989
benign I-Disease 1 0.9987577199935913
epidermolysis I-Disease 1 0.9987267851829529
bullosa I-Disease 1 0.9958139061927795
who O 0 1.57843987835804e-05
share O 0 2.7120979666506173e-06
the O 0 2.1468106297106715e-06
same O 0 1.578692717885133e-05
COL17A1 O 0 0.15270930528640747
mutation O 0 0.0010984333930537105
. O 0 3.659672802314162e-05

Affected O 0 5.1240494940429926e-05
individuals O 0 1.0617586667649448e-06
in O 0 1.0004083605963388e-07
three O 0 6.592599532950771e-08
families O 0 1.3319525749011518e-07
are O 0 1.1713144232317063e-08
homozygous O 0 1.356509528704919e-06
for O 0 5.72714995428214e-08
4003delTC O 0 7.102570089045912e-05
, O 0 1.2433197582595312e-07
whereas O 0 3.3562358225935895e-07
those O 0 2.7402277780197437e-08
in O 0 3.480781884945827e-08
two O 0 2.607800908549507e-08
others O 0 4.171572811628721e-07
are O 0 1.2853928410549997e-07
compound O 0 0.00011509854084579274
heterozygotes O 0 0.0043811011128127575
. O 0 3.450749136391096e-05

To O 0 7.567944066977361e-07
determine O 0 7.05179957094515e-07
if O 0 1.4302608519756177e-07
the O 0 9.097813347125339e-08
occurrence O 0 1.6522393480045139e-06
of O 0 6.726244095034417e-08
4003delTC O 0 7.735325198154896e-05
in O 0 1.2107759062018886e-07
these O 0 6.798875062941079e-08
unrelated O 0 6.115337782830466e-06
families O 0 4.991023843103903e-07
signifies O 0 4.864394213655032e-06
propagation O 0 2.3713798213975679e-07
of O 0 2.2097950136412692e-08
an O 0 1.3913289365063974e-07
ancestral O 0 8.904638889362104e-06
allele O 0 4.953839379595593e-06
or O 0 6.550247917402885e-07
a O 0 3.036504040210275e-06
mutational O 0 0.0016786252381280065
hot O 0 3.6522920709103346e-05
spot O 0 4.315687419875758e-06
, O 0 2.12823067613499e-07
haplotypes O 0 9.014158422360197e-06
were O 0 3.5324415392778974e-08
determined O 0 1.5986054791028437e-07
for O 0 2.3792079417717105e-08
polymorphisms O 0 1.9802976112259785e-06
both O 0 3.287232530624351e-08
within O 0 2.092260302788418e-07
and O 0 1.300510234614194e-06
flanking O 0 0.003829500637948513
COL17A1 O 0 0.13352032005786896
. O 0 5.4750424169469625e-05

Five O 0 9.073532964976039e-06
intragenic O 0 0.0006098714075051248
polymorphisms O 0 1.485013126512058e-05
were O 0 6.261601726009758e-08
chosen O 0 5.8587730222825485e-08
based O 0 9.835618186571082e-08
on O 0 2.907399050400272e-07
their O 0 6.162350132399297e-07
informativeness O 0 0.0015972621040418744
. O 0 2.3014716134639457e-05

One O 0 4.626942597951711e-07
of O 0 6.487828585477473e-08
these O 0 8.428204978372378e-08
, O 0 1.631872521556943e-07
not O 0 6.28483860509732e-08
previously O 0 7.400999493256677e-07
reported O 0 3.9468345676141325e-06
, O 0 8.982821242398131e-08
was O 0 4.185064597095334e-07
2988 O 0 1.1224923582631163e-05
A O 0 3.328983950723341e-07
or O 0 9.169500714278911e-08
C O 0 6.790644988541317e-07
that O 0 6.187410583891051e-09
introduces O 0 2.365859046449259e-07
a O 0 8.941897533532028e-08
new O 0 1.012030992342261e-07
restriction O 0 9.611458153813146e-07
site O 0 6.420945624086016e-07
for O 0 2.9004340262872574e-07
Eco0109 O 0 0.00018086540512740612
I O 0 4.274599996278994e-05
. O 0 7.106726116035134e-06

All O 0 1.7949687958207505e-07
the O 0 3.481227395241149e-07
4003delTC O 0 3.57866520062089e-05
alleles O 0 1.9000601696461672e-06
showed O 0 1.1250333500356646e-06
the O 0 6.385064210689961e-08
same O 0 1.2631281265385041e-07
haplotype O 0 1.3945910723123234e-05
for O 0 2.6165896116481235e-08
these O 0 2.0942239942201013e-08
five O 0 5.263965476842714e-07
polymorphic O 0 0.0003936146094929427
markers O 0 0.0007742192829027772
. O 0 3.640555951278657e-05

Fourteen O 0 9.755992505233735e-05
microsatellite O 0 0.0009945209603756666
polymorphisms O 0 2.6203457309748046e-05
were O 0 9.139206724739779e-08
selected O 0 2.8499352211497353e-08
based O 0 1.8999115170004188e-08
on O 0 1.2174609764770139e-08
their O 0 1.2844194152705768e-08
high O 0 1.0881022944886354e-06
heterozygosity O 0 1.0181768629990984e-05
and O 0 8.872189205533232e-09
their O 0 2.763488993196006e-09
location O 0 1.189933982459479e-07
within O 0 1.1757781237520248e-07
10q23 O 0 0.00013056372699793428
- O 0 3.838421980617568e-05
q25 O 0 0.0001233294024132192
near O 0 4.9802696594269946e-05
COL17A1 O 0 0.008148475550115108
. O 0 3.653351086541079e-05

Three O 0 1.5763283727210364e-06
families O 0 2.4773949007794727e-06
shared O 0 5.484465418703621e-06
microsatellite O 0 0.0009768030140548944
polymorphisms O 0 7.466031820513308e-05
covering O 0 1.2994952157896478e-05
at O 0 1.4275819921749644e-06
most O 0 1.8370815269008745e-07
19 O 0 2.4277157990582054e-06
cM O 0 7.240712875500321e-05
, O 0 6.268652441576705e-08
whereas O 0 3.0105397286206426e-07
the O 0 2.9712401428128032e-08
others O 0 7.129850132514548e-08
shared O 0 8.782939886486929e-08
smaller O 0 1.7445420041894977e-07
regions O 0 1.6911130273911112e-07
consistent O 0 4.468373049348884e-07
with O 0 1.0350252921398351e-07
cross O 0 1.5422538126586005e-06
- O 0 5.33223612819711e-07
over O 0 1.4355103772345501e-08
events O 0 1.220043621685818e-08
during O 0 6.1468192313896e-08
passage O 0 7.98295189952114e-08
of O 0 9.964165492704069e-09
this O 0 8.190660594209476e-08
mutation O 0 1.7425312535124249e-06
through O 0 1.6059829022196936e-07
several O 0 6.072218070585222e-07
generations O 0 1.8146130969398655e-05
. O 0 1.835619332268834e-05

These O 0 1.1583482546484447e-06
results O 0 5.317054728948278e-06
indicate O 0 5.584603968600277e-06
that O 0 1.728280381030345e-07
4003delTC O 0 2.8924838261445984e-05
occurs O 0 5.914333200962574e-07
on O 0 5.3144063372201344e-08
a O 0 1.2418657036050718e-07
single O 0 2.7203876129533455e-07
ancestral O 0 8.491823791700881e-06
allele O 0 1.1152877050335519e-05
. O 0 1.6222425074374769e-06
. O 0 6.800003575335722e-06

The O 0 3.835538518615067e-05
haptoglobin O 0 0.004225227050483227
- O 0 5.4347121476894245e-05
gene O 0 1.2339761269686278e-05
deletion O 0 8.155228715622798e-05
responsible O 0 9.948301340045873e-06
for O 0 2.783078116408433e-06
anhaptoglobinemia B-Disease 0 0.017245862632989883
. O 0 5.288077227305621e-05

We O 0 7.473714163097611e-07
have O 0 7.842776028610388e-08
found O 0 1.2017936512620508e-07
an O 0 8.02269966015956e-08
allelic O 0 1.1085530786658637e-05
deletion O 0 5.586441602645209e-06
of O 0 6.460354029513837e-08
the O 0 8.423076565122756e-07
haptoglobin O 0 0.0007589798187837005
( O 0 8.575333367843996e-07
Hp O 0 6.7360660978010856e-06
) O 0 1.0035731889956878e-07
gene O 0 1.4471534370841255e-07
from O 0 3.178356422495199e-08
an O 0 3.171235007926043e-08
individual O 0 9.819123647503147e-08
with O 0 1.5884976392044337e-06
anhaptoglobinemia B-Disease 0 0.008093106560409069
. O 0 2.0097524611628614e-05

The O 0 6.878321983094793e-06
Hp O 0 7.726110925432295e-05
gene O 0 4.057738351548323e-06
cluster O 0 2.713634785322938e-06
consists O 0 9.609224349560463e-08
of O 0 2.5138742643093792e-08
coding O 0 2.1536554868362145e-06
regions O 0 4.434817313381245e-08
of O 0 1.074741717843608e-08
the O 0 6.83802099388231e-08
alpha O 0 1.6309106740663992e-06
chain O 0 2.8549134185595904e-06
and O 0 6.505561600533838e-08
beta O 0 2.7005353331333026e-06
chain O 0 6.468750939347956e-07
of O 0 1.1067869287728627e-08
the O 0 2.0763010866176046e-07
haptoglobin O 0 0.00014225217455532402
gene O 0 2.6807929316419177e-06
( O 0 6.482633807536331e-07
Hp O 0 2.8970248422410805e-06
) O 0 1.7835221299833393e-08
and O 0 3.241635626594075e-09
of O 0 3.596234643410412e-09
the O 0 4.822569010798361e-08
alpha O 0 1.2110037914681016e-06
chain O 0 3.741981345228851e-06
and O 0 6.83944207935383e-08
beta O 0 4.232824267091928e-06
chain O 0 1.766013156156987e-06
of O 0 3.146256233321765e-08
the O 0 7.454494834746583e-07
haptoglobin O 0 0.0013749832287430763
- O 0 1.2277853784325998e-05
related O 0 1.5803954056536895e-06
gene O 0 2.5762155928532593e-06
( O 0 1.3381038570514647e-06
Hpr O 0 0.00037202201201580465
) O 0 1.2757790557316184e-07
, O 0 6.005642916306897e-08
in O 0 5.863524421556576e-08
tandem O 0 3.1318502351496136e-06
from O 0 1.3940676524271112e-07
the O 0 3.7973509847688547e-07
5 O 0 2.492017756594578e-06
side O 0 1.3495465282176156e-05
. O 0 1.298204642807832e-05

Southern O 0 5.4226758948061615e-05
blot O 0 0.0005202040774747729
and O 0 2.2551782876689686e-06
PCR O 0 5.216851786826737e-05
analyses O 0 2.7890830551768886e-06
have O 0 1.1914590913875145e-07
indicated O 0 9.063811035048275e-07
that O 0 9.552808322155215e-09
the O 0 8.223247860428273e-09
individual O 0 9.134915934794208e-09
with O 0 7.536011281672472e-08
anhaptoglobinemia B-Disease 0 0.0001265502069145441
was O 0 5.079134552943287e-07
homozygous O 0 7.973424658302974e-07
for O 0 1.60089310696776e-08
the O 0 5.4654684333854675e-08
gene O 0 1.0883222785196267e-06
deletion O 0 4.782357336807763e-06
and O 0 1.4329116559963495e-08
that O 0 9.699208547431226e-09
the O 0 3.85796283808304e-08
gene O 0 6.785465984648908e-07
deletion O 0 4.458247985894559e-06
was O 0 1.4594164099435147e-07
included O 0 2.6022508592404847e-08
at O 0 6.752814840638166e-08
least O 0 1.6657326185054444e-08
from O 0 1.931620374762133e-08
the O 0 4.595017699671189e-08
promoter O 0 7.611904948134907e-06
region O 0 2.0822162127842603e-07
of O 0 3.537235215844703e-08
Hp O 0 9.237158337782603e-06
to O 0 1.3342358329282433e-07
Hpr O 0 0.00018172278942074627
alpha O 0 2.141114237019792e-06
but O 0 4.377978157776852e-08
not O 0 2.0553876822759776e-08
to O 0 7.817327229986404e-08
Hpr O 0 0.00035379070322960615
beta O 0 4.706337858806364e-05
( O 0 5.039213647251017e-06
Hpdel O 0 0.0004049290146213025
) O 0 4.551849087874871e-06
. O 0 7.800236744515132e-06

In O 0 1.7663129483480589e-06
addition O 0 1.1400688890716992e-06
, O 0 2.0900984054605942e-07
we O 0 2.5633632105837023e-08
found O 0 5.88742814500165e-08
seven O 0 3.0356211766502383e-08
individuals O 0 2.987703595636049e-08
with O 0 1.3415161959073885e-07
hypohaptoglobinemia B-Disease 0 0.00013032826245762408
in O 0 5.3085710050027046e-08
three O 0 3.885908128609117e-08
families O 0 5.818304771310068e-08
, O 0 2.9346812979724746e-08
and O 0 5.754400511648328e-09
the O 0 1.3038500945583564e-08
genotypes O 0 7.647840902791359e-07
of O 0 5.153530491242009e-09
six O 0 1.301943974851838e-08
of O 0 5.845788741964952e-09
the O 0 3.305919804574842e-08
seven O 0 4.947519016695878e-08
individuals O 0 3.977961071655045e-08
were O 0 2.781867713963493e-08
found O 0 1.2605840993273887e-07
to O 0 6.753458592356765e-08
be O 0 4.31885183616032e-07
Hp2 O 0 0.0011671020183712244
/ O 0 0.0010691243223845959
Hpdel O 0 0.0017475711647421122
. O 0 3.652946907095611e-05

The O 0 7.331638244068017e-06
phenotypes O 0 0.00012166144006187096
and O 0 6.891454518154205e-07
genotypes O 0 1.7958667740458623e-05
in O 0 3.710074736318347e-08
one O 0 9.064138772885144e-09
of O 0 5.485088383494485e-09
these O 0 6.665183516219031e-09
three O 0 2.3520454917047573e-08
families O 0 1.4131745729173417e-07
showed O 0 1.0748666454674094e-06
the O 0 3.729806508090405e-08
father O 0 1.129293423218769e-06
to O 0 3.635055279005428e-08
be O 0 1.0101064162881812e-07
hypohaptoglobinemic B-Disease 0 7.094548345776275e-05
( O 0 8.860420166456606e-07
Hp2 O 0 6.255615880945697e-05
) O 0 3.848468281830719e-07
and O 0 5.625092285299615e-07
Hp2 O 0 0.0006818705587647855
/ O 0 0.00011616509436862543
Hpdel O 0 6.29320929874666e-05
, O 0 7.103868426838744e-08
the O 0 6.863082546715304e-08
mother O 0 1.6023250282160006e-06
to O 0 2.3321442554902205e-08
be O 0 9.598691264045556e-08
Hp2 O 0 7.334508700296283e-05
- O 0 3.3760954920580843e-06
1 O 0 3.133930874810176e-07
and O 0 2.2451965264735918e-07
Hp1 O 0 0.00029375264421105385
/ O 0 4.146307401242666e-05
Hp2 O 0 1.5760168025735766e-05
, O 0 1.3284508604272105e-08
one O 0 2.580841540478218e-09
of O 0 1.876959476732054e-09
the O 0 1.5083525539694165e-08
two O 0 9.08189434767337e-09
children O 0 1.1036652836082794e-07
to O 0 1.5026268229689776e-08
be O 0 6.353320713969879e-08
hypohaptoglobinemic B-Disease 0 7.31617838027887e-05
( O 0 8.08520439932181e-07
Hp2 O 0 8.279118628706783e-05
) O 0 4.20583035065647e-07
and O 0 3.069372667141579e-07
Hp2 O 0 0.0007734394166618586
/ O 0 0.00013388377556111664
Hpdel O 0 0.00010205802391283214
, O 0 4.108088802468046e-08
and O 0 1.3231606921237926e-08
the O 0 2.6154221899332697e-08
other O 0 1.2045630271018126e-08
child O 0 9.622996230973513e-07
to O 0 4.790646812580235e-08
be O 0 1.0023622110111319e-07
Hp1 O 0 5.998674896545708e-05
and O 0 8.036956842261134e-07
Hp1 O 0 0.0033826495055109262
/ O 0 0.0003160229534842074
Hpdel O 0 0.0001728923962218687
, O 0 3.034000997104158e-07
showing O 0 1.5148417560340022e-06
an O 0 3.0048113330849446e-07
anomalous O 0 1.8095635823556222e-05
inheritance O 0 1.0098748134623747e-05
of O 0 7.123963996491511e-07
Hp O 0 0.00032744251075200737
phenotypes O 0 0.00010984659456880763
in O 0 2.8267007223803375e-07
the O 0 5.848366981808795e-07
child O 0 4.451007043826394e-05
with O 0 8.726092346478254e-06
Hp1 O 0 0.015965210273861885
. O 0 5.478169987327419e-05

The O 0 0.00011103620636276901
Hp2 O 0 0.06428387016057968
/ O 0 0.005058186128735542
Hpdel O 0 0.0010320442961528897
individuals O 0 1.2128346043027705e-06
had O 0 1.4065045661482145e-06
an O 0 2.3817193550712545e-07
extremely O 0 2.2782910491514485e-06
low O 0 1.1081767752330052e-06
level O 0 1.741905180097092e-07
of O 0 4.0705643300498195e-08
Hp O 0 1.2143565982114524e-05
( O 0 3.18657555453683e-07
mean O 0 1.967836851690663e-06
+ O 0 1.712332414172124e-05
/ O 0 1.1016154530807398e-05
- O 0 1.4449678928940557e-06
SD O 0 7.071160325722303e-06
= O 0 8.010725309759437e-07
0 O 0 1.091202577185868e-07
. O 0 1.2271529215013288e-07
049 O 0 0.00019078659533988684
+ O 0 2.3592901925439946e-05
/ O 0 1.2765895007760264e-05
- O 0 6.501009011117276e-07
0 O 0 1.7794351947486575e-07
. O 0 2.2773822649924114e-07
043 O 0 0.00010517812916077673
mg O 0 0.00014940013352315873
/ O 0 3.6444529541768134e-05
ml O 0 1.4991397620178759e-05
; O 0 3.0902174330549315e-07
n O 0 2.0061302166141104e-06
= O 0 2.8028684937453363e-06
6 O 0 2.2455326131876063e-07
) O 0 3.85923648593689e-08
, O 0 9.54162793220803e-09
compared O 0 4.1194734734517624e-08
with O 0 4.347006310467805e-09
the O 0 1.8598262485625128e-08
level O 0 1.4820737703757914e-07
( O 0 4.264230923922696e-08
1 O 0 2.0412448620277246e-08
. O 0 1.6611004127753404e-08
64 O 0 4.13551106248633e-07
+ O 0 3.1253757697413675e-06
/ O 0 2.6162610993196722e-06
- O 0 2.7814385816782305e-07
1 O 0 4.863276714672793e-08
. O 0 5.754974452543138e-08
07 O 0 1.0835948160092812e-05
mg O 0 4.7237212129402906e-05
/ O 0 9.171061719825957e-06
ml O 0 7.24496476323111e-06
) O 0 4.331985792305204e-08
obtained O 0 1.5482427784263564e-07
from O 0 1.7901376736517705e-07
52 O 0 2.8252848096599337e-06
healthy O 0 1.2499668628151994e-05
volunteers O 0 2.585410811661859e-06
having O 0 2.89947934106749e-06
phenotype O 0 0.00010086758993566036
Hp2 O 0 0.00020268582738935947
, O 0 1.306783303789416e-07
whereas O 0 5.969645258119272e-07
the O 0 4.784884595210315e-07
serum O 0 0.00042738791671581566
Hp O 0 5.3853050303587224e-06
level O 0 9.59457295834909e-08
of O 0 7.784976219227246e-09
an O 0 2.5553770655051267e-08
individual O 0 5.07015229800345e-08
with O 0 3.699264254919399e-07
Hp1 O 0 0.0027431456837803125
/ O 0 0.0003996972809545696
Hpdel O 0 0.00037910635001026094
was O 0 6.996501269895816e-06
0 O 0 7.88733632361982e-06
. O 0 7.733838174317498e-06

50 O 0 6.946590292500332e-05
mg O 0 0.005554674658924341
/ O 0 0.0005686628865078092
ml O 0 0.00010841676703421399
, O 0 7.036523896886138e-08
which O 0 1.5299214339847822e-08
was O 0 3.30988179086944e-08
approximately O 0 8.034456655536815e-09
half O 0 1.0072201739319553e-08
the O 0 4.0860341776749465e-09
level O 0 5.85875099545774e-08
of O 0 2.1435683450476972e-08
Hp O 0 6.726225819875253e-06
in O 0 1.4429886618927412e-07
control O 0 1.3373766023505596e-06
sera O 0 3.700455999933183e-05
from O 0 9.699138558971754e-08
the O 0 2.927101832028711e-07
Hp1 O 0 0.0002235169376945123
phenotype O 0 1.6278576367767528e-05
( O 0 1.4621720367813396e-07
1 O 0 9.7147093924832e-08
. O 0 3.372402446188971e-08
26 O 0 6.766647970835038e-07
+ O 0 4.727804025606019e-06
/ O 0 1.390651391375286e-06
- O 0 1.2544056460228603e-07
0 O 0 3.246228175157739e-08
. O 0 1.1976559299853307e-08
33 O 0 3.6229843658475147e-07
mg O 0 3.153617581119761e-05
/ O 0 5.589500688074622e-06
ml O 0 6.535885404446162e-06
; O 0 7.407764712752396e-08
n O 0 5.415771511252387e-07
= O 0 1.0047796195067349e-06
9 O 0 1.2018212203201983e-07
) O 0 2.8089479187087818e-08
, O 0 8.538194151697098e-09
showing O 0 2.5244409584956884e-07
a O 0 5.162732463759312e-07
gene O 0 1.3173043953429442e-05
- O 0 3.301848846604116e-05
dosage O 0 0.00018233929586131126
effect O 0 1.6476069504278712e-05
. O 0 1.3962691809865646e-05

The O 0 1.2231772643644945e-06
other O 0 3.1799331168258504e-07
allele O 0 9.92303012026241e-06
( O 0 1.5031048405944603e-06
Hp2 O 0 5.017868897994049e-05
) O 0 1.121321417940635e-07
of O 0 3.061029474338284e-08
individuals O 0 2.292194665187708e-07
with O 0 1.2473082051656093e-06
Hp2 O 0 0.03431078791618347
/ O 0 0.001474588643759489
Hpdel O 0 0.001087303040549159
was O 0 1.9106885247310856e-06
found O 0 1.1985076753262547e-07
to O 0 1.033821295237658e-08
have O 0 5.684897885771534e-09
, O 0 3.299926776278994e-09
in O 0 3.080390831300406e-09
all O 0 1.7145872499568782e-09
exons O 0 3.173879861151363e-07
, O 0 4.114644269748169e-08
no O 0 1.0690502705301697e-07
mutation O 0 7.344791583818733e-07
, O 0 3.139973259180806e-08
by O 0 8.062168888045562e-08
DNA O 0 5.694287665392039e-06
sequencing O 0 1.3101369404466823e-05
. O 0 1.045485714712413e-05

On O 0 3.273530637670774e-07
the O 0 5.8574880057449263e-08
basis O 0 7.285212877405911e-09
of O 0 9.95024418415369e-09
the O 0 4.5605375476043264e-08
present O 0 1.493566799126711e-07
study O 0 1.62706299988713e-07
, O 0 1.7335189284040098e-08
the O 0 1.0229254776561447e-08
mechanism O 0 2.1719910137107945e-07
of O 0 2.395102960406348e-08
anhaptoglobinemia B-Disease 0 2.9822103897458874e-05
and O 0 1.5043417178617347e-08
the O 0 1.2532667348352788e-08
mechanism O 0 2.543410744237917e-07
of O 0 3.403880555197247e-08
anomalous O 0 6.089556700317189e-05
inheritance O 0 2.1484476746991277e-05
of O 0 1.1287173720120336e-06
Hp O 0 0.0013948518317192793
phenotypes O 0 0.0002721748314797878
were O 0 7.427458399433817e-07
well O 0 2.070957179967081e-06
explained O 0 5.0881139031844214e-05
. O 0 1.7785199815989472e-05

However O 0 4.9976524678641e-06
, O 0 5.078132403468771e-07
the O 0 2.8075183422515693e-07
mechanism O 0 3.911141448043054e-06
of O 0 1.3375819207794848e-06
hypohaptoglobinemia B-Disease 0 0.008252558298408985
remains O 0 0.00021487973572220653
unknown O 0 0.0003436315164435655

ATM O 0 0.0024896860122680664
mutations O 0 0.00020966268493793905
and O 0 9.795338883122895e-06
phenotypes O 0 0.008032354526221752
in O 0 0.0006553223938681185
ataxia B-Disease 1 0.999491810798645
- I-Disease 1 0.792681097984314
telangiectasia I-Disease 1 0.9908688068389893
families O 0 1.3131200375937624e-06
in O 0 1.522593464642341e-07
the O 0 1.6979264216843148e-07
British O 0 1.6450618431917974e-06
Isles O 0 9.372365070703381e-07
: O 0 3.498940515100912e-08
expression O 0 3.910227874825978e-08
of O 0 1.9480033586205536e-08
mutant O 0 6.595079867111053e-06
ATM O 0 1.4648165233666077e-05
and O 0 7.447745531408145e-08
the O 0 4.4333035020827083e-07
risk O 0 0.0002564711030572653
of O 0 1.716932274575811e-05
leukemia B-Disease 1 0.999902606010437
, O 0 0.05703532695770264
lymphoma B-Disease 1 0.9999643564224243
, O 0 0.00037244593841023743
and O 0 0.0021991890389472246
breast B-Disease 1 0.9993771910667419
cancer I-Disease 1 0.9986010193824768
. O 0 0.00017585033492650837

We O 0 7.215022037598828e-07
report O 0 6.200035045367258e-07
the O 0 3.9959228814723247e-08
spectrum O 0 3.248551649903675e-07
of O 0 5.7667751462986416e-08
59 O 0 6.6242259890714195e-06
ATM O 0 6.095122080296278e-05
mutations O 0 1.3659726391779259e-05
observed O 0 4.672759587265318e-06
in O 0 1.5698587958468124e-05
ataxia B-Disease 1 0.9989104270935059
- I-Disease 0 0.16999512910842896
telangiectasia I-Disease 1 0.9932291507720947
( O 0 2.5634211851865984e-05
A B-Disease 0 0.020282432436943054
- I-Disease 0 0.15077462792396545
T I-Disease 1 0.9959020018577576
) O 0 2.4594266960775713e-06
patients O 0 0.000162233947776258
in O 0 1.826350484179784e-07
the O 0 8.903756452127709e-07
British O 0 2.6639276256901212e-05
Isles O 0 0.00010961764928651974
. O 0 2.9628179618157446e-05

Of O 0 1.4734953310835408e-06
51 O 0 3.573658977984451e-05
ATM O 0 0.00045935605885460973
mutations O 0 3.8189140468603e-05
identified O 0 1.8616985926200869e-06
in O 0 1.0577770126474206e-07
families O 0 1.440675845287842e-07
native O 0 7.898093201674783e-08
to O 0 1.756437306710268e-08
the O 0 1.1732825555554882e-07
British O 0 1.6340588899765862e-06
Isles O 0 3.033016810150002e-06
, O 0 8.705868026481767e-08
11 O 0 2.2723186532402906e-07
were O 0 3.2106736824744075e-08
founder O 0 3.852683676086599e-06
mutations O 0 6.498566449408827e-07
, O 0 1.2855223552321604e-08
and O 0 3.4786431513111893e-09
2 O 0 1.710661656773027e-08
of O 0 3.3644729224846515e-09
these O 0 1.7844781652343045e-08
11 O 0 9.905575097945984e-07
conferred O 0 1.720435102470219e-05
a O 0 3.8119585497042863e-06
milder O 0 0.0022439579479396343
clinical O 0 0.0004083183885086328
phenotype O 0 0.0001619336544536054
with O 0 1.8513222244109784e-07
respect O 0 2.121367401741736e-07
to O 0 2.1888507717449102e-07
both O 0 4.671387614507694e-06
cerebellar B-Disease 1 0.997931718826294
degeneration I-Disease 1 0.9993185997009277
and O 0 1.6059282643254846e-05
cellular O 0 0.001653769752010703
features O 0 0.00011455435742391273
. O 0 5.885552673134953e-05

We O 0 1.1008728506567422e-06
report O 0 6.632213853663416e-07
, O 0 4.254400565173455e-08
in O 0 2.9239650700674247e-08
two O 0 1.2603220511664404e-07
A B-Disease 0 0.0009532792610116303
- I-Disease 0 0.0008040599641390145
T I-Disease 0 0.08161349594593048
families O 0 9.694995384279537e-08
, O 0 2.0202360673238218e-08
an O 0 4.6821263310903305e-08
ATM O 0 7.2489110607421026e-06
mutation O 0 2.1150356133148307e-06
( O 0 4.6004987552805687e-07
7271T O 0 5.163408422959037e-05
- O 0 1.966251693374943e-05
- O 0 7.126897799025755e-06
> O 0 1.870887899713125e-05
G O 0 1.7458616639487445e-05
) O 0 1.7819485265135881e-07
that O 0 3.667872050527876e-08
may O 0 1.6285532922211132e-07
be O 0 9.702151082535693e-09
associated O 0 4.9181544170551206e-08
with O 0 3.1197895822288046e-08
an O 0 1.9249895899520197e-07
increased O 0 6.674722499155905e-06
risk O 0 0.0002065537846647203
of O 0 1.0054092854261398e-05
breast B-Disease 1 0.999776303768158
cancer I-Disease 1 0.9985666871070862
in O 0 3.405459381156106e-07
both O 0 2.8558289955071814e-07
homozygotes O 0 0.0014739625621587038
and O 0 6.69706309963658e-07
heterozygotes O 0 0.0005427025025710464
( O 0 1.0538476544752484e-06
relative O 0 2.6511174837651197e-06
risk O 0 1.2122796761104837e-05
12 O 0 1.566881451253721e-07
. O 0 4.4537628696161846e-08
7 O 0 3.52198753716948e-07
; O 0 3.8350989939317515e-07
P O 0 6.309759191935882e-05
= O 0 4.961617378285155e-06
. O 0 2.2547772005054867e-07
0025 O 0 0.0004228537727613002
) O 0 9.428057268223711e-08
, O 0 1.3242917873412807e-08
although O 0 1.9991041710909485e-08
there O 0 1.0942534878211063e-08
is O 0 2.566856416308383e-08
a O 0 5.05862885802344e-07
less O 0 5.1501365305739455e-06
severe O 1 0.9899590611457825
A B-Disease 0 0.2797543406486511
- I-Disease 0 0.22424431145191193
T I-Disease 1 0.9940284490585327
phenotype O 0 2.3246882847161032e-05
in O 0 1.4547412163778972e-08
terms O 0 1.2684945538410375e-08
of O 0 9.344394591437322e-09
the O 0 1.5585921175897965e-07
degree O 0 6.342790584312752e-06
of O 0 9.897635209199507e-06
cerebellar B-Disease 1 0.9980886578559875
degeneration I-Disease 1 0.9991559982299805
. O 0 0.001113620470277965

This O 0 2.2210895167518174e-06
mutation O 0 2.58110994764138e-05
( O 0 7.069494586176006e-06
7271T O 0 0.00043360170093365014
- O 0 9.495436097495258e-05
- O 0 1.4193949027685449e-05
> O 0 1.6951229554251768e-05
G O 0 6.4679020397306886e-06
) O 0 3.1204979933363575e-08
also O 0 5.849815298830663e-09
allows O 0 8.192047928901047e-09
expression O 0 1.0090083435443375e-08
of O 0 4.057725266903844e-09
full O 0 1.9775299620050646e-07
- O 0 5.720817171095405e-07
length O 0 1.7627374404582952e-07
ATM O 0 1.920995146065252e-06
protein O 0 1.6610789543847204e-07
at O 0 8.173307008974007e-08
a O 0 8.389391581431482e-08
level O 0 2.3724338404917944e-07
comparable O 0 7.068484251249174e-07
with O 0 3.437993001398354e-08
that O 0 1.4665850756045984e-07
in O 0 1.1593141380217276e-06
unaffected O 0 0.00032988088787533343
individuals O 0 3.7607776448567165e-06
. O 0 1.2570485523610841e-05

In O 0 2.2590268144995207e-06
addition O 0 1.3665452343047946e-06
, O 0 1.1628892337967045e-07
we O 0 2.0777047637920987e-08
have O 0 3.0041835685779006e-08
studied O 0 5.697154961126216e-07
18 O 0 5.3220210247673094e-06
A B-Disease 0 0.016665900126099586
- I-Disease 0 0.40361446142196655
T I-Disease 1 0.9987403750419617
patients O 0 0.0005105439922772348
, O 0 5.927585888798603e-08
in O 0 2.7041533456895195e-08
15 O 0 1.9946827478634077e-07
families O 0 1.4975718443110964e-07
, O 0 2.4664515763106465e-07
who O 0 6.544667485286482e-06
developed O 0 0.01056045014411211
leukemia B-Disease 1 0.9997946619987488
, O 0 0.003895470639690757
lymphoma B-Disease 1 0.9999080896377563
, O 0 0.00018191765411756933
preleukemic O 1 0.9592827558517456
T O 1 0.9959408044815063
- O 0 0.001359016285277903
cell O 0 0.000617179844994098
proliferation O 0 0.004092469345778227
, O 0 1.2601572962012142e-05
or O 0 0.0024414951913058758
Hodgkin B-Disease 1 0.9998522996902466
lymphoma I-Disease 1 0.9999518394470215
, O 0 4.632502623280743e-06
mostly O 0 2.227019876954728e-06
in O 0 5.1481820264598355e-06
childhood O 0 0.0115486029535532
. O 0 6.041017695679329e-05

A O 0 8.198604518838692e-06
wide O 0 1.961977432074491e-06
variety O 0 5.341418045645696e-07
of O 0 1.2374027846817626e-07
ATM O 0 0.00016497969045303762
mutation O 0 1.5072451788000762e-05
types O 0 6.757362029929936e-07
, O 0 6.896570425851678e-08
including O 0 2.0229165897944767e-07
missense O 0 6.76532436045818e-05
mutations O 0 3.2324460335075855e-06
and O 0 1.5274903830686526e-07
in O 0 2.823424551934295e-07
- O 0 9.48038086789893e-06
frame O 0 6.944040706002852e-06
deletions O 0 6.944418146304088e-06
, O 0 1.8004928392656439e-07
were O 0 1.3944585930403264e-07
seen O 0 1.5875299368417473e-06
in O 0 2.9186085725996236e-07
these O 0 8.991544291347964e-07
patients O 0 0.0192120224237442
. O 0 3.504717460600659e-05

We O 0 6.61478622987488e-07
also O 0 1.1907548014278291e-07
show O 0 6.643760741553706e-08
that O 0 3.6508751577457588e-09
25 O 0 1.6779999612026586e-08
% O 0 1.399865201534567e-08
of O 0 1.017436357386714e-08
all O 0 1.4483603649750876e-07
A B-Disease 0 0.016267720609903336
- I-Disease 0 0.16656441986560822
T I-Disease 1 0.9962682127952576
patients O 0 0.00029544654535129666
carried O 0 7.58935186695453e-07
in O 0 3.206995984328387e-07
- O 0 5.0777284741343465e-06
frame O 0 9.30321493797237e-06
deletions O 0 4.925861958327005e-06
or O 0 7.00266298281349e-07
missense O 0 5.5565975344507024e-05
mutations O 0 3.0625997169408947e-06
, O 0 2.1007652506455088e-08
many O 0 3.412583327033758e-09
of O 0 3.9473642132747955e-09
which O 0 2.0141762036018918e-08
were O 0 9.896623076599553e-09
also O 0 1.908006019846198e-08
associated O 0 6.403187313708258e-08
with O 0 1.0617081436237186e-08
expression O 0 9.805835787801698e-08
of O 0 1.1778925568250997e-07
mutant O 0 4.5418826630339026e-05
ATM O 0 0.000214616404264234
protein O 0 4.220682239974849e-05
. O 0 1.813756716728676e-05

The O 0 5.068423706688918e-05
DMPK O 0 0.03386171907186508
gene O 0 0.00026212737429887056
of O 0 9.5270988822449e-05
severely O 1 0.9950824975967407
affected O 1 0.9893336892127991
myotonic B-Disease 1 0.9998199343681335
dystrophy I-Disease 1 0.9999421834945679
patients O 1 0.9952638149261475
is O 0 2.0400269931997173e-05
hypermethylated O 0 0.008372437208890915
proximal O 0 0.0005370444850996137
to O 0 5.482235678755387e-07
the O 0 7.318724897231732e-07
largely O 0 4.777160484081833e-06
expanded O 0 3.132653728243895e-05
CTG O 0 0.01716787926852703
repeat O 0 0.0007644522120244801
. O 0 3.141167326248251e-05

Using O 0 8.513888133165892e-06
methylation O 0 8.300107583636418e-05
- O 0 2.438152841932606e-05
sensitive O 0 2.502873712728615e-06
restriction O 0 1.7858353658084525e-06
enzymes O 0 1.0837122772500152e-06
, O 0 7.946643876266535e-08
we O 0 2.730195625133547e-08
characterized O 0 1.4375442560776719e-06
the O 0 2.591492531678341e-08
methylation O 0 6.205578415574564e-07
pattern O 0 9.387913451064378e-07
on O 0 2.0705639869333936e-08
the O 0 3.779758728228444e-08
5 O 0 7.487855668841803e-08
side O 0 6.859797707647886e-08
of O 0 8.808620499678455e-09
the O 0 1.5198573066754761e-07
CTG O 0 0.00042563193710520864
repeat O 0 3.921389634342631e-06
in O 0 5.797544844199365e-08
the O 0 1.943127898584862e-07
DMPK O 0 9.613724250812083e-05
gene O 0 2.9576372639894544e-07
of O 0 2.3815234229118687e-08
normal O 0 8.25784354674397e-07
individuals O 0 1.5540295805749338e-07
and O 0 2.0884685625333077e-07
of O 0 3.1119564027903834e-06
patients O 1 0.9333663582801819
affected O 0 0.0025688831228762865
with O 0 0.007291676010936499
myotonic B-Disease 1 0.9998811483383179
dystrophy I-Disease 1 0.9998730421066284
, O 0 6.714516530337278e-06
showing O 0 1.430130305379862e-05
expansions O 0 6.801580184401246e-06
of O 0 1.1547973599590478e-07
the O 0 2.204286374762887e-06
repetitive O 0 0.0017386034596711397
sequence O 0 3.5926579585066065e-05
. O 0 3.6073786759516224e-05

The O 0 4.20506239606766e-06
gene O 0 1.3117083653924055e-05
segment O 0 7.911927241366357e-06
analyzed O 0 1.5338155208155513e-06
corresponds O 0 6.996628485467227e-07
to O 0 8.064291989740013e-08
the O 0 5.960191060694342e-07
genomic O 0 6.096180732129142e-05
SacI O 0 0.002440898446366191
- O 0 3.2909592846408486e-05
HindIII O 0 6.582999048987404e-05
fragment O 0 6.530452537845122e-06
carrying O 0 1.1117939493487938e-06
exons O 0 1.1214085134270135e-05
11 O 0 3.499419108266011e-06
- O 0 1.6878317183000036e-05
15 O 0 3.4376564599369885e-06
. O 0 5.136892468726728e-06

There O 0 1.390639567944163e-06
is O 0 2.995338377331791e-07
constitutive O 0 1.29982981889043e-05
methylation O 0 3.2990337786031887e-06
in O 0 4.0308836446456553e-07
intron O 0 0.0001355395361315459
12 O 0 3.453694716881728e-07
at O 0 1.5264041053342225e-07
restriction O 0 2.7340317387825053e-07
sites O 0 4.271907627639848e-08
of O 0 5.677608072574003e-08
SacII O 0 0.0001589361490914598
and O 0 2.711891511353315e-07
HhaI O 0 9.952823165804148e-05
, O 0 3.2251253401227586e-07
localized O 0 6.146653504401911e-06
1 O 0 3.192561734977062e-07
, O 0 8.97848764225273e-08
159 O 0 1.2030587868139264e-06
- O 0 7.149895395741623e-07
1 O 0 6.040023947662121e-08
, O 0 1.756591316848244e-08
232 O 0 5.590351861428644e-07
bp O 0 2.319182158316835e-06
upstream O 0 3.4944395110869664e-07
of O 0 2.1361930890861913e-08
the O 0 4.646930733542831e-07
CTG O 0 0.0011662396136671305
repeat O 0 2.3455808332073502e-05
, O 0 1.1428596735640895e-07
whereas O 0 2.9065702733532817e-07
most O 0 2.733619197670123e-08
, O 0 2.935817811078323e-08
if O 0 1.0402140482312916e-08
not O 0 1.093042989452897e-09
all O 0 5.193214192011908e-10
, O 0 1.4368874978742951e-09
of O 0 9.349577778650087e-10
the O 0 3.665443726319495e-09
other O 0 2.399033416367047e-09
sites O 0 2.9174580973290176e-08
of O 0 3.9424826070444396e-08
SacII O 0 0.00024570681853219867
, O 0 4.6815281962153676e-07
HhaI O 0 9.33429691940546e-05
, O 0 1.0475514500285499e-07
and O 0 1.5150396848184755e-07
HpaII O 0 4.884436566499062e-05
in O 0 5.422573678970366e-08
this O 0 2.693513145857196e-08
region O 0 1.3307895585512597e-07
are O 0 8.205026880148125e-09
unmethylated O 0 2.3442144083674066e-05
, O 0 6.020701448505861e-08
in O 0 4.0821568347837456e-08
normal O 0 3.730593221007439e-07
individuals O 0 3.4917601254846886e-08
and O 0 8.232820647435801e-09
most O 0 1.5645184703316772e-08
of O 0 9.351190755069183e-08
the O 0 1.2054467333655339e-05
patients O 0 0.1963314265012741
. O 0 3.715976345119998e-05

In O 0 6.056129109310859e-07
a O 0 3.0849378163111396e-07
number O 0 5.113642487231118e-08
of O 0 2.5584986929061415e-07
young O 0 2.5050156182260253e-05
and O 0 8.400395017815754e-06
severely O 1 0.983316957950592
affected O 0 0.0008416066993959248
patients O 0 0.01946416310966015
, O 0 1.4112607971128455e-07
however O 0 8.66698286472456e-08
, O 0 1.049655118379178e-08
complete O 0 4.4705718238446934e-08
methylation O 0 8.182619382068879e-08
of O 0 2.025613676792659e-09
these O 0 4.267914910371928e-09
restriction O 0 2.3997768039407674e-07
sites O 0 5.1133302036987516e-08
was O 0 1.9474468615499063e-07
found O 0 8.762960845842827e-08
in O 0 8.116138872082956e-08
the O 0 7.167003559516161e-07
mutated O 0 0.00013091377331875265
allele O 0 9.87909734249115e-05
. O 0 2.0237386706867255e-05

In O 0 7.642794912499085e-07
most O 0 1.1045224113104268e-07
of O 0 8.119730665612224e-08
these O 0 7.961206165418844e-07
patients O 0 0.005311587825417519
, O 0 8.010984515749442e-07
the O 0 1.8904427179222694e-06
onset O 1 0.8126800656318665
of O 0 5.551384674618021e-06
the O 0 0.004054118413478136
disease O 1 0.999517560005188
was O 1 0.7338900566101074
congenital O 1 0.9997418522834778
. O 0 0.001107341144233942

Preliminary O 0 1.9093979062745348e-05
in O 0 4.629892373486655e-06
vivo O 0 0.0001017299946397543
footprinting O 0 0.0015009093331173062
data O 0 2.9797996603520005e-07
gave O 0 4.4126267084720894e-07
evidence O 0 2.3772670942889818e-07
for O 0 2.795846754111153e-08
protein O 0 1.0464076467542327e-06
- O 0 1.3760813999397215e-06
DNA O 0 2.6430140565025795e-07
contact O 0 1.3223285577623756e-07
in O 0 1.634608359779577e-08
normal O 0 3.5400373121774464e-07
genes O 0 1.319161953006187e-07
at O 0 1.2167210172719933e-07
an O 0 1.9662503802919673e-07
Sp1 O 0 0.0003550388209987432
consensus O 0 1.3391641573434754e-07
binding O 0 1.4993752017744555e-07
site O 0 1.6635299004974513e-07
upstream O 0 2.1980129361054423e-07
of O 0 1.4566265527093947e-08
the O 0 2.9722784233854327e-07
CTG O 0 0.00031821971060708165
repeat O 0 2.174570226998185e-06
and O 0 9.986901972069973e-09
for O 0 5.4486868350522855e-09
a O 0 3.3015904676858554e-08
significant O 0 6.367101690329946e-08
reduction O 0 2.9389954647740524e-07
of O 0 1.6718495476908402e-09
this O 0 3.517675262187936e-09
interaction O 0 5.585386020356964e-08
in O 0 6.976280531034718e-08
cells O 0 1.178085199171619e-06
with O 0 8.644942539604017e-08
a O 0 2.582113893367932e-06
hypermethylated O 0 0.0018751304596662521
DMPK O 0 0.013219804503023624
gene O 0 5.013037662138231e-05
. O 0 4.463587174541317e-06
. O 0 1.2993986274523195e-05

The O 0 0.00021256765467114747
hemochromatosis B-Disease 1 0.9960822463035583
gene O 0 3.3860480471048504e-05
product O 0 6.229977316252189e-06
complexes O 0 1.0001590453612152e-05
with O 0 1.5544594589300686e-07
the O 0 6.698959964523965e-07
transferrin O 0 0.0018864870071411133
receptor O 0 1.03906668300624e-05
and O 0 1.4514714052893396e-07
lowers O 0 7.5494812335819e-05
its O 0 4.509787743245397e-08
affinity O 0 4.304591527670709e-07
for O 0 5.070916131444392e-08
ligand O 0 9.045332262758166e-06
binding O 0 9.716229214973282e-06
. O 0 1.3999358998262323e-05

We O 0 2.4847254280757625e-06
recently O 0 1.1553514013940003e-05
reported O 0 2.353691570533556e-06
the O 0 1.3497266593276436e-07
positional O 0 1.8118594198313076e-06
cloning O 0 1.0576434306130977e-06
of O 0 3.078178067994486e-08
a O 0 5.158735802979209e-07
candidate O 0 1.563429009365791e-06
gene O 0 2.3513724954682402e-05
for O 0 2.3467599021387286e-05
hereditary B-Disease 1 0.9989151954650879
hemochromatosis I-Disease 1 0.9998406171798706
called O 0 0.0602811761200428
HFE O 1 0.993073582649231
. O 0 0.00023106826120056212

The O 0 1.7077753682315233e-06
gene O 0 5.060489911556942e-06
product O 0 8.093119845398178e-07
, O 0 3.1828090385488395e-08
a O 0 3.1664121991070715e-08
member O 0 2.334556370442442e-08
of O 0 5.255374802004553e-09
the O 0 2.45451730052082e-07
major O 0 1.4951793673390057e-05
histocompatibility O 1 0.6667933464050293
complex O 0 3.264487168053165e-05
class O 0 6.903336907271296e-05
I O 0 2.565076829341706e-05
- O 0 4.401633304951247e-06
like O 0 1.2517763536834536e-07
family O 0 3.072465233344701e-07
, O 0 3.046938701345425e-08
was O 0 1.0729438315593143e-07
found O 0 2.791306918936698e-08
to O 0 3.263958214816398e-09
have O 0 4.705230427504148e-09
a O 0 1.169007006751599e-07
mutation O 0 2.155599531761254e-06
, O 0 8.892088203538151e-07
Cys O 0 0.0024818943347781897
- O 0 2.4507902708137408e-05
282 O 0 5.8405494200997055e-05
- O 0 5.9760306612588465e-05
- O 0 1.2940661690663546e-05
> O 0 2.623190994199831e-05
Tyr O 0 0.00023520532704424113
( O 0 3.4125565662179724e-07
C282Y O 0 3.1439101348951226e-06
) O 0 2.4568679535263982e-08
, O 0 7.853341088548405e-09
in O 0 9.406714518434e-09
85 O 0 2.3142828808886406e-07
% O 0 7.716576533312036e-08
of O 0 1.8817858915554098e-07
patient O 0 0.000906436936929822
chromosomes O 0 6.746280996594578e-05
. O 0 4.5715616579400375e-05

This O 0 1.9347528450452955e-06
mutation O 0 1.9669287212309428e-05
eliminates O 0 1.80429397005355e-05
the O 0 2.3255664416410582e-07
ability O 0 4.2663705812628905e-07
of O 0 2.569811101693631e-07
HFE O 0 0.015784213319420815
to O 0 2.2804923105468333e-07
associate O 0 2.1161208678677212e-06
with O 0 9.022706990435836e-07
beta2 O 0 0.0022644337732344866
- O 0 5.641868483508006e-05
microglobulin O 0 0.00021045639005023986
( O 0 1.8667014956008643e-06
beta2m O 0 0.00011023746628779918
) O 0 4.347622279965435e-07
and O 0 2.544017263517162e-07
prevents O 0 7.651200576219708e-05
cell O 0 0.00030068313935771585
- O 0 4.219527181703597e-05
surface O 0 1.4386975635716226e-05
expression O 0 6.952675448701484e-06
. O 0 1.2326119758654386e-05

A O 0 1.791997237887699e-05
second O 0 4.197221642243676e-06
mutation O 0 1.610555591469165e-05
that O 0 1.5658507379612274e-07
has O 0 1.841587788931065e-07
no O 0 2.44220046852206e-07
effect O 0 1.131083763539209e-06
on O 0 8.68389179231599e-07
beta2m O 0 0.001060240319930017
association O 0 1.5026394976302981e-05
, O 0 4.791122023561911e-07
H63D O 0 0.0002731405838858336
, O 0 9.298651093558874e-08
was O 0 1.65063781309982e-07
found O 0 2.910360841212878e-08
in O 0 4.0908765264191516e-09
eight O 0 4.808174303150281e-09
out O 0 3.6191074581637395e-09
of O 0 7.797012813171023e-09
nine O 0 7.310312071240332e-07
patients O 0 0.00010864549403777346
heterozygous O 0 2.407268311799271e-06
for O 0 1.0111955361935543e-07
the O 0 1.056651399267139e-06
C282Y O 0 0.0005389748839661479
mutant O 0 0.0002595499390736222
. O 0 2.3069054805091582e-05

In O 0 2.453927891110652e-06
this O 0 4.780350764121977e-07
report O 0 1.0399638767921715e-06
, O 0 8.278109930870414e-08
we O 0 1.0367714686765339e-08
demonstrate O 0 2.661988958152506e-07
in O 0 1.6143425796144584e-07
cultured O 0 1.879202318377793e-05
293 O 0 9.279459482058883e-05
cells O 0 6.452793604694307e-05
overexpressing O 0 0.0014228635700419545
wild O 0 9.452449376112781e-06
- O 0 2.681381556612905e-05
type O 0 8.695238648215309e-06
or O 0 5.344153919395467e-07
mutant O 0 3.97290350520052e-05
HFE O 0 0.004085362423211336
proteins O 0 3.411863360724965e-07
that O 0 1.6373668643154815e-08
both O 0 1.681238970263621e-08
the O 0 8.139936369389034e-08
wild O 0 3.384971023479011e-06
- O 0 1.2381751730572432e-05
type O 0 5.595404672931181e-06
and O 0 3.422853183110419e-07
H63D O 0 0.002220426918938756
HFE O 0 0.007962043397128582
proteins O 0 9.308657240580942e-07
form O 0 1.360337705591519e-06
stable O 0 1.871232052508276e-05
complexes O 0 1.0836279216164257e-05
with O 0 2.739277533692075e-07
the O 0 1.0861604096135125e-06
transferrin O 0 0.015898048877716064
receptor O 0 0.0001521883677924052
( O 0 1.67459984368179e-05
TfR O 0 0.03709091246128082
) O 0 1.0359024599893019e-05
. O 0 1.5858980987104587e-05

The O 0 2.1524505427805707e-05
C282Y O 0 0.0008343139779753983
mutation O 0 7.417187589453533e-05
nearly O 0 9.446122930967249e-06
completely O 0 1.376333057123702e-05
prevents O 0 1.4143021871859673e-05
the O 0 1.7954687336896313e-07
association O 0 1.5126446442081942e-06
of O 0 4.5323290009946504e-08
the O 0 5.153985398465011e-07
mutant O 0 6.552334525622427e-05
HFE O 0 0.010334177874028683
protein O 0 5.499723101820564e-06
with O 0 1.5748679516036646e-06
the O 0 1.0352980098105036e-05
TfR O 1 0.5934761166572571
. O 0 7.502731023123488e-05

Studies O 0 2.0346720702946186e-05
on O 0 7.308776275749551e-06
cell O 0 0.00025050397380255163
- O 0 4.388728484627791e-05
associated O 0 4.879686002823291e-06
transferrin O 0 0.00020528897584881634
at O 0 6.022332854627166e-07
37 O 0 7.171981337705802e-07
degrees O 0 7.033557949398528e-07
C O 0 9.764718924998306e-06
suggest O 0 7.041208505143004e-07
that O 0 3.750072252728387e-08
the O 0 1.9839183096337365e-07
overexpressed O 0 0.00016568451246712357
wild O 0 5.424804840004072e-06
- O 0 1.2587399396579713e-05
type O 0 1.4951023331377655e-05
HFE O 0 0.002127749612554908
protein O 0 1.7531623370814486e-06
decreases O 0 1.3314260058905347e-06
the O 0 2.7518556322547738e-08
affinity O 0 4.0156206182473397e-07
of O 0 7.806539770172094e-08
the O 0 1.5082409845490474e-06
TfR O 0 0.016492128372192383
for O 0 6.092879175412236e-06
transferrin O 0 0.04402218014001846
. O 0 3.4020631574094296e-05

The O 0 3.564792132237926e-05
overexpressed O 0 0.005482983775436878
H63D O 0 0.005843278486281633
protein O 0 1.5400479242089204e-05
does O 0 8.588501714257291e-07
not O 0 4.072676773603234e-08
have O 0 7.877764218733319e-09
this O 0 8.771150028508146e-09
effect O 0 5.807162040127878e-08
, O 0 3.621662081343402e-09
providing O 0 9.75049552209839e-09
the O 0 3.851153174139199e-09
first O 0 6.98867763659905e-09
direct O 0 1.010547290292152e-08
evidence O 0 5.4866603704795125e-08
for O 0 8.299528175825799e-09
a O 0 1.2905000801310962e-07
functional O 0 8.313139687743387e-07
consequence O 0 2.7642604436550755e-06
of O 0 1.0821244700309762e-07
the O 0 3.5836010283674113e-06
H63D O 0 0.05418780446052551
mutation O 0 0.00038476366898976266
. O 0 3.1205778213916346e-05

Addition O 0 6.98127769283019e-06
of O 0 2.2071176317695063e-06
soluble O 0 0.003633646760135889
wild O 0 0.0001257868716493249
- O 0 0.0006741335964761674
type O 0 0.0013597840443253517
HFE O 1 0.976965069770813
/ O 0 0.002755544614046812
beta2m O 0 0.0015168143436312675
heterodimers O 0 0.0031200291123241186
to O 0 1.2783115153069957e-06
cultured O 0 6.820482667535543e-05
cells O 0 1.6429828974651173e-05
also O 0 3.2154912332771346e-07
decreased O 0 5.433326805359684e-06
the O 0 7.803696178143582e-08
apparent O 0 2.0147274426562944e-06
affinity O 0 3.8328209939209046e-07
of O 0 1.2839564966782291e-08
the O 0 2.4874705673028075e-07
TfR O 0 0.00034459715243428946
for O 0 1.250337078317898e-08
its O 0 4.088226646103976e-08
ligand O 0 1.4880959042784525e-06
under O 0 1.2553573469631374e-06
steady O 0 2.1080571968923323e-05
- O 0 1.946835482158349e-06
state O 0 1.367666015994473e-07
conditions O 0 1.1265869943599682e-06
, O 0 3.5546101173622446e-08
both O 0 1.8902749587823564e-08
in O 0 1.443349333385413e-07
293 O 0 2.4773269615252502e-05
cells O 0 4.995012659492204e-06
and O 0 2.7436175287220976e-07
in O 0 3.7901472751400433e-06
HeLa O 0 0.0446532778441906
cells O 0 0.00021835340885445476
. O 0 2.29100878641475e-05

Furthermore O 0 1.28715892060427e-05
, O 0 2.6190519974989e-07
at O 0 1.8392113076970418e-07
4 O 0 1.6912777311972604e-07
degrees O 0 1.7171613819755294e-07
C O 0 3.105730002062046e-06
, O 0 1.5925515128856205e-08
the O 0 3.981262963748122e-08
added O 0 5.679730179508624e-07
soluble O 0 1.9924344087485224e-05
complex O 0 2.8471154109865893e-06
of O 0 1.7293632481596433e-06
HFE O 1 0.9829372763633728
/ O 0 0.001304586068727076
beta2m O 0 0.00037594392779283226
inhibited O 0 1.604265889909584e-05
binding O 0 9.188809144689003e-07
of O 0 4.202329932923021e-07
transferrin O 0 0.003182979766279459
to O 0 2.3745940325170523e-06
HeLa O 0 0.0048539843410253525
cell O 0 0.00013238968676887453
TfR O 0 0.0027636976446956396
in O 0 3.5670362308337644e-07
a O 0 3.294914677098859e-06
concentration O 0 0.00027826300356537104
- O 0 3.2762389309937134e-05
dependent O 0 4.150582299189409e-06
manner O 0 9.154888175544329e-06
. O 0 1.4000935152580496e-05

Scatchard O 0 0.00017752646817825735
plots O 0 1.5782476339154528e-06
of O 0 4.4427839185345874e-08
these O 0 2.774337914956959e-08
data O 0 1.7455272427469026e-07
indicate O 0 3.655978275673988e-07
that O 0 2.2426428714084068e-08
the O 0 6.930366680535371e-08
added O 0 8.010816827663803e-07
heterodimer O 0 0.00026645249454304576
substantially O 0 1.546989551570732e-05
reduced O 0 9.140834436038858e-07
the O 0 5.942800740399434e-08
affinity O 0 1.5435266504937317e-06
of O 0 3.8363171483979386e-07
TfR O 0 0.02497699111700058
for O 0 2.637963007146027e-06
transferrin O 0 0.048092763870954514
. O 0 2.9715049095102586e-05

These O 0 5.34429148046911e-07
results O 0 1.2227026218170067e-06
establish O 0 6.239331469259923e-07
a O 0 1.0435425110699725e-06
molecular O 0 7.728116543148644e-06
link O 0 1.9079925550613552e-05
between O 0 1.6045270285758306e-06
HFE O 0 0.026274463161826134
and O 0 8.578403054571027e-08
a O 0 1.0994085641868878e-07
key O 0 1.2012344541290076e-07
protein O 0 4.208405925965053e-07
involved O 0 3.1057192018124624e-07
in O 0 4.2029191149595135e-07
iron O 0 0.013965200632810593
transport O 0 8.556833563488908e-06
, O 0 1.724937703784235e-07
the O 0 2.9458422545758367e-07
TfR O 0 0.0031190640293061733
, O 0 8.607117507608564e-08
and O 0 2.549383992800358e-08
raise O 0 1.4289480532170273e-07
the O 0 2.66013291394529e-08
possibility O 0 3.053725947665953e-07
that O 0 3.783321389505545e-08
alterations O 0 3.3276173780905083e-06
in O 0 3.844432683308696e-08
this O 0 3.098145739954816e-08
regulatory O 0 4.486542366066715e-06
mechanism O 0 1.007496962301957e-06
may O 0 1.3364162043671968e-07
play O 0 8.6051272774057e-09
a O 0 6.970122257143885e-08
role O 0 1.5485558435557323e-07
in O 0 9.01675747400077e-08
the O 0 9.940893050952582e-07
pathogenesis O 0 0.30098292231559753
of O 0 0.0001343725889455527
hereditary B-Disease 1 0.9995063543319702
hemochromatosis I-Disease 1 0.999937891960144
. O 0 0.00015856118989177048
. O 0 0.00010134155309060588

Genomic O 0 4.117747084819712e-05
organization O 0 8.417037520302983e-07
of O 0 1.4568105655143881e-07
the O 0 5.839923687744886e-06
UBE3A O 0 0.08046534657478333
/ O 0 0.000680171069689095
E6 O 0 0.004131623078137636
- O 0 3.083852425334044e-05
AP O 0 1.6442854757769965e-05
gene O 0 4.104739218746545e-06
and O 0 7.662192729185335e-07
related O 0 2.2958005502005108e-05
pseudogenes O 0 0.0010943656088784337
. O 0 6.624707020819187e-05

The O 0 1.9674296709126793e-05
UBE3A O 0 0.0011593303643167019
gene O 0 4.291963705327362e-06
encodes O 0 2.7001208309229696e-06
the O 0 1.2493355825426988e-06
E6 O 0 0.0017555367667227983
- O 0 2.605414920253679e-05
AP O 0 1.1528716640896164e-05
ubiquitin O 0 4.232705759932287e-05
- O 0 2.7666185360430973e-06
protein O 0 1.9440042251517298e-06
ligase O 0 4.3008469219785184e-05
and O 0 2.520789053050976e-07
has O 0 1.7859363765637681e-07
recently O 0 1.0027712278315448e-06
been O 0 6.395033835815411e-08
shown O 0 2.3776615876158758e-07
to O 0 8.977015397704236e-08
be O 0 8.503968160766817e-07
mutated O 0 0.004952060524374247
in O 0 0.006413154304027557
Angelman B-Disease 1 0.9998999834060669
syndrome I-Disease 1 0.9999873638153076
patients O 1 0.9977172613143921
who O 0 7.700586866121739e-05
lack O 0 0.0003153247816953808
15q11 O 0 0.0038846482057124376
- O 0 0.00017603571177460253
q13 O 0 0.00013012535055167973
deletions O 0 3.1623269023839384e-05
or O 0 3.772484433284262e-06
chromosome O 0 9.978395974030718e-05
15 O 0 2.6144452931475826e-05
paternal O 0 0.00473869638517499
uniparental B-Disease 1 0.975821316242218
disomy I-Disease 0 0.37142103910446167
. O 0 0.00016071827849373221

Previous O 0 7.218091923277825e-05
UBE3A O 0 0.002295719925314188
cDNA O 0 1.7522866983199492e-05
analysis O 0 9.738257631397573e-07
has O 0 2.8483245273491775e-07
shown O 0 2.41333594885873e-07
a O 0 2.2715560987762728e-07
coding O 0 4.197113867121516e-06
region O 0 1.5417920451454847e-07
of O 0 4.142946963270333e-08
approximately O 0 1.0291034868714632e-06
2 O 0 8.483623787469696e-06
. O 0 1.0258023394271731e-05

6 O 0 3.957845183322206e-05
kb O 0 6.859895074740052e-05
and O 0 3.4437556450939155e-07
a O 0 8.59106648931629e-07
3 O 0 3.1470358408114407e-06
- O 0 1.1035553143301513e-05
untranslated O 0 1.383053768222453e-05
region O 0 3.8842489402668434e-07
( O 0 2.600247341888462e-07
UTR O 0 2.413929905742407e-05
) O 0 4.5616513233426303e-08
of O 0 2.835517953769795e-08
< O 0 1.1334742339386139e-05
50 O 0 2.547367330407724e-07
bp O 0 5.543702627619496e-06
, O 0 3.330424647174368e-08
whereas O 0 2.840899639977579e-07
Northern O 0 3.9324568490428646e-08
analysis O 0 4.6031757960918185e-08
has O 0 5.276268666420947e-08
indicated O 0 1.8985353733569355e-07
mRNA O 0 6.187459433704134e-08
sizes O 0 4.5914081425735276e-08
of O 0 1.7752510572677238e-08
5 O 0 1.408445427841798e-06
- O 0 3.911376097676111e-06
8 O 0 1.7173788364743814e-06
kb O 0 0.00010235283843940124
. O 0 8.933900062402245e-06

We O 0 6.810295758441498e-07
have O 0 7.604785423609428e-08
analyzed O 0 3.9530513618046825e-07
additional O 0 9.952392332479576e-08
cDNA O 0 4.481167707126588e-06
clones O 0 8.23001846583793e-06
and O 0 2.446132363331799e-08
provide O 0 4.8439840583114346e-08
evidence O 0 8.957413655252822e-08
for O 0 9.106543075176887e-09
an O 0 4.084142446458827e-08
additional O 0 4.571397766994778e-07
0 O 0 6.545978521899087e-06
. O 0 8.440980309387669e-06

5 O 0 1.1082539458584506e-05
kb O 0 5.268195673124865e-05
of O 0 3.862602397930459e-07
5 O 0 8.225757483160123e-06
- O 0 1.0560112968960311e-05
UTR O 0 4.275558239896782e-05
and O 0 1.3136607890373853e-07
> O 0 8.484546015097294e-06
2 O 0 5.960986300124205e-07
kb O 0 1.4021884453541134e-05
of O 0 1.5654086382710375e-07
3 O 0 1.0680831110221334e-05
- O 0 0.0001504647807450965
UTR O 0 0.0009959718445315957
. O 0 1.5005416571511887e-05

We O 0 6.669776553280826e-07
have O 0 6.384138373505266e-08
established O 0 1.0463772781577063e-07
the O 0 6.251541861956866e-08
genomic O 0 1.9174533463228727e-06
organization O 0 2.4213585447796504e-07
of O 0 5.427395777246602e-08
UBE3A O 0 0.00016873945423867553
and O 0 9.876144346776528e-09
the O 0 1.0697107200030587e-08
sequence O 0 9.956816882095154e-08
of O 0 2.416219331280445e-07
intron O 0 0.013361696153879166
- O 0 0.000118114439828787
exon O 0 0.00016684929141774774
borders O 0 1.6917607354116626e-05
. O 0 1.695795617706608e-05

We O 0 8.71465488216927e-07
have O 0 7.621193987006336e-08
also O 0 5.580466222454561e-08
mapped O 0 4.530237447397667e-07
two O 0 3.333074971578753e-08
highly O 0 8.532261404070596e-07
homologous O 0 7.977729183039628e-06
processed O 0 3.871655735565582e-06
pseudogenes O 0 7.09256055415608e-05
, O 0 1.3078785059406073e-06
UBE3AP1 O 0 0.0009117597946897149
and O 0 2.819918165641866e-07
UBE3AP2 O 0 0.00011396557238185778
, O 0 2.6474131331610806e-08
to O 0 4.883947468670158e-09
chromosomes O 0 1.2302722041113157e-07
2 O 0 1.1512598518947925e-07
and O 0 3.5178310042738303e-08
21 O 0 1.7856588385711802e-07
, O 0 4.2954383161486476e-08
respectively O 0 1.1189775506181832e-07
, O 0 3.0464910594218964e-08
and O 0 1.4523762636997617e-08
determined O 0 1.1090251206269386e-07
their O 0 5.7162910849228865e-08
genomic O 0 1.7379046767018735e-05
organization O 0 1.0496237337065395e-05
. O 0 1.6041434719227254e-05

These O 0 3.6211051224199764e-07
results O 0 4.777369895236916e-07
will O 0 1.733287469107836e-08
form O 0 2.1195205590629485e-08
the O 0 4.275336973336152e-09
basis O 0 2.3045991781600605e-09
for O 0 2.631412643339104e-09
studies O 0 2.1401733718562355e-08
of O 0 1.6508638012169286e-08
mutation O 0 2.981378656841116e-06
and O 0 2.2090961238063755e-07
imprinting O 0 7.634968642378226e-05
of O 0 5.0407229537086096e-06
UBE3A O 1 0.6130800247192383
. O 0 8.653875556774437e-05

Mutation O 0 0.0001238377735717222
spectrum O 0 2.5682124032755382e-05
and O 0 4.91179343953263e-06
genotype O 0 0.0008521921699866652
- O 0 0.00026774968137033284
phenotype O 0 0.0006537566077895463
analyses O 0 8.505026926286519e-05
in O 0 0.00023846165277063847
Cowden B-Disease 1 0.9979642629623413
disease I-Disease 1 0.9991587400436401
and O 0 0.0002596281701698899
Bannayan B-Disease 1 0.9904453754425049
- I-Disease 1 0.9941869974136353
Zonana I-Disease 1 0.9982520937919617
syndrome I-Disease 1 0.9997311234474182
, O 0 7.699119123572018e-06
two O 0 1.6931180653045885e-05
hamartoma B-Disease 1 0.9977444410324097
syndromes I-Disease 1 0.9960748553276062
with O 0 0.0005033487686887383
germline O 1 0.9760133028030396
PTEN O 1 0.9807544946670532
mutation O 0 0.002887951908633113
. O 0 6.838986155344173e-05

The O 0 0.0008384055108763278
tumour B-Disease 1 0.9935576319694519
suppressor O 0 0.02178994193673134
gene O 0 0.00022043014178052545
PTEN O 0 0.03327415511012077
, O 0 3.426497983127774e-07
which O 0 1.2566242446609976e-07
maps O 0 2.1878042844036827e-06
to O 0 9.97437723526673e-07
10q23 O 0 0.000599053455516696
. O 0 2.099282392009627e-05

3 O 0 1.2789992069883738e-06
and O 0 7.654744393903457e-08
encodes O 0 4.6475864223793906e-07
a O 0 1.2845104890857328e-07
403 O 0 1.2156508546468103e-06
amino O 0 3.2470833843945e-07
acid O 0 8.282757335109636e-06
dual O 0 9.9156886790297e-07
specificity O 0 3.852819645544514e-06
phosphatase O 0 0.0005283721257001162
( O 0 7.708176212872786e-07
protein O 0 2.4738208139751805e-06
tyrosine O 0 1.5987236110959202e-05
phosphatase O 0 0.0011031653266400099
; O 0 1.528944835627044e-06
PTPase O 0 0.0001883854711195454
) O 0 2.721412499795406e-07
, O 0 1.1626119800212109e-07
was O 0 4.66220058115141e-07
shown O 0 2.2641268060397124e-07
recently O 0 1.1526495313773921e-07
to O 0 2.880454985643155e-09
play O 0 1.3328288694935964e-08
a O 0 1.3733556158967986e-07
broad O 0 3.4544400477898307e-06
role O 0 2.0763318389072083e-06
in O 0 3.0429105208895635e-06
human O 0 0.00017624598694965243
malignancy B-Disease 1 0.9917464256286621
. O 0 9.224467794410884e-05

Somatic O 0 0.0045714848674833775
PTEN O 0 0.06911196559667587
deletions O 0 6.829470657976344e-05
and O 0 8.104025255306624e-07
mutations O 0 6.123385446699103e-06
were O 0 2.1636181202211446e-07
observed O 0 1.2586070852194098e-06
in O 0 2.397707248746883e-06
sporadic B-Disease 0 0.0037642118986696005
breast I-Disease 1 0.9985986351966858
, I-Disease 0 0.00015867827460169792
brain I-Disease 1 0.9975045323371887
, I-Disease 0 0.001647872501052916
prostate I-Disease 1 0.9998053908348083
and I-Disease 0 0.009927565231919289
kidney I-Disease 1 0.9999207258224487
cancer I-Disease 1 0.9997281432151794
cell O 0 0.0007491993601433933
lines O 0 4.014956630271627e-06
and O 0 8.549410068781071e-08
in O 0 1.5908521788787766e-07
several O 0 6.372483767336234e-07
primary O 0 6.864284659968689e-05
tumours B-Disease 1 0.9952253103256226
such O 0 7.0179848989937454e-06
as O 0 0.0009055237169377506
endometrial B-Disease 1 0.9986609220504761
carcinomas I-Disease 1 0.9997254014015198
, O 1 0.9805408120155334
malignant B-Disease 1 0.9999690055847168
melanoma I-Disease 1 0.9999749660491943
and O 1 0.9642567038536072
thyroid B-Disease 1 0.9999096393585205
tumours I-Disease 1 0.9991899132728577
. O 0 0.0017894854536280036

In O 0 3.2015732358559035e-06
addition O 0 3.7939480534987524e-06
, O 0 4.008399173471844e-06
PTEN O 0 0.022658061236143112
was O 0 3.4993490771739744e-06
identified O 0 1.0913832966252812e-06
as O 0 7.206853069874342e-08
the O 0 3.2542226335863234e-07
susceptibility O 0 3.4336895623710006e-05
gene O 0 4.709615041065263e-06
for O 0 1.2834052540711127e-06
two O 0 5.90632225794252e-05
hamartoma B-Disease 1 0.9990267753601074
syndromes I-Disease 1 0.9996886253356934
Cowden B-Disease 1 0.9995442032814026
disease I-Disease 1 0.9994218349456787
( O 0 4.6498469600919634e-05
CD B-Disease 0 0.000296439160592854
; O 0 1.2327613148954697e-05
MIM O 0 0.01719254069030285
158350 O 0 0.00038735163980163634
) O 0 1.325360244663898e-06
and O 0 1.5688806342950556e-06
Bannayan B-Disease 0 0.0026228975038975477
- I-Disease 0 0.00032083431142382324
Zonana I-Disease 0 0.012453095987439156
( I-Disease 0 1.4246768841985613e-05
BZS I-Disease 0 0.003362824209034443
) I-Disease 0 3.665163148980355e-06
or I-Disease 0 9.336412404081784e-06
Ruvalcaba I-Disease 0 0.1448037475347519
- I-Disease 0 0.0019088853150606155
Riley I-Disease 0 0.004536426160484552
- I-Disease 0 0.007816044613718987
Smith I-Disease 0 0.011036795563995838
syndrome I-Disease 1 0.9990267753601074
( O 0 8.09913472039625e-05
MIM O 0 0.43916085362434387
153480 O 0 0.0039008879102766514
) O 0 2.4504419343429618e-05
. O 0 2.6909130610874854e-05

Constitutive O 0 0.0001825657964218408
DNA O 0 1.3336268239072524e-05
from O 0 9.05510205484461e-07
37 O 0 3.746119773495593e-06
CD B-Disease 0 6.016752195137087e-06
families O 0 2.2729298621015914e-07
and O 0 7.962636061620287e-08
seven O 0 1.7562012999405852e-06
BZS B-Disease 0 0.005363034550100565
families O 0 1.37849303882831e-06
was O 0 3.2755183383414987e-06
screened O 0 1.4774445844523143e-05
for O 0 2.3178886294772383e-06
germline O 0 0.024802356958389282
PTEN O 1 0.8935025930404663
mutations O 0 0.0006301807006821036
. O 0 4.801872273674235e-05

PTEN O 0 0.41001391410827637
mutations O 0 6.356176163535565e-05
were O 0 5.540714482776821e-07
identified O 0 5.234439868218033e-07
in O 0 6.477121416992304e-08
30 O 0 9.497870934183084e-08
of O 0 1.503842739225547e-08
37 O 0 4.858075612901303e-07
( O 0 2.253285487086032e-07
81 O 0 1.5495545540034072e-06
% O 0 1.2034382734782412e-07
) O 0 7.071694341220791e-08
CD B-Disease 0 9.583687869962887e-07
families O 0 5.004492820148698e-08
, O 0 1.2048687381138734e-08
including O 0 3.370152157344819e-08
missense O 0 6.8979770730948076e-06
and O 0 7.296661408418004e-08
nonsense O 0 2.8419667614798527e-06
point O 0 2.3329501175339828e-07
mutations O 0 1.4884408301440999e-06
, O 0 4.3980396213783024e-08
deletions O 0 1.5642312973795924e-06
, O 0 6.151592657488436e-08
insertions O 0 1.4521126558975084e-06
, O 0 8.626609115935935e-08
a O 0 7.544963409600314e-07
deletion O 0 8.346109098056331e-05
/ O 0 3.4194581530755386e-05
insertion O 0 7.498862487409497e-06
and O 0 6.403834618140536e-07
splice O 0 9.659036004450172e-05
site O 0 5.343688098946586e-05
mutations O 0 0.00012628368858713657
. O 0 2.242245500383433e-05

These O 0 1.8869016003009165e-06
mutations O 0 1.2708147551165894e-05
were O 0 1.0366631642000357e-07
scattered O 0 2.0573767756104644e-07
over O 0 3.892517952408525e-08
the O 0 2.1441776354436115e-08
entire O 0 2.0015083634916664e-07
length O 0 2.6796527663464076e-07
of O 0 5.400907809871569e-08
PTEN O 0 0.004166719503700733
, O 0 3.2532323501754945e-08
with O 0 6.349066605793041e-09
the O 0 8.72975824961486e-09
exception O 0 1.9803525930228716e-08
of O 0 2.960157452491785e-09
the O 0 1.594685272721108e-08
first O 0 1.863021559245226e-08
, O 0 3.583179619681687e-08
fourth O 0 2.479228840002179e-07
and O 0 6.692638976346643e-08
last O 0 2.387992708463571e-06
exons O 0 5.591243098024279e-05
. O 0 1.298842289543245e-05

A O 0 3.8930331356823444e-05
hot O 0 6.492648390121758e-05
spot O 0 6.738198862876743e-06
for O 0 1.071164433597005e-06
PTEN O 0 0.003677705070003867
mutation O 0 6.367482001223834e-06
in O 0 1.5321472801588243e-07
CD B-Disease 0 4.4841599446954206e-06
was O 0 8.214728950406425e-07
identified O 0 3.5151623478668625e-07
in O 0 5.3839059432903014e-08
exon O 0 3.883777480950812e-06
5 O 0 1.5286488519450359e-07
that O 0 1.0789028337399031e-08
contains O 0 5.760476540217496e-08
the O 0 1.1068781446965659e-07
PTPase O 0 2.9361506676650606e-05
core O 0 9.236851497007592e-07
motif O 0 1.9010153664567042e-06
, O 0 1.3939156495723637e-08
with O 0 6.771320393283986e-09
13 O 0 2.3025791051622946e-08
of O 0 2.81678991242984e-09
30 O 0 5.3609220174166694e-08
( O 0 3.1535137168248184e-08
43 O 0 7.914802324648917e-08
% O 0 4.205838166626563e-08
) O 0 6.02536545102339e-08
CD B-Disease 0 1.756613414727326e-06
mutations O 0 1.1626513014562079e-06
identified O 0 3.0700519459969655e-07
in O 0 9.661749800216057e-08
this O 0 3.1726148108646157e-07
exon O 0 0.0002408579457551241
. O 0 1.5198952496575657e-05

Seven O 0 6.11137465966749e-07
of O 0 9.386286592416582e-08
30 O 0 5.416236490418669e-07
( O 0 2.1998164356773486e-07
23 O 0 2.0113166954160988e-07
% O 0 4.4356546879953385e-08
) O 0 1.223994328114486e-08
were O 0 2.5846937923290625e-09
within O 0 4.625555050097319e-09
the O 0 1.905623925324562e-08
core O 0 3.515725666147773e-07
motif O 0 1.2929197055200348e-06
, O 0 1.6171616934457234e-08
the O 0 1.1926591270139397e-08
majority O 0 3.032241835398963e-08
( O 0 1.6657262236208226e-08
five O 0 2.7371864774750065e-09
of O 0 1.6417159853787666e-09
seven O 0 1.828134266190773e-08
) O 0 1.153123996289196e-08
of O 0 2.2559241141806297e-09
which O 0 1.9605201018180196e-08
were O 0 3.79919420367969e-08
missense O 0 2.0266741557861678e-05
mutations O 0 3.759049150175997e-06
, O 0 1.1812313971404365e-07
possibly O 0 4.955447252541489e-07
pointing O 0 4.431435343121848e-07
to O 0 7.76932651547213e-09
the O 0 3.27349241047159e-08
functional O 0 3.4017980965472816e-07
significance O 0 1.0068133349250274e-07
of O 0 3.566773543184354e-08
this O 0 5.392780053625756e-07
region O 0 5.269166194921127e-06
. O 0 1.8964061382575892e-05

Germline O 0 0.25751811265945435
PTEN O 0 0.2801874876022339
mutations O 0 5.689120007446036e-05
were O 0 4.5122831693333865e-07
identified O 0 5.065339223619958e-07
in O 0 1.840962049470818e-08
four O 0 8.638707527097722e-09
of O 0 6.95748880730207e-09
seven O 0 1.4146417015581392e-07
( O 0 3.875095160310593e-07
57 O 0 1.6833425888762577e-06
% O 0 5.001878093935375e-07
) O 0 1.2644842399822664e-06
BZS B-Disease 0 0.0023221303708851337
families O 0 2.517392431400367e-06
studied O 0 1.936232001753524e-05
. O 0 2.0823857994400896e-05

Interestingly O 0 0.0001658756227698177
, O 0 5.214261591390823e-07
none O 0 3.4576430607557995e-07
of O 0 1.6415601322705697e-08
these O 0 4.0801015899205595e-08
mutations O 0 2.9661666758329375e-06
was O 0 5.173333761376853e-07
observed O 0 2.1359939239573578e-07
in O 0 9.285678714832102e-08
the O 0 8.800099635664083e-07
PTPase O 0 0.0005273789283819497
core O 0 4.053763041156344e-05
motif O 0 0.00040935512515716255
. O 0 3.816522075794637e-05

It O 0 9.31268857584655e-07
is O 0 2.4873304482753156e-07
also O 0 4.275648990414993e-08
worthy O 0 1.949821779589911e-07
of O 0 1.0224749047438308e-08
note O 0 3.619510096086742e-07
that O 0 1.0091103952447611e-08
a O 0 7.642329791224256e-08
single O 0 6.805414187738279e-08
nonsense O 0 2.873668563552201e-06
point O 0 2.4023597688938025e-07
mutation O 0 3.1511924589722184e-06
, O 0 1.9520730631938932e-07
R233X O 0 1.0325450602977071e-05
, O 0 7.590439565774432e-08
was O 0 1.1881933659196875e-07
observed O 0 9.445787441109132e-08
in O 0 1.5755867721622963e-08
the O 0 1.0410104067659631e-07
germline O 0 2.9498916774173267e-05
DNA O 0 7.484563298021385e-07
from O 0 5.4090726564481884e-08
two O 0 3.2514520853510476e-08
unrelated O 0 8.794346285867505e-06
CD B-Disease 0 1.5865622117416933e-05
families O 0 6.658844995399704e-07
and O 0 3.837319582089549e-07
one O 0 2.1481007479451364e-06
BZS B-Disease 0 0.038589995354413986
family O 0 7.695543172303587e-05
. O 0 2.9974245990160853e-05

Genotype O 0 0.007550830952823162
- O 0 0.0004983957041986287
phenotype O 0 0.00020287105871830136
studies O 0 8.006998086784733e-07
were O 0 4.221920590907757e-08
not O 0 1.59273678690397e-08
performed O 0 5.867283192628747e-08
on O 0 1.2368242430227383e-08
this O 0 1.7114121675376737e-08
small O 0 1.3597109216334502e-07
group O 0 3.4181198316218797e-07
of O 0 5.707226478079974e-07
BZS B-Disease 0 0.05642232671380043
families O 0 2.35021816479275e-05
. O 0 2.0729507014038973e-05

However O 0 1.942105336638633e-05
, O 0 7.624662885064026e-06
genotype O 0 0.0002994193055201322
- O 0 4.9208756536245346e-05
phenotype O 0 3.0826882721157745e-05
analysis O 0 7.432773259097303e-07
inthe O 0 5.943635187577456e-05
group O 0 2.4885858351808565e-07
of O 0 7.361172293940399e-08
CD B-Disease 0 1.2811948181479238e-05
families O 0 5.536784897230973e-07
revealed O 0 1.7207100881933002e-06
two O 0 1.3847494706453745e-08
possible O 0 9.372064369017608e-08
associations O 0 1.0961464624870132e-07
worthy O 0 2.414533071259939e-07
of O 0 1.7688698505935463e-08
follow O 0 4.505953086209047e-07
- O 0 9.991437082135235e-07
up O 0 3.1746907325214124e-08
in O 0 3.9116301309150003e-08
independent O 0 4.890559921477688e-07
analyses O 0 1.0315548934158869e-05
. O 0 1.4359042324940674e-05

The O 0 1.2806249287677929e-06
first O 0 9.741555686559877e-07
was O 0 1.1616493793553673e-06
an O 0 3.430382093938533e-07
association O 0 4.3705294956453145e-06
noted O 0 3.5848273682859144e-07
in O 0 3.081338206811779e-08
the O 0 4.601095326961513e-08
group O 0 1.0326018440309781e-07
of O 0 4.6660883157301214e-08
CD B-Disease 0 8.137081749737263e-05
families O 0 1.750359297147952e-05
with O 0 0.0016737745609134436
breast B-Disease 1 0.9994598031044006
disease I-Disease 1 0.99924635887146
. O 0 0.0003630189457908273

A O 0 2.017722545133438e-05
correlation O 0 7.025404556770809e-06
was O 0 8.26083692118118e-07
observed O 0 2.574948041456082e-07
between O 0 6.444453504172998e-08
the O 0 2.459789811837254e-07
presence O 0 1.186869894809206e-06
/ O 0 7.934502718853764e-06
absence O 0 4.5495386302718543e-07
of O 0 2.6954097620546236e-08
a O 0 2.256449761262047e-06
PTEN O 0 0.006828610319644213
mutation O 0 2.3889449494163273e-06
and O 0 3.172953455532479e-08
the O 0 1.8394902667751012e-07
type O 0 2.125605897163041e-05
of O 0 3.2474904401169624e-06
breast O 1 0.99598628282547
involvement O 0 0.00037590626743622124
( O 0 7.030634151306003e-05
unaffected O 0 0.026140877977013588
versus O 0 0.03457867354154587
benign O 1 0.9956066012382507
versus O 1 0.8824942111968994
malignant O 1 0.9992374181747437
) O 0 0.00010628485324559733
. O 0 7.696739339735359e-05

Specifically O 0 9.57969041337492e-06
and O 0 2.5617509891162626e-07
more O 0 3.906060896952113e-08
directly O 0 2.710112596560066e-07
, O 0 9.248912391512931e-08
an O 0 1.1582539372056999e-07
association O 0 2.5431395442865323e-06
was O 0 2.1594664190160984e-07
also O 0 1.214969547191913e-08
observed O 0 2.4832601752677874e-08
between O 0 8.436837894976179e-09
the O 0 9.021089653060699e-09
presence O 0 6.125156204461746e-08
of O 0 3.0117337956880874e-08
a O 0 1.5247078408719972e-05
PTEN O 1 0.9248868227005005
mutation O 0 0.005974663887172937
and O 0 0.0022252770140767097
malignant B-Disease 1 0.9998890161514282
breast I-Disease 1 0.9998138546943665
disease I-Disease 1 0.9994407296180725
. O 0 0.0007612314075231552

Secondly O 0 0.00038440347998403013
, O 0 1.3199691011323011e-06
there O 0 3.162425628033816e-07
appeared O 0 9.567469305693521e-07
to O 0 2.3778016000619573e-08
be O 0 3.888228761184109e-08
an O 0 7.66742829227951e-08
interdependent O 0 1.4178214769344777e-05
association O 0 2.0177828901069006e-06
between O 0 1.903608222164621e-07
mutations O 0 2.107736463585752e-06
upstream O 0 6.502398264274234e-07
and O 0 1.78430799024909e-08
within O 0 1.8981438643095316e-08
the O 0 1.1034590841063618e-07
PTPase O 0 5.274398790788837e-05
core O 0 1.4939741959096864e-06
motif O 0 2.4332530301762745e-06
, O 0 2.2002900834650063e-08
the O 0 3.273074256071595e-08
core O 0 4.4176877622703614e-07
motif O 0 7.482829005311942e-07
containing O 0 1.1479653494461672e-07
the O 0 2.2070866023682356e-08
majority O 0 7.128558365820936e-08
of O 0 5.173140849024094e-08
missense O 0 5.6364737247349694e-05
mutations O 0 4.148500920564402e-06
, O 0 3.940791160061963e-08
and O 0 8.9835880956457e-09
the O 0 2.969608559055814e-08
involvement O 0 3.154867727062083e-07
of O 0 1.177840491806137e-08
all O 0 7.079602681869801e-08
major O 0 1.2071446690242738e-05
organ O 0 0.011516760103404522
systems O 0 0.00012368860188871622
( O 0 6.2658941715199035e-06
central O 0 1.8356840882916003e-05
nervous O 0 0.03321101889014244
system O 0 0.00030534924007952213
, O 0 0.0001199411999550648
thyroid O 1 0.9994946718215942
, O 0 0.0003093223203904927
breast O 1 0.9992247819900513
, O 0 0.0010835392167791724
skin O 1 0.9990905523300171
and O 0 0.0017790746642276645
gastrointestinal O 1 0.999622106552124
tract O 1 0.9982299208641052
) O 0 0.00012104224879294634
. O 0 5.558314296649769e-05

However O 0 6.879070042487001e-06
, O 0 3.6838932260252477e-07
these O 0 2.229770501571693e-08
observations O 0 1.6820062853639683e-07
would O 0 4.401908526574516e-08
need O 0 3.31415854759598e-08
to O 0 5.13371301025245e-09
be O 0 5.3264694876986596e-09
confirmed O 0 3.856057873008467e-08
by O 0 4.4581969227408536e-09
studying O 0 3.584567309644626e-08
a O 0 3.9858978340134854e-08
larger O 0 4.9445944227954897e-08
number O 0 9.97920945877695e-09
of O 0 5.2003962025537476e-08
CD B-Disease 0 4.0663817344466224e-05
families O 0 5.133537797519239e-06
. O 0 1.6427384252892807e-05

Molecular O 0 0.007729691918939352
defects O 1 0.9866853952407837
leading O 0 1.0533952263358515e-05
to O 0 5.151459276930836e-07
human O 0 6.790199677197961e-06
complement B-Disease 0 9.076898277271539e-05
component I-Disease 0 0.031430862843990326
C6 I-Disease 1 0.9995110034942627
deficiency I-Disease 1 0.9998040795326233
in O 0 1.4780470110054011e-06
an O 0 9.064969503924658e-07
African O 0 1.0852641025849152e-05
- O 0 3.64333791367244e-05
American O 0 2.3196287202154053e-06
family O 0 1.7048600057023577e-05
. O 0 9.730898455018178e-06

Complement B-Disease 0 0.001020199852064252
component I-Disease 0 0.1436789184808731
C6 I-Disease 1 0.9989388585090637
deficiency I-Disease 1 0.999798595905304
( O 0 0.00011755478044506162
C6D B-Disease 0 0.13142631947994232
) O 0 8.24458220449742e-06
was O 0 7.784950139466673e-05
diagnosed O 1 0.959895133972168
in O 0 8.712296306612188e-08
a O 0 2.897089075304393e-07
16 O 0 1.0810326784849167e-06
- O 0 3.090737891398021e-06
year O 0 3.8896016008038714e-07
- O 0 1.4659868838862167e-06
old O 0 1.343025928690622e-06
African O 0 5.839829100295901e-07
- O 0 2.7988032798020868e-06
American O 0 5.486827490130963e-07
male O 0 1.2465586223697755e-05
with O 0 9.913324902299792e-05
meningococcal B-Disease 1 0.9989849925041199
meningitis I-Disease 1 0.9988131523132324
. O 0 0.0002833676990121603

The O 0 0.00011876838107127696
patients O 0 0.008772841654717922
father O 0 1.4090907825448085e-05
and O 0 2.3423044126502646e-07
two O 0 1.334551598120015e-07
brothers O 0 1.9818618966382928e-05
also O 0 5.001696763429209e-07
had O 0 2.0815264178963844e-06
C6D B-Disease 0 0.0004598881641868502
, O 0 8.864547851317184e-08
but O 0 1.985821995731385e-08
gave O 0 1.9772319603816868e-07
no O 0 1.4175155627071945e-07
history O 0 4.7036539285727486e-07
of O 0 8.378404459108424e-07
meningitis B-Disease 1 0.9988790154457092
or O 0 1.4550872037943918e-05
other O 0 5.676650744135259e-06
neisserial B-Disease 1 0.988125205039978
infection I-Disease 1 0.9976078271865845
. O 0 9.005030733533204e-05

By O 0 1.541518486192217e-06
using O 0 1.930473217726103e-06
exon O 0 9.287542343372479e-05
- O 0 7.648666723980568e-06
specific O 0 3.3238572427762847e-07
polymerase O 0 2.7735164621844888e-05
chain O 0 2.7626907467492856e-05
reaction O 0 7.0541527747991495e-06
( O 0 5.43256305718387e-07
PCR O 0 6.745071914338041e-06
) O 0 3.527163983108039e-07
/ O 0 3.157756509608589e-06
single O 0 1.3211915472766123e-07
- O 0 9.480854714638554e-07
strand O 0 6.943100174794381e-07
conformation O 0 1.18076218313945e-06
polymorphism O 0 6.324279979708081e-07
as O 0 2.0165288105999934e-08
a O 0 4.0605918627534265e-08
screening O 0 1.3610133464680985e-07
step O 0 2.6594685564873544e-08
and O 0 1.5205126047135309e-09
nucleotide O 0 2.0148526402863354e-08
sequencing O 0 1.8509862087512374e-08
of O 0 3.68629482494498e-09
target O 0 8.269177698139174e-08
exons O 0 4.4753238626071834e-07
, O 0 2.283562494653779e-08
we O 0 7.358207820828966e-09
determined O 0 2.7962094861777587e-08
that O 0 6.878214886540945e-09
the O 0 6.515843153920287e-08
proband O 0 2.091313581331633e-05
was O 0 2.810229204897041e-07
a O 0 1.773678235394982e-07
compound O 0 3.265360192017397e-06
heterozygote O 0 1.1432402970967814e-05
for O 0 9.74183649304905e-08
two O 0 7.449704639839183e-07
C6 O 0 0.386210173368454
gene O 0 8.182899910025299e-05
mutations O 0 0.00011647057544905692
. O 0 2.6407960831420496e-05

The O 0 1.332528540842759e-06
first O 0 4.2531189592409646e-07
, O 0 2.9849869065401435e-07
1195delC O 0 1.3551889423979446e-05
located O 0 2.9387376798695186e-07
in O 0 6.743739788817038e-08
exon O 0 6.975335054448806e-06
7 O 0 2.344651051089386e-07
, O 0 1.5648049966898725e-08
is O 0 1.050967313176443e-08
a O 0 5.7340468373467957e-08
novel O 0 2.2857200576709147e-07
mutation O 0 5.888882128601836e-07
, O 0 1.1366072527607685e-08
while O 0 8.084540148445285e-09
the O 0 9.016307700449033e-09
second O 0 5.1292033731442643e-08
, O 0 4.303261391669366e-08
1936delG O 0 4.191618245386053e-06
in O 0 9.579030546547074e-08
exon O 0 1.0582634786260314e-05
12 O 0 6.61258525269659e-07
, O 0 8.533933026910745e-08
has O 0 9.991592975211461e-08
been O 0 5.705268080191672e-08
described O 0 3.9769756199348194e-07
before O 0 1.594649603475773e-07
to O 0 1.4061811270948965e-07
cause O 0 5.39551219844725e-05
C6D B-Disease 0 0.0009177174651995301
in O 0 1.900854300629362e-07
an O 0 4.5016881244919205e-07
unrelated O 0 5.253566268947907e-05
African O 0 9.014975148602389e-06
- O 0 1.7934744391823187e-05
American O 0 9.955408586392878e-07
individual O 0 8.175456400749681e-07
. O 0 1.0046463103208225e-05

Both O 0 4.589185664372053e-06
mutations O 0 5.299647818901576e-05
result O 0 1.0619333806971554e-05
in O 0 3.907301561412169e-06
premature O 0 0.025976160541176796
termination O 0 0.0015222119400277734
codons O 0 6.860960274934769e-05
and O 0 8.266816621471662e-06
C6 O 0 0.11007241904735565
null O 0 0.0001252898364327848
alleles O 0 0.00015090171655174345
. O 0 3.113218554062769e-05

Allele O 0 0.0001249780470971018
- O 0 1.3424607459455729e-05
specific O 0 5.186557814340631e-07
PCR O 0 2.6257865101797506e-05
indicated O 0 3.308656005174271e-06
that O 0 5.069949082781022e-08
the O 0 1.5790139684668247e-07
probands O 0 3.700226443470456e-05
two O 0 1.4558827388100326e-07
brothers O 0 1.0386406756879296e-05
also O 0 4.0925340272224275e-07
inherited O 0 0.0002801143273245543
the O 0 3.028947332950338e-07
1195delC O 0 6.315152131719515e-05
mutation O 0 1.7159185290438472e-06
from O 0 6.155935494689402e-08
their O 0 3.440885620875633e-08
heterozygous O 0 2.224054924226948e-06
mother O 0 3.368319312357926e-06
and O 0 5.562793603530736e-08
the O 0 1.1740279859395741e-07
1936delG O 0 2.349196256545838e-05
mutation O 0 1.4644343764302903e-06
from O 0 1.381744993977918e-07
their O 0 1.335437644911508e-07
homozygous O 0 4.3982305214740336e-05
father O 0 4.4519580114865676e-05
. O 0 4.854916824115207e-06
. O 0 1.3095685062580742e-05

PAX6 O 1 0.8270601630210876
mutations O 0 0.0037404224276542664
reviewed O 0 0.0012779629323631525
. O 0 0.00028205852140672505

Mutations O 0 0.0003897786664310843
in O 0 5.2065274758206215e-06
PAX6 O 0 0.011880265548825264
are O 0 1.545425050153426e-07
responsible O 0 1.2855588238380733e-06
for O 0 2.416975064534199e-07
human O 0 1.1788262781919912e-05
aniridia B-Disease 0 0.2923455536365509
and O 0 2.0316900872785482e-07
have O 0 7.738198348761216e-08
also O 0 9.385123433958142e-08
been O 0 1.8196588769114896e-07
found O 0 1.5247135252138833e-06
in O 0 1.651665911595046e-06
patients O 0 0.006123019382357597
with O 0 1.4713086784468032e-05
Peters B-Disease 1 0.9448767304420471
anomaly I-Disease 1 0.9938923120498657
, O 0 8.24579838081263e-05
with O 0 0.021151110529899597
congenital B-Disease 1 0.9999778270721436
cataracts I-Disease 1 0.9998675584793091
, O 0 4.218111280351877e-05
with O 0 6.427220796467736e-05
autosomal B-Disease 1 0.9963667392730713
dominant I-Disease 0 0.3057698607444763
keratitis I-Disease 1 0.9970943927764893
, O 0 9.448114724364132e-06
and O 0 1.803027203095553e-06
with O 0 3.852592271869071e-05
isolated B-Disease 0 0.08726353198289871
foveal I-Disease 1 0.9911435842514038
hypoplasia I-Disease 1 0.9966931343078613
. O 0 0.0005574054666794837

No O 0 8.510608495271299e-06
locus O 0 1.8501552403904498e-05
other O 0 1.1670855570855565e-07
than O 0 2.2903655860773142e-07
chromosome O 0 5.772668737336062e-05
11p13 O 0 0.00022797720157541335
has O 0 9.394415201313677e-07
been O 0 9.774946647667093e-07
implicated O 0 4.27751183451619e-05
in O 0 7.529810659434588e-07
aniridia B-Disease 0 0.04580697789788246
, O 0 2.273823156428989e-07
and O 0 2.6425504984217696e-07
PAX6 O 0 0.006036043167114258
is O 0 9.782147714076928e-08
clearly O 0 3.196394402493752e-07
the O 0 5.395914115524647e-08
major O 0 2.245918295784577e-07
, O 0 1.8502133158904144e-08
if O 0 1.534524329827036e-08
not O 0 3.2106597380732183e-09
only O 0 9.812660017871622e-09
, O 0 7.634550058810419e-08
gene O 0 3.420970642764587e-06
responsible O 0 1.0528689927014057e-05
. O 0 1.0171365829592105e-05

Twenty O 0 2.919320104410872e-05
- O 0 9.971200597647112e-06
eight O 0 2.2524109510868584e-07
percent O 0 3.352425892444444e-07
of O 0 8.609809754034359e-08
identified O 0 1.1608892236836255e-05
PAX6 O 0 0.010761750862002373
mutations O 0 1.721926855680067e-05
are O 0 2.92473572471863e-07
C O 0 0.00042688995017670095
- O 0 9.49093810049817e-05
T O 0 0.0005092705832794309
changes O 0 5.858404392711236e-07
at O 0 9.971486178983469e-07
CpG O 0 4.780699237016961e-05
dinucleotides O 0 6.37578486930579e-05
, O 0 7.844571570103653e-08
20 O 0 6.606244085105573e-08
% O 0 3.2501251467920156e-08
are O 0 4.541127029966674e-09
splicing O 0 3.6270498071644397e-07
errors O 0 7.508677981604706e-07
, O 0 2.0908593967305933e-08
and O 0 3.4024056905224143e-09
more O 0 1.2080897393573764e-09
than O 0 4.826661292867129e-09
30 O 0 3.013629878978463e-08
% O 0 3.9399267848239106e-08
are O 0 6.801661012190152e-09
deletion O 0 7.673888831050135e-06
or O 0 5.358606927075016e-07
insertion O 0 2.8375518013490364e-05
events O 0 3.836034920823295e-06
. O 0 1.7207436030730605e-05

There O 0 3.950329301005695e-06
is O 0 1.570287736285536e-06
a O 0 4.665457254304783e-06
noticeably O 0 0.00023482755932491273
elevated O 0 0.0005487203015945852
level O 0 2.3615264410636883e-07
of O 0 1.4965946704137423e-08
mutation O 0 1.2254540706635453e-06
in O 0 1.82455348607391e-08
the O 0 3.5090454986175246e-08
paired O 0 9.779618039829074e-07
domain O 0 2.9094684350639e-07
compared O 0 2.2747774153231148e-07
with O 0 1.518287717772182e-08
the O 0 3.7405715858085387e-08
rest O 0 1.0594065003033393e-07
of O 0 3.713267560101485e-08
the O 0 8.180331292351184e-07
gene O 0 3.282806574134156e-05
. O 0 1.198622521769721e-05

Increased O 0 1.5022169463918544e-05
mutation O 0 2.2683600036543794e-05
in O 0 3.0215730362215254e-07
the O 0 6.084251822358056e-07
homeodomain O 0 0.00012273600441403687
is O 0 1.2821925565731362e-07
accounted O 0 2.211663598927771e-07
for O 0 2.0410734435927225e-08
by O 0 6.670260432883879e-08
the O 0 4.4887457306685974e-07
hypermutable O 0 0.00017718554590828717
CpG O 0 0.00010432538692839444
dinucleotide O 0 0.00010690264025470242
in O 0 8.887798230716726e-07
codon O 0 2.6984478608937934e-05
240 O 0 2.824422699632123e-05
. O 0 2.369310095673427e-05

Very O 0 5.839851382916095e-06
nearly O 0 2.8552890398714226e-06
all O 0 2.1863890253825957e-07
mutations O 0 1.6892536223167554e-05
appear O 0 3.276965117038344e-06
to O 0 3.31104416773087e-07
cause O 0 5.267286178423092e-05
loss O 0 3.5266432405478554e-06
of O 0 8.96602525557455e-09
function O 0 4.3379138503496506e-08
of O 0 1.2237282298599439e-08
the O 0 1.222468881678651e-07
mutant O 0 4.507888661464676e-06
allele O 0 1.0377982562204124e-06
, O 0 1.228902046790381e-08
and O 0 1.7973861288211879e-09
more O 0 5.650895307240944e-10
than O 0 1.0882315049087765e-09
80 O 0 1.6952105497125558e-08
% O 0 1.0650933468525636e-08
of O 0 1.0941053396607003e-08
exonic O 0 2.8818314603995532e-05
substitutions O 0 1.4793357649978134e-06
result O 0 1.2776058611052576e-06
in O 0 4.932217620989832e-07
nonsense O 0 6.26222972641699e-05
codons O 0 8.00994603196159e-05
. O 0 2.5860252208076417e-05

In O 0 1.0379397963333759e-06
a O 0 1.3134543905835017e-06
gene O 0 2.26043198381376e-06
with O 0 1.4150451477235038e-07
such O 0 1.4033545880920428e-07
extraordinarily O 0 2.1475463654496707e-05
high O 0 1.0832968655449804e-06
sequence O 0 3.6834930483564676e-07
conservation O 0 4.145485377193836e-07
throughout O 0 4.488026661420008e-08
evolution O 0 2.409008459380857e-07
, O 0 4.065497449801114e-08
there O 0 4.602798142627762e-08
are O 0 2.211726268797065e-08
presumed O 0 1.2978134691365995e-05
undiscovered O 0 8.38188934721984e-05
missense O 0 6.355285586323589e-05
mutations O 0 4.015657395939343e-06
, O 0 3.4497439571623545e-08
these O 0 1.0627089430670367e-08
are O 0 6.09224981573675e-09
hypothesized O 0 1.2431031564119621e-06
to O 0 1.646360914264733e-08
exist O 0 6.088430382078514e-08
in O 0 4.63273579498491e-08
as O 0 2.2401724208975793e-07
- O 0 6.964514341234462e-06
yet O 0 1.818916075535526e-06
unidentified O 0 8.3865576016251e-05
phenotypes O 0 0.00022545631509274244
. O 0 3.021249767698464e-06
. O 0 9.132791092270054e-06

Genetic O 0 0.0002023452107096091
heterogeneity O 0 0.00014184539031703025
and O 0 1.0608821412461111e-06
penetrance O 0 0.00029034819453954697
analysis O 0 1.9992496902432322e-07
of O 0 5.685518900122588e-08
the O 0 1.4366712548508076e-06
BRCA1 O 0 0.001156796352006495
and O 0 2.6112807063327637e-06
BRCA2 O 0 0.0032936707139015198
genes O 0 9.240729559678584e-05
in O 0 0.0005103336297906935
breast B-Disease 1 0.9995929598808289
cancer I-Disease 1 0.9992597699165344
families O 0 8.595555846113712e-05
. O 0 6.5719781559892e-05

The O 0 0.04112624004483223
Breast B-Disease 1 0.9989771842956543
Cancer I-Disease 1 0.9983627200126648
Linkage O 0 0.035656534135341644
Consortium O 0 0.002740296768024564
. O 0 0.00011207946226932108

The O 0 2.0157231119810604e-06
contribution O 0 4.304662979848217e-06
of O 0 1.0145353144253022e-06
BRCA1 O 0 0.003379860194399953
and O 0 8.590872312197462e-06
BRCA2 O 0 0.2323756068944931
to O 0 0.0004237821267452091
inherited B-Disease 1 0.9998390674591064
breast I-Disease 1 0.9999265670776367
cancer I-Disease 1 0.9999127388000488
was O 0 8.326037641381845e-05
assessed O 0 1.0463265425642021e-05
by O 0 1.957109674322055e-07
linkage O 0 7.167569492594339e-06
and O 0 3.69284158807659e-08
mutation O 0 9.332932791039639e-07
analysis O 0 6.581154821105883e-08
in O 0 8.498716397298267e-08
237 O 0 2.9240152343845693e-06
families O 0 4.0754898122941086e-08
, O 0 3.5484712945788033e-09
each O 0 9.817616719587363e-10
with O 0 6.018552323183712e-09
at O 0 5.0850179178496546e-08
least O 0 2.0852281679140106e-08
four O 0 4.678073750596923e-08
cases O 0 2.5962131076084916e-06
of O 0 1.3990909792482853e-05
breast B-Disease 1 0.999464213848114
cancer I-Disease 1 0.9980490207672119
, O 0 3.88840362575138e-07
collected O 0 6.340040954455617e-07
by O 0 5.170298663870199e-06
the O 0 0.0008192838868126273
Breast B-Disease 1 0.9996362924575806
Cancer I-Disease 1 0.9993163347244263
Linkage O 0 0.011882348917424679
Consortium O 0 0.0012391813797876239
. O 0 5.086464443593286e-05

Families O 0 5.805124146718299e-06
were O 0 2.6082889803547005e-07
included O 0 1.9662709860313043e-07
without O 0 1.8104275056884944e-07
regard O 0 1.9384268057365261e-07
to O 0 4.738275904969669e-08
the O 0 2.4498962147845305e-07
occurrence O 0 3.360601840540767e-05
of O 0 8.331526260008104e-06
ovarian B-Disease 1 0.9994970560073853
or I-Disease 0 0.0001128740914282389
other I-Disease 0 2.8668924642261118e-05
cancers I-Disease 1 0.9952355027198792
. O 0 5.2516577852657065e-05

Overall O 0 0.0025450033135712147
, O 0 0.0006214316235855222
disease O 1 0.998609185218811
was O 0 3.0353890906553715e-05
linked O 0 2.8282152925385162e-05
to O 0 2.1795482041397918e-07
BRCA1 O 0 3.090267637162469e-05
in O 0 2.2262177878928924e-08
an O 0 3.269885695544872e-08
estimated O 0 1.9287715247173765e-07
52 O 0 1.832484741726148e-07
% O 0 3.3707308944030956e-08
of O 0 7.81704034835684e-09
families O 0 1.0407324424477338e-07
, O 0 3.022783090500525e-08
to O 0 3.1345877005151124e-08
BRCA2 O 0 9.991361366701312e-06
in O 0 2.1104924030623806e-08
32 O 0 6.84568135511654e-08
% O 0 1.5187394453164416e-08
of O 0 5.8290092752599776e-09
families O 0 7.715502903238303e-08
, O 0 1.69293574714402e-08
and O 0 6.727678858453601e-09
to O 0 6.078553660415764e-09
neither O 0 1.2266802684735012e-07
gene O 0 1.420724373701887e-07
in O 0 1.911725355796534e-08
16 O 0 1.0013972229216961e-07
% O 0 4.8856367840244275e-08
( O 0 5.4241564129142716e-08
95 O 0 9.1864990281465e-08
% O 0 6.326729362626793e-08
confidence O 0 7.931537311378634e-07
interval O 0 2.5374777123943204e-06
[ O 0 1.3418707567325328e-05
CI O 0 0.0008933455101214349
] O 0 1.8178927803091938e-06
6 O 0 1.7030963306297053e-07
% O 0 1.1471050953559825e-07
- O 0 4.2083257767444593e-07
28 O 0 8.524431649448161e-08
% O 0 4.140008513786597e-08
) O 0 4.669845310445453e-08
, O 0 5.240343625700916e-08
suggesting O 0 2.589146333775716e-06
other O 0 2.2334997140660562e-07
predisposition O 0 0.004910522140562534
genes O 0 2.6290259484085254e-05
. O 0 1.669000630499795e-05

The O 0 1.9759229417104507e-06
majority O 0 1.7796809288483928e-06
( O 0 1.2994305507163517e-06
81 O 0 2.3151292225520592e-06
% O 0 1.2878248867309594e-07
) O 0 1.1840239011462472e-07
of O 0 1.9740572554383107e-07
the O 0 0.0002632297691889107
breast B-Disease 1 0.9995527863502502
- I-Disease 1 0.998609185218811
ovarian I-Disease 1 0.9999638795852661
cancer I-Disease 1 0.999708354473114
families O 0 4.350353265181184e-06
were O 0 1.9573673171180417e-07
due O 0 4.50732113677077e-06
to O 0 2.0358679364562704e-07
BRCA1 O 0 0.0002811315353028476
, O 0 4.385240615079056e-08
with O 0 1.694463946932956e-08
most O 0 1.877246802450827e-08
others O 0 5.179232331897765e-08
( O 0 5.483626708269185e-08
14 O 0 1.2867666043803183e-07
% O 0 1.3161988476895203e-07
) O 0 2.3535315563094628e-07
due O 0 2.3281279482034734e-06
to O 0 1.985369408430415e-06
BRCA2 O 0 0.0036644358187913895
. O 0 1.57403846969828e-05

Conversely O 0 4.98455083288718e-05
, O 0 3.3277459010605526e-07
the O 0 8.598306067142403e-08
majority O 0 1.6316374740199535e-07
of O 0 2.1848169495797265e-08
families O 0 3.864570032874326e-07
with O 0 4.275412663901079e-07
male B-Disease 0 2.5476630980847403e-05
and I-Disease 0 6.357652182487072e-06
female I-Disease 0 0.028994031250476837
breast I-Disease 1 0.9996763467788696
cancer I-Disease 1 0.9988645315170288
were O 0 6.427599146263674e-07
due O 0 5.9439503274916206e-06
to O 0 7.577347105325316e-07
BRCA2 O 0 0.0003745255817193538
( O 0 1.3725950793741504e-06
76 O 0 1.5726760466350242e-05
% O 0 2.134823944288655e-06
) O 0 2.9103996439516777e-06
. O 0 8.763761798036285e-06

The O 0 2.8181782454339555e-06
largest O 0 5.867882009624736e-06
proportion O 0 1.994101921809488e-06
( O 0 4.3077616851405764e-07
67 O 0 1.0985697826981777e-06
% O 0 8.130703577080567e-08
) O 0 1.5224751237497003e-08
of O 0 8.403770124232324e-09
families O 0 6.511867667313709e-08
due O 0 3.969503268308472e-07
to O 0 8.742604862277403e-09
other O 0 1.0871739952733606e-08
genes O 0 2.404881342954468e-07
was O 0 2.684722630874603e-07
found O 0 7.826308490166412e-08
in O 0 8.491664260645848e-09
families O 0 1.337453436889291e-08
with O 0 1.1437576219464063e-08
four O 0 1.3652299735156248e-08
or O 0 7.859667761067612e-08
five O 0 9.408584844550205e-08
cases O 0 8.223672693929984e-07
of O 0 9.861632861429825e-07
female O 0 0.05221876874566078
breast B-Disease 1 0.9996206760406494
cancer I-Disease 1 0.998810887336731
only O 0 6.078862952563213e-06
. O 0 3.96615760109853e-05

These O 0 1.17646845865238e-06
estimates O 0 8.851147867972031e-06
were O 0 2.360769855158651e-07
not O 0 3.4625929856701987e-07
substantially O 0 2.863015470211394e-05
affected O 0 7.439715545842773e-07
either O 0 6.765435500710737e-08
by O 0 4.305592682385395e-08
changing O 0 4.201476144771732e-07
the O 0 1.792228516706018e-07
assumed O 0 6.971132734179264e-06
penetrance O 0 0.00036217240267433226
model O 0 1.7541558463562978e-06
for O 0 2.4580123181294766e-07
BRCA1 O 0 0.00031094293808564544
or O 0 1.1466347871191829e-07
by O 0 6.034670008148169e-08
including O 0 1.0748814815997321e-07
or O 0 6.937322609701368e-07
excluding O 0 1.0510560969123617e-05
BRCA1 O 0 0.002334409626200795
mutation O 0 4.003443245892413e-05
data O 0 1.0737830962170847e-05
. O 0 2.1071769879199564e-05

Among O 0 3.408095153645263e-06
those O 0 1.8667495851332205e-06
families O 0 1.4260091120377183e-05
with O 0 0.00011741485650418326
disease O 1 0.999382734298706
due O 0 6.868835771456361e-05
to O 0 1.0355174708820414e-06
BRCA1 O 0 0.002255120314657688
that O 0 7.558842440857916e-08
were O 0 3.117273550401478e-08
tested O 0 2.5710269824230636e-07
by O 0 4.321065727452833e-09
one O 0 2.8003124263875634e-09
of O 0 3.45636808063432e-09
the O 0 4.042146528604462e-08
standard O 0 7.800747425790178e-07
screening O 0 9.285108717449475e-07
methods O 0 1.0937426253576632e-07
, O 0 9.069329820476923e-08
mutations O 0 5.889348244636494e-07
were O 0 2.4606009674243978e-08
detected O 0 5.422355684459035e-07
in O 0 3.818429128443768e-09
the O 0 1.1245615105792695e-08
coding O 0 6.817625717303599e-07
sequence O 0 5.468189812063429e-08
or O 0 4.355091220986651e-08
splice O 0 1.4061357660466456e-06
sites O 0 2.9625763175999964e-08
in O 0 8.465288914294433e-09
an O 0 1.9047481814027378e-08
estimated O 0 1.953823840494806e-07
63 O 0 3.138195836527302e-07
% O 0 3.812318638551915e-08
( O 0 6.727783841142809e-08
95 O 0 1.8300922022262966e-07
% O 0 2.751992838057049e-07
CI O 0 0.00043298170203343034
51 O 0 8.844945682540128e-07
% O 0 3.865461906116252e-07
- O 0 2.530742449380341e-06
77 O 0 1.7079285044019343e-06
% O 0 4.195762812742032e-07
) O 0 1.0138146535609849e-06
. O 0 2.841462674041395e-06

The O 0 6.556073913088767e-06
estimated O 0 5.274163868307369e-06
sensitivity O 0 6.0931524785701185e-06
was O 0 3.927157763428113e-07
identical O 0 1.5944760889397003e-07
for O 0 8.569552178983031e-09
direct O 0 4.920810070530024e-08
sequencing O 0 3.785328885896888e-07
and O 0 3.9301323084828255e-08
other O 0 5.148129744725338e-08
techniques O 0 4.124987754039466e-06
. O 0 1.1082148375862744e-05

The O 0 8.735491974221077e-06
penetrance O 0 0.0014989881310611963
of O 0 1.7989599427892244e-06
BRCA2 O 0 0.0015783017734065652
was O 0 1.8509103938413318e-06
estimated O 0 3.3954646028178104e-07
by O 0 4.227625893804543e-08
maximizing O 0 7.849478151911171e-07
the O 0 1.5295312039143028e-07
LOD O 0 0.00010242011194350198
score O 0 2.2621887296736531e-07
in O 0 6.320589704955637e-07
BRCA2 O 0 0.0008986703469417989
- O 0 1.2973086086276453e-05
mutation O 0 1.6326567902069655e-06
families O 0 8.495799619367972e-08
, O 0 1.3817945010430321e-08
over O 0 1.7404630625605932e-08
all O 0 1.1927433263281273e-08
possible O 0 6.622285013690998e-07
penetrance O 0 0.0010671451454982162
functions O 0 2.9879824978706893e-06
. O 0 1.9431407054071315e-05

The O 0 1.0388893315393943e-05
estimated O 0 3.422884037718177e-05
cumulative O 0 0.00024666875833645463
risk O 0 0.0011045464780181646
of O 0 8.9192571977037e-06
breast B-Disease 1 0.9994456171989441
cancer I-Disease 1 0.994512677192688
reached O 0 1.7157680076707038e-06
28 O 0 7.482749992959725e-07
% O 0 1.0445208431519859e-07
( O 0 7.071667340596832e-08
95 O 0 1.8350624486629386e-07
% O 0 2.609547777865373e-07
CI O 0 0.00017096551891881973
9 O 0 1.7246154015992943e-07
% O 0 7.42755759119973e-08
- O 0 2.7901526777895924e-07
44 O 0 8.655468519691567e-08
% O 0 2.6910534245416784e-08
) O 0 1.1812804956434775e-08
by O 0 9.14951137076514e-09
age O 0 2.0389884980431816e-07
50 O 0 2.955318478825575e-08
years O 0 3.927172187445649e-08
and O 0 1.1434217128680757e-08
84 O 0 2.6485881221560703e-07
% O 0 3.979820561994529e-08
( O 0 4.227238648013554e-08
95 O 0 1.2389001824431034e-07
% O 0 2.1812532224885217e-07
CI O 0 0.0003389505436643958
43 O 0 3.522887936924235e-07
% O 0 1.123798654134589e-07
- O 0 3.4139401350330445e-07
95 O 0 7.788187872392882e-08
% O 0 3.2037551278563114e-08
) O 0 3.8253784140351854e-08
by O 0 4.1241673187641936e-08
age O 0 1.3889773526898352e-06
70 O 0 1.7507264828964253e-06
years O 0 5.9876165323657915e-06
. O 0 6.631115411437349e-06

The O 0 0.0006428940687328577
corresponding O 1 0.9238981604576111
ovarian B-Disease 1 0.9999245405197144
cancer I-Disease 1 0.9998152852058411
risks O 0 0.06666447967290878
were O 0 4.634380275092553e-06
0 O 0 1.8954768165713176e-05
. O 0 2.0923866031807847e-05

4 O 0 4.405832896736683e-06
% O 0 1.2085971548003727e-06
( O 0 4.405819140629319e-07
95 O 0 8.003631251085608e-07
% O 0 6.786410722270375e-07
CI O 0 0.0002553830563556403
0 O 0 1.1288297940836856e-07
% O 0 1.0738425260115037e-07
- O 0 2.6257970375809236e-07
1 O 0 2.822556766091111e-08
% O 0 2.2839282465270117e-08
) O 0 1.0303743636086438e-08
by O 0 8.190484734882375e-09
age O 0 1.83643507511988e-07
50 O 0 5.788738377532354e-08
years O 0 3.634563228160914e-08
and O 0 6.38934993801854e-09
27 O 0 9.018942392913232e-08
% O 0 2.2370080898781453e-08
( O 0 2.7582981232399106e-08
95 O 0 1.0595479693620291e-07
% O 0 1.5524861396443157e-07
CI O 0 9.06191926333122e-05
0 O 0 7.263848544880602e-08
% O 0 8.753221436563763e-08
- O 0 4.6597557457062067e-07
47 O 0 1.27214889289462e-07
% O 0 3.537673975984035e-08
) O 0 3.868957421104824e-08
by O 0 4.135139164418433e-08
age O 0 2.4171051791199716e-06
70 O 0 1.943514917002176e-06
years O 0 7.366927547991509e-06
. O 0 9.248836249753367e-06

The O 0 4.1903986129909754e-05
lifetime O 0 0.0035538359079509974
risk O 0 0.0040787942707538605
of O 0 0.00011148967314511538
breast B-Disease 1 0.9997753500938416
cancer I-Disease 1 0.9995757937431335
appears O 0 2.1473046217579395e-05
similar O 0 3.9647213156968064e-07
to O 0 7.381531474948133e-08
the O 0 6.876643396935833e-07
risk O 0 0.00015481650189030915
in O 0 2.093219336529728e-06
BRCA1 O 0 0.01642606593668461
carriers O 0 2.682248486962635e-05
, O 0 5.638691646936422e-08
but O 0 2.6915564887985965e-08
there O 0 1.4095346223541583e-08
was O 0 2.9433307346948823e-08
some O 0 5.5152806766045614e-09
suggestion O 0 2.4036225454437954e-07
of O 0 2.2540199040577136e-08
a O 0 1.1562534609765862e-06
lower O 0 0.00020115714869461954
risk O 0 0.0001034153247019276
in O 0 8.389573622480384e-07
BRCA2 O 0 0.0012953472323715687
carriers O 0 3.887379352818243e-05
< O 0 3.908366124960594e-05
50 O 0 2.8200608426232066e-07
years O 0 1.953525554654334e-07
of O 0 9.045179183431173e-08
age O 0 3.6022775020683184e-05
. O 0 1.3824193956679665e-05

Eye B-Disease 1 0.5076032280921936
movement I-Disease 0 0.00033858249662443995
abnormalities I-Disease 1 0.8352265357971191
correlate O 0 0.00011994600936304778
with O 0 1.0473338988958858e-05
genotype O 0 0.004373864270746708
in O 0 5.438268635771237e-05
autosomal O 1 0.9924747347831726
dominant O 1 0.9052440524101257
cerebellar B-Disease 1 0.9990129470825195
ataxia I-Disease 1 0.999218225479126
type I-Disease 1 0.991787850856781
I I-Disease 0 0.018966348841786385
. O 0 9.942464384948835e-05

We O 0 1.408877142239362e-05
compared O 0 8.287049422506243e-05
horizontal O 0 0.000711259082891047
eye O 0 0.0031231811735779047
movements O 0 7.4030999712704215e-06
( O 0 6.985280379012693e-06
visually O 0 6.879442662466317e-05
guided O 0 6.838542321929708e-05
saccades O 0 0.005447070579975843
, O 0 1.1719947679011966e-06
antisaccades O 0 9.657193731982261e-05
, O 0 9.944100298753256e-08
and O 0 4.7552244808457544e-08
smooth O 0 2.2430849639931694e-06
pursuit O 0 1.864799401118944e-06
) O 0 9.95506965750792e-08
in O 0 3.482660915210545e-08
control O 0 4.166769826952077e-07
subjects O 0 5.152634230398689e-07
( O 0 3.0470670253635035e-07
n O 0 2.550734734541038e-06
= O 0 3.5538589600037085e-06
14 O 0 2.4051379909906245e-07
) O 0 7.811961211245944e-08
and O 0 7.879646091168979e-08
patients O 0 2.384801882726606e-05
with O 0 2.1205396549817124e-08
three O 0 3.41580879137382e-08
forms O 0 6.742080813637585e-07
of O 0 7.609862677782075e-07
autosomal O 1 0.9395867586135864
dominant O 0 0.03533594682812691
cerebellar B-Disease 1 0.9978106617927551
ataxias I-Disease 1 0.9936762452125549
type I-Disease 1 0.632308304309845
I I-Disease 0 0.008532139472663403
spinocerebellar B-Disease 1 0.9921002984046936
ataxias I-Disease 0 0.0009528633090667427
1 I-Disease 0 9.398420957040798e-07
and I-Disease 0 1.3522235065011046e-07
2 I-Disease 0 7.928292689030059e-07
( O 0 5.46397188827541e-07
SCA1 B-Disease 0 4.2458810639800504e-05
, O 0 1.3111649366237543e-07
n O 0 1.8367519487583195e-06
= O 0 1.9599315237428527e-06
11 O 0 1.975136285636836e-07
; O 0 1.100084077165775e-07
SCA2 B-Disease 0 2.6384754164610058e-05
, O 0 6.751964320983461e-08
n O 0 7.324199486902216e-07
= O 0 5.696036282643036e-07
10 O 0 5.721330964547633e-08
) O 0 5.8518153878139856e-08
and O 0 4.079332143192005e-07
SCA3 B-Disease 0 0.06121804565191269
/ O 0 0.0004512667655944824
Machado B-Disease 0 0.0005852626054547727
- I-Disease 0 0.00017330172704532743
Joseph I-Disease 0 0.0002546912874095142
disease I-Disease 1 0.9925469756126404
( O 0 1.151075503003085e-05
MJD B-Disease 0 0.07352357357740402
) O 0 8.847130175126949e-07
( O 0 6.10034021519823e-07
n O 0 5.145791874383576e-06
= O 0 9.50500452745473e-06
16 O 0 2.859390178855392e-06
) O 0 1.6356772221115534e-06
. O 0 4.991817149857525e-06

In O 0 1.2628484910237603e-05
SCA1 B-Disease 0 0.0011883322149515152
, O 0 1.1581273611227516e-06
saccade O 0 6.349402974592522e-05
amplitude O 0 6.843997198302532e-06
was O 0 6.475407190009719e-06
significantly O 0 2.2132799131213687e-05
increased O 0 2.0855102320638252e-06
, O 0 3.1115001775106066e-07
resulting O 0 1.0874978215724695e-05
in O 0 3.571240313249291e-06
hypermetria B-Disease 0 0.0036579156294465065
. O 0 2.5523051590425894e-05

The O 0 3.4193333249277202e-06
smooth O 0 5.623443576041609e-05
pursuit O 0 4.959218131261878e-05
gain O 0 3.5879256756743416e-05
was O 0 7.142467075027525e-05
decreased O 0 0.0011986242607235909
. O 0 3.0127015634207055e-05

In O 0 2.0677618522313423e-05
SCA2 B-Disease 0 0.002558075590059161
, O 0 3.3810249533416936e-06
saccade O 0 0.00031097675673663616
velocity O 0 4.336102938395925e-05
was O 0 0.00020656068227253854
markedly O 0 0.004901487845927477
decreased O 0 0.0007894912268966436
. O 0 2.1565270799328573e-05

The O 0 1.0300402664142894e-06
percentage O 0 1.7190927792398725e-06
of O 0 9.448165627645722e-08
errors O 0 9.496187885815743e-06
in O 0 1.1183891501787002e-06
antisaccades O 0 0.0025075115263462067
was O 0 6.4859941630857065e-06
greatly O 0 3.619299832280376e-06
increased O 0 5.332978503247432e-07
and O 0 8.586244604202875e-08
was O 0 1.1379692068658187e-06
significantly O 0 5.821939794259379e-06
correlated O 0 6.425383162422804e-06
with O 0 8.423662620771211e-07
age O 0 0.0006712390459142625
at O 0 0.006454074289649725
disease O 1 0.9992904663085938
onset O 1 0.9967367053031921
. O 0 0.0005883157136850059

In O 0 5.002450507163303e-07
addition O 0 3.02488302850179e-07
, O 0 6.522495255012473e-08
a O 0 6.83602507933756e-08
correlation O 0 4.698143811765476e-07
between O 0 1.1082892825697854e-07
smooth O 0 3.894017481798073e-06
pursuit O 0 2.682388412722503e-06
gain O 0 3.186378023656289e-07
and O 0 1.4868553499525206e-08
the O 0 3.520858626870904e-08
number O 0 1.9675853835110502e-08
of O 0 3.0722102906111104e-07
trinucleotide O 0 0.2921704351902008
repeats O 0 0.00027046859031543136
was O 0 2.7156565920449793e-05
found O 0 1.42103908729041e-05
. O 0 1.5918938515824266e-05

In O 0 0.0001049122802214697
SCA3 B-Disease 1 0.9542605876922607
, O 0 2.8245305657037534e-05
gaze B-Disease 0 0.007126318756490946
- I-Disease 0 0.0008530253544449806
evoked I-Disease 0 0.0018416220555081964
nystagmus I-Disease 0 0.03000573255121708
was O 0 5.392206730903126e-06
often O 0 2.900530944316415e-07
present O 0 2.8327619361334655e-07
as O 0 1.9492044600610825e-07
was O 0 2.1974817627778975e-06
saccade O 0 7.162457768572494e-05
hypometria O 0 5.502432395587675e-05
and O 0 1.6471342689783341e-07
smooth O 0 8.966078894445673e-06
pursuit O 0 2.8713713618344627e-05
gain O 0 3.160376945743337e-05
was O 0 0.00015513449034187943
markedly O 0 0.010798224247992039
decreased O 0 0.001752346521243453
. O 0 3.851086148642935e-05

Three O 0 1.8551127141108736e-06
major O 0 6.244419637368992e-06
criteria O 0 1.2968455394002376e-06
, O 0 3.0673214723719866e-07
saccade O 0 1.9672008420457132e-05
amplitude O 0 2.5288436518167146e-06
, O 0 1.574609456156395e-07
saccade O 0 1.4742945495527238e-05
velocity O 0 1.0856674634851515e-06
, O 0 7.477094499108716e-08
and O 0 2.5635635836351867e-08
presence O 0 2.4944927190517774e-07
of O 0 2.2125453824628494e-07
gaze B-Disease 0 0.0006059382576495409
- I-Disease 0 7.010403351159766e-05
evoked I-Disease 0 0.00012930281809531152
nystagmus I-Disease 0 0.0005502233980223536
, O 0 6.986200418168664e-08
permitted O 0 9.530572242510971e-08
the O 0 2.3986276076470858e-08
correct O 0 6.796748266424402e-07
assignment O 0 2.3336978927090968e-07
of O 0 6.3138640982174365e-09
90 O 0 4.687541377279558e-08
% O 0 1.609361355292549e-08
of O 0 5.722440743483048e-09
the O 0 8.596666134508268e-08
SCA1 B-Disease 0 6.0626880440395325e-05
, O 0 1.4310407969730932e-08
90 O 0 2.466432214021097e-08
% O 0 1.148008621498775e-08
of O 0 3.5077458715448984e-09
the O 0 6.735885449415946e-08
SCA2 B-Disease 0 9.849204798229039e-05
, O 0 3.085407840330845e-08
and O 0 1.2026323936709105e-08
93 O 0 2.2093215079621586e-07
% O 0 2.5783583268434995e-08
of O 0 1.6892618859287722e-08
the O 0 7.807408906046476e-07
patients O 0 0.0004440242482814938
with O 0 5.410557832874474e-07
SCA3 B-Disease 0 0.08605808764696121
to O 0 5.754710841188171e-08
their O 0 8.148386854145429e-08
genetically O 0 2.4537253921153024e-05
confirmed O 0 1.8730441297520883e-05
patient O 0 0.0001469893177272752
group O 0 2.4902666950765706e-07
and O 0 5.631308042097771e-08
, O 0 9.338732098740365e-08
therefore O 0 2.4942667664618057e-07
, O 0 2.735820885391149e-07
may O 0 1.8726229882304324e-06
help O 0 1.474828195568989e-06
orient O 0 5.734711157856509e-05
diagnoses O 0 0.00027628379757516086
of O 0 5.395573339228577e-07
SCA1 B-Disease 0 0.008800087496638298
, O 0 1.6980263808363816e-06
SCA2 B-Disease 0 0.001457585603930056
, O 0 2.734793156378146e-07
and O 0 2.214935364008852e-07
SCA3 B-Disease 0 0.004263857379555702
at O 0 8.432302820438053e-07
early O 0 1.2160404594396823e-06
clinical O 0 1.5962690667947754e-05
stages O 0 5.342759777704487e-06
of O 0 6.587986263184575e-07
the O 0 0.0001727052149362862
diseases O 1 0.9989325404167175
. O 0 7.5721845860243775e-06
. O 0 1.6136456906679086e-05

Genetic O 0 3.692689278977923e-05
basis O 0 6.842403763585025e-07
and O 0 5.74987154777773e-07
molecular O 0 6.637175829382613e-05
mechanism O 0 0.0004724554601125419
for O 0 0.001133038429543376
idiopathic B-Disease 1 0.9998928308486938
ventricular I-Disease 1 0.9994626641273499
fibrillation I-Disease 1 0.9996426105499268
. O 0 0.007875356823205948

Ventricular B-Disease 1 0.9929065704345703
fibrillation I-Disease 1 0.9961811304092407
causes O 0 0.002641180530190468
more O 0 2.775190921511239e-07
than O 0 3.135688757538446e-07
300 O 0 1.3326402950042393e-06
, O 0 3.5051598956670205e-07
000 O 0 6.106584351073252e-06
sudden O 0 0.0006559984758496284
deaths O 0 5.0575658860907424e-06
each O 0 2.2084931217136727e-08
year O 0 5.043801252213598e-07
in O 0 1.282556922888034e-07
the O 0 6.313529183898936e-07
USA O 0 2.9492786779883318e-05
alone O 0 1.122065350500634e-05
. O 0 1.1082708624599036e-05

In O 0 5.539382641472912e-07
approximately O 0 4.966968276676198e-07
5 O 0 1.310996594838798e-06
- O 0 9.87429871202039e-07
12 O 0 4.2455404525298945e-08
% O 0 1.5044163248489895e-08
of O 0 4.478805770702365e-09
these O 0 2.093561235483321e-08
cases O 0 4.832444346902776e-07
, O 0 5.2457838961572634e-08
there O 0 4.2436301583848035e-08
are O 0 1.4152536920164493e-08
no O 0 1.1132834742966224e-06
demonstrable O 0 0.019802454859018326
cardiac O 1 0.9971535205841064
or O 0 3.562127676559612e-05
non O 0 0.0006851216894574463
- O 0 0.10056624561548233
cardiac O 1 0.9940217137336731
causes O 0 3.3119496947620064e-05
to O 0 1.8598973028360888e-08
account O 0 1.7321209355714018e-08
for O 0 7.993964601382686e-09
the O 0 3.775961232577174e-08
episode O 0 9.607077799955732e-07
, O 0 3.7483559367501584e-08
which O 0 2.488732064875876e-08
is O 0 1.1662088184039021e-07
therefore O 0 1.2226677199578262e-06
classified O 0 0.0005812924937345088
as O 0 0.00030671435524709523
idiopathic B-Disease 1 0.9997116923332214
ventricular I-Disease 1 0.9991376399993896
fibrillation I-Disease 1 0.9994940757751465
( O 0 0.005856294650584459
IVF B-Disease 1 0.9903627038002014
) O 0 5.561744546866976e-05
. O 0 2.9370718038990162e-05

A O 0 1.6621943359496072e-05
distinct O 0 5.3839189604332205e-06
group O 0 5.483037512021838e-06
of O 0 7.257890047185356e-06
IVF B-Disease 1 0.9980649352073669
patients O 1 0.5222435593605042
has O 0 6.534169756378105e-07
been O 0 1.0068114164596409e-07
found O 0 9.522049992938264e-08
to O 0 1.2023388507031996e-08
present O 0 9.103089837481093e-08
with O 0 9.152010704838176e-08
a O 0 2.52082327278913e-06
characteristic O 0 9.028891508933157e-05
electrocardiographic O 0 0.034073829650878906
pattern O 0 0.0013620263198390603
. O 0 5.148441778146662e-05

Because O 0 1.4998929600551492e-06
of O 0 4.508256878921202e-08
the O 0 9.173751180924228e-08
small O 0 9.829204827838112e-08
size O 0 1.5157884547534195e-07
of O 0 1.1669815336290412e-08
most O 0 8.215240399067625e-08
pedigrees O 0 5.983501068840269e-06
and O 0 6.886501324743222e-08
the O 0 2.768075262338243e-07
high O 0 2.0608755221473984e-05
incidence O 0 0.0038726399652659893
of O 0 3.5946595744462684e-07
sudden B-Disease 0 0.09085387736558914
death I-Disease 0 4.4537067878991365e-05
, O 0 1.1142750366843757e-07
however O 0 1.3051318603629625e-07
, O 0 8.523683447947406e-08
molecular O 0 1.9689384771481855e-06
genetic O 0 3.5422629025561037e-06
studies O 0 3.5656080399348866e-07
of O 0 2.3367444157429418e-07
IVF B-Disease 0 0.4342226982116699
have O 0 1.5210913772989443e-07
not O 0 1.1107144359812082e-07
yet O 0 5.125154984852998e-07
been O 0 4.1508337744744495e-07
done O 0 2.340663741051685e-06
. O 0 5.533393050427549e-06

Because O 0 0.005019263830035925
IVF B-Disease 1 0.9892436265945435
causes O 1 0.9879970550537109
cardiac O 1 0.9976558685302734
rhythm O 0 0.14486610889434814
disturbance O 0 0.15884184837341309
, O 0 1.3529797797673382e-06
we O 0 2.0674669087838993e-07
investigated O 0 5.999362201691838e-06
whether O 0 8.919300853449386e-07
malfunction O 0 0.00032379990443587303
of O 0 5.4943789962180745e-08
ion O 0 2.8996317269047722e-05
channels O 0 3.5393588859733427e-06
could O 0 1.9338046968186973e-06
cause O 0 8.140427235048264e-05
the O 0 1.6350797977793263e-06
disorder O 1 0.9800205230712891
by O 0 1.9106941806512623e-07
studying O 0 1.6043219375205808e-06
mutations O 0 5.147981028130744e-06
in O 0 1.6485013532019366e-07
the O 0 1.1241903621339588e-06
cardiac O 0 0.42109715938568115
sodium O 0 0.00010014991858042777
channel O 0 2.2040336261852644e-05
gene O 0 6.656890036538243e-05
SCN5A O 0 0.009614694863557816
. O 0 3.171075877617113e-05

We O 0 1.4766633285034914e-06
have O 0 2.549088264913735e-07
now O 0 4.08151890951558e-07
identified O 0 7.007967610661581e-07
a O 0 8.167055511876242e-07
missense O 0 3.373603249201551e-05
mutation O 0 2.9865122996852733e-06
, O 0 8.943125351379422e-08
a O 0 5.481806510942988e-07
splice O 0 9.604726074030623e-05
- O 0 1.3979707546241116e-05
donor O 0 5.456964572658762e-06
mutation O 0 2.3094376047083642e-06
, O 0 3.483857113906197e-08
and O 0 1.7316352796115098e-08
a O 0 4.084875797616405e-07
frameshift O 0 0.00017361613572575152
mutation O 0 1.2752564089169027e-06
in O 0 2.9276703727987297e-08
the O 0 6.620852133210064e-08
coding O 0 2.9953321245557163e-06
region O 0 2.2439313340782974e-07
of O 0 6.452411582813511e-08
SCN5A O 0 0.0006003406597301364
in O 0 4.2038490732920764e-07
three O 0 2.6514160254009767e-06
IVF B-Disease 0 0.22871644794940948
families O 0 1.5695281035732478e-05
. O 0 2.1482897864189e-05

We O 0 4.4405734911379113e-07
show O 0 3.150418308450753e-07
that O 0 2.2354170070570945e-08
sodium O 0 4.6105438400445564e-07
channels O 0 5.660825763698085e-08
with O 0 3.3981400804350415e-08
the O 0 2.3763672629684152e-07
missense O 0 6.71513334964402e-05
mutation O 0 4.691845606430434e-05
recover O 0 0.00023502152180299163
from O 0 1.3443482203001622e-06
inactivation O 0 0.0007038507610559464
more O 0 8.266260920208879e-08
rapidly O 0 1.1108262469861074e-06
than O 0 1.2492596290769598e-08
normal O 0 8.719595001593916e-08
and O 0 1.2875517541033332e-08
that O 0 1.7224188297859655e-08
the O 0 1.9827533037641842e-07
frameshift O 0 0.0008733551949262619
mutation O 0 1.3407209735305514e-05
causes O 0 7.442593414452858e-06
the O 0 1.7222353676515922e-07
sodium O 0 3.475327048363397e-06
channel O 0 5.498739596987434e-07
to O 0 3.021722250196035e-08
be O 0 9.52441183699193e-08
non O 0 2.159661335099372e-06
- O 0 1.4107339666225016e-05
functional O 0 1.1948597602895461e-05
. O 0 1.125990820582956e-05

Our O 0 4.194065240881173e-06
results O 0 4.293048732506577e-06
indicate O 0 4.2505380406510085e-06
that O 0 4.2560324686746753e-07
mutations O 0 7.01086173648946e-06
in O 0 1.2349594271654496e-06
cardiac O 0 0.11204586178064346
ion O 0 0.00011632616224233061
- O 0 5.764823526988039e-06
channel O 0 5.002765419703792e-07
genes O 0 1.098404709409806e-07
contribute O 0 1.9028277620236622e-07
to O 0 1.520870185345302e-08
the O 0 1.848541728577402e-07
risk O 0 4.940893632010557e-06
of O 0 1.434900553931584e-07
developing O 0 2.6406902179587632e-05
IVF B-Disease 1 0.5074851512908936
. O 0 4.459889623831259e-06
. O 0 1.0799715710163582e-05

Molecular O 0 0.00016524277452845126
heterogeneity O 0 0.0002082868159050122
in O 0 3.7702652662119363e-06
mucopolysaccharidosis B-Disease 0 0.00605757674202323
IVA I-Disease 0 0.08145086467266083
in O 0 2.773349478957243e-07
Australia O 0 1.798244824158246e-07
and O 0 2.873443705198042e-08
Northern O 0 9.158593883284993e-08
Ireland O 0 1.4679535809136723e-07
: O 0 9.097761477505628e-08
nine O 0 1.2986434683170955e-07
novel O 0 6.513954531328636e-07
mutations O 0 1.2451678230718244e-06
including O 0 1.3176506286072254e-07
T312S O 0 2.6588184482534416e-05
, O 0 6.830264709378753e-08
a O 0 2.4883530613806215e-07
common O 0 6.918795634192065e-07
allele O 0 6.8183358052920084e-06
that O 0 8.127507271638024e-07
confers O 0 0.00033651170087978244
a O 0 0.0001276081893593073
mild O 1 0.9858831763267517
phenotype O 0 0.14796344935894012
. O 0 0.00012871957733295858

Mucopolysaccharidosis B-Disease 0 0.12516126036643982
IVA I-Disease 1 0.9532864689826965
( O 0 0.00018305142293684185
MPS B-Disease 0 0.023947417736053467
IVA I-Disease 1 0.9738730192184448
) O 0 5.126390078658005e-06
is O 0 1.8962748526973883e-06
an O 0 1.12883990368573e-05
autosomal B-Disease 1 0.9961702227592468
recessive I-Disease 1 0.9988006353378296
lysosomal I-Disease 1 0.9996687173843384
storage I-Disease 1 0.9989292025566101
disorder I-Disease 1 0.9998136162757874
caused O 0 0.40462541580200195
by O 0 4.111474027013173e-06
a O 0 0.00013895760639570653
genetic B-Disease 0 0.3790786862373352
defect I-Disease 1 0.9873502850532532
in O 0 1.5900117205092101e-06
N O 0 0.00012961019820068032
- O 0 2.781566399789881e-05
acetylgalactosamine O 0 0.00016032520215958357
- O 0 1.0391290743427817e-05
6 O 0 9.433537343284115e-06
- O 0 7.024416117928922e-05
sulfate O 0 0.005620132200419903
sulfatase O 0 0.051004793494939804
( O 0 1.1078651368734427e-05
GALNS O 0 0.004304925445467234
) O 0 5.925160166952992e-06
. O 0 1.7338654288323596e-05

Previous O 0 1.9603165128501132e-05
studies O 0 3.5155687783117173e-06
of O 0 9.921297987602884e-07
patients O 0 0.0009462417801842093
from O 0 5.352748644327221e-07
a O 0 1.8144911564377253e-06
British O 0 1.0964526154566556e-05
- O 0 3.7331237763282843e-06
Irish O 0 7.582110583825852e-07
population O 0 2.658702591418205e-08
showed O 0 2.530717893023393e-07
that O 0 6.487393733323188e-09
the O 0 3.045137830781641e-08
I113F O 0 6.537007266160799e-06
mutation O 0 4.4013464162162563e-07
is O 0 5.338766762008618e-09
the O 0 7.910951005385414e-09
most O 0 5.976444228394939e-09
common O 0 1.3942697307811613e-07
single O 0 3.0753764690416574e-07
mutation O 0 2.823428985720966e-05
among O 0 4.793023435922805e-06
MPS B-Disease 0 0.2254132181406021
IVA I-Disease 1 0.9992031455039978
patients O 1 0.635647177696228
and O 0 3.875578386214329e-06
produces O 0 0.0004000409389846027
a O 0 0.0013355121482163668
severe O 1 0.9973828196525574
clinical O 1 0.8498973250389099
phenotype O 1 0.6212022304534912
. O 0 0.0002179920847993344

We O 0 8.19619856429199e-07
studied O 0 1.6599656191829126e-06
mutations O 0 2.8527849735837663e-06
in O 0 1.1624645424035407e-07
the O 0 2.9392646183623583e-07
GALNS O 0 0.00030189502285793424
gene O 0 1.8245763158120099e-06
from O 0 2.6538242536844336e-07
23 O 0 2.341134631933528e-06
additional O 0 4.68658572572167e-06
MPS B-Disease 0 0.018434807658195496
IVA I-Disease 1 0.9974690675735474
patients O 0 0.008005168288946152
( O 0 7.07876495198434e-07
15 O 0 1.9969782272255543e-07
from O 0 7.0814664354657e-08
Australia O 0 6.818589071144743e-08
, O 0 1.5143138298867598e-08
8 O 0 6.512687633630776e-08
from O 0 2.1801961125333946e-08
Northern O 0 2.8566619292291762e-08
Ireland O 0 8.477120161387575e-08
) O 0 2.6858641533067384e-08
, O 0 1.0963383978435104e-08
with O 0 2.8772332072435347e-08
various O 0 1.532325484276953e-07
clinical O 0 0.0015253425808623433
phenotypes O 0 0.04056983441114426
( O 0 0.00017100463446695358
severe O 1 0.9952921867370605
, O 0 7.501199092985189e-07
16 O 0 1.358885469926463e-06
cases O 0 1.3177202617953299e-06
; O 0 2.1363869961987803e-07
intermediate O 0 6.9342536335170735e-06
, O 0 2.7601987540037953e-07
4 O 0 1.8532065269027953e-06
cases O 0 6.065589786885539e-06
; O 0 3.317116807011189e-06
mild O 0 0.020882338285446167
, O 0 4.897121357316792e-07
3 O 0 2.6447537493368145e-06
cases O 0 6.494381068478106e-06
) O 0 2.6427119337313343e-06
. O 0 7.554499006801052e-06

We O 0 9.155447742159595e-07
found O 0 6.073723852750845e-07
two O 0 3.7206689285085304e-08
common O 0 5.880862090634764e-07
mutations O 0 8.687329113854503e-07
that O 0 6.557157483655374e-09
together O 0 8.673826101812665e-09
accounted O 0 6.524697937493329e-08
for O 0 4.492280325507636e-09
32 O 0 2.3002394655691205e-08
% O 0 6.2359624131147484e-09
of O 0 2.1990849141673152e-09
the O 0 4.804252995427305e-08
44 O 0 7.806329449522309e-07
unrelated O 0 1.1663132681860588e-05
alleles O 0 6.423201739380602e-06
in O 0 7.211046408883703e-07
these O 0 2.2551353140443098e-06
patients O 0 0.07940123975276947
. O 0 4.155570059083402e-05

One O 0 6.984615197325184e-07
is O 0 3.10146901938424e-07
the O 0 3.321753183627152e-07
T312S O 0 3.5970799217466265e-05
mutation O 0 2.8403137548593804e-06
, O 0 8.402491147307956e-08
a O 0 4.822173309548816e-07
novel O 0 3.517895947879879e-06
mutation O 0 6.179084721225081e-06
found O 0 1.049032562150387e-06
exclusively O 0 3.202333800800261e-06
in O 0 1.7619571735849604e-05
milder O 1 0.9508182406425476
patients O 1 0.8020023703575134
. O 0 0.00011549345072126016

The O 0 8.294189228763571e-07
other O 0 6.74663525046526e-08
is O 0 9.911001797036079e-08
the O 0 1.5860499047448684e-07
previously O 0 1.6211615729844198e-06
described O 0 6.978754754527472e-06
I113F O 0 6.0425099945859984e-05
that O 0 5.669188567480887e-07
produces O 0 2.7295838663121685e-05
a O 0 0.00016020785551518202
severe O 1 0.9957665205001831
phenotype O 0 0.43552130460739136
. O 0 0.00010845741053344682

The O 0 1.6687316019670106e-05
I113F O 0 0.00030556792626157403
and O 0 2.3702250473434106e-06
T312S O 0 0.0001423626090399921
mutations O 0 6.758819836250041e-06
accounted O 0 6.943583912288886e-07
for O 0 3.7584289458436615e-08
8 O 0 2.2575571279048745e-07
( O 0 6.230116156302756e-08
18 O 0 7.360470988260204e-08
% O 0 3.368378287404994e-08
) O 0 1.4429083705636003e-08
and O 0 4.9699035997718966e-09
6 O 0 6.57529497516407e-08
( O 0 1.7842094024445032e-08
14 O 0 1.3292010159204892e-08
% O 0 1.0560188279384874e-08
) O 0 5.833803218280309e-09
of O 0 4.386794483224321e-09
44 O 0 4.051092901136144e-07
unrelated O 0 7.578173153888201e-06
alleles O 0 6.379820661095437e-06
, O 0 1.0405116199763143e-06
respectively O 0 1.058773159456905e-05
. O 0 2.1071609808132052e-05

The O 0 4.5715119085798506e-06
relatively O 0 1.633156898606103e-05
high O 0 3.45472690241877e-05
residual O 0 0.0006051210802979767
GALNS O 0 0.00420070206746459
activity O 0 1.9272779354650993e-06
seen O 0 6.903754865561496e-07
when O 0 8.54207513611982e-08
the O 0 7.754598385645295e-08
T312S O 0 7.846680091461167e-06
mutant O 0 3.6941207781637786e-06
cDNA O 0 2.520683665352408e-06
is O 0 2.6299548494534974e-07
overexpressed O 0 3.258658398408443e-05
in O 0 1.771436615172206e-07
mutant O 0 9.404506272403523e-06
cells O 0 7.693106454098597e-07
provides O 0 6.10800654499144e-08
an O 0 3.933326553351435e-08
explanation O 0 3.485572790395963e-07
for O 0 4.8765315341370297e-08
the O 0 3.3671183246042347e-06
mild O 1 0.9738141894340515
phenotype O 0 0.01729622110724449
in O 0 4.084539341420168e-06
patients O 0 0.001665429095737636
with O 0 3.1643716624785156e-07
this O 0 1.1486150697237463e-06
mutation O 0 0.0001552197354612872
. O 0 1.9208893718314357e-05

The O 0 6.292431180554559e-07
distribution O 0 2.1862616961243475e-07
and O 0 3.5401981790528225e-08
relative O 0 1.3852651647994207e-07
frequencies O 0 2.7478222364152316e-08
of O 0 1.5875050607405683e-08
the O 0 1.9435985620930296e-07
I113F O 0 1.8558683223091066e-05
and O 0 1.8341212637551507e-07
T312S O 0 3.0688734113937244e-05
mutations O 0 1.8827637404683628e-06
in O 0 5.73928815583713e-08
Australia O 0 1.0277368289735023e-07
corresponded O 0 3.061426809836121e-07
to O 0 1.0260304605935744e-08
those O 0 1.6988130013828595e-08
observed O 0 1.338987942745007e-07
in O 0 2.705860957519235e-08
Northern O 0 5.4759443202101465e-08
Ireland O 0 6.111782369089269e-08
and O 0 6.094714066762208e-09
are O 0 1.1587323323070109e-09
unique O 0 6.883031922200189e-09
to O 0 2.570005097624062e-09
these O 0 3.846704288434921e-09
two O 0 9.799549616218428e-09
populations O 0 1.3525045972073713e-07
, O 0 5.019127868877149e-08
suggesting O 0 8.263043014267168e-07
that O 0 1.4817763904773074e-08
both O 0 2.1140861505841713e-08
mutations O 0 9.594040193405817e-07
were O 0 5.5201670789983837e-08
probably O 0 3.508270367547084e-07
introduced O 0 9.296612546449978e-08
to O 0 1.067230570583888e-08
Australia O 0 5.708947270477438e-08
by O 0 2.731883164130977e-08
Irish O 0 4.2635804220481077e-07
migrants O 0 2.92311852945204e-07
during O 0 2.519669237699418e-07
the O 0 1.937537774665543e-07
19th O 0 6.234167358343257e-06
century O 0 9.946214049705304e-06
. O 0 1.082068592950236e-05

Haplotype O 0 0.0002639148442540318
analysis O 0 2.1296793875080766e-06
using O 0 7.807118436176097e-07
6 O 0 5.76429556531366e-06
RFLPs O 0 7.085515971994027e-05
provides O 0 3.392752319086867e-07
additional O 0 5.615112996792959e-08
data O 0 4.805032105537066e-08
that O 0 1.2677737970534508e-08
the O 0 8.751185021083074e-08
I113F O 0 2.2796300982008688e-05
mutation O 0 3.967761585954577e-06
originated O 0 7.213646426862397e-07
from O 0 1.6123976820381358e-07
a O 0 1.0550403430897859e-06
common O 0 7.072050266287988e-06
ancestor O 0 9.532478725304827e-05
. O 0 3.863847450702451e-05

The O 0 1.1543297659954987e-06
other O 0 1.490976586637771e-07
9 O 0 3.86272358809947e-06
novel O 0 4.754702786158305e-06
mutations O 0 5.843868166266475e-06
identified O 0 9.86171698968974e-07
in O 0 8.972992304734362e-08
these O 0 8.806524931515014e-08
23 O 0 9.24804226087872e-06
patients O 0 5.430132296169177e-05
were O 0 7.268557755679694e-09
each O 0 2.7437201399749256e-09
limited O 0 2.666172527199251e-08
to O 0 7.998585793700386e-09
a O 0 2.864333623620041e-07
single O 0 7.090135909493256e-07
family O 0 1.1844471373478882e-05
. O 0 7.879337317717727e-06

These O 0 5.180438051866076e-07
data O 0 6.01985220782808e-07
provide O 0 2.5260041525143606e-07
further O 0 8.955090891049622e-08
evidence O 0 3.42512549877938e-07
for O 0 1.1939933131088765e-07
extensive O 0 9.187142495648004e-06
allelic O 0 0.00035160218249075115
heterogeneity O 0 0.0001766475907061249
in O 0 5.600679287454113e-06
MPS B-Disease 0 0.010802696458995342
IVA I-Disease 1 0.9925717711448669
in O 0 3.7852596506127156e-06
British O 0 0.00014186541375238448
- O 0 0.0004845443181693554
Irish O 0 0.0001226592721650377
patients O 0 0.00028647089493460953
and O 0 4.647116824685327e-08
provide O 0 6.5344494259989e-08
evidence O 0 1.2532444770840812e-07
for O 0 1.2466651710951737e-08
their O 0 1.2179627084663025e-08
transmission O 0 3.2548016406508395e-06
to O 0 2.500436835362052e-08
Australia O 0 1.3797962594708224e-07
by O 0 1.8646041155534476e-07
British O 0 8.195900591090322e-06
- O 0 7.5019952419097535e-06
Irish O 0 4.035486199427396e-06
migrants O 0 1.2610665862666792e-06
. O 0 8.571360012865625e-07
. O 0 7.882839781814255e-06

Identification O 0 5.3560902415483724e-06
of O 0 1.6435799352620961e-06
constitutional O 0 7.524784450652078e-05
WT1 O 1 0.8631612062454224
mutations O 0 0.00019880215404555202
, O 0 5.45048442290863e-06
in O 0 8.32915884529939e-06
patients O 0 0.027449501678347588
with O 0 7.083894888637587e-05
isolated O 1 0.8438066840171814
diffuse B-Disease 1 0.9968191385269165
mesangial I-Disease 1 0.9996738433837891
sclerosis I-Disease 1 0.9998959302902222
, O 0 1.3503565696737496e-06
and O 0 1.201103856374175e-07
analysis O 0 2.429533196846023e-07
of O 0 2.3276766114577185e-07
genotype O 0 0.0009076131391339004
/ O 0 0.0005666952929459512
phenotype O 0 3.657429260783829e-05
correlations O 0 1.3985942359795445e-06
by O 0 2.4963101807884414e-08
use O 0 3.8213674002918196e-08
of O 0 3.587583563557928e-08
a O 0 2.472148707965971e-06
computerized O 0 0.0002951506176032126
mutation O 0 0.00012944714399054646
database O 0 4.620253821485676e-05
. O 0 2.8391486921464093e-05

Constitutional O 0 2.217571272922214e-05
mutations O 0 5.580499419011176e-06
of O 0 1.7489129788827995e-07
the O 0 1.0810945241246372e-06
WT1 O 0 0.0029482177924364805
gene O 0 2.53123948823486e-06
, O 0 1.711080130917253e-07
encoding O 0 9.708880952530308e-07
a O 0 9.365376172354445e-06
zinc O 0 0.03849814832210541
- O 0 3.90423447242938e-05
finger O 0 4.4354987039696425e-05
transcription O 0 1.2418694495863747e-05
factor O 0 2.9795312457281398e-06
involved O 0 6.315694463410182e-06
in O 0 1.9120530851068906e-05
renal O 1 0.9995959401130676
and O 0 5.143574071553303e-06
gonadal O 0 0.3532629907131195
development O 0 1.551463469695591e-06
, O 0 1.5450832790975255e-07
are O 0 1.7146208008966823e-08
found O 0 2.1029546815043432e-07
in O 0 2.708546844587545e-07
most O 0 9.839911854214733e-07
patients O 0 0.009750555269420147
with O 0 4.501805597101338e-05
Denys B-Disease 1 0.98972487449646
- I-Disease 1 0.9670000076293945
Drash I-Disease 1 0.995235025882721
syndrome I-Disease 1 0.9997591376304626
( O 0 0.000832411227747798
DDS B-Disease 1 0.9978076815605164
) O 0 9.917778697854374e-06
, O 0 6.124752417235868e-06
or O 0 0.0001618427486391738
diffuse B-Disease 1 0.9885417222976685
mesangial I-Disease 1 0.9991589784622192
sclerosis I-Disease 1 0.9998784065246582
( O 0 0.002842299873009324
DMS B-Disease 1 0.9952736496925354
) O 0 7.922261829662602e-06
associated O 0 1.2720418453682214e-05
with O 0 4.075601282238495e-06
pseudohermaphroditism B-Disease 0 0.43340522050857544
and O 0 7.8311531979125e-06
/ O 0 0.007290610112249851
or O 0 0.00024320665397681296
Wilms B-Disease 1 0.9978545308113098
tumor I-Disease 1 0.9969610571861267
( O 0 8.853334293235093e-05
WT B-Disease 1 0.9266090989112854
) O 0 1.2926921954203863e-05
. O 0 1.3225851034803782e-05

Most O 0 2.5483845092821866e-05
mutations O 0 0.0010234416695311666
in O 0 0.000204993222723715
DDS B-Disease 1 0.9990039467811584
patients O 0 0.33884066343307495
lie O 0 2.2369100406649522e-05
in O 0 5.743191309193207e-07
exon O 0 2.3286154828383587e-05
8 O 0 1.0709662774388562e-06
or O 0 2.0658782773352868e-07
exon O 0 5.623179276881274e-06
9 O 0 8.672851095070655e-07
, O 0 5.442291595159077e-08
encoding O 0 1.793678507056029e-06
zinc O 0 0.0009162456262856722
finger O 0 3.9973245293367654e-05
2 O 0 1.501740939602314e-06
or O 0 1.303131170971028e-06
zinc O 0 0.001437805243767798
finger O 0 1.719231113384012e-05
3 O 0 2.682593276404077e-07
, O 0 2.685664313162306e-08
respectively O 0 6.839911748102168e-08
, O 0 8.847584886950699e-09
with O 0 1.0975016451197916e-08
a O 0 2.047861187293165e-07
hot O 0 3.3329022244288353e-06
spot O 0 5.636960054289375e-07
( O 0 1.6632729682442005e-07
R394W O 0 6.74271177558694e-06
) O 0 1.2429237017386185e-07
in O 0 2.5118427515735675e-07
exon O 0 7.270941569004208e-05
9 O 0 1.565416096127592e-05
. O 0 5.51127368453308e-06

We O 0 4.817907779397501e-07
analyzed O 0 9.04074340724037e-07
a O 0 1.4066719700167596e-07
series O 0 1.288925801645746e-07
of O 0 1.0131318362027741e-07
24 O 0 1.0070185453514569e-05
patients O 0 0.0003341938427183777
, O 0 1.4587929797471588e-07
10 O 0 2.2113937347967294e-07
with O 0 6.373961127792427e-07
isolated B-Disease 0 0.00045216106809675694
DMS I-Disease 1 0.9866705536842346
( O 0 2.1810710677527823e-05
IDMS B-Disease 1 0.6652851700782776
) O 0 5.665805247190292e-07
, O 0 1.373122415770922e-07
10 O 0 3.085579294292984e-07
with O 0 6.628679329878651e-07
DDS B-Disease 1 0.9556953310966492
, O 0 9.33087989096748e-08
and O 0 5.611247999581792e-08
4 O 0 1.6321617977155256e-06
with O 0 5.052812412031926e-06
urogenital B-Disease 1 0.9948581457138062
abnormalities I-Disease 1 0.99565190076828
and O 0 1.7349171685054898e-05
/ O 0 0.007808275055140257
or O 0 6.206883699633181e-05
WT B-Disease 1 0.9728363156318665
. O 0 5.353301821742207e-05

We O 0 9.215837962983642e-06
report O 0 5.2425810281420127e-05
WT1 O 0 0.007532793562859297
heterozygous O 0 2.8163940442027524e-05
mutations O 0 2.2651907784165815e-05
in O 0 8.07283072390419e-07
16 O 0 1.3790760931442492e-05
patients O 0 0.0004998177173547447
, O 0 8.814759411279738e-08
4 O 0 1.490618473098948e-07
of O 0 5.485907195179607e-08
whom O 0 3.575469463612535e-06
presented O 0 1.3093875168124214e-05
with O 0 3.7361562135629356e-05
IDMS B-Disease 1 0.9863802790641785
. O 0 9.803133434616029e-05

One O 0 1.789038492461259e-06
male O 0 5.28356758877635e-06
and O 0 5.081043923382822e-07
two O 0 1.314509518124396e-06
female O 0 0.001584316953085363
IDMS B-Disease 1 0.9962947964668274
patients O 0 0.4131835103034973
with O 0 8.465008431812748e-05
WT1 O 1 0.9919347763061523
mutations O 0 0.02778535522520542
underwent O 1 0.9929977655410767
normal O 0 0.0018413116922602057
puberty O 1 0.6629975438117981
. O 0 0.00020401825895532966

Two O 0 4.488254489842802e-06
mutations O 0 0.0001388225209666416
associated O 0 1.6298321497743018e-05
with O 0 6.68167103867745e-06
IDMS B-Disease 1 0.9522765278816223
are O 0 5.976229999760108e-08
different O 0 3.9166025089798495e-08
from O 0 4.2233304498040525e-07
those O 0 8.924396865950257e-07
described O 0 0.0003396752872504294
in O 0 0.00025244292919524014
DDS B-Disease 1 0.9990390539169312
patients O 1 0.9775654077529907
. O 0 0.00013362040044739842

No O 0 0.00022880664619151503
WT1 O 0 0.22723732888698578
mutations O 0 3.38965401169844e-05
were O 0 4.1752855395316146e-07
detected O 0 6.742454388586339e-06
in O 0 8.261989137281489e-08
the O 0 1.607144355375567e-07
six O 0 1.1609960210989811e-06
other O 0 2.7887106170965126e-06
IDMS B-Disease 1 0.9986335635185242
patients O 0 0.09551271796226501
, O 0 8.473513162243762e-07
suggesting O 0 2.2018904928700067e-05
genetic O 0 3.318975359434262e-05
heterogeneity O 0 0.00010922971705440432
of O 0 2.5826802811934613e-06
this O 0 0.00027696212055161595
disease O 1 0.9986465573310852
. O 0 0.00017754676810000092

We O 0 4.473396074899938e-06
analyzed O 0 5.960174894426018e-05
genotype O 0 0.0009327844018116593
/ O 0 0.0009274773765355349
phenotype O 0 0.00010409454262116924
correlations O 0 4.629057457350427e-06
, O 0 3.857735109136229e-08
on O 0 4.765746020041206e-09
the O 0 1.9314942978354566e-09
basis O 0 8.093731240776947e-10
of O 0 8.686006358615828e-10
the O 0 1.1172007319260047e-08
constitution O 0 1.2339214094936324e-08
of O 0 8.621671376829454e-09
a O 0 5.048700018051022e-07
WT1 O 0 0.0007459777989424765
mutation O 0 1.7306434756392264e-06
database O 0 3.9283941077883355e-07
of O 0 8.739124979229018e-08
84 O 0 9.046334162121639e-05
germ O 0 0.08662911504507065
- O 0 6.806089459132636e-06
line O 0 7.286507752723992e-07
mutations O 0 8.666006010571436e-07
, O 0 1.0244464831998812e-08
to O 0 3.407874205052508e-09
compare O 0 1.1504575070375722e-07
the O 0 7.593882855871925e-09
distribution O 0 3.459760122836997e-08
and O 0 1.2349173239556421e-08
type O 0 5.066373205409036e-07
of O 0 1.2208117183831746e-08
mutations O 0 1.8073103547067149e-06
, O 0 2.4525512287709716e-08
according O 0 2.5507654655143597e-08
to O 0 1.3406586951703048e-08
the O 0 2.6741997771750903e-07
different O 0 1.3248054528958164e-06
symptoms O 1 0.9937745332717896
. O 0 5.485939254867844e-05

This O 0 2.1711596218665363e-06
demonstrated O 0 7.367489160969853e-06
( O 0 7.470308105439472e-07
1 O 0 4.142150089592178e-07
) O 0 1.3356211070458812e-07
the O 0 5.172292460997596e-08
association O 0 9.243098588740395e-07
between O 0 7.052351236325194e-08
mutations O 0 6.418766247406893e-07
in O 0 2.8785782646423286e-08
exons O 0 8.635348649477237e-07
8 O 0 1.9985786536835803e-07
and O 0 4.219199567501164e-08
9 O 0 5.450871753964748e-07
and O 0 1.800870563783974e-07
DMS B-Disease 0 0.02877216227352619
; O 0 1.4949547733067448e-07
( O 0 1.565059477570685e-07
2 O 0 2.3388801650980895e-07
) O 0 1.4912312451542675e-07
among O 0 1.6066354646682157e-07
patients O 0 0.00014710667892359197
with O 0 7.232644634314056e-07
DMS B-Disease 0 0.28833773732185364
, O 0 6.182870748716596e-08
a O 0 2.7463602947364052e-08
higher O 0 4.525962182810872e-08
frequency O 0 1.9331499956365406e-08
of O 0 1.3197378301299523e-08
exon O 0 5.739173502661288e-06
8 O 0 5.182167228667822e-07
mutations O 0 5.787920827060589e-07
among O 0 4.1668563710572926e-08
46 O 0 1.0454391485836823e-06
, O 0 7.774546020300477e-07
XY O 0 0.05880913883447647
patients O 0 0.0003159660554956645
with O 0 3.9655756722822844e-07
female O 0 9.74007161858026e-06
phenotype O 0 0.00010783072502817959
than O 0 1.06668558430556e-07
among O 0 3.3709113722579787e-07
46 O 0 6.796956768084783e-06
, O 0 3.448357574598049e-06
XY O 0 0.3324313461780548
patients O 0 0.0009182766661979258
with O 0 2.617403822569031e-07
sexual O 0 4.492378138820641e-06
ambiguity O 0 1.787845576473046e-05
or O 0 4.0316472222912125e-06
male O 0 3.2482988899573684e-05
phenotype O 0 0.00024493614910170436
; O 0 1.7668071450316347e-07
and O 0 2.4299449563613962e-08
( O 0 9.001430356647688e-08
3 O 0 7.237227350742614e-08
) O 0 2.991318837075596e-08
statistically O 0 6.262175133997516e-08
significant O 0 4.144930798588575e-08
evidence O 0 1.587819156156911e-07
that O 0 1.933747384441631e-08
mutations O 0 2.374258230020132e-07
in O 0 1.5773396810914164e-08
exons O 0 6.284118967414543e-07
8 O 0 1.2973758600764995e-07
and O 0 2.5339822684600222e-08
9 O 0 1.7699439069929213e-07
preferentially O 0 3.9683072827756405e-07
affect O 0 4.56604709597741e-08
amino O 0 5.8903708577418e-08
acids O 0 8.84669404399574e-08
with O 0 8.936011930416043e-09
different O 0 7.03920566280658e-09
functions O 0 3.231501182199281e-07
. O 0 1.705805857454834e-06
. O 0 9.100083843804896e-06

The O 0 2.919793587352615e-05
185delAG O 0 0.004553918726742268
BRCA1 O 0 0.0036864234134554863
mutation O 0 2.6614874514052644e-05
originated O 0 1.7103130858231452e-06
before O 0 1.3577451341006963e-07
the O 0 3.319365049492262e-08
dispersion O 0 5.578534114647482e-07
of O 0 8.35129565501802e-09
Jews O 0 8.32759852187337e-08
in O 0 2.1690636842208733e-08
the O 0 3.706304951833772e-08
diaspora O 0 1.8913429755684774e-07
and O 0 1.9896853942213966e-08
is O 0 4.872319792070812e-08
not O 0 2.7505121735771354e-08
limited O 0 2.579820090886642e-07
to O 0 3.712772524977481e-07
Ashkenazim O 0 0.0005120980204083025
. O 0 1.8592943888506852e-05

The O 0 6.987985671003116e-06
185delAG O 0 0.0005574030801653862
mutation O 0 4.585459464578889e-05
in O 0 2.9157727112760767e-06
BRCA1 O 0 0.0011520545231178403
is O 0 1.3209451026341412e-06
detected O 0 2.5117516997852363e-05
in O 0 2.9755003083664633e-07
Ashkenazi O 0 2.9199994969530962e-05
Jews O 0 3.6481068832472374e-07
both O 0 3.0811921192253067e-07
in O 0 1.113499001803575e-05
familial B-Disease 1 0.9984379410743713
breast I-Disease 1 0.9997591376304626
and I-Disease 0 0.44871580600738525
ovarian I-Disease 1 0.9999831914901733
cancer I-Disease 1 0.9997898936271667
and O 0 5.250248023003223e-07
in O 0 1.9309432275349536e-07
the O 0 2.6170070555053826e-07
general O 0 1.8188743524660822e-06
population O 0 1.3583489817392547e-06
. O 0 7.234311397041893e-06

All O 0 3.166794385833782e-06
tested O 0 0.00010028753604274243
Ashkenazi O 0 0.00019884707580786198
mutation O 0 1.8825710867531598e-05
carriers O 0 4.147867912251968e-06
share O 0 6.7086908472902e-08
the O 0 9.404995893191881e-08
same O 0 2.4971299694698246e-07
allelic O 0 3.50389200320933e-05
pattern O 0 1.310831885348307e-05
at O 0 2.1205250959610566e-06
the O 0 3.7530069221247686e-06
BRCA1 O 0 0.004403629805892706
locus O 0 0.00025085650850087404
. O 0 2.4844364816090092e-05

Our O 0 3.221401129849255e-06
previous O 0 5.25500445291982e-06
study O 0 4.155992883170256e-06
showed O 0 2.8697907055175165e-06
that O 0 5.1517837107439846e-08
this O 0 6.854029521718985e-08
Ashkenazi O 0 1.3829561794409528e-05
mutation O 0 2.3593074729433283e-06
also O 0 8.082030689138264e-08
occurs O 0 5.096466679788136e-07
in O 0 4.55771989038567e-08
Iraqi O 0 4.1858908161884756e-07
Jews O 0 8.804526174799321e-08
with O 0 5.7909915085474495e-08
a O 0 1.1388594884920167e-06
similar O 0 1.0228171049675439e-05
allelic O 0 0.0025909324176609516
pattern O 0 0.001053187414072454
. O 0 6.584424409084022e-05

We O 0 5.568068672801019e-07
extended O 0 8.182406645573792e-07
our O 0 2.7583821449184143e-08
analysis O 0 5.5802214404820916e-08
to O 0 1.9570530085388782e-08
other O 0 2.7979540462297336e-08
non O 0 8.678916287863103e-07
- O 0 2.3547399905510247e-06
Ashkenazi O 0 1.5769554693179089e-06
subsets O 0 3.342268257711112e-07
354 O 0 8.871750765138131e-07
of O 0 3.334995213322145e-08
Moroccan O 0 1.467319748371665e-06
origin O 0 1.404776526214846e-07
, O 0 1.7447614197863004e-07
200 O 0 5.202192028264108e-07
Yemenites O 0 5.350428546080366e-05
and O 0 1.4318658259071526e-07
150 O 0 9.300386523136694e-07
Iranian O 0 2.8538981950987363e-06
Jews O 0 4.876912953477586e-06
. O 0 1.297103244723985e-05

Heteroduplex O 0 0.000418490992160514
analysis O 0 2.3434802187694004e-06
complemented O 0 3.501161700114608e-06
by O 0 9.026187086647042e-08
direct O 0 1.8984158600687806e-07
DNA O 0 1.5275966234185034e-06
sequencing O 0 9.101751174966921e-07
of O 0 5.174295552023978e-07
abnormally O 0 0.008575043641030788
migrating O 0 5.8435730352357496e-06
bands O 0 3.4427355330990395e-06
were O 0 5.204881858844601e-07
employed O 0 2.0679315639426932e-05
. O 0 1.2497451280069072e-05

Four O 0 2.977038775497931e-07
of O 0 1.215336311588544e-07
Moroccan O 0 2.227370259788586e-06
origin O 0 1.0341727829654701e-07
( O 0 1.2702723495294777e-07
1 O 0 5.647593326330025e-08
. O 0 1.3313704805284488e-08
1 O 0 3.59039695752017e-08
% O 0 2.244162011777462e-08
) O 0 1.193407772603905e-08
and O 0 4.9445918470780725e-09
none O 0 2.4229565909195117e-08
of O 0 6.808410724090663e-09
the O 0 1.0469342015539951e-07
Yemenites O 0 5.290084664011374e-05
or O 0 1.1440766201076258e-07
Iranians O 0 1.4056099928438925e-07
was O 0 1.454320113225549e-07
a O 0 1.0930210692094988e-07
carrier O 0 1.3036656127951574e-06
of O 0 3.890966127073625e-08
the O 0 7.243751838359458e-07
185delAG O 0 0.0006798077956773341
mutation O 0 9.750457684276626e-05
. O 0 1.5547917428193614e-05

BRCA1 O 0 0.01763797551393509
allelic O 0 0.0006795681547373533
patterns O 0 7.31484942662064e-06
were O 0 7.456956296891804e-08
determined O 0 1.6971654304143158e-07
for O 0 3.66122354655829e-09
four O 0 3.39523564818478e-09
of O 0 3.7565923705074056e-09
these O 0 5.429732663486675e-09
individuals O 0 1.0871096911557743e-08
and O 0 6.58432819378163e-09
for O 0 6.096271931710362e-09
12 O 0 1.0264908212320734e-07
additional O 0 2.0070783079972898e-07
non O 0 2.8294050480326405e-06
- O 0 3.060021117562428e-05
Ashkenazi O 0 5.9559813962550834e-05
185delAG O 0 0.00023546178999822587
mutation O 0 0.0001101789457607083
carriers O 0 0.00018563929188530892
who O 0 4.083043313585222e-05
had O 0 0.006956607569009066
breast B-Disease 1 0.9991399049758911
/ I-Disease 1 0.9976478219032288
ovarian I-Disease 1 0.9998927116394043
cancer I-Disease 1 0.9994335770606995
. O 0 0.0006792658241465688

Six O 0 3.144971196888946e-05
non O 0 7.513584569096565e-05
- O 0 0.00010728590859798715
Ashkenazi O 0 3.3677821193123236e-05
individuals O 0 1.5826473998004076e-07
shared O 0 2.387727988661936e-07
the O 0 3.2713148812035797e-07
common O 0 4.003951744380174e-06
Ashkenazi O 0 0.00016762124141678214
haplotype O 0 0.0002624469343572855
, O 0 2.431016525861196e-07
four O 0 1.4784428969960572e-07
had O 0 3.9806408835829643e-07
a O 0 5.908458433623309e-07
closely O 0 5.682965138475993e-07
related O 0 1.413802920069429e-06
pattern O 0 1.045485714712413e-05
, O 0 6.695153587088498e-08
and O 0 1.780327352207678e-08
the O 0 3.1616021800573435e-08
rest O 0 3.2973179031614563e-07
( O 0 1.5021088017874717e-07
n O 0 7.116277060958964e-07
= O 0 1.3717601632379228e-06
6 O 0 1.4496757216875267e-07
) O 0 3.768586154251352e-08
displayed O 0 3.851460519399552e-07
a O 0 6.171548534439353e-07
distinct O 0 5.19415834787651e-06
BRCA1 O 0 0.003217131132259965
allelic O 0 0.0018426320748403668
pattern O 0 0.0012026174226775765
. O 0 5.9862632042495534e-05

We O 0 1.395829258399317e-06
conclude O 0 3.0705134577146964e-06
that O 0 7.972163729164095e-08
the O 0 3.903655851900112e-07
185delAG O 0 0.00026759045431390405
BRCA1 O 0 0.000826778938062489
mutation O 0 1.7596481484360993e-05
occurs O 0 2.786009872579598e-06
in O 0 1.6738196961796348e-07
some O 0 1.4315874352632818e-07
non O 0 6.482018306996906e-06
- O 0 3.5982120607513934e-05
Ashkenazi O 0 2.5043298592208885e-05
populations O 0 3.966362669416412e-07
at O 0 3.5272717013867805e-07
rates O 0 1.7923669020092348e-06
comparable O 0 1.0491376087884419e-06
with O 0 8.024505859793862e-08
that O 0 1.196148531334984e-07
of O 0 5.111741074870224e-07
Ashkenazim O 0 0.002227785298600793
. O 0 4.810787140741013e-05

The O 0 5.182048994356592e-07
majority O 0 6.619197279178479e-07
of O 0 1.9174501630914165e-07
Jewish O 0 4.980789526598528e-06
185delAG O 0 0.0007683803560212255
mutation O 0 6.515261338790879e-05
carriers O 0 2.440288517391309e-05
have O 0 1.2348210987056518e-07
a O 0 7.395623242700822e-07
common O 0 2.983355670949095e-06
allelic O 0 0.00019543863891158253
pattern O 0 2.1555502826231532e-05
, O 0 2.410423860510491e-07
supporting O 0 4.0124280076270225e-07
the O 0 2.874721758416854e-07
founder O 0 9.068281542568002e-06
effect O 0 7.365891292465676e-07
notion O 0 3.754510373710218e-07
, O 0 3.939220505344565e-08
but O 0 2.2970082724782515e-08
dating O 0 2.7725877771445084e-07
the O 0 3.833990547263966e-08
mutations O 0 3.120569829206943e-07
origin O 0 1.977484131998608e-08
to O 0 1.2678705196833562e-08
an O 0 4.661746899614627e-08
earlier O 0 6.125810614321381e-07
date O 0 5.353473397917696e-07
than O 0 1.0904826552859959e-07
currently O 0 8.648477205497329e-07
estimated O 0 1.15754173748428e-05
. O 0 1.7228612705366686e-05

However O 0 4.393966264615301e-06
, O 0 2.273380914630252e-07
the O 0 7.899058118709945e-08
different O 0 3.2635362856581196e-08
allelic O 0 3.4704113204497844e-05
pattern O 0 8.650318704894744e-06
at O 0 8.728611078367976e-07
the O 0 6.652662705164403e-07
BRCA1 O 0 0.00032147052115760744
locus O 0 4.011749297205824e-06
even O 0 1.0422939311638402e-07
in O 0 1.550142059159043e-08
some O 0 2.1663140614691656e-08
Jewish O 0 7.88382351402106e-07
mutation O 0 2.6354322471888736e-05
carriers O 0 1.4149119124340359e-05
, O 0 1.1043518099995708e-07
might O 0 2.639679053118016e-07
suggest O 0 2.320842753533725e-07
that O 0 3.621208222170935e-08
the O 0 1.5457700897059112e-07
mutation O 0 1.3050144843873568e-05
arose O 0 8.187150342564564e-06
independently O 0 1.3251656127977185e-06
. O 0 1.4381161008714116e-06
. O 0 1.4833247405476868e-05

Crystal O 0 0.001942066359333694
structure O 0 3.1649426091462374e-05
of O 0 2.4376313376706094e-06
the O 0 8.14796076156199e-05
hemochromatosis B-Disease 1 0.9986617565155029
protein O 0 0.00023414652969222516
HFE O 0 0.16297022998332977
and O 0 1.5407189835059398e-07
characterization O 0 1.3202310356064118e-06
of O 0 2.4849043711583363e-08
its O 0 7.040564753424405e-08
interaction O 0 7.476123755623121e-07
with O 0 2.6379377686680527e-06
transferrin O 0 0.056973885744810104
receptor O 0 0.0007475878810510039
. O 0 2.0349245460238308e-05

HFE O 0 0.08355070650577545
is O 0 6.767992090317421e-06
an O 0 5.052176675235387e-06
MHC O 0 0.02020427957177162
- O 0 1.4261247088143136e-05
related O 0 9.900777513394132e-07
protein O 0 5.752098672928696e-07
that O 0 2.8628363679672475e-08
is O 0 8.532581574627329e-08
mutated O 0 7.568286491732579e-06
in O 0 2.664228873072716e-07
the O 0 1.1583611922105774e-05
iron B-Disease 1 0.9986338019371033
- I-Disease 1 0.9959825277328491
overload I-Disease 1 0.9989058971405029
disease I-Disease 1 0.9997561573982239
hereditary B-Disease 1 0.9992061257362366
hemochromatosis I-Disease 1 0.9997710585594177
. O 0 0.003551825415343046

HFE O 0 0.033354081213474274
binds O 0 5.7486569858156145e-05
to O 0 4.0740314943832345e-06
transferrin O 0 0.006482296623289585
receptor O 0 0.00011551591887837276
( O 0 4.496163001022069e-06
TfR O 0 0.0018600011244416237
) O 0 3.4607177212819806e-07
and O 0 6.073167213571651e-08
reduces O 0 3.2035554795584176e-06
its O 0 1.0081353707391827e-07
affinity O 0 1.512387825641781e-06
for O 0 2.852609100045811e-07
iron O 0 0.025460507720708847
- O 0 2.3050210074870847e-05
loaded O 0 1.181448624265613e-05
transferrin O 0 0.001360186724923551
, O 0 3.2224950246018125e-06
implicating O 0 0.007096878718584776
HFE O 1 0.7489411234855652
in O 0 1.8312010070076212e-05
iron O 1 0.9447744488716125
metabolism O 0 0.044471606612205505
. O 0 7.554305193480104e-05

The O 0 2.3710779714747332e-05
2 O 0 0.0001114456681534648
. O 0 6.789833423681557e-05

6 O 0 2.7311409212416038e-05
A O 0 1.9291155695100315e-05
crystal O 0 0.00023267639335244894
structure O 0 1.015440375340404e-05
of O 0 6.160646535136038e-07
HFE O 1 0.653373658657074
reveals O 0 1.5326399079640396e-05
the O 0 1.728962928382316e-07
locations O 0 4.207691688407067e-07
of O 0 1.6014329276003991e-06
hemochromatosis B-Disease 1 0.9996020197868347
mutations O 0 6.991749251028523e-05
and O 0 2.9838312798347033e-07
a O 0 6.279306035139598e-06
patch O 0 0.057024892419576645
of O 0 1.7946128139101347e-07
histidines O 0 0.0009014320676214993
that O 0 7.50356718981493e-08
could O 0 4.675602838233317e-08
be O 0 8.412782470657021e-09
involved O 0 2.1555489126967586e-07
in O 0 5.658429245158914e-07
pH O 0 0.0015795128419995308
- O 0 2.938349462056067e-05
dependent O 0 6.65364132146351e-06
interactions O 0 7.13043982614181e-06
. O 0 2.7903444788535126e-05

We O 0 2.8956437745364383e-06
also O 0 1.2495644341470324e-06
demonstrate O 0 5.367457561078481e-06
that O 0 1.8104465198121034e-06
soluble O 0 0.01016266644001007
TfR O 0 0.11260056495666504
and O 0 2.9388904749794165e-06
HFE O 0 0.114547498524189
bind O 0 5.488771876116516e-06
tightly O 0 1.278479658139986e-06
at O 0 1.5223118055018858e-07
the O 0 4.414233956140379e-08
basic O 0 2.0291419389195653e-07
pH O 0 5.7771849242271855e-06
of O 0 1.4338084497467207e-08
the O 0 2.5817053028731607e-07
cell O 0 1.7957314412342384e-05
surface O 0 2.3396528376906645e-06
, O 0 2.3115823921671108e-08
but O 0 9.135577627716884e-09
not O 0 4.138167142286875e-09
at O 0 6.211190850535786e-08
the O 0 9.547401447207449e-08
acidic O 0 8.223293843911961e-05
pH O 0 0.00010188940359512344
of O 0 1.3129460967320483e-06
intracellular O 0 0.0018956131534650922
vesicles O 0 0.00850160326808691
. O 0 9.836918616201729e-05

TfR O 1 0.7184617519378662
HFE O 0 0.15993613004684448
stoichiometry O 0 0.0003856100665871054
( O 0 3.4742135994747514e-06
2 O 0 1.619341333025659e-06
1 O 0 6.219252099981532e-07
) O 0 1.9067951484430523e-07
differs O 0 2.7190515083930222e-06
from O 0 1.5986831840564264e-06
TfR O 0 0.02132255584001541
transferrin O 0 0.0016244053840637207
stoichiometry O 0 2.4737551939324476e-05
( O 0 4.724144275769504e-07
2 O 0 1.6461511620491365e-07
2 O 0 1.1221793982940653e-07
) O 0 3.077878574231363e-08
, O 0 1.8279008529020757e-08
implying O 0 1.0712220444020204e-07
a O 0 6.024329035625442e-09
different O 0 6.636953764349585e-10
mode O 0 3.047991015137086e-08
of O 0 6.99537183734833e-09
binding O 0 4.3421110262897855e-07
for O 0 4.0485517160959716e-07
HFE O 0 0.0686575248837471
and O 0 4.5051928054817836e-07
transferrin O 0 0.0017171548679471016
to O 0 4.0940719259197067e-07
TfR O 0 0.005733795464038849
, O 0 1.3843724389062118e-07
consistent O 0 3.2166258279175963e-07
with O 0 5.568961469748501e-08
our O 0 1.3761284378688288e-07
demonstration O 0 2.161189968319377e-06
that O 0 5.988542284285359e-07
HFE O 0 0.029836328700184822
, O 0 1.4795249398957822e-06
transferrin O 0 0.001121256616897881
, O 0 2.375966090539805e-07
and O 0 1.9748348734083265e-07
TfR O 0 0.0010450029512867332
form O 0 7.764705856061482e-07
a O 0 4.109886049263878e-06
ternary O 0 0.0008857728098519146
complex O 0 0.0005497232777997851
. O 0 5.94962366449181e-05

Identification O 0 1.3312786677488475e-06
of O 0 5.8200914310191365e-08
three O 0 1.1319690429445473e-07
novel O 0 1.1398808510421077e-06
mutations O 0 5.570670964516466e-07
and O 0 1.14943938811507e-08
a O 0 4.2209222783640143e-08
high O 0 9.937900813383749e-08
frequency O 0 1.7618358327808892e-08
of O 0 6.1840359499854e-09
the O 0 1.810040970440241e-07
Arg778Leu O 0 0.00025027216179296374
mutation O 0 1.6376659914385527e-05
in O 0 2.1224045667622704e-06
Korean O 0 0.005653508938848972
patients O 0 0.2670769989490509
with O 0 0.00012699193030130118
Wilson B-Disease 1 0.9213258028030396
disease I-Disease 1 0.9988529682159424
. O 0 0.00015805747534614056

Four O 0 1.71358205989236e-05
mutations O 0 0.0002495130756869912
- O 0 0.00011843124229926616
- O 0 2.278182546433527e-05
R778L O 0 2.293198849656619e-05
, O 0 3.203828953246557e-07
A874V O 0 1.917379086080473e-05
, O 0 3.164987276704778e-07
L1083F O 0 1.3678028153663035e-05
, O 0 1.1325457194288902e-07
and O 0 8.157623199167574e-08
2304delC O 0 7.756613194942474e-05
- O 0 7.76259730628226e-06
- O 0 5.332937575985852e-07
in O 0 2.4548210575403573e-08
the O 0 9.561324532114668e-08
copper O 0 4.978811921318993e-05
- O 0 1.799872848096129e-06
transporting O 0 7.905424013188167e-07
enzyme O 0 3.658775995063479e-06
, O 0 2.514517802865157e-07
P O 0 0.00011950303451158106
- O 0 1.1092394743172918e-05
type O 0 6.2630983848066535e-06
ATPase O 0 3.382858994882554e-05
( O 0 1.025484493766271e-06
ATP7B O 0 0.00017389697313774377
) O 0 2.3010630911812768e-07
, O 0 5.54493340132467e-08
were O 0 4.151688060005654e-08
identified O 0 9.600198609405197e-07
in O 0 8.707859251444461e-07
Korean O 0 0.004977355245500803
Patients O 0 0.3771716058254242
with O 0 0.0001419827458448708
Wilson B-Disease 1 0.952415406703949
disease I-Disease 1 0.998128354549408
. O 0 0.00020353969011921436

Arg778Leu O 0 0.0018209698610007763
, O 0 1.4417000784305856e-06
the O 0 3.6253828739063465e-07
most O 0 1.915671674623809e-07
frequently O 0 1.1117917892988771e-06
reported O 0 1.2925239616379258e-06
mutation O 0 2.633749716096645e-07
of O 0 6.884436576370945e-09
this O 0 4.495171168628076e-08
enzyme O 0 2.378102180955466e-06
, O 0 7.761050824228732e-08
was O 0 1.2482264821755962e-07
found O 0 3.476256793533139e-08
in O 0 5.425922822155371e-09
six O 0 1.4157072847353902e-08
of O 0 1.914699510052742e-08
eight O 0 1.5260123973348527e-06
unrelated O 0 0.00064424256561324
patients O 0 0.0005308975232765079
studied O 0 6.153541676212626e-07
, O 0 2.655930231298953e-08
an O 0 2.5147327775698614e-08
allele O 0 4.088562661763717e-07
frequency O 0 1.8260300294059562e-07
of O 0 1.1452731740746458e-07
37 O 0 1.8297469068784267e-05
. O 0 1.0908079275395721e-05

5 O 0 7.561504844488809e-06
% O 0 1.4427729411181645e-06
, O 0 1.6013031256534305e-07
which O 0 5.4896752033073426e-08
is O 0 1.5030116173875285e-07
considerably O 0 2.491217173883342e-06
higher O 0 1.116789931643325e-07
than O 0 7.2477090995448634e-09
those O 0 1.3207525739744597e-08
in O 0 3.545658699977139e-08
other O 0 7.398939771974256e-08
Asian O 0 7.546908818767406e-06
populations O 0 9.766348739503883e-06
. O 0 8.2634505815804e-06

The O 0 1.6720342728149262e-06
novel O 0 2.8959336759726284e-06
single O 0 5.558894713431073e-07
nucleotide O 0 4.348387392383302e-06
deletion O 0 4.0242663089884445e-05
, O 0 7.17018906470912e-07
2304delC O 0 5.3856576414546e-05
, O 0 3.0297360353870317e-07
was O 0 5.020363005314721e-07
found O 0 4.953619168190926e-07
in O 0 3.4152293437728076e-07
one O 0 1.5412628044941812e-06
patient O 0 0.0017848941497504711
. O 0 1.9938353943871334e-05

Since O 0 7.042054221528815e-06
a O 0 1.2958181514477474e-06
mutation O 0 3.01118802781275e-06
at O 0 1.0078871355290175e-06
cDNA O 0 9.16818498808425e-06
nucleotide O 0 1.1696248293446843e-05
2302 O 0 0.0028562976513057947
( O 0 2.5251542865589727e-06
2302insC O 0 0.0001027684920700267
) O 0 4.105159803202696e-07
had O 0 2.990971097460715e-07
been O 0 8.791538164132362e-08
previously O 0 3.5507960660652316e-07
described O 0 4.94625453484332e-07
, O 0 1.576656849522351e-08
this O 0 4.288134292096402e-09
region O 0 2.395682940914412e-08
of O 0 7.343836649909008e-09
the O 0 5.236646529738209e-07
ATP7B O 0 0.010141275823116302
gene O 0 1.3549317372962832e-05
may O 0 2.6217810500384076e-06
be O 0 1.6827250703954633e-07
susceptible O 0 9.621446952223778e-05
to O 0 4.180787982477341e-07
gene O 0 7.993280451046303e-05
rearrangements O 0 0.015740862116217613
causing O 1 0.9920767545700073
Wilson B-Disease 1 0.9876149892807007
disease I-Disease 1 0.9984399676322937
. O 0 0.00030851655174046755

Disruption O 0 0.00015034260286483914
of O 0 3.576508902369824e-07
splicing O 0 6.753806701453868e-06
regulated O 0 3.831421054201201e-06
by O 0 4.4254636577534257e-07
a O 0 6.659113296336727e-06
CUG O 0 0.00472587626427412
- O 0 1.9993645764770918e-05
binding O 0 6.3654783843958285e-06
protein O 0 6.947974907234311e-05
in O 0 0.00018121686298400164
myotonic B-Disease 1 0.9989840388298035
dystrophy I-Disease 1 0.9993452429771423
. O 0 0.0007847706438042223

Myotonic B-Disease 1 0.9986187219619751
dystrophy I-Disease 1 0.9996871948242188
( O 0 0.043028831481933594
DM B-Disease 1 0.9989882111549377
) O 0 8.229814739024732e-06
is O 0 8.992161610876792e-07
caused O 0 3.715302955242805e-05
by O 0 1.277672510013872e-07
a O 0 8.093258543340198e-07
CTG O 0 0.00016320243594236672
expansion O 0 7.399800097118714e-07
in O 0 2.0643572185008452e-08
the O 0 3.552109362203737e-08
3 O 0 2.147169766431034e-07
untranslated O 0 8.72548480401747e-06
region O 0 1.2629016055143438e-07
of O 0 6.221055315336343e-08
the O 0 1.111098663386656e-05
DM B-Disease 1 0.9952211976051331
gene O 0 0.00023718889860901982
. O 0 2.415772178210318e-05

One O 0 4.114058356208261e-06
model O 0 1.8080161680700257e-05
of O 0 1.0729355381045025e-05
DM B-Disease 1 0.998768150806427
pathogenesis O 1 0.6512954831123352
suggests O 0 1.4167590052238666e-05
that O 0 2.0771508957295737e-07
RNAs O 0 1.4731252122146543e-05
from O 0 6.153305776024354e-08
the O 0 1.7372162375295375e-08
expanded O 0 1.1748500838848486e-07
allele O 0 1.570061556321889e-07
create O 0 2.8681489183668418e-08
a O 0 8.107335247586889e-08
gain O 0 3.879969199260813e-07
- O 0 3.097259764217597e-07
of O 0 1.1682932843370963e-08
- O 0 5.880121989321196e-07
function O 0 7.416912239932572e-08
mutation O 0 4.5026368411527073e-07
by O 0 1.481143385717587e-08
the O 0 2.3626521183928162e-08
inappropriate O 0 2.0294787361763156e-07
binding O 0 2.1366169278280722e-08
of O 0 5.894953858387453e-09
proteins O 0 6.919152895079606e-08
to O 0 3.7041001377247085e-08
the O 0 1.090494720301649e-06
CUG O 0 0.002227246994152665
repeats O 0 0.00020522144041024148
. O 0 1.88716767297592e-05

Data O 0 6.4043379097711295e-06
presented O 0 5.0689804993453436e-06
here O 0 4.917479259347601e-07
indicate O 0 8.194955967155693e-07
that O 0 1.881254263480514e-08
the O 0 1.1653738596351104e-07
conserved O 0 4.963216724718222e-06
heterogeneous O 0 0.0001728561328491196
nuclear O 0 0.00023622476146556437
ribonucleoprotein O 0 0.016804222017526627
, O 0 1.4968049981689546e-06
CUG O 0 0.00033470202470198274
- O 0 3.0516375773004256e-06
binding O 0 5.780330525340105e-07
protein O 0 2.916228822869016e-06
( O 0 2.3237892037286656e-06
CUG O 0 0.0017212056554853916
- O 0 2.6661613446776755e-05
BP O 0 4.7070741857169196e-05
) O 0 1.2661382697842782e-07
, O 0 8.813162111209749e-08
may O 0 5.127902795720729e-07
mediate O 0 3.32114950651885e-06
the O 0 4.641562725282711e-07
trans O 0 4.44706529378891e-05
- O 0 2.541626599850133e-06
dominant O 0 4.5816545934940223e-07
effect O 0 2.132228758000565e-07
of O 0 2.256734177308317e-08
the O 0 7.825784109627421e-07
RNA O 0 3.443020978011191e-05
. O 0 7.726097464910708e-06

CUG O 1 0.6981895565986633
- O 0 0.002867903094738722
BP O 0 0.0011934787034988403
was O 0 3.439929287196719e-06
found O 0 3.7264649677126727e-07
to O 0 3.9626414150006894e-08
bind O 0 8.946304319579212e-07
to O 0 8.537042361922431e-08
the O 0 1.5279449598892825e-06
human O 0 8.15964667708613e-05
cardiac O 1 0.997104823589325
troponin O 1 0.9963914752006531
T O 0 0.46517860889434814
( O 0 4.110262580070412e-06
cTNT O 0 8.331406570505351e-05
) O 0 7.56670317514363e-07
pre O 0 1.276017337659141e-05
- O 0 1.647850467634271e-06
messenger O 0 1.4873794498271309e-06
RNA O 0 3.4015840810752707e-07
and O 0 8.42119529664842e-09
regulate O 0 3.1311645898313145e-07
its O 0 4.190727764807889e-08
alternative O 0 1.33115429434838e-06
splicing O 0 3.3210137189598754e-05
. O 0 1.0732814189395867e-05

Splicing O 0 5.625358608085662e-05
of O 0 4.334177901910152e-06
cTNT O 0 0.006109647918492556
was O 0 0.00012323653209023178
disrupted O 0 0.002564196940511465
in O 0 0.00014137104153633118
DM B-Disease 1 0.9985015392303467
striated O 1 0.9896427989006042
muscle O 0 0.0813421830534935
and O 0 4.6154488586580555e-07
in O 0 6.294760055425286e-07
normal O 0 2.0023566321469843e-05
cells O 0 1.6786578271421604e-05
expressing O 0 6.077274065319216e-06
transcripts O 0 9.091938409255818e-06
that O 0 9.730757710713078e-07
contain O 0 3.1915940780891106e-05
CUG O 0 0.018317759037017822
repeats O 0 0.0009066322818398476
. O 0 4.1812694689724594e-05

Altered O 0 6.551578553626314e-05
expression O 0 1.381334186589811e-06
of O 0 2.80535573438101e-07
genes O 0 4.927497229800792e-06
regulated O 0 2.1234260202618316e-05
posttranscriptionally O 0 0.0005052128108218312
by O 0 6.8528211158991326e-06
CUG O 0 0.371830552816391
- O 0 0.0003872058296110481
BP O 0 0.0003020003787241876
therefore O 0 6.721941190335201e-07
may O 0 1.826184870878933e-06
contribute O 0 3.5080802263109945e-06
to O 0 5.651451829180587e-06
DM B-Disease 1 0.9980707764625549
pathogenesis O 1 0.8713078498840332
. O 0 7.364862540271133e-06
. O 0 1.8432025171932764e-05

Identification O 0 1.7180635722979787e-06
of O 0 1.494102548349474e-07
a O 0 2.350346903767786e-06
novel O 0 7.202378583315294e-06
nonsense O 0 3.19142964144703e-05
mutation O 0 2.2539784367836546e-06
and O 0 3.7705994770931284e-08
a O 0 2.0216630503000488e-07
missense O 0 4.560856268653879e-06
substitution O 0 3.7215494330666843e-07
in O 0 8.308116150601563e-08
the O 0 4.162004074714787e-07
vasopressin O 0 0.00028600069344975054
- O 0 2.8279831894906238e-05
neurophysin O 0 0.00016683863941580057
II O 0 7.161447138059884e-05
gene O 0 4.7460002861043904e-07
in O 0 2.8594310919061172e-08
two O 0 5.320035256772826e-08
Spanish O 0 4.865271421294892e-06
kindreds O 0 0.0003328802704345435
with O 0 2.4647762984386645e-05
familial B-Disease 1 0.9945047497749329
neurohypophyseal I-Disease 1 0.9976487755775452
diabetes I-Disease 1 0.999812662601471
insipidus I-Disease 1 0.9968065023422241
. O 0 0.0010839904425665736

Familial B-Disease 1 0.9904705286026001
neurohypophyseal I-Disease 1 0.9959474205970764
diabetes I-Disease 1 0.9997578263282776
insipidus I-Disease 1 0.9979817867279053
( O 0 0.0012869726633653045
FNDI B-Disease 1 0.9866874814033508
) O 0 7.426973297697259e-06
is O 0 1.8850562355510192e-06
an O 0 1.9694043658091687e-05
autosomal B-Disease 1 0.997492790222168
dominant I-Disease 1 0.9947540760040283
disease I-Disease 1 0.9998096823692322
caused O 1 0.9971400499343872
by O 0 0.002427628729492426
deficiency O 1 0.9998238682746887
in O 0 8.450646419078112e-06
the O 0 1.3304890671861358e-05
antidiuretic O 0 0.035249870270490646
hormone O 0 0.0016951259458437562
arginine O 0 0.00010732121154433116
vasopressin O 0 0.00029463841929100454
( O 0 4.55777353636222e-06
AVP O 0 0.00021243681840132922
) O 0 6.832428312009142e-08
encoded O 0 4.564827804642846e-08
by O 0 1.2537118720956641e-07
the O 0 1.0065155038319062e-06
AVP O 0 0.011689726263284683
- O 0 0.00010838866728590801
neurophysin O 0 0.0007739102002233267
II O 0 0.0023063120897859335
( O 0 9.49709374253871e-06
AVP O 0 0.006158642470836639
- O 0 2.5391373128513806e-05
NPII O 0 0.00015065328625496477
) O 0 2.7127089197165333e-07
gene O 0 1.5383654954348458e-06
on O 0 1.1348566886226763e-06
chromosome O 0 9.972658881451935e-05
20p13 O 0 0.0007020255434326828
. O 0 2.4866312742233276e-05

In O 0 8.945238505475572e-07
this O 0 1.7295515419846197e-07
study O 0 4.993413540432812e-07
, O 0 4.690698673925908e-08
we O 0 1.0816266993174395e-08
analyzed O 0 8.6303955981748e-08
two O 0 7.143459601621771e-09
families O 0 8.120242256381971e-08
with O 0 1.0972320296787075e-07
FNDI B-Disease 0 0.0006899007712490857
using O 0 5.566316829686002e-08
direct O 0 6.66350814526595e-08
automated O 0 1.74418062215409e-06
fluorescent O 0 6.184503035910893e-06
, O 0 4.180277457521697e-08
solid O 0 5.422490403361735e-07
phase O 0 8.298216584989859e-07
, O 0 4.041483592231998e-08
single O 0 1.1482303108323322e-07
- O 0 6.66050880226976e-07
stranded O 0 3.9732148593429883e-07
DNA O 0 1.7510959082756017e-07
sequencing O 0 1.3765944117949402e-07
of O 0 1.0985576182065415e-07
PCR O 0 0.00010019365436164662
- O 0 6.768841558368877e-05
amplified O 0 0.00010189756721956655
AVP O 0 0.01764753647148609
- O 0 0.00023518808302469552
NPII O 0 0.0024763979017734528
DNA O 0 0.0001377678127028048
. O 0 1.6698730178177357e-05

In O 0 4.4892937012264156e-07
one O 0 6.288914988772376e-08
of O 0 3.1093048136199286e-08
the O 0 1.642704177129417e-07
families O 0 5.470964197229478e-07
, O 0 1.973693883883243e-07
affected O 0 6.255954758671578e-07
individuals O 0 3.945152826645426e-08
presented O 0 2.0212195295243873e-07
a O 0 1.6662895063745964e-07
novel O 0 1.3399899216892663e-06
nonsense O 0 5.412908649304882e-06
mutation O 0 7.544524578406708e-07
in O 0 3.253921221357814e-08
exon O 0 1.3747513776252163e-06
3 O 0 2.6470546643508897e-08
of O 0 2.3029382845152213e-09
the O 0 1.4886317067919208e-08
gene O 0 1.1991970438884891e-07
, O 0 6.4979448488600156e-09
consisting O 0 2.3062140641627593e-08
in O 0 4.102451001131158e-08
a O 0 3.3548502642588574e-07
G O 0 1.3060264791420195e-05
to O 0 1.5432013356075913e-07
T O 0 0.00021416998060885817
transition O 0 6.219809733920556e-07
at O 0 2.973418133933592e-07
nucleotide O 0 2.002420160351903e-06
2101 O 0 0.0002178181748604402
, O 0 5.531264690716853e-08
which O 0 2.56176484469961e-08
produces O 0 2.0866610839220812e-07
a O 0 1.2825043427255878e-07
stop O 0 5.360267891774129e-07
signal O 0 5.503954412233725e-07
in O 0 6.128299645524748e-08
codon O 0 3.11222652271681e-06
82 O 0 5.754563517257338e-06
( O 0 3.5568932617024984e-06
Glu O 0 0.0012304859701544046
) O 0 4.437737004536757e-07
of O 0 1.092741285901866e-06
NPII O 0 0.01244425494223833
. O 0 3.127746094833128e-05

The O 0 5.803146996186115e-05
premature O 0 0.010556209832429886
termination O 0 0.0004274772072676569
eliminates O 0 2.2547314074472524e-05
part O 0 2.416527991044859e-07
of O 0 2.849038338581522e-08
the O 0 5.914124017181166e-07
C O 0 0.00010828741505974904
- O 0 6.306263003352797e-06
terminal O 0 7.814694981789216e-06
domain O 0 1.8941443613584852e-07
of O 0 3.869060449801509e-08
NPII O 0 0.00014168575580697507
, O 0 3.3691172518501844e-08
including O 0 1.6881024578196957e-08
a O 0 9.497364317212487e-08
cysteine O 0 1.3747539924224839e-06
residue O 0 2.916440280387178e-06
in O 0 6.304227895270742e-08
position O 0 1.3599753856397e-07
85 O 0 6.848814564364147e-07
, O 0 2.4253886010683345e-08
which O 0 7.465349227686602e-09
could O 0 1.6847506500994314e-08
be O 0 3.2020852636094332e-09
involved O 0 2.6585910362086906e-08
in O 0 1.3164519252484297e-08
the O 0 5.326401009142501e-08
correct O 0 2.3957575194799574e-06
folding O 0 3.1258528906619176e-05
of O 0 1.479642008916926e-07
the O 0 4.8357633204432204e-06
prohormone O 0 0.22316376864910126
. O 0 2.974623566842638e-05

In O 0 6.688165399282298e-07
the O 0 1.468858243924842e-07
second O 0 4.789093850376958e-07
family O 0 6.24033759777376e-07
, O 0 2.457739789463176e-08
a O 0 8.226091097185417e-08
G279A O 0 1.8836706203728681e-06
substitution O 0 2.2250935671763727e-07
at O 0 9.751857277251474e-08
position O 0 7.238787702590344e-08
- O 0 1.4427355665702635e-07
1 O 0 6.504839333842938e-09
of O 0 1.2100083157662311e-09
the O 0 2.0597830996393895e-08
signal O 0 6.286156803980703e-07
peptide O 0 3.0696292014908977e-06
was O 0 3.316334300507151e-07
observed O 0 3.1432097102879197e-07
in O 0 5.970316863113112e-08
all O 0 5.0410790208843537e-08
affected O 0 6.0234683587623294e-06
individuals O 0 2.1821947484568227e-06
. O 0 1.2832954780606087e-05

This O 0 8.8675988081377e-06
missense O 0 0.00033470202470198274
mutation O 0 3.613369699451141e-05
, O 0 9.833270269155037e-07
which O 0 8.168286740328767e-07
replaces O 0 0.0009048862848430872
Ala O 0 0.003082963405176997
with O 0 2.060008910120814e-06
Thr O 0 0.032645974308252335
, O 0 4.237814721363975e-07
is O 0 3.489597020234214e-07
frequent O 0 1.4374674719874747e-05
among O 0 8.230646926676854e-06
FNDI B-Disease 1 0.9986875653266907
patients O 0 0.012713845819234848
and O 0 1.2216285938393412e-07
is O 0 6.693111487265924e-08
thought O 0 5.450269568996191e-08
to O 0 9.208248386016749e-09
reduce O 0 1.6338640307367314e-07
the O 0 1.431731533330094e-08
efficiency O 0 2.7799006829809514e-07
of O 0 4.4710748881016116e-08
cleavage O 0 0.00012818713730666786
by O 0 4.4207223481862457e-07
signal O 0 1.0893599210248794e-05
peptidases O 0 0.0003984025970567018
. O 0 2.0286981907702284e-06
. O 0 9.402962859894615e-06

Genetic O 0 0.0005070925108157098
heterogeneity O 0 0.0005031854379922152
of O 0 4.01741053792648e-05
Saethre B-Disease 1 0.9848581552505493
- I-Disease 1 0.9883226752281189
Chotzen I-Disease 1 0.99538654088974
syndrome I-Disease 1 0.9997692704200745
, O 0 4.200990133540472e-06
due O 0 1.8244010789203458e-05
to O 0 9.344902878183348e-07
TWIST O 0 0.00021422306599561125
and O 0 4.4681187318929005e-06
FGFR O 0 0.07309503853321075
mutations O 0 0.00032635702518746257
. O 0 2.199338996433653e-05

Thirty O 0 8.302022615680471e-05
- O 0 6.185883830767125e-05
two O 0 9.522628943159361e-07
unrelated O 0 0.0002654230920597911
patients O 0 0.0003859004355035722
with O 0 2.40617509916774e-07
features O 0 2.0540962850645883e-06
of O 0 2.4952187231974676e-06
Saethre B-Disease 1 0.9933132529258728
- I-Disease 1 0.917366623878479
Chotzen I-Disease 1 0.9958689212799072
syndrome I-Disease 1 0.9997251629829407
, O 0 8.818944365884818e-07
a O 0 4.688096851168666e-06
common O 0 8.865415293257684e-05
autosomal B-Disease 1 0.9919874668121338
dominant I-Disease 0 0.1091613844037056
condition I-Disease 1 0.9912494421005249
of O 0 6.62643724353984e-05
craniosynostosis B-Disease 1 0.9993810653686523
and O 0 0.0003991579287685454
limb B-Disease 1 0.9984461665153503
anomalies I-Disease 0 0.3012927174568176
, O 0 6.853662739558786e-07
were O 0 1.8254310418797104e-07
screened O 0 1.4068493783270242e-06
for O 0 5.978224493219386e-08
mutations O 0 2.9060149699944304e-06
in O 0 2.2095682084000146e-07
TWIST O 0 0.0001538826763862744
, O 0 1.6613814750598976e-06
FGFR2 O 0 0.0022569773718714714
, O 0 1.2830137166019995e-06
and O 0 2.0798793229914736e-06
FGFR3 O 0 0.010111709125339985
. O 0 4.5779488573316485e-05

Nine O 0 6.155669325380586e-06
novel O 0 4.489958428166574e-06
and O 0 4.016068544387963e-07
three O 0 8.577779340157576e-07
recurrent O 0 0.048281315714120865
TWIST O 0 0.0011394259054213762
mutations O 0 2.608492832223419e-05
were O 0 1.3696370615434716e-07
found O 0 6.051245122762339e-07
in O 0 2.0878155737591442e-07
12 O 0 2.0712534478661837e-06
families O 0 4.358949354354991e-06
. O 0 9.221605068887584e-06

Seven O 0 9.36480410018703e-06
families O 0 2.368117293372052e-06
were O 0 1.6866580665464426e-07
found O 0 2.0725936167309555e-07
to O 0 3.328050013351458e-08
have O 0 2.287398714884148e-08
the O 0 2.6023110422102036e-07
FGFR3 O 0 0.0008045629947446287
P250R O 0 7.932375592645258e-05
mutation O 0 5.476426849782001e-06
, O 0 2.1406062700179973e-08
and O 0 6.421995824013038e-09
one O 0 1.1205127492530664e-08
individual O 0 3.626820799240704e-08
was O 0 3.651845474905713e-07
found O 0 6.22385627480071e-08
to O 0 7.116533140560932e-09
have O 0 1.7114841099896694e-08
an O 0 1.8524984568557556e-07
FGFR2 O 0 0.0009328102460131049
VV269 O 0 0.0002845876442734152
- O 0 3.116200605290942e-05
270 O 0 1.3739920177613385e-05
deletion O 0 0.00020684015180449933
. O 0 1.9119179341942072e-05

To O 0 4.6310037760122214e-07
date O 0 8.953944075074105e-07
, O 0 9.524756450218774e-08
our O 0 8.894303960005345e-08
detection O 0 1.9211545350117376e-06
rate O 0 4.5201562670627027e-07
for O 0 5.1657462307730384e-08
TWIST O 0 1.2750466339639388e-05
or O 0 8.568736689085199e-07
FGFR O 0 0.0005266002845019102
mutations O 0 1.9722197066585068e-06
is O 0 8.312363775075937e-08
68 O 0 1.2389301673465525e-06
% O 0 2.0508768727722781e-07
in O 0 2.8106902050240024e-07
our O 0 2.6670099941839e-06
Saethre B-Disease 0 0.4361981153488159
- I-Disease 1 0.823310375213623
Chotzen I-Disease 1 0.9972646236419678
syndrome I-Disease 1 0.9999209642410278
patients O 0 0.12298378348350525
, O 0 2.7631378429759934e-07
including O 0 1.0824815888099693e-07
our O 0 2.1620175516545714e-07
five O 0 2.096999651257647e-06
patients O 0 0.0034883602056652308
elsewhere O 0 3.1981799111235887e-06
reported O 0 8.396134035137948e-06
with O 0 2.031456915574381e-06
TWIST O 0 0.002616336802020669
mutations O 0 0.0004407627566251904
. O 0 3.5155062505509704e-05

More O 0 1.9313796428832575e-07
than O 0 8.447292287883101e-08
35 O 0 2.156511271778072e-07
different O 0 4.670103592729902e-08
TWIST O 0 9.678739297669381e-05
mutations O 0 6.904012025188422e-06
are O 0 3.5211002114010626e-08
now O 0 1.8125180645256478e-07
known O 0 2.5560356675669027e-07
in O 0 7.150468661620835e-08
the O 0 3.091257667620084e-07
literature O 0 3.4509071156207938e-06
. O 0 1.2504234291554894e-05

The O 0 1.3264275366964284e-06
most O 0 2.3982943275768775e-07
common O 0 7.587101436001831e-07
phenotypic O 0 7.401179573207628e-06
features O 0 6.822204454692837e-07
, O 0 8.241214288773335e-08
present O 0 6.434492405560377e-08
in O 0 8.463771017375166e-09
more O 0 1.8301675730469924e-09
than O 0 2.462534176572717e-09
a O 0 1.871462274039004e-08
third O 0 2.366043538870599e-08
of O 0 2.1475543121596274e-08
our O 0 3.572452840217011e-07
patients O 0 0.00012142430932726711
with O 0 3.166636020068836e-07
TWIST O 0 0.00013733957894146442
mutations O 0 1.0436628144816495e-05
, O 0 1.5177236889485357e-07
are O 0 1.2173802588222316e-07
coronal B-Disease 0 0.0009535154676996171
synostosis I-Disease 0 0.002863311441615224
, O 0 4.2531937651801854e-06
brachycephaly B-Disease 0 0.001360575552098453
, O 0 1.0723821105784737e-05
low B-Disease 0 0.002630600705742836
frontal I-Disease 1 0.9956766963005066
hairline I-Disease 1 0.9993395209312439
, O 0 0.00014753131836187094
facial B-Disease 1 0.9958077669143677
asymmetry I-Disease 0 0.42042824625968933
, O 0 0.00020361269707791507
ptosis B-Disease 1 0.9972639083862305
, O 0 6.250804290175438e-05
hypertelorism B-Disease 1 0.9463689923286438
, O 0 4.204653578199213e-06
broad B-Disease 0 8.498217357555404e-05
great I-Disease 0 8.272394916275516e-05
toes I-Disease 0 0.0026269173249602318
, O 0 1.3531720242099254e-06
and O 0 1.6835867882036837e-06
clinodactyly B-Disease 0 0.0019439990865066648
. O 0 3.258341894252226e-05

Significant O 0 6.41721417196095e-05
intra O 0 0.0004877362516708672
- O 0 4.085914042661898e-05
and O 0 1.1441218248364748e-06
interfamilial O 0 0.00014428353460971266
phenotypic O 0 2.0996789316996e-05
variability O 0 3.449528230703436e-05
is O 0 3.3342388405799284e-07
present O 0 3.065920566314162e-07
for O 0 1.8606907303819753e-07
either O 0 2.4129985831677914e-06
TWIST O 0 0.0005392758175730705
mutations O 0 0.00012026461627101526
or O 0 3.0675448215333745e-05
FGFR O 0 0.403240442276001
mutations O 0 0.0004908284172415733
. O 0 4.6541899791918695e-05

The O 0 4.636387529899366e-06
overlap O 0 1.0688952897908166e-05
in O 0 1.003052489068068e-06
clinical O 0 1.685869210632518e-05
features O 0 4.1307495735054545e-07
and O 0 3.542670867773268e-08
the O 0 3.0559540675767494e-08
presence O 0 1.0785616666453279e-07
, O 0 6.863445811688962e-09
in O 0 3.879063736889066e-09
the O 0 5.471139541413095e-09
same O 0 1.1966581503486395e-08
genes O 0 3.235750511976221e-08
, O 0 4.2086125695561805e-09
of O 0 3.92812937732856e-09
mutations O 0 2.4658541519784194e-07
for O 0 3.450400409832355e-09
more O 0 3.754858646232151e-09
than O 0 5.592091056882964e-08
one O 0 6.262993110794923e-07
craniosynostotic B-Disease 0 0.00505726458504796
condition I-Disease 0 0.01640000380575657
- O 0 7.878571523178834e-06
such O 0 9.908223574939257e-08
as O 0 8.741173473936215e-07
Saethre B-Disease 0 0.0007854514406062663
- I-Disease 0 3.6574747355189174e-05
Chotzen I-Disease 0 0.00012316818174440414
, I-Disease 0 1.1418979966038023e-06
Crouzon I-Disease 0 0.00042490483610890806
, I-Disease 0 1.7145755464298418e-06
and I-Disease 0 7.624735189892817e-06
Pfeiffer I-Disease 1 0.9869564771652222
syndromes I-Disease 1 0.9958707690238953
- O 0 2.971462527057156e-05
support O 0 2.0454935167890653e-07
the O 0 9.471332163002444e-08
hypothesis O 0 2.0571465029206593e-06
that O 0 1.1630800145212561e-07
TWIST O 0 1.3409946404863149e-05
and O 0 6.141135600046255e-08
FGFRs O 0 9.633274203224573e-06
are O 0 1.9185040223135275e-09
components O 0 1.870120769353889e-08
of O 0 2.4441069168545937e-09
the O 0 1.701219076721827e-08
same O 0 3.7671487262969094e-08
molecular O 0 9.712806559036835e-07
pathway O 0 1.7908563449964277e-06
involved O 0 8.596535394644889e-08
in O 0 4.231570827073483e-08
the O 0 1.015031259044008e-07
modulation O 0 6.829939593444578e-06
of O 0 2.0853929072472965e-06
craniofacial O 1 0.9966095685958862
and O 0 1.255214556294959e-05
limb O 1 0.9226490259170532
development O 0 1.1704471944540273e-05
in O 0 2.3206002879305743e-06
humans O 0 2.518638393667061e-05
. O 0 2.4205005502153654e-06
. O 0 1.0717799341364298e-05

Mutation O 0 0.00021767722500953823
analysis O 0 2.593466342659667e-05
of O 0 6.923476757947356e-05
UBE3A O 1 0.9850088357925415
in O 1 0.8129495978355408
Angelman B-Disease 1 0.9998531341552734
syndrome I-Disease 1 0.9999790191650391
patients O 1 0.9974581599235535
. O 0 0.0010800688760355115

Angelman B-Disease 1 0.9996784925460815
syndrome I-Disease 1 0.9998784065246582
( O 0 0.00036407914012670517
AS B-Disease 0 0.00011661781900329515
) O 0 3.6930994156136876e-06
is O 0 1.975952955035609e-06
caused O 0 0.00020902273536194116
by O 0 1.176309183392732e-06
chromosome O 0 7.578029180876911e-05
15q11 O 0 0.0003446474438533187
- O 0 9.528619557386264e-06
q13 O 0 1.378907745674951e-05
deletions O 0 1.7322601024716278e-06
of O 0 9.428578806591759e-08
maternal O 0 3.954035128117539e-05
origin O 0 6.092903959142859e-07
, O 0 3.5910346696255147e-07
by O 0 1.6446603012809646e-06
paternal O 0 0.0012819798430427909
uniparental B-Disease 1 0.9550771713256836
disomy I-Disease 0 0.03118673525750637
( O 0 4.0951199480332434e-05
UPD B-Disease 1 0.859270453453064
) O 0 7.3651466436786e-07
15 O 0 4.962470825375931e-07
, O 0 1.5304824785289384e-07
by O 0 8.046405355344177e-07
imprinting O 0 0.002056072000414133
defects O 1 0.9260293245315552
, O 0 1.249824919113962e-07
and O 0 3.506135470843219e-08
by O 0 1.0448196974266466e-07
mutations O 0 2.079591695292038e-06
in O 0 1.6517117273906479e-07
the O 0 2.4031876364460913e-06
UBE3A O 0 0.0296980869024992
gene O 0 8.231123501900584e-05
. O 0 1.6050402336986735e-05

UBE3A O 0 0.00663633830845356
encodes O 0 2.850336932169739e-05
a O 0 1.2316965694481041e-05
ubiquitin O 0 0.0002574908430688083
- O 0 2.3832832084735855e-05
protein O 0 5.930870429438073e-06
ligase O 0 9.055845293914899e-05
and O 0 1.5521767409154563e-06
shows O 0 4.0308423194801435e-05
brain O 0 0.23817504942417145
- O 0 4.423805876285769e-05
specific O 0 2.471028892614413e-06
imprinting O 0 0.0008306107483804226
. O 0 2.368438072153367e-05

Here O 0 5.890589818591252e-06
we O 0 8.621425990895659e-07
describe O 0 1.5237978914228734e-05
UBE3A O 0 0.016781562939286232
coding O 0 0.0004003925423603505
- O 0 5.750976561103016e-05
region O 0 3.1454694635613123e-06
mutations O 0 1.3275867786433082e-05
detected O 0 1.2411212082952261e-05
by O 0 2.4505365558979975e-07
SSCP O 0 0.0002673604467418045
analysis O 0 5.404080525295285e-07
in O 0 2.5386174229424796e-07
13 O 0 1.943025608852622e-06
AS B-Disease 0 6.476599082816392e-06
individuals O 0 5.729509098273411e-07
or O 0 2.010619709835737e-06
families O 0 5.589085048995912e-06
. O 0 1.403090118401451e-05

Two O 0 7.071208187880984e-07
identical O 0 1.0783107427414507e-05
de O 0 1.6431662515969947e-05
novo O 0 1.559922930027824e-05
5 O 0 3.488559741526842e-06
- O 0 1.0429165740788449e-05
bp O 0 1.925237666000612e-05
duplications O 0 3.826115516858408e-06
in O 0 1.6424880300291989e-07
exon O 0 1.8008644474321045e-05
16 O 0 1.5723736623840523e-06
were O 0 3.721964958458557e-07
found O 0 4.28106159233721e-06
. O 0 6.91415289111319e-06

Among O 0 8.952372354542604e-07
the O 0 1.3312465796389006e-07
other O 0 3.9316393696253726e-08
11 O 0 2.981470572649414e-07
unique O 0 3.057814694784611e-07
mutations O 0 1.7832995808930718e-06
, O 0 7.171366434022275e-08
8 O 0 2.288014400164684e-07
were O 0 2.5714578910651653e-08
small O 0 1.7536545726670738e-07
deletions O 0 2.222072680524434e-06
or O 0 5.188012437429279e-07
insertions O 0 1.8368486053077504e-05
predicted O 0 2.5916469894582406e-05
to O 0 2.3137333471368038e-07
cause O 0 9.004756429931149e-05
frameshifts O 0 0.00013024103827774525
, O 0 9.684313084790119e-08
1 O 0 1.0692562568692665e-07
was O 0 5.8427819027428995e-08
a O 0 3.350130839407939e-08
mutation O 0 1.5931749430819764e-07
to O 0 3.008838511675549e-09
a O 0 2.6806949549040837e-08
stop O 0 1.5785502682774677e-07
codon O 0 2.1023529939157015e-07
, O 0 1.4778643198098962e-08
1 O 0 4.133759290425587e-08
was O 0 1.3618937089177052e-07
a O 0 1.8444087857005798e-07
missense O 0 9.842777217272669e-06
mutation O 0 2.0969655452063307e-06
, O 0 3.231118483881801e-08
and O 0 2.7164618998654078e-08
1 O 0 2.0818508517095324e-07
was O 0 7.102391350599646e-07
predicted O 0 1.9181227344233776e-06
to O 0 2.970911694433198e-08
cause O 0 1.7263001836909098e-06
insertion O 0 7.064925853228488e-07
of O 0 1.4369486045495705e-08
an O 0 9.177497162227155e-08
isoleucine O 0 4.022310167783871e-05
in O 0 3.987616636891289e-08
the O 0 4.2534189503840025e-08
hect O 0 3.747080654648016e-06
domain O 0 3.3670616517156304e-08
of O 0 7.711203231508534e-09
the O 0 2.773968219571543e-07
UBE3A O 0 0.00024972515529952943
protein O 0 4.046127912715747e-07
, O 0 9.795270372592313e-09
which O 0 4.224584682077648e-09
functions O 0 1.090869261588523e-08
in O 0 6.628888371551511e-08
E2 O 0 6.793344073230401e-05
binding O 0 1.1051404271711363e-06
and O 0 2.446849123316497e-07
ubiquitin O 0 6.660839426331222e-05
transfer O 0 9.037683412316255e-06
. O 0 1.659865847614128e-05

Eight O 0 1.1777942745538894e-06
of O 0 1.7943253283192462e-07
the O 0 7.827426315998309e-07
cases O 0 3.3068261018343037e-06
were O 0 4.579042354180274e-07
familial O 0 0.0021910739596933126
, O 0 2.562691747698409e-07
and O 0 5.5185772396271204e-08
five O 0 2.9647083010786446e-07
were O 0 5.588742055806506e-07
sporadic O 0 9.372069325763732e-05
. O 0 1.6273548681056127e-05

In O 0 2.8504216516012093e-06
two O 0 1.4236961760616396e-06
familial O 0 0.1364441066980362
cases O 0 1.6809231965453364e-05
and O 0 2.0136506861945236e-07
one O 0 3.6396900782165176e-07
sporadic O 0 3.373130311956629e-05
case O 0 9.510326890449505e-06
, O 0 1.052850166161079e-06
mosaicism O 0 0.0014829207211732864
for O 0 1.4234614127417444e-06
UBE3A O 0 0.06649180501699448
mutations O 0 2.7617636078502983e-05
was O 0 3.1152226256381255e-06
detected O 0 4.073712716490263e-06
in O 0 3.2525189652687914e-08
the O 0 8.94495073566759e-08
mother O 0 9.69361508396105e-07
of O 0 1.7567019838793385e-08
three O 0 8.956389052627856e-08
AS B-Disease 0 4.422587608132744e-06
sons O 0 6.609284355363343e-06
, O 0 3.897257272456045e-08
in O 0 2.3474383326060888e-08
the O 0 9.604789852346585e-08
maternal O 0 1.5933777831378393e-05
grandfather O 0 1.655182131798938e-06
of O 0 4.261520913928507e-09
two O 0 1.5751540516362184e-08
AS B-Disease 0 3.7081866821608855e-07
first O 0 6.24857321440686e-08
cousins O 0 4.0641180021339096e-07
, O 0 1.1769512475723332e-08
and O 0 6.111593009450189e-09
in O 0 9.09042086050249e-09
the O 0 2.8820831943221492e-08
mother O 0 1.1248123428231338e-06
of O 0 2.9873728379925524e-08
an O 0 9.350465575153066e-07
AS B-Disease 0 4.793861080543138e-05
daughter O 0 0.001485498738475144
. O 0 2.3132944988901727e-05

The O 0 4.457710929273162e-07
frequencies O 0 4.273749425465212e-07
with O 0 1.3694790368390386e-07
which O 0 1.4128417546999117e-07
we O 0 1.1905640207032775e-07
detected O 0 6.268111519602826e-06
mutations O 0 7.335935947594407e-07
were O 0 2.2151461109842785e-08
5 O 0 6.886159553687321e-08
( O 0 2.9378622201647886e-08
14 O 0 3.564780826081915e-08
% O 0 1.8631673981417407e-08
) O 0 7.905943455455144e-09
of O 0 4.233538408726645e-09
35 O 0 1.0606924405465179e-07
in O 0 6.130017737859816e-08
sporadic O 0 3.230686161259655e-06
cases O 0 4.5168468432166264e-07
and O 0 2.7741526409386097e-08
8 O 0 1.8440552196352655e-07
( O 0 3.482016808220578e-08
80 O 0 3.173334661710214e-08
% O 0 1.0325147847822791e-08
) O 0 4.090314753568691e-09
of O 0 2.1095212243693595e-09
10 O 0 1.1843005154332786e-07
in O 0 4.301316778310138e-07
familial O 0 0.04763110354542732
cases O 0 8.05427844170481e-05
. O 0 4.62008665635949e-06
. O 0 2.0033268810948357e-05

The O 0 0.0007312649395316839
hemochromatosis B-Disease 1 0.9946877956390381
845 O 0 0.03862344101071358
G O 0 0.012285600416362286
- O 0 0.0001918488269438967
- O 0 1.1445024938439019e-05
> O 0 5.047206741437549e-06
A O 0 4.292948574402544e-07
and O 0 1.0763196200969105e-07
187 O 0 4.016565071651712e-06
C O 0 2.9797542083542794e-05
- O 0 9.241228326573037e-06
- O 0 5.958354449830949e-06
> O 0 1.1953726243518759e-05
G O 0 2.120586759701837e-05
mutations O 0 8.052629709709436e-06
: O 0 1.4672596080345102e-06
prevalence O 0 0.00040360697312280536
in O 0 6.104897352088301e-07
non O 0 1.279461048397934e-05
- O 0 0.00011387812992325053
Caucasian O 0 0.0002572032972238958
populations O 0 1.1425569027778693e-05
. O 0 1.3424262760963757e-05

Hemochromatosis B-Disease 1 0.9937839508056641
, O 0 0.00013660191325470805
the O 0 0.0011315623996779323
inherited B-Disease 1 0.9994850158691406
disorder I-Disease 1 0.9996888637542725
of I-Disease 0 1.9183211406925693e-05
iron I-Disease 1 0.9977783560752869
metabolism I-Disease 0 0.0881972461938858
, O 0 3.4600516300997697e-06
leads O 0 1.9139428331982344e-05
, O 0 1.7418068409824627e-06
if O 0 4.138953499932541e-06
untreated O 0 0.44424933195114136
, O 0 4.4221224015927874e-07
to O 0 1.227405050485686e-06
progressive O 0 0.012168782763183117
iron B-Disease 1 0.9974699020385742
overload I-Disease 1 0.9964709281921387
and O 0 7.922351505840197e-05
premature B-Disease 1 0.963868260383606
death I-Disease 0 0.00357326352968812
. O 0 6.878727435832843e-05

The O 0 0.00037257213261909783
hemochromatosis B-Disease 1 0.9979878664016724
gene O 0 0.0003063458716496825
, O 0 1.3787343050353229e-05
HFE O 1 0.8501073718070984
, O 0 1.8798320979840355e-06
recently O 0 6.390159796865191e-06
has O 0 1.8980828997428034e-07
been O 0 5.1951218438262003e-08
identified O 0 1.1172182468044412e-07
, O 0 8.501208625943946e-09
and O 0 8.061443068640983e-09
characterization O 0 3.084049353674345e-07
of O 0 9.299251146899223e-09
this O 0 5.5010161759128096e-08
gene O 0 1.0528823395361542e-06
has O 0 5.7668852804226844e-08
shown O 0 4.056473557056961e-08
that O 0 2.7721152040527386e-09
it O 0 1.9324595257330657e-09
contains O 0 1.1192823556882558e-08
two O 0 7.41056016551056e-09
mutations O 0 2.9889409347561013e-07
that O 0 1.6371295430417376e-08
result O 0 8.313711674645674e-08
in O 0 2.7016527681666958e-08
amino O 0 3.7774384509248193e-07
acid O 0 1.2108283954148646e-05
substitutions O 0 1.290506475015718e-06
- O 0 1.4497742313324125e-06
cDNA O 0 2.988284450111678e-06
nucleotides O 0 4.787304078490706e-06
845 O 0 7.938640919746831e-05
G O 0 0.00022618989169131964
- O 0 1.3808790754410438e-05
- O 0 3.75190461454622e-06
> O 0 4.0370223359786905e-06
A O 0 3.311681950890488e-07
( O 0 2.175054731878845e-07
C282Y O 0 3.2171578823181335e-06
) O 0 3.314443119961652e-08
and O 0 5.016362081278203e-08
187 O 0 2.673544486242463e-06
C O 0 3.7616060581058264e-05
- O 0 1.6010808394639753e-05
- O 0 1.1233362783968914e-05
> O 0 2.678107557585463e-05
G O 0 4.003947469755076e-05
( O 0 2.2730694126948947e-06
H63D O 0 0.000863104360178113
) O 0 2.8046224542777054e-06
. O 0 6.7427631620375905e-06

Although O 0 0.001613981556147337
hemochromatosis B-Disease 1 0.9986666440963745
is O 0 5.706095180357806e-06
common O 0 5.567921562033007e-06
in O 0 9.080855534193688e-07
Caucasians O 0 8.326069655595347e-05
, O 0 4.3173528752049606e-07
affecting O 0 3.1525992199021857e-06
> O 0 6.268131983233616e-05
= O 0 8.443895239906851e-06
1 O 0 5.800862936666817e-07
/ O 0 2.800984702844289e-06
300 O 0 4.4430468193468187e-08
individuals O 0 2.7948003911149044e-09
of O 0 3.4657947622918073e-09
northern O 0 8.248589722370525e-08
European O 0 5.940488989608639e-08
origin O 0 2.1144973771924924e-08
, O 0 2.26584777607286e-08
it O 0 1.7071837277171653e-08
has O 0 3.3619020456399085e-08
not O 0 1.3795666831128983e-08
been O 0 2.9405196499965314e-08
recognized O 0 7.056724626863797e-08
in O 0 3.69291193180743e-08
other O 0 1.4514243673602323e-07
populations O 0 6.194962679728633e-06
. O 0 7.566756266896846e-06

The O 0 1.9114245333184954e-06
present O 0 1.109329332393827e-06
study O 0 1.3801056866213912e-06
used O 0 5.67536631024268e-07
PCR O 0 1.1895115676452406e-05
and O 0 1.8675689261726802e-07
restriction O 0 4.036844984511845e-06
- O 0 3.2208236007136293e-06
enzyme O 0 1.6534420410607709e-06
digestion O 0 2.9899949822720373e-06
to O 0 7.214153274759383e-09
analyze O 0 3.067007980916969e-08
the O 0 4.8258699258951765e-09
frequency O 0 1.724736264918647e-08
of O 0 8.268937534694487e-09
the O 0 1.758677399266162e-07
845 O 0 0.0001199625912704505
G O 0 0.0001360480091534555
- O 0 5.791295279777842e-06
- O 0 9.485086707172741e-07
> O 0 8.542544946976705e-07
A O 0 6.641595007295109e-08
and O 0 2.466912008003419e-08
187 O 0 1.3882608982385136e-06
C O 0 1.46860866152565e-05
- O 0 4.187909780739574e-06
- O 0 2.801721848300076e-06
> O 0 9.06880904949503e-06
G O 0 1.0910606761171948e-05
mutations O 0 2.765953468042426e-06
in O 0 3.890885409418843e-07
HLA O 0 0.0023717032745480537
- O 0 1.2926004728797125e-06
typed O 0 5.150698711986479e-07
samples O 0 2.1185428522585426e-07
from O 0 1.7534773633087752e-07
non O 0 2.5742731395439478e-06
- O 0 1.1846889719890896e-05
Caucasian O 0 1.843833706516307e-05
populations O 0 1.5539052355961758e-07
, O 0 2.050774661199739e-08
comprising O 0 1.412185781646258e-07
Australian O 0 7.974245477271324e-07
Aboriginal O 0 1.1771351182687795e-06
, O 0 1.2267116744624218e-07
Chinese O 0 3.9787360606169386e-07
, O 0 1.5229782945880288e-07
and O 0 1.8197717110979283e-07
Pacific O 0 2.665856300154701e-05
Islanders O 0 4.889656338491477e-05
. O 0 1.3077938092465047e-05

Results O 0 1.9027593225473538e-05
showed O 0 5.528792826225981e-06
that O 0 1.4661404179605597e-07
the O 0 5.32305989509041e-07
845 O 0 0.00029274309054017067
G O 0 0.00039112832746468484
- O 0 2.7045200113207102e-05
- O 0 5.041424628871027e-06
> O 0 4.379337497084634e-06
A O 0 5.48763352981041e-07
mutation O 0 2.3551733647764195e-06
was O 0 1.8849613070415216e-07
present O 0 7.896406373220088e-08
in O 0 1.4470673548316881e-08
these O 0 4.621022675621589e-09
populations O 0 4.259426944486222e-08
( O 0 1.2954046724189539e-08
allele O 0 5.330263164182725e-08
frequency O 0 1.932991366970782e-08
0 O 0 1.9702479647776272e-08
. O 0 4.186802904371234e-09
32 O 0 2.323393211156599e-08
% O 0 3.498339751217827e-08
) O 0 2.223239015108902e-08
, O 0 1.3479072080713195e-08
and O 0 1.1885986417325967e-08
, O 0 3.2188040677283425e-08
furthermore O 0 2.3246860791914514e-07
, O 0 4.2869263694456095e-08
it O 0 1.8865362605424707e-08
was O 0 1.7720752509831073e-07
always O 0 5.243643030894418e-08
seen O 0 9.830910840946672e-08
in O 0 2.0633690311910868e-08
conjunction O 0 1.0795160960697103e-06
with O 0 1.6694657460902818e-06
HLA O 1 0.6785409450531006
haplotypes O 0 0.00021019989799242467
common O 0 2.0828688320762012e-06
in O 0 4.935897095492692e-07
Caucasians O 0 4.328381328377873e-05
, O 0 2.2235958851979376e-07
suggesting O 0 2.891148824346601e-06
that O 0 2.2408819688735093e-07
845 O 0 0.00037703412817791104
G O 0 0.0019357269629836082
- O 0 0.00012939298176206648
- O 0 2.4301816665683873e-05
> O 0 1.7566739188623615e-05
A O 0 1.2131573612350621e-06
may O 0 2.40998730305364e-07
have O 0 7.0420393960546335e-09
been O 0 7.166550464177135e-09
introduced O 0 2.746292260269456e-08
into O 0 7.872957397125901e-09
these O 0 1.526755788461287e-08
populations O 0 4.757093279295077e-07
by O 0 9.201069133268902e-07
Caucasian O 0 0.002173234475776553
admixture O 0 0.010011179372668266
. O 0 9.612368739908561e-05

187 O 0 0.0002711527922656387
C O 0 0.00030441267881542444
- O 0 7.378803275059909e-05
- O 0 1.4344821465783753e-05
> O 0 2.494357613613829e-05
G O 0 1.3294490599946585e-05
was O 0 1.9907906789740082e-07
present O 0 4.3114770420515924e-08
at O 0 3.125924763480725e-08
an O 0 1.1016374479311253e-08
allele O 0 2.12577219826926e-07
frequency O 0 7.234453391902207e-08
of O 0 1.0948989626058392e-07
2 O 0 6.988932000240311e-06
. O 0 4.533082119451137e-06

68 O 0 3.8961603422649205e-05
% O 0 2.2748022274754476e-06
in O 0 1.3776976004464814e-07
the O 0 7.30082305722135e-08
two O 0 6.772769012286517e-08
populations O 0 7.135222972465272e-07
analyzed O 0 2.7175844934390625e-06
( O 0 5.983221740279987e-07
Australian O 0 1.4063892876947648e-06
Aboriginal O 0 2.102514599755523e-06
and O 0 2.076710927667591e-07
Chinese O 0 2.9172581434977474e-06
) O 0 3.2541404380026506e-06
. O 0 9.714181942399591e-06

In O 0 1.4011200164532056e-06
the O 0 4.7631763777644665e-07
Australian O 0 2.692350335564697e-06
Aboriginal O 0 1.557663495077577e-06
samples O 0 4.424796600233094e-07
, O 0 1.3886884175917658e-07
187 O 0 4.405202616908355e-06
C O 0 2.665175088623073e-05
- O 0 1.0030151315731928e-05
- O 0 2.3563034119433723e-06
> O 0 5.784373570349999e-06
G O 0 4.041394277010113e-06
was O 0 1.8232597653877747e-07
found O 0 3.2421134221749526e-08
to O 0 8.952013352825361e-09
be O 0 1.9390732575175207e-08
associated O 0 7.655312401766423e-07
with O 0 1.067953348865558e-06
HLA O 1 0.613232433795929
haplotypes O 0 0.00025105196982622147
common O 0 5.3403091442305595e-06
in O 0 9.833720469032414e-07
Caucasians O 0 0.00010591676982585341
, O 0 2.555933065195859e-07
suggesting O 0 2.878992972910055e-06
that O 0 3.099168210951575e-08
it O 0 2.3471159238397377e-08
was O 0 2.2276498157225433e-07
introduced O 0 1.8227521536573477e-07
by O 0 1.801812032908856e-07
recent O 0 6.713357834087219e-06
admixture O 0 0.0014289914397522807
. O 0 3.430265496717766e-05

In O 0 8.892444611774408e-07
the O 0 4.863341587224568e-07
Chinese O 0 6.124583933342365e-07
samples O 0 6.440183710765268e-07
analyzed O 0 8.191705660465232e-07
, O 0 1.944323457792052e-07
187 O 0 5.147249794390518e-06
C O 0 3.101075708400458e-05
- O 0 1.3546849913836922e-05
- O 0 5.28794316778658e-06
> O 0 1.362319653708255e-05
G O 0 1.0179322998737916e-05
was O 0 2.2838898416921438e-07
present O 0 6.996054935370921e-08
in O 0 3.606382037446565e-08
association O 0 3.1977785397430125e-07
with O 0 1.966617446669261e-08
a O 0 5.4635606261399516e-08
wide O 0 2.3856566144786484e-07
variety O 0 1.7354899739530083e-07
of O 0 1.71564394690904e-07
HLA O 1 0.7023870348930359
haplotypes O 0 5.752424112870358e-05
, O 0 1.0146053597281934e-07
showing O 0 6.245880399546877e-07
this O 0 2.9726347605674164e-08
mutation O 0 9.182029430121474e-07
to O 0 2.036407131811302e-08
be O 0 2.738352122833021e-08
widespread O 0 1.2868712246927316e-06
and O 0 7.674729118889445e-08
likely O 0 2.4360434736081515e-07
to O 0 2.3250956715514803e-08
predate O 0 8.31433408166049e-06
the O 0 6.514377304256413e-08
more O 0 4.516777707408437e-08
genetically O 0 2.166786771340412e-06
restricted O 0 2.120266117344727e-06
845 O 0 0.00032848751288838685
G O 0 0.0006881888257339597
- O 0 7.266768807312474e-05
- O 0 1.2825540579797234e-05
> O 0 3.0116991183604114e-05
A O 0 8.209339284803718e-06
mutation O 0 5.597153722192161e-05
. O 0 1.3176208994991612e-05

Genotype O 0 0.01539122685790062
- O 0 0.003015125636011362
phenotype O 0 0.0029921443201601505
correlations O 0 0.0007698723347857594
in O 0 0.000609288108535111
attenuated B-Disease 1 0.9890503883361816
adenomatous I-Disease 1 0.9987927675247192
polyposis I-Disease 1 0.998040497303009
coli I-Disease 1 0.9945926070213318
. O 0 0.001559194177389145

Germ O 0 0.2187829613685608
- O 0 5.9104233514517546e-05
line O 0 5.04117451782804e-06
mutations O 0 1.464162096453947e-06
of O 0 1.207132527270005e-07
the O 0 1.423076173523441e-05
tumor B-Disease 1 0.9933018684387207
suppressor O 0 0.010908978059887886
APC O 0 0.002464913995936513
are O 0 7.340799470512138e-07
implicated O 0 0.0008670489187352359
in O 0 8.949676703196019e-05
attenuated B-Disease 1 0.9926208257675171
adenomatous I-Disease 1 0.9993590712547302
polyposis I-Disease 1 0.9995250701904297
coli I-Disease 1 0.9986910223960876
( O 0 0.0008825200493447483
AAPC B-Disease 1 0.9929807186126709
) O 0 1.7037899624483543e-06
, O 0 5.039964321440493e-07
a O 0 3.298838464615983e-06
variant O 0 0.0012272506719455123
of O 0 3.26697263517417e-05
familial B-Disease 1 0.9991436004638672
adenomatous I-Disease 1 0.9995970129966736
polyposis I-Disease 1 0.9997150301933289
( O 0 0.017910614609718323
FAP B-Disease 1 0.9887821078300476
) O 0 6.540567119373009e-05
. O 0 5.8022505982080474e-05

AAPC B-Disease 1 0.9739605188369751
is O 0 3.3133133001683746e-06
recognized O 0 1.0337552112105186e-06
by O 0 1.445547894718402e-07
the O 0 1.873448525202548e-07
occurrence O 0 3.5654995826917e-06
of O 0 4.6446623969131906e-07
< O 0 0.000915275770239532
100 O 0 1.2746320862788707e-05
colonic B-Disease 1 0.8052902817726135
adenomas I-Disease 0 0.0421745702624321
and O 0 2.3403038085234584e-07
a O 0 2.3416171188728185e-06
later O 0 2.9017119231866673e-05
onset O 1 0.9941263198852539
of O 0 0.00325013161636889
colorectal B-Disease 1 0.9999828338623047
cancer I-Disease 1 0.9998124241828918
( O 0 2.3388778572552837e-05
age O 0 7.777840801281855e-05
> O 0 0.0003916469286195934
40 O 0 2.260005203424953e-06
years O 0 3.65563687410031e-06
) O 0 2.096293655995396e-06
. O 0 7.476904102077242e-06

The O 0 7.13171971256088e-07
aim O 0 6.304155704128789e-07
of O 0 2.9222922748317615e-08
this O 0 3.875316423318509e-08
study O 0 3.712177658599103e-07
was O 0 3.9432052290067077e-07
to O 0 1.325502694271563e-07
assess O 0 1.2302514733164571e-05
genotype O 0 0.00015757684013806283
- O 0 9.504668560111895e-05
phenotype O 0 0.00013216126535553485
correlations O 0 5.4878230002941564e-05
in O 0 2.1565290808212012e-05
AAPC B-Disease 1 0.9909166693687439
families O 0 4.17028677475173e-05
. O 0 4.10492648370564e-05

By O 0 4.702506430476205e-06
protein O 0 1.6891845007194206e-05
- O 0 1.7053884221240878e-05
truncation O 0 3.2501113309990615e-05
test O 0 1.359175826110004e-06
( O 0 4.7189885776788287e-07
PTT O 0 4.3578643271757755e-06
) O 0 4.953004761887314e-08
assay O 0 3.635818757175002e-07
, O 0 1.2021851070187495e-08
the O 0 2.0832800373682403e-08
entire O 0 3.417708853703516e-07
coding O 0 1.254865424016316e-06
region O 0 5.727444829517481e-08
of O 0 1.1099516861179382e-08
the O 0 5.282038273435319e-07
APC B-Disease 0 0.00029495375929400325
gene O 0 3.8818002394691575e-06
was O 0 1.3314665920916013e-06
screened O 0 3.5719490369956475e-06
in O 0 1.5718624979399465e-07
affected O 0 1.5140431059990078e-06
individuals O 0 1.3527537134905288e-07
from O 0 7.904790209067869e-07
11 O 0 5.492555646924302e-05
AAPC B-Disease 1 0.9941961765289307
kindreds O 0 0.0004467869584914297
, O 0 1.0914377668314046e-07
and O 0 2.7742744990177926e-08
their O 0 3.0975076725781037e-08
phenotypic O 0 1.9403076294111088e-05
differences O 0 1.5022082152427174e-05
were O 0 3.2038458357419586e-06
examined O 0 0.00021936441771686077
. O 0 2.1827065211255103e-05

Five O 0 1.3151116036169697e-05
novel O 0 0.00019827265350613743
germ O 1 0.614171028137207
- O 0 8.701173646841198e-05
line O 0 1.6979625797830522e-05
APC B-Disease 0 0.0006054050754755735
mutations O 0 5.98457381784101e-06
were O 0 1.6308005967857753e-07
identified O 0 1.08822780475748e-06
in O 0 2.953679825168365e-07
seven O 0 8.413695468334481e-06
kindreds O 0 0.0030545403715223074
. O 0 7.099671347532421e-05

Mutations O 0 2.554194907133933e-05
were O 0 1.3058141234978393e-07
located O 0 1.209977114058347e-07
in O 0 1.3149738187223647e-08
three O 0 2.2863244630855206e-09
different O 0 1.1492459206507988e-09
regions O 0 1.6668703750610803e-08
of O 0 1.4568765749345403e-08
the O 0 2.019824449916996e-07
APC B-Disease 0 9.367083839606494e-05
gene O 0 1.5599587186443387e-06
( O 0 1.4521498314934433e-07
1 O 0 6.245821282391262e-08
) O 0 1.3454568126292088e-08
at O 0 1.2005354044219985e-08
the O 0 8.316547450704093e-09
5 O 0 4.439742795625534e-08
end O 0 1.1990003656592307e-07
spanning O 0 6.835927024440025e-07
exons O 0 7.373791390818951e-07
4 O 0 7.835718918158818e-08
and O 0 9.315335169901573e-09
5 O 0 4.7199019803656483e-08
, O 0 7.641903110311432e-09
( O 0 1.7444046207515385e-08
2 O 0 1.6138491432116098e-08
) O 0 9.248344312595691e-09
within O 0 8.567117681934633e-09
exon O 0 2.083178515022155e-06
9 O 0 1.9755846381031006e-07
, O 0 1.3726348946363487e-08
and O 0 6.162617971483542e-09
( O 0 2.3504131974050324e-08
3 O 0 1.6209012798640288e-08
) O 0 5.291928228956522e-09
at O 0 1.0001313555108027e-08
the O 0 8.961921871275536e-09
3 O 0 1.0208442091652614e-07
distal O 0 1.2268864338693675e-05
end O 0 2.9357516950767604e-07
of O 0 5.7706262879264614e-08
the O 0 9.438868460165395e-07
gene O 0 3.485868364805356e-05
. O 0 8.84811015566811e-06

Variability O 0 0.00012561101175379008
in O 0 8.616165132480091e-07
the O 0 4.5431738726620097e-07
number O 0 6.66863172682497e-07
of O 0 4.178251765551977e-05
colorectal B-Disease 1 0.9999316930770874
adenomas I-Disease 1 0.9993601441383362
was O 0 2.2014119167579338e-05
most O 0 2.765341662325227e-07
apparent O 0 2.2705804440192878e-05
in O 0 9.215894891667631e-08
individuals O 0 7.131047397024304e-08
with O 0 1.2118987058329367e-07
mutations O 0 1.9257329313404625e-06
in O 0 7.34624876486123e-08
region O 0 3.627322939792066e-07
1 O 0 5.06131186739367e-07
, O 0 1.564083618177392e-07
and O 0 9.12713232992246e-07
upper O 0 0.2543376386165619
- O 0 0.29037368297576904
gastrointestinal O 1 0.9974431991577148
manifestations O 0 0.0004911522846668959
were O 0 1.9136955415888224e-06
more O 0 1.8761497813102324e-06
severe O 1 0.9772257208824158
in O 0 1.1445278005339787e-06
them O 0 8.658504953018564e-07
. O 0 8.836996130412444e-06

In O 0 1.4822676348558161e-06
individuals O 0 5.657490191879333e-07
with O 0 2.925371518358588e-07
mutations O 0 3.410963245187304e-06
in O 0 1.216546792193185e-07
either O 0 3.795377665483102e-07
region O 0 2.6646125661500264e-07
2 O 0 2.387712072504655e-07
or O 0 6.712223665772399e-08
region O 0 1.0974329711643804e-07
3 O 0 3.8454004425148014e-08
, O 0 6.886012648976703e-09
the O 0 8.32970759034879e-09
average O 0 9.115199617326653e-08
number O 0 1.2444318464588378e-08
of O 0 6.362573401474947e-08
adenomas B-Disease 0 0.1671942174434662
tended O 0 2.2831675323686795e-06
to O 0 2.3159250517323926e-08
be O 0 1.847201858140579e-08
lower O 0 1.0779832564367098e-06
than O 0 1.029564966614771e-08
those O 0 8.109002358480666e-09
in O 0 1.1024740231846408e-08
individuals O 0 2.077946348322257e-08
with O 0 2.954743649752345e-08
mutations O 0 1.3778580978396349e-06
in O 0 7.210262964463254e-08
region O 0 2.858752736756287e-07
1 O 0 1.677188095072779e-07
, O 0 4.275608489479055e-08
although O 0 2.0290180202664487e-07
age O 0 6.295291314017959e-06
at O 0 1.809686000342481e-05
diagnosis O 1 0.7817181944847107
was O 0 1.28955971376854e-05
similar O 0 1.95374341274146e-05
. O 0 2.0986377421650104e-05

In O 0 9.160835361399222e-06
all O 0 5.685741143679479e-06
AAPC B-Disease 1 0.9798294305801392
kindreds O 0 0.0006492723478004336
, O 0 5.441222015178937e-07
a O 0 8.950733558776847e-07
predominance O 0 6.480370211647823e-05
of O 0 1.7119955373345874e-06
right O 0 0.0016105981776490808
- O 1 0.6811099648475647
sided O 1 0.9960963129997253
colorectal B-Disease 1 0.9998966455459595
adenomas I-Disease 1 0.9992327690124512
and O 0 0.0009741811663843691
rectal B-Disease 1 0.9993488192558289
polyp I-Disease 1 0.9981645941734314
sparing O 0 0.002922155661508441
was O 0 0.00012121029431000352
observed O 0 6.654871685896069e-05
. O 0 4.321827509556897e-05

No O 0 0.0019421485485509038
desmoid B-Disease 1 0.9824680685997009
tumors I-Disease 1 0.9975100755691528
were O 0 1.4446068234974518e-06
found O 0 1.9584274468797958e-06
in O 0 3.5798532849184994e-07
these O 0 5.821257218485698e-07
kindreds O 0 0.0013077310286462307
. O 0 3.4543409128673375e-05

Our O 0 1.9344854536029743e-06
data O 0 1.714599989099952e-06
suggest O 0 3.1437480174645316e-06
that O 0 1.3197256976127392e-07
, O 0 4.3367563762330974e-07
in O 0 1.232832005371165e-06
AAPC B-Disease 1 0.9077633023262024
families O 0 2.02864072207376e-07
, O 0 1.9815882268403584e-08
the O 0 7.900546883377046e-09
location O 0 4.3151789697049026e-08
of O 0 2.3223078571277256e-08
the O 0 7.209079626591119e-07
APC B-Disease 0 0.0031914985738694668
mutation O 0 0.0001300199219258502
may O 0 1.5673160305595957e-05
partially O 0 8.088097092695534e-05
predict O 0 1.4789529814152047e-05
specific O 0 1.6457506717415527e-06
phenotypic O 0 0.0001275507966056466
expression O 0 6.886485061841086e-05
. O 0 6.147131352918223e-05

This O 0 1.3604466175820562e-06
should O 0 2.4143764676409774e-07
help O 0 2.0977306292024878e-07
in O 0 2.2290645773637152e-08
the O 0 3.7663873797555425e-08
design O 0 1.167417849501362e-06
of O 0 2.1035161523741408e-07
tailored O 0 0.00018847639148589224
clinical O 0 0.0009888210333883762
- O 0 6.904429756104946e-05
management O 0 4.144163085584296e-06
protocols O 0 1.1017151564374217e-06
in O 0 5.8480775777525196e-08
this O 0 9.721474469870373e-08
subset O 0 3.163060682709329e-06
of O 0 4.251008249411825e-06
FAP B-Disease 1 0.996508777141571
patients O 0 0.4616967737674713
. O 0 7.502782409574138e-06
. O 0 2.9622504371218383e-05

Wilms B-Disease 1 0.9908877611160278
' I-Disease 0 0.0035534745547920465
tumor I-Disease 0 0.10569477826356888
1 O 0 4.826121312362375e-06
and O 0 5.546254442378995e-07
Dax O 0 0.00029870111029595137
- O 0 1.7270181160711218e-06
1 O 0 2.2783771669310227e-07
modulate O 0 7.0126334321685135e-06
the O 0 6.209473326634907e-07
orphan O 0 0.0006801562267355621
nuclear O 0 6.931847019586712e-05
receptor O 0 0.00018179092148784548
SF O 0 0.0037871012464165688
- O 0 3.300081516499631e-06
1 O 0 1.4165884465455747e-07
in O 0 5.213933107484081e-08
sex O 0 5.683604626938177e-07
- O 0 1.5131395230127964e-06
specific O 0 2.3587401187796786e-07
gene O 0 5.034150944993598e-06
expression O 0 9.617183422960807e-06
. O 0 1.494224306952674e-05

Products O 0 2.4404491341556422e-05
of O 0 1.6526884110135143e-06
steroidogenic O 0 0.008259087800979614
factor O 0 5.582634003076237e-06
1 O 0 3.0697228794451803e-06
( O 0 2.095144509439706e-06
SF O 0 0.003407934680581093
- O 0 1.9068473875449854e-06
1 O 0 2.1109437398081354e-07
) O 0 1.5577303713598667e-07
and O 0 9.73449800767412e-07
Wilms B-Disease 1 0.9934784173965454
tumor I-Disease 1 0.5440451502799988
1 O 0 2.627262574605993e-06
( O 0 1.6105148006317904e-06
WT1 O 0 0.0007081347866915166
) O 0 7.065209928214244e-08
genes O 0 4.092736105576478e-08
are O 0 1.7230782356492114e-09
essential O 0 3.292804606758182e-08
for O 0 2.5411068804714887e-08
mammalian O 0 6.32700994174229e-06
gonadogenesis O 0 0.00011110865307273343
prior O 0 5.713576456400915e-07
to O 0 8.751703006737444e-08
sexual O 0 1.2106863323424477e-05
differentiation O 0 0.0002674833231139928
. O 0 2.5183597244904377e-05

In O 0 5.654201231664047e-06
males O 0 1.5456093024113216e-05
, O 0 3.980986093665706e-06
SF O 0 0.013338546268641949
- O 0 4.675728632719256e-06
1 O 0 1.6845490335981594e-07
participates O 0 4.352808389285201e-07
in O 0 2.5189860863861213e-08
sexual O 0 2.717696077070286e-07
development O 0 1.752743372662735e-07
by O 0 5.198442565301775e-08
regulating O 0 9.633960189603386e-07
expression O 0 1.7241499961073714e-07
of O 0 6.352739490012027e-08
the O 0 1.4295915207185317e-06
polypeptide O 0 0.0035999389365315437
hormone O 0 0.0212833471596241
Mullerian O 0 0.07647652924060822
inhibiting O 0 0.001490966184064746
substance O 0 0.0034950384870171547
( O 0 4.592150798998773e-05
MIS O 0 0.021764211356639862
) O 0 1.2929338481626473e-05
. O 0 1.7234464394277893e-05

Here O 0 6.6874658841697965e-06
, O 0 5.794780690848711e-07
we O 0 8.20118088995514e-08
show O 0 8.839355132295168e-07
that O 0 8.357224601240887e-07
WT1 O 0 0.01806735061109066
- O 0 6.075646888348274e-05
KTS O 0 0.002196274697780609
isoforms O 0 4.153865120315459e-06
associate O 0 4.198322585580172e-06
and O 0 3.185961929830228e-07
synergize O 0 0.0003420401189941913
with O 0 5.532369414140703e-06
SF O 0 0.16511666774749756
- O 0 7.510234809160465e-06
1 O 0 3.1248640652847826e-07
to O 0 1.0595196897611459e-07
promote O 0 2.4296914489241317e-06
MIS O 0 0.0019535175524652004
expression O 0 2.6713534680311568e-05
. O 0 1.6634199710097164e-05

In O 0 9.578503522789106e-06
contrast O 0 3.082170951529406e-05
, O 0 9.898653843265492e-06
WT1 O 0 0.05166155844926834
missense O 0 0.0003763532731682062
mutations O 0 2.03430336114252e-05
, O 0 3.884271109200199e-07
associated O 0 1.1236641057621455e-06
with O 0 6.735718329764495e-07
male B-Disease 0 0.00010270704660797492
pseudohermaphroditism I-Disease 1 0.9348596930503845
in O 0 9.608903928892687e-05
Denys B-Disease 1 0.9863177537918091
- I-Disease 1 0.9763280749320984
Drash I-Disease 1 0.9953935146331787
syndrome I-Disease 1 0.9997395873069763
, O 0 5.581595360126812e-06
fail O 0 4.274216917110607e-05
to O 0 4.1612577206251444e-07
synergize O 0 0.0008509060717187822
with O 0 8.126367902150378e-06
SF O 1 0.8684300780296326
- O 0 7.494736200897023e-05
1 O 0 8.178191819752101e-06
. O 0 7.815857316018082e-06

Additionally O 0 2.0951520127709955e-05
, O 0 1.0421402976135141e-06
the O 0 1.6441082379969885e-06
X O 0 0.0002586401242297143
- O 0 2.5008694137795828e-05
linked O 0 5.563011654885486e-06
, O 0 1.2092007750652556e-07
candidate O 0 1.1155972288179328e-06
dosage O 0 0.00012666755355894566
- O 0 9.901391422317829e-06
sensitive O 0 1.7294620420216233e-06
sex O 0 4.059619641338941e-06
- O 0 1.2028630408167373e-05
reversal O 0 3.136922896374017e-05
gene O 0 4.848494427278638e-06
, O 0 6.712261324537394e-07
Dax O 0 0.00038267424679361284
- O 0 2.903247604990611e-06
1 O 0 2.5748155962901365e-07
, O 0 1.48814393696739e-07
antagonizes O 0 3.2532123441342264e-05
synergy O 0 1.0962120541080367e-05
between O 0 3.4045738175336737e-06
SF O 0 0.03317415341734886
- O 0 3.193772499798797e-06
1 O 0 3.409222415484692e-07
and O 0 2.6150289045290265e-07
WT1 O 0 0.0009495753329247236
, O 0 3.60733807269753e-08
most O 0 7.484225683640489e-09
likely O 0 2.023236156389885e-08
through O 0 3.0139732931644403e-09
a O 0 1.8493594211577147e-08
direct O 0 2.68298645522691e-08
interaction O 0 2.6376332584732154e-07
with O 0 2.8951385502296034e-06
SF O 1 0.6025180816650391
- O 0 2.8535325327538885e-05
1 O 0 3.5036468943872023e-06
. O 0 3.0897715532773873e-06

We O 0 2.93494986181031e-06
propose O 0 2.098181539622601e-05
that O 0 1.6119653309942805e-06
WT1 O 0 0.0028381068259477615
and O 0 1.316268367190787e-06
Dax O 0 0.0008347528637386858
- O 0 3.589593688957393e-06
1 O 0 2.402863970019098e-07
functionally O 0 1.9666645130200777e-06
oppose O 0 1.2339289412466314e-07
each O 0 4.8502961647045595e-09
other O 0 1.1427241375372432e-08
in O 0 1.399264988322102e-07
testis O 0 0.00011325965169817209
development O 0 6.596787898160983e-07
by O 0 1.3246008165879175e-06
modulating O 0 0.003082843264564872
SF O 1 0.559788167476654
- O 0 2.7463940568850376e-05
1 O 0 3.0493392841890454e-06
- O 0 1.011301083053695e-05
mediated O 0 5.22302943863906e-05
transactivation O 0 0.0007441630004905164
. O 0 5.4563511184824165e-06
. O 0 1.1605017789406702e-05

A O 0 0.00011532639473443851
mouse O 0 0.0005819119396619499
model O 0 0.00012131436233175918
for O 0 0.00012608406541403383
Prader B-Disease 1 0.9982635378837585
- I-Disease 1 0.9957705140113831
Willi I-Disease 1 0.9991474151611328
syndrome I-Disease 1 0.9997311234474182
imprinting O 0 0.313831090927124
- O 0 0.0028425976634025574
centre O 0 0.0002090797497658059
mutations O 0 0.00038340839091688395
. O 0 4.561149762594141e-05

Imprinting O 0 0.00021844649745617062
in O 0 1.071716155820468e-06
the O 0 3.5110119824821595e-06
15q11 O 0 0.000604110537096858
- O 0 2.9415314202196896e-05
q13 O 0 3.015656693605706e-05
region O 0 5.954656785434054e-07
involves O 0 6.519771886814851e-07
an O 0 2.3303573470911942e-07
imprinting O 0 4.022156645078212e-05
centre O 0 5.253235940472223e-06
( O 0 1.2992582014703657e-06
IC O 0 4.648077810998075e-05
) O 0 8.530596318223616e-08
, O 0 8.58738680165061e-09
mapping O 0 1.2567717533329414e-07
in O 0 8.111755711581736e-09
part O 0 2.007763200140289e-08
to O 0 3.5213940652312203e-09
the O 0 2.1570947694726783e-08
promoter O 0 4.611313670466188e-06
and O 0 4.5447510643725764e-08
first O 0 1.5365034755632223e-07
exon O 0 3.061612005694769e-05
of O 0 2.2241863462113542e-06
SNRPN O 0 0.06491392105817795
. O 0 5.752955985371955e-05

Deletion O 0 9.857256372924894e-05
of O 0 8.776473805482965e-07
this O 0 2.1960613594274037e-06
IC O 0 0.0025335634127259254
abolishes O 0 0.0003085956850554794
local O 0 2.484846163497423e-06
paternally O 0 8.95181146916002e-05
derived O 0 2.1231535356491804e-06
gene O 0 4.170293777860934e-06
expression O 0 1.612598907740903e-06
and O 0 7.160335826483788e-07
results O 0 3.532986011123285e-05
in O 0 0.0003431187360547483
Prader B-Disease 1 0.9989798665046692
- I-Disease 1 0.9972240924835205
Willi I-Disease 1 0.9995842576026917
syndrome I-Disease 1 0.9999037981033325
( O 0 0.019675467163324356
PWS B-Disease 1 0.9988849759101868
) O 0 7.393283885903656e-05
. O 0 6.624864909099415e-05

We O 0 6.08173422733671e-07
have O 0 7.372723587195651e-08
created O 0 1.795126394199542e-07
two O 0 9.452924842889843e-08
deletion O 0 0.00010027844837168232
mutations O 0 2.936234523076564e-05
in O 0 2.0082895844097948e-06
mice O 0 0.0002580758009571582
to O 0 5.77538287416246e-07
understand O 0 2.8989181373617612e-05
PWS B-Disease 1 0.9953291416168213
and O 0 1.0185744514501494e-07
the O 0 5.261957269908635e-08
mechanism O 0 7.863534392527072e-07
of O 0 1.0931690752613576e-07
this O 0 1.964958528333227e-06
IC O 0 0.011056602001190186
. O 0 3.5007193218916655e-05

Mice O 0 0.02187068574130535
harbouring O 0 0.010870753787457943
an O 0 1.9505596355884336e-05
intragenic O 0 0.0022149214055389166
deletion O 0 0.0004235811938997358
in O 0 4.1073276406677905e-06
Snrpn O 0 0.002143027726560831
are O 0 4.782594373864413e-07
phenotypically O 0 0.0004579299420583993
normal O 0 5.097281700727763e-06
, O 0 4.533642936621618e-07
suggesting O 0 3.6621931940317154e-06
that O 0 6.124081153302541e-08
mutations O 0 6.975654969210154e-07
of O 0 3.9322618050618985e-08
SNRPN O 0 0.0017991199856624007
are O 0 1.994073528521767e-08
not O 0 5.327000707211482e-08
sufficient O 0 1.4593123296435806e-06
to O 0 1.8101599152942072e-06
induce O 0 0.003786471439525485
PWS B-Disease 1 0.9943704009056091
. O 0 0.0001366710930597037

Mice O 0 0.00034427520586177707
with O 0 5.677282501892478e-07
a O 0 1.6050719295890303e-06
larger O 0 2.2999381599220214e-06
deletion O 0 4.218380490783602e-05
involving O 0 2.5384385935467435e-06
both O 0 2.53787192150412e-07
Snrpn O 0 0.0002915126096922904
and O 0 4.151871166868659e-07
the O 0 3.826564352493733e-06
putative O 0 0.007325669750571251
PWS O 1 0.9979259967803955
- O 0 0.00047028905828483403
IC O 0 0.0006020464934408665
lack O 0 2.4348639726667898e-06
expression O 0 4.181162864824728e-07
of O 0 5.983506667917027e-08
the O 0 8.582950385971344e-07
imprinted O 0 0.00016934338782448322
genes O 0 6.117548309703125e-06
Zfp127 O 0 0.000444307312136516
( O 0 3.53965242538834e-06
mouse O 0 2.0533150745905004e-05
homologue O 0 5.537120523513295e-05
of O 0 7.608316536789062e-07
ZNF127 O 0 0.0044546788558363914
) O 0 1.7033544281730428e-06
, O 0 9.9941632925038e-07
Ndn O 0 0.001366477576084435
and O 0 5.164554295333801e-07
Ipw O 0 0.00028273757197894156
, O 0 2.0093114017072367e-07
and O 0 1.42579935413778e-07
manifest O 0 1.4254924280976411e-05
several O 0 1.2037279475407558e-06
phenotypes O 0 0.0009259326616302133
common O 0 9.703579416964203e-05
to O 0 0.00011204674956388772
PWS B-Disease 1 0.9989011287689209
infants O 1 0.9785687327384949
. O 0 0.00022085467935539782

These O 0 5.796311484118633e-07
data O 0 9.567158940626541e-07
demonstrate O 0 5.375266027840553e-07
that O 0 1.8759296338544118e-08
both O 0 8.478700408431905e-09
the O 0 1.5594359581427852e-08
position O 0 2.294814471781592e-08
of O 0 1.1425715484847387e-08
the O 0 1.3812707777560718e-07
IC O 0 7.313694368349388e-05
and O 0 2.1550839335304772e-08
its O 0 1.3231127304891288e-08
role O 0 3.71369246465747e-08
in O 0 5.979785111520641e-09
the O 0 1.2118428927010427e-08
coordinate O 0 7.335314222700617e-08
expression O 0 4.6357058636203874e-08
of O 0 9.878085016623572e-09
genes O 0 1.8388325884188816e-07
is O 0 3.790826497152011e-08
conserved O 0 2.7457065243652323e-07
between O 0 2.3765824153088033e-07
mouse O 0 9.425390089745633e-06
and O 0 3.75218327519633e-08
human O 0 1.5166500588748022e-07
, O 0 3.12462518081702e-08
and O 0 1.2765673851333759e-08
indicate O 0 1.7336950008939311e-07
that O 0 1.0009137518807165e-08
the O 0 4.241898210466388e-08
mouse O 0 1.7598227941562072e-06
is O 0 1.973027075052869e-08
a O 0 8.725533717779399e-08
suitable O 0 4.556625015084137e-07
model O 0 6.129656071607315e-07
system O 0 3.2445944952996797e-07
in O 0 1.8116567801484962e-08
which O 0 8.515327110103499e-09
to O 0 7.750041497445181e-09
investigate O 0 1.5937949626732006e-07
the O 0 1.795293691486677e-08
molecular O 0 4.4978216351410083e-07
mechanisms O 0 1.9983880861218495e-07
of O 0 2.9969839943078114e-08
imprinting O 0 7.1436033977079205e-06
in O 0 2.4285409239155342e-08
this O 0 1.8360108100523576e-08
region O 0 4.482029680730193e-08
of O 0 1.077046185571362e-08
the O 0 4.23175634978179e-07
genome O 0 1.3055333511147182e-05
. O 0 1.120908109442098e-06
. O 0 1.0166205356654245e-05

Mutations O 0 1.8739805454970337e-05
of O 0 2.013178175275243e-07
the O 0 1.9905260160157923e-06
ATM O 0 0.000236138075706549
gene O 0 3.740529791684821e-05
detected O 0 0.0001436236925655976
in O 0 8.338679435837548e-06
Japanese O 0 0.04249913617968559
ataxia B-Disease 1 0.9997195601463318
- I-Disease 1 0.9970093965530396
telangiectasia I-Disease 1 0.999098539352417
patients O 0 0.13167795538902283
: O 0 1.6477075632792548e-06
possible O 0 4.860059448219545e-07
preponderance O 0 3.2637337426422164e-05
of O 0 2.488732064875876e-08
the O 0 1.1442337921607759e-07
two O 0 1.5866763192207145e-07
founder O 0 7.24511846783571e-05
mutations O 0 2.7614605642156675e-05
4612del165 O 0 0.00021282075613271445
and O 0 2.9567702313215705e-06
7883del5 O 0 0.00106630171649158
. O 0 3.714388731168583e-05

The O 0 6.948307145648869e-06
ATM O 0 0.0002927464374806732
( O 0 1.5574269127682783e-05
A O 0 0.0017521941335871816
- O 0 0.002875130856409669
T O 1 0.6578018665313721
, O 0 4.4949743482902704e-07
mutated O 0 6.408798071788624e-06
) O 0 1.7019988263200503e-07
gene O 0 1.1975185998380766e-06
on O 0 4.0576117044111015e-07
human O 0 6.546652912220452e-06
chromosome O 0 0.0004188851162325591
11q22 O 0 0.0018207533285021782
. O 0 2.9347676900215447e-05

3 O 0 2.078735087707173e-05
has O 0 2.0637528450606624e-06
recently O 0 5.209536993788788e-06
been O 0 8.46695513700979e-08
identified O 0 1.4227974531877408e-07
as O 0 1.0450624365887506e-08
the O 0 2.5136777992429415e-08
gene O 0 2.86442400465603e-07
responsible O 0 1.8688874092731567e-07
for O 0 9.062742378773692e-08
the O 0 4.578419066092465e-06
human O 0 0.0034807769116014242
recessive B-Disease 1 0.999184787273407
disease I-Disease 1 0.9998728036880493
ataxia B-Disease 1 0.9997640252113342
- I-Disease 1 0.9945143461227417
telangiectasia I-Disease 1 0.9971393346786499
( O 0 0.0003028206410817802
A B-Disease 0 0.1631888747215271
- I-Disease 0 0.12975163757801056
T I-Disease 1 0.9872671961784363
) O 0 6.778728220524499e-06
. O 0 1.0060097338282503e-05

In O 0 6.427169978451275e-07
order O 0 1.9926406480408332e-07
to O 0 3.1835256208978535e-08
define O 0 3.631569995832251e-07
the O 0 1.7988313061323424e-07
types O 0 3.0463279472314753e-06
of O 0 5.286440682539251e-06
disease O 1 0.9995445609092712
- O 0 0.0006581938359886408
causing O 0 0.0004887032555416226
ATM O 0 0.00013146395212970674
mutations O 0 9.838572623266373e-06
in O 0 6.067135700504878e-07
Japanese O 0 0.000253189675277099
A B-Disease 0 0.4670569598674774
- I-Disease 1 0.9677878618240356
T I-Disease 1 0.9991441965103149
patients O 0 0.0007423603092320263
as O 0 6.26565181960359e-08
well O 0 2.7217000209134312e-08
as O 0 1.842736274682011e-08
to O 0 8.514515315027893e-09
look O 0 1.631432269277866e-07
for O 0 2.9535829781934808e-08
possible O 0 8.251380450019496e-07
mutational O 0 0.00028327046311460435
hotspots O 0 8.851722668623552e-06
, O 0 1.6288950632770138e-07
reverse O 0 5.663694082613802e-06
- O 0 1.6262312101389398e-06
transcribed O 0 6.186244831951626e-07
RNA O 0 5.67608083201776e-07
derived O 0 1.5094728667008894e-07
from O 0 2.57750343735097e-07
ten O 0 6.99641475421231e-07
patients O 0 0.00011011108290404081
belonging O 0 4.953231496074295e-07
to O 0 3.8311391392653604e-08
eight O 0 4.1767313518903393e-07
unrelated O 0 6.4094529079739e-05
Japanese O 0 0.00021136717987246811
A B-Disease 0 0.05439281463623047
- I-Disease 0 0.041048597544431686
T I-Disease 1 0.8921054005622864
families O 0 6.240355219233606e-07
was O 0 3.0056224886720884e-07
analyzed O 0 3.411024067645485e-07
for O 0 1.8291213876864276e-08
mutations O 0 4.192022799998085e-07
by O 0 2.1577696074359665e-08
the O 0 1.2187672382424353e-07
restriction O 0 7.645648111065384e-06
endonuclease O 0 0.00023494601191487163
fingerprinting O 0 2.775194116111379e-05
method O 0 2.5309741431556176e-06
. O 0 8.282425369543489e-06

As O 0 7.4460931500652805e-06
has O 0 2.44501620727533e-06
been O 0 5.260342277324526e-07
reported O 0 2.1365206066548126e-06
by O 0 5.5241901719682573e-08
others O 0 1.139920655646165e-07
, O 0 7.516659650264046e-08
mutations O 0 4.594746485508949e-07
that O 0 1.0632969171808782e-08
lead O 0 1.1485018802659397e-07
to O 0 4.279434762111123e-08
exon O 0 2.7844005671795458e-05
skipping O 0 3.300107709947042e-05
or O 0 2.1752091470261803e-06
premature O 0 0.0002622775500640273
protein O 0 2.8691283660009503e-06
truncation O 0 2.0634399334085174e-05
were O 0 8.299310394477288e-08
also O 0 1.1537669308836485e-07
predominant O 0 1.3520935908672982e-06
in O 0 1.737521841960188e-07
our O 0 5.648357159770967e-07
mutants O 0 0.00013279833365231752
. O 0 1.185425844596466e-05

Six O 0 1.5119148883968592e-06
different O 0 1.3493533401742752e-07
mutations O 0 1.824012656470586e-06
were O 0 3.836916562249826e-08
identified O 0 1.1981956049567088e-07
on O 0 1.1354826412457442e-08
12 O 0 1.3304363832844501e-08
of O 0 4.9996908835225895e-09
the O 0 1.3825410860590637e-07
16 O 0 1.2430783726813388e-06
alleles O 0 1.2184073966636788e-05
examined O 0 0.00010883534559980035
. O 0 1.4465244021266699e-05

Four O 0 1.4754850781173445e-06
were O 0 6.088489499234129e-07
deletions O 0 4.786007593793329e-06
involving O 0 1.0218684565188596e-06
a O 0 4.632771037904604e-07
loss O 0 2.2010515294823563e-06
of O 0 7.205270158294752e-09
a O 0 1.1616699424621402e-07
single O 0 1.5964602084750368e-07
exon O 0 9.261581908504013e-06
exon O 0 6.892565124871908e-06
7 O 0 4.5632523892891186e-07
, O 0 6.673695907011279e-08
exon O 0 3.0447070002992405e-06
16 O 0 2.476274971741077e-07
, O 0 5.618133869234043e-08
exon O 0 6.426020263461396e-06
33 O 0 8.56952851790993e-07
or O 0 5.778578042736626e-07
exon O 0 4.40451804024633e-05
35 O 0 1.5219534361676779e-05
. O 0 1.3635714822157752e-05

The O 0 2.585218453532434e-06
others O 0 1.0015421594289364e-06
were O 0 9.362541675272951e-08
minute O 0 4.5677197135773895e-07
deletions O 0 4.111077942070551e-06
, O 0 1.6125945023759414e-07
4649delA O 0 9.185521776089445e-06
in O 0 6.824652132308984e-08
exon O 0 8.954302757047117e-06
33 O 0 7.675321285205428e-07
and O 0 7.905810406327873e-08
7883del5 O 0 1.4956870472815353e-05
in O 0 4.52649743465372e-07
exon O 0 7.871694106142968e-05
55 O 0 2.5573997845640406e-05
. O 0 1.2558324669953436e-05

The O 0 1.56965234054951e-05
mutations O 0 8.592974336352199e-05
4612del165 O 0 0.00019761812291108072
and O 0 9.151240192295518e-07
7883del5 O 0 7.269430352607742e-05
were O 0 1.320937030868663e-07
found O 0 2.4143028554135526e-07
in O 0 1.6284282366996194e-08
more O 0 3.884676136323151e-09
than O 0 7.889177311426465e-09
two O 0 1.3075583282784464e-08
unrelated O 0 3.3033593354048207e-06
families O 0 1.1706023883562011e-07
; O 0 7.093781562161894e-08
44 O 0 1.5122392937882978e-07
% O 0 5.545811632146069e-08
( O 0 2.0322360683167062e-08
7 O 0 5.610603093231248e-09
of O 0 7.54536766400804e-10
16 O 0 1.3405103693742149e-08
) O 0 2.4079500615670213e-09
of O 0 6.376721373158034e-10
the O 0 1.6649925882461503e-08
mutant O 0 8.91419858817244e-07
alleles O 0 3.05782322129744e-07
had O 0 4.0595850236968545e-08
one O 0 4.260350738860552e-09
of O 0 5.431358918173146e-09
the O 0 6.506120087124145e-08
two O 0 3.616894446167862e-07
mutations O 0 5.653641346725635e-05
. O 0 9.208212759403978e-06

The O 0 6.992738690314582e-06
4612del165 O 0 0.00022429507225751877
mutations O 0 6.707208740408532e-06
in O 0 6.433179322584692e-08
three O 0 1.529661730614862e-08
different O 0 8.880942203859377e-09
families O 0 5.83747947757729e-08
were O 0 1.1855329162813177e-08
all O 0 3.7126426377653843e-09
ascribed O 0 5.703787451238895e-07
to O 0 1.333345078791126e-08
the O 0 8.597945111432637e-08
same O 0 6.831899668213737e-07
T O 0 0.014668388292193413
- O 0 4.622682808985701e-06
- O 0 5.147354045220709e-07
> O 0 6.494638569165545e-07
A O 0 5.02093762122513e-08
substitution O 0 1.1253666087895908e-07
at O 0 8.684341423759179e-08
the O 0 8.915382210261669e-08
splice O 0 1.2189443623356055e-05
donor O 0 5.657755991705926e-06
site O 0 3.2164525691769086e-06
in O 0 2.2388642264559167e-06
intron O 0 0.002188335871323943
33 O 0 5.201378371566534e-05
. O 0 2.4878481781342998e-05

Microsatellite O 0 0.0018301489762961864
genotyping O 0 0.00014387795818038285
around O 0 8.722869893063034e-07
the O 0 1.0279990192429977e-06
ATM O 0 8.685489592608064e-05
locus O 0 1.9298147890367545e-05
also O 0 4.078686401953746e-07
indicated O 0 2.2673493731417693e-06
that O 0 3.1561135926949646e-08
a O 0 2.917612391684088e-07
common O 0 1.4653467133030063e-06
haplotype O 0 0.00014633692626375705
was O 0 3.3212211292266147e-07
shared O 0 7.611112096128636e-08
by O 0 2.414316035981301e-08
the O 0 7.217747821641751e-08
mutant O 0 5.193048764340347e-06
alleles O 0 2.007228886213852e-06
in O 0 1.2495507917265058e-07
both O 0 5.005304046790116e-07
mutations O 0 9.904991020448506e-05
. O 0 2.0674444385804236e-05

This O 0 1.5002492546045687e-06
suggests O 0 4.488331796892453e-06
that O 0 4.980600465387397e-08
these O 0 1.0372441572314983e-08
two O 0 1.0014277762593338e-07
founder O 0 5.0751270464388654e-05
mutations O 0 1.1180532055732328e-05
may O 0 7.239904675770958e-07
be O 0 6.054638390651235e-08
predominant O 0 1.2192547274025856e-06
among O 0 2.148550350966616e-07
Japanese O 0 9.129934369411785e-06
ATM O 0 0.0002115442039212212
mutant O 0 0.0001190596740343608
alleles O 0 7.983286923263222e-05
. O 0 2.6784447982208803e-05

W474C O 0 0.0003297406656201929
amino O 0 1.4859027942293324e-05
acid O 0 0.0001090376972570084
substitution O 0 6.9491093199758325e-06
affects O 0 8.88258819031762e-06
early O 0 1.9377392845854047e-07
processing O 0 7.433198589978929e-08
of O 0 3.3710891855776026e-09
the O 0 1.9979262688707422e-08
alpha O 0 4.683386123360833e-07
- O 0 1.3758830164078972e-07
subunit O 0 7.821085290515839e-08
of O 0 3.204072740459196e-08
beta O 0 1.9399467419134453e-05
- O 0 3.941147497243946e-06
hexosaminidase O 0 9.689643775345758e-06
A O 0 3.52745985310321e-07
and O 0 3.5922877117400276e-08
is O 0 1.276144274697799e-07
associated O 0 1.5510344155700295e-06
with O 0 2.5673271011328325e-06
subacute O 1 0.9872620701789856
G B-Disease 0 0.0074568516574800014
( I-Disease 0 2.3451424567610957e-05
M2 I-Disease 0 0.017591990530490875
) I-Disease 0 1.1726437151082791e-05
gangliosidosis I-Disease 0 0.002044028602540493
. O 0 3.355740773258731e-05

Mutations O 0 4.376771175884642e-05
in O 0 1.170619611912116e-06
the O 0 1.52956476995314e-06
HEXA O 0 0.0016899011097848415
gene O 0 5.905411057938181e-07
, O 0 1.0563653063400125e-08
encoding O 0 3.279798477251461e-08
the O 0 1.830091633792108e-08
alpha O 0 2.1143407025192573e-07
- O 0 8.516208538367209e-08
subunit O 0 3.825699224080381e-08
of O 0 1.3924540631649052e-08
beta O 0 1.2474980394472368e-05
- O 0 3.891823325830046e-06
hexosaminidase O 0 1.0066402865049895e-05
A O 0 3.4066158605128294e-07
( O 0 1.7010526676131121e-07
Hex O 0 2.012730192291201e-06
A O 0 2.2495923701626452e-07
) O 0 6.195265456199195e-08
, O 0 1.4935263692450462e-08
that O 0 1.9300074427519576e-08
abolish O 0 3.630206492744037e-06
Hex O 0 9.4009546955931e-06
A O 0 2.3126776795834303e-06
enzyme O 0 6.88250656821765e-05
activity O 0 8.546230674255639e-05
cause O 1 0.8950015902519226
Tay B-Disease 1 0.9986556768417358
- I-Disease 1 0.9880017638206482
Sachs I-Disease 1 0.9980171918869019
disease I-Disease 1 0.9988223910331726
( O 0 5.463792331283912e-05
TSD B-Disease 1 0.6759025454521179
) O 0 1.3662090623256518e-06
, O 0 4.6330538339134364e-07
the O 0 3.819302037300076e-06
fatal O 1 0.9605982899665833
infantile B-Disease 0 0.28049135208129883
form I-Disease 0 1.3427749081529328e-06
of I-Disease 0 4.5293302264326485e-07
G I-Disease 0 0.0010524442186579108
( I-Disease 0 6.647381724178558e-06
M2 I-Disease 0 0.0020988998003304005
) I-Disease 0 1.3848044773112633e-06
gangliosidosis I-Disease 0 0.00014704398927278817
, I-Disease 0 5.671124654327286e-07
Type I-Disease 0 4.20636533817742e-05
1 I-Disease 0 5.591884018940618e-06
. O 0 6.759000370948343e-06

Less O 0 0.002073145704343915
severe O 1 0.9948787689208984
, O 0 0.0002516700769774616
subacute O 1 0.9953299760818481
( O 0 0.0009655129979364574
juvenile O 1 0.996300458908081
- O 0 0.1612187922000885
onset O 1 0.9967677593231201
) O 0 2.555305945861619e-05
and O 0 3.02363059745403e-05
chronic O 1 0.9994814991950989
( O 0 4.197885937173851e-05
adult O 0 0.00025220715906471014
- O 0 0.0017925807042047381
onset O 1 0.859250545501709
) O 0 9.90347757579002e-07
variants O 0 1.3523231245926581e-06
are O 0 1.96236094041069e-08
characterized O 0 9.512440556136426e-06
by O 0 9.76948797415389e-08
a O 0 7.755115234431287e-07
broad O 0 7.86049167800229e-06
spectrum O 0 8.278540917672217e-06
of O 0 6.606546207876818e-07
clinical O 0 0.001941341906785965
manifestations O 0 0.0001757162535795942
and O 0 1.2450045971945656e-07
are O 0 1.6298141503057195e-08
associated O 0 5.012813630855817e-07
with O 0 2.0748304052631283e-07
residual O 0 3.4915803553303704e-05
levels O 0 1.5554887795588002e-06
of O 0 6.158695242675094e-08
Hex O 0 2.220260830654297e-05
A O 0 6.317290626611793e-06
enzyme O 0 3.9772286982042715e-05
activity O 0 1.410594086337369e-05
. O 0 1.4061308320378885e-05

We O 0 1.8755738437903346e-06
identified O 0 6.160931661725044e-06
a O 0 8.145034371409565e-06
1422 O 0 0.01610499620437622
G O 0 0.0014109615003690124
- O 0 3.968314194935374e-05
- O 0 5.329451596480794e-06
> O 0 4.3169343371118885e-06
C O 0 1.7489441006546258e-06
( O 0 4.772479300640953e-08
amino O 0 1.0488409429854073e-07
acid O 0 5.467425125971204e-06
W474C O 0 2.6103223262907704e-06
) O 0 1.274268424111824e-08
substitution O 0 3.106607593394983e-08
in O 0 2.898261186601303e-09
the O 0 2.8282893804743026e-09
first O 0 3.211149790516288e-09
position O 0 6.9991226148147234e-09
of O 0 3.893815492261865e-09
exon O 0 3.4552208489913028e-06
13 O 0 1.277693115753209e-07
of O 0 5.212650577846034e-08
HEXA O 0 0.0004206962476018816
of O 0 6.446064304554966e-08
a O 0 1.399848542860127e-06
non O 0 4.001161869382486e-06
- O 0 7.955263754411135e-06
Jewish O 0 1.5320728152801166e-06
proband O 0 0.0001931080041686073
who O 0 2.9893933515268145e-06
manifested O 0 0.00016484869411215186
a O 0 1.5490313671762124e-05
subacute O 1 0.9687820076942444
variant O 0 0.0010373974218964577
of O 0 2.1179421310080215e-06
G B-Disease 0 0.00847364030778408
( I-Disease 0 4.03608828491997e-05
M2 I-Disease 0 0.04816905036568642
) I-Disease 0 9.24725736695109e-06
gangliosidosis I-Disease 0 0.0024948592763394117
. O 0 3.131249832222238e-05

On O 0 1.2151477903898922e-06
the O 0 9.257927899852803e-07
second O 0 6.2655412875756156e-06
maternally O 0 0.0015357339289039373
inherited O 0 0.007661326788365841
allele O 0 1.2514029549492989e-05
, O 0 1.8536010770731082e-07
we O 0 8.960694941606562e-08
identified O 0 1.5474648762392462e-06
the O 0 3.205884240742307e-06
common O 0 0.0013234445359557867
infantile O 1 0.9992782473564148
disease O 1 0.9995843768119812
- O 0 0.004687643144279718
causing O 0 0.0011306743836030364
4 O 0 1.3645001672557555e-05
- O 0 1.956984488060698e-05
bp O 0 2.9048067517578602e-05
insertion O 0 1.0934460988210049e-05
, O 0 1.214505914504116e-06
+ O 0 9.589031833456829e-05
TATC O 0 0.0017718245508149266
1278 O 0 0.0020500761456787586
, O 0 4.244953970555798e-07
in O 0 4.43025214735826e-07
exon O 0 0.00010338467836845666
11 O 0 1.5496209016419016e-05
. O 0 1.0791293789225165e-05

Pulse O 0 0.0017419519135728478
- O 0 9.78180396487005e-05
chase O 0 3.801334969466552e-05
analysis O 0 1.9091019112238428e-06
using O 0 2.4523510546714533e-06
proband O 0 0.0014262822223827243
fibroblasts O 0 0.0001622410782147199
revealed O 0 7.880983503127936e-06
that O 0 6.933750995585797e-08
the O 0 1.3046664548710396e-07
W474C O 0 1.1314891708025243e-05
- O 0 8.356922194252547e-07
containing O 0 2.494335546998627e-07
alpha O 0 1.1913186881429283e-06
- O 0 5.6661940561753e-07
subunit O 0 3.412976639083354e-07
precursor O 0 3.6983153677283553e-06
was O 0 2.611529623663955e-07
normally O 0 1.8338273832796403e-07
synthesized O 0 4.835961817661882e-07
, O 0 1.5072712855612735e-08
but O 0 1.0308795594937692e-08
not O 0 4.926770991175999e-09
phosphorylated O 0 6.166488901726552e-07
or O 0 1.0984780374201364e-07
secreted O 0 6.335689022307633e-07
, O 0 2.2597278714897584e-08
and O 0 1.8351109076775174e-08
the O 0 1.3722008418426412e-07
mature O 0 9.784219400899019e-06
lysosomal O 0 0.0013237231178209186
alpha O 0 1.3800313354295213e-05
- O 0 3.7846969007659936e-06
subunit O 0 1.878418061096454e-06
was O 0 1.508120249127387e-06
not O 0 3.8710544458808727e-07
detected O 0 9.333735943073407e-05
. O 0 1.2924851034767926e-05

When O 0 6.130712790763937e-06
the O 0 1.0173342843700084e-06
W474C O 0 3.508814552333206e-05
- O 0 2.4552316517656436e-06
containing O 0 5.445743340715126e-07
alpha O 0 2.9369266485446133e-06
- O 0 9.785449037735816e-07
subunit O 0 1.289053898290149e-06
was O 0 2.220799387941952e-06
transiently O 0 0.00014901740360073745
co O 0 8.971544048108626e-06
- O 0 6.594108299395884e-07
expressed O 0 4.2003787115163504e-08
with O 0 8.775986160003413e-09
the O 0 2.1805663052987256e-08
beta O 0 1.2896293810626958e-06
- O 0 1.621518777028541e-07
subunit O 0 4.5928359782010375e-08
to O 0 7.3106862785721205e-09
produce O 0 7.475725283256907e-08
Hex O 0 2.0536260763037717e-06
A O 0 2.686448965505406e-07
( O 0 1.6030664085064927e-07
alphabeta O 0 1.720520231174305e-05
) O 0 2.0490587360200152e-07
in O 0 2.661156202066195e-07
COS O 0 0.0030195037834346294
- O 0 2.520813495721086e-06
7 O 0 3.0389642802219896e-07
cells O 0 1.8445759053520305e-07
, O 0 5.452502005454107e-09
the O 0 1.9646678950380192e-08
mature O 0 8.077220172708621e-07
alpha O 0 9.491312766840565e-07
- O 0 3.191015593984048e-07
subunit O 0 2.2790834464103682e-07
was O 0 9.370545228648552e-08
present O 0 4.179336698939551e-08
, O 0 8.996139833072903e-09
but O 0 5.937903058139682e-09
its O 0 5.369259703513762e-09
level O 0 8.672009954580062e-08
was O 0 6.822686771101871e-08
much O 0 1.921757153411363e-08
lower O 0 3.018174652424932e-07
than O 0 4.098139605446249e-09
that O 0 5.024173077572414e-09
from O 0 1.8108622157342324e-08
normal O 0 1.7959756348773226e-07
alpha O 0 6.98596011261543e-07
- O 0 5.094503308100684e-07
subunit O 0 6.05102002282365e-07
transfections O 0 1.4677349099656567e-05
, O 0 2.9062890760656046e-08
although O 0 4.933261976702852e-08
higher O 0 9.813263091018598e-08
than O 0 1.4004206683182474e-08
in O 0 3.065984444106107e-08
those O 0 5.135576230941297e-08
cells O 0 1.7648850416662754e-06
transfected O 0 7.4135141403530724e-06
with O 0 2.1729725574459735e-08
an O 0 7.00569628975245e-08
alpha O 0 1.6365213468816364e-06
- O 0 2.3231909835885745e-06
subunit O 0 2.321319470866001e-06
associated O 0 7.491778433177387e-06
with O 0 1.550933848193381e-05
infantile O 1 0.9914988875389099
TSD B-Disease 1 0.9884310960769653
. O 0 0.0001294188987230882

Furthermore O 0 2.4162216504919343e-05
, O 0 3.600962656946649e-07
the O 0 1.6458780294215103e-07
precursor O 0 3.676221695059212e-06
level O 0 1.9234994397265837e-07
of O 0 1.3852250013712819e-08
the O 0 6.53635652270168e-08
W474C O 0 8.217446520575322e-06
alpha O 0 1.3300972341312445e-06
- O 0 2.0293896341172513e-07
subunit O 0 1.920543013511633e-07
was O 0 6.777809602453999e-08
found O 0 3.054060115914581e-08
to O 0 8.075262236673098e-09
accumulate O 0 7.225681315503607e-07
in O 0 5.680226067283911e-09
comparison O 0 5.9378717054414665e-08
to O 0 3.6036229555946875e-09
the O 0 1.4798528624737628e-08
normal O 0 4.795304562321689e-07
alpha O 0 1.6490090501974919e-06
- O 0 2.025651383519289e-06
subunit O 0 3.291861730758683e-06
precursor O 0 5.035821595811285e-05
levels O 0 2.5477529561612755e-05
. O 0 7.87071530794492e-06

We O 0 1.8394234757579397e-06
conclude O 0 7.445745268341852e-06
that O 0 2.0620480256638984e-07
the O 0 1.85393480478524e-06
1422 O 0 0.013956458307802677
G O 0 0.001135944970883429
- O 0 6.576973828487098e-05
- O 0 8.650632480566856e-06
> O 0 1.0672593816707376e-05
C O 0 5.567279004026204e-06
mutation O 0 8.2065469086956e-07
is O 0 3.0746281964866284e-08
the O 0 4.577863066401733e-08
cause O 0 1.91202457244799e-06
of O 0 6.722242318346616e-08
Hex B-Disease 0 0.00015949651424307376
A I-Disease 0 0.0002866173454094678
enzyme I-Disease 1 0.950717568397522
deficiency I-Disease 1 0.9997417330741882
in O 0 3.129972355964128e-06
the O 0 5.712694473913871e-06
proband O 0 0.009260905906558037
. O 0 3.808545079664327e-05

The O 0 1.1530179108376615e-05
resulting O 0 8.316506864503026e-05
W474C O 0 0.00025426768115721643
substitution O 0 1.53864730236819e-05
clearly O 0 5.949547812633682e-06
interferes O 0 1.3094087080389727e-05
with O 0 2.5098842115767184e-07
alpha O 0 2.5320025542896474e-06
- O 0 5.788854195998283e-07
subunit O 0 2.5225349986612855e-07
processing O 0 2.3197142695607909e-07
, O 0 2.650115860092228e-08
but O 0 1.1532230281829925e-08
because O 0 1.4523847013947488e-08
the O 0 1.5546872234040165e-08
base O 0 8.02530237820065e-08
substitution O 0 2.0039682624428679e-07
falls O 0 3.824714440270327e-06
at O 0 1.8138349489049688e-08
the O 0 2.5323818597655645e-09
first O 0 2.4068389503639764e-09
position O 0 5.412692072326308e-09
of O 0 6.139212693767604e-09
exon O 0 4.348038601165172e-06
13 O 0 2.655044397670281e-07
, O 0 5.874517228221521e-08
aberrant O 0 6.783235221519135e-06
splicing O 0 2.5988836114265723e-06
may O 0 4.0958994418360817e-07
also O 0 4.6678859888515944e-08
contribute O 0 1.7045847755525756e-07
to O 0 1.064622452418007e-07
Hex B-Disease 0 5.519554906641133e-05
A I-Disease 0 0.00028973404550924897
deficiency I-Disease 1 0.9993446469306946
in O 0 5.755687197961379e-07
this O 0 9.477835192228667e-07
proband O 0 0.0016335105756297708
. O 0 3.794468966589193e-06
. O 0 9.83989502856275e-06

Two O 0 6.202707027114229e-06
frequent O 0 0.0002060372498817742
missense O 0 0.007939567789435387
mutations O 0 0.0061900620348751545
in O 0 0.00231947866268456
Pendred B-Disease 1 0.9987444877624512
syndrome I-Disease 1 0.9998899698257446
. O 0 0.0007584625855088234

Pendred B-Disease 1 0.9965576529502869
syndrome I-Disease 1 0.999842643737793
is O 0 0.001096857013180852
an O 0 0.05475875735282898
autosomal B-Disease 1 0.9997920393943787
recessive I-Disease 1 0.9999101161956787
disorder I-Disease 1 0.9999799728393555
characterized O 1 0.9956297874450684
by O 0 0.0018340260721743107
early O 0 0.4048597812652588
childhood O 1 0.9980169534683228
deafness B-Disease 1 0.9998711347579956
and O 0 0.07058130204677582
goiter B-Disease 1 0.9997040629386902
. O 0 0.001708056777715683

A O 0 1.325553694186965e-05
century O 0 3.7161023556109285e-06
after O 0 1.6100786979222903e-06
its O 0 2.752678085471416e-07
recognition O 0 1.7437448605051031e-06
as O 0 2.5144076971628238e-06
a O 0 0.00040941991028375924
syndrome O 1 0.9995661377906799
by O 0 2.5418228233320406e-06
Vaughan O 0 0.0002780980139505118
Pendred O 0 0.0024480505380779505
, O 0 1.71124793268973e-06
the O 0 1.4128300790616777e-05
disease O 1 0.9964901804924011
gene O 0 4.297153282095678e-05
( O 0 8.917521881812718e-06
PDS O 0 0.01766391471028328
) O 0 4.6585739710280905e-07
was O 0 6.165853960737877e-07
mapped O 0 1.9832402813335648e-06
to O 0 2.172687061374745e-07
chromosome O 0 4.430569242686033e-05
7q22 O 0 0.0010387023212388158
- O 0 0.00034386012703180313
q31 O 0 0.0006003992748446763
. O 0 2.4559563826187514e-05

1 O 0 1.0091970580106135e-05
and O 0 9.86958184512332e-07
, O 0 7.14994996542373e-07
recently O 0 2.683944330783561e-06
, O 0 3.809817883393407e-08
found O 0 3.547755511590367e-08
to O 0 6.968112753469313e-09
encode O 0 1.465391079591427e-07
a O 0 1.5523485217272537e-06
putative O 0 0.0003257835051044822
sulfate O 0 0.4225897789001465
transporter O 0 0.0961829349398613
. O 0 7.268189801834524e-05

We O 0 1.3445763897834695e-06
performed O 0 1.2257744401722448e-06
mutation O 0 1.4265000345403678e-06
analysis O 0 8.770167880811641e-08
of O 0 5.380672618571225e-08
the O 0 1.0507648084967514e-06
PDS B-Disease 0 0.03784586489200592
gene O 0 1.4222986465028953e-05
in O 0 1.1313717322991579e-06
patients O 0 0.00044602551497519016
from O 0 8.958222679211758e-07
14 O 0 3.7268844153004466e-06
Pendred B-Disease 0 0.0003697536594700068
families O 0 2.8679582442237006e-07
originating O 0 4.547456455838983e-07
from O 0 6.441761968289939e-08
seven O 0 4.9161378967710334e-08
countries O 0 1.4251816615740154e-08
and O 0 4.280790122379585e-08
identified O 0 6.887465815452742e-07
all O 0 1.3475941784690804e-07
mutations O 0 3.725741044036113e-05
. O 0 8.966745554062072e-06

The O 0 1.920694558066316e-06
mutations O 0 3.6156777696305653e-06
include O 0 1.2710042085473106e-07
three O 0 4.1506350356712574e-08
single O 0 1.0836776453970742e-07
base O 0 2.569227888216119e-07
deletions O 0 1.1931741710213828e-06
, O 0 1.428591822616454e-08
one O 0 2.2516266184879896e-08
splice O 0 5.3880326049693394e-06
site O 0 9.467735821999668e-07
mutation O 0 2.4343462428078055e-06
and O 0 1.09061367936647e-07
10 O 0 2.010715661526774e-06
missense O 0 0.00031342098372988403
mutations O 0 0.00016250304179266095
. O 0 2.2567750420421362e-05

One O 0 1.624728065507952e-05
missense O 0 0.0004316031117923558
mutation O 0 5.528103429242037e-05
( O 0 2.454639343341114e-06
L236P O 0 6.653500895481557e-05
) O 0 4.323261180161353e-07
was O 0 4.981322945241118e-07
found O 0 6.951283637590677e-08
in O 0 2.2651866160572354e-08
a O 0 1.4817459259575116e-07
homozygous O 0 1.336746663582744e-06
state O 0 6.31698640063405e-08
in O 0 4.513806217687488e-08
two O 0 4.241428896989419e-08
consanguineous O 0 8.8599139417056e-05
families O 0 1.6914873413043097e-07
and O 0 1.7804596907922132e-08
in O 0 1.0496651547953206e-08
a O 0 4.5747299282083986e-08
heterozygous O 0 3.038512375042046e-07
state O 0 1.55716524119498e-08
in O 0 1.187116893675011e-08
five O 0 4.025167044119371e-08
additional O 0 2.8359460202409537e-07
non O 0 1.1742147762561217e-05
- O 0 8.655789133626968e-05
consanguineous O 0 0.0008720720652490854
families O 0 1.6483001672895625e-05
. O 0 2.3775945010129362e-05

Another O 0 4.725000690086745e-05
missense O 0 0.00041183235589414835
mutation O 0 3.789340553339571e-05
( O 0 3.7212907955108676e-06
T416P O 0 6.210916035342962e-05
) O 0 2.8180659228382865e-07
was O 0 2.446615781082073e-07
found O 0 4.6339287962382514e-08
in O 0 1.637969759826774e-08
a O 0 7.041759886305954e-08
homozygous O 0 6.728386665599828e-07
state O 0 2.1778978620545786e-08
in O 0 1.4350998611689647e-08
one O 0 8.09773492704835e-09
family O 0 8.933186990134345e-08
and O 0 8.50854142697699e-09
in O 0 1.2938958349195673e-08
a O 0 6.597090163040775e-08
heterozygous O 0 3.3499108553769474e-07
state O 0 2.9867745610090424e-08
in O 0 8.217465818916025e-08
four O 0 3.2588221188234456e-07
families O 0 3.721326493177912e-06
. O 0 1.0115586519532371e-05

Pendred B-Disease 1 0.8138430714607239
patients O 0 0.010844028554856777
in O 0 1.2024188436043914e-06
three O 0 1.3740881286139484e-06
non O 0 3.759315222851001e-05
- O 0 7.101073424564674e-05
consanguineous O 0 0.0004882800276391208
families O 0 6.029067662893794e-07
were O 0 6.702769184130375e-08
shown O 0 1.7339280589112605e-07
to O 0 1.7529700357954425e-08
be O 0 5.0586287159148924e-08
compound O 0 5.982336460874649e-06
heterozygotes O 0 5.947671888861805e-05
for O 0 6.494204853879637e-07
L236P O 0 0.0002258948516100645
and O 0 3.5326211218489334e-06
T416P O 0 0.0008498515817336738
. O 0 2.871990182029549e-05

In O 0 8.522201824234799e-07
total O 0 3.2091128332467633e-07
, O 0 4.0963207936783874e-08
one O 0 1.2615817723826694e-08
or O 0 1.2187317821599208e-08
both O 0 2.151468558864167e-09
of O 0 3.3473568361586103e-09
these O 0 1.4369760492627393e-08
mutations O 0 4.383309146760439e-07
were O 0 1.2693464945812138e-08
found O 0 2.9407944523995866e-08
in O 0 3.755560751272924e-09
nine O 0 9.58818535679029e-09
of O 0 5.765001809265868e-09
the O 0 9.317648164142156e-08
14 O 0 9.35034961457859e-07
families O 0 1.0421641718494357e-06
analyzed O 0 1.2352360499789938e-05
. O 0 1.0377802937000524e-05

The O 0 4.0174592186303926e-07
identification O 0 1.572837078356315e-07
of O 0 4.0654200006429164e-08
two O 0 1.2384110448238062e-07
frequent O 0 2.1147283405298367e-05
PDS B-Disease 0 0.01953945681452751
mutations O 0 2.865261876650038e-06
will O 0 2.529148979135698e-08
facilitate O 0 2.6265308861184167e-07
the O 0 1.0012976190409972e-06
molecular O 0 0.00032739571179263294
diagnosis O 1 0.9868141412734985
of O 0 0.00044458714546635747
Pendred B-Disease 1 0.9988473653793335
syndrome I-Disease 1 0.9998747110366821
. O 0 0.0013630682369694114

Insertional O 0 0.0036825670395046473
mutation O 0 8.164675091393292e-05
by O 0 1.9780552520387573e-06
transposable O 0 0.00017469917656853795
element O 0 7.297242518689018e-06
, O 0 1.0155962399949203e-06
L1 O 0 0.0003003433521371335
, O 0 2.0777609677224973e-07
in O 0 2.57303355510885e-07
the O 0 2.696572209970327e-06
DMD B-Disease 1 0.9932907819747925
gene O 0 2.0997569663450122e-05
results O 0 6.05168816036894e-06
in O 0 8.291924132208806e-06
X B-Disease 0 0.13641402125358582
- I-Disease 0 0.04159073531627655
linked I-Disease 0 0.19703613221645355
dilated I-Disease 1 0.9936121106147766
cardiomyopathy I-Disease 1 0.9992892742156982
. O 0 0.0008939487743191421

X B-Disease 1 0.6927566528320312
- I-Disease 0 0.48535600304603577
linked I-Disease 0 0.43647143244743347
dilated I-Disease 1 0.9935445785522461
cardiomyopathy I-Disease 1 0.9996638298034668
( O 0 0.00014836620539426804
XLDCM B-Disease 0 0.02804916724562645
) O 0 9.55647237788071e-07
is O 0 3.2424787832496804e-07
a O 0 1.5813980098755565e-06
clinical O 0 7.836716395104304e-05
phenotype O 0 5.727617462980561e-05
of O 0 3.132412871309498e-07
dystrophinopathy B-Disease 0 0.0034057688899338245
which O 0 7.131916959224327e-07
is O 0 7.211617116809066e-07
characterized O 0 0.0002979695564135909
by O 0 5.048564162279945e-06
preferential O 0 0.006479920353740454
myocardial B-Disease 1 0.9993769526481628
involvement I-Disease 0 0.00012976748985238373
without O 0 2.7571020382310962e-06
any O 0 1.7125704516729456e-06
overt O 0 0.00043527543311938643
clinical O 0 0.010756751522421837
signs O 0 0.014099745079874992
of O 0 0.0003090284881182015
skeletal B-Disease 1 0.999482274055481
myopathy I-Disease 1 0.9995529055595398
. O 0 0.004765076097100973

To O 0 4.4362388962326804e-07
date O 0 8.66934499299532e-07
, O 0 1.4812992787938128e-07
several O 0 2.2694253232202755e-07
mutations O 0 1.018444982037181e-05
in O 0 2.3224488359119277e-06
the O 0 0.00034005046472884715
Duchenne B-Disease 1 0.9992409944534302
muscular I-Disease 1 0.9994495511054993
dystrophy I-Disease 1 0.9995133876800537
gene O 0 0.002823842456564307
, O 0 8.286267257062718e-05
DMD O 1 0.9992350339889526
, O 0 7.066232683428098e-07
have O 0 9.113235677205012e-08
been O 0 9.455087734977496e-08
identified O 0 6.440988045142149e-07
in O 0 5.254406119092891e-07
patients O 0 0.000550530559848994
with O 0 1.0588969416858163e-06
XLDCM B-Disease 0 0.010105624794960022
, O 0 1.0695458030340887e-07
but O 0 3.775211965262315e-08
a O 0 9.911039455801074e-08
pathogenic O 0 8.328772764798487e-07
correlation O 0 1.4742261100764154e-07
of O 0 2.444084934438706e-08
these O 0 1.5115558937850437e-07
cardiospecific O 0 0.0009749026503413916
mutations O 0 3.5979068343294784e-05
in O 0 4.36681330029387e-06
DMD O 1 0.9971073269844055
with O 0 9.347978107143717e-07
the O 0 6.359428880386986e-06
XLDCM B-Disease 1 0.5180899500846863
phenotype O 0 0.0015904715983197093
has O 0 8.618137599114561e-07
remained O 0 3.6759377053385833e-06
to O 0 1.4180184848555655e-07
be O 0 5.243252871878212e-07
elucidated O 0 0.00046147979446686804
. O 0 1.634370710235089e-05

We O 0 1.3476021649694303e-06
report O 0 1.0756336905615171e-06
here O 0 5.645697953582385e-08
the O 0 1.1385361098348312e-08
identification O 0 3.2069095823317184e-08
of O 0 4.049336421729777e-09
a O 0 9.532462996730828e-08
unique O 0 1.4695139327614015e-07
de O 0 1.3641324585478287e-06
novo O 0 5.043799774284707e-06
L1 O 0 4.596124199451879e-05
insertion O 0 6.398562618414871e-06
in O 0 1.9176238197360362e-07
the O 0 4.324118663134868e-07
muscle O 0 0.0006583904614672065
exon O 0 6.0281668993411586e-05
1 O 0 3.087679942836985e-06
in O 0 1.8150933556171367e-06
DMD O 1 0.9955706000328064
in O 0 7.326560762521694e-07
three O 0 1.5362469412139035e-06
XLDCM B-Disease 1 0.8164736032485962
patients O 0 0.0010490847053006291
from O 0 5.495027721735823e-07
two O 0 3.27058785387635e-07
unrelated O 0 0.0001705181202851236
Japanese O 0 0.00023998550022952259
families O 0 2.5476410883129574e-05
. O 0 4.1983028495451435e-05

The O 0 1.3254714303911896e-06
insertion O 0 1.2636025530810002e-05
was O 0 1.0387290103608393e-06
a O 0 6.790249926780234e-07
5 O 0 7.498059062527318e-07
- O 0 9.223629717780568e-07
truncated O 0 1.284273366763955e-06
form O 0 2.997338199861588e-08
of O 0 1.338783128801424e-08
human O 0 5.9731416968134e-07
L1 O 0 7.117853238014504e-05
inversely O 0 1.3820483673043782e-06
integrated O 0 8.555785484531953e-07
in O 0 3.3960663614607256e-08
the O 0 8.600290613003381e-08
5 O 0 9.458584031563078e-07
- O 0 4.125208306504646e-06
untranslated O 0 9.855062671704218e-06
region O 0 1.7085754677736986e-07
in O 0 2.8717781930254205e-08
the O 0 3.1829432600716245e-07
muscle O 0 0.0002853054029401392
exon O 0 3.362403731443919e-05
1 O 0 6.324593755380192e-07
, O 0 4.04841955514712e-08
which O 0 1.807859817404278e-08
affected O 0 1.147059265349526e-07
the O 0 1.0257956262194057e-08
transcription O 0 3.435043822719308e-07
or O 0 3.999506503760131e-08
the O 0 3.979069163051463e-08
stability O 0 2.2831015655810916e-07
of O 0 1.4391127400870118e-08
the O 0 3.1127763122640317e-07
muscle O 0 0.00027498352574184537
form O 0 2.853215619325056e-07
of O 0 2.2653082965007343e-07
dystrophin O 0 0.003900421317666769
transcripts O 0 2.953520606752136e-06
but O 0 3.844285956233762e-08
not O 0 3.5149254618005443e-09
that O 0 2.8966307130673385e-09
of O 0 1.6110352163423158e-08
the O 0 9.811687959881965e-07
brain O 0 0.0216685701161623
or O 0 3.8036935166019248e-06
Purkinje O 0 0.03186021000146866
cell O 0 6.503635086119175e-05
form O 0 7.531440928687516e-07
, O 0 1.9682840957102599e-07
probably O 0 7.554841658929945e-07
due O 0 2.9093297371218796e-07
to O 0 4.525847696612573e-09
its O 0 7.885220476566701e-09
unique O 0 4.784893548048785e-08
site O 0 3.238183126086369e-07
of O 0 6.35066754739455e-08
integration O 0 1.0419124919280875e-05
. O 0 1.507837532699341e-05

We O 0 2.0300335563661065e-06
speculate O 0 5.198043709242484e-06
that O 0 2.417417199751526e-08
this O 0 1.144883921000428e-08
insertion O 0 5.534240017368575e-07
of O 0 1.5006763831593162e-08
an O 0 1.6982663453291025e-07
L1 O 0 0.00017484599084127694
sequence O 0 2.676598342077341e-06
in O 0 2.9868315323255956e-06
DMD O 1 0.9978519678115845
is O 0 1.6787787160410517e-07
responsible O 0 8.874071966147312e-08
for O 0 2.664463094603775e-09
some O 0 1.5242467288345551e-09
of O 0 2.41489983565657e-09
the O 0 2.0343730255945047e-08
population O 0 3.9696693932000926e-08
of O 0 1.1598655191846774e-07
Japanese O 0 0.0002560362045187503
patients O 0 0.004905396606773138
with O 0 3.848699179798132e-06
XLDCM B-Disease 0 0.32797253131866455
. O 0 4.050686129630776e-06
. O 0 1.363882256555371e-05

Severe O 1 0.9900650382041931
early O 0 0.13124337792396545
- O 1 0.9890778064727783
onset O 1 0.9991180300712585
obesity B-Disease 1 0.9995438456535339
, O 0 0.008729660883545876
adrenal B-Disease 1 0.9982312321662903
insufficiency I-Disease 1 0.9992530941963196
and O 0 0.0007459926418960094
red O 1 0.9936559200286865
hair O 1 0.997136116027832
pigmentation O 1 0.9941436648368835
caused O 0 0.0674932524561882
by O 0 4.588236697600223e-05
POMC O 1 0.9872790575027466
mutations O 0 0.0003968074161093682
in O 0 6.292980742728105e-06
humans O 0 0.000106774277810473
. O 0 3.435225517023355e-05

Sequential O 0 1.7252799807465635e-05
cleavage O 0 5.5220923968590796e-05
of O 0 9.906730724651425e-08
the O 0 6.173868314363062e-07
precursor O 0 2.337196383450646e-05
protein O 0 7.034395821392536e-06
pre O 0 8.736942982068285e-05
- O 0 3.400279092602432e-05
pro O 0 2.6855605028686114e-05
- O 0 1.9319104467285797e-05
opiomelanocortin O 0 9.900287841446698e-05
( O 0 3.255416459069238e-06
POMC O 0 0.0014275263529270887
) O 0 2.4341784410353284e-07
generates O 0 1.2277070027266745e-06
the O 0 1.3814487829222344e-06
melanocortin O 0 0.00434175506234169
peptides O 0 5.221595347393304e-05
adrenocorticotrophin O 0 0.0008328991825692356
( O 0 6.030750682839425e-06
ACTH O 0 0.0030624151695519686
) O 0 1.4020262142366846e-06
, O 0 1.756234837557713e-06
melanocyte O 0 0.01305382326245308
- O 0 5.749781121267006e-05
stimulating O 0 8.104796870611608e-05
hormones O 0 9.620125638321042e-05
( O 0 3.151114242427866e-06
MSH O 0 0.020076224580407143
) O 0 2.1977824360419618e-07
alpha O 0 5.580178026320937e-07
, O 0 3.5224033467784466e-08
beta O 0 7.109547937034222e-07
and O 0 1.687574346931342e-08
gamma O 0 4.390128367504076e-07
as O 0 7.780330157913795e-09
well O 0 5.44017186854262e-09
as O 0 1.140076832939485e-08
the O 0 6.942869390513806e-08
opioid O 0 7.961164374137297e-05
- O 0 1.0789236512209754e-05
receptor O 0 1.673720180406235e-05
ligand O 0 3.5851826396537945e-05
beta O 0 0.00042193307308480144
- O 0 0.0003521338221617043
endorphin O 0 0.01652790792286396
. O 0 2.168370338040404e-05

While O 0 6.570833647856489e-06
a O 0 4.299846295907628e-06
few O 0 2.1460693915287266e-06
cases O 0 7.396155979222385e-06
of O 0 5.539316589420196e-06
isolated O 1 0.7836293578147888
ACTH B-Disease 1 0.9985404014587402
deficiency I-Disease 1 0.999616265296936
have O 0 1.5140864206841798e-06
been O 0 2.799793492158642e-06
reported O 0 5.413917824625969e-05
( O 0 1.553484435135033e-05
OMIM O 1 0.7445279359817505
201400 O 0 0.0006169169209897518
) O 0 1.7670979559625266e-06
, O 0 9.364360380459402e-07
an O 0 9.18697605811758e-06
inherited O 1 0.9934669137001038
POMC O 1 0.9978296160697937
defect O 1 0.9943647384643555
has O 0 4.345957677287515e-06
not O 0 2.9558211167568516e-07
been O 0 4.993651714357839e-07
described O 0 5.909562787564937e-06
so O 0 8.114766956168751e-07
far O 0 4.063338110427139e-06
. O 0 1.2344057722657453e-05

Recent O 0 4.225616066833027e-05
studies O 0 7.077468126226449e-06
in O 0 1.379787249788933e-06
animal O 0 1.3263604159874376e-05
models O 0 5.044772024120903e-06
elucidated O 0 4.6138258767314255e-05
a O 0 6.17607042840973e-07
central O 0 6.32093986041582e-07
role O 0 1.30152486121915e-07
of O 0 7.926148271053535e-08
alpha O 0 2.0784953449037857e-05
- O 0 4.021071072202176e-05
MSH O 0 0.004824645817279816
in O 0 1.720832720764065e-08
the O 0 1.283743422675343e-08
regulation O 0 2.48019830451085e-07
of O 0 1.756557921339663e-08
food O 0 5.499232429428957e-07
intake O 0 3.997210114903282e-06
by O 0 4.481944415601902e-08
activation O 0 7.293508588190889e-07
of O 0 5.342772624317149e-08
the O 0 2.2345084289554507e-06
brain O 0 0.01695788837969303
melanocortin O 0 0.008458486758172512
- O 0 9.60282159212511e-06
4 O 0 1.582968820912356e-06
- O 0 4.8331676225643605e-06
receptor O 0 6.182538527355064e-06
( O 0 1.441911877009261e-06
MC4 O 0 0.009574227966368198
- O 0 8.388770766032394e-06
R O 0 1.2273826541786548e-05
; O 0 1.2114458058931632e-07
refs O 0 1.2501469427661505e-05
3 O 0 4.529917703166575e-07
- O 0 6.069971618671843e-07
5 O 0 4.752095961180203e-08
) O 0 9.564767644576477e-09
and O 0 2.890978789693577e-09
the O 0 2.1082675161210318e-08
linkage O 0 2.562704366937396e-06
of O 0 1.1688955936506318e-07
human O 0 1.686309951764997e-05
obesity B-Disease 1 0.9454330205917358
to O 0 1.2118779579850525e-07
chromosome O 0 2.280260559928138e-06
2 O 0 1.478561415524382e-07
in O 0 2.463061399282651e-08
close O 0 1.0464231792184364e-07
proximity O 0 1.775875091425405e-07
to O 0 3.2325857546311454e-08
the O 0 2.567660146723938e-07
POMC O 0 0.0038718432188034058
locus O 0 3.144701850033016e-06
, O 0 4.2809940481447484e-08
led O 0 8.278330909661236e-08
to O 0 4.712721324295899e-09
the O 0 9.96878402048651e-09
proposal O 0 8.517605465385714e-08
of O 0 6.1283085273089455e-09
an O 0 1.8873106455430388e-07
association O 0 6.459352789534023e-06
of O 0 6.639783123318921e-07
POMC O 1 0.9552557468414307
with O 0 1.4132127944321837e-05
human O 0 0.0007260902784764767
obesity B-Disease 1 0.9975481629371643
. O 0 0.0001855840819189325

The O 0 9.169585837298655e-07
dual O 0 2.0847962787229335e-06
role O 0 6.947796578060661e-07
of O 0 2.216516037378824e-07
alpha O 0 8.33147787488997e-05
- O 0 0.0002306652459083125
MSH O 0 0.11846056580543518
in O 0 6.510377374979726e-07
regulating O 0 2.6877229174715467e-05
food O 0 1.522740421933122e-05
intake O 0 9.304552077082917e-05
and O 0 8.908716608857503e-07
influencing O 0 7.340721640503034e-05
hair O 0 0.39078593254089355
pigmentation O 0 0.2514748275279999
predicts O 0 0.000134255678858608
that O 0 8.393489281388611e-08
the O 0 3.909244412625412e-07
phenotype O 0 0.0002745811070781201
associated O 0 2.369291678405716e-06
with O 0 5.965798095530772e-07
a O 0 1.601965050213039e-05
defect O 0 0.499642550945282
in O 0 3.404697054065764e-06
POMC O 0 0.4169405698776245
function O 0 2.3799739210517146e-06
would O 0 9.356273267258075e-07
include O 0 1.2598532521224115e-05
obesity B-Disease 1 0.9970473647117615
, O 0 4.874969363299897e-06
alteration O 0 0.001951123122125864
in O 0 3.4311717172386125e-05
pigmentation O 1 0.9920247793197632
and O 0 0.0006909443181939423
ACTH B-Disease 1 0.9978871941566467
deficiency I-Disease 1 0.9994103908538818
. O 0 0.00018254978931508958

The O 0 1.9528361008269712e-06
observation O 0 9.157769454759546e-06
of O 0 4.4669582166534383e-07
these O 0 2.1957011995255016e-06
symptoms O 1 0.9251648783683777
in O 0 4.086130331870663e-07
two O 0 3.5381975749260164e-07
probands O 0 0.0006819450645707548
prompted O 0 6.528291578433709e-06
us O 0 2.1401208982751996e-07
to O 0 3.967911332836138e-09
search O 0 3.90370011871255e-08
for O 0 2.706222446136053e-08
mutations O 0 9.830552016865113e-07
within O 0 1.0706623498890622e-07
their O 0 5.452140499073721e-07
POMC O 0 0.27652910351753235
genes O 0 3.067693978664465e-05
. O 0 1.3897252756578382e-05

Patient O 0 0.0020546535961329937
1 O 0 4.253757651895285e-06
was O 0 1.399137204316503e-06
found O 0 9.913024712204788e-08
to O 0 5.080420528713603e-09
be O 0 6.22742835076906e-09
a O 0 7.113115430001926e-08
compound O 0 9.661636113378336e-07
heterozygote O 0 4.281747806089697e-06
for O 0 2.3920213365613563e-08
two O 0 4.0584239968666225e-08
mutations O 0 1.2390412393870065e-06
in O 0 1.1184143033915461e-07
exon O 0 1.2162063285359181e-05
3 O 0 1.0175351690122625e-06
( O 0 6.692179113088059e-07
G7013T O 0 1.97838744497858e-05
, O 0 2.3383628899864561e-07
C7133delta O 0 1.934620740939863e-05
) O 0 4.0063248718524846e-08
which O 0 8.15951839427953e-09
interfere O 0 6.694847343169386e-08
with O 0 8.92793661222413e-09
appropriate O 0 4.965329125639073e-08
synthesis O 0 5.009401320421603e-07
of O 0 1.9616167890035285e-07
ACTH O 0 0.005721306893974543
and O 0 2.103758106386522e-06
alpha O 0 0.00021013699006289244
- O 0 0.0012928476789966226
MSH O 1 0.5861021280288696
. O 0 1.9868541130563244e-05

Patient O 0 0.0008444171398878098
2 O 0 4.644291038857773e-06
was O 0 1.7488807770860149e-06
homozygous O 0 1.4367726635100553e-06
for O 0 1.8478079510941825e-08
a O 0 2.3372190582904295e-07
mutation O 0 1.3716268085772754e-06
in O 0 8.338771806393197e-08
exon O 0 9.846100510912947e-06
2 O 0 1.2100722415198106e-06
( O 0 5.190803449295345e-07
C3804A O 0 1.911073923110962e-05
) O 0 4.3353253431632766e-07
which O 0 1.0993306887030485e-06
abolishes O 0 0.001753882970660925
POMC O 0 0.1880446821451187
translation O 0 0.00011461478425189853
. O 0 4.4035943574272096e-05

These O 0 3.613853323258809e-07
findings O 0 9.384403938383912e-07
represent O 0 3.689525485128797e-08
the O 0 1.9864963007876213e-08
first O 0 2.551709421538817e-08
examples O 0 8.332381185027771e-08
of O 0 3.5880351134665034e-08
a O 0 1.089420220523607e-05
genetic B-Disease 0 0.045195966958999634
defect I-Disease 1 0.9776802659034729
within O 0 7.826732257854019e-07
the O 0 1.5855372339501628e-06
POMC O 0 0.10094812512397766
gene O 0 2.4180342279578326e-06
and O 0 1.0308406217518495e-07
define O 0 2.350593604205642e-06
a O 0 5.774403234681813e-06
new O 0 7.66403172747232e-05
monogenic B-Disease 1 0.9966525435447693
endocrine I-Disease 1 0.9991841912269592
disorder I-Disease 1 0.999439537525177
resulting O 0 0.001301773707382381
in O 0 2.1321369786164723e-05
early O 0 0.004102599341422319
- O 1 0.9638161063194275
onset O 1 0.999152421951294
obesity B-Disease 1 0.9995478987693787
, O 0 0.0018806376028805971
adrenal B-Disease 1 0.998969554901123
insufficiency I-Disease 1 0.9993793964385986
and O 0 0.0004989565932191908
red O 1 0.9877333641052246
hair O 1 0.9952567219734192
pigmentation O 1 0.9256678819656372
. O 0 1.0784669939312153e-05
. O 0 2.90278549073264e-05

A O 0 5.68154027860146e-05
European O 0 3.325799843878485e-05
multicenter O 0 0.003565303049981594
study O 0 8.171705303539056e-06
of O 0 7.99600275058765e-06
phenylalanine B-Disease 1 0.9919965863227844
hydroxylase I-Disease 1 0.9965822100639343
deficiency I-Disease 1 0.9999105930328369
: O 0 5.555340976570733e-06
classification O 0 2.7851710910908878e-05
of O 0 8.793114858463014e-08
105 O 0 2.0212746676406823e-06
mutations O 0 2.3004911327006994e-06
and O 0 3.356968392154158e-08
a O 0 1.2612754574092833e-07
general O 0 4.651888048101682e-07
system O 0 9.853349638433428e-07
for O 0 2.0463639316403714e-07
genotype O 0 3.740957981790416e-05
- O 0 3.6604722026822856e-06
based O 0 3.0770573289373715e-07
prediction O 0 1.4533827197737992e-05
of O 0 2.165367732231971e-06
metabolic O 1 0.9558471441268921
phenotype O 0 0.08323585242033005
. O 0 8.784334931988269e-05

Phenylketonuria B-Disease 1 0.9810406565666199
( O 0 0.0014842567034065723
PKU B-Disease 1 0.9917101263999939
) O 0 4.319306026445702e-05
and O 0 2.4640170522616245e-05
mild B-Disease 1 0.9951895475387573
hyperphenylalaninemia I-Disease 1 0.9957275390625
( O 0 0.0011233011027798057
MHP B-Disease 1 0.9974315762519836
) O 0 7.595386250613956e-06
are O 0 1.8469854694558308e-06
allelic B-Disease 1 0.9137614369392395
disorders I-Disease 1 0.9995135068893433
caused O 0 0.011341597884893417
by O 0 7.521506972807401e-07
mutations O 0 3.925273631466553e-06
in O 0 5.635143907056772e-08
the O 0 1.6349179077224107e-07
gene O 0 3.378794644959271e-06
encoding O 0 8.846743185131345e-06
phenylalanine O 0 0.001497823279350996
hydroxylase O 0 0.013704519718885422
( O 0 0.0002657971053849906
PAH O 1 0.9950072765350342
) O 0 1.0136155651707668e-05
. O 0 1.4560325325874146e-05

Previous O 0 1.621427873033099e-05
studies O 0 3.2814052701723995e-06
have O 0 1.771149555906959e-07
suggested O 0 8.810966392047703e-07
that O 0 2.5478334109152456e-08
the O 0 1.514352021558807e-07
highly O 0 6.824021056672791e-06
variable O 0 4.142232864978723e-05
metabolic O 1 0.8274359107017517
phenotypes O 0 0.0789681002497673
of O 0 0.0050868140533566475
PAH B-Disease 1 0.9998452663421631
deficiency I-Disease 1 0.9998094439506531
correlate O 0 0.02654031664133072
with O 0 0.004339381121098995
PAH O 1 0.9988358616828918
genotypes O 0 0.11434773355722427
. O 0 0.0001626079756533727

We O 0 3.3547460134286666e-06
identified O 0 4.25175448981463e-06
both O 0 7.125322554202285e-07
causative O 0 0.0002961473655886948
mutations O 0 7.090112194418907e-05
in O 0 5.844213774253149e-06
686 O 0 0.2028190791606903
patients O 0 0.006566056050360203
from O 0 9.660667501520948e-07
seven O 0 1.5547544762739562e-06
European O 0 7.609574822708964e-06
centers O 0 1.6373864127672277e-05
. O 0 1.2020418580505066e-05

On O 0 3.3736128557393386e-07
the O 0 5.7565333833053955e-08
basis O 0 9.966958813834026e-09
of O 0 7.64632090977102e-09
the O 0 7.552415581812966e-08
phenotypic O 0 4.794577762368135e-06
characteristics O 0 1.1310750096527045e-06
of O 0 7.306451266231306e-07
297 O 0 0.001010341802611947
functionally O 0 0.009428603574633598
hemizygous O 0 0.24810832738876343
patients O 0 0.0006758833769708872
, O 0 3.5208518767149144e-08
105 O 0 7.987414818444449e-08
of O 0 5.6966094064137e-09
the O 0 4.159186062224762e-08
mutations O 0 2.976272241994593e-07
were O 0 2.982259106332208e-09
assigned O 0 1.8448428562578556e-08
to O 0 8.482028412970521e-10
one O 0 1.0746612488787832e-09
of O 0 2.1185453391581177e-09
four O 0 4.1324426547362236e-08
arbitrary O 0 1.3533979199564783e-06
phenotype O 0 0.0003853160887956619
categories O 0 1.479820639360696e-05
. O 0 1.290631371375639e-05

We O 0 9.415887802788347e-07
proposed O 0 1.7633373090575333e-06
and O 0 1.6579390660353965e-07
tested O 0 1.362538455396134e-06
a O 0 7.68337073964176e-08
simple O 0 1.5858230995036138e-07
model O 0 1.9697451136835298e-07
for O 0 1.7722401324249404e-08
correlation O 0 5.725849518967152e-07
between O 0 2.496667832474486e-07
genotype O 0 1.9009405150427483e-05
and O 0 3.778951622734894e-07
phenotypic O 0 5.826802953379229e-05
outcome O 0 5.5232932936633006e-05
. O 0 4.570646342472173e-05

The O 0 4.901363354292698e-06
observed O 0 2.7086318368674256e-05
phenotype O 0 0.0001877028844319284
matched O 0 5.219144895818317e-06
the O 0 6.754656283192162e-07
predicted O 0 2.819624205585569e-05
phenotype O 0 2.5340837964904495e-05
in O 0 6.634125071514063e-08
79 O 0 6.465605224548199e-07
% O 0 2.234394003153284e-08
of O 0 3.180938179525583e-09
the O 0 7.252897660237068e-08
cases O 0 2.6288162757737155e-07
, O 0 2.2751759587436027e-08
and O 0 5.315194506749776e-09
in O 0 6.435803445725696e-09
only O 0 2.7006676894814063e-09
5 O 0 2.5889235644172004e-08
of O 0 3.067446741056301e-08
184 O 0 3.648410347523168e-05
patients O 0 0.0004003102658316493
was O 0 3.8476974850709666e-07
the O 0 4.597831804176167e-08
observed O 0 4.054455473578855e-07
phenotype O 0 4.015653757960536e-06
more O 0 6.221195558708814e-09
than O 0 1.0548854234571081e-08
one O 0 1.3671061616093994e-08
category O 0 3.964498205277778e-07
away O 0 8.048372279745308e-08
from O 0 6.743354674654256e-08
that O 0 9.163329650618834e-08
expected O 0 1.97566100723634e-06
. O 0 4.556404746836051e-06

Among O 0 6.050113938727009e-07
the O 0 2.8277793262532214e-07
seven O 0 5.034833634454117e-07
contributing O 0 2.9690675091842422e-06
centers O 0 6.042698714736616e-07
, O 0 3.98459825134978e-08
the O 0 3.7152155130115716e-08
proportion O 0 4.210513679936412e-07
of O 0 2.3301818430354615e-07
patients O 0 0.0007429558900184929
for O 0 1.2213781985792593e-07
whom O 0 8.912166435948166e-07
the O 0 2.2867492077693896e-07
observed O 0 2.904012035287451e-06
phenotype O 0 6.006820694892667e-05
did O 0 1.686478015017201e-07
not O 0 1.0896505919788524e-08
match O 0 9.808378820252983e-08
the O 0 8.983695209963116e-08
predicted O 0 5.641936240863288e-06
phenotype O 0 9.702627721708268e-06
was O 0 2.307635895704152e-07
4 O 0 2.0576594295107498e-07
% O 0 1.5420641830132809e-07
- O 0 8.360987635569472e-07
23 O 0 1.9769811387959635e-07
% O 0 1.1589256843080875e-07
( O 0 6.373213068400219e-07
P O 0 9.411796781932935e-05
< O 0 3.738949817488901e-05
. O 0 2.773457765670173e-07
0001 O 0 0.0001678525295574218
) O 0 1.1051187698285503e-07
, O 0 5.215355258769705e-08
suggesting O 0 4.923101073472935e-07
that O 0 1.612787770000068e-08
differences O 0 9.691612490314583e-08
in O 0 6.789399709106192e-09
methods O 0 1.6236086253229587e-08
used O 0 1.98310043941774e-08
for O 0 4.4091937212442645e-08
mutation O 0 8.274893843918107e-06
detection O 0 3.763698259717785e-05
or O 0 2.8924750949954614e-06
phenotype O 0 0.001101045636460185
classification O 0 0.00024412944912910461
may O 0 4.3901783897126734e-07
account O 0 3.169813922454523e-08
for O 0 7.614535668665212e-09
a O 0 6.787227135873763e-08
considerable O 0 6.255364723983803e-07
proportion O 0 7.195768603196484e-07
of O 0 3.078848180848581e-07
genotype O 0 0.0038315097335726023
- O 0 0.0012423440348356962
phenotype O 0 0.0024656231980770826
inconsistencies O 0 0.0007261558785103261
. O 0 4.1576950025046244e-05

Our O 0 2.163551243938855e-06
data O 0 1.5217384543575463e-06
indicate O 0 2.6239472390443552e-06
that O 0 3.17020152351688e-07
the O 0 6.908589966769796e-06
PAH O 1 0.9969942569732666
- O 0 9.509410119790118e-06
mutation O 0 1.726995151329902e-06
genotype O 0 2.1576438484771643e-06
is O 0 1.1825767920470298e-08
the O 0 1.7021148934759367e-08
main O 0 2.631422262311389e-07
determinant O 0 3.715581442520488e-06
of O 0 5.059950467511953e-07
metabolic O 1 0.8809832334518433
phenotype O 0 0.014237869530916214
in O 0 7.22743607184384e-06
most O 0 4.614155841409229e-05
patients O 1 0.9900745749473572
with O 0 0.17368033528327942
PAH B-Disease 1 0.9998501539230347
deficiency I-Disease 1 0.9997264742851257
. O 0 0.0004150234744884074

In O 0 7.475040320059634e-07
the O 0 2.2787641285049176e-07
present O 0 3.396957879431284e-07
study O 0 2.3546495242499077e-07
, O 0 3.878725252093318e-08
the O 0 7.10653864643973e-08
classification O 0 1.270331358682597e-05
of O 0 3.0761478342355986e-07
105 O 0 0.0006424203747883439
PAH O 1 0.9987496137619019
mutations O 0 8.8551842054585e-06
may O 0 2.2827640577816055e-07
allow O 0 1.1060420135322602e-08
the O 0 2.190424908121713e-08
prediction O 0 5.400813734013354e-07
of O 0 8.67156035866401e-09
the O 0 1.5927618335354055e-07
biochemical O 0 4.563890979625285e-05
phenotype O 0 4.889497722615488e-05
in O 0 2.785999697607622e-07
> O 0 1.2015295396849979e-05
10 O 0 2.4203518478316255e-07
, O 0 8.625375613746655e-08
000 O 0 1.2829634670197265e-06
genotypes O 0 1.0785225640574936e-05
, O 0 5.4490538303753056e-08
which O 0 2.0677855872008877e-08
may O 0 7.705487092835028e-08
be O 0 1.2796187442987161e-09
useful O 0 1.1285775869396275e-08
for O 0 4.847234613691853e-09
the O 0 8.898733483420074e-08
management O 0 4.78011406812584e-06
of O 0 3.6004095704811334e-07
hyperphenylalaninemia B-Disease 1 0.7521930932998657
in O 0 2.676004260138143e-05
newborns O 0 0.20430250465869904
. O 0 4.9425801989855245e-05

Somatic O 0 0.0003260712546762079
instability O 0 5.3380950703285635e-05
of O 0 3.2848637943061476e-07
the O 0 3.4019610666291555e-06
CTG O 0 0.01295376755297184
repeat O 0 0.00016029205289669335
in O 0 1.9300498479424277e-06
mice O 0 0.0002159774157917127
transgenic O 0 3.817002652795054e-05
for O 0 1.1684269338729791e-06
the O 0 0.0002552431251388043
myotonic B-Disease 1 0.9997887015342712
dystrophy I-Disease 1 0.9998416900634766
region O 0 2.3274944396689534e-05
is O 0 5.824489335282124e-07
age O 0 7.316586561501026e-06
dependent O 0 1.1018444183719112e-06
but O 0 4.285855226271451e-08
not O 0 9.46852907190987e-09
correlated O 0 2.23378094688087e-07
to O 0 1.018286610587893e-08
the O 0 5.8894723764524315e-08
relative O 0 4.087988145329291e-06
intertissue O 0 0.00034324437729083
transcription O 0 7.566446583950892e-05
levels O 0 7.529858703492209e-05
and O 0 6.239907179406146e-06
proliferative O 1 0.9749991297721863
capacities O 0 0.0003435335529502481
. O 0 3.733064659172669e-05

A O 0 3.784343061852269e-05
( O 0 1.3330825822777115e-05
CTG O 0 0.0012593965511769056
) O 0 1.428607561138051e-06
nexpansion O 0 2.6911979148280807e-05
in O 0 1.783167391522511e-07
the O 0 1.8524647771300806e-07
3 O 0 1.7754462078301003e-06
- O 0 8.919018910091836e-06
untranslated O 0 2.073205541819334e-05
region O 0 6.933883014426101e-07
( O 0 2.177092710553552e-07
UTR O 0 9.130909347732086e-06
) O 0 2.316640568267303e-08
of O 0 1.2959904260867461e-08
the O 0 6.872552376080421e-07
DM O 0 0.4473763406276703
protein O 0 4.1473772398603614e-06
kinase O 0 1.766946297721006e-05
gene O 0 4.199135219096206e-06
( O 0 1.3338354847292067e-06
DMPK O 0 0.0003906055062543601
) O 0 4.1438491393819277e-07
is O 0 2.832556731391378e-07
responsible O 0 6.218496764631709e-06
for O 0 1.2618877917702775e-05
causing O 1 0.9911388754844666
myotonic B-Disease 1 0.9995843768119812
dystrophy I-Disease 1 0.999797523021698
( O 0 0.08181916177272797
DM B-Disease 1 0.9989315867424011
) O 0 5.912487176829018e-05
. O 0 4.591450124280527e-05

Major O 0 0.00024113392282743007
instability O 0 0.0005041655385866761
, O 0 3.527116803070385e-07
with O 0 1.773569806573505e-07
very O 0 2.075348959351686e-07
large O 0 3.268059458605421e-07
expansions O 0 2.916657194873551e-06
between O 0 1.0761697666339387e-07
generations O 0 9.089493460123776e-07
and O 0 5.490544552344545e-08
high O 0 7.570088200736791e-07
levels O 0 6.078684577914828e-07
of O 0 3.7983898693028095e-08
somatic O 0 3.061197276110761e-05
mosaicism O 0 0.005537630058825016
, O 0 3.1229990327119594e-07
is O 0 3.0175186793712783e-07
observed O 0 5.6793633120832965e-06
in O 0 1.1037184776796494e-05
patients O 0 0.05505042150616646
. O 0 3.347213350934908e-05

There O 0 1.0005320518757799e-06
is O 0 1.4457823738212028e-07
a O 0 2.1052380816399818e-07
good O 0 2.2767829932490713e-07
correlation O 0 4.863916842623439e-07
between O 0 2.123547346855048e-07
repeat O 0 1.2147365850978531e-05
size O 0 1.1844795153592713e-06
( O 0 1.2087707546015736e-07
at O 0 6.54461516091942e-08
least O 0 3.295123107704967e-08
in O 0 9.109273690910413e-08
leucocytes O 0 0.0001289755164179951
) O 0 3.82233366735818e-07
, O 0 4.4981817381994915e-07
clinical O 0 0.00017576768004801124
severity O 0 0.0033047269098460674
and O 0 6.314613187896612e-07
age O 0 3.499317244859412e-05
of O 0 6.745709015376633e-06
onset O 1 0.9956780076026917
. O 0 0.00027583815972320735

The O 0 0.00026437771157361567
trinucleotide O 1 0.9542607069015503
repeat O 0 0.004211558494716883
instability O 0 0.00042798600043170154
mechanisms O 0 2.3388822228298523e-05
involved O 0 1.4622038179368246e-05
in O 0 1.871551648946479e-05
DM B-Disease 1 0.9988343119621277
and O 0 1.3499264923666487e-06
other O 0 1.0849161071746494e-06
human O 0 0.0005427157157100737
genetic B-Disease 1 0.9981361627578735
diseases I-Disease 1 0.9996839761734009
are O 0 1.8355419797444483e-06
unknown O 0 9.032068192027509e-05
. O 0 3.066053250222467e-05

We O 0 1.87187663414079e-06
studied O 0 9.422980838280637e-06
somatic O 0 7.491721044061705e-05
instability O 0 5.26171425008215e-05
by O 0 2.685823972115031e-07
measuring O 0 1.2046309166180436e-05
the O 0 2.4493779164913576e-06
CTG O 0 0.0031207557767629623
repeat O 0 2.24857940338552e-05
length O 0 1.4487707176158438e-06
at O 0 1.9386301630675007e-07
several O 0 3.051055941227787e-08
ages O 0 7.429668471559125e-07
in O 0 2.5500552780499675e-08
various O 0 2.753031402846773e-08
tissues O 0 9.949553714250214e-06
of O 0 2.3122002801301278e-07
transgenic O 0 0.0001676468236837536
mice O 0 4.851463017985225e-05
carrying O 0 1.2520347354438854e-06
a O 0 1.4918514352757484e-06
( O 0 2.576102588136564e-06
CTG O 0 0.0009392048814333975
) O 0 1.103574390981521e-06
55expansion O 0 9.898420103127137e-05
surrounded O 0 5.353153483156348e-06
by O 0 1.0751049472901286e-07
45 O 0 2.6547888865025016e-07
kb O 0 5.261036676529329e-06
of O 0 7.291972536904723e-08
the O 0 9.188617013933253e-07
human O 0 2.4323147954419255e-05
DM B-Disease 1 0.9977200627326965
region O 0 1.3786416275252122e-06
, O 0 9.389796673531237e-08
using O 0 1.4515433122141985e-07
small O 0 2.634953261804185e-06
- O 0 3.2125968573382124e-05
pool O 0 6.686358392471448e-05
PCR O 0 0.0001173030468635261
. O 0 1.812259324651677e-05

These O 0 1.7703583580441773e-05
mice O 0 0.0007647986640222371
have O 0 3.332236246933462e-07
been O 0 1.3156945044556778e-07
shown O 0 1.2320968778567476e-07
to O 0 2.5570932038476712e-08
reproduce O 0 6.070185918360949e-07
the O 0 1.3841770396538777e-07
intergenerational O 0 1.7056292563211173e-05
and O 0 1.6414919912222103e-07
somatic O 0 9.757392035680823e-06
instability O 0 6.263916475290898e-06
of O 0 2.249922204100585e-08
the O 0 3.038419720269303e-07
55 O 0 1.0130705049959943e-05
CTG O 0 0.0027074762620031834
repeat O 0 2.877821862057317e-05
suggesting O 0 1.5576931673422223e-06
that O 0 2.6210351222744066e-08
surrounding O 0 1.1552048562180062e-07
sequences O 0 1.0627134372498404e-07
and O 0 4.147801746512414e-08
the O 0 1.1592020143780246e-07
chromatin O 0 3.277188807260245e-05
environment O 0 1.6454682736366522e-06
are O 0 2.993093772829525e-08
involved O 0 1.4002237094246084e-06
in O 0 1.2834370863856748e-06
instability O 0 0.0002761913347057998
mechanisms O 0 0.00011055643699364737
. O 0 4.015051672467962e-05

As O 0 1.223021058649465e-06
observed O 0 7.269863431247359e-07
in O 0 4.074463788583671e-08
some O 0 1.3139032972731002e-08
of O 0 2.4053072422702826e-08
the O 0 1.0755875337054022e-06
tissues O 0 0.0005426732823252678
of O 0 2.8482769266702235e-05
DM B-Disease 1 0.9998618364334106
patients O 0 0.3790128529071808
, O 0 2.6039245426545676e-07
there O 0 6.22372553493733e-08
is O 0 3.4159519657350756e-08
a O 0 1.897890911095601e-07
tendency O 0 1.4740322740181e-06
for O 0 5.492942989349103e-08
repeat O 0 7.635053407284431e-06
length O 0 8.474757464682625e-07
and O 0 7.295687254327277e-08
somatic O 0 1.3171814316592645e-05
mosaicism O 0 0.0006110330577939749
to O 0 2.144590816044456e-08
increase O 0 1.1264704369295941e-07
with O 0 1.4692974836805206e-08
the O 0 2.1890381063371933e-08
age O 0 3.92265860682528e-07
of O 0 4.8437623689778775e-08
the O 0 1.6529202184756286e-06
mouse O 0 0.00017158592527266592
. O 0 1.1313186405459419e-05

Furthermore O 0 2.5382512831129134e-05
, O 0 3.5134198128616845e-07
we O 0 4.089560334818998e-08
observed O 0 1.280137524872771e-07
no O 0 3.270883652817247e-08
correlation O 0 1.4070813847411046e-07
between O 0 3.0885814794601174e-08
the O 0 1.6231419408541115e-07
somatic O 0 1.5311879906221293e-05
mutation O 0 1.4122038010100368e-05
rate O 0 7.825441571185365e-06
and O 0 2.9921886834927136e-06
tissue O 0 0.25154343247413635
proliferation O 0 0.013676297850906849
capacity O 0 3.248815846745856e-05
. O 0 1.352619528915966e-05

The O 0 7.849906069168355e-06
somatic O 0 0.00011146756150992587
mutation O 0 6.1014496168354526e-05
rates O 0 5.495444838743424e-06
in O 0 1.1013836598294802e-07
different O 0 6.989385781253077e-08
tissues O 0 2.7654376026475802e-05
were O 0 5.640197997536234e-08
also O 0 2.8110809680015336e-08
not O 0 1.0632137836807942e-08
correlated O 0 3.5422928590378433e-07
to O 0 8.732706113789845e-09
the O 0 5.3797592158844054e-08
relative O 0 1.7425677469873335e-06
inter O 0 5.751991193392314e-05
- O 0 2.971711910504382e-05
tissue O 0 2.4068085622275248e-05
difference O 0 1.391861275124029e-07
in O 0 2.749384542255484e-08
transcriptional O 0 1.0404501153971069e-06
levels O 0 1.9774884663092962e-07
of O 0 3.0926476934922675e-09
the O 0 2.085013228736443e-08
three O 0 1.7557907128207262e-08
genes O 0 3.8647834799121483e-07
( O 0 5.882842515347875e-07
DMAHP O 0 0.00024359000963158906
, O 0 2.6052808266285865e-07
DMPK O 0 0.00011790637654485181
and O 0 1.0328086830213579e-07
59 O 0 1.5979941281329957e-06
) O 0 1.204774946472753e-07
surrounding O 0 9.176697517432331e-07
the O 0 6.47899980776856e-07
repeat O 0 8.477804658468813e-05
. O 0 2.809486431942787e-06
. O 0 8.685004104336258e-06

A O 0 5.712725396733731e-05
novel O 0 7.434047438437119e-05
missense O 0 0.0009845467284321785
mutation O 0 0.0002425887796562165
in O 0 6.998509888944682e-06
patients O 0 0.003235483542084694
from O 0 3.6692936191684566e-06
a O 0 4.7500976506853476e-05
retinoblastoma B-Disease 1 0.9512170553207397
pedigree O 0 0.002290025819092989
showing O 0 1.4975867088651285e-05
only O 0 9.134028573498654e-07
mild O 0 0.00489634508267045
expression O 0 1.7259231981370249e-06
of O 0 8.758647140894027e-07
the O 0 0.00012048178177792579
tumor B-Disease 1 0.9966757297515869
phenotype O 0 0.048954322934150696
. O 0 6.18366539129056e-05

We O 0 7.000405730650527e-07
have O 0 5.782382217489612e-08
used O 0 6.22890397039555e-08
single O 0 1.4764928835120372e-07
strand O 0 2.355171091039665e-06
conformation O 0 1.744478367982083e-06
polymorphism O 0 5.558863449550699e-07
analysis O 0 4.533980302312557e-08
to O 0 6.885854997307206e-09
study O 0 4.592091684685329e-08
the O 0 2.0423975399808114e-08
27 O 0 9.469471962120224e-08
exons O 0 2.770346441138827e-07
of O 0 1.376200131630867e-08
the O 0 4.4229236095816304e-07
RB1 O 0 0.16258391737937927
gene O 0 1.0293252898918581e-06
in O 0 3.703633666418682e-08
individuals O 0 6.547112718635617e-08
from O 0 1.1417637324484531e-07
a O 0 7.681295528527698e-07
family O 0 4.836662810703274e-06
showing O 0 2.9851868021069095e-05
mild O 0 0.00643531559035182
expression O 0 5.876499926671386e-07
of O 0 1.9759086455906072e-07
the O 0 1.611652442079503e-05
retinoblastoma B-Disease 1 0.9888078570365906
phenotype O 0 0.06526090204715729
. O 0 9.700989176053554e-05

In O 0 6.952562671358464e-06
this O 0 2.109011120410287e-06
family O 0 4.805193384527229e-05
affected O 0 5.148957279743627e-05
individuals O 0 5.156097813596716e-06
developed O 0 0.00041010387940332294
unilateral B-Disease 0 0.012291694059967995
tumors I-Disease 1 0.99925297498703
and O 0 2.2419850154165033e-07
, O 0 8.12823799378748e-08
as O 0 3.558829675398556e-08
a O 0 6.909565541945994e-08
result O 0 1.1756379336702594e-07
of O 0 3.223405897756493e-08
linkage O 0 1.0376317732152529e-05
analysis O 0 9.121528137256973e-07
, O 0 1.1866842442032066e-06
unaffected O 0 0.00040483911288902164
mutation O 0 5.2391475037438795e-05
carriers O 0 1.420487660652725e-05
were O 0 4.47699761707554e-08
also O 0 8.679969454306047e-08
identified O 0 4.041237957608246e-07
within O 0 2.3835553975004586e-07
the O 0 1.9706631064764224e-06
pedigree O 0 0.0015611790586262941
. O 0 2.858301013475284e-05

A O 0 1.6978427083813585e-05
single O 0 1.3881285667594057e-06
band O 0 3.8829257391626015e-06
shift O 0 1.3577196114056278e-06
using O 0 4.691651724897383e-07
SSCP O 0 0.0007484482484869659
was O 0 1.0274873147864128e-06
identified O 0 3.5847247659148707e-07
in O 0 3.151156846570302e-08
exon O 0 5.1201163842051756e-06
21 O 0 2.920632766745257e-07
which O 0 1.1045893089089986e-08
resulted O 0 2.869533943794522e-07
in O 0 1.6350542253462663e-08
a O 0 1.0744756906433395e-07
missense O 0 4.867870302405208e-06
mutation O 0 7.332480436161859e-07
converting O 0 2.664711473698844e-07
a O 0 1.938125024025794e-06
cys O 0 0.015055859461426735
- O 0 2.7784964913735166e-05
- O 0 4.6951481635915115e-06
> O 0 7.3593296292528976e-06
arg O 0 3.742541593965143e-06
at O 0 5.9573160626769095e-08
nucleotide O 0 7.778715627182464e-08
position O 0 8.508837368026434e-08
28 O 0 4.095774670531682e-07
in O 0 8.384113669990256e-08
the O 0 4.4074033667129697e-07
exon O 0 0.0001303707540500909
. O 0 1.1217872270208318e-05

The O 0 1.2439140846254304e-05
mutation O 0 7.50135732232593e-05
destroyed O 0 4.7372999688377604e-05
an O 0 2.243825520054088e-06
NdeI O 0 0.0006167381070554256
restriction O 0 3.680349618662149e-05
enzyme O 0 0.00011412902676966041
site O 0 6.103009218350053e-05
. O 0 2.098221557389479e-05

Analysis O 0 8.765499046603509e-07
of O 0 9.344255147425429e-08
all O 0 9.005654533211782e-08
family O 0 1.1137665296701016e-06
members O 0 9.206214457435635e-08
demonstrated O 0 5.091482080388232e-07
that O 0 3.1059023797297414e-08
the O 0 2.3825417372336233e-07
missense O 0 6.0718070017173886e-05
mutation O 0 0.00010562832176219672
co O 0 0.0001837533782236278
- O 0 4.1884970414685085e-05
segregated O 0 4.906293543172069e-05
with O 0 5.188187969906721e-06
patients O 0 0.4706321954727173
with O 0 0.00017124383884947747
tumors B-Disease 1 0.9997987151145935
or O 0 2.239037257822929e-06
who O 0 2.7121706125399214e-07
, O 0 2.5465363151511156e-08
as O 0 1.3259775499818716e-08
a O 0 5.875346431594153e-08
result O 0 1.0145085838075829e-07
of O 0 1.5616445026012116e-08
linkage O 0 1.6458465324831195e-05
analysis O 0 4.796086727765214e-07
had O 0 6.494818762803334e-07
been O 0 1.20175926099364e-07
predicted O 0 8.163567599694943e-07
to O 0 1.3517536423535148e-08
carry O 0 1.3885639305044606e-07
the O 0 7.689761787332827e-07
predisposing O 0 0.0005694198189303279
mutation O 0 0.0002280165790580213
. O 0 2.795111868181266e-05

These O 0 2.081088581462609e-07
observations O 0 4.180182315849379e-07
point O 0 1.8281401992226165e-07
to O 0 2.2165913549088145e-08
another O 0 8.244028038006945e-08
region O 0 8.102651349872758e-08
of O 0 1.7575665367530746e-08
the O 0 6.702168207084469e-07
RB1 O 0 0.1445014625787735
gene O 0 2.0356574168545194e-06
where O 0 1.4324422181744012e-07
mutations O 0 4.4904751916874375e-07
only O 0 1.126899817904814e-08
modify O 0 2.433368422316562e-07
the O 0 9.34013577591486e-09
function O 0 1.3850718794117256e-08
of O 0 2.7034299243666737e-09
the O 0 4.852306290104025e-08
gene O 0 5.691518367711978e-07
and O 0 2.0317592941410112e-08
raise O 0 1.87026742537455e-07
important O 0 1.641820013276174e-08
questions O 0 9.519598620499892e-08
for O 0 1.0361076618892184e-07
genetic O 0 1.1203053873032331e-05
counseling O 0 1.0128232133865822e-05
in O 0 1.147906232290552e-07
families O 0 1.2712004604509275e-07
with O 0 5.9236075600210825e-08
these O 0 1.5707475142789917e-07
distinctive O 0 0.0001064506868715398
phenotypes O 0 0.0012932921526953578
. O 0 6.075953024264891e-06
. O 0 2.1976238713250495e-05

Maternal B-Disease 0 0.041953857988119125
disomy I-Disease 1 0.5429620146751404
and O 0 0.002811033744364977
Prader B-Disease 1 0.9988321661949158
- I-Disease 1 0.9976662397384644
Willi I-Disease 1 0.9994339346885681
syndrome I-Disease 1 0.9996167421340942
consistent O 0 3.626411853474565e-05
with O 0 4.423347036208725e-06
gamete O 0 0.0020667207427322865
complementation O 0 0.00889375526458025
in O 0 2.88912900714422e-07
a O 0 3.395315673060395e-07
case O 0 5.986200903862482e-07
of O 0 1.0206534284407098e-07
familial O 0 0.006156028248369694
translocation O 0 0.000298679166007787
( O 0 1.2698135378741426e-06
3 O 0 4.3856465481439955e-07
; O 0 1.9379129412300244e-07
15 O 0 1.9015379848497105e-07
) O 0 1.8966677828302636e-07
( O 0 3.474030449979182e-07
p25 O 0 6.563666102010757e-05
; O 0 2.7773515398621385e-07
q11 O 0 1.7175758330267854e-05
. O 0 1.2166258045454015e-07
2 O 0 7.646323751941964e-07
) O 0 1.2884984244010411e-06
. O 0 2.287862571392907e-06

Maternal B-Disease 0 0.1026749387383461
uniparental I-Disease 1 0.9768232107162476
disomy I-Disease 0 0.38943347334861755
( I-Disease 0 0.00020290743850637227
UPD I-Disease 1 0.9290699362754822
) I-Disease 0 6.801118956900609e-07
for I-Disease 0 9.020886437838271e-08
chromosome I-Disease 0 2.8354559162835358e-06
15 I-Disease 0 1.0722256860162815e-07
is O 0 1.235975322089189e-08
responsible O 0 2.0319800952961486e-08
for O 0 2.6012916265472086e-09
an O 0 8.531747752726915e-09
estimated O 0 8.082893288019477e-08
30 O 0 1.8044147509499453e-08
% O 0 2.6245571049798855e-08
of O 0 3.8504644805925636e-08
cases O 0 1.1991153769486118e-05
of O 0 4.291821096558124e-05
Prader B-Disease 1 0.9994634985923767
- I-Disease 1 0.9983068704605103
Willi I-Disease 1 0.999582827091217
syndrome I-Disease 1 0.999860405921936
( O 0 0.009751614183187485
PWS B-Disease 1 0.998082160949707
) O 0 6.652675801888108e-05
. O 0 6.869668141007423e-05

We O 0 1.43013699016592e-06
report O 0 1.2663753068409278e-06
on O 0 5.861131668893904e-08
an O 0 5.318077000993071e-08
unusual O 0 6.597278456865752e-07
case O 0 3.199462526026764e-07
of O 0 8.797778150437807e-08
maternal B-Disease 0 0.0003023928147740662
disomy I-Disease 0 0.001077289110980928
15 I-Disease 0 3.895209374604747e-06
in O 0 3.706507186507224e-06
PWS B-Disease 1 0.998235821723938
that O 0 8.662735950792921e-08
is O 0 2.302583546054393e-08
most O 0 1.3054800795941901e-08
consistent O 0 1.282857908790902e-07
with O 0 5.696960059253797e-08
adjacent O 0 1.4463258821706404e-06
- O 0 1.2569602176881745e-06
1 O 0 8.977853838132432e-08
segregation O 0 1.2089752772226348e-06
of O 0 1.3563922429682407e-08
a O 0 1.4376416856975993e-06
paternal O 0 0.00010309788922313601
t O 0 0.00025316409301012754
( O 0 1.5322861202093918e-07
3 O 0 7.980805349916409e-08
; O 0 3.075173538036324e-08
15 O 0 5.516472256772431e-08
) O 0 4.633822570099255e-08
( O 0 1.2373791946629353e-07
p25 O 0 3.447617928031832e-05
; O 0 1.5090468252765277e-07
q11 O 0 3.939922862628009e-06
. O 0 2.0472455730669026e-08
2 O 0 4.242367523943358e-08
) O 0 1.5960880617171824e-08
with O 0 2.788742037296288e-08
simultaneous O 0 6.36057734482165e-07
maternal O 0 0.00021563378686551005
meiotic O 0 0.004692477639764547
nondisjunction O 0 0.0008528961334377527
for O 0 1.595253365849203e-06
chromosome O 0 0.00010087201371788979
15 O 0 1.0216589544143062e-05
. O 0 1.2913097634736914e-05

The O 0 5.9760306612588465e-05
patient O 0 0.0017185728065669537
( O 0 1.3483025213645305e-05
J O 0 0.0023358003236353397
. O 0 3.8415302583416633e-07
B O 0 2.4072819542197976e-06
. O 0 2.1915614212275614e-08
) O 0 1.6107431832779184e-08
, O 0 7.766022491750846e-09
a O 0 7.294267589941228e-08
17 O 0 8.234314918809105e-07
- O 0 3.467229589659837e-06
year O 0 7.817981781954586e-07
- O 0 4.957375040248735e-06
old O 0 6.453977221099194e-06
white O 0 2.802382005029358e-05
male O 0 5.3668122745875735e-06
with O 0 7.329143500101054e-06
PWS B-Disease 1 0.9992689490318298
, O 0 6.20377932136762e-07
was O 0 6.504122325168282e-07
found O 0 8.97528522614266e-08
to O 0 8.26045720714319e-09
have O 0 6.005330899228056e-09
47 O 0 1.1882092820769685e-07
chromosomes O 0 1.291675886250232e-07
with O 0 5.304380934489927e-08
a O 0 1.4723182175657712e-06
supernumerary O 0 0.00037513411371037364
, O 0 5.803806857329619e-07
paternal O 0 7.736816041870043e-05
der O 0 9.621915523894131e-05
( O 0 1.2793221060292126e-07
15 O 0 3.5226047856440346e-08
) O 0 1.0462012589584901e-08
consisting O 0 1.2640916757789e-08
of O 0 9.532332256867448e-09
the O 0 1.3618054595099238e-07
short O 0 3.6105434446653817e-06
arm O 0 3.780122278840281e-05
and O 0 9.108439513738631e-08
the O 0 3.1079534323907865e-07
proximal O 0 0.0007534659234806895
long O 0 4.970254303771071e-05
arm O 0 6.946100620552897e-05
of O 0 8.849883670336567e-08
chromosome O 0 1.4002509487909265e-05
15 O 0 6.857912921987008e-07
, O 0 1.7949858488464088e-07
and O 0 4.3914178604609333e-07
distal O 0 0.009236602112650871
chromosome O 0 0.007336555980145931
arm O 0 0.39247873425483704
3p O 1 0.9461463093757629
. O 0 0.00019830063683912158

The O 0 2.035388388321735e-05
t O 0 0.0020127093885093927
( O 0 9.855436928773997e-07
3 O 0 4.2096021957149787e-07
; O 0 1.0225669910823854e-07
15 O 0 9.375175835657501e-08
) O 0 2.3188997388956523e-08
was O 0 2.3266881754580027e-08
present O 0 1.7480152436633034e-08
in O 0 5.861072516211152e-09
the O 0 8.249324778830669e-09
balanced O 0 8.462935596753596e-08
state O 0 3.923144475947993e-08
in O 0 6.244462724680488e-08
the O 0 4.790162506651541e-07
patients O 0 0.0009674784378148615
father O 0 5.43207306691329e-06
and O 0 3.03251994182574e-07
a O 0 5.9879530454054475e-06
sister O 0 0.00028434954583644867
. O 0 1.4096190170675982e-05

Fluorescent O 0 0.00020515119831543416
in O 0 1.348179353044543e-06
situ O 0 4.248850018484518e-05
hybridization O 0 3.109268618572969e-06
analysis O 0 7.074918357830029e-07
demonstrated O 0 5.089228125143563e-06
that O 0 3.8701094240423117e-07
the O 0 3.881200427713338e-06
PWS B-Disease 1 0.9965967535972595
critical O 0 1.0328434655093588e-05
region O 0 1.2456190461307415e-06
resided O 0 3.0358701224031392e-06
on O 0 5.161392735431036e-08
the O 0 8.659117867182431e-08
derivative O 0 3.918402853742009e-06
chromosome O 0 5.490855528478278e-06
3 O 0 2.201703210857886e-07
and O 0 1.1530405075177441e-08
that O 0 1.1899551566330047e-08
there O 0 1.762985490927349e-08
was O 0 8.668801854128105e-08
no O 0 5.138868175436073e-08
deletion O 0 1.1851009276142577e-06
of O 0 5.5716704139285866e-08
the O 0 1.8289927083969815e-06
PWS B-Disease 1 0.9967017769813538
region O 0 4.3243909431112115e-07
on O 0 2.5362355771108014e-08
the O 0 4.318365398603419e-08
normal O 0 4.549213201698876e-07
pair O 0 3.683057059333805e-07
of O 0 9.336309858554159e-08
15s O 0 0.00021379599638748914
present O 0 3.4203508221253287e-06
in O 0 7.219053259177599e-06
J O 0 0.1630105823278427
. O 0 3.2766201911726967e-05

B O 0 0.01069441344588995
. O 0 0.0003228317655157298

Methylation O 0 5.919681370869512e-06
analysis O 0 6.531633403028536e-07
at O 0 4.0008731616580917e-07
exon O 0 5.5098021221056115e-06
alpha O 0 5.961418878541735e-07
of O 0 1.2972739327210547e-08
the O 0 1.3532387299619586e-07
small O 0 1.315113877353724e-06
nuclear O 0 4.929206988890655e-05
ribonucleoprotein O 0 0.03251262009143829
- O 0 1.006884212984005e-05
associated O 0 2.1962582650303375e-06
polypeptide O 0 2.5861165340756997e-05
N O 0 1.4192879461916164e-05
( O 0 7.662441703359946e-07
SNRPN O 0 0.000130105996504426
) O 0 2.2604979221796384e-07
gene O 0 6.53796575988963e-07
showed O 0 4.6452467472590797e-07
a O 0 5.1367319287010105e-08
pattern O 0 7.319729888877191e-07
characteristic O 0 1.1396880950087507e-07
of O 0 4.627690231018278e-09
only O 0 1.1060546256658199e-08
the O 0 9.423329316859963e-08
maternal O 0 3.667631608550437e-05
chromosome O 0 1.2992943993594963e-05
15 O 0 1.7007719179673586e-06
in O 0 1.4361562534759287e-06
J O 0 0.07096344977617264
. O 0 1.1817889571830165e-05

B O 0 0.01239841990172863
. O 0 0.00043866297346539795

Maternal B-Disease 0 0.006061154417693615
disomy I-Disease 0 0.007566710002720356
was O 0 1.1482546142360661e-05
confirmed O 0 3.5543130252335686e-06
by O 0 1.44522815048731e-07
polymerase O 0 1.0526591722737066e-05
chain O 0 7.925859790702816e-06
reaction O 0 7.255546847773076e-07
analysis O 0 4.580116552688196e-08
of O 0 4.544465070921433e-08
microsatellite O 0 6.367429887177423e-05
repeats O 0 9.077254617295694e-06
at O 0 4.940455937685329e-07
the O 0 2.0817238066683785e-07
gamma O 0 1.5615392840118147e-05
- O 0 8.121084647427779e-06
aminobutyric O 0 4.528864155872725e-05
acid O 0 3.2069950975710526e-05
receptor O 0 1.4112452845438384e-05
beta3 O 0 5.310702181304805e-05
subunit O 0 6.193532954057446e-06
( O 0 3.4248814699822105e-06
GABRB3 O 0 0.0007883120561018586
) O 0 3.6651597383752232e-06
locus O 0 0.00012662239896599203
. O 0 2.060657243418973e-05

A O 0 7.567103602923453e-05
niece O 0 0.0006749429157935083
( O 0 3.959434252465144e-06
B O 0 2.7010737539967522e-05
. O 0 1.0902081726271717e-07
B O 0 2.0899419723718893e-06
. O 0 1.1648689124399425e-08
) O 0 6.402476770972498e-09
with O 0 4.149690813193274e-09
45 O 0 2.2994630199946187e-08
chromosomes O 0 5.239284206481898e-08
and O 0 6.654373496672861e-09
the O 0 1.957112694128682e-08
derivative O 0 5.670648874911421e-07
3 O 0 1.0665736738246778e-07
but O 0 3.1731655525391034e-08
without O 0 3.401239112577059e-08
the O 0 1.3637600204674527e-07
der O 0 2.7063904781243764e-05
( O 0 7.728817053020975e-08
15 O 0 8.216306213171265e-08
) O 0 3.818118088361189e-08
demonstrated O 0 4.115586875741428e-07
a O 0 3.8273131508503866e-07
phenotype O 0 1.8842129065888003e-05
consistent O 0 5.076219622424105e-07
with O 0 6.715489320185952e-08
that O 0 7.935526724622832e-08
reported O 0 1.0625396953400923e-06
for O 0 5.968131233657914e-08
haploinsufficiency O 0 3.067299257963896e-05
of O 0 2.54447343195352e-07
distal O 0 0.0038681630976498127
3 O 0 0.00012537861766759306
p O 0 0.0031207073479890823
. O 0 2.8767628464265727e-05

Uniparental B-Disease 1 0.9838587641716003
disomy I-Disease 1 0.8958725929260254
associated O 0 0.00014231755631044507
with O 0 6.852683782199165e-06
unbalanced O 0 0.0022227480076253414
segregation O 0 0.0002572454686742276
of O 0 1.074221131602826e-06
non O 0 3.7662368413293734e-05
- O 0 0.00013826752547174692
Robertsonian O 0 0.0006104724598117173
translocations O 0 0.00015183424693532288
has O 0 1.3320787957127322e-06
been O 0 6.27225233529316e-07
reported O 0 6.314483925962122e-06
previously O 0 5.913256018175161e-07
but O 0 1.1882092820769685e-07
has O 0 6.202300539825956e-08
not O 0 6.208996872203443e-09
, O 0 7.1890853270417665e-09
to O 0 2.3065429566315743e-09
our O 0 4.770138062326623e-09
knowledge O 0 2.268537713234764e-08
, O 0 1.6450330875272812e-08
been O 0 1.6813286762840107e-08
observed O 0 1.003194256554707e-07
in O 0 3.765783773701514e-08
a O 0 4.935238280268095e-07
case O 0 5.729105851060012e-06
of O 0 6.9340489972091746e-06
PWS B-Disease 1 0.9976041913032532
. O 0 0.00011221580643905327

Furthermore O 0 0.0001064648968167603
, O 0 1.2024119087072904e-06
our O 0 1.8421640390897664e-07
findings O 0 6.91921854922839e-07
are O 0 8.286479058483565e-09
best O 0 4.2114731257925087e-08
interpreted O 0 2.719300766784727e-07
as O 0 1.2324751708092663e-07
true O 0 3.584886371754692e-06
gamete O 0 0.0005309015978127718
complementation O 0 0.0258552934974432
resulting O 0 0.0002439958625473082
in O 0 2.4382552510360256e-05
maternal B-Disease 0 0.21254746615886688
UPD I-Disease 1 0.9899824261665344
15 I-Disease 0 0.00015257894119713455
and O 0 0.00012865799362771213
PWS B-Disease 1 0.986158549785614

Schwartz B-Disease 0 0.3882075250148773
- I-Disease 1 0.6315522789955139
Jampel I-Disease 1 0.9853120446205139
syndrome I-Disease 1 0.999334990978241
type I-Disease 0 0.0008545141317881644
2 I-Disease 0 2.002519067900721e-05
and O 0 1.350646107312059e-05
Stuve B-Disease 1 0.9739149212837219
- I-Disease 1 0.9435742497444153
Wiedemann I-Disease 1 0.9977113008499146
syndrome I-Disease 1 0.9997151494026184
: O 0 4.384903604659485e-06
a O 0 2.072565393973491e-06
case O 0 2.791845190586173e-06
for O 0 5.30541342413926e-07
" O 0 2.7256201065029018e-06
lumping O 0 0.00022547264234162867
" O 0 6.475024292740272e-06
. O 0 7.677007488382515e-06

Recent O 0 1.4574718989024404e-05
studies O 0 1.6987860362860374e-06
demonstrated O 0 1.207177888318256e-06
the O 0 1.0243707038171124e-07
existence O 0 2.0556490198941901e-07
of O 0 2.382968311565037e-08
a O 0 7.985112233654945e-07
genetically O 0 2.9577290661109146e-06
distinct O 0 3.091175244662736e-07
, O 0 6.634985538767069e-08
usually O 0 1.9371923087874166e-07
lethal O 0 2.0434904399735387e-06
form O 0 1.1996317539342272e-07
of O 0 1.209148763336998e-07
the O 0 8.405723747273441e-06
Schwartz B-Disease 0 0.009317404590547085
- I-Disease 0 0.07375149428844452
Jampel I-Disease 1 0.9842948913574219
syndrome I-Disease 1 0.9995019435882568
( O 0 0.00037182559026405215
SJS B-Disease 1 0.9895636439323425
) O 0 3.010562068084255e-06
of O 0 5.119847628520802e-06
myotonia B-Disease 1 0.9959532022476196
and O 0 0.00019255622464697808
skeletal B-Disease 1 0.9991193413734436
dysplasia I-Disease 1 0.9995463490486145
, O 0 3.5968068914371543e-06
which O 0 9.597315511200577e-07
we O 0 1.0260107501380844e-06
called O 0 9.065652557183057e-05
SJS B-Disease 1 0.9678092002868652
type I-Disease 0 0.00010682805441319942
2 I-Disease 0 1.039709968608804e-05
. O 0 7.567376997030806e-06

This O 0 0.0001336908753728494
disorder O 1 0.9955801367759705
is O 0 1.7639343923292472e-06
reminiscent O 0 2.5961067876778543e-05
of O 0 3.5364871564524947e-07
another O 0 1.3851788935426157e-05
rare O 0 0.001712782308459282
condition O 0 0.10762665420770645
, O 0 3.5477498840918997e-06
the O 0 2.766281431831885e-05
Stuve B-Disease 1 0.9378736019134521
- I-Disease 1 0.88359135389328
Wiedemann I-Disease 1 0.9965135455131531
syndrome I-Disease 1 0.99970942735672
( O 0 5.57568455405999e-05
SWS B-Disease 1 0.5140532851219177
) O 0 4.818220418201236e-07
, O 0 5.315997952948237e-08
which O 0 2.0053366966976682e-08
comprises O 0 4.596859071170911e-07
campomelia B-Disease 0 0.0001324379409197718
at O 0 4.143392288824543e-06
birth O 0 0.00019391579553484917
with O 0 0.00019212489132769406
skeletal B-Disease 1 0.9991441965103149
dysplasia I-Disease 1 0.9997276663780212
, O 0 0.00032618813565932214
contractures B-Disease 1 0.9866153001785278
, O 0 2.1924745396972867e-06
and O 0 9.951811534847366e-07
early B-Disease 0 1.580102434672881e-05
death I-Disease 0 0.0005615703412331641
. O 0 3.400434798095375e-05

To O 0 1.1220599844818935e-06
test O 0 2.073443056360702e-06
for O 0 2.1337014288747014e-07
possible O 0 2.3575350951432483e-06
nosologic O 0 0.0004897826001979411
identity O 0 1.518385374765785e-06
between O 0 9.400625913258409e-07
these O 0 3.9351834857370704e-06
disorders O 1 0.9995471835136414
, O 0 2.790727364754275e-07
we O 0 3.2645139924625255e-08
reviewed O 0 1.8241503596527764e-07
the O 0 1.3948944221908732e-08
literature O 0 4.134500386498985e-08
and O 0 1.7515995764938452e-08
obtained O 0 7.151506054015044e-08
a O 0 5.920072254639308e-08
follow O 0 4.2968068214577215e-08
- O 0 6.49750049319664e-08
up O 0 2.0426107472104604e-09
of O 0 4.3169035013335133e-10
the O 0 5.153628190868176e-09
only O 0 5.1878705775720846e-09
two O 0 4.035021561321628e-08
surviving O 0 0.00021299169748090208
patients O 0 0.00024098475114442408
, O 0 3.85089080623402e-08
one O 0 6.875345093249052e-08
with O 0 1.4479198853223352e-06
SJS B-Disease 1 0.9218146204948425
type I-Disease 0 6.020465207257075e-06
2 I-Disease 0 3.071580749747227e-07
at O 0 2.2173362879129854e-07
age O 0 7.428988055835362e-07
10 O 0 7.017732883696226e-08
years O 0 6.489834447620524e-08
and O 0 1.0044614029425247e-08
another O 0 9.81010046530173e-08
with O 0 2.7285670967103215e-07
SWS B-Disease 0 0.014686478301882744
at O 0 8.871497243490012e-07
age O 0 6.879738975840155e-06
7 O 0 7.017168627498904e-06
years O 0 6.154254606371978e-06
. O 0 7.390684004349168e-06

Patients O 1 0.6606029868125916
reported O 0 8.112274372251704e-05
as O 0 1.3323531220521545e-06
having O 0 2.4596105504315346e-05
either O 0 0.0002036336372839287
neonatal O 1 0.9989694356918335
SJS B-Disease 1 0.9965497255325317
or O 0 1.1916211406060029e-05
SWS B-Disease 0 0.07689202576875687
presented O 0 1.1809040643129265e-06
a O 0 5.452072855405277e-07
combination O 0 2.651678869369789e-06
of O 0 3.273031268236082e-07
a O 0 0.0001018870752886869
severe O 1 0.9971694350242615
, O 0 0.00018024818564299494
prenatal O 1 0.9950579404830933
- O 1 0.9938331842422485
onset O 1 0.9994279742240906
neuromuscular B-Disease 1 0.9998842477798462
disorder I-Disease 1 0.999769389629364
( O 0 0.0033023469150066376
with O 0 0.014034447260200977
congenital B-Disease 1 0.9999334812164307
joint I-Disease 1 0.996482253074646
contractures I-Disease 1 0.9996395111083984
, O 0 0.07212602347135544
respiratory O 1 0.9997113347053528
and O 0 1.5936011550365947e-05
feeding O 0 0.0017209810903295875
difficulties O 0 0.002675273222848773
, O 0 3.475724724921747e-06
tendency O 0 8.568099292460829e-05
to O 0 2.0332226995378733e-06
hyperthermia B-Disease 1 0.992547333240509
, O 0 3.1759631724526116e-07
and O 0 1.7018980713601195e-07
frequent O 0 1.0787354767671786e-05
death O 0 1.6182364561245777e-05
in O 0 3.749193240309978e-07
infancy O 0 0.00022346856712829322
) O 0 1.8880197671933274e-07
with O 0 1.535546942932342e-07
a O 0 3.21578386319743e-06
distinct O 0 6.258784560486674e-05
campomelic B-Disease 1 0.8654108047485352
- I-Disease 0 0.18858465552330017
metaphyseal I-Disease 1 0.9418233633041382
skeletal I-Disease 1 0.9956734776496887
dysplasia I-Disease 1 0.9983141422271729
. O 0 0.0011097518727183342

The O 0 1.9052259858653997e-06
similarity O 0 3.6353997074911604e-06
of O 0 2.6201760761068726e-07
the O 0 1.7818071000874625e-06
clinical O 0 0.00023469100415240973
and O 0 1.3118095694153453e-06
radiographic O 0 0.015915410593152046
findings O 0 1.5188043107627891e-05
is O 0 3.991094672528561e-07
so O 0 2.6828337240658584e-07
extensive O 0 5.349448656488676e-06
that O 0 3.0327569788823894e-07
these O 0 1.5082957816048292e-06
disorders O 1 0.9987416863441467
appear O 0 1.905927433654142e-06
to O 0 3.998949793526663e-08
be O 0 2.9567505777094993e-08
a O 0 2.5097358502534917e-07
single O 0 1.0793185083457502e-06
entity O 0 1.1614274626481347e-05
. O 0 1.5240289030771237e-05

The O 0 2.1691294023185037e-06
follow O 0 2.3126178803067887e-06
- O 0 2.675067207746906e-06
up O 0 1.1538329403038006e-07
observation O 0 2.512911692065245e-07
of O 0 6.757205461838112e-09
an O 0 4.971735734216054e-08
identical O 0 3.695300847539329e-07
and O 0 4.509142570441327e-08
unique O 0 2.672165635431156e-07
pattern O 0 1.7737027519615367e-05
of O 0 2.435230953778955e-06
progressive O 1 0.9856648445129395
bone B-Disease 1 0.9997370839118958
dysplasia I-Disease 1 0.9995203018188477
in O 0 8.265178621513769e-07
the O 0 5.5668471077297e-07
two O 0 4.004442359928362e-07
patients O 0 0.0016926312819123268
( O 0 3.275247877354559e-07
one O 0 9.611020601596465e-08
with O 0 2.9929221909696935e-06
SJS B-Disease 1 0.9737985134124756
type I-Disease 0 7.233656560856616e-06
2 I-Disease 0 2.632614837239089e-07
, O 0 1.9326707345612704e-08
one O 0 2.227521811448696e-08
with O 0 3.9739424551044067e-07
SWS B-Disease 0 0.026202494278550148
) O 0 6.550910143232613e-07
surviving O 0 1.0975185432471335e-05
beyond O 0 1.7692666460789042e-06
infancy O 0 0.00013122409291099757
adds O 0 2.57430497185851e-06
to O 0 2.261974429984548e-08
the O 0 3.784541391382845e-08
evidence O 0 1.6031154359552602e-07
in O 0 3.323241770658569e-08
favor O 0 1.9413570839788008e-07
of O 0 1.618853531226705e-07
identity O 0 1.1762108442781027e-05
. O 0 2.4791066607576795e-05

The O 0 1.3916443094785791e-05
hypothesis O 0 0.00011660225572995842
that O 0 1.3011928785999771e-05
SWS B-Disease 1 0.7938601970672607
and O 0 1.5949970475048758e-05
SJS B-Disease 1 0.9827985167503357
type I-Disease 0 1.8469027054379694e-05
2 I-Disease 0 2.2956075440561108e-07
are O 0 1.3526409325947952e-08
the O 0 1.379743537199829e-07
same O 0 3.0762932965444634e-06
disorder O 1 0.9968396425247192
should O 0 1.0796751581665376e-07
be O 0 2.416264699434123e-08
testable O 0 2.983527167543798e-07
by O 0 3.237374102127433e-08
molecular O 0 1.768064066709485e-06
methods O 0 5.700372298633738e-07
. O 0 1.6029761127356323e-06
. O 0 7.29834164303611e-06

A O 0 8.192339009838179e-05
mouse O 0 0.0003871847875416279
model O 0 8.806972618913278e-05
of O 0 8.487300510751083e-05
severe O 1 0.9994958639144897
von B-Disease 1 0.999580442905426
Willebrand I-Disease 1 0.9998145699501038
disease I-Disease 1 0.9999257326126099
: O 0 0.2739609181880951
defects O 1 0.9989350438117981
in O 0 0.0008368833805434406
hemostasis O 1 0.9972255229949951
and O 0 0.0025552203878760338
thrombosis B-Disease 1 0.998773992061615
. O 0 0.000503011338878423

von B-Disease 1 0.9246306419372559
Willebrand I-Disease 1 0.9821808338165283
factor I-Disease 0 0.0015188045799732208
( I-Disease 0 0.0009928093058988452
vWf I-Disease 1 0.9674504399299622
) I-Disease 0 0.11282248795032501
deficiency I-Disease 1 0.9998095631599426
causes O 1 0.9985734224319458
severe O 1 0.9998290538787842
von B-Disease 1 0.9997703433036804
Willebrand I-Disease 1 0.9998562335968018
disease I-Disease 1 0.9998700618743896
in O 0 0.00023565473384223878
humans O 0 0.0009214665624313056
. O 0 8.328927651746199e-05

We O 0 9.013333510665689e-07
generated O 0 9.959302360584843e-07
a O 0 1.4254501365940087e-06
mouse O 0 1.1659373740258161e-05
model O 0 1.383761627948843e-06
for O 0 1.613625215668435e-07
this O 0 1.5986190646799514e-06
disease O 1 0.6244776248931885
by O 0 1.83628088734622e-07
using O 0 6.840811579422734e-07
gene O 0 1.6279524061246775e-05
targeting O 0 1.5560803149128333e-05
. O 0 1.381846141157439e-05

vWf B-Disease 1 0.9641238451004028
- I-Disease 1 0.9486823678016663
deficient I-Disease 1 0.9935257434844971
mice O 0 0.0029799530748277903
appeared O 0 1.5123435332498048e-05
normal O 0 4.319611434766557e-06
at O 0 1.349254603155714e-06
birth O 0 1.1987860489170998e-05
; O 0 1.768992063944097e-07
they O 0 1.646087532947149e-08
were O 0 3.464844766654096e-08
viable O 0 1.1145592679895344e-06
and O 0 4.643789566216583e-07
fertile O 0 0.00010699442646000534
. O 0 2.7570114980335347e-05

Neither O 0 0.0030217566527426243
vWf O 0 0.08105401694774628
nor O 0 0.0013967687264084816
vWf O 0 0.05856259912252426
propolypeptide O 0 0.0431826077401638
( O 0 0.0003826957254204899
von B-Disease 1 0.7624919414520264
Willebrand I-Disease 1 0.9921969175338745
antigen O 0 0.18733713030815125
II O 0 0.003779736580327153
) O 0 6.555196705448907e-07
were O 0 1.4068385212340218e-07
detectable O 0 1.2452184819267131e-05
in O 0 2.5048336738109356e-07
plasma O 0 1.758336293278262e-05
, O 0 5.285495490170433e-07
platelets O 0 0.0003502668987493962
, O 0 1.8230024068088824e-07
or O 0 8.866954885888845e-07
endothelial O 0 0.00039097474655136466
cells O 0 8.395969075536414e-07
of O 0 4.2214693962705496e-08
the O 0 1.1864218549817451e-06
homozygous O 0 0.0002326337998965755
mutant O 0 0.0008198610157705843
mice O 0 0.00360235502012074
. O 0 3.3190357498824596e-05

The O 0 6.521341856569052e-05
mutant O 0 0.00935269519686699
mice O 0 0.1357564479112625
exhibited O 0 0.007169241551309824
defects O 1 0.9949377775192261
in O 0 6.582487458217656e-06
hemostasis O 1 0.8718228340148926
with O 0 1.8775673424897832e-06
a O 0 2.5714520234032534e-05
highly O 0 0.0008216340211220086
prolonged O 1 0.9981105327606201
bleeding O 1 0.9987478256225586
time O 0 1.1604303153944784e-06
and O 0 8.265155315712036e-07
spontaneous O 0 0.00029280222952365875
bleeding O 1 0.9733859300613403
events O 0 2.512921071229357e-07
in O 0 5.731302366029922e-08
approximately O 0 1.2450735198399343e-07
10 O 0 2.4469355253131653e-07
% O 0 4.4612619376493967e-07
of O 0 6.846424867035239e-07
neonates O 0 0.1326596885919571
. O 0 4.073479794897139e-05

As O 0 3.828725311905146e-06
in O 0 9.81657422016724e-07
the O 0 3.746566108020488e-06
human O 0 0.0001399773609591648
disease O 1 0.996924102306366
, O 0 1.684414030478365e-07
the O 0 2.2278240408013517e-07
factor O 0 2.6249533675581915e-06
VIII O 0 0.000986670725978911
level O 0 1.4943660744393128e-06
in O 0 9.819909507768898e-08
these O 0 8.701618270379186e-08
mice O 0 0.00010690090857679024
was O 0 8.016013453016058e-07
reduced O 0 1.2336516874711378e-06
strongly O 0 7.844197114081908e-08
as O 0 7.515122746326597e-09
a O 0 3.578555762828728e-08
result O 0 5.4110124381168134e-08
of O 0 4.914288975754744e-09
the O 0 1.1421851553450324e-07
lack O 0 1.494964635639917e-06
of O 0 1.2364803581021988e-07
protection O 0 3.197363912477158e-05
provided O 0 6.444056907639606e-06
by O 0 8.49351636134088e-06
vWf O 0 0.01017556432634592
. O 0 5.827831046190113e-05

Defective O 1 0.9901559352874756
thrombosis B-Disease 1 0.9984499216079712
in O 0 6.523785850731656e-05
mutant O 0 0.004670929629355669
mice O 0 0.0017344309017062187
was O 0 2.276193072248134e-06
also O 0 1.3822379685279884e-07
evident O 0 5.841789629812411e-07
in O 0 2.108749974638613e-08
an O 0 4.1661728289454913e-08
in O 0 1.7510743077764346e-07
vivo O 0 1.0944488167297095e-05
model O 0 5.3555895647150464e-06
of O 0 1.1786014511017129e-05
vascular B-Disease 1 0.9996165037155151
injury I-Disease 1 0.9954156875610352
. O 0 0.0002076283417409286

In O 0 1.38339203203941e-06
this O 0 3.1722277071821736e-07
model O 0 1.070977418748953e-06
, O 0 2.2660169918253814e-07
the O 0 4.516674323440384e-07
exteriorized O 0 0.00039637263398617506
mesentery O 0 0.0012563978089019656
was O 0 9.711495295050554e-06
superfused O 0 0.0001848827232606709
with O 0 1.1369213552825386e-06
ferric O 1 0.9034727215766907
chloride O 0 0.0004891760763712227
and O 0 3.1868188443695544e-07
the O 0 3.891560709234909e-07
accumulation O 0 0.00010569460573606193
of O 0 1.8180072629547794e-06
fluorescently O 0 0.4705966114997864
labeled O 0 0.004044156987220049
platelets O 0 0.005699196830391884
was O 0 5.17180751558044e-06
observed O 0 3.070982074859785e-06
by O 0 2.1760972686024616e-06
intravital O 0 0.002014609519392252
microscopy O 0 0.00033313361927866936
. O 0 3.745670255739242e-05

We O 0 2.6402583443996264e-06
conclude O 0 1.1393231943657156e-05
that O 0 4.459909348497604e-07
these O 0 6.148848683551478e-07
mice O 0 0.0003821552381850779
very O 0 3.906638085027225e-06
closely O 0 7.03577243257314e-05
mimic O 1 0.9733126759529114
severe O 1 0.9992152452468872
human O 1 0.9742463827133179
von B-Disease 1 0.9997045397758484
Willebrand I-Disease 1 0.999903678894043
disease I-Disease 1 0.9998694658279419
and O 0 1.1313275081192842e-06
will O 0 5.466198516046461e-08
be O 0 8.266698436898423e-09
very O 0 1.2842406249546912e-08
useful O 0 2.1714685161100533e-08
for O 0 1.0745591971783597e-08
investigating O 0 2.9695357284253987e-07
the O 0 3.67432839709636e-08
role O 0 8.763111480902808e-08
of O 0 1.3386612351951044e-07
vWf O 0 0.0005024017882533371
in O 0 5.731782835027843e-07
normal O 0 1.3014945579925552e-05
physiology O 0 0.000307132228044793
and O 0 2.505096972527099e-06
in O 0 3.811607894022018e-05
disease O 1 0.9984471201896667
models O 0 6.031796146999113e-05
. O 0 4.5663014134333935e-06
. O 0 1.7985610611503944e-05

Oral O 0 0.003325191792100668
contraceptives O 0 0.001777942874468863
and O 0 1.5158880160015542e-06
the O 0 9.482515451963991e-06
risk O 0 0.004030455835163593
of O 0 0.0002159761788789183
hereditary B-Disease 1 0.9995706677436829
ovarian I-Disease 1 0.9999748468399048
cancer I-Disease 1 0.9997789263725281
. O 0 0.0013356106355786324

Hereditary B-Disease 1 0.9953404664993286
Ovarian I-Disease 1 0.999658465385437
Cancer I-Disease 1 0.9987773299217224
Clinical O 0 0.051037754863500595
Study O 0 0.00017149318591691554
Group O 0 4.7234010708052665e-05
. O 0 5.57554631086532e-05

BACKGROUND O 0 4.8995891120284796e-05
Women O 0 1.3662116771229194e-06
with O 0 2.0909118347844924e-07
mutations O 0 1.7360324591209064e-06
in O 0 5.6151236549339956e-08
either O 0 1.4773830514513975e-07
the O 0 1.997315308699399e-07
BRCA1 O 0 9.647244587540627e-05
or O 0 1.4177804530390858e-07
the O 0 2.2446934622166737e-07
BRCA2 O 0 0.00010346909402869642
gene O 0 5.949780756964174e-07
have O 0 2.4697181189026196e-08
a O 0 6.284934102041007e-07
high O 0 4.411933696246706e-05
lifetime O 0 0.0017754117725417018
risk O 0 0.012034159153699875
of O 0 0.001172967255115509
ovarian B-Disease 1 0.999934196472168
cancer I-Disease 1 0.9996733665466309
. O 0 0.00048621249152347445

Oral O 0 0.08682414144277573
contraceptives O 1 0.7774932384490967
protect O 0 0.031006718054413795
against O 1 0.8058629035949707
ovarian B-Disease 1 0.9999357461929321
cancer I-Disease 1 0.9997137188911438
in O 0 1.4099385907684336e-06
general O 0 1.1353729405527702e-06
, O 0 1.330038372771014e-07
but O 0 3.884648336338614e-08
it O 0 1.9885131763430763e-08
is O 0 2.273128707486194e-08
not O 0 1.7879260738595804e-08
known O 0 1.008845202932207e-07
whether O 0 5.509500766720521e-08
they O 0 2.0300664260730628e-08
also O 0 1.1851829384568191e-07
protect O 0 1.8745366787698003e-06
against O 0 2.7053092708229087e-06
hereditary B-Disease 0 0.010001249611377716
forms I-Disease 0 0.00014379197091329843
of I-Disease 0 0.005033147055655718
ovarian I-Disease 1 0.9999791383743286
cancer I-Disease 1 0.9997935891151428
. O 0 0.0005319320480339229

METHODS O 0 1.2233977031428367e-05
We O 0 2.2063052256271476e-06
enrolled O 0 3.809820191236213e-05
207 O 0 0.00014839731738902628
women O 0 2.306894566572737e-05
with O 0 0.0002672546834219247
hereditary B-Disease 1 0.9993107318878174
ovarian I-Disease 1 0.9999809265136719
cancer I-Disease 1 0.9997519850730896
and O 0 4.1947583895307616e-07
161 O 0 1.5117057046154514e-06
of O 0 2.3224053791182087e-08
their O 0 4.2987412740558284e-08
sisters O 0 1.7748045593179995e-06
as O 0 6.180241740594283e-08
controls O 0 5.24129347923008e-07
in O 0 1.0537556960343863e-07
a O 0 9.659277111495612e-07
case O 0 4.9273326112597715e-06
- O 0 8.048200470511802e-06
control O 0 1.342622454103548e-06
study O 0 5.785989742435049e-06
. O 0 1.1383316632418428e-05

All O 0 9.5462337412755e-07
the O 0 3.1845538615016267e-06
patients O 0 0.00012584072828758508
carried O 0 5.363315835893445e-07
a O 0 9.568509540258674e-07
pathogenic O 0 1.0785472113639116e-05
mutation O 0 3.641964667622233e-06
in O 0 1.6551871340197977e-07
either O 0 8.35064440707356e-07
BRCA1 O 0 0.00032105675200000405
( O 0 7.567020361420873e-07
179 O 0 5.260670604911866e-06
women O 0 5.283973223413341e-07
) O 0 2.848699693913659e-07
or O 0 1.3118947208567988e-06
BRCA2 O 0 0.00044490760774351656
( O 0 1.6481349121022504e-06
28 O 0 3.569187356333714e-06
women O 0 1.7715999547363026e-06
) O 0 1.6561326674491283e-06
. O 0 6.8212953010515776e-06

The O 0 2.8949809802725213e-06
control O 0 8.958112630352844e-06
women O 0 8.14390944015031e-07
were O 0 1.2669161719713884e-07
enrolled O 0 1.2649738891923334e-06
regardless O 0 1.3184427416490507e-07
of O 0 2.3283885042246766e-08
whether O 0 2.380150334602149e-07
or O 0 3.3102548968599876e-07
not O 0 4.26167794387311e-08
they O 0 8.293439890394438e-08
had O 0 8.805254196886381e-07
either O 0 2.229346819149214e-06
mutation O 0 7.894336158642545e-05
. O 0 1.1571697541512549e-05

Lifetime O 0 0.00024148040392901748
histories O 0 3.0204200811567716e-05
of O 0 2.334370947210118e-06
oral O 0 0.004754857160151005
- O 0 0.0006256006308831275
contraceptive O 0 0.0003708770382218063
use O 0 1.762297046070671e-07
were O 0 3.1756353990886055e-08
obtained O 0 2.4673454390722327e-07
by O 0 1.4613300436394638e-07
interview O 0 1.949068519024877e-06
or O 0 4.814205567527097e-08
by O 0 2.089663375670625e-08
written O 0 3.970509609985129e-08
questionnaire O 0 1.2691536994680064e-06
and O 0 3.100279855061672e-08
were O 0 5.52655095020782e-08
compared O 0 3.2924708648351952e-06
between O 0 1.9891426745743956e-06
patients O 0 0.00243718596175313
and O 0 1.40360072009571e-07
control O 0 1.6563885765208397e-06
women O 0 3.813227920090867e-07
, O 0 8.753722369192474e-08
after O 0 2.8486806513683405e-07
adjustment O 0 1.6324606804118957e-06
for O 0 1.9020035324501805e-08
year O 0 1.2234369251018506e-07
of O 0 3.547924620761478e-08
birth O 0 1.4714264580106828e-05
and O 0 7.515555466852675e-07
parity O 0 0.0003745291323866695
. O 0 1.326898200204596e-05

RESULTS O 0 3.304907659185119e-05
The O 0 3.5476348330121255e-06
adjusted O 0 6.177036266308278e-05
odds O 0 0.0007363102631643414
ratio O 0 0.00047355020069517195
for O 0 0.004405783489346504
ovarian B-Disease 1 0.9999744892120361
cancer I-Disease 1 0.9998458623886108
associated O 0 6.850396857771557e-06
with O 0 5.253874491017996e-08
any O 0 3.6327609365116587e-08
past O 0 4.1469949252359584e-08
use O 0 2.3169853591298306e-08
of O 0 5.653811996353397e-08
oral O 0 0.0005952620413154364
contraceptives O 0 0.0027288843411952257
was O 0 2.1818616005475633e-05
0 O 0 1.2141528713982552e-05
. O 0 1.4813300367677584e-05

5 O 0 9.993934327212628e-06
( O 0 1.8356732880420168e-06
95 O 0 1.2627127716768882e-06
percent O 0 4.4583359226635366e-07
confidence O 0 4.0410682800029463e-07
interval O 0 3.568390525288123e-07
, O 0 2.8136664553812807e-08
0 O 0 3.620020549988112e-08
. O 0 5.188127705224588e-09
3 O 0 1.2268949411975427e-08
to O 0 3.1010352063987057e-09
0 O 0 3.616052168808892e-08
. O 0 1.6802450986119766e-08
8 O 0 3.8718593486919417e-07
) O 0 4.668745816616138e-07
. O 0 1.3977261232867022e-06

The O 0 5.043367127655074e-05
risk O 0 0.0018968406366184354
decreased O 0 4.676372554968111e-05
with O 0 1.5616899418091634e-07
increasing O 0 6.276679869188229e-07
duration O 0 6.982123750276514e-07
of O 0 1.0329442190482041e-08
use O 0 7.730925233317976e-08
( O 0 2.811939623370563e-07
P O 0 5.709116067009745e-06
for O 0 3.5031607836799594e-08
trend O 0 1.8039145288639702e-06
, O 0 6.658413553850551e-08
< O 0 1.1512621313158888e-05
0 O 0 2.1541268324654084e-07
. O 0 7.12725380935808e-08
001 O 0 7.030458618828561e-06
) O 0 1.4004741366591134e-08
; O 0 4.637303874233112e-09
use O 0 2.003661014882141e-09
for O 0 1.8295740478180278e-09
six O 0 1.0927100113633514e-08
or O 0 1.9565305819924106e-08
more O 0 3.536471115950235e-09
years O 0 1.0362104063688093e-07
was O 0 2.3077326716247626e-07
associated O 0 8.9287233606683e-08
with O 0 2.0551485846453943e-08
a O 0 2.0043047754825238e-07
60 O 0 6.079577019590943e-07
percent O 0 3.092654424108332e-06
reduction O 0 4.4151664042146876e-05
in O 0 2.7252433483226923e-06
risk O 0 0.0006418661214411259
. O 0 1.789218731573783e-05

Oral O 0 0.005920092575252056
- O 0 0.001588183455169201
contraceptive O 0 0.002016293816268444
use O 0 7.341230684687616e-06
protected O 0 0.0032053568866103888
against O 0 0.0968903973698616
ovarian B-Disease 1 0.9999544620513916
cancer I-Disease 1 0.9994307160377502
both O 0 1.3064519066574576e-07
for O 0 1.1547202660722178e-07
carriers O 0 1.7092580719690886e-06
of O 0 3.4777688284748365e-08
the O 0 9.738174640006036e-07
BRCA1 O 0 0.0008362528751604259
mutation O 0 1.3019265679758973e-05
( O 0 7.437338922500203e-07
odds O 0 7.2168368205893785e-06
ratio O 0 6.950699571461882e-07
, O 0 4.044853696427708e-08
0 O 0 5.7941843323305875e-08
. O 0 1.0838550501546251e-08
5 O 0 6.51553264674476e-08
; O 0 1.643772229442675e-08
95 O 0 7.66380168215619e-08
percent O 0 8.374108517728018e-08
confidence O 0 9.190161165406607e-08
interval O 0 1.2283425121495384e-07
, O 0 9.66567093030335e-09
0 O 0 1.1951572176371883e-08
. O 0 2.060862591690693e-09
3 O 0 6.3291532015341545e-09
to O 0 1.3995388181697876e-09
0 O 0 1.1416326550772737e-08
. O 0 3.9246619287780504e-09
9 O 0 2.955493272338572e-08
) O 0 4.436837119925485e-09
and O 0 7.451404493430402e-10
for O 0 2.6378146333883024e-09
carriers O 0 1.1314899239778242e-07
of O 0 4.799900032992355e-09
the O 0 3.370789158907428e-07
BRCA2 O 0 0.00021245887910481542
mutation O 0 4.4759653974324465e-06
( O 0 3.663985239654721e-07
odds O 0 5.80141067985096e-06
ratio O 0 3.1717254955765384e-07
, O 0 2.27876775227287e-08
0 O 0 3.5810955978377024e-08
. O 0 5.394758417764933e-09
4 O 0 3.399086168087706e-08
; O 0 1.4678157356229349e-08
95 O 0 1.449332955871796e-07
percent O 0 1.3495309758582152e-07
confidence O 0 1.6986972184440674e-07
interval O 0 1.5779723128162004e-07
, O 0 1.5731753677528104e-08
0 O 0 3.987281615991378e-08
. O 0 6.104556415920115e-09
2 O 0 1.769652868688354e-08
to O 0 3.6987537477273236e-09
1 O 0 4.9935653834154436e-08
. O 0 2.512867780524175e-08
1 O 0 2.060420172256272e-07
) O 0 4.1916632653737906e-07
. O 0 1.3948990726930788e-06

CONCLUSIONS O 0 0.0002809214638546109
Oral O 0 0.0022833668626844883
- O 0 0.0007997927023097873
contraceptive O 0 0.0010366946225985885
use O 0 1.649599084885267e-06
may O 0 4.996803909307346e-06
reduce O 0 1.256481664313469e-05
the O 0 2.259571829199558e-06
risk O 0 0.0013682447606697679
of O 0 0.000203670933842659
ovarian B-Disease 1 0.999967098236084
cancer I-Disease 1 0.999757707118988
in O 0 9.057641250365123e-07
women O 0 6.185525194268848e-07
with O 0 2.366143263543563e-07
pathogenic O 0 1.8575718058855273e-05
mutations O 0 4.881761924480088e-06
in O 0 3.647550101959496e-07
the O 0 5.186288035474718e-06
BRCA1 O 0 0.011720377951860428
or O 0 8.139720739563927e-05
BRCA2 O 0 0.03542979434132576
gene O 0 0.001891096937470138

A O 0 8.638893632451072e-05
Japanese O 0 0.0001229475747095421
family O 0 2.309271803824231e-05
with O 0 6.926745300006587e-06
adrenoleukodystrophy B-Disease 1 0.9970940351486206
with O 0 3.342112222526339e-07
a O 0 9.404132015333744e-07
codon O 0 8.948131835495587e-06
291 O 0 1.7966667655855417e-05
deletion O 0 3.161802305839956e-05
: O 0 1.1836935982501018e-06
a O 0 1.5222275351334247e-06
clinical O 0 6.675464828731492e-05
, O 0 5.160634941603348e-07
biochemical O 0 0.00011294730211375281
, O 0 1.4201123121893033e-06
pathological O 0 0.002822977490723133
, O 0 8.263579047707026e-07
and O 0 8.842356464811019e-07
genetic O 0 0.00021780261886306107
report O 0 7.432077109115198e-05
. O 0 2.5859018933260813e-05

We O 0 3.4597810554259922e-06
report O 0 6.9119437284825835e-06
a O 0 3.1902411592454882e-06
Japanese O 0 3.16508776450064e-05
family O 0 3.6871861084364355e-05
with O 0 0.00013199263776186854
adrenoleukodystrophy B-Disease 1 0.999515175819397
( O 0 0.0007599986274726689
ALD B-Disease 1 0.9988380074501038
) O 0 2.4576607415838225e-07
with O 0 2.04905425960078e-08
a O 0 4.886857496444463e-08
three O 0 1.3751819238905227e-08
base O 0 2.4304972612299025e-07
pair O 0 4.496603480674821e-07
deletion O 0 1.2720079212158453e-05
( O 0 6.790600082240417e-07
delGAG O 0 3.474352342891507e-05
291 O 0 8.053644705796614e-06
) O 0 2.541223977914342e-07
in O 0 3.2414709494332783e-07
the O 0 1.072338181984378e-05
ALD B-Disease 1 0.996672511100769
gene O 0 0.0002942723222076893
. O 0 4.516636545304209e-05

A O 0 8.882062502379995e-06
variety O 0 1.208351591230894e-06
of O 0 3.124506520180148e-07
phenotypes O 0 8.399979560635984e-05
were O 0 2.3348464139871794e-07
observed O 0 7.483028525712143e-07
within O 0 1.7968493182252132e-07
this O 0 3.6801361602556426e-07
family O 0 2.953035436803475e-05
. O 0 1.3815825695928652e-05

While O 0 4.5232882257550955e-06
the O 0 3.0544645142072113e-06
proband O 0 0.0011393759632483125
( O 0 4.130341949348804e-06
patient O 0 9.356049122288823e-05
1 O 0 9.952294703907683e-07
) O 0 2.6772363526106346e-07
was O 0 5.404925786933745e-07
classified O 0 1.0611269090077258e-06
as O 0 1.660292880956149e-08
having O 0 9.838169745535197e-08
a O 0 1.5034646594358492e-07
rare O 0 3.518218136377982e-06
intermediate O 0 1.3878936442779377e-05
type O 0 1.6093319572973996e-05
of O 0 4.7074772169253265e-07
adult O 0 0.00037125605740584433
cerebral O 1 0.9963842630386353
and O 0 2.246397707494907e-05
cerebello O 1 0.9759029746055603
- O 0 0.05045325681567192
brain O 0 0.22175587713718414
stem O 0 7.519677456002682e-05
forms O 0 1.177141825792205e-06
, O 0 4.293161453006178e-07
his O 0 1.282491211895831e-06
younger O 0 1.4004393051436637e-05
brother O 0 1.3647084415424615e-05
( O 0 2.4416399355686735e-06
patient O 0 5.575104660238139e-05
2 O 0 4.587845410242153e-07
) O 0 1.9066024492531142e-07
and O 0 1.653416887847925e-07
nephew O 0 8.995777898235247e-05
( O 0 1.2065978580722003e-06
patient O 0 7.228273898363113e-05
3 O 0 6.664092211394745e-07
) O 0 5.727094958274392e-07
had O 0 2.0971156118321232e-06
a O 0 2.4269740606541745e-05
childhood O 1 0.8712142109870911
ALD B-Disease 1 0.9986233711242676
type O 0 0.07673697173595428
. O 0 0.00013731980288866907

Another O 0 5.6640674301888794e-05
nephew O 0 0.002021698048338294
( O 0 1.817890370148234e-05
patient O 0 0.00012873444939032197
4 O 0 8.461569791506918e-07
) O 0 1.0981281661770481e-07
of O 0 7.92847671959862e-08
patient O 0 0.00016403102199546993
1 O 0 1.0385447239968926e-06
was O 0 1.8395163579043583e-06
classified O 0 2.3509253423981136e-06
as O 0 5.7352497861984375e-08
having O 0 4.721154027720331e-07
an O 0 7.555569254691363e-07
adolescent O 0 0.0019623925909399986
form O 0 2.365564796491526e-05
. O 0 3.1218252843245864e-05

The O 0 8.138597877405118e-06
tau O 0 7.77942841523327e-05
level O 0 3.1285726436180994e-06
in O 0 5.314568625180982e-07
the O 0 3.0861197046760935e-06
cerebrospinal O 0 0.08018170297145844
fluid O 0 0.0012685933616012335
( O 0 1.723676541587338e-05
CSF O 0 0.06816624850034714
) O 0 6.700621497657266e-07
in O 0 2.152902851548788e-07
patient O 0 3.105206633335911e-05
1 O 0 2.1903542801737785e-07
was O 0 2.602566837595077e-07
as O 0 2.4822705668725575e-08
high O 0 2.3234869672705827e-07
as O 0 1.773082125566816e-08
that O 0 2.6597323454780053e-08
of O 0 4.259784418536583e-07
patients O 1 0.8545106649398804
with O 0 0.0035820803605020046
Alzheimers B-Disease 1 0.9998757839202881
disease I-Disease 1 0.9996080994606018
( O 0 5.104969386593439e-05
AD B-Disease 0 0.0005258424789644778
) O 0 6.742197001585737e-06
. O 0 1.0114043107023463e-05

His O 0 0.00012924020120408386
brain O 0 0.006721435114741325
magnetic O 0 3.3132953831227496e-05
resonance O 0 8.980059647001326e-05
image O 0 0.00013874933938495815
( O 0 1.3207209121901542e-05
MRI O 0 0.004217297770082951
) O 0 3.5415266665950185e-06
showed O 0 9.204574598697945e-05
abnormalities B-Disease 0 0.021703271195292473
in I-Disease 0 4.106549909010937e-07
the I-Disease 0 1.4424551864067325e-06
bilateral I-Disease 0 0.0001425190712325275
cerebellar I-Disease 1 0.990749180316925
hemispheres I-Disease 0 0.0011681102914735675
and O 0 3.15608449454885e-05
brain O 1 0.9913614392280579
stem O 0 0.0006608425755985081
, O 0 2.670733465492958e-07
but O 0 5.3205933880917655e-08
not O 0 2.0834630021226985e-08
in O 0 1.0581140230669916e-07
the O 0 3.41886379828793e-06
cerebral O 1 0.9971840977668762
white O 0 0.00011111967614851892
matter O 0 3.8759159792789433e-07
, O 0 4.048635915410159e-08
where O 0 3.7735347291345533e-08
marked O 0 7.924241458567849e-07
reductions O 0 2.3400277768814703e-06
of O 0 6.702538968283989e-08
the O 0 9.19951344258152e-06
cerebral O 1 0.9985070824623108
blood O 0 0.008897130377590656
flow O 0 1.0468705113453325e-05
and O 0 4.922659968542575e-07
oxygen O 0 0.000221776615944691
metabolism O 0 9.207920084008947e-05
were O 0 1.2414689365414233e-07
clearly O 0 5.987462827761192e-07
demonstrated O 0 5.582519975178002e-07
by O 0 4.2359801000202424e-07
positron O 0 0.00016425075591541827
emission O 0 2.8372594897518866e-05
tomography O 0 9.199142368743196e-05
( O 0 1.5856847312534228e-05
PET O 0 0.0007266135071404278
) O 0 5.215631972532719e-06
. O 0 1.3523113921110053e-05

In O 0 3.2474719773745164e-05
patients O 0 0.00117120158392936
2 O 0 1.13810585844476e-06
and O 0 9.976853476700853e-08
3 O 0 2.605772806418827e-07
, O 0 5.0274252316739876e-08
the O 0 1.889439289470829e-07
autopsy O 0 7.339902367675677e-05
findings O 0 1.6095315004349686e-05
showed O 0 3.628404374467209e-05
massive O 0 0.001753245247527957
demyelination B-Disease 1 0.9941154718399048
of I-Disease 0 8.988748732008389e-07
the I-Disease 0 6.329223833745345e-05
cerebral I-Disease 1 0.9982840418815613
white I-Disease 0 8.779670315561816e-05
matter I-Disease 0 1.412253141097608e-07
with O 0 4.047392465622579e-08
sparing O 0 1.6185199456231203e-06
of O 0 4.7309249850968627e-08
the O 0 1.7982807776206755e-06
U O 0 0.010824955999851227
- O 0 9.131269325735047e-05
fibers O 0 3.9227496017701924e-05
, O 0 3.4537599447048706e-08
compatible O 0 1.7690055642560765e-07
with O 0 7.010922331573965e-08
the O 0 3.1917033993522637e-07
findings O 0 8.536960194760468e-06
of O 0 5.733243597205728e-06
childhood O 1 0.9582270383834839
ALD B-Disease 1 0.9987993240356445
. O 0 0.0003279811644461006

Oleic O 0 0.012656878679990768
and O 0 2.499982474546414e-05
erucic O 0 0.09017972648143768
acids O 0 7.79232505010441e-05
( O 0 1.3430306353257038e-05
Lorenzos O 0 0.0008351483265869319
Oil O 0 1.0469862900208682e-05
) O 0 3.0929416539038357e-07
were O 0 7.540597835031804e-08
administered O 0 9.67144387686858e-07
to O 0 1.3464546100294683e-07
patients O 0 4.6146004024194553e-05
1 O 0 2.0970865932667948e-07
and O 0 2.6277076514702458e-08
4 O 0 1.403488312234913e-07
, O 0 2.35455459574041e-08
but O 0 2.9062393380741014e-08
sufficient O 0 4.724576854187035e-07
effectiveness O 0 3.5053813007834833e-06
was O 0 8.29506745958497e-07
not O 0 1.2121483905502828e-07
obtained O 0 2.387364247624646e-06
. O 0 5.6871294873417355e-06

The O 0 3.9833635128161404e-06
findings O 0 8.989041816676036e-06
in O 0 2.493993065399991e-07
this O 0 1.6315877360284503e-07
family O 0 1.8245555111207068e-06
suggest O 0 1.0967671641992638e-06
that O 0 8.361404013612628e-08
delGAG291 O 0 8.183996214938816e-06
is O 0 1.5441987244457778e-08
part O 0 9.72564428991518e-09
of O 0 9.08310671121626e-09
the O 0 2.997784633862466e-07
cause O 0 3.25461478496436e-05
of O 0 5.338993673831283e-07
Japanese O 0 0.0019618733786046505
ALD B-Disease 1 0.9976910352706909
with O 0 5.448634055937873e-06
phenotypic O 0 0.0003431305231060833
variations O 0 0.00018391077173873782
. O 0 7.831382390577346e-05

Moreover O 0 5.211556708673015e-05
, O 0 3.736899429895857e-07
although O 0 1.9668469519729115e-07
the O 0 4.318604496234002e-08
scale O 0 2.3396432879962958e-07
of O 0 1.1692652179817742e-08
the O 0 6.887486136974985e-08
study O 0 2.1584185105893994e-07
is O 0 3.888295552201271e-08
limited O 0 6.625222681577725e-08
, O 0 2.1456667553820807e-08
there O 0 1.5171529810231732e-08
is O 0 2.2262772958470123e-08
a O 0 1.899502564128852e-07
possibility O 0 1.6478600173286395e-06
that O 0 3.6349103993416065e-07
PET O 0 7.401424227282405e-05
can O 0 3.066569433940458e-07
detect O 0 3.768575697904453e-05
an O 0 2.8873710107291117e-06
insidious B-Disease 1 0.5225528478622437
lesion I-Disease 1 0.996156632900238
which O 0 5.703994361283549e-07
is O 0 8.181556268027634e-07
undetectable O 0 0.00030952796805649996
by O 0 2.269929666454118e-07
computed O 0 6.9924385570629966e-06
tomogram O 0 0.000901194172911346
( O 0 6.212794687598944e-06
CT O 0 0.0037869105581194162
) O 0 3.573733806661039e-07
or O 0 2.3486749967105425e-07
MRI O 0 2.7982106985291466e-05
analysis O 0 1.1798421439834783e-07
, O 0 2.1207338107842588e-08
and O 0 5.9779039496277164e-09
that O 0 4.037405965107155e-09
the O 0 1.0314794351984347e-08
higher O 0 6.003730135262231e-08
level O 0 4.174994927552689e-08
of O 0 9.940835710153806e-09
tau O 0 5.0381759137962945e-06
reflects O 0 1.5992763735539484e-07
the O 0 1.9135748985377177e-08
process O 0 6.882049774503685e-08
of O 0 9.600317980584805e-07
neuronal B-Disease 0 0.14969339966773987
degeneration I-Disease 1 0.99908447265625
in O 0 0.0020162523724138737
ALD B-Disease 1 0.9987704157829285
. O 0 0.00037236319622024894

Lorenzos O 0 0.007758080959320068
Oil O 0 5.936248635407537e-05
should O 0 4.274931768577517e-07
be O 0 2.2580044500841723e-08
given O 0 3.013698801623832e-08
in O 0 2.9719032568209514e-08
the O 0 8.926237882178611e-08
early O 0 7.826201908756047e-07
stage O 0 1.0410116374259815e-05
. O 0 1.4040721225683228e-06
. O 0 4.740318672702415e-06

Nonsense O 0 0.00017610052600502968
mutation O 0 1.5478424757020548e-05
in O 0 4.839237703890831e-07
exon O 0 2.0977093299734406e-05
4 O 0 4.6195441427698825e-07
of O 0 5.309796335950523e-08
human O 0 9.316827913607995e-07
complement O 0 5.989289547869703e-06
C9 O 0 0.016230693086981773
gene O 0 3.084513309659087e-06
is O 0 1.6632823474083125e-07
the O 0 1.6735260999212187e-07
major O 0 2.018510485868319e-06
cause O 0 3.908854705514386e-05
of O 0 6.662999112450052e-07
Japanese O 0 0.0007530449074693024
complement B-Disease 0 0.007841244339942932
C9 I-Disease 1 0.9968248605728149
deficiency I-Disease 1 0.9993116855621338
. O 0 0.00025779151474125683

Deficiency B-Disease 1 0.9946922659873962
of I-Disease 0 4.838988161282032e-07
the I-Disease 0 3.525946681293135e-07
ninth I-Disease 0 6.018634394422406e-06
component I-Disease 0 9.159220439869387e-07
of I-Disease 0 5.341274800230167e-08
human I-Disease 0 9.96056542135193e-07
complement I-Disease 0 3.2895770800678292e-06
( O 0 2.0270445020287298e-06
C9 O 0 0.004872630815953016
) O 0 1.5975172118487535e-07
is O 0 3.355912170377451e-08
the O 0 8.595420553092481e-08
most O 0 2.1621784185299475e-07
common O 0 2.5341152650071308e-05
complement B-Disease 0 0.04867575317621231
deficiency I-Disease 1 0.9999047517776489
in O 0 1.0607627700665034e-06
Japan O 0 1.7029180526151322e-05
but O 0 2.3185044994988857e-07
is O 0 1.6249725831585238e-07
rare O 0 2.82308997157088e-06
in O 0 1.3397391285252525e-07
other O 0 8.025363484875925e-08
countries O 0 3.8621530507043644e-07
. O 0 7.044841368042398e-06

We O 0 1.012969278235687e-06
studied O 0 7.192475095507689e-07
the O 0 1.1484668505090667e-07
molecular O 0 1.9486706150928512e-06
basis O 0 4.195490532765689e-07
of O 0 5.651015271723736e-06
C9 B-Disease 1 0.9971117973327637
deficiency I-Disease 1 0.9992071986198425
in O 0 2.395008323219372e-06
four O 0 4.5938177208881825e-06
Japanese O 0 0.005729165393859148
C9 B-Disease 1 0.9980699419975281
- I-Disease 1 0.9888661503791809
deficient I-Disease 1 0.9977836012840271
patients O 1 0.6607033610343933
who O 0 7.13391782483086e-05
had O 0 0.0007899085758253932
suffered O 1 0.9968158602714539
from O 0 0.007000300567597151
meningococcal B-Disease 1 0.9988865256309509
meningitis I-Disease 1 0.9989603757858276
. O 0 0.0005301539204083383

Direct O 0 2.583670720923692e-06
sequencing O 0 3.862259291054215e-06
of O 0 8.441652994406468e-07
amplified O 0 0.0001784459745977074
C9 O 0 0.003327162005007267
cDNA O 0 1.161666659754701e-05
and O 0 3.079217947288271e-07
DNA O 0 4.530394562607398e-06
revealed O 0 3.882259079546202e-06
a O 0 5.262600097921677e-07
nonsense O 0 7.71093436924275e-06
substitution O 0 2.8640160962822847e-06
( O 0 2.1271887362672715e-06
CGA O 0 0.0004189003084320575
- O 0 2.247368320240639e-05
- O 0 6.1615432969119865e-06
> O 0 1.2911348676425405e-05
TGA O 0 9.324715210823342e-05
) O 0 6.938395102906725e-08
at O 0 4.484638083113168e-08
codon O 0 1.710447179448238e-07
95 O 0 1.344269691117006e-07
in O 0 2.3528352599555546e-08
exon O 0 2.3444461021426832e-06
4 O 0 2.208460045949323e-07
in O 0 2.9046489657957864e-08
the O 0 2.0012066670460626e-07
four O 0 4.592634923028527e-06
C9 B-Disease 1 0.9862369298934937
- I-Disease 0 0.010098605416715145
deficient I-Disease 0 0.3895750343799591
individuals O 0 8.902788067643996e-06
. O 0 2.6777499442687258e-05

An O 0 6.599521384487161e-06
allele O 0 3.728322189999744e-05
- O 0 1.207211516884854e-05
specific O 0 8.398227464567753e-07
polymerase O 0 6.202914664754644e-05
chain O 0 7.383068441413343e-05
reaction O 0 1.9613635231507942e-05
system O 0 5.9359626902733e-06
designed O 0 2.685306299099466e-06
to O 0 5.276067582826727e-08
detect O 0 1.7623739267946803e-06
exclusively O 0 2.6630877059119484e-08
only O 0 2.962710521359213e-09
one O 0 2.3106643265435878e-09
of O 0 2.983112423748935e-09
the O 0 2.6414964438004063e-08
normal O 0 3.663007248633221e-07
and O 0 6.858410728227682e-08
mutant O 0 2.5269944217143347e-06
alleles O 0 1.191124397337262e-06
indicated O 0 5.793908144369198e-07
that O 0 4.5701660233987695e-09
all O 0 1.2867212850764531e-09
the O 0 2.1807951000596404e-08
four O 0 1.5612818060617428e-07
patients O 0 4.930519207846373e-05
were O 0 1.4283437543838318e-08
homozygous O 0 2.4861282099664095e-07
for O 0 6.8440852984963385e-09
the O 0 2.324403958198218e-08
mutation O 0 6.70882457143307e-07
in O 0 3.8009844161024375e-08
exon O 0 5.2313484957267065e-06
4 O 0 1.287071000888318e-07
and O 0 1.248349690285977e-08
that O 0 1.0262026783891542e-08
the O 0 2.193786485804594e-08
parents O 0 1.390063744111103e-07
of O 0 4.824648414114563e-08
patient O 0 0.000179911483428441
2 O 0 1.409107767358364e-06
were O 0 8.043965067372483e-07
heterozygous O 0 5.644832708640024e-05
. O 0 1.9426237486186437e-05

The O 0 1.4510897017316893e-06
common O 0 1.7607628706173273e-06
mutation O 0 3.4095839964720653e-06
at O 0 3.2936472393885197e-07
codon O 0 9.585972975401091e-07
95 O 0 4.5276803462002135e-07
in O 0 6.077617342725716e-08
exon O 0 8.785150384937879e-06
4 O 0 4.4538225552059885e-07
might O 0 2.180591707201529e-07
be O 0 1.1584590176028087e-08
responsible O 0 1.5631650285286014e-07
for O 0 9.771910214340096e-08
most O 0 1.6889869129954604e-06
Japanese O 0 0.002626457717269659
C9 B-Disease 1 0.9984956979751587
deficiency I-Disease 1 0.999657392501831
. O 0 2.6260418962920085e-05
. O 0 3.134004145977087e-05

BRCA1 O 0 0.0010465247323736548
required O 0 3.7467448237293866e-06
for O 0 1.2186096682853531e-06
transcription O 0 0.00030497246189042926
- O 0 0.0003953599079977721
coupled O 0 0.0003332101332489401
repair O 0 0.010258018970489502
of O 0 4.528027147898683e-06
oxidative O 1 0.5090441703796387
DNA O 0 0.01143060065805912
damage O 1 0.7137712836265564
. O 0 0.0001101415473385714

The O 0 0.0011224155314266682
breast B-Disease 1 0.9961440563201904
and I-Disease 0 0.010240159928798676
ovarian I-Disease 1 0.9999014139175415
cancer I-Disease 1 0.9995558857917786
susceptibility O 0 0.0182478167116642
gene O 0 8.73684257385321e-05
BRCA1 O 0 0.0007878179894760251
encodes O 0 9.952761502063368e-06
a O 0 1.638601861486677e-05
zinc O 0 0.026125768199563026
finger O 0 8.15286475699395e-05
protein O 0 2.9486602670658613e-06
of O 0 2.486868027062883e-07
unknown O 0 1.2267144484212622e-05
function O 0 1.2215441529406235e-05
. O 0 2.753878834482748e-05

Association O 0 2.448837403790094e-05
of O 0 2.1864933330562053e-07
the O 0 1.0978450291077024e-06
BRCA1 O 0 5.9766010963357985e-05
protein O 0 4.5521599645326205e-07
with O 0 8.217121205689182e-08
the O 0 2.1069232047921105e-07
DNA O 0 1.6425394278485328e-05
repair O 0 0.0042525529861450195
protein O 0 9.503445653535891e-06
Rad51 O 0 0.0008356506004929543
and O 0 2.8982571009805724e-08
changes O 0 4.613310267131965e-08
in O 0 5.826564120070543e-09
the O 0 6.494079052288271e-09
phosphorylation O 0 6.013918607550295e-08
and O 0 1.5823117038848977e-08
cellular O 0 6.804465897403134e-07
localization O 0 5.364460662349302e-07
of O 0 7.224163933727823e-09
the O 0 8.452240507494935e-08
protein O 0 1.6882719364730292e-06
after O 0 2.4307646526722237e-06
exposure O 0 3.307959923404269e-05
to O 0 1.207296094207777e-07
DNA O 0 3.2374959118897095e-05
- O 0 2.239514287794009e-05
damaging O 0 2.8725984520860948e-05
agents O 0 2.5515251422802976e-07
are O 0 3.250861357884105e-09
consistent O 0 8.252523286955693e-08
with O 0 1.7981207633965823e-08
a O 0 1.9019387309526792e-07
role O 0 4.2735376837299555e-07
for O 0 3.3600181836845877e-07
BRCA1 O 0 0.0011361473007127643
in O 0 2.1409671262517804e-06
DNA O 0 0.0006201252690516412
repair O 1 0.8718464374542236
. O 0 7.305901090148836e-05

Here O 0 3.20335675496608e-06
, O 0 2.0576162285124155e-07
it O 0 5.28614059192023e-08
is O 0 9.356900676493751e-08
shown O 0 4.4331343929115974e-07
that O 0 1.6601968866325478e-07
mouse O 0 8.38980486150831e-05
embryonic O 0 0.0005594802205450833
stem O 0 0.002717471681535244
cells O 0 0.0013075367314741015
deficient B-Disease 1 0.5452825427055359
in I-Disease 0 2.6684322165237973e-06
BRCA1 I-Disease 0 0.0026089497841894627
are O 0 1.7407826646831381e-07
defective O 0 0.000449893792392686
in O 0 7.472845453548871e-08
the O 0 3.91687891010406e-08
ability O 0 7.29521403286526e-08
to O 0 6.726946999435768e-09
carry O 0 4.2485378770606985e-08
out O 0 8.78919053093341e-08
transcription O 0 1.3381981261773035e-05
- O 0 3.856988769257441e-05
coupled O 0 3.893203756888397e-05
repair O 0 0.0009045079932548106
of O 0 6.41943302071013e-07
oxidative O 0 0.08194977045059204
DNA O 0 0.0016490212874487042
damage O 0 0.06203129515051842
, O 0 4.034210405734484e-07
and O 0 1.5053326762881625e-07
are O 0 7.499404119926112e-08
hypersensitive O 0 0.000333761126967147
to O 0 6.62476736579265e-07
ionizing O 0 0.0016744998283684254
radiation O 0 0.0022071953862905502
and O 0 1.7847968365458655e-06
hydrogen O 0 0.00019823125330731273
peroxide O 0 0.010757538489997387
. O 0 3.672321327030659e-05

These O 0 1.0053997812065063e-06
results O 0 4.814183284906903e-06
suggest O 0 4.756449015985709e-06
that O 0 6.130053407105152e-07
BRCA1 O 0 0.00050798972370103
participates O 0 5.561160378420027e-06
, O 0 8.897664116602755e-08
directly O 0 1.226516417318635e-07
or O 0 1.1913681419173372e-07
indirectly O 0 5.497355459738174e-07
, O 0 3.20654898189332e-08
in O 0 5.6375089485527496e-08
transcription O 0 1.7364600353175774e-05
- O 0 4.1728722862899303e-05
coupled O 0 5.6445958762196824e-05
repair O 0 0.0012690138537436724
of O 0 5.892831609344285e-07
oxidative O 0 0.12076358497142792
DNA O 0 0.003649144433438778
damage O 0 0.12964139878749847
. O 0 5.403006525739329e-06
. O 0 1.567363869980909e-05

Truncation O 0 0.0007158106309361756
mutations O 0 2.5157671188935637e-05
in O 0 3.1272608680410485e-07
the O 0 9.132277796197741e-07
transactivation O 0 0.00041052731103263795
region O 0 1.375257511426753e-06
of O 0 4.021737254333857e-07
PAX6 O 0 0.04105943813920021
result O 0 1.0105673936777748e-05
in O 0 1.9981393961643334e-06
dominant O 0 8.567985787522048e-05
- O 0 8.791013533482328e-05
negative O 0 1.1855230695800856e-05
mutants O 0 0.00022907690436113626
. O 0 1.5503806935157627e-05

PAX6 O 0 0.00733094522729516
is O 0 9.708445531941834e-07
a O 0 4.34692594808439e-07
transcription O 0 4.009652911918238e-06
factor O 0 3.4551314342934347e-07
with O 0 3.279523141941354e-08
two O 0 4.6266514175385964e-08
DNA O 0 3.7023876302555436e-06
- O 0 1.0172460633839364e-06
binding O 0 2.3425747031069477e-07
domains O 0 1.1679422868837719e-06
( O 0 4.510910684984992e-07
paired O 0 6.5591757447691634e-06
box O 0 1.1406114026613068e-05
and O 0 2.213360232872219e-07
homeobox O 0 0.0002384323306614533
) O 0 1.550110084735934e-07
and O 0 2.885972527622016e-08
a O 0 4.482624262891477e-07
proline O 0 3.1970161217032e-05
- O 0 3.7172364955040393e-06
serine O 0 5.093612799100811e-06
- O 0 4.053723387187347e-06
threonine O 0 6.0935012697882485e-06
( O 0 1.6655886838634615e-06
PST O 0 0.00036620793980546296
) O 0 1.3852034044248285e-06
- O 0 6.7203973230789416e-06
rich O 0 2.9205427836132003e-06
transactivation O 0 0.00020412332378327847
domain O 0 4.132333197048865e-05
. O 0 3.7973964936099946e-05

PAX6 O 1 0.9264469146728516
regulates O 0 0.015882868319749832
eye O 0 0.009438403882086277
development O 0 5.2969271564506926e-06
in O 0 1.014491658679617e-06
animals O 0 2.8806491627619835e-06
ranging O 0 3.018646339114639e-06
from O 0 8.161566142916854e-07
jellyfish O 0 1.4672003089799546e-05
to O 0 1.1914521991229776e-07
Drosophila O 0 2.186002348025795e-06
to O 0 5.103606213197054e-07
humans O 0 2.4709614081075415e-05
. O 0 1.3353806025406811e-05

Heterozygous O 0 0.0001506840344518423
mutations O 0 2.437004877720028e-05
in O 0 3.9645624383410905e-07
the O 0 5.477218678606732e-07
human O 0 5.664758191414876e-06
PAX6 O 0 0.04129735007882118
gene O 0 7.610626653331565e-06
result O 0 9.8868974873767e-07
in O 0 9.3023771796652e-08
various O 0 1.2338465182892833e-07
phenotypes O 0 0.00014529080362990499
, O 0 9.990494618250523e-07
including O 0 3.5480848055158276e-06
aniridia B-Disease 1 0.9658581018447876
, O 0 2.6262749088346027e-05
Peters B-Disease 1 0.7066676020622253
anomaly I-Disease 1 0.9555348753929138
, O 0 2.0883440811303444e-05
autosomal B-Disease 1 0.7711793184280396
dominant I-Disease 0 0.017254231497645378
keratitis I-Disease 1 0.9944236874580383
, O 0 2.4659799237269908e-05
and O 0 4.325389818404801e-05
familial B-Disease 1 0.994963526725769
foveal I-Disease 1 0.9957822561264038
dysplasia I-Disease 1 0.9993365406990051
. O 0 0.0014269310049712658

It O 0 9.489104400017823e-07
is O 0 2.992374845689483e-07
believed O 0 7.999487934284844e-07
that O 0 3.507172152694693e-08
the O 0 1.2911426949813176e-07
mutated O 0 5.482284905156121e-06
allele O 0 6.807451882195892e-07
of O 0 9.450238280805934e-08
PAX6 O 0 0.002097849501296878
produces O 0 3.301315246062586e-06
an O 0 4.1675883721836726e-07
inactive O 0 2.080527883663308e-05
protein O 0 5.526757831830764e-06
and O 0 8.708656196176889e-07
aniridia B-Disease 0 0.20765237510204315
is O 0 6.054135610611411e-06
caused O 0 0.0007979546790011227
due O 0 1.5247209375957027e-05
to O 0 1.339952859780169e-06
genetic O 0 0.00044286009506322443
haploinsufficiency O 0 0.030948160216212273
. O 0 7.961954543134198e-05

However O 0 5.930491170147434e-06
, O 0 4.7253067236852075e-07
several O 0 4.272184810361068e-07
truncation O 0 0.0001980831439141184
mutations O 0 1.3108167877362575e-05
have O 0 4.761459493352049e-08
been O 0 5.4816396755086316e-08
found O 0 4.611365866935557e-08
to O 0 6.280941100555992e-09
occur O 0 5.605011565990026e-08
in O 0 1.690515816221705e-08
the O 0 1.512037499651342e-07
C O 0 2.8447044314816594e-05
- O 0 5.684624738933053e-06
terminal O 0 9.045823389897123e-06
half O 0 7.061329654334259e-08
of O 0 2.4644060658829403e-07
PAX6 O 0 0.0633828267455101
in O 0 4.516464741755044e-06
patients O 0 0.0018982728943228722
with O 0 2.974517428810941e-06
Aniridia B-Disease 0 0.15572328865528107
resulting O 0 2.3147929823608138e-05
in O 0 2.382391812716378e-07
mutant O 0 3.3609776437515393e-06
proteins O 0 7.461209605708063e-08
that O 0 1.5920988971629413e-08
retain O 0 1.7237933036540198e-07
the O 0 5.3860116366877264e-08
DNA O 0 1.9043703787247068e-06
- O 0 6.043701432645321e-07
binding O 0 1.0383194393170925e-07
domains O 0 2.2115665387900663e-07
but O 0 3.587275543281976e-08
have O 0 1.1018329360013013e-08
lost O 0 9.621309970953007e-08
most O 0 5.5800377651848976e-09
of O 0 1.1193763249650601e-08
the O 0 5.682119876837533e-07
transactivation O 0 0.0003313038614578545
domain O 0 3.9372949686367065e-05
. O 0 2.021362161030993e-05

It O 0 1.8258643876833958e-06
is O 0 4.3667617433129635e-07
not O 0 5.9037219557467324e-08
clear O 0 3.9180076782940887e-07
whether O 0 1.6770536603871733e-07
such O 0 1.7606575397621782e-07
mutants O 0 2.2512014766107313e-05
really O 0 1.5274335964932106e-06
behave O 0 1.7825242366598104e-06
as O 0 1.7540226338041975e-07
loss O 0 2.0861407392658293e-05
- O 0 1.2559656852317858e-06
of O 0 5.5232213469480484e-08
- O 0 2.1373439267335925e-06
function O 0 2.2708455560405127e-07
mutants O 0 7.294849183381302e-06
as O 0 3.40999292802735e-07
predicted O 0 2.0429219148354605e-05
by O 0 2.653712954270304e-06
haploinsufficiency O 0 0.0034042848274111748
. O 0 2.6906616767519154e-05

Contrary O 0 1.4717352314619347e-05
to O 0 2.002661574351805e-07
this O 0 7.291041015378141e-08
theory O 0 2.246903676450529e-07
, O 0 5.925279822349694e-08
our O 0 2.9464425566061436e-08
data O 0 2.081056749148047e-07
showed O 0 5.755253482675471e-07
that O 0 1.6677768499562262e-08
these O 0 1.535806859465083e-08
mutants O 0 2.7089909053756855e-06
are O 0 2.4577724744290208e-08
dominant O 0 3.4185281947429758e-06
- O 0 3.6300853025750257e-06
negative O 0 5.675452712239348e-07
in O 0 2.9709067916883214e-07
transient O 0 0.00012220838107168674
transfection O 0 0.00022379177971743047
assays O 0 4.490116680244682e-06
when O 0 4.575576326715236e-07
they O 0 4.445267620667437e-08
are O 0 5.1768918041261713e-08
coexpressed O 0 4.306280970922671e-05
with O 0 7.925888780846435e-07
wild O 0 3.9140395529102534e-05
- O 0 0.0002059239341178909
type O 0 0.0008071559714153409
PAX6 O 0 0.3102249801158905
. O 0 4.2023639252875e-05

We O 0 6.64473702727264e-07
found O 0 5.554194899559661e-07
that O 0 3.884218813254847e-08
the O 0 1.290588755864519e-07
dominant O 0 1.111147412302671e-05
- O 0 8.258321940957103e-06
negative O 0 6.225447464203171e-07
effects O 0 4.76533477922203e-06
result O 0 4.865661367148277e-07
from O 0 6.608992464407493e-08
the O 0 8.103779691737145e-08
enhanced O 0 1.4647696389147313e-06
DNA O 0 1.028433416649932e-06
binding O 0 2.481726824044017e-07
ability O 0 1.2868574117419485e-07
of O 0 3.3168905844149776e-08
these O 0 2.1184662557516276e-07
mutants O 0 0.00012817871174775064
. O 0 9.27400014916202e-06

Kinetic O 0 1.9061319108004682e-05
studies O 0 1.3916622947363066e-06
of O 0 7.901137166754779e-08
binding O 0 3.6648100376623916e-06
and O 0 6.273340886764345e-07
dissociation O 0 0.0001258786505786702
revealed O 0 1.4795059541938826e-05
that O 0 8.27757276056218e-08
various O 0 1.2462935217172344e-07
truncation O 0 5.839307777932845e-05
mutants O 0 1.2121374311391264e-05
have O 0 7.705575910676998e-08
3 O 0 5.740174060520076e-07
- O 0 1.8106968582287664e-06
5 O 0 3.1275115475182247e-07
- O 0 6.975108703954902e-07
fold O 0 4.6225588334891654e-07
higher O 0 7.607614094240489e-08
affinity O 0 6.062727919697863e-08
to O 0 1.6499845933992674e-09
various O 0 6.504367711102077e-09
DNA O 0 6.95109690695972e-07
- O 0 2.6129396246687975e-07
binding O 0 2.9889573482932974e-08
sites O 0 1.8497898324199014e-08
when O 0 3.902352574414181e-08
compared O 0 7.443470906309813e-08
with O 0 1.910493274692726e-08
the O 0 2.755017760591727e-07
wild O 0 9.196223800245207e-06
- O 0 0.00013761762238573283
type O 0 0.00033315009204670787
PAX6 O 0 0.0857139453291893
. O 0 2.5388757421751507e-05

These O 0 5.159995453141164e-07
results O 0 7.243855293381785e-07
provide O 0 2.2491161644211388e-07
a O 0 1.5272500775154185e-07
new O 0 6.987919931589204e-08
insight O 0 3.2876280897653487e-07
into O 0 1.6985344686304416e-08
the O 0 4.095922534474994e-08
role O 0 1.9693618469318608e-07
of O 0 1.1319723114411318e-07
mutant O 0 0.00020449051226023585
PAX6 O 0 0.18805047869682312
in O 0 1.1641840501397382e-05
causing O 0 0.08028630167245865
aniridia B-Disease 1 0.9672263264656067
. O 0 1.346644785371609e-05
. O 0 3.1334573577623814e-05

Reversal O 0 0.04960796982049942
of O 0 0.0013697179965674877
severe O 1 0.9996032118797302
hypertrophic B-Disease 1 0.9998064637184143
cardiomyopathy I-Disease 1 0.9998573064804077
and O 0 1.954082472366281e-05
excellent O 0 0.00012335693463683128
neuropsychologic O 0 0.0015777834923937917
outcome O 0 4.422267011250369e-06
in O 0 5.476163096318487e-07
very B-Disease 0 1.8827331587090157e-06
- I-Disease 0 3.061617826460861e-05
long I-Disease 0 1.6112329831230454e-05
- I-Disease 0 1.687522672000341e-05
chain I-Disease 0 3.576849849196151e-05
acyl I-Disease 0 0.0003420854627620429
- I-Disease 0 8.514944784110412e-05
coenzyme I-Disease 0 0.0003741406835615635
A I-Disease 0 0.0013053505681455135
dehydrogenase I-Disease 1 0.985582709312439
deficiency I-Disease 1 0.9988634586334229
. O 0 0.0001931978767970577

Very B-Disease 0 6.83746620779857e-05
- I-Disease 0 0.00017891294555738568
long I-Disease 0 3.719472078955732e-05
- I-Disease 0 2.6414332751301117e-05
chain I-Disease 0 2.4323657271452248e-05
acyl I-Disease 0 0.0001550691231386736
- I-Disease 0 1.492808496550424e-05
coenzyme I-Disease 0 3.342119816807099e-05
A I-Disease 0 1.2566554687509779e-05
dehydrogenase I-Disease 0 0.0032538380473852158
( I-Disease 0 2.7933132514590397e-05
VLCAD I-Disease 0 0.43035048246383667
) I-Disease 0 0.00015887946938164532
deficiency I-Disease 1 0.9993433356285095
is O 0 2.896223804782494e-06
a O 0 1.3959484022052493e-05
disorder O 1 0.987138032913208
of O 0 4.877155106441933e-07
fatty O 0 0.001714962301775813
acid O 0 0.0006112045957706869
beta O 0 5.4261159675661474e-05
oxidation O 0 6.914754339959472e-05
that O 0 2.907199530000071e-07
reportedly O 0 1.0404637578176335e-05
has O 0 2.7478753850118665e-07
high O 0 1.1865994338222663e-06
rates O 0 1.541500978419208e-06
of O 0 3.115378035545291e-07
morbidity O 0 0.4033157229423523
and O 0 4.923293090541847e-06
mortality O 0 0.015195932239294052
. O 0 2.9117296435288154e-05

We O 0 3.6565501204677275e-07
describe O 0 7.285257197509054e-07
the O 0 4.442513201752263e-08
outcome O 0 1.0261423710744566e-07
of O 0 1.6428257865186424e-08
a O 0 4.766893653140869e-07
5 O 0 2.316695372428512e-06
- O 0 8.306123163492884e-06
year O 0 1.436031539014948e-06
- O 0 9.557270459481515e-06
old O 0 1.8203551007900387e-05
girl O 0 0.00018073816318064928
with O 0 5.4105421440908685e-05
VLCAD B-Disease 1 0.9992966651916504
deficiency I-Disease 1 0.9999057054519653
who O 0 1.3266476344142575e-06
was O 0 4.495737471188477e-07
first O 0 4.271051778914625e-08
seen O 0 2.3460424358745513e-07
at O 0 8.782286897712765e-08
5 O 0 8.922425109858523e-08
months O 0 2.0691612689915928e-07
of O 0 8.571403498081054e-08
age O 0 0.00021130552340764552
with O 0 0.0014002330135554075
severe O 1 0.9996670484542847
hypertrophic B-Disease 1 0.9998879432678223
cardiomyopathy I-Disease 1 0.9999586343765259
, O 1 0.8949295878410339
hepatomegaly B-Disease 1 0.9996919631958008
, O 0 0.2447178214788437
encephalopathy B-Disease 1 0.9995751976966858
, O 0 6.07172041782178e-05
and O 0 3.861743971356191e-05
hypotonia B-Disease 1 0.9826695919036865
. O 0 0.00012334092753008008

Biochemical O 0 0.007784740999341011
studies O 0 0.0014346514362841845
indicated O 1 0.9661068320274353
VLCAD B-Disease 1 0.9989638328552246
deficiency I-Disease 1 0.9999252557754517
caused O 0 0.20588555932044983
by O 0 4.489954335440416e-06
a O 0 1.8836450180970132e-05
stable O 0 0.00024166649382095784
yet O 0 1.2357179002719931e-05
inactive O 0 0.00022233344498090446
enzyme O 0 0.000252656260272488
. O 0 1.975137274712324e-05

Molecular O 0 4.9227910494664684e-05
genetic O 0 9.640958523959853e-06
analysis O 0 3.1051564519657404e-07
of O 0 1.8228494980121468e-07
her O 0 8.484594218316488e-06
VLCAD O 0 0.0069318534806370735
gene O 0 1.632717794564087e-05
revealed O 0 1.1927581908821594e-05
a O 0 1.198549171022023e-06
T1372C O 0 8.107804751489311e-05
( O 0 1.6103674624901032e-06
F458L O 0 2.6429222998558544e-05
) O 0 6.432271675294032e-07
missense O 0 2.6888457796303555e-05
mutation O 0 6.246813882171409e-06
and O 0 3.0134003736748127e-07
a O 0 2.0885869162157178e-05
1668 O 0 0.17973680794239044
ACAG O 0 0.150847926735878
1669 O 0 0.021304642781615257
splice O 0 0.0007989038131199777
site O 0 7.368888327619061e-05
mutation O 0 0.00028360201395116746
. O 0 2.7003963623428717e-05

After O 0 6.739349919371307e-05
initial O 0 0.00015517030260525644
treatment O 0 0.002724669873714447
with O 0 5.491551746672485e-06
intravenous O 0 0.08742039650678635
glucose O 0 0.0020957484375685453
and O 0 3.702875119415694e-06
carnitine O 0 0.3411947190761566
, O 0 5.801958309348265e-07
the O 0 6.893964723531099e-07
patient O 0 0.0001582304248586297
has O 0 4.3281411876705533e-07
thrived O 0 8.996519682114013e-06
on O 0 1.5050197532673337e-07
a O 0 7.31843158519041e-07
low O 0 2.4423654394922778e-05
- O 0 1.347042871202575e-05
fat O 0 2.1541980459005572e-05
diet O 0 1.3911546375311445e-05
supplemented O 0 1.8935460275315563e-06
with O 0 3.925892144707177e-07
medium O 0 1.3870983821107075e-05
- O 0 2.9197211915743537e-05
chain O 0 3.4399392461637035e-05
triglyceride O 0 0.00013729282363783568
oil O 0 8.79048093338497e-06
and O 0 1.2815779655284132e-06
carnitine O 0 0.0036671876441687346
and O 0 8.320976121467538e-07
avoidance O 0 0.00023383823281619698
of O 0 3.079992211496574e-06
fasting O 0 0.0006115183350630105
. O 0 5.183161920285784e-05

Her O 0 0.004608410410583019
ventricular O 1 0.9899673461914062
hypertrophy O 1 0.9860551953315735
resolved O 0 0.0002730663982219994
significantly O 0 5.637920185108669e-05
over O 0 6.991532472966355e-07
1 O 0 1.4067165921005653e-06
year O 0 8.995729672278685e-07
, O 0 1.6632156984996982e-07
and O 0 1.10660998586809e-07
cognitively O 0 8.107750909402966e-05
, O 0 9.238122089527678e-08
she O 0 1.2981482200302707e-07
is O 0 1.2076964317486727e-08
in O 0 8.57678017496255e-09
the O 0 2.990018188597787e-08
superior O 0 3.2104767342389096e-06
range O 0 3.9985806665754353e-07
for O 0 1.746436311123034e-07
age O 0 3.54539297404699e-05
. O 0 1.27853045341908e-05

Clinical O 0 0.001464222907088697
recognition O 0 8.246703509939834e-05
of O 0 0.0003274868940934539
VLCAD B-Disease 1 0.9996446371078491
deficiency I-Disease 1 0.9999464750289917
is O 0 2.017380893448717e-06
important O 0 2.014618587509176e-07
because O 0 1.0405558015236238e-07
it O 0 6.407289809828853e-09
is O 0 3.9815497565598434e-09
one O 0 1.2938902171910627e-09
of O 0 5.683997716943168e-09
the O 0 2.0697790148460626e-07
few O 0 2.5767708393686917e-06
directly O 0 5.682103801518679e-05
treatable O 1 0.9987099170684814
causes O 0 0.08083686232566833
of O 0 7.217713573481888e-05
cardiomyopathy B-Disease 1 0.9998568296432495
in O 0 5.839307777932845e-05
children O 0 0.00012631753634195775
. O 0 9.419441084901337e-06
. O 0 2.2950802303967066e-05

Cloning O 0 2.6327519663027488e-05
of O 0 1.7675924368631968e-07
a O 0 7.179810381785501e-07
novel O 0 9.315361921835574e-07
member O 0 1.3491191452885687e-07
of O 0 2.3705924334649353e-08
the O 0 3.165524447013013e-07
low O 0 2.475078872521408e-05
- O 0 1.2302315553824883e-05
density O 0 7.224521141324658e-06
lipoprotein O 0 0.023696795105934143
receptor O 0 0.00020456640049815178
family O 0 5.4546602768823504e-05
. O 0 2.7019086701329798e-05

A O 0 6.011068307998357e-06
gene O 0 1.8308373910258524e-06
encoding O 0 6.131819532129157e-07
a O 0 7.549627412117843e-07
novel O 0 2.5195975013048155e-06
transmembrane O 0 4.885214366368018e-05
protein O 0 2.391502675891388e-06
was O 0 4.090863967576297e-07
identified O 0 7.429711956774554e-08
by O 0 8.620832936401257e-09
DNA O 0 8.37051530311328e-08
sequence O 0 3.44244810435157e-08
analysis O 0 4.952220677978403e-08
within O 0 1.5689897736592684e-07
the O 0 4.9486648094898555e-06
insulin B-Disease 0 0.33699288964271545
- I-Disease 0 0.028959352523088455
dependent I-Disease 0 0.013788430951535702
diabetes I-Disease 1 0.9998445510864258
mellitus I-Disease 1 0.9992226362228394
( O 0 5.83751498197671e-05
IDDM B-Disease 0 0.016988947987556458
) O 0 3.054461785723106e-06
locus O 0 7.815111166564748e-05
IDDM4 O 0 0.0018791211768984795
on O 0 6.213197139004478e-06
chromosome O 0 0.00028379540890455246
11q13 O 0 0.0010321484878659248
. O 0 3.6110337532591075e-05

Based O 0 1.1798099421866937e-06
on O 0 2.5696641614558757e-07
its O 0 1.6287131643366592e-07
chromosomal O 0 1.959804467333015e-05
position O 0 2.2912068686764542e-07
, O 0 2.7995341156383802e-08
this O 0 1.278906847090866e-08
gene O 0 2.2084390138843446e-07
is O 0 1.4688772864701605e-08
a O 0 9.65012745268723e-08
candidate O 0 2.374708714114604e-07
for O 0 2.99013805715731e-07
conferring O 0 0.00019469040853437036
susceptibility O 0 0.030973441898822784
to O 0 0.00010537006892263889
diabetes B-Disease 1 0.9992689490318298
. O 0 0.00021817795641254634

The O 0 4.503359377849847e-06
gene O 0 1.1176161024195608e-05
, O 0 1.591926661603793e-06
termed O 0 8.805897959973663e-05
low O 0 3.516143260640092e-05
- O 0 1.0859223948500585e-05
density O 0 3.5194261727156118e-06
lipoprotein O 0 0.0022974854800850153
receptor O 0 1.2094160410924815e-05
related O 0 8.139289207065303e-07
protein O 0 1.1011416063411161e-06
5 O 0 4.12230406254821e-07
( O 0 3.441608669163543e-07
LRP5 O 0 4.367610381450504e-05
) O 0 1.762837520402627e-08
, O 0 3.65553654013695e-09
encodes O 0 3.371309276190004e-08
a O 0 1.5921505891469678e-08
protein O 0 5.948970382974039e-08
of O 0 1.3290946121458092e-08
1615 O 0 1.328868620475987e-05
amino O 0 2.888594394789834e-07
acids O 0 1.1235221819561048e-07
that O 0 7.083678976727015e-09
contains O 0 3.5354950966848264e-08
conserved O 0 1.1376226893844432e-07
modules O 0 1.5478735804208554e-07
which O 0 7.83407116955459e-09
are O 0 1.2105763058656294e-09
characteristic O 0 6.590160950281643e-08
of O 0 7.150466441174785e-09
the O 0 1.1259259480311812e-07
low O 0 1.5785391951794736e-05
- O 0 9.796114682103507e-06
density O 0 3.6311066651251167e-06
lipoprotein O 0 0.017311813309788704
( O 0 9.055257578438614e-06
LDL O 0 0.23363707959651947
) O 0 1.887013240775559e-06
receptor O 0 4.3315074435668066e-05
family O 0 1.699449603620451e-05
. O 0 7.4514559855742846e-06

These O 0 3.191843234162661e-07
modules O 0 3.1093693451111903e-06
include O 0 2.8359730208649125e-07
a O 0 4.187571960301284e-07
putative O 0 7.652533895452507e-06
signal O 0 1.3971730368211865e-06
peptide O 0 1.6038691228459356e-06
for O 0 1.4101826373291715e-08
protein O 0 3.820711924618081e-07
export O 0 2.2888568196322012e-07
, O 0 5.2916384163381736e-08
four O 0 2.1020363760726468e-07
epidermal O 0 0.0028207870200276375
growth O 0 1.3784028851659968e-05
factor O 0 4.072640876984224e-06
( O 0 3.5418574952927884e-06
EGF O 0 0.001486223191022873
) O 0 2.1306371422724624e-07
repeats O 0 3.890353582391981e-06
with O 0 1.4995640640336205e-07
associated O 0 1.509363414697873e-06
spacer O 0 6.762700650142506e-05
domains O 0 3.6201699913362972e-06
, O 0 5.319888032317976e-07
three O 0 1.1614577033469686e-06
LDL O 1 0.8918940424919128
- O 0 3.101474794675596e-05
receptor O 0 9.195171514875256e-06
( O 0 7.192461453087162e-07
LDLR O 0 8.476754010189325e-05
) O 0 1.2621261191725353e-07
repeats O 0 9.37864228944818e-07
, O 0 1.491823731214481e-08
a O 0 2.9865013573271426e-08
single O 0 8.213110191945816e-08
transmembrane O 0 4.740174517792184e-06
spanning O 0 9.660741397965467e-07
domain O 0 2.2207116501249402e-07
, O 0 3.228026557167141e-08
and O 0 2.53902356917024e-08
a O 0 3.5186707236789516e-07
cytoplasmic O 0 2.397389107500203e-05
domain O 0 1.3277044672577176e-05
. O 0 1.2606705240614247e-05

The O 0 4.7740275022079e-07
encoded O 0 6.904110705363564e-07
protein O 0 1.1390744703021483e-06
has O 0 1.1055741566678989e-07
a O 0 7.811693336634562e-08
unique O 0 6.592008361394619e-08
organization O 0 1.866267496097862e-07
of O 0 1.6488284870774805e-07
EGF O 0 0.007168888114392757
and O 0 4.120118717310106e-07
LDLR O 0 0.001718556392006576
repeats O 0 2.544382914493326e-05
; O 0 2.587396465969505e-07
therefore O 0 3.4650437896743824e-07
, O 0 2.0863943461790768e-07
LRP5 O 0 0.00039695401210337877
likely O 0 4.710157952558802e-07
represents O 0 1.1767159691089546e-07
a O 0 1.0807197270423785e-07
new O 0 5.44366187682499e-08
category O 0 3.2627156087983167e-07
of O 0 5.789003409972793e-08
the O 0 2.4443284019071143e-06
LDLR O 0 0.01476264838129282
family O 0 9.050114022102207e-05
. O 0 2.1690693756681867e-05

Both O 0 8.046888069657143e-06
human O 0 1.70859057107009e-05
and O 0 6.957948244235013e-06
mouse O 0 0.0020403116941452026
LRP5 O 0 0.07835983484983444
cDNAs O 0 0.0009295372292399406
have O 0 1.7823155928908818e-07
been O 0 1.0674467887383798e-07
isolated O 0 5.605652404483408e-07
and O 0 5.09852471353156e-09
the O 0 8.945663765302925e-09
encoded O 0 4.276570919614642e-08
mature O 0 2.8554777031786216e-07
proteins O 0 2.5800357406069452e-08
are O 0 2.227448447911229e-09
95 O 0 7.1706416804318e-08
% O 0 3.118082148034773e-08
identical O 0 2.24357194156255e-07
, O 0 3.810246695934438e-08
indicating O 0 6.613846608161111e-07
a O 0 9.241787779501465e-08
high O 0 2.9897674380663375e-07
degree O 0 2.5536721182106703e-07
of O 0 2.5974854267474257e-08
evolutionary O 0 5.452075129142031e-06
conservation O 0 1.0775078408187255e-05
. O 0 1.382223672408145e-06
. O 0 6.6233164943696465e-06

The O 0 2.202739051426761e-05
APC B-Disease 0 0.0012178121833130717
variants O 0 3.573399590095505e-05
I1307K O 0 0.00013431611296255141
and O 0 8.038858254622028e-07
E1317Q O 0 0.00014456335338763893
are O 0 8.342660180460371e-07
associated O 0 0.0001711148943286389
with O 0 0.08295837044715881
colorectal B-Disease 1 0.9999908208847046
tumors I-Disease 1 0.9999661445617676
, O 0 2.7502558168635005e-06
but O 0 1.832247278343857e-07
not O 0 1.438445806911659e-08
always O 0 5.974235506300829e-08
with O 0 3.226610445494771e-08
a O 0 6.402173653441423e-07
family O 0 5.662581315846182e-06
history O 0 1.2238504496053793e-05
. O 0 1.6636180589557625e-05

Classical O 0 0.032333001494407654
familial B-Disease 1 0.99652498960495
adenomatous I-Disease 1 0.9985104203224182
polyposis I-Disease 1 0.9991631507873535
( O 0 0.001771124778315425
FAP B-Disease 1 0.8266588449478149
) O 0 1.9921005787182366e-06
is O 0 5.300477141645388e-07
a O 0 1.399087750542094e-06
high O 0 0.00021547183860093355
- O 0 0.0037262500263750553
penetrance O 1 0.9248674511909485
autosomal B-Disease 1 0.9974950551986694
dominant I-Disease 1 0.9797217845916748
disease I-Disease 1 0.9995424747467041
that O 0 5.329365194484126e-06
predisposes O 0 0.004914204590022564
to O 0 1.900412058830625e-07
hundreds O 0 8.677732807882421e-07
or O 0 9.823297659750096e-07
thousands O 0 9.443997441849206e-06
of O 0 0.00010661018313840032
colorectal B-Disease 1 0.9999685287475586
adenomas I-Disease 1 0.9997040629386902
and I-Disease 0 0.001529824105091393
carcinoma I-Disease 1 0.9999213218688965
and O 0 3.704058144649025e-07
that O 0 8.210682267417724e-08
results O 0 2.819033682044392e-07
from O 0 2.5813704951360705e-07
truncating O 0 0.00013600495003629476
mutations O 0 4.902476121060317e-06
in O 0 2.2224341478249698e-07
the O 0 1.2262572681720485e-06
APC B-Disease 0 0.0011721658520400524
gene O 0 6.201121868798509e-05
. O 0 1.760460509103723e-05

A O 0 8.768860425334424e-05
variant O 0 0.0013724574819207191
of O 0 1.4903334886184894e-05
FAP B-Disease 1 0.9866389036178589
is O 0 0.0013168009463697672
attenuated B-Disease 1 0.9908609390258789
adenomatous I-Disease 1 0.9991924166679382
polyposis I-Disease 1 0.9992343187332153
coli I-Disease 1 0.996812641620636
, O 0 1.2428910167727736e-06
which O 0 3.2655731274644495e-07
results O 0 2.0232148472132394e-06
from O 0 2.05746232495585e-06
germ O 0 0.0852365717291832
- O 0 5.661501745635178e-06
line O 0 5.261953219815041e-07
mutations O 0 3.3190551107509236e-07
in O 0 4.8408685948686525e-09
the O 0 6.952434183915557e-09
5 O 0 2.1834921426489018e-08
and O 0 4.487638705086283e-09
3 O 0 2.3397763726507037e-08
regions O 0 6.825170206781195e-09
of O 0 1.3516272545643915e-08
the O 0 1.09276004423009e-06
APC B-Disease 0 0.0017094436334446073
gene O 0 6.852198566775769e-05
. O 0 2.5881272449623793e-05

Attenuated B-Disease 1 0.98109370470047
adenomatous I-Disease 1 0.9989897608757019
polyposis I-Disease 1 0.9995274543762207
coli I-Disease 1 0.9995189905166626
patients O 1 0.9878081679344177
have O 0 5.5220061767613515e-06
" O 0 1.0713271876738872e-05
multiple O 0 0.00023505580611526966
" O 0 0.005983905401080847
colorectal B-Disease 1 0.9999247789382935
adenomas I-Disease 1 0.99898761510849
( O 0 4.84335532746627e-06
typically O 0 7.811840418980864e-07
fewer O 0 2.1687992557417601e-07
than O 0 1.77403585155389e-08
100 O 0 5.2509491865748714e-08
) O 0 2.618422101363649e-08
without O 0 4.580116552688196e-08
the O 0 1.480370173112533e-07
florid O 0 0.001224811770953238
phenotype O 0 6.179870251799002e-05
of O 0 5.882051254957332e-07
classical O 0 0.00025290666962973773
FAP B-Disease 1 0.9637150764465332
. O 0 8.555665408493951e-05

Another O 0 1.4914738130755723e-05
group O 0 4.937818175676512e-06
of O 0 1.6669998785801e-06
patients O 0 0.004826949443668127
with O 0 2.617613745314884e-06
multiple O 0 0.00012561689072754234
adenomas B-Disease 1 0.9910145401954651
has O 0 7.714081107224047e-07
no O 0 4.379348297334218e-07
mutations O 0 1.143963686445204e-06
in O 0 4.609255199738982e-08
the O 0 1.9391517014355486e-07
APC B-Disease 0 0.0001043684605974704
gene O 0 1.191124397337262e-06
, O 0 3.7964053234418316e-08
and O 0 2.2290306489480827e-08
their O 0 4.851991874943451e-08
phenotype O 0 1.973738289962057e-05
probably O 0 4.1421421315135376e-07
results O 0 1.1335830407688263e-07
from O 0 3.898231426546772e-08
variation O 0 2.676511314803065e-07
at O 0 1.2263456028449582e-07
a O 0 1.754894327632428e-07
locus O 0 1.3535102425521472e-06
, O 0 3.941640258631196e-08
or O 0 1.171198675820051e-07
loci O 0 2.1506302800844423e-06
, O 0 5.943753222936721e-08
elsewhere O 0 2.1814278738929715e-07
in O 0 6.511718453339199e-08
the O 0 6.092137141422427e-07
genome O 0 4.782007817993872e-05
. O 0 1.3189284800319001e-05

Recently O 0 7.448388350894675e-05
, O 0 5.741230779676698e-07
however O 0 4.868725227424875e-07
, O 0 1.2742154353873048e-07
a O 0 7.378658892776002e-07
missense O 0 4.870853808824904e-05
variant O 0 4.559962326311506e-05
of O 0 4.235859023538069e-07
APC B-Disease 0 0.0015607986133545637
( O 0 3.320598580103251e-06
I1307K O 0 7.753648242214695e-05
) O 0 4.266028952315537e-07
was O 0 1.0852223795154714e-06
described O 0 1.733693011374271e-06
that O 0 1.2568268914492364e-07
confers O 0 2.4014210794121027e-05
an O 0 1.2048523103658226e-06
increased O 0 5.189908551983535e-05
risk O 0 0.012612812221050262
of O 0 0.0009069873485714197
colorectal B-Disease 1 0.9999831914901733
tumors I-Disease 1 0.9999023675918579
, O 0 6.083780590415699e-06
including O 0 2.6550494567345595e-06
multiple O 0 0.0005184549372643232
adenomas B-Disease 1 0.9945683479309082
, O 0 7.590766017528949e-06
in O 0 1.0311880032531917e-05
Ashkenazim O 0 0.004535773769021034
. O 0 5.1629114750539884e-05

We O 0 3.865137330194557e-07
have O 0 3.3585759950938154e-08
studied O 0 6.809334962554203e-08
a O 0 3.7698228538829426e-08
set O 0 3.1905219799455153e-08
of O 0 1.5929761332245107e-07
164 O 0 0.0001310987863689661
patients O 0 0.01072017289698124
with O 0 4.199135219096206e-05
multiple O 1 0.7702524065971375
colorectal B-Disease 1 0.9999521970748901
adenomas I-Disease 1 0.9993366599082947
and I-Disease 0 0.00047579535748809576
/ I-Disease 1 0.7965439558029175
or I-Disease 0 0.0010055815801024437
carcinoma I-Disease 1 0.9996557235717773
and O 0 8.671412388139288e-07
analyzed O 0 1.1513389836181886e-05
codons O 0 9.732168109621853e-05
1263 O 0 0.016699040308594704
- O 0 9.929191583069041e-05
1377 O 0 0.0014731669798493385
( O 0 1.19865660508367e-06
exon O 0 1.0816785106726456e-05
15G O 0 1.6188416338991374e-05
) O 0 2.5927089808419623e-08
of O 0 8.139218188318864e-09
the O 0 1.7643958472035592e-07
APC B-Disease 0 6.173142901388928e-05
gene O 0 3.3729672850313364e-06
for O 0 7.917147968328209e-07
germ O 0 0.14069241285324097
- O 0 2.6653911845642142e-05
line O 0 5.303923444444081e-06
variants O 0 1.6290225175907835e-05
. O 0 9.661178410169668e-06

Three O 0 1.9170409359503537e-05
patients O 0 0.000970851571764797
with O 0 5.501351552084088e-07
the O 0 1.163185856967175e-06
I1307K O 0 0.00019697625248227268
allele O 0 6.118178589531453e-06
were O 0 1.4183160601533018e-07
detected O 0 3.253830300309346e-06
, O 0 1.612803046668887e-08
each O 0 7.772483989754164e-09
of O 0 1.4789704039230855e-07
Ashkenazi O 0 0.00010466926323715597
descent O 0 8.761622302699834e-05
. O 0 2.5843364710453898e-05

Four O 0 7.657741662114859e-05
patients O 0 0.02007802575826645
had O 0 1.0330897566745989e-05
a O 0 1.3460234185913578e-05
germ O 0 0.14161716401576996
- O 0 1.762382271408569e-05
line O 0 4.164261099504074e-06
E1317Q O 0 3.8898193452041596e-05
missense O 0 4.173158959019929e-05
variant O 0 2.7901742214453407e-05
of O 0 1.0979333353589027e-07
APC O 0 0.0008878636872395873
that O 0 8.657169559000977e-08
was O 0 2.734730628617399e-07
not O 0 8.12042433295801e-09
present O 0 4.201893233357623e-08
in O 0 2.1196662203237793e-08
controls O 0 1.8266484858031617e-07
; O 0 2.5787958435330438e-08
one O 0 3.1215203755152743e-09
of O 0 3.2423774776191294e-09
these O 0 6.3061014188292575e-09
individuals O 0 4.109679707653413e-08
had O 0 1.386504919764775e-07
an O 0 5.124245561205498e-08
unusually O 0 4.500143859331729e-06
large O 0 1.0412050244212878e-07
number O 0 2.2325494342112506e-08
of O 0 1.261269488850303e-07
metaplastic B-Disease 0 0.004636569879949093
polyps I-Disease 0 0.0038206668104976416
of I-Disease 0 4.4418354150366213e-07
the I-Disease 0 7.38185099180555e-06
colorectum I-Disease 0 0.01872447319328785
. O 0 4.189271930954419e-05

There O 0 1.8653597635420738e-06
is O 0 5.176882496016333e-07
increasing O 0 1.3673835610461538e-06
evidence O 0 1.050472178576456e-06
that O 0 5.186557672232084e-08
there O 0 1.6012938885978656e-07
exist O 0 7.162739734667412e-07
germ O 0 0.004610834643244743
- O 0 1.2677249969783588e-06
line O 0 1.9611717050338484e-07
variants O 0 1.0711607245639243e-07
of O 0 7.6181239094808e-09
the O 0 1.153894544358991e-07
APC B-Disease 0 0.00013896437303628772
gene O 0 7.972184334903432e-07
that O 0 4.6375891571415195e-08
predispose O 0 2.9040065783192404e-06
to O 0 1.2397411097708755e-08
the O 0 3.6942786607596645e-08
development O 0 4.6203024339774856e-07
of O 0 1.2024371471852646e-06
multiple O 1 0.5474268794059753
colorectal B-Disease 1 0.9999736547470093
adenomas I-Disease 1 0.9997896552085876
and I-Disease 0 0.012456449680030346
carcinoma I-Disease 1 0.9999682903289795
, O 0 1.652699552323611e-06
but O 0 8.551432273407045e-08
without O 0 9.484040930374249e-08
the O 0 3.3894278317347926e-07
florid O 0 0.0008773194276727736
phenotype O 0 3.0421646442846395e-05
of O 0 1.4140967152798112e-07
classical O 0 1.7907806977746077e-05
FAP B-Disease 0 0.2432292103767395
, O 0 2.26344681664159e-07
and O 0 3.31678293719051e-08
possibly O 0 2.8621764158742735e-07
with O 0 1.744591884289548e-07
importance O 0 1.825730942073278e-05
for O 0 0.0016246846644207835
colorectal B-Disease 1 0.999987006187439
cancer I-Disease 1 0.9999407529830933
risk O 0 0.004228472243994474
in O 0 1.9625187519523024e-07
the O 0 2.387882886978332e-07
general O 0 1.1300119240331696e-06
population O 0 4.0336294659937266e-07
. O 0 8.219822689170542e-07
. O 0 4.0428744796372484e-06

Genomic O 0 8.615372644271702e-05
structure O 0 1.9560757209546864e-05
of O 0 1.8686856719796197e-06
the O 0 7.994333282113075e-05
human O 0 0.17056798934936523
congenital B-Disease 1 0.9999158382415771
chloride I-Disease 1 0.9994459748268127
diarrhea I-Disease 1 0.9999121427536011
( O 0 0.020033597946166992
CLD B-Disease 1 0.9957565665245056
) O 0 5.8251309383194894e-05
gene O 0 0.0001882921060314402
. O 0 3.669132638606243e-05

Congenital B-Disease 1 0.9997727274894714
chloride I-Disease 1 0.9990111589431763
diarrhea I-Disease 1 0.9998763799667358
( O 0 0.008936273865401745
CLD B-Disease 1 0.9969879984855652
) O 0 1.0723626473918557e-05
is O 0 2.0349182250356534e-06
caused O 0 7.028415711829439e-05
by O 0 1.7616048353374936e-07
mutations O 0 7.872343417147931e-07
in O 0 2.799309939405248e-08
a O 0 2.1464572341756138e-07
gene O 0 8.067950716394989e-07
which O 0 9.251806432075682e-08
encodes O 0 2.9645434551639482e-06
an O 0 7.915587048046291e-06
intestinal O 1 0.9974879026412964
anion O 1 0.6683985590934753
transporter O 0 0.22271738946437836
. O 0 5.067877646069974e-05

We O 0 1.937404249474639e-06
report O 0 1.008070739771938e-06
here O 0 1.0549522500014064e-07
the O 0 3.9784545435850305e-08
complete O 0 3.1518067089564283e-07
genomic O 0 1.3556624480770552e-06
organization O 0 9.144472556954497e-08
of O 0 1.6222621468386933e-08
the O 0 3.1519508070232405e-07
human O 0 4.904743946099188e-06
CLD B-Disease 0 0.4933715760707855
gene O 0 2.358335677854484e-06
which O 0 1.0170428055289449e-07
spans O 0 5.814427368022734e-06
approximately O 0 1.0559613201621687e-06
39kb O 0 0.00010114198084920645
, O 0 9.535244771541329e-08
and O 0 4.261295671881271e-08
comprises O 0 3.6261158697925566e-07
21 O 0 2.126233312083059e-06
exons O 0 3.769758404814638e-05
. O 0 9.349456377094612e-06

All O 0 3.4792269616445992e-06
exon O 0 0.00048775572213344276
/ O 0 0.00022878528397995979
intron O 0 0.00016666279407218099
boundaries O 0 3.851254746223276e-07
conform O 0 3.9155975173343904e-06
to O 0 1.5535525221821445e-07
the O 0 3.264846327510895e-06
GT O 0 0.031307391822338104
/ O 0 0.005252050701528788
AG O 0 0.04706535115838051
rule O 0 2.1067189663881436e-05
. O 0 2.083875733660534e-05

An O 0 4.78022286642954e-07
analysis O 0 9.859980565352089e-08
of O 0 2.3142160188172056e-08
the O 0 2.884399066260812e-07
putative O 0 1.6366089766961522e-05
promoter O 0 1.6450523617095314e-05
region O 0 2.1401535832410445e-07
sequence O 0 1.1149553102995924e-07
shows O 0 1.831193827683819e-07
a O 0 9.141714940597012e-07
putative O 0 0.0001229031477123499
TATA O 0 0.008686015382409096
box O 0 2.2704505681758747e-05
and O 0 2.1114067294547567e-07
predicts O 0 1.755752782628406e-05
multiple O 0 1.0647092949511716e-06
transcription O 0 1.7434289475204423e-05
factor O 0 4.666164386435412e-06
binding O 0 5.9197382142883725e-06
sites O 0 7.4773106462089345e-06
. O 0 1.4956228369555902e-05

The O 0 5.1007145884796046e-06
genomic O 0 3.374996958882548e-05
structure O 0 1.215921020047972e-05
was O 0 1.6915241758397315e-06
determined O 0 3.6296933103585616e-07
using O 0 4.068383319122404e-08
DNA O 0 3.58763884378277e-07
from O 0 3.0725995969760334e-08
several O 0 1.453947984231263e-08
sources O 0 6.479432101968996e-08
including O 0 4.8670720786958555e-08
multiple O 0 1.8506278820495936e-06
large O 0 2.936954615506693e-06
- O 0 2.472564301569946e-05
insert O 0 6.669794674962759e-05
libaries O 0 4.350396557128988e-05
and O 0 1.3697727752060018e-07
genomic O 0 4.581375378620578e-06
DNA O 0 1.1410857041482814e-05
from O 0 1.0866880984394811e-05
Finnish O 0 0.22461961209774017
CLD B-Disease 1 0.9979204535484314
patients O 0 0.12989921867847443
and O 0 4.9326877160638105e-06
controls O 0 0.00012143171625211835
. O 0 5.587234045378864e-05

Exon O 0 0.0009165555238723755
- O 0 3.2763888157205656e-05
specific O 0 4.167230827079038e-07
primers O 0 1.0243144970445428e-05
developed O 0 9.084874932341336e-07
in O 0 2.7775467259516518e-08
this O 0 6.512163253091785e-09
study O 0 4.972541844949774e-08
will O 0 5.416141757308424e-09
facilitate O 0 1.492325338858791e-07
mutation O 0 1.8179830476583447e-06
screening O 0 2.091136138915317e-06
studies O 0 4.5680508264922537e-07
of O 0 3.967860777720489e-07
patients O 0 0.07664157450199127
with O 0 1.2367177077976521e-05
the O 0 0.0006832245853729546
disease O 1 0.9988566637039185
. O 0 0.0001394250721205026

Genomic O 0 1.8137738152290694e-05
sequencing O 0 2.6621919460012577e-06
of O 0 2.371492939801101e-07
a O 0 1.664043520577252e-05
BAC O 0 0.026510125026106834
clone O 0 0.016178902238607407
H O 0 0.05272967740893364
_ O 0 6.889114956720732e-06
RG364P16 O 0 5.468868766911328e-05
revealed O 0 2.2677429569739616e-06
the O 0 3.240258550363251e-08
presence O 0 4.882320681076635e-08
of O 0 4.607820347501956e-09
another O 0 8.789894678784549e-08
, O 0 1.9315393728902563e-08
highly O 0 6.841425914672072e-08
homologous O 0 7.702708444412565e-07
gene O 0 2.793925943933573e-07
3 O 0 4.820564214469414e-08
of O 0 1.4635581635502604e-08
the O 0 6.132579528639326e-07
CLD B-Disease 0 0.18370556831359863
gene O 0 1.3203392654759227e-06
, O 0 2.7881570829890734e-08
with O 0 2.12215809369809e-08
a O 0 1.5499860239742702e-07
similar O 0 3.498013825264934e-07
genomic O 0 6.842450602562167e-06
structure O 0 1.567417712067254e-05
, O 0 4.288488355541631e-07
recently O 0 5.1331458053027745e-06
identified O 0 1.9614312805060763e-06
as O 0 7.635371161995863e-07
the O 0 3.0563904147129506e-05
Pendred B-Disease 1 0.9975811243057251
syndrome I-Disease 1 0.9998733997344971
gene O 0 0.000467717822175473
( O 0 6.088447480578907e-05
PDS B-Disease 0 0.4784422516822815
) O 0 2.065422449959442e-06
. O 0 1.3295125427248422e-06
. O 0 5.792101546830963e-06

The O 0 5.278217577142641e-05
APCI1307K O 0 0.05267593637108803
allele O 0 0.0007924074307084084
and O 0 8.76873527886346e-05
cancer B-Disease 1 0.9987125396728516
risk O 0 0.00018117192666977644
in O 0 1.5701724009886675e-07
a O 0 7.96421318227658e-07
community O 0 4.541571172467229e-07
- O 0 1.592567400621192e-06
based O 0 6.223073256705902e-08
study O 0 2.46894131805675e-07
of O 0 2.3292510320516158e-07
Ashkenazi O 0 0.0002510129997972399
Jews O 0 1.1910031389561482e-05
. O 0 1.858842369983904e-05

Mutations O 0 0.0002916493685916066
in O 0 1.0662523891369347e-05
APC O 0 0.007699602283537388
are O 0 1.6355055549865938e-06
classically O 0 0.019402848556637764
associated O 0 0.00011432584869908169
with O 0 0.00027370391762815416
familial B-Disease 1 0.9992327690124512
adenomatous I-Disease 1 0.9996405839920044
polyposis I-Disease 1 0.9996997117996216
( O 0 0.002751440042629838
FAP B-Disease 1 0.9673603177070618
) O 0 2.9885895855841227e-06
, O 0 1.645038310016389e-06
a O 0 3.209611168131232e-05
highly O 0 0.0020596550311893225
penetrant O 1 0.9957550764083862
autosomal B-Disease 1 0.9993771910667419
dominant I-Disease 1 0.9968159794807434
disorder I-Disease 1 0.9998713731765747
characterized O 1 0.9898214340209961
by O 0 0.0008682816987857223
multiple O 1 0.949919581413269
intestinal O 1 0.999804675579071
polyps B-Disease 1 0.9972923398017883
and O 0 2.388742132097832e-06
, O 0 1.3374479976846487e-06
without O 0 5.556861651712097e-06
surgical O 0 0.023602215573191643
intervention O 0 1.0288847079209518e-05
, O 0 1.830916147582684e-07
the O 0 2.6582418399812013e-07
development O 0 6.190344720380381e-06
of O 0 0.00011316928430460393
colorectal B-Disease 1 0.9999779462814331
cancer I-Disease 1 0.9998985528945923
( O 0 0.0006270144367590547
CRC B-Disease 1 0.8397003412246704
) O 0 2.289698204549495e-05
. O 0 2.4310600565513596e-05

APC B-Disease 0 0.004199080169200897
is O 0 1.1132294275739696e-05
a O 0 0.00017463573021814227
tumour O 1 0.9982159733772278
- O 0 0.00015088330837897956
suppressor O 0 5.385128679336049e-05
gene O 0 1.6748398365962203e-06
, O 0 9.777503606756e-08
and O 0 1.8898681730661337e-07
somatic O 0 8.399907528655604e-05
loss O 0 0.001283365418203175
occurs O 0 0.00023201489238999784
in O 0 9.663024684414268e-05
tumours B-Disease 1 0.9973652958869934
. O 0 0.00015283143147826195

The O 0 7.472121069440618e-05
germline O 0 0.04964975640177727
T O 0 0.29716548323631287
- O 0 1.6171812603715807e-05
to O 0 1.9429573683282797e-07
- O 0 3.117624146398157e-06
A O 0 9.187442628899589e-07
transversion O 0 2.2127123884274624e-05
responsible O 0 2.8398542895047285e-07
for O 0 2.0607812345474485e-08
the O 0 1.917755412250699e-07
APC O 0 5.540839265449904e-05
I1307K O 0 1.1917552910745144e-05
allele O 0 7.834371444914723e-07
converts O 0 1.931225028783956e-07
the O 0 8.083818414661437e-08
wild O 0 8.202962362702237e-07
- O 0 1.0838652997335885e-06
type O 0 4.028493094665464e-07
sequence O 0 8.575033660918052e-08
to O 0 5.713206618906952e-08
a O 0 2.066230308628292e-06
homopolymer O 0 0.011870183981955051
tract O 1 0.8634845018386841
( O 0 2.1694211682188325e-05
A8 O 0 0.10317080467939377
) O 0 8.001707669791358e-07
that O 0 1.939373532877653e-07
is O 0 7.499110097342054e-07
genetically O 0 3.405467941774987e-05
unstable O 0 0.0018887141486629844
and O 0 1.2415393939591013e-06
prone O 0 0.0005940497503615916
to O 0 8.46399871079484e-07
somatic O 0 0.000142686054459773
mutation O 0 0.00018507918866816908
. O 0 1.4518450370815117e-05

The O 0 1.232452177646337e-05
I1307K O 0 0.0003681908128783107
allele O 0 3.6248486139811575e-05
was O 0 5.800514372822363e-06
found O 0 2.330544930373435e-06
in O 0 1.0862815997825237e-06
6 O 0 8.975935088528786e-06
. O 0 1.1045619430660736e-05

1 O 0 5.4402539717557374e-06
% O 0 1.9422179775574477e-06
of O 0 7.968779414113669e-07
unselected O 0 0.00921038817614317
Ashkenazi O 0 0.00033244353835470974
Jews O 0 1.0687551821320085e-06
and O 0 1.770440150039576e-07
higher O 0 3.2141558676812565e-06
proportions O 0 2.7403844796936028e-05
of O 0 2.4055373160081217e-07
Ashkenazim O 0 0.00030266388785094023
with O 0 8.19728484202642e-07
family O 0 6.089109319873387e-06
or O 0 9.428522389498539e-07
personal O 0 1.920238446473377e-06
histories O 0 1.1362665645719972e-05
of O 0 1.5436311286975979e-06
CRC B-Disease 0 0.32588788866996765
( O 0 2.125873652403243e-05
ref O 0 0.0026140136178582907
. O 0 4.024507234134944e-07
2 O 0 1.7239360659004888e-06
) O 0 1.1018307759513846e-06
. O 0 4.627115686162142e-06

To O 0 1.180647359433351e-06
evaluate O 0 2.798471996356966e-06
the O 0 1.6696043303454644e-07
role O 0 6.9419814963112e-07
of O 0 2.3843330154704745e-07
I1307K O 0 0.0008483842248097062
in O 0 1.6491523638251238e-05
cancer B-Disease 1 0.9740321040153503
, O 0 3.077890937674965e-07
we O 0 1.0599683974987784e-07
genotyped O 0 4.1319864976685494e-05
5 O 0 6.996321531005378e-07
, O 0 5.121236767990922e-07
081 O 0 0.001394782797433436
Ashkenazi O 0 3.252986061852425e-05
volunteers O 0 1.008458298201731e-06
in O 0 8.370275850211328e-08
a O 0 6.8530482622009e-07
community O 0 1.320681803917978e-06
survey O 0 2.7801368560176343e-05
. O 0 1.355117819912266e-05

Risk O 0 0.002842917572706938
of O 0 3.376178574399091e-05
developing O 0 0.2175360918045044
colorectal B-Disease 1 0.9997497200965881
, I-Disease 0 0.0006269749719649553
breast I-Disease 1 0.9979592561721802
and I-Disease 0 1.7485939451944432e-06
other I-Disease 0 2.0178617887722794e-06
cancers I-Disease 1 0.8143071532249451
were O 0 2.2165961865994177e-07
compared O 0 3.798654461206752e-06
between O 0 2.142613539035665e-06
genotyped O 0 0.004493565298616886
I1307K O 0 0.0006665123510174453
carriers O 0 3.093295526923612e-05
and O 0 2.3856838993197016e-07
non O 0 3.3055082440114347e-06
- O 0 7.978642315720208e-06
carriers O 0 6.71305542709888e-07
and O 0 8.91330387275957e-09
their O 0 9.616225149500224e-09
first O 0 1.9883165691680915e-07
- O 0 4.9687673708831426e-06
degree O 0 2.2347003323375247e-06
relatives O 0 2.3514645363320597e-05
. O 0 1.283476740354672e-05

Sperm O 0 6.105657666921616e-05
DNA O 0 1.5114971574803349e-05
analysis O 0 3.872623437928269e-06
in O 0 4.423220161697827e-06
a O 0 6.409415800590068e-05
Friedreich B-Disease 1 0.9849334359169006
ataxia I-Disease 1 0.9955695271492004
premutation O 0 0.3150303065776825
carrier O 0 0.0008475410286337137
suggests O 0 7.448046289937338e-06
both O 0 2.2461281901087204e-07
meiotic O 0 0.0002408547152299434
and O 0 2.999045705109893e-07
mitotic O 0 0.00010452463902765885
expansion O 0 4.659165369957918e-06
in O 0 3.357340290222055e-07
the O 0 1.7877746358863078e-06
FRDA B-Disease 0 0.0054960697889328
gene O 0 0.00010636971273925155
. O 0 2.4850834961398505e-05

Friedreich B-Disease 1 0.9862215518951416
ataxia I-Disease 1 0.9952176809310913
is O 0 4.039792838739231e-05
usually O 0 2.3435259208781645e-05
caused O 0 0.00027826966834254563
by O 0 1.1294285684471106e-07
an O 0 6.163384114188375e-08
expansion O 0 5.652819936585729e-07
of O 0 3.759239319833796e-08
a O 0 2.400223820586689e-06
GAA O 0 0.0009057731367647648
trinucleotide O 0 0.015194306150078773
repeat O 0 1.4306977391242981e-05
in O 0 2.126623712683795e-07
intron O 0 0.00012742375838570297
1 O 0 2.3516109592947032e-07
of O 0 4.75384602793838e-08
the O 0 1.6717152675482794e-06
FRDA B-Disease 0 0.006375542376190424
gene O 0 9.86229715636e-05
. O 0 2.014803612837568e-05

Occasionally O 0 5.0691101932898164e-05
, O 0 2.0959598714398453e-06
a O 0 1.507378215137578e-06
fully O 0 2.8445481348171597e-06
expanded O 0 2.6708203222369775e-06
allele O 0 5.139543645782396e-06
has O 0 1.9730313738364202e-07
been O 0 6.728528489929886e-08
found O 0 5.252752188766863e-08
to O 0 1.2543548422172535e-08
arise O 0 1.6608160535724892e-07
from O 0 1.6019042092807467e-08
a O 0 1.0300465902446376e-07
premutation O 0 6.8212557380320504e-06
of O 0 1.19025926892391e-08
100 O 0 9.654841193196262e-08
or O 0 1.5904910810604633e-07
less O 0 1.1070169421145692e-06
triplet O 0 0.0008321162895299494
repeats O 0 0.00034231593599542975
. O 0 1.9231109035899863e-05

We O 0 1.3610409723696648e-06
have O 0 1.3856642055998236e-07
examined O 0 1.7679780057733296e-06
the O 0 4.917282581118343e-08
sperm O 0 5.46747969565331e-07
DNA O 0 6.284436722125974e-07
of O 0 1.1064157945384068e-07
a O 0 1.2570882063300814e-05
premutation O 0 0.013593282550573349
carrier O 0 0.001732559292577207
. O 0 3.161139466101304e-05

This O 0 3.022587179657421e-06
mans O 0 6.835217936895788e-05
leucocyte O 0 0.00018910029029939324
DNA O 0 9.50080811890075e-06
showed O 0 3.4215906907775206e-06
one O 0 8.474824397808334e-08
normal O 0 3.9101615811887314e-07
allele O 0 4.5278184757080453e-07
and O 0 7.277185520848661e-09
one O 0 7.669735957449575e-09
allele O 0 1.91688513950794e-07
of O 0 1.0075909884221801e-08
approximately O 0 2.7978265393358015e-07
100 O 0 1.6020804878280615e-06
repeats O 0 7.06918362993747e-05
. O 0 1.0099402970809024e-05

His O 0 1.602458542038221e-05
sperm O 0 2.387280073889997e-05
showed O 0 3.735990731001948e-06
an O 0 1.4706131423736224e-07
expanded O 0 7.318124630728562e-07
allele O 0 9.373366651743709e-07
in O 0 3.7685143894350404e-08
a O 0 1.2922144776439382e-07
tight O 0 9.93060211840202e-07
range O 0 6.39782768985242e-08
centering O 0 2.2339172289775888e-07
on O 0 2.4216443961222467e-08
a O 0 7.903020815547279e-08
size O 0 2.2841838642762013e-07
of O 0 4.779748863370514e-08
approximately O 0 3.6042547435499728e-06
320 O 0 9.160669287666678e-05
trinucleotide O 0 0.058581382036209106
repeats O 0 0.0005859581287950277
. O 0 3.659240246633999e-05

His O 0 5.804630563943647e-05
affected O 0 0.00011400665243854746
son O 0 0.00039446091977879405
has O 0 1.7180176428155391e-06
repeat O 0 1.1205703231098596e-05
sizes O 0 9.062670187631738e-07
of O 0 1.9567065123737848e-07
1040 O 0 0.0011524485889822245
and O 0 2.1569769614870893e-06
540 O 0 0.00011090034240623936
. O 0 1.5870178685872816e-05

These O 0 5.261641717879684e-07
data O 0 1.3024751979173743e-06
suggest O 0 2.680146280908957e-06
that O 0 7.11386221041721e-08
expansion O 0 9.021899245453824e-07
occurs O 0 3.991086998667015e-07
in O 0 2.2206114280720612e-08
two O 0 1.3350475391860073e-08
stages O 0 6.922545026100124e-07
, O 0 1.7673793095696055e-08
the O 0 8.531487516449943e-09
first O 0 2.5250374235952222e-08
during O 0 1.435051046883018e-07
meiosis O 0 2.170826519432012e-06
followed O 0 9.559428093552924e-08
by O 0 3.184898034191974e-08
a O 0 1.660847743778504e-07
second O 0 4.1913995119102765e-07
mitotic O 0 0.0003278386138845235
expansion O 0 5.4484633437823504e-05
. O 0 9.804049113881774e-06

We O 0 1.1520916132212733e-06
also O 0 3.862838013901637e-07
show O 0 2.260362066408561e-07
that O 0 1.0405930339629776e-08
in O 0 9.709352433162621e-09
all O 0 7.717309458143973e-09
informative O 0 1.6888581058083219e-06
carrier O 0 3.7203837564447895e-05
father O 0 2.4357652819162467e-06
to O 0 1.3504681817266828e-07
affected O 0 1.830949031500495e-06
child O 0 2.484497827026644e-06
transmissions O 0 1.4424069831875386e-06
, O 0 1.9079479329775495e-08
with O 0 5.029618943552805e-09
the O 0 1.8358530695650188e-08
notable O 0 5.729039997959262e-08
exception O 0 9.269964351688031e-08
of O 0 1.3067181114934101e-08
the O 0 3.168581486079347e-07
premutation O 0 0.0003886201302520931
carrier O 0 1.5081637684488669e-05
, O 0 5.134890557201288e-08
the O 0 5.739714836749954e-08
expansion O 0 1.7103441223298432e-06
size O 0 2.5660642677394208e-06
decreases O 0 1.570131462358404e-05
. O 0 8.996938731797854e-07
. O 0 3.797669478444732e-06

The O 0 6.360690349538345e-06
R496H O 0 0.00019596466154325753
mutation O 0 1.2763496670231689e-05
of O 0 4.554808867851534e-07
arylsulfatase O 0 0.0016673663631081581
A O 0 2.4863300495781004e-05
does O 0 6.2703356888960116e-06
not O 0 4.858891315961955e-06
cause O 0 0.032745834439992905
metachromatic B-Disease 1 0.9912624359130859
leukodystrophy I-Disease 1 0.9978437423706055
. O 0 0.00028348335763439536

Deficiency B-Disease 1 0.996174693107605
of I-Disease 0 6.239157301024534e-06
arylsulfatase I-Disease 0 0.009131071157753468
A I-Disease 0 8.780130883678794e-05
( O 0 3.051794192288071e-05
ARSA O 0 0.16294744610786438
) O 0 4.584867838275386e-06
enzyme O 0 8.471920591546223e-05
activity O 0 7.273660594364628e-05
causes O 0 0.09878947585821152
metachromatic B-Disease 1 0.9936119914054871
leukodystrophy I-Disease 1 0.9978963136672974
( O 0 0.0029747835360467434
MLD B-Disease 1 0.9927061200141907
) O 0 0.00011428911238908768
. O 0 7.068333798088133e-05

A O 0 4.939654900226742e-06
number O 0 2.3113184965950495e-07
of O 0 6.396742264769273e-07
ARSA O 0 0.19157645106315613
gene O 0 1.5227273252094164e-05
mutations O 0 1.6719175619073212e-05
responsible O 0 5.670292921422515e-06
for O 0 4.827409611607436e-06
MLD B-Disease 1 0.9982566237449646
have O 0 1.3336142501430004e-06
been O 0 1.708316176518565e-06
identified O 0 1.1337250725773629e-05
. O 0 9.153324754151981e-06

Recently O 0 5.7705776271177456e-05
, O 0 8.136906899380847e-07
the O 0 7.42920121865609e-07
R496H O 0 7.200630352599546e-05
mutation O 0 6.2056178649072535e-06
of O 0 5.744379905081587e-07
ARSA O 1 0.6855356693267822
was O 0 1.6957883417489938e-06
proposed O 0 6.881458034513344e-07
to O 0 2.1859548837710463e-08
be O 0 3.90291070573312e-08
a O 0 6.113158406151342e-07
cause O 0 2.1907959308009595e-05
of O 0 1.469927610742161e-06
MLD B-Disease 1 0.9951146841049194
( O 0 1.6253387002507225e-05
Draghia O 0 0.0017027565045282245
et O 0 8.627442002762109e-05
al O 0 7.06311993781128e-06
. O 0 2.610287026527658e-07
, O 0 4.0617931063025026e-07
1997 O 0 1.145361784438137e-05
) O 0 2.5433628252358176e-06
. O 0 8.655822966829874e-06

We O 0 1.9335041088197613e-06
have O 0 2.3681434413447278e-07
investigated O 0 3.1254860459739575e-06
the O 0 3.3794702858358505e-07
R496H O 0 3.99467971874401e-05
mutation O 0 2.749170107563259e-06
and O 0 2.856623559921445e-08
found O 0 5.571861905195874e-08
this O 0 1.3492551076410564e-08
mutation O 0 7.237294994411059e-07
at O 0 9.584147164787282e-08
a O 0 1.1184484804971362e-07
relatively O 0 1.1969621027674293e-07
high O 0 2.3406340687870397e-07
frequency O 0 5.9435375732164175e-08
in O 0 9.613969176314185e-09
an O 0 1.9549602825463808e-08
African O 0 1.1479084349730329e-07
American O 0 5.911936540314855e-08
population O 0 2.059382353536421e-08
( O 0 6.277242903252045e-08
f O 0 6.643697361141676e-07
= O 0 7.033349902485497e-07
0 O 0 3.752225907760476e-08
. O 0 2.2637614449649845e-08
09 O 0 1.7244244645553408e-06
, O 0 3.8098903587524546e-08
n O 0 1.4570066468877485e-06
= O 0 3.680427653307561e-06
61 O 0 2.4389635200350313e-06
subjects O 0 3.937639121431857e-06
) O 0 2.3752938886900665e-06
. O 0 7.264066880452447e-06

The O 0 2.5311253921245225e-05
ARSA O 0 0.06443160027265549
enzyme O 0 2.7864594812854193e-05
activity O 0 1.1272446727161878e-06
in O 0 7.769951793079599e-08
subjects O 0 1.8042364047232695e-07
with O 0 3.9952599450998605e-08
and O 0 3.845701357363396e-08
without O 0 1.5091015370671812e-07
the O 0 2.6480955739316414e-07
R496H O 0 7.78595931478776e-05
mutation O 0 1.4698949598823674e-05
was O 0 1.2555967714433791e-06
determined O 0 3.836968289760989e-07
and O 0 3.8739639052209895e-08
found O 0 1.558920672550812e-07
to O 0 5.293677673989805e-08
be O 0 1.7530459217596217e-07
normal O 0 9.72371799434768e-06
. O 0 9.70625569607364e-06

It O 0 1.8518726392358076e-06
is O 0 3.756952935418667e-07
therefore O 0 4.950086349708727e-07
concluded O 0 2.7605144623521483e-06
that O 0 8.720525812577762e-08
the O 0 1.911725888703586e-07
R496H O 0 3.834302333416417e-05
mutation O 0 7.3997398430947214e-06
of O 0 5.632005581901467e-07
ARSA O 1 0.8721033930778503
does O 0 7.412386366922874e-07
not O 0 7.021642289828378e-08
negatively O 0 4.3567408170019917e-07
influence O 0 7.968774440314519e-08
the O 0 5.8002324720973775e-08
activity O 0 3.071416472266719e-07
of O 0 2.3964949491528387e-07
ARSA O 0 0.06661558896303177
and O 0 1.2628618151211413e-07
is O 0 1.5964359079134738e-07
not O 0 1.1634816132755077e-07
a O 0 2.493865167707554e-06
cause O 0 0.00025795013061724603
of O 0 2.2106476535554975e-05
MLD B-Disease 1 0.9930406808853149

Down O 0 0.00013068692351225764
- O 0 2.451316140650306e-05
regulation O 0 6.1958489823155105e-06
of O 0 1.157302676801919e-06
transmembrane O 0 0.004477306269109249
carbonic O 1 0.6824221611022949
anhydrases O 0 0.36195340752601624
in O 0 0.001292537897825241
renal B-Disease 1 0.9996558427810669
cell I-Disease 1 0.9963723421096802
carcinoma I-Disease 1 0.9998610019683838
cell O 0 0.001061133574694395
lines O 0 1.5453040759894066e-05
by O 0 1.8514328985475004e-06
wild O 0 3.6238117900211364e-05
- O 0 0.0003381547285243869
type O 0 0.0006228642305359244
von B-Disease 0 0.020109042525291443
Hippel I-Disease 1 0.6510455012321472
- I-Disease 0 0.0032537791412323713
Lindau I-Disease 0 0.17317992448806763
transgenes O 0 0.01736719161272049
. O 0 0.0001290349173359573

To O 0 5.306199000187917e-06
discover O 0 2.092071736115031e-05
genes O 0 2.8722931801894447e-06
involved O 0 3.095735337410588e-06
in O 0 4.075434389960719e-06
von B-Disease 0 0.014038637280464172
Hippel I-Disease 0 0.39852175116539
- I-Disease 0 0.0015747171128168702
Lindau I-Disease 0 0.05987023189663887
( O 0 4.923518645227887e-05
VHL B-Disease 1 0.7988874912261963
) O 0 1.072049872163916e-05
- O 0 5.792675437987782e-05
mediated O 0 0.00015263029490597546
carcinogenesis O 0 0.025281310081481934
, O 0 1.4085704833632917e-06
we O 0 1.2476425581553485e-06
used O 0 9.242800297215581e-05
renal B-Disease 1 0.9997068047523499
cell I-Disease 1 0.9972299933433533
carcinoma I-Disease 1 0.9999219179153442
cell O 0 0.008561896160244942
lines O 0 0.00010210784967057407
stably O 0 0.0005533811636269093
transfected O 0 0.0010395020944997668
with O 0 4.255701242072973e-06
wild O 0 9.445946488995105e-05
- O 0 0.0008670531096868217
type O 0 0.0029015736654400826
VHL O 1 0.988271176815033
- O 0 0.000502788694575429
expressing O 0 0.00018483336316421628
transgenes O 0 0.005940514616668224
. O 0 6.462277087848634e-05

Large O 0 1.977432839339599e-05
- O 0 1.3344309081730898e-05
scale O 0 3.62776631845918e-06
RNA O 0 3.55556039721705e-06
differential O 0 1.9791912109212717e-06
display O 0 1.081944446923444e-06
technology O 0 9.09220773337438e-07
applied O 0 2.1803838023970457e-07
to O 0 3.471340548344415e-08
these O 0 4.588519431081295e-08
cell O 0 1.7727321392158046e-05
lines O 0 2.898121920225094e-06
identified O 0 7.941634407870879e-07
several O 0 1.1736003102669201e-07
differentially O 0 6.634012606809847e-06
expressed O 0 4.231433763379755e-07
genes O 0 1.931355768647336e-07
, O 0 2.682234345741108e-08
including O 0 3.3483548378399064e-08
an O 0 3.1042208092912915e-07
alpha O 0 3.910879240720533e-05
carbonic O 0 0.005848218686878681
anhydrase O 0 0.01053658127784729
gene O 0 7.236694364110008e-05
, O 0 5.164266895008041e-06
termed O 0 0.0013736977707594633
CA12 O 0 0.08151436597108841
. O 0 0.0001035551613313146

The O 0 7.710609679634217e-07
deduced O 0 3.698015689224121e-06
protein O 0 1.7940907355296076e-06
sequence O 0 9.6555004347465e-07
was O 0 1.1705571978382068e-06
classified O 0 1.6345450148946838e-06
as O 0 2.782584118676823e-08
a O 0 1.3332208936844836e-07
one O 0 1.0002652572893567e-07
- O 0 1.5013398524388322e-06
pass O 0 6.855820515738742e-07
transmembrane O 0 5.0791360990842804e-05
CA O 0 7.813950105628464e-06
possessing O 0 1.341746951766254e-06
an O 0 1.7590161860425724e-07
apparently O 0 2.6028521915577585e-06
intact O 0 3.91304774893797e-06
catalytic O 0 3.0795663406024687e-06
domain O 0 3.905882692833984e-07
in O 0 5.7304934131252594e-08
the O 0 3.3817886446740886e-07
extracellular O 0 7.972498860908672e-05
CA O 0 0.00025045883376151323
module O 0 0.00035298150032758713
. O 0 1.4400634427147452e-05

Reintroduced O 0 0.0008203337783925235
wild O 0 0.00044389389222487807
- O 0 0.0015215345192700624
type O 0 0.0012352655176073313
VHL B-Disease 1 0.5204412937164307
strongly O 0 1.0962046872009523e-05
inhibited O 0 1.6480282283737324e-05
the O 0 1.796013293642318e-07
overexpression O 0 5.1739880291279405e-06
of O 0 3.713777374514393e-08
the O 0 6.833053021182423e-07
CA12 O 0 0.0006775915389880538
gene O 0 2.6506372705625836e-06
in O 0 5.195785774958495e-07
the O 0 7.756484592391644e-06
parental O 0 0.04423413798213005
renal B-Disease 1 0.9996895790100098
cell I-Disease 1 0.9968591928482056
carcinoma I-Disease 1 0.9998816251754761
cell O 0 0.24731393158435822
lines O 0 0.0007290098583325744
. O 0 7.053143781377003e-05

Similar O 0 1.2590749065566342e-05
results O 0 3.363004225320765e-06
were O 0 3.088605637913133e-07
obtained O 0 1.4143572570901597e-06
with O 0 8.989443358586868e-07
CA9 O 0 0.01850711554288864
, O 0 1.5805989050932112e-07
encoding O 0 8.070567218965152e-07
another O 0 1.8015317664321628e-06
transmembrane O 0 0.00023598276311531663
CA O 0 1.3293412848724984e-05
with O 0 6.57419221283817e-08
an O 0 1.9180261290330236e-07
intact O 0 2.5453920898144133e-05
catalytic O 0 5.5905231420183554e-05
domain O 0 2.7265243261354044e-05
. O 0 1.887351209006738e-05

Although O 0 2.0146139831922483e-06
both O 0 1.0884109258313401e-07
domains O 0 7.820785299372801e-07
of O 0 9.796450939347778e-08
the O 0 1.4930654970157775e-06
VHL B-Disease 0 0.20223912596702576
protein O 0 1.5993815623005503e-06
contribute O 0 2.973783921333961e-07
to O 0 1.4932670211464938e-08
regulation O 0 6.321253067653743e-07
of O 0 9.283996149633822e-08
CA12 O 0 0.000441397016402334
expression O 0 5.911271045988542e-07
, O 0 9.258566535663704e-08
the O 0 1.955714026280475e-07
elongin O 0 6.601928180316463e-05
binding O 0 1.7506430367575376e-06
domain O 0 4.378180619823979e-06
alone O 0 6.748565738234902e-06
could O 0 1.0528933671594132e-06
effectively O 0 9.508176844974514e-06
regulate O 0 0.00017554560326971114
CA9 O 1 0.6777486801147461
expression O 0 5.172747842152603e-05
. O 0 2.91832911898382e-05

We O 0 5.926052836002782e-06
mapped O 0 0.00013693746586795896
CA12 O 0 0.006114879157394171
and O 0 6.903808298375225e-06
CA9 O 0 0.18974396586418152
loci O 0 2.9727663786616176e-05
to O 0 7.037569957901724e-07
chromosome O 0 3.759641185752116e-05
bands O 0 1.4713114978803787e-05
15q22 O 0 0.00026525784051045775
and O 0 3.52362417288532e-06
17q21 O 0 0.0012594590662047267
. O 0 3.1010400562081486e-05

2 O 0 1.9957988115493208e-05
respectively O 0 7.688217010581866e-06
, O 0 7.670776653867506e-07
regions O 0 1.323468154623697e-06
prone O 0 7.62662966735661e-05
to O 0 1.1695178159243369e-07
amplification O 0 1.4251566426537465e-05
in O 0 6.760675432815333e-07
some O 0 1.3980154562887037e-06
human O 0 0.00012991446419619024
cancers B-Disease 1 0.991540253162384
. O 0 5.529590634978376e-05

Additional O 0 3.915485649486072e-06
experiments O 0 2.389263954682974e-06
are O 0 1.993925202725677e-08
needed O 0 1.1822118040072382e-07
to O 0 1.0972735609016127e-08
define O 0 1.1637435193279089e-07
the O 0 2.8229822035541474e-08
role O 0 1.2134913163208694e-07
of O 0 2.6388485707684595e-07
CA O 0 0.0007725897012278438
IX O 0 0.011601456440985203
and O 0 9.275160550714645e-07
CA O 0 0.00011507001909194514
XII O 0 0.00040319468826055527
enzymes O 0 2.567351771176618e-07
in O 0 1.0543242723315416e-08
the O 0 1.2483973854671149e-08
regulation O 0 2.3395092796363315e-07
of O 0 2.6823368415307414e-08
pH O 0 1.810041612770874e-05
in O 0 4.686566867917463e-08
the O 0 5.883499198944264e-08
extracellular O 0 4.3722557165892795e-06
microenvironment O 0 3.4354910894762725e-05
and O 0 4.7285972470945126e-08
its O 0 1.4686382598938508e-07
potential O 0 1.5636542229913175e-06
impact O 0 9.617026989872102e-06
on O 0 1.4496673429675866e-05
cancer B-Disease 1 0.997593343257904
cell O 0 0.002950450638309121
growth O 0 0.0002392525930190459
. O 0 1.189931390399579e-05

A O 0 5.843745839229086e-06
gene O 0 2.1845287392352475e-06
encoding O 0 9.25941151308507e-07
a O 0 1.4593721289202222e-06
transmembrane O 0 4.970932059222832e-05
protein O 0 1.5336692740675062e-05
is O 0 2.637834768393077e-06
mutated O 0 0.0006847972981631756
in O 0 3.513836782076396e-05
patients O 1 0.9928223490715027
with O 0 0.4223862290382385
diabetes B-Disease 1 0.9999691247940063
mellitus I-Disease 1 0.9998235106468201
and O 0 0.4076245427131653
optic B-Disease 1 0.9996938705444336
atrophy I-Disease 1 0.9991180300712585
( O 1 0.836310625076294
Wolfram B-Disease 1 0.9990159273147583
syndrome I-Disease 1 0.9999336004257202
) O 0 0.00022955946042202413
. O 0 9.972345287678763e-05

Wolfram B-Disease 1 0.9933139681816101
syndrome I-Disease 1 0.9997439980506897
( O 0 0.014680004678666592
WFS B-Disease 1 0.991348922252655
; O 0 0.0008399071521125734
OMIM O 1 0.9889238476753235
222300 O 0 0.004319078288972378
) O 0 4.231976618029876e-06
is O 0 3.5419252526480705e-06
an O 0 5.817753481096588e-05
autosomal B-Disease 1 0.9983246922492981
recessive I-Disease 1 0.999420166015625
neurodegenerative I-Disease 1 0.9998931884765625
disorder I-Disease 1 0.9997318387031555
defined O 0 0.0002590416115708649
by O 0 3.7564048398053274e-05
young O 0 0.0015615687007084489
- O 0 0.019661951810121536
onset O 1 0.9969406127929688
non O 0 0.002350265858694911
- O 0 0.3465038537979126
immune O 1 0.9924657344818115
insulin B-Disease 1 0.9801415205001831
- I-Disease 1 0.7075756788253784
dependent I-Disease 0 0.3446749746799469
diabetes I-Disease 1 0.9998955726623535
mellitus I-Disease 1 0.9996490478515625
and O 0 0.0020354785956442356
progressive O 1 0.9916926622390747
optic B-Disease 1 0.9990147352218628
atrophy I-Disease 1 0.9973331689834595
. O 0 0.0006320549873635173

Linkage O 0 0.00019579190120566636
to O 0 1.5348484794230899e-06
markers O 0 3.982185444328934e-05
on O 0 3.3123308185167843e-06
chromosome O 0 0.0005103610455989838
4p O 1 0.8446020483970642
was O 0 9.883297934720758e-06
confirmed O 0 2.923950887634419e-06
in O 0 1.3805122023313743e-07
five O 0 4.013216425846622e-07
families O 0 3.2395780635852134e-06
. O 0 1.2442190381989349e-05

On O 0 6.546850386257574e-07
the O 0 2.1523526072542154e-07
basis O 0 1.6321823181897344e-07
of O 0 9.269749057239096e-07
meiotic O 1 0.6165364980697632
recombinants O 1 0.897749125957489
and O 0 0.0003936847497243434
disease O 1 0.9990705847740173
- O 0 0.000340305850841105
associated O 0 1.3336447409528773e-05
haplotypes O 0 6.411329377442598e-05
, O 0 4.438443568233197e-07
the O 0 1.8405147557132295e-06
WFS B-Disease 0 0.328910231590271
gene O 0 1.2841953321185429e-05
was O 0 2.752370619418798e-06
localized O 0 2.1089279471198097e-05
to O 0 2.8519860961750965e-07
a O 0 5.680506092176074e-06
BAC O 0 0.0022162641398608685
/ O 0 0.00012263633834663779
P1 O 0 0.0002548192860558629
contig O 0 1.6809857697808184e-05
of O 0 1.650794523300192e-08
less O 0 1.705417247421792e-07
than O 0 1.530759874412979e-07
250 O 0 2.588052666396834e-06
kb O 0 0.0003876834234688431
. O 0 1.962113856279757e-05

Mutations O 0 2.4237846446339972e-05
in O 0 3.2368185998166155e-07
a O 0 8.550173333787825e-07
novel O 0 2.478957185303443e-06
gene O 0 3.691173333209008e-06
( O 0 7.994087809493067e-07
WFS1 O 0 8.33489466458559e-05
) O 0 5.384963941423848e-08
encoding O 0 1.327217944435688e-07
a O 0 2.3538278526302747e-07
putative O 0 1.7101359844673425e-05
transmembrane O 0 1.9564806279959157e-05
protein O 0 2.0142585981375305e-06
were O 0 5.4038856944771396e-08
found O 0 1.1181114700775652e-07
in O 0 2.7160474758147757e-08
all O 0 1.1851689407649246e-08
affected O 0 5.846331987413578e-07
individuals O 0 8.954049235398998e-08
in O 0 1.9054500910442584e-07
six O 0 2.3721177058178e-06
WFS B-Disease 1 0.9638540744781494
families O 0 4.546771208424616e-07
, O 0 7.404516111364501e-08
and O 0 2.4336138437774935e-08
these O 0 3.145476412669268e-08
mutations O 0 2.166332251363201e-06
were O 0 8.687091934689306e-08
associated O 0 1.6465027101730811e-06
with O 0 2.5521144380036276e-06
the O 0 0.0001976836792891845
disease O 1 0.9992949962615967
phenotype O 0 0.4812825918197632
. O 0 7.012910646153614e-05

WFS1 O 0 0.02919892594218254
appears O 0 2.279367072333116e-05
to O 0 2.0162427460945764e-07
function O 0 6.009137223372818e-07
in O 0 2.2323115445033181e-07
survival O 0 1.748804425005801e-05
of O 0 1.4972376050081948e-07
islet O 0 0.00026274885749444366
beta O 0 0.0002816116902977228
- O 0 3.818517143372446e-05
cells O 0 3.89065053241211e-06
and O 0 2.0311863124788943e-07
neurons O 0 2.1977937649353407e-05
. O 0 7.363095733126102e-07
. O 0 6.0985757954767905e-06

Stable O 0 4.639734834199771e-05
interaction O 0 8.304438665618363e-07
between O 0 2.2308239522317308e-07
the O 0 1.174915027490897e-07
products O 0 2.2360615048455657e-07
of O 0 4.872700998248547e-08
the O 0 8.923162795326789e-07
BRCA1 O 0 0.0012876236578449607
and O 0 1.5392341765618767e-06
BRCA2 O 0 0.022841908037662506
tumor B-Disease 0 0.4715004861354828
suppressor O 0 8.722108032088727e-05
genes O 0 1.189026988868136e-06
in O 0 3.3708150226630096e-07
mitotic O 0 0.0005965930758975446
and O 0 3.2269235816784203e-06
meiotic O 0 0.27875468134880066
cells O 0 0.000845884729642421
. O 0 2.5927914975909516e-05

BRCA1 O 0 0.007069319020956755
and O 0 5.8259056459064595e-06
BRCA2 O 0 0.0004753093817271292
account O 0 4.790948651134386e-07
for O 0 7.256122103171947e-08
most O 0 1.107771510078237e-07
cases O 0 6.256719302655256e-07
of O 0 2.047703020480185e-07
familial O 0 0.43120160698890686
, O 0 1.5583376807626337e-05
early O 0 0.0009717514622025192
onset O 1 0.9992627501487732
breast B-Disease 1 0.9991330504417419
and I-Disease 0 0.0004339895967859775
/ I-Disease 1 0.9842318296432495
or I-Disease 0 0.4332442581653595
ovarian I-Disease 1 0.9999672174453735
cancer I-Disease 1 0.9996298551559448
and O 0 1.8828700376616325e-07
encode O 0 2.5875962705868005e-07
products O 0 3.666592931494961e-07
that O 0 8.669673867700567e-09
each O 0 7.521088640771723e-09
interact O 0 5.979503043818113e-07
with O 0 1.5388790188808343e-06
hRAD51 O 0 0.0019481222843751311
. O 0 1.738881110213697e-05

Results O 0 2.7287716875434853e-05
presented O 0 7.342294793488691e-06
here O 0 1.102335318137193e-06
show O 0 1.8866352320401347e-06
that O 0 3.9181048805403407e-07
BRCA1 O 0 0.00030561862513422966
and O 0 9.1886346353931e-07
BRCA2 O 0 0.0004830368561670184
coexist O 0 4.131657533434918e-06
in O 0 1.375677101123074e-07
a O 0 6.26823407401389e-07
biochemical O 0 2.7787402359535918e-05
complex O 0 5.86943815505947e-06
and O 0 4.6663507191624376e-07
colocalize O 0 0.0003158955369144678
in O 0 1.1768365766329225e-06
subnuclear O 0 0.00037803215673193336
foci O 0 7.035845919745043e-05
in O 0 9.208056326315273e-07
somatic O 0 2.1707435735152103e-05
cells O 0 1.746918883327453e-06
and O 0 1.635662449928077e-08
on O 0 1.624389334153875e-08
the O 0 4.559954902561003e-08
axial O 0 2.8655517780862283e-06
elements O 0 1.484151539443701e-07
of O 0 4.0318138871953124e-07
developing O 0 5.0783317419700325e-05
synaptonemal O 0 0.011831030249595642
complexes O 0 0.0022265943698585033
. O 0 4.1130926547339186e-05

Like O 0 0.00014485424617305398
BRCA1 O 0 0.004296021535992622
and O 0 1.487641111452831e-05
RAD51 O 0 0.347210168838501
, O 0 7.838130841264501e-06
BRCA2 O 0 0.0005532032228074968
relocates O 0 0.00011658980656648055
to O 0 1.2854999340561335e-06
PCNA O 0 0.0039031715132296085
+ O 0 1.6127873095683753e-05
replication O 0 5.6306867008970585e-06
sites O 0 4.5213030830382195e-07
following O 0 1.3631531601276947e-06
exposure O 0 2.3627375412615947e-05
of O 0 1.1567790636490827e-07
S O 0 0.0003445966576691717
phase O 0 2.127143307006918e-05
cells O 0 1.0876138730964158e-05
to O 0 8.338579959854542e-07
hydroxyurea O 0 0.004205632023513317
or O 0 2.4031985958572477e-05
UV O 0 0.4362911283969879
irradiation O 0 0.0013707306934520602
. O 0 9.01018429431133e-05

Thus O 0 1.2892756785731763e-05
, O 0 8.626248927612323e-06
BRCA1 O 0 0.0010507236002013087
and O 0 7.977257610036759e-07
BRCA2 O 0 9.901279554469511e-05
participate O 0 1.1333063554275213e-07
, O 0 3.017270699956498e-08
together O 0 1.4042214502296702e-08
, O 0 1.0257819482717423e-08
in O 0 7.18975723401627e-09
a O 0 1.4487996224943345e-07
pathway O 0 1.9776969111262588e-06
( O 0 3.325239958940074e-07
s O 0 8.749507287575398e-06
) O 0 4.4449453895367697e-08
associated O 0 6.673632668707796e-08
with O 0 1.0006827366737525e-08
the O 0 2.6422975807349758e-08
activation O 0 8.58180442264711e-07
of O 0 6.831802323858938e-08
double O 0 1.324364620813867e-05
- O 0 1.446408532501664e-05
strand O 0 1.3427706107904669e-05
break O 0 9.67785126704257e-06
repair O 0 0.0028213178738951683
and O 0 4.2478896489228646e-07
/ O 0 2.0411731384228915e-05
or O 0 3.5391931874073634e-07
homologous O 0 2.900834624597337e-05
recombination O 0 0.0001656709355302155
. O 0 3.07659174723085e-05

Dysfunction O 1 0.5135220289230347
of O 0 7.960150583130599e-07
this O 0 1.2266501698832144e-06
pathway O 0 4.246841126587242e-05
may O 0 1.2922528185299598e-06
be O 0 1.6881216424735612e-08
a O 0 6.098554194977623e-08
general O 0 9.819010671208162e-08
phenomenon O 0 3.853213002003031e-07
in O 0 7.939096491327291e-09
the O 0 1.530061588539411e-08
majority O 0 5.091598609396897e-08
of O 0 3.3270534771645544e-08
cases O 0 3.361897825016058e-06
of O 0 3.530556568875909e-06
hereditary B-Disease 1 0.998141884803772
breast I-Disease 1 0.999366819858551
and I-Disease 0 0.00023530088947154582
/ I-Disease 1 0.9922847747802734
or I-Disease 1 0.6107320785522461
ovarian I-Disease 1 0.9999446868896484
cancer I-Disease 1 0.9997333884239197
. O 0 4.199672184768133e-05
. O 0 4.189128230791539e-05

A O 0 2.9398486731224693e-05
novel O 0 3.457719139987603e-05
Arg362Ser O 0 0.0005098048131912947
mutation O 0 6.931146344868466e-06
in O 0 1.6604580821422132e-07
the O 0 5.467651931212458e-07
sterol O 0 0.00039467139868065715
27 O 0 1.3031712114752736e-05
- O 0 1.0411834409751464e-05
hydroxylase O 0 2.822252645273693e-05
gene O 0 2.166671265513287e-06
( O 0 6.531359986183816e-07
CYP27 O 0 0.0001325627526966855
) O 0 9.871703809949395e-08
: O 0 4.2463341287657386e-08
its O 0 2.3215328326386953e-08
effects O 0 6.615953225264093e-07
on O 0 2.6638394601263826e-08
pre O 0 1.5717184851382626e-06
- O 0 3.2182890663534636e-07
mRNA O 0 1.1189136017719647e-07
splicing O 0 6.635921749875706e-07
and O 0 1.0808351902369395e-07
enzyme O 0 1.2388530194584746e-05
activity O 0 6.8285653469501995e-06
. O 0 1.0701957762648817e-05

A O 0 1.3571535419032443e-05
novel O 0 8.714872819837183e-06
C O 0 1.3101243894197978e-05
to O 0 7.189362349890871e-08
A O 0 8.38166499761428e-07
mutation O 0 1.2279108432267094e-06
in O 0 3.8089314813305464e-08
the O 0 2.413727315797587e-07
sterol O 0 0.00018297639326192439
27 O 0 7.220086445158813e-06
- O 0 6.265750471357023e-06
hydroxylase O 0 1.6879557733773254e-05
gene O 0 2.8942079097760143e-06
( O 0 8.067611929618579e-07
CYP27 O 0 0.0001700433494988829
) O 0 1.9264221862158593e-07
was O 0 2.3434373019881605e-07
identified O 0 1.6169434502444346e-07
by O 0 3.7657123641565704e-08
sequencing O 0 1.1120547469545272e-06
amplified O 0 1.6854899513418786e-05
CYP27 O 0 0.0005607866914942861
gene O 0 5.479148512677057e-06
products O 0 2.068227558993385e-06
from O 0 8.41533619677648e-07
a O 0 6.688913344987668e-06
patient O 0 0.0014778977492824197
with O 0 2.0642468371079303e-05
cerebrotendinous B-Disease 1 0.9883483052253723
xanthomatosis I-Disease 1 0.9819944500923157
( O 0 0.00022789440117776394
CTX B-Disease 1 0.985840916633606
) O 0 1.522875390946865e-05
. O 0 1.798698394850362e-05

The O 0 8.096469173324294e-06
mutation O 0 3.856216790154576e-05
changed O 0 5.197364316700259e-06
the O 0 1.222413402501843e-06
adrenodoxin O 0 0.00019108245032839477
cofactor O 0 2.3775945010129362e-05
binding O 0 5.896491074963706e-06
residue O 0 7.141097739804536e-05
362Arg O 0 0.00018892873777076602
to O 0 1.5845744201214984e-06
362Ser O 0 0.00031579859205521643
( O 0 9.08175661606947e-06
CGT O 0 0.003191838040947914
362Arg O 0 0.0003719835076481104
to O 0 4.867587449552957e-06
AGT O 1 0.6675599217414856
362Ser O 0 0.00022697150416206568
) O 0 4.7192182250910264e-07
, O 0 7.512202415682623e-08
and O 0 5.249146539654248e-08
was O 0 8.098014063762093e-07
responsible O 0 1.354928258479049e-06
for O 0 1.2783797274096287e-06
deficiency O 1 0.9991069436073303
in O 0 1.1039937675150213e-07
the O 0 4.1359368196935975e-07
sterol O 0 0.00029771681874990463
27 O 0 8.081727173703257e-06
- O 0 4.675300715462072e-06
hydroxylase O 0 7.104388259904226e-06
activity O 0 9.390100785822142e-08
, O 0 1.2832343188051709e-08
as O 0 1.3409962917876328e-08
confirmed O 0 9.033799841517975e-08
by O 0 7.540450930321185e-09
expression O 0 4.008541765188056e-08
of O 0 1.647846836760891e-08
mutant O 0 3.138469992336468e-06
cDNA O 0 5.822639650432393e-06
into O 0 1.5141658877837472e-06
COS O 0 0.011286604218184948
- O 0 4.496026667766273e-05
1 O 0 5.60966009288677e-06
cells O 0 2.9364306101342663e-05
. O 0 7.216451649583178e-06

Quantitative O 0 1.19903752420214e-05
analysis O 0 1.834913632592361e-06
showed O 0 2.0636898625525646e-06
that O 0 1.8333267348680238e-08
the O 0 2.7601979368796492e-08
expression O 0 9.82699290830169e-08
of O 0 1.9501039005831444e-08
CYP27 O 0 5.212406540522352e-05
gene O 0 6.738262641192705e-07
mRNA O 0 6.062913371351897e-07
in O 0 8.707462484380812e-08
the O 0 6.126260814198758e-07
patient O 0 0.00014364902745001018
represented O 0 2.731289896473754e-06
52 O 0 3.0433773645199835e-05
. O 0 1.7169895727420226e-05

5 O 0 2.6131940558116185e-06
% O 0 2.438725914544193e-07
of O 0 4.9005318913941665e-08
the O 0 4.6092293359834e-07
normal O 0 8.002593858691398e-06
level O 0 2.289645817654673e-05
. O 0 1.6448986571049318e-05

As O 0 1.4331037618831033e-06
the O 0 6.343797167573939e-07
mutation O 0 9.274239346268587e-06
occurred O 0 1.4450891967499047e-06
at O 0 1.3504605078651366e-07
the O 0 3.3751504702195234e-08
penultimate O 0 2.347358758925111e-06
nucleotide O 0 8.849984567405045e-08
of O 0 1.8693111059064904e-08
exon O 0 6.513962944154628e-06
6 O 0 5.889820045013039e-07
( O 0 1.9200649603590136e-07
- O 0 1.454053801808186e-07
2 O 0 1.2017449257939461e-08
position O 0 3.754758726159935e-09
of O 0 7.734373141943252e-09
exon O 0 6.121248588897288e-06
6 O 0 1.4496497442451073e-06
- O 0 2.9782245292153675e-06
intron O 0 3.5016273614019156e-05
6 O 0 4.591916535900964e-07
splice O 0 3.734067604455049e-06
site O 0 2.2680967504129512e-07
) O 0 1.2382003866662217e-08
of O 0 5.703785443955667e-09
the O 0 5.8277006331763914e-08
gene O 0 7.552010288236488e-07
, O 0 4.960530120001749e-08
we O 0 1.4642282941679241e-08
hypothesized O 0 8.164197993210109e-07
that O 0 2.6438303990516943e-08
the O 0 1.5107056583474332e-07
mutation O 0 1.5815376173122786e-05
may O 0 1.768065658325213e-06
partially O 0 1.0012260645453352e-05
affect O 0 1.3971396128908964e-07
the O 0 2.336342674880143e-08
normal O 0 2.7867540097759047e-07
splicing O 0 8.934786706049636e-07
efficiency O 0 8.208636472772923e-07
in O 0 7.393987999648743e-08
exon O 0 1.500859343650518e-05
6 O 0 9.62871467891091e-07
and O 0 1.0013781093221041e-07
cause O 0 5.258273176877992e-06
alternative O 0 4.239860231791681e-07
splicing O 0 2.602122549433261e-06
elsewhere O 0 4.002796458735247e-07
, O 0 3.763672751233571e-08
which O 0 2.5822709304179625e-08
resulted O 0 1.8394567860013922e-06
in O 0 1.8594614914491103e-07
decreased O 0 3.592599750845693e-05
transcript O 0 4.897304461337626e-05
in O 0 8.193330245376274e-07
the O 0 4.374900072434684e-06
patient O 0 0.005734861362725496
. O 0 3.20422877848614e-05

Transfection O 0 0.0004835583968088031
of O 0 1.136080300057074e-06
constructed O 0 0.00014552164066117257
minigenes O 0 0.0007837273296900094
, O 0 1.632188428857262e-07
with O 0 5.714219852848146e-08
or O 0 7.791842193682896e-08
without O 0 4.711726120376625e-08
the O 0 5.849594941764735e-08
mutation O 0 9.669673772805254e-07
, O 0 9.48849177007105e-08
into O 0 5.080200367046928e-07
COS O 0 0.005010094493627548
- O 0 4.9602404033066705e-06
1 O 0 5.378516902965202e-07
cells O 0 1.6604311667833827e-06
confirmed O 0 1.4911472590029007e-07
that O 0 7.3294228464249045e-09
the O 0 4.215346649516505e-08
mutant O 0 5.378217792895157e-06
minigene O 0 3.379692498128861e-05
was O 0 3.4830472372959775e-07
responsible O 0 1.1007830380549422e-07
for O 0 1.1410948630441453e-08
a O 0 1.2445939034932962e-07
mRNA O 0 3.80541024469494e-07
species O 0 1.4748533772035444e-07
alternatively O 0 1.89571790087939e-06
spliced O 0 5.8354144130134955e-06
at O 0 5.679914352185733e-07
an O 0 3.197394562448608e-07
activated O 0 2.2220994651434012e-05
cryptic O 0 2.0033421606058255e-05
5 O 0 5.621466812044673e-07
splice O 0 9.325965038442519e-06
site O 0 1.45472972690186e-06
88 O 0 1.759476958795858e-06
bp O 0 6.28113866696367e-06
upstream O 0 4.974159537596279e-07
from O 0 1.7640955363162902e-08
the O 0 9.861424565826837e-09
3 O 0 5.223518684260853e-08
end O 0 1.167607663887793e-07
of O 0 5.513537360002374e-08
exon O 0 7.480019849026576e-05
6 O 0 1.0740432117017917e-05
. O 0 5.887096449441742e-06

Our O 0 2.0081211005162913e-06
data O 0 8.664964070703718e-07
suggest O 0 1.850262606239994e-06
that O 0 2.9153165215234367e-08
the O 0 3.278804072692765e-08
C O 0 1.4739437119715149e-06
to O 0 7.995688555695324e-09
A O 0 1.1468174676565468e-07
mutation O 0 2.167978294664863e-07
at O 0 2.0709194359369576e-08
the O 0 9.921760302233906e-09
penultimate O 0 5.229151156527223e-07
nucleotide O 0 3.4856117991921565e-08
of O 0 3.0360713942911843e-09
exon O 0 1.1555171113286633e-06
6 O 0 5.5662006559487054e-08
of O 0 8.063381073952769e-09
the O 0 1.1986711001554795e-07
CYP27 O 0 0.00012601508933585137
gene O 0 6.464545094786445e-07
not O 0 3.249957813977744e-08
only O 0 8.347397084662589e-08
causes O 0 0.00011251591786276549
the O 0 6.910619504196802e-06
deficiency B-Disease 1 0.9988899827003479
in I-Disease 0 1.8312111649265717e-07
the I-Disease 0 7.163313853197906e-07
sterol I-Disease 0 0.0003485035849735141
27 I-Disease 0 1.2279856491659302e-05
- I-Disease 0 1.0149833542527631e-05
hydroxylase I-Disease 0 1.4638976608694065e-05
activity I-Disease 0 2.900871152178297e-07
, O 0 6.03166654400411e-08
but O 0 3.339992460382746e-08
also O 0 5.619709853021959e-08
partially O 0 2.108900389430346e-06
leads O 0 1.6768426291946525e-07
to O 0 8.608509460827918e-09
alternative O 0 1.1596421245485544e-07
pre O 0 1.2519928986876039e-06
- O 0 2.0758280072641355e-07
mRNA O 0 3.3032343083050364e-08
splicing O 0 7.445898830837905e-08
of O 0 1.1655868270565861e-08
the O 0 4.746362662899628e-07
gene O 0 1.9431110558798537e-05
. O 0 8.68154256750131e-06

To O 0 4.032298477341101e-07
our O 0 1.0890693147302954e-07
knowledge O 0 1.3448466518184432e-07
, O 0 1.8885595309825476e-08
this O 0 4.259944397233539e-09
is O 0 6.844829592012047e-09
the O 0 1.3471773030460099e-08
first O 0 2.5011667403873616e-08
report O 0 1.0984737741637218e-07
regarding O 0 8.138957952041892e-08
effects O 0 1.3297052419147803e-06
on O 0 5.527700253082912e-08
pre O 0 1.3278753385748132e-06
- O 0 9.504341136334915e-08
mRNA O 0 1.748481892605014e-08
splicing O 0 2.074528993034619e-08
of O 0 2.664889864334441e-09
a O 0 8.329774914273003e-08
mutation O 0 6.113671702223655e-07
at O 0 5.946156633740429e-08
the O 0 5.318553775168766e-08
- O 0 2.9615094376822526e-07
2 O 0 2.405738541710889e-08
position O 0 9.503756892570436e-09
of O 0 6.288181086944178e-09
a O 0 3.59745826017388e-07
5 O 0 2.088668679789407e-06
splice O 0 7.343354081967846e-05
site O 0 2.2420765162678435e-05
. O 0 9.937207323673647e-06

ATM O 0 0.004444352351129055
germline O 0 0.006469098385423422
mutations O 0 9.851083450485021e-05
in O 0 7.915602509456221e-06
classical O 0 0.004949589259922504
ataxia B-Disease 1 0.9997178912162781
- I-Disease 1 0.9979477524757385
telangiectasia I-Disease 1 0.9990755319595337
patients O 0 0.08237583190202713
in O 0 1.1170684501848882e-06
the O 0 2.91789820039412e-06
Dutch O 0 5.1870338211301714e-05
population O 0 4.102602360944729e-06
. O 0 1.8769138478091918e-05

Germline O 0 0.005731787066906691
mutations O 0 2.222612420155201e-05
in O 0 1.9614184054717043e-07
the O 0 2.8161906584500684e-07
ATM O 0 2.7297191991237924e-05
gene O 0 1.5373829000964179e-06
are O 0 3.0953756890994555e-08
responsible O 0 8.224017733482469e-07
for O 0 1.14950057650276e-06
the O 0 0.00029513490153476596
autosomal B-Disease 1 0.99969482421875
recessive I-Disease 1 0.9999063014984131
disorder I-Disease 1 0.9999892711639404
ataxia B-Disease 1 0.9999017715454102
- I-Disease 1 0.9978592991828918
telangiectasia I-Disease 1 0.998420238494873
( O 0 0.0004150349705014378
A B-Disease 1 0.5558123588562012
- I-Disease 1 0.5473618507385254
T I-Disease 1 0.993934690952301
) O 0 7.066940270306077e-06
. O 0 1.4180215657688677e-05

In O 0 1.6655395711495657e-06
our O 0 2.783455386179412e-07
study O 0 5.826733513458748e-07
, O 0 4.866487302024325e-08
we O 0 1.1817920864132248e-08
have O 0 4.064394598657373e-09
determined O 0 2.892364570072914e-08
the O 0 2.4489891004009223e-08
ATM O 0 6.215402208908927e-06
mutation O 0 1.090736077458132e-06
spectrum O 0 4.221687390781881e-07
in O 0 8.679638341391183e-08
19 O 0 1.0220760486845393e-06
classical O 0 1.3147153367754072e-05
A B-Disease 0 0.13631445169448853
- I-Disease 1 0.9545660614967346
T I-Disease 1 0.9991418123245239
patients O 0 0.0013492497382685542
, O 0 1.6319719975399494e-07
including O 0 3.780472468406515e-08
some O 0 3.985327978739406e-08
immigrant O 0 7.959201866469812e-07
populations O 0 1.3469593795889523e-07
, O 0 1.953744899196863e-08
as O 0 7.902083432043128e-09
well O 0 5.464152241785314e-09
as O 0 5.8393139212853384e-09
12 O 0 1.1137348820966508e-08
of O 0 7.248925459890643e-09
Dutch O 0 1.4000981991557637e-06
ethnic O 0 4.5970517703608493e-07
origin O 0 3.024769966941676e-06
. O 0 1.2711590898106806e-05

Both O 0 3.6806136449740734e-07
the O 0 2.9980077442814945e-07
protein O 0 1.4748309240530943e-06
truncation O 0 1.4079395441513043e-05
test O 0 8.941169653553516e-07
( O 0 3.0908393000572687e-07
PTT O 0 2.7498572308104485e-06
) O 0 3.4842226881437455e-08
and O 0 6.244543993005891e-09
the O 0 5.019577997700253e-08
restriction O 0 2.353873242100235e-06
endonuclease O 0 0.00010459921031724662
fingerprinting O 0 3.0469609555439092e-05
( O 0 1.936890612341813e-06
REF O 0 0.00048493457143194973
) O 0 2.1122522397831744e-08
method O 0 1.3970590906353664e-08
were O 0 5.296714622460286e-09
used O 0 1.2062966625592253e-08
and O 0 5.580506279301289e-09
compared O 0 5.089054511131508e-08
for O 0 2.5912636480995843e-09
their O 0 5.559788629483364e-09
detection O 0 1.2480363693612162e-06
efficiency O 0 4.224175995659607e-07
, O 0 3.056484487728994e-08
identifying O 0 2.9202510631876066e-07
76 O 0 9.603706985217286e-07
% O 0 4.9628489762199024e-08
and O 0 5.057632090910147e-09
60 O 0 5.03571691012894e-08
% O 0 1.939750227109016e-08
of O 0 9.329755634723824e-09
the O 0 2.7591985940489394e-07
mutations O 0 4.617836111719953e-06
, O 0 3.062758366922935e-07
respectively O 0 6.458662483055377e-06
. O 0 1.5169326616160106e-05

Most O 0 6.341875268844888e-05
patients O 0 0.0045960573479533195
were O 0 2.788886490634468e-07
found O 0 3.8923548117963946e-07
to O 0 7.164148030369688e-08
be O 0 3.6852426887890033e-07
compound O 0 4.304100730223581e-05
heterozygote O 0 0.0013317296979948878
. O 0 2.4808852685964666e-05

Seventeen O 0 3.819988342002034e-05
mutations O 0 1.582299591973424e-05
were O 0 9.453699334471821e-08
distinct O 0 1.540040415193289e-07
, O 0 3.0253961114112826e-08
of O 0 9.298506853383515e-09
which O 0 3.9430165799103634e-08
10 O 0 1.1628870311142236e-07
were O 0 5.9233588700635664e-08
not O 0 1.398008606656731e-07
reported O 0 6.608786407014122e-06
previously O 0 8.918925232137553e-06
. O 0 9.8532582342159e-06

Mutations O 0 6.368668982759118e-05
are O 0 1.7080247971534845e-07
small O 0 1.4155851886243909e-06
deletions O 0 1.5930860172375105e-05
or O 0 1.4295451364887413e-06
point O 0 3.9531632864964195e-06
mutations O 0 2.8906089937663637e-05
frequently O 0 8.482490557071287e-06
affecting O 0 3.267969805165194e-05
splice O 0 0.00035281997406855226
sites O 0 2.2112339138402604e-05
. O 0 3.737844599527307e-05

Moreover O 0 0.00016552787565160543
, O 0 3.554343493306078e-06
a O 0 1.0281381946697365e-05
16 O 0 2.435048736515455e-05
. O 0 2.3872777092037722e-05

7 O 0 3.898669092450291e-05
- O 0 1.3532012417272199e-05
kb O 0 1.5963179976097308e-05
genomic O 0 1.8345951957599027e-06
deletion O 0 1.4963439980419935e-06
of O 0 1.2212916011833386e-08
the O 0 3.3702100665777834e-08
3 O 0 5.821435067332459e-08
end O 0 3.3951014444255634e-08
of O 0 1.4320612473639471e-09
the O 0 1.791958048613651e-08
gene O 0 1.661174025002765e-07
, O 0 1.1186015669295557e-08
most O 0 7.246671707150654e-09
likely O 0 4.238533790612564e-08
a O 0 2.216676087130054e-08
result O 0 3.874717791063631e-08
of O 0 4.547740406479761e-09
recombination O 0 5.950274726274074e-07
between O 0 5.30890531535988e-08
two O 0 3.9295098730462996e-08
LINE O 0 2.3936702291393885e-06
elements O 0 2.5385546109646384e-07
, O 0 6.242403287615161e-07
was O 0 5.819708349008579e-06
identified O 0 1.5926942069199868e-05
. O 0 1.506026728748111e-05

The O 0 4.125436589674791e-06
most O 0 5.140393000147014e-07
frequently O 0 1.9295566744403914e-06
found O 0 1.5554397805317421e-06
mutation O 0 4.447084393177647e-06
, O 0 6.864587476229644e-08
identified O 0 2.338784383937309e-07
in O 0 2.421930744844758e-08
three O 0 6.305466371259172e-08
unrelated O 0 3.461784217506647e-05
Turkish O 0 3.464482506387867e-05
A B-Disease 0 0.023445092141628265
- I-Disease 0 0.012463843449950218
T I-Disease 1 0.8908216953277588
individuals O 0 2.9232910492282826e-07
, O 0 1.1397207089203221e-07
was O 0 4.5658509861823404e-07
previously O 0 3.1034571179588966e-07
described O 0 3.646179891347856e-07
to O 0 8.037860155241106e-09
be O 0 9.47937106587915e-09
a O 0 2.9569858384093095e-07
Turkish O 0 7.495359113818267e-06
A B-Disease 0 0.0011536215897649527
- I-Disease 0 0.003433667588979006
T I-Disease 1 0.9638016819953918
founder O 0 0.00018008516053669155
mutation O 0 0.00024481845321133733
. O 0 2.6667794372770004e-05

The O 0 1.1616737083386397e-06
presence O 0 5.794404955850041e-07
of O 0 9.97401841118517e-08
a O 0 2.415614062556415e-06
founder O 0 3.825478779617697e-05
mutation O 0 1.3391324500844348e-05
among O 0 1.1024071966403426e-07
relatively O 0 4.4109188479524164e-07
small O 0 1.448578501594966e-07
ethnic O 0 5.22403702518659e-08
population O 0 3.2250415671342125e-08
groups O 0 3.289471450784731e-08
in O 0 7.27657862853448e-08
Western O 0 4.398828536977817e-07
Europe O 0 3.7275950148796255e-07
could O 0 8.792510897137618e-08
indicate O 0 2.4632592499074235e-07
a O 0 2.0468947070639842e-07
high O 0 2.0060460883541964e-06
carrier O 0 3.88885518987081e-06
frequency O 0 3.0573247045140306e-07
in O 0 1.7366073734592646e-07
such O 0 2.356033235173527e-07
communities O 0 3.182273758284282e-06
. O 0 1.1585578249651007e-05

In O 0 1.3257345017336775e-05
patients O 0 0.00014484208077192307
of O 0 1.4233363287985412e-07
Dutch O 0 3.5031523566431133e-06
ethnic O 0 1.0001183170516015e-07
origin O 0 1.638861135688785e-07
, O 0 8.780996552104625e-08
however O 0 1.6731877394704497e-07
, O 0 6.237975469502999e-08
no O 0 1.5038919798371353e-07
significant O 0 8.168652811946231e-07
founder O 0 2.845513154170476e-05
effect O 0 2.9121933948772494e-06
could O 0 4.428304691828089e-07
be O 0 1.1628714702283105e-07
identified O 0 6.583133654203266e-06
. O 0 7.006222858763067e-06

The O 0 3.343892331031384e-06
observed O 0 6.3567308643541764e-06
genetic O 0 1.502676877862541e-05
heterogeneity O 0 7.157549134717556e-06
including O 0 6.57656187286193e-08
the O 0 6.152238540835242e-08
relative O 0 4.3197746890655253e-07
high O 0 4.466174345907348e-07
percentage O 0 1.97801270473974e-07
of O 0 2.834869050616362e-08
splice O 0 3.8853111618664116e-05
- O 0 6.553186722157989e-06
site O 0 1.090588284569094e-06
mutations O 0 1.167930008705298e-06
had O 0 1.936239186761668e-07
no O 0 8.291399211657335e-08
reflection O 0 6.46736907583545e-07
on O 0 2.5832025585259544e-07
the O 0 1.7903167872646009e-06
phenotype O 0 0.001551336608827114
. O 0 2.1310394004103728e-05

All O 0 3.148146060993895e-05
patients O 0 0.006870890036225319
manifested O 0 0.0005903462297283113
classical O 0 0.00012192517169751227
A B-Disease 0 0.0771419107913971
- I-Disease 0 0.026464717462658882
T I-Disease 1 0.7179373502731323
and O 0 2.537809109526279e-07
increased O 0 1.8831515262718312e-06
cellular O 0 1.63126751431264e-05
radioresistant O 0 0.00011867259308928624
DNA O 0 1.2439129022823181e-05
synthesis O 0 3.5811372072203085e-05
. O 0 9.953407243301626e-06

Determination O 0 2.3141469682741445e-06
of O 0 5.5186720970823444e-08
the O 0 1.2868119370068598e-07
genomic O 0 1.7062386632460402e-06
structure O 0 8.42073063722637e-07
of O 0 3.3334501381432347e-08
the O 0 3.95478593873122e-07
COL4A4 O 0 0.0005098296096548438
gene O 0 1.445098860131111e-06
and O 0 8.565061904164395e-08
of O 0 3.1361432206722384e-07
novel O 0 0.00022338506823871285
mutations O 0 0.023156486451625824
causing O 1 0.9907435774803162
autosomal B-Disease 1 0.9986943602561951
recessive I-Disease 1 0.9992849230766296
Alport I-Disease 1 0.9995829463005066
syndrome I-Disease 1 0.9998641014099121
. O 0 0.011010553687810898

Autosomal B-Disease 1 0.9951973557472229
recessive I-Disease 1 0.9987014532089233
Alport I-Disease 1 0.9996711015701294
syndrome I-Disease 1 0.999840259552002
is O 0 0.00010598113294690847
a O 0 0.0004287400224711746
progressive O 1 0.9494838118553162
hematuric B-Disease 1 0.9953345656394958
glomerulonephritis I-Disease 1 0.9990469813346863
characterized O 1 0.8654693961143494
by O 0 0.0007718203705735505
glomerular B-Disease 1 0.9990009665489197
basement I-Disease 1 0.995924711227417
membrane I-Disease 0 0.4270085096359253
abnormalities I-Disease 1 0.9854356646537781
and O 0 1.0198958761975518e-06
associated O 0 3.3976195936702425e-06
with O 0 3.4269160664734954e-07
mutations O 0 3.6876863305224106e-06
in O 0 7.951708624887033e-08
either O 0 2.6722341317508835e-07
the O 0 4.1015167084879067e-07
COL4A3 O 0 0.0006015333929099143
or O 0 2.49114094685865e-07
the O 0 2.815530137922906e-07
COL4A4 O 0 0.0002963289152830839
gene O 0 8.041135401981592e-07
, O 0 2.592555503611038e-08
which O 0 1.1768299224002021e-08
encode O 0 5.1871218431642774e-08
the O 0 2.3119885383948713e-07
alpha3 O 0 0.0001233554066857323
and O 0 7.147182259359397e-07
alpha4 O 0 0.003507747547701001
type O 0 0.00706166448071599
IV O 1 0.9953493475914001
collagen O 1 0.9333829283714294
chains O 0 0.0002660668396856636
, O 0 2.261104555145721e-06
respectively O 0 1.3282364307087846e-05
. O 0 1.3263490473036654e-05

To O 0 5.268083782539179e-07
date O 0 1.3101366675982717e-06
, O 0 1.8155178338474798e-07
mutation O 0 2.8627628125832416e-06
screening O 0 7.25619031527458e-07
in O 0 1.823297601788454e-08
the O 0 8.813191954004651e-09
two O 0 8.979511356699277e-09
genes O 0 2.3375824298454972e-07
has O 0 1.845902772856789e-07
been O 0 1.7616619629734487e-07
hampered O 0 2.251398836961016e-05
by O 0 4.491246130555737e-08
the O 0 4.365695360775135e-08
lack O 0 6.814577204750094e-07
of O 0 7.102703847294833e-08
genomic O 0 2.295032209076453e-05
structure O 0 2.7023363145417534e-05
information O 0 5.848445653100498e-06
. O 0 1.8658007320482284e-05

We O 0 7.253823923747404e-07
report O 0 6.330724886538519e-07
here O 0 4.4831239165432635e-08
the O 0 1.3992912606397567e-08
complete O 0 1.328892267338233e-07
characterization O 0 3.626364843967167e-07
of O 0 5.823753035372192e-09
the O 0 1.7776059735297167e-08
48 O 0 8.163569020780415e-08
exons O 0 1.3286691569192044e-07
of O 0 7.879868313409588e-09
the O 0 1.40082988764334e-07
COL4A4 O 0 0.00010994699550792575
gene O 0 5.829879228258505e-07
, O 0 2.105719509870596e-08
a O 0 1.0259348925956147e-07
comprehensive O 0 9.601563988326234e-07
gene O 0 9.11441532025492e-07
screen O 0 3.886983677148237e-07
, O 0 1.640170488315107e-08
and O 0 4.672016995499462e-09
the O 0 1.1351945161663934e-08
subsequent O 0 1.6830459514949325e-07
detection O 0 3.5825820532409125e-07
of O 0 8.124142247822874e-09
10 O 0 9.084097740696961e-08
novel O 0 9.514186558590154e-07
mutations O 0 4.22475068262429e-06
in O 0 1.0571665143288556e-06
eight O 0 0.00021513969113584608
patients O 1 0.9985124468803406
diagnosed O 1 0.999776303768158
with O 0 0.1100127100944519
autosomal B-Disease 1 0.9995118379592896
recessive I-Disease 1 0.9997385144233704
Alport I-Disease 1 0.9998723268508911
syndrome I-Disease 1 0.9999176263809204
. O 0 0.010019264183938503

Furthermore O 0 5.2193896408425644e-05
, O 0 7.911910415714374e-07
we O 0 7.133672852432937e-08
identified O 0 2.240604146663827e-07
a O 0 8.360319725397858e-08
glycine O 0 2.4925645902840188e-06
to O 0 2.5830935612702888e-08
alanine O 0 4.530791557044722e-06
substitution O 0 8.608535040366405e-07
in O 0 6.225328519349205e-08
the O 0 3.730874027496611e-07
collagenous O 0 0.0010134073672816157
domain O 0 1.173089458461618e-06
that O 0 1.1186575221699968e-07
is O 0 2.5892106236824475e-07
apparently O 0 3.1968077109922888e-06
silent O 0 8.491993867210113e-06
in O 0 6.250206041613637e-08
the O 0 2.463686996634351e-07
heterozygous O 0 8.792962034931406e-06
carriers O 0 1.5470544894924387e-05
, O 0 3.568400757103518e-07
in O 0 8.984583814708458e-07
11 O 0 1.022460128297098e-05
. O 0 7.778493454679847e-06

5 O 0 2.5527936031721765e-06
% O 0 2.986564311413531e-07
of O 0 2.6151926846296192e-08
all O 0 3.430414352578737e-08
control O 0 6.186551786413474e-07
individuals O 0 4.6275339116164105e-08
, O 0 1.863146081859668e-08
and O 0 6.274690544927353e-09
in O 0 4.308400303187909e-09
one O 0 7.317982220200747e-09
control O 0 6.13040427310807e-08
individual O 0 1.6027874139012965e-08
homozygous O 0 5.174611601432844e-07
for O 0 2.9797817546750593e-08
this O 0 1.396875717318835e-07
glycine O 0 4.135092967771925e-05
substitution O 0 2.723883699218277e-05
. O 0 1.597315349499695e-05

There O 0 3.295147052995162e-06
has O 0 4.6984621349110967e-07
been O 0 4.6318167079562045e-08
no O 0 2.7705834071412028e-08
previous O 0 2.5346059473463356e-08
finding O 0 2.779390939622317e-08
of O 0 4.082489457601923e-09
a O 0 6.781106520747926e-08
glycine O 0 2.2267797703534598e-06
substitution O 0 5.321435878613556e-07
that O 0 3.5516013241476685e-08
is O 0 2.418897793177166e-08
not O 0 1.345133515684438e-08
associated O 0 1.0612185974423483e-07
with O 0 3.5847861568072403e-08
any O 0 2.590761880583159e-07
obvious O 0 2.5369830837007612e-05
phenotype O 0 0.0003569053078535944
in O 0 1.6814044556667795e-06
homozygous O 0 0.00011023232218576595
individuals O 0 9.908098945743404e-06
. O 0 5.066031371825375e-05

Founder O 0 0.0026661555748432875
BRCA1 O 0 0.0033005517907440662
and O 0 1.0556356755841989e-05
BRCA2 O 0 0.0024471296928822994
mutations O 0 3.347171877976507e-05
in O 0 4.076868663105415e-06
French O 0 0.0003341692790854722
Canadian O 0 0.014627893455326557
breast B-Disease 1 0.9988455772399902
and I-Disease 0 0.06534044444561005
ovarian I-Disease 1 0.999962568283081
cancer I-Disease 1 0.9997369647026062
families O 0 0.00046442635357379913
. O 0 9.192443394567817e-05

We O 0 6.799892844355782e-07
have O 0 5.081459875100336e-08
identified O 0 1.1609278516289123e-07
four O 0 1.492905354893992e-08
mutations O 0 2.0460673511024652e-07
in O 0 1.2238356106308856e-08
each O 0 6.509456529357749e-09
of O 0 8.434187037664742e-08
the O 0 0.00010447899694554508
breast B-Disease 1 0.999541163444519
cancer I-Disease 1 0.9990645051002502
- O 0 0.00015601269842591137
susceptibility O 0 9.623172809369862e-05
genes O 0 1.1245764426348615e-06
, O 0 7.441830121024395e-07
BRCA1 O 0 0.00033429134055040777
and O 0 5.13959435011202e-07
BRCA2 O 0 0.00030055243405513465
, O 0 3.5718326785172394e-07
in O 0 1.020269451146305e-06
French O 0 0.00025654080673120916
Canadian O 0 0.008990364149212837
breast B-Disease 1 0.9992107152938843
cancer I-Disease 1 0.9993498921394348
and O 0 0.010717346332967281
breast B-Disease 1 0.9998679161071777
/ I-Disease 1 0.9994756579399109
ovarian I-Disease 1 0.9999723434448242
cancer I-Disease 1 0.9997444748878479
families O 0 5.2242554374970496e-05
from O 0 2.3503122065449134e-05
Quebec O 0 0.0013801566092297435
. O 0 6.119169847806916e-05

To O 0 4.3562981772993226e-06
identify O 0 3.359160109539516e-05
founder O 0 0.000129861815366894
effects O 0 7.499082130379975e-05
, O 0 6.510427397188323e-07
we O 0 1.8096542930834403e-07
examined O 0 5.430068995337933e-06
independently O 0 1.4274158957050531e-06
ascertained O 0 7.980105874594301e-05
French O 0 5.5686599807813764e-05
Canadian O 0 0.0003904549521394074
cancer B-Disease 1 0.8179232478141785
families O 0 1.2684346017977077e-07
for O 0 7.695335035862172e-09
the O 0 9.555195745747369e-09
distribution O 0 2.9664551703945108e-08
of O 0 1.3374967799961723e-08
these O 0 4.812975262780128e-08
eight O 0 1.1562557347133406e-06
mutations O 0 5.2840248827124014e-05
. O 0 1.204561885970179e-05

Mutations O 0 3.530558024067432e-05
were O 0 4.0084580632537836e-07
found O 0 3.307216047687689e-07
in O 0 9.511322929256494e-08
41 O 0 5.092899755254621e-07
of O 0 1.1189263915412084e-07
97 O 0 3.351196210132912e-05
families O 0 6.869643129903125e-06
. O 0 1.5615049051120877e-05

Six O 0 4.0652807342667074e-07
of O 0 5.08725932490961e-08
eight O 0 4.516950014021859e-07
mutations O 0 2.6713373699749354e-06
were O 0 4.550128807068177e-08
observed O 0 5.700242127204547e-07
at O 0 1.4503965530821006e-06
least O 0 1.2794237136404263e-06
twice O 0 1.0693071089917794e-05
. O 0 8.378272468689829e-06

The O 0 2.7557653083931655e-05
BRCA1 O 0 0.00433735828846693
C4446T O 0 0.00048436890938319266
mutation O 0 1.837293712014798e-05
was O 0 5.641735469907871e-07
the O 0 1.2099020807454508e-07
most O 0 6.136510677379192e-08
common O 0 5.059748104940809e-07
mutation O 0 3.243330866098404e-06
found O 0 1.6542780656436662e-07
, O 0 3.1113692955386796e-08
followed O 0 2.2533757260134735e-07
by O 0 1.9813336393781356e-07
the O 0 2.969908791783382e-06
BRCA2 O 0 0.005011896137148142
8765delAG O 0 0.0022162452805787325
mutation O 0 0.0004074944299645722
. O 0 5.199588122195564e-05

Together O 0 2.2505053038912592e-06
, O 0 4.4746838057108107e-07
these O 0 6.4721817238933e-08
mutations O 0 1.3162621144147124e-06
were O 0 2.5338566800314766e-08
found O 0 6.990465806211432e-08
in O 0 1.2705648977373585e-08
28 O 0 7.178058325507664e-08
of O 0 6.559309095877097e-09
41 O 0 4.4955316980122006e-07
families O 0 8.286213670771758e-08
identified O 0 1.071804476282523e-07
to O 0 1.1635011176736043e-08
have O 0 2.3292233919391947e-08
a O 0 9.77924401013297e-07
mutation O 0 4.663155414164066e-05
. O 0 6.71838552079862e-06

The O 0 4.454112968232948e-06
odds O 0 1.482712286815513e-05
of O 0 5.678420222920977e-08
detection O 0 7.712390015512938e-07
of O 0 4.811486320477343e-09
any O 0 7.70529240412543e-09
of O 0 4.573671663621326e-09
the O 0 1.1950983491715306e-07
four O 0 4.945169393977267e-07
BRCA1 O 0 0.0012933106627315283
mutations O 0 1.6945363313425332e-05
was O 0 7.291579549928429e-06
18 O 0 1.5772362530697137e-05
. O 0 1.327991958532948e-05

7x O 0 0.01279675867408514
greater O 0 2.343332880627713e-06
if O 0 4.17395199292514e-07
one O 0 7.930170653480673e-08
or O 0 1.686194792682727e-07
more O 0 6.879648140056815e-08
cases O 0 3.0098904971964657e-05
of O 0 0.0003436364349909127
ovarian B-Disease 1 0.9999822378158569
cancer I-Disease 1 0.9997859597206116
were O 0 5.700350698134571e-07
also O 0 1.6457101992273238e-07
present O 0 2.7634726507130836e-07
in O 0 2.2648352171472652e-07
the O 0 7.773099923724658e-07
family O 0 1.943003553606104e-05
. O 0 1.3059729099040851e-05

The O 0 2.310116087755887e-06
odds O 0 1.337547382718185e-05
of O 0 5.609118503002719e-08
detection O 0 1.1746936934287078e-06
of O 0 5.1041193493972514e-09
any O 0 8.905334247799601e-09
of O 0 9.081963625590106e-09
the O 0 1.4592383479339333e-07
four O 0 7.180330499068077e-07
BRCA2 O 0 0.0003979868779424578
mutations O 0 1.3790695447823964e-05
was O 0 4.121877736906754e-06
5 O 0 1.0473418114997912e-05
. O 0 6.258208941289922e-06

3x O 0 0.00041481820517219603
greater O 0 2.845853259714204e-06
if O 0 4.0770686382529675e-07
there O 0 5.360993782232981e-08
were O 0 1.2056686315986553e-08
at O 0 6.052156464875225e-08
least O 0 3.697514472378316e-08
five O 0 7.941977742120798e-08
cases O 0 1.5068895891090506e-06
of O 0 8.73994122230215e-06
breast B-Disease 1 0.999671220779419
cancer I-Disease 1 0.9986487030982971
in O 0 1.0582770073597203e-06
the O 0 3.154897058266215e-06
family O 0 6.845994357718155e-05
. O 0 2.2077696485212073e-05

Interestingly O 0 9.892305388348177e-05
, O 0 3.484296371425444e-07
the O 0 1.4630199984821957e-07
presence O 0 5.478628963828669e-07
of O 0 4.0155211422643333e-07
a O 0 0.0009850552305579185
breast B-Disease 1 0.9993226528167725
cancer I-Disease 1 0.9985357522964478
case O 0 4.424337384989485e-05
< O 0 0.0002377234195591882
36 O 0 4.911967721454857e-07
years O 0 6.344541958469563e-08
of O 0 1.0301287822755967e-08
age O 0 1.2816439038942917e-06
was O 0 2.1908597602759983e-07
strongly O 0 6.12695529866869e-08
predictive O 0 7.169451521349401e-08
of O 0 3.4884102273480266e-09
the O 0 8.842590659696725e-09
presence O 0 1.8944472657267397e-08
of O 0 1.4840468853805078e-09
any O 0 2.6610145198446844e-09
of O 0 5.362054356083945e-09
the O 0 1.0418168727710508e-07
eight O 0 1.219887508341344e-06
mutations O 0 4.131446985411458e-05
screened O 0 7.72743733250536e-05
. O 0 1.3824300367559772e-05

Carriers O 0 2.8629227017518133e-05
of O 0 1.0466467159631065e-07
the O 0 2.813543744650815e-07
same O 0 4.4838850499218097e-07
mutation O 0 2.7753917493100744e-06
, O 0 2.3927785974819926e-08
from O 0 1.6053757434519866e-08
different O 0 6.090646653689191e-09
families O 0 5.461821217522811e-08
, O 0 2.2914596442547008e-08
shared O 0 8.417441677011084e-08
similar O 0 3.8365217847058375e-07
haplotypes O 0 3.4692729968810454e-05
, O 0 1.0605407396724331e-07
indicating O 0 1.2818468348996248e-06
that O 0 2.5892989086173657e-08
the O 0 6.828454246488036e-08
mutant O 0 3.9515011849289294e-06
alleles O 0 7.187592814261734e-07
were O 0 6.939401231420561e-08
likely O 0 1.6253446233349678e-07
to O 0 5.646890510746516e-09
be O 0 4.823265342679406e-09
identical O 0 3.8622406606236837e-08
by O 0 2.3132143311954678e-08
descent O 0 2.794064357658499e-07
for O 0 1.975037733359386e-08
a O 0 3.6616307852455066e-07
mutation O 0 1.504092779214261e-06
in O 0 7.702313098434388e-08
the O 0 3.8312643368954014e-07
founder O 0 2.285568007209804e-05
population O 0 1.2987404716113815e-06
. O 0 6.427086645999225e-06

The O 0 6.303332042989496e-07
identification O 0 9.540882501823944e-07
of O 0 1.7021774567638204e-07
common O 0 9.901580597215798e-06
BRCA1 O 0 0.0017608426278457046
and O 0 1.4247815443013678e-06
BRCA2 O 0 0.0009381964919157326
mutations O 0 3.930930233764229e-06
will O 0 6.289695164696241e-08
facilitate O 0 4.981104666512692e-07
carrier O 0 3.06374131469056e-05
detection O 0 2.3750177206238732e-05
in O 0 1.6766024373282562e-06
French O 0 0.00011297972378088161
Canadian O 0 0.003034802619367838
breast B-Disease 1 0.9987713694572449
cancer I-Disease 1 0.9993788003921509
and O 0 0.012468873523175716
breast B-Disease 1 0.9997878670692444
/ I-Disease 1 0.9992892742156982
ovarian I-Disease 1 0.999954342842102
cancer I-Disease 1 0.999646782875061
families O 0 0.00030034134397283196
. O 0 0.00011326407548040152

Are O 0 6.3845554905128665e-06
Dp71 O 0 0.0018714427715167403
and O 0 1.3822204891766887e-05
Dp140 O 0 0.0060401801019907
brain O 0 0.4464271366596222
dystrophin O 0 0.009648771956562996
isoforms O 0 2.6988751415046863e-05
related O 0 4.146702849538997e-05
to O 0 8.912106750358362e-06
cognitive B-Disease 0 0.18549470603466034
impairment I-Disease 1 0.9977074861526489
in O 0 0.1136561930179596
Duchenne B-Disease 1 0.9994401335716248
muscular I-Disease 1 0.9994515776634216
dystrophy I-Disease 1 0.9993464350700378
? O 0 0.45139411091804504

Molecular O 0 0.00015814190555829555
study O 0 8.318576874444261e-06
and O 0 8.765532015786448e-07
neuropsychological O 0 0.00014600994472857565
analysis O 0 7.237668455672974e-07
were O 0 1.240666591684203e-07
performed O 0 7.019123700047203e-07
concurrently O 0 1.2187176707811886e-06
on O 0 1.9819904082396533e-06
49 O 0 0.00020816433243453503
patients O 0 0.29548147320747375
with O 0 0.0025235849898308516
Duchenne B-Disease 1 0.9996042847633362
muscular I-Disease 1 0.9997243285179138
dystrophy I-Disease 1 0.9997771382331848
( O 0 0.01707904040813446
DMD B-Disease 1 0.9992289543151855
) O 0 8.39668132357474e-07
in O 0 3.723835462210445e-08
order O 0 2.300919632602927e-08
to O 0 5.900240740430718e-09
find O 0 3.5175961698996616e-08
a O 0 7.036214810796082e-08
molecular O 0 4.966324240740505e-07
explanation O 0 5.124031190462119e-07
for O 0 5.638197464463701e-08
the O 0 7.619971711392282e-07
cognitive B-Disease 0 0.0008027545991353691
impairment I-Disease 1 0.8823710680007935
observed O 0 1.671576319495216e-05
in O 0 9.783016139408574e-06
most O 0 0.00030881291604600847
DMD B-Disease 1 0.9995805621147156
patients O 1 0.9873025417327881
. O 0 0.00011522977001732215

Complete O 0 5.247802619123831e-06
analysis O 0 2.953555622298154e-07
of O 0 7.316213412877914e-08
the O 0 7.678110023334739e-07
dystrophin O 0 0.003262292593717575
gene O 0 3.5313478292664513e-06
was O 0 2.612829916870396e-07
performed O 0 5.344189446532255e-08
to O 0 4.346094151230773e-09
define O 0 3.757224575906548e-08
the O 0 1.5887106741274692e-08
localization O 0 9.061728292181215e-07
of O 0 3.4211030452979685e-08
deletions O 0 2.2077722405811073e-06
and O 0 1.0626587254591868e-07
duplications O 0 4.172792159806704e-06
in O 0 4.334539482897526e-08
relation O 0 4.120016683373251e-07
to O 0 6.421031173431402e-08
the O 0 4.426679254265764e-07
different O 0 1.8142419548894395e-06
DMD B-Disease 1 0.9971778392791748
promoters O 0 0.006665315479040146
. O 0 3.95182978536468e-05

Qualitative O 0 3.3429514587624e-06
analysis O 0 4.657099168525747e-07
of O 0 7.233114729388035e-08
the O 0 5.565790957007266e-07
Dp71 O 0 0.0001595456269569695
transcript O 0 1.0178681804973166e-05
and O 0 4.67179646079785e-08
testing O 0 1.4105651757745363e-07
for O 0 2.6484117121583495e-09
the O 0 4.996040026128412e-09
specific O 0 8.619089442163386e-09
first O 0 4.5662563508130916e-08
exon O 0 2.5979120437114034e-06
of O 0 8.413748986413339e-08
Dp140 O 0 3.472444223007187e-05
were O 0 8.941197648937305e-08
also O 0 2.0293160218898265e-07
carried O 0 5.764399588770175e-07
out O 0 9.221861319019808e-07
. O 0 5.069551207270706e-06

Neuropsychological O 0 0.004051510244607925
analysis O 0 2.3848473574616946e-05
assessed O 0 7.468060357496142e-05
verbal O 0 7.611386536154896e-05
and O 0 1.101571433537174e-05
visuospatial O 0 0.0101393423974514
intelligence O 0 3.734926940524019e-05
, O 0 8.929394539336499e-07
verbal O 0 1.8149956304114312e-05
memory O 0 7.765139889670536e-05
, O 0 4.381432745503844e-07
and O 0 2.4278330101878964e-07
reading O 0 1.4126698260952253e-05
skills O 0 2.2958727640798315e-05
. O 0 1.3411082363745663e-05

Comparison O 0 7.78197318140883e-06
of O 0 4.933590957989509e-07
molecular O 0 1.927945777424611e-05
and O 0 2.173919256165391e-06
psychometric O 0 0.0004766476631630212
findings O 0 2.0859873984591104e-05
demonstrated O 0 4.661854745791061e-06
that O 0 1.4870884967876918e-07
deletions O 0 4.672376689995872e-06
and O 0 1.2832984452870733e-07
duplications O 0 7.878000360506121e-06
that O 0 6.294507670645544e-08
were O 0 6.85069707628827e-08
localized O 0 2.5980707505368628e-06
in O 0 3.901303102793463e-08
the O 0 5.003566982964003e-08
distal O 0 2.941407910839189e-05
part O 0 8.872853385355484e-08
of O 0 1.3432670087354381e-08
the O 0 3.045916514565761e-07
gene O 0 2.4379264687013347e-06
seemed O 0 8.700927196514385e-07
to O 0 2.398600074116075e-08
be O 0 2.6143796461042257e-08
preferentially O 0 2.2027061277185567e-06
associated O 0 4.627764610631857e-06
with O 0 4.5674946704821195e-06
cognitive B-Disease 0 0.028485028073191643
impairment I-Disease 1 0.9947273135185242
. O 0 0.00035061236121691763

Two O 0 3.8999005482764915e-06
altered O 0 6.111407128628343e-05
Dp71 O 0 0.00011553520016605034
transcripts O 0 2.9415009521471802e-06
and O 0 4.897915673041098e-08
two O 0 3.6713156958967375e-08
deleted O 0 3.2743505471444223e-06
Dp140 O 0 5.579498974839225e-06
DNA O 0 6.147499789221911e-07
sequences O 0 1.210891298342176e-07
were O 0 4.35957936417708e-08
found O 0 2.4607493287476245e-07
in O 0 3.9168943999357e-07
four O 0 5.5915907068992965e-06
patients O 1 0.6909685730934143
with O 0 0.002257229760289192
severe O 1 0.9996223449707031
cerebral B-Disease 1 0.9997484087944031
dysfunction I-Disease 1 0.9990480542182922
. O 0 0.002279700245708227

These O 0 1.625721097298083e-06
findings O 0 4.641829036700074e-06
suggest O 0 7.681273928028531e-07
that O 0 1.0048254672767598e-08
some O 0 3.2719367215605644e-09
sequences O 0 3.892020217222125e-08
located O 0 1.0085508250767816e-07
in O 0 1.3700113932202385e-08
the O 0 3.613336119201449e-08
distal O 0 1.7186705008498393e-05
part O 0 4.1624318214417144e-08
of O 0 1.1558038970349571e-08
the O 0 6.571220723117221e-08
gene O 0 3.57915666882036e-07
and O 0 1.907733171435666e-08
, O 0 1.6753489262555377e-08
in O 0 1.2427999962483227e-08
particular O 0 6.50528804158057e-08
, O 0 7.350411124207312e-08
some O 0 2.7687721626534767e-07
DMD B-Disease 1 0.9901337027549744
isoforms O 0 4.593428002408473e-06
expressed O 0 1.3135534118191572e-06
in O 0 6.302568635874195e-07
the O 0 7.348389317485271e-06
brain O 1 0.7362805008888245
may O 0 4.299460670154076e-06
be O 0 5.636476885229058e-08
related O 0 4.548159324713197e-07
to O 0 8.972187259814746e-08
the O 0 2.3939328457345255e-06
cognitive B-Disease 0 0.008401814848184586
impairment I-Disease 1 0.996756374835968
associated O 0 0.0005267782835289836
with O 0 0.0002385753468843177
DMD B-Disease 1 0.9991331696510315
. O 0 3.984255454270169e-05
. O 0 4.053515294799581e-05

I1307K O 0 0.0032751080580055714
APC O 0 0.0019720110576599836
and O 0 2.157318476747605e-06
hMLH1 O 0 0.0001701108121778816
mutations O 0 6.20622131464188e-06
in O 0 1.039034600580635e-07
a O 0 7.040584364403912e-07
non O 0 2.5757094590517227e-06
- O 0 3.7421170873130905e-06
Jewish O 0 3.670567139124614e-07
family O 0 3.763016138691455e-06
with O 0 6.8610202106356155e-06
hereditary B-Disease 1 0.9930607080459595
non I-Disease 1 0.6844071745872498
- I-Disease 1 0.9961510896682739
polyposis I-Disease 1 0.9993268251419067
colorectal I-Disease 1 0.999942421913147
cancer I-Disease 1 0.9995759129524231
. O 0 0.0015098382718861103

We O 0 2.5136021122307284e-06
describe O 0 7.028836535027949e-06
a O 0 4.457283012015978e-06
French O 0 7.504733366658911e-05
Canadian O 0 0.0004011847195215523
hereditary B-Disease 1 0.9707093238830566
non I-Disease 1 0.5624156594276428
- I-Disease 1 0.9953820109367371
polyposis I-Disease 1 0.9994744658470154
colorectal I-Disease 1 0.9999513626098633
cancer I-Disease 1 0.9998155236244202
( O 0 0.005826134234666824
HNPCC B-Disease 1 0.9973813891410828
) O 0 1.0055502571049146e-05
kindred O 0 0.00014073404599912465
which O 0 1.7979705546622426e-07
carries O 0 1.8786743112286786e-06
a O 0 1.2448899724404328e-06
novel O 0 8.30819863040233e-06
truncating O 0 0.0007726118201389909
mutation O 0 9.337483788840473e-05
in O 0 6.209595994732808e-06
hMLH1 O 0 0.0036672470159828663
. O 0 5.020846219849773e-05

Interestingly O 0 0.0001628110621822998
, O 0 1.3170217698643683e-06
the O 0 1.9997046365460847e-06
I1307K O 0 0.00018404585716780275
APC O 0 0.0006780472467653453
polymorphism O 0 1.6248117390205152e-05
, O 0 5.261536557554791e-07
associated O 0 9.735704225022346e-07
with O 0 1.198673373892234e-07
an O 0 1.1554840284588863e-06
increased O 0 0.00010532826854614541
risk O 0 0.004980303347110748
of O 0 0.0003667772398330271
colorectal B-Disease 1 0.9999834299087524
cancer I-Disease 1 0.9998642206192017
, O 0 5.59319971671357e-07
is O 0 7.507475885404347e-08
also O 0 4.052676416677059e-08
present O 0 9.1194785056814e-08
in O 0 9.583032323234875e-08
this O 0 2.0311128423600167e-07
family O 0 2.3154110749601386e-05
. O 0 1.5305427950806916e-05

The O 0 1.0023935828940012e-05
I1307K O 0 0.00023089253227226436
polymorphism O 0 3.0390820029424503e-05
has O 0 9.077920140043716e-07
previously O 0 7.258792606990028e-07
only O 0 3.800861136937783e-08
been O 0 1.2174463392966572e-07
identified O 0 2.3188185593880917e-07
in O 0 2.4556310762591238e-08
individuals O 0 3.9599367340770186e-08
of O 0 8.836205012130449e-08
self O 0 3.131214180029929e-05
- O 0 0.00015598413301631808
reported O 0 2.870933349186089e-05
Ashkenazi O 0 4.548332071863115e-05
Jewish O 0 2.501511289665359e-06
origins O 0 3.9442060369765386e-05
. O 0 3.1100255000637844e-05

In O 0 2.9300110782060074e-06
addition O 0 2.0497129753493937e-06
, O 0 3.2183626785808883e-07
in O 0 7.785499178680766e-08
this O 0 7.80317535031827e-08
family O 0 1.0186283816437935e-06
, O 0 5.717686946127287e-08
there O 0 5.1738613393581545e-08
appears O 0 4.815220790987951e-07
to O 0 6.448213518694956e-09
be O 0 9.748339024895358e-09
no O 0 4.250458829346826e-08
relationship O 0 1.712154187316628e-07
between O 0 4.121461927297787e-08
the O 0 1.2240369073879265e-07
I1307K O 0 1.1834377801278606e-05
polymorphism O 0 6.822139653195336e-07
and O 0 2.1374361836024036e-08
the O 0 5.10660527197615e-08
presence O 0 3.4872286391873786e-07
or O 0 3.9626797843084205e-07
absence O 0 1.2736491044051945e-05
of O 0 3.1130250590649666e-06
cancer B-Disease 1 0.9985119700431824
. O 0 5.209587015997386e-06
. O 0 1.5022369552752934e-05

Identification O 0 1.0133670684808749e-06
of O 0 6.061524970846222e-08
a O 0 4.714324290944205e-07
novel O 0 8.562103062104143e-07
mutation O 0 6.343162226585264e-07
of O 0 2.044007096912992e-08
the O 0 2.492238593276852e-07
CPO O 0 3.6726120015373453e-05
gene O 0 2.191172143284348e-06
in O 0 2.7338859354131273e-07
a O 0 5.851296464243205e-06
Japanese O 0 0.0001921487128129229
hereditary B-Disease 0 0.342289000749588
coproporphyria I-Disease 0 0.0840117335319519
family O 0 0.0003730987082235515
. O 0 6.105162901803851e-05

Hereditary B-Disease 1 0.852452278137207
coproporphyria I-Disease 0 0.3938397467136383
( O 0 0.0002659664023667574
HCP B-Disease 1 0.9665898680686951
) O 0 3.2370116969104856e-06
is O 0 1.7104941889556358e-06
an O 0 1.5434356100740843e-05
autosomal B-Disease 1 0.9951280355453491
dominant I-Disease 1 0.9618518352508545
disease I-Disease 1 0.9996544122695923
characterized O 0 0.1335882991552353
by O 0 1.3634466085932218e-05
a O 0 0.001401623827405274
deficiency B-Disease 1 0.9995586276054382
of I-Disease 0 1.4120309970167e-06
coproporphyrinogen I-Disease 0 0.012703645043075085
oxidase I-Disease 0 0.0005205120542086661
( O 0 5.482603683049092e-06
CPO O 0 0.00014055168139748275
) O 0 5.073238753539044e-07
caused O 0 9.872898772300687e-06
by O 0 6.628951609854994e-08
a O 0 5.159306510904571e-07
mutation O 0 3.260160610807361e-06
in O 0 2.1835009533788252e-07
the O 0 1.510231641077553e-06
CPO O 0 0.00041842437349259853
gene O 0 3.783274951274507e-05
. O 0 1.5963665646268055e-05

Only O 0 4.4016485389875015e-07
11 O 0 7.201535368039913e-07
mutations O 0 3.938229440336727e-07
of O 0 8.125786266077739e-09
the O 0 1.3534697984596278e-07
gene O 0 2.0884538116661133e-06
have O 0 1.0108907844141868e-07
been O 0 8.647709819342708e-07
reported O 0 3.3350101148243994e-05
in O 0 2.045262954197824e-05
HCP B-Disease 1 0.9975489974021912
patients O 1 0.7353590130805969
. O 0 0.0001070371872629039

We O 0 1.901835048556677e-06
report O 0 2.5164276848954614e-06
another O 0 9.161928460343916e-07
mutation O 0 3.985202511103125e-06
in O 0 2.9663459599760245e-07
a O 0 3.6246192394173704e-06
Japanese O 0 5.5060121667338535e-05
family O 0 5.109498670208268e-05
. O 0 2.431053144391626e-05

Polymerase O 0 0.00074182846583426
chain O 0 0.00035541236866265535
reaction O 0 5.3415988077176735e-05
- O 0 6.656433924945304e-06
single O 0 3.3225640549972013e-07
strand O 0 4.511156930675497e-06
conformational O 0 2.389052042417461e-06
polymorphism O 0 4.2414535528223496e-07
and O 0 1.5261704788827046e-08
direct O 0 1.4526976954698512e-08
sequence O 0 1.2297888929424516e-07
analyses O 0 5.278050707602233e-07
demonstrated O 0 6.275315627135569e-07
a O 0 2.4776946361271257e-07
C O 0 4.29523561251699e-06
to O 0 4.973452760737018e-08
T O 0 2.776822293526493e-05
substitution O 0 1.0763996982632307e-07
in O 0 9.54719769907797e-09
exon O 0 7.706602787038719e-07
1 O 0 1.687349104884106e-08
of O 0 1.6445553807642455e-09
the O 0 1.9599816880599974e-08
CPO O 0 2.7347982722858433e-06
gene O 0 5.931736524189546e-08
at O 0 2.3493733181112475e-08
nucleotide O 0 4.92792970874234e-08
position O 0 7.19506871860176e-08
85 O 0 2.7701668159352266e-07
, O 0 1.4297012462805014e-08
which O 0 5.286409976434925e-09
lies O 0 1.2349377698228636e-07
in O 0 1.4543999782290484e-08
the O 0 6.182882117400368e-08
putative O 0 8.614442776888609e-06
presequence O 0 1.668126969889272e-05
for O 0 4.175647916326852e-08
targeting O 0 7.599869036312157e-07
to O 0 4.483073041683383e-07
mitochondria O 0 0.00010313279199181125
. O 0 1.8501130398362875e-05

This O 0 1.838993739511352e-06
mutation O 0 4.302385150367627e-06
changes O 0 1.576919288481804e-07
the O 0 3.100386081200668e-08
codon O 0 2.762650410659262e-07
for O 0 6.206415825715794e-09
glutamine O 0 6.434523243115109e-07
to O 0 6.050965506432249e-09
a O 0 8.261043404900192e-08
termination O 0 4.0718368836678565e-06
codon O 0 4.969052724845824e-07
at O 0 1.2385953596094623e-07
amino O 0 8.346934237124515e-07
acid O 0 6.040671723894775e-05
position O 0 3.781089162657736e-06
29 O 0 2.977558324346319e-05
. O 0 1.907215846586041e-05

MaeI O 0 0.0011744523653760552
restriction O 0 1.695475475571584e-05
analysis O 0 1.8971793451783014e-06
showed O 0 2.4607616069260985e-06
two O 0 6.437181099272493e-08
other O 0 6.204228952810809e-08
carriers O 0 6.846007636340801e-06
in O 0 2.257645377312656e-07
the O 0 5.872713018106879e-07
family O 0 1.355893436993938e-05
. O 0 1.078588411473902e-05

The O 0 1.9216095097362995e-05
C O 0 0.0031372178345918655
- O 0 0.000679651100654155
T O 0 0.005123291630297899
mutation O 0 2.1248915800242685e-06
is O 0 2.8431214715851638e-08
located O 0 6.83255763078705e-08
within O 0 2.4956198885206504e-08
a O 0 1.9329202416429325e-07
recently O 0 8.298414400087495e-07
proposed O 0 3.4349554312029795e-07
putative O 0 1.6257303059319383e-06
alternative O 0 1.8534950640969328e-07
translation O 0 3.6691605487249035e-07
initiation O 0 4.6520749492628966e-06
codon O 0 1.3620962818094995e-05
( O 0 5.143593625689391e-06
TIC O 0 0.014450336806476116
- O 0 3.2397417726315325e-06
1 O 0 1.5017793941751734e-07
) O 0 4.5058325071067884e-08
, O 0 2.5527999270025248e-08
supporting O 0 2.0518120891210856e-07
that O 0 2.512168748580734e-07
TIC O 0 0.01266240980476141
- O 0 1.6244098333118018e-06
1 O 0 6.60057679624515e-08
is O 0 2.784936192767873e-08
the O 0 7.656219480622894e-08
real O 0 2.9694554086745484e-06
TIC O 0 0.006985506508499384
rather O 0 1.1049370414184523e-06
than O 0 1.177743797597941e-06
TIC O 1 0.555284321308136
- O 0 1.0513197594264057e-05
2 O 0 9.50198170812655e-07
. O 0 6.164266892483283e-07
. O 0 3.817335255007492e-06

Human B-Disease 0 0.00013014694559387863
complement I-Disease 0 0.0007501651998609304
factor I-Disease 0 0.020127808675169945
H I-Disease 1 0.9982883334159851
deficiency I-Disease 1 0.9996515512466431
associated O 1 0.7087751030921936
with O 1 0.9831368327140808
hemolytic B-Disease 1 0.999962568283081
uremic I-Disease 1 0.9999724626541138
syndrome I-Disease 1 0.9999135732650757
. O 0 0.013143753632903099

This O 0 1.0960175131913275e-06
study O 0 1.4580866718461039e-06
reports O 0 1.027599068947893e-06
on O 0 1.8148426761399605e-07
six O 0 4.387700869301625e-07
cases O 0 5.768332357547479e-06
of O 0 2.6265811357006896e-06
deficiency B-Disease 1 0.9996683597564697
in I-Disease 0 8.735758427746987e-08
the I-Disease 0 4.964259403550386e-08
human I-Disease 0 1.1608570815724306e-07
complement I-Disease 0 3.5840685086441226e-07
regulatory I-Disease 0 8.342569344677031e-06
protein I-Disease 0 4.3164532144146506e-06
Factor I-Disease 0 8.386722583964001e-06
H I-Disease 0 0.004002837929874659
( O 0 2.20815331886115e-06
FH O 0 0.0006561376503668725
) O 0 5.908374234309122e-08
in O 0 1.0690397012069752e-08
the O 0 4.484937221604923e-08
context O 0 3.582797489798395e-07
of O 0 1.8062453364109388e-06
an O 0 0.013527312316000462
acute B-Disease 1 0.9998736381530762
renal I-Disease 1 0.9999899864196777
disease I-Disease 1 0.9999200105667114
. O 0 0.0037269722670316696

Five O 0 2.8263181661714043e-07
of O 0 1.0185744514501494e-07
the O 0 4.470913097520679e-07
cases O 0 1.9204655927751446e-06
were O 0 1.4535271475324407e-07
observed O 0 1.687441340436635e-06
in O 0 1.1943911886191927e-06
children O 0 1.8263963283970952e-05
presenting O 0 0.0007581956451758742
with O 0 0.13507874310016632
idiopathic O 1 0.9998971223831177
hemolytic B-Disease 1 0.9999805688858032
uremic I-Disease 1 0.9999923706054688
syndrome I-Disease 1 0.9999815225601196
( O 1 0.9512419700622559
HUS B-Disease 1 0.9989385008811951
) O 0 0.0002958482364192605
. O 0 7.895396993262693e-05

Two O 0 1.421880568841516e-07
of O 0 1.3164851964120317e-07
the O 0 1.0658227438398171e-06
children O 0 9.499874067842029e-06
exhibited O 0 0.00012472685193642974
a O 0 0.0001904467208078131
homozygous O 1 0.6447030901908875
deficiency O 1 0.9998249411582947
characterized O 0 0.0009364612051285803
by O 0 2.917431345395016e-07
the O 0 9.971355297011542e-08
absence O 0 5.989507485537615e-07
of O 0 1.3925178343754396e-08
the O 0 1.0910444814271614e-07
150 O 0 6.976513304834953e-07
- O 0 2.663306759131956e-06
kD O 0 1.3299423699209001e-05
form O 0 5.509280498472435e-08
of O 0 2.6019083776418483e-08
Factor O 0 3.2930172437772853e-06
H O 0 0.0001445931411581114
and O 0 2.551913880211032e-08
the O 0 3.387190972148346e-08
presence O 0 1.5850368129122216e-07
, O 0 3.8379486255735173e-08
upon O 0 1.0363586966377625e-07
immunoblotting O 0 1.1586264008656144e-05
, O 0 1.062402876783608e-08
of O 0 1.0056557364634955e-08
the O 0 1.348949325574722e-07
42 O 0 2.309270257683238e-06
- O 0 6.469993422797415e-06
kD O 0 9.766687435330823e-05
Factor O 0 1.3502740330295637e-06
H O 0 0.00012948815128766
- O 0 6.05201250891696e-07
like O 0 3.975313944692971e-08
protein O 0 2.4492513261975546e-07
1 O 0 2.285650282374263e-07
( O 0 4.3702027596737025e-07
FHL O 0 0.002198216039687395
- O 0 7.163115469666081e-07
1 O 0 5.415441961531542e-08
) O 0 1.7090634685246187e-08
and O 0 1.8818354874383658e-08
other O 0 1.0828657082129212e-07
FH O 0 0.008944897912442684
- O 0 6.925450634298613e-06
related O 0 1.3578205653175246e-06
protein O 0 3.4049892292387085e-06
( O 0 2.5889291919156676e-06
FHR O 0 0.000908843707293272
) O 0 1.5640523542970186e-06
bands O 0 2.0435338228708133e-05
. O 0 1.1163304407091346e-05

Southern O 0 1.4967143215471879e-05
blot O 0 7.527110574301332e-05
and O 0 1.0883425005658864e-07
PCR O 0 1.7392457039022702e-06
analysis O 0 2.8274387275928348e-08
of O 0 1.162658058717625e-08
DNA O 0 5.319660090208345e-07
of O 0 4.386788177157541e-08
one O 0 8.887620310815691e-07
patient O 0 0.0009089719387702644
with O 0 2.4557408323744312e-05
homozygous O 0 0.4908078610897064
deficiency O 1 0.9997798800468445
ruled O 0 1.0293596460542176e-05
out O 0 6.932322804686919e-08
the O 0 2.8197426615861332e-08
presence O 0 3.399611259169433e-08
of O 0 4.717685797572813e-09
a O 0 3.9006412322351025e-08
large O 0 6.82450860267636e-08
deletion O 0 1.5725986486359034e-06
of O 0 3.12908632338349e-08
the O 0 7.434771873704449e-07
FH O 0 0.008510706946253777
gene O 0 1.87002990514884e-06
as O 0 1.7127372586855927e-07
the O 0 7.810797910678957e-07
underlying O 0 0.001384051749482751
defect O 1 0.7940360903739929
for O 0 6.215212124516256e-06
the O 0 0.0006552222184836864
deficiency O 1 0.9993873834609985
. O 0 0.00015325783169828355

The O 0 6.890625741107215e-07
other O 0 6.820579301347607e-08
four O 0 2.0026712377330114e-07
children O 0 1.1322536010993645e-06
presented O 0 3.2784898849058663e-06
with O 0 5.080285973235732e-06
heterozygous O 0 0.04149368777871132
deficiency O 1 0.9996895790100098
and O 0 9.498320991951914e-07
exhibited O 0 9.882732229016256e-06
a O 0 7.293766088878328e-07
normal O 0 2.2494646145787556e-06
immunoblotting O 0 0.00010475573071744293
pattern O 0 1.3046494586888002e-06
of O 0 1.6037139616287277e-08
proteins O 0 2.1203095457167365e-07
of O 0 1.3427320766368211e-07
the O 0 1.229571171279531e-05
FH O 1 0.8892505168914795
family O 0 0.00013831198157276958
. O 0 3.6255954910302535e-05

Factor B-Disease 0 0.016168376430869102
H I-Disease 1 0.9971969127655029
deficiency I-Disease 1 0.9992125034332275
is O 0 2.5611675482650753e-06
the O 0 2.1074790765851503e-06
only O 0 5.106491244077915e-06
complement B-Disease 0 0.32286205887794495
deficiency I-Disease 1 0.9998841285705566
associated O 0 0.0005547928158193827
with O 0 0.00015106701175682247
HUS B-Disease 1 0.9971984624862671
. O 0 0.00023457377392333

These O 0 3.242633397348982e-07
observations O 0 1.4753429695701925e-06
suggest O 0 1.6986500668281224e-06
a O 0 6.673097914244863e-07
role O 0 8.337069061781222e-07
for O 0 5.123073378854315e-07
FH O 0 0.040486596524715424
and O 0 1.0882464493988664e-06
/ O 0 0.00010318571730749682
or O 0 1.9565327420423273e-06
FH O 0 0.018916882574558258
receptors O 0 1.3895224583393428e-05
in O 0 4.4540348653754336e-07
the O 0 2.4140758796420414e-06
pathogenesis O 0 0.19897711277008057
of O 0 0.00014100271800998598
idiopathic O 1 0.9996148347854614
HUS B-Disease 1 0.999036431312561
. O 0 5.8528996305540204e-05
. O 0 5.334096204023808e-05

Further O 0 1.7732970718498109e-06
evidence O 0 8.783649150245765e-07
for O 0 7.049218453403228e-08
a O 0 8.508332030032761e-07
major O 0 9.047436833498068e-06
ancient O 0 9.83074787654914e-05
mutation O 0 0.08953309059143066
underlying O 1 0.9908958077430725
myotonic B-Disease 1 0.9997554421424866
dystrophy I-Disease 1 0.9996615648269653
from O 0 8.46546099637635e-05
linkage O 0 0.003234699135646224
disequilibrium O 0 0.007434130180627108
studies O 0 2.331271844013827e-06
in O 0 3.912198280886514e-07
the O 0 8.682004022375622e-07
Japanese O 0 2.2709700715495273e-05
population O 0 2.757430820565787e-06
. O 0 1.006389720714651e-05

The O 0 0.00980862695723772
myotonic B-Disease 1 0.9982237219810486
dystrophy I-Disease 1 0.9994033575057983
( O 0 0.015045187436044216
DM B-Disease 1 0.9983757734298706
) O 0 1.3188190678192768e-05
mutation O 0 3.2530570024391636e-05
is O 0 4.294193445275596e-07
an O 0 9.786904229258653e-07
unstable O 0 0.0017592625226825476
( O 0 2.3735117338219425e-06
CTG O 0 0.0004254858649801463
) O 0 3.3866038506857876e-07
n O 0 1.5754657169964048e-06
repeat O 0 3.0239534680731595e-06
, O 0 1.785056902292581e-08
present O 0 3.157119010666065e-08
at O 0 5.4527237836055065e-08
a O 0 3.453681074461201e-08
copy O 0 8.960540753832902e-08
number O 0 1.2232025392577839e-09
of O 0 3.985667795802783e-09
5 O 0 1.4240762880035618e-07
- O 0 3.962857704209455e-07
37 O 0 1.1227681540049161e-07
repeats O 0 4.789130230165028e-07
on O 0 1.6519976497875177e-08
normal O 0 2.7255293844064e-07
chromosomes O 0 1.618237632783348e-07
but O 0 4.1948784001988315e-08
amplified O 0 7.155407502068556e-07
to O 0 3.7177393608089915e-08
50 O 0 3.18205081839551e-07
- O 0 2.8122153707954567e-06
3000 O 0 2.597619868538459e-06
copies O 0 7.382432158919983e-07
on O 0 2.6494342364458134e-06
DM B-Disease 1 0.9868780970573425
chromosomes O 0 4.975836054654792e-05
. O 0 1.6428341041319072e-05

Previous O 0 3.153608486172743e-05
findings O 0 2.2452861230704002e-05
in O 0 1.5282553249562625e-06
Caucasian O 0 7.202292908914387e-05
populations O 0 8.439109251412447e-07
of O 0 1.3787753516680823e-07
a O 0 6.166648381622508e-05
DM B-Disease 1 0.9987390637397766
founder O 0 8.480481483275071e-05
chromosome O 0 1.1726347111107316e-05
raise O 0 5.087017029836716e-07
a O 0 6.146783704252812e-08
question O 0 4.111694451580661e-08
about O 0 9.390061173064623e-09
the O 0 2.304864032964815e-08
molecular O 0 4.250191523169633e-07
events O 0 3.558707817319373e-08
involved O 0 1.2597703857863962e-07
in O 0 4.7379597134522555e-08
the O 0 2.3320735920151492e-07
expansion O 0 2.68316416622838e-05
mutation O 0 0.0001484590320615098
. O 0 2.0364968804642558e-05

To O 0 1.681439812273311e-06
investigate O 0 1.0273492080159485e-05
whether O 0 9.669267910794588e-07
a O 0 9.147767059403122e-07
founder O 0 1.1693437045323662e-05
chromosome O 0 4.751588676299434e-06
for O 0 1.5243790585373063e-07
the O 0 3.835194092971506e-06
DM B-Disease 1 0.9986199140548706
mutation O 0 2.8828126232838258e-05
exists O 0 7.279048190866888e-07
in O 0 6.23009199784974e-08
the O 0 1.2331607024407276e-07
Japanese O 0 3.2423599805042613e-06
population O 0 7.945826041577675e-08
, O 0 4.6843776857485864e-08
we O 0 4.0850384408486207e-08
genotyped O 0 1.623366551939398e-05
families O 0 1.6707576833141502e-07
using O 0 1.6649821077407978e-07
polymorphic O 0 1.2216980394441634e-05
markers O 0 8.097125828498974e-06
near O 0 2.8942135941179004e-06
the O 0 4.5295593054106575e-07
( O 0 2.2083365820435574e-06
CTG O 0 0.0004295746039133519
) O 0 4.923467145090399e-07
n O 0 5.622288881568238e-06
repeat O 0 1.5116153917915653e-05
region O 0 1.1446893495303812e-06
and O 0 3.2376152603319497e-07
constructed O 0 5.3110616136109456e-05
haplotypes O 0 0.000884892069734633
. O 0 3.496511999401264e-05

Six O 0 2.735601583481184e-06
different O 0 5.562623073274153e-07
haplotypes O 0 0.00010545087570790201
were O 0 8.723717996872438e-07
found O 0 1.8848224954126636e-06
and O 0 1.919941951200599e-06
DM B-Disease 1 0.9968728423118591
alleles O 0 6.32375258646789e-06
were O 0 3.2391716331403586e-07
always O 0 2.737204113145708e-06
haplotype O 0 0.0005136504187248647
A O 0 3.9015740185277537e-05
. O 0 1.9153925677528605e-05

To O 0 3.9285362163354876e-07
find O 0 2.627984088121593e-07
an O 0 2.136804511110313e-08
origin O 0 1.602943378031796e-08
of O 0 1.8178250016376296e-08
the O 0 2.459320569414558e-07
( O 0 1.7080767520383233e-06
CTG O 0 0.00023944381973706186
) O 0 3.91650218034556e-07
n O 0 2.933108817160246e-06
repeat O 0 6.9547445491480175e-06
mutation O 0 6.299335382209392e-07
and O 0 7.616510977470625e-09
to O 0 5.1973785275549744e-09
investigate O 0 5.829990712413746e-08
the O 0 6.164204702230336e-09
mechanism O 0 5.756522369892991e-08
of O 0 4.290703348175384e-09
the O 0 4.1559900409993134e-08
expansion O 0 1.0234913361273357e-06
mutation O 0 9.675659384811297e-07
in O 0 4.1135141515269424e-08
the O 0 7.405123625403576e-08
Japanese O 0 1.541537699267792e-06
population O 0 3.624144895297832e-08
we O 0 8.810636664691174e-09
have O 0 1.808470173614296e-08
studied O 0 4.0799935163704504e-07
90 O 0 2.384861318205367e-06
Japanese O 0 0.00012396420061122626
DM B-Disease 1 0.9920622110366821
families O 0 1.2495501096054795e-06
comprising O 0 1.2013574632874224e-06
190 O 0 6.531884992000414e-06
affected O 0 4.430954959389055e-06
and O 0 3.746905576917925e-07
130 O 0 7.075214398355456e-06
unaffected O 0 0.0001333625114057213
members O 0 3.698893806358683e-06
. O 0 1.188894657389028e-05

The O 0 3.748446033569053e-06
results O 0 3.933517746190773e-06
suggest O 0 1.1606528005358996e-06
that O 0 7.195357198952479e-08
a O 0 3.372396975009906e-07
few O 0 2.3059683940118703e-07
common O 0 1.034938918564876e-06
ancestral O 0 1.1144211384817027e-05
mutations O 0 5.233049705566373e-06
in O 0 1.5354984839177632e-07
both O 0 2.2280535461050022e-07
Caucasian O 0 0.00013424671487882733
and O 0 2.6337295366829494e-07
Japanese O 0 9.94405218079919e-06
populations O 0 2.423673493012757e-07
have O 0 1.378385761086065e-08
originated O 0 9.674418066651924e-08
by O 0 9.949447488111218e-09
expansion O 0 8.76869492572041e-08
of O 0 3.6998404340238267e-09
an O 0 2.9484832353432466e-08
ancestral O 0 1.0596869515211438e-06
n O 0 1.2119188568249228e-06
= O 0 1.2925660257678828e-06
5 O 0 6.759012904922201e-08
repeat O 0 4.3563255758272135e-07
to O 0 1.1774361929894894e-08
n O 0 6.387463713508623e-07
= O 0 2.2297570012597134e-06
19 O 0 7.970778028720815e-07
- O 0 1.8928744793811347e-06
37 O 0 5.57068176476605e-07
copies O 0 1.9328531379869673e-06
. O 0 3.469942157607875e-06

These O 0 4.044746617637429e-07
data O 0 5.900215001020115e-07
support O 0 5.884834308744757e-07
multistep O 0 1.6587153368163854e-05
models O 0 1.495498054282507e-06
of O 0 1.4079873267291987e-07
triplet O 0 0.002089329995214939
repeat O 0 0.00014552872744388878
expansion O 0 5.500226507137995e-06
that O 0 6.253544881928974e-08
have O 0 2.9311960858535713e-08
been O 0 3.659159020230618e-08
proposed O 0 1.271957188464512e-07
for O 0 1.3298557632879238e-07
both O 0 3.6799153804167872e-06
DM B-Disease 1 0.9975230097770691
and O 0 9.790687727218028e-06
Friedreichs B-Disease 0 0.2307026982307434
ataxia I-Disease 1 0.9934644103050232
. O 0 2.3293929189094342e-05
. O 0 3.960676986025646e-05

The O 0 1.0586425105429953e-06
molecular O 0 9.293930816056672e-06
basis O 0 1.7379738892486785e-06
of O 0 3.8339367165463045e-05
C6 B-Disease 1 0.9995912909507751
deficiency I-Disease 1 0.9997535347938538
in O 0 4.7031602434799424e-07
the O 0 4.538609346127487e-07
western O 0 1.1916697530978126e-06
Cape O 0 1.5613739378750324e-05
, O 0 3.9646531035941734e-07
South O 0 3.554662043825374e-06
Africa O 0 5.210441486269701e-06
. O 0 8.504020115651656e-06

Deficiency B-Disease 1 0.9936453104019165
of I-Disease 0 2.393450415638654e-07
the I-Disease 0 3.491228142138425e-07
sixth I-Disease 0 2.543231630625087e-06
component I-Disease 0 7.649707640666747e-07
of I-Disease 0 3.735245712732649e-08
human I-Disease 0 6.55214080325095e-07
complement I-Disease 0 2.8311137612035964e-06
( O 0 4.185669695289107e-06
C6 O 0 0.019023723900318146
) O 0 2.0829868674354657e-07
has O 0 6.86589700649165e-08
been O 0 3.252289459965141e-08
reported O 0 1.544390926255801e-07
in O 0 2.839413149047232e-09
a O 0 1.02548067815178e-08
number O 0 8.86643314323976e-10
of O 0 1.9483925584040662e-09
families O 0 1.9714134324999577e-08
from O 0 1.8341486551776143e-08
the O 0 4.613099235939444e-08
western O 0 3.287176753019594e-07
Cape O 0 6.366194611473475e-06
, O 0 1.9878994805822003e-07
South O 0 2.6004925075540086e-06
Africa O 0 4.995060407964047e-06
. O 0 7.089073278621072e-06

Meningococcal B-Disease 1 0.99748694896698
disease I-Disease 1 0.9992215633392334
is O 0 2.7892270736629143e-05
endemic O 0 0.0005970305646769702
in O 0 1.9517975147209654e-07
the O 0 2.0313761694978894e-07
Cape O 0 3.0830426567263203e-06
and O 0 1.5090748206603166e-08
almost O 0 2.4403163934039185e-08
all O 0 7.049067107800511e-09
pedigrees O 0 2.8709978323604446e-06
of O 0 3.039776004243322e-07
total O 0 9.374903311254457e-05
C6 B-Disease 1 0.9995429515838623
deficiency I-Disease 1 0.999896764755249
( O 0 3.528019806253724e-05
C6Q0 O 0 0.02462495118379593
) O 0 1.097276708605932e-06
have O 0 1.0184424326098451e-07
been O 0 4.6138558218444814e-07
ascertained O 0 2.250853503937833e-05
because O 0 4.7870025809970684e-06
of O 0 1.2528706065495498e-05
recurrent O 1 0.9975749850273132
disease O 1 0.9991907477378845
. O 0 0.0004555989580694586

We O 0 6.424388061532227e-07
have O 0 6.084170678377632e-08
sequenced O 0 6.017866098773084e-07
the O 0 4.009030973861627e-08
expressed O 0 1.4100540113304305e-07
exons O 0 6.211795380295371e-07
of O 0 3.546226778894379e-08
the O 0 7.847487495382666e-07
C6 O 0 0.021219981834292412
gene O 0 2.044205757556483e-06
from O 0 1.3820348954141082e-07
selected O 0 1.0099677183461608e-07
cases O 0 3.3349991213071917e-07
and O 0 3.6334750319610976e-08
have O 0 1.5618024207242343e-08
found O 0 9.134170397828711e-08
three O 0 9.553613011803463e-08
molecular O 0 9.165073424810544e-05
defects O 1 0.971045196056366
leading O 0 3.5699431464308873e-06
to O 0 4.3216368794674054e-07
total O 0 2.4959090296761133e-05
deficiency O 1 0.9997907280921936
879delG O 0 0.0008098111138679087
, O 0 1.7840196164797817e-07
which O 0 2.3543435645478894e-08
is O 0 3.578774254719974e-08
the O 0 1.3696801204332587e-07
common O 0 5.858566510141827e-06
defect O 0 0.009130739606916904
in O 0 1.5598621416756941e-07
the O 0 3.409287216982193e-07
Cape O 0 1.9558854546630755e-05
and O 0 2.750869896317454e-07
hitherto O 0 1.8766775610856712e-05
unreported O 0 1.1606943189690355e-05
, O 0 1.5308152967463684e-07
and O 0 1.294414744279493e-07
1195delC O 0 3.681536327349022e-05
and O 0 1.7771796478882607e-07
1936delG O 0 7.77736640884541e-05
, O 0 8.393601547140861e-08
which O 0 2.1361401536523772e-08
have O 0 1.56979442778038e-08
been O 0 5.692561444448074e-08
previously O 0 4.056288673837116e-07
reported O 0 2.090033603963093e-06
in O 0 3.805192250183609e-07
African O 0 5.6235330703202635e-06
- O 0 2.9096674552420154e-05
Americans O 0 3.422720055823447e-06
. O 0 6.020281489327317e-06

We O 0 1.2022031796732335e-06
also O 0 4.009528709048027e-07
show O 0 3.629354239365057e-07
that O 0 5.049788143196565e-08
the O 0 2.5632905931161076e-07
879delG O 0 0.00015368089952971786
and O 0 2.296295633641421e-06
1195delC O 0 0.04408516734838486
defects O 1 0.9029760956764221
are O 0 1.4945186421755352e-07
associated O 0 3.093911345786182e-06
with O 0 1.822326112232986e-06
characteristic O 0 0.0007001032936386764
C6 O 1 0.9954474568367004
/ O 0 0.0040524667128920555
C7 O 0 0.07327428460121155
region O 0 1.034851152326155e-06
DNA O 0 6.014164682710543e-06
marker O 0 1.9704528313013725e-05
haplotypes O 0 4.767200516653247e-05
, O 0 1.8148668345929764e-07
although O 0 1.8532510637214727e-07
small O 0 3.421710630391317e-07
variations O 0 1.6779189309090725e-06
were O 0 5.856124971614918e-07
observed O 0 1.671424979576841e-05
. O 0 1.193445405078819e-05

The O 0 7.447471580235288e-05
1936delG O 0 0.08180923759937286
defect O 1 0.6747933626174927
was O 0 4.450113465281902e-06
observed O 0 5.096573545415595e-07
only O 0 2.994681125301213e-08
once O 0 2.983808542467159e-07
in O 0 3.1177552983763235e-08
the O 0 8.541325513533593e-08
Cape O 0 3.2165139600692783e-06
, O 0 4.492985539172878e-08
but O 0 5.4914139013817476e-08
its O 0 1.5459750102309044e-07
associated O 0 6.575472525582882e-06
haplotype O 0 0.0003288221196271479
could O 0 6.767978106836381e-07
be O 0 3.1069635042513255e-07
deduced O 0 3.5564768040785566e-05
. O 0 1.1923872989427764e-05

The O 0 1.0400552810096997e-06
data O 0 6.663273097728961e-07
from O 0 3.428714308029157e-07
the O 0 5.116623356116179e-07
haplotypes O 0 5.085048542241566e-05
indicate O 0 1.3055318959231954e-06
that O 0 1.3632575956989967e-08
these O 0 1.503392432766759e-08
three O 0 1.2111685521176696e-07
molecular O 0 0.00018384645227342844
defects O 1 0.7750464677810669
account O 0 3.038158808976732e-07
for O 0 7.967208404124904e-08
the O 0 1.0316525731468573e-06
defects O 0 0.18898332118988037
in O 0 4.431359101886301e-08
all O 0 5.8858984353094e-09
the O 0 1.1570416802442196e-07
38 O 0 3.0152568797348067e-06
unrelated O 0 8.940208499552682e-05
C6Q0 O 0 0.006654847878962755
individuals O 0 2.4452651814499404e-07
we O 0 3.18818003108845e-08
have O 0 1.4044009510882915e-08
studied O 0 1.151133588450648e-07
from O 0 1.8067640894514625e-07
the O 0 8.905029744710191e-07
Cape O 0 0.00011249264207435772
. O 0 1.020164472720353e-05

We O 0 9.54845518208458e-07
have O 0 1.0673144146267077e-07
also O 0 4.0876809492829125e-08
observed O 0 2.1069594424716342e-07
the O 0 2.74369625685722e-07
879delG O 0 0.0005136221880093217
defect O 0 0.002985470462590456
in O 0 3.538312398632115e-07
two O 0 1.357459382234083e-06
Dutch O 0 0.0017562221037223935
C6 B-Disease 1 0.9988930821418762
- I-Disease 0 0.3093760311603546
deficient I-Disease 1 0.9940429329872131
kindreds O 0 0.0001599687966518104
, O 0 2.57613720577865e-07
but O 0 1.0437780417760223e-07
the O 0 1.0642443157848902e-06
879delG O 0 0.00088834686903283
defect O 0 0.017622411251068115
in O 0 3.4917277957902115e-07
the O 0 6.282440949689772e-07
Cape O 0 2.8685852157650515e-05
probably O 0 2.203807071055053e-06
did O 0 9.345806262217593e-08
not O 0 8.323688405198482e-09
come O 0 1.2033436469494063e-08
from O 0 1.6140832670430427e-08
The O 0 6.156945175916917e-08
Netherlands O 0 1.025974597723689e-06
. O 0 6.816520681240945e-07
. O 0 3.422236659389455e-06

Complement B-Disease 0 0.10290756076574326
C7 I-Disease 1 0.9980621933937073
deficiency I-Disease 1 0.9995273351669312
: O 0 9.226778274751268e-06
seven O 0 2.7471101020637434e-06
further O 0 6.449005923059303e-06
molecular O 0 0.0012616682797670364
defects O 1 0.9682120680809021
and O 0 5.951092134637292e-07
their O 0 4.345972399733e-07
associated O 0 3.211383955203928e-05
marker O 0 0.0009244820685125887
haplotypes O 0 0.004808440338820219
. O 0 6.958132871659473e-05

Seven O 0 3.856874627672369e-06
further O 0 2.2343144792102976e-06
molecular O 0 2.0961395421181805e-05
bases O 0 5.731439159717411e-06
of O 0 6.380918784998357e-05
C7 B-Disease 1 0.9995679259300232
deficiency I-Disease 1 0.9998739957809448
are O 0 2.8536339868878713e-06
described O 0 0.0005179551080800593
. O 0 4.818243542104028e-05

All O 0 3.268096691044775e-07
these O 0 3.2219926993093395e-07
new O 0 2.70250893663615e-06
molecular O 0 0.00023652832896914333
defects O 0 0.49606266617774963
involve O 0 2.5034823920577765e-06
single O 0 6.453248033722048e-07
- O 0 1.7891186416818528e-06
nucleotide O 0 2.64444111053308e-07
events O 0 5.8997819962769427e-08
, O 0 2.9453302019533112e-08
deletions O 0 3.885515980073251e-07
and O 0 1.4911522683291878e-08
substitutions O 0 1.2477741506700113e-07
, O 0 6.845965128121634e-09
some O 0 1.5675166720185985e-09
of O 0 6.571506006025629e-09
which O 0 5.5103729579286664e-08
alter O 0 3.6308294966147514e-06
splice O 0 9.353219866170548e-06
sites O 0 1.6769705268870894e-07
, O 0 6.814961039935952e-08
and O 0 9.22590146501534e-08
others O 0 7.791713869664818e-07
codons O 0 6.28380075795576e-05
. O 0 1.2013542800559662e-05

They O 0 3.1959800139702566e-07
are O 0 1.3434616974450364e-08
distributed O 0 1.2267760496342817e-07
along O 0 1.9786730831583554e-07
the O 0 4.955272743245587e-07
C7 O 0 0.019353562965989113
gene O 0 1.4472958582700812e-06
, O 0 4.457383084854882e-08
but O 0 1.30701476308559e-08
predominantly O 0 2.8682745067953874e-08
towards O 0 4.568843792185362e-08
the O 0 1.4348923116358492e-07
3 O 0 1.4377293382494827e-06
end O 0 8.033899575821124e-06
. O 0 7.297368028957862e-06

All O 0 4.137874043408374e-07
were O 0 4.0355223518417915e-07
found O 0 1.0202013527305098e-06
in O 0 3.8486442122120934e-07
compound O 0 4.698096017818898e-05
heterozygous O 0 6.737646617693827e-05
individuals O 0 9.472672900301404e-06
. O 0 4.12724148191046e-05

The O 0 0.00018878484843298793
C6 O 1 0.9797208309173584
/ O 0 0.019484486430883408
C7 O 1 0.682983934879303
marker O 0 0.0003311163163743913
haplotypes O 0 0.0006675189943052828
associated O 0 2.8446258511394262e-05
with O 0 6.639335424551973e-06
most O 0 5.83528853894677e-05
C7 B-Disease 1 0.9984102249145508
defects I-Disease 1 0.9966705441474915
are O 0 1.261345573766448e-06
tabulated O 0 0.00012344516289886087
. O 0 7.4349100032122806e-06
. O 0 2.064069667540025e-05

A O 0 4.479335984797217e-05
genome O 0 4.569592056213878e-05
- O 0 4.277037987776566e-06
wide O 0 6.669865229014249e-07
search O 0 4.756394957894372e-07
for O 0 6.129118332864891e-07
chromosomal O 0 0.0013961183140054345
loci O 0 0.0002855165512301028
linked O 0 0.0013802186585962772
to O 0 1.8602700947667472e-05
mental O 1 0.997376561164856
health O 0 0.2903214693069458
wellness O 0 0.005102397408336401
in O 0 1.7344486877846066e-06
relatives O 0 2.08387373277219e-05
at O 0 3.1071882403921336e-05
high O 0 0.0007785963243804872
risk O 0 0.061742350459098816
for O 0 0.000517466978635639
bipolar B-Disease 1 0.999852180480957
affective I-Disease 1 0.9989489912986755
disorder I-Disease 1 0.9995377063751221
among O 0 2.1356997876864625e-06
the O 0 1.4885572454659268e-06
Old O 0 5.616750422632322e-05
Order O 0 5.206070454732981e-06
Amish O 0 0.0002299631742062047
. O 0 2.1238593035377562e-05

Bipolar B-Disease 1 0.9990720748901367
affective I-Disease 1 0.9956597685813904
disorder I-Disease 1 0.9993247985839844
( O 0 0.05443684384226799
BPAD B-Disease 1 0.9982566237449646
; O 1 0.586884081363678
manic B-Disease 1 0.9997033476829529
- I-Disease 1 0.9988346695899963
depressive I-Disease 1 0.9997937083244324
illness I-Disease 1 0.9992173910140991
) O 0 8.643276487418916e-06
is O 0 1.1473473477963125e-06
characterized O 0 3.839513010461815e-05
by O 0 2.6147944254262256e-07
episodes O 0 4.9251339078182355e-06
of O 0 2.429473624943057e-06
mania B-Disease 1 0.9971073269844055
and O 0 8.767490726313554e-06
/ O 0 0.0016977650811895728
or O 0 6.55356188872247e-06
hypomania B-Disease 1 0.9288055896759033
interspersed O 0 3.142827335977927e-05
with O 0 1.0484264976184932e-06
periods O 0 7.6646676461678e-05
of O 0 1.9065009837504476e-05
depression B-Disease 1 0.9969950914382935
. O 0 0.0002675700525287539

Compelling O 0 2.6009960492956452e-05
evidence O 0 6.301014764176216e-06
supports O 0 3.4099221011274494e-06
a O 0 4.420030847995804e-07
significant O 0 1.1400243238313124e-06
genetic O 0 4.4261914808885194e-06
component O 0 2.2894296307640616e-06
in O 0 2.791994688777777e-07
the O 0 8.536713949069963e-07
susceptibility O 0 0.0003069495433010161
to O 0 1.965449428098509e-06
develop O 0 0.00033484981395304203
BPAD B-Disease 1 0.9826724529266357
. O 0 5.151093864697032e-05

To O 0 9.476931381868781e-07
date O 0 2.0540962850645883e-06
, O 0 2.2334785398925305e-07
however O 0 3.750874100205692e-07
, O 0 1.3822037203681248e-07
linkage O 0 4.531461399892578e-06
studies O 0 1.2607259236574464e-07
have O 0 1.489057677162009e-08
attempted O 0 2.384824142609432e-07
only O 0 1.3589454894713526e-08
to O 0 1.9126918715528518e-08
identify O 0 6.633770226471825e-07
chromosomal O 0 0.00014142983127385378
loci O 0 1.589510793564841e-05
that O 0 7.159380288612738e-07
cause O 0 0.00014277738227974623
or O 0 1.0571775419521146e-06
increase O 0 1.4051450989427394e-06
the O 0 5.688772262146813e-07
risk O 0 3.51670641975943e-05
of O 0 7.35327887468884e-07
developing O 0 0.0003266654966864735
BPAD B-Disease 1 0.9904727339744568
. O 0 6.780722469557077e-05

To O 0 4.550788332835509e-07
determine O 0 9.832971272771829e-07
whether O 0 5.933490001552855e-07
there O 0 3.1578119319419784e-07
could O 0 2.54825920364965e-07
be O 0 8.632139980591091e-08
protective O 0 0.00012369237083476037
alleles O 0 1.620071884644858e-06
that O 0 1.4707113393797044e-07
prevent O 0 6.145334282336989e-06
or O 0 8.330186460625555e-07
reduce O 0 9.658940143708605e-06
the O 0 3.682404212668189e-07
risk O 0 1.5080703633429948e-05
of O 0 8.420572328304843e-08
developing O 0 2.07122338906629e-05
BPAD B-Disease 1 0.6618378162384033
, O 0 1.2316010611357342e-07
similar O 0 1.305973569287744e-07
to O 0 1.2064462318051028e-08
what O 0 3.5841843271100515e-08
is O 0 4.78365258516078e-08
observed O 0 3.5510669249561033e-07
in O 0 2.438044361952052e-07
other O 0 2.3465306639991468e-06
genetic B-Disease 1 0.9964775443077087
disorders I-Disease 1 0.9999061822891235
, O 0 7.88915713201277e-06
we O 0 1.2778336895280518e-06
used O 0 2.5936271413229406e-05
mental O 1 0.9952802658081055
health O 0 0.05270406976342201
wellness O 0 0.00545094721019268
( O 0 2.9372572498687077e-06
absence O 0 8.351086762559135e-06
of O 0 6.345739507196413e-07
any O 0 8.52835364639759e-05
psychiatric B-Disease 1 0.999300479888916
disorder I-Disease 1 0.9995315074920654
) O 0 9.888256045087473e-07
as O 0 1.0306892761491326e-07
the O 0 1.4676791693091218e-07
phenotype O 0 2.4827171728247777e-05
in O 0 5.606583641792895e-08
our O 0 1.4121668812094867e-07
genome O 0 5.532300747290719e-06
- O 0 1.9036531284655211e-06
wide O 0 4.712534860118467e-07
linkage O 0 8.451306712231599e-06
scan O 0 3.9421324800059665e-06
of O 0 2.112256147768221e-08
several O 0 1.4899559630521253e-07
large O 0 1.6926150010476704e-06
multigeneration O 0 0.0004163630655966699
Old O 0 1.3024705367570277e-05
Order O 0 8.474854666928877e-07
Amish O 0 5.1045219152001664e-05
pedigrees O 0 8.717801392776892e-05
exhibiting O 0 3.574493894120678e-05
an O 0 1.5773478025948862e-06
extremely O 0 7.404820644296706e-05
high O 0 0.00016664293070789427
incidence O 0 0.2409873753786087
of O 0 1.1629457731032744e-05
BPAD B-Disease 1 0.9915401339530945
. O 0 0.00017351831775158644

We O 0 1.0249408433082863e-06
have O 0 1.3342511806513357e-07
found O 0 1.405744143312404e-07
strong O 0 7.34608107677559e-08
evidence O 0 8.501991288767385e-08
for O 0 1.1319664316999933e-08
a O 0 2.436103727632144e-07
locus O 0 4.101589183846954e-06
on O 0 4.84133295231004e-07
chromosome O 0 4.539353903965093e-05
4p O 0 0.016869792714715004
at O 0 1.7718111848807894e-06
D4S2949 O 0 2.467471313138958e-05
( O 0 3.6857383634014695e-07
maximum O 0 9.867897006188286e-07
GENEHUNTER O 0 0.00042233392014168203
- O 0 3.6559820273396326e-06
PLUS O 0 1.085940880329872e-06
nonparametric O 0 4.285350769350771e-06
linkage O 0 2.733671635724022e-06
score O 0 1.9002527551492676e-07
= O 0 2.1978212316753343e-06
4 O 0 1.584807165500024e-07
. O 0 4.6603066294892415e-08
05 O 0 3.4252734621986747e-06
, O 0 5.8580472028779695e-08
P O 0 4.726027782453457e-06
= O 0 8.108956990326988e-07
5 O 0 3.170866236246184e-08
. O 0 1.0835077723925224e-08
22 O 0 2.527398557106153e-08
x O 0 8.864649458928398e-08
10 O 0 2.55104275481699e-08
( O 0 5.025401961233911e-08
- O 0 1.571886372175868e-07
4 O 0 5.170467787252164e-08
) O 0 2.3936825854775634e-08
; O 0 6.088198745146656e-08
SIBPAL O 0 2.5646195354056545e-05
Pempirical O 0 8.852161045069806e-06
value O 0 5.72040299573473e-08
< O 0 8.415043339482509e-06
3 O 0 1.5826624633064057e-07
x O 0 6.081073138375359e-07
10 O 0 8.084081315473668e-08
( O 0 1.0312575682291936e-07
- O 0 1.7412973818409228e-07
5 O 0 2.5303553030653347e-08
) O 0 1.0275972961437674e-08
) O 0 4.243255524727374e-09
and O 0 2.275734711787436e-09
suggestive O 0 2.741392108873697e-07
evidence O 0 2.4689596145321957e-08
for O 0 4.508916795487039e-09
a O 0 1.2251182113232062e-07
locus O 0 2.0371896880533313e-06
on O 0 3.01016910952967e-07
chromosome O 0 6.552672130055726e-05
4q O 0 0.040027786046266556
at O 0 1.455880124012765e-06
D4S397 O 0 3.1146824767347425e-05
( O 0 5.029804128753312e-07
maximum O 0 1.5949019598338054e-06
GENEHUNTER O 0 0.0004910169518552721
- O 0 4.068285306857433e-06
PLUS O 0 1.4159564898363897e-06
nonparametric O 0 4.201398496661568e-06
linkage O 0 1.8733213664745563e-06
score O 0 1.1627073348563499e-07
= O 0 1.3962247749077505e-06
3 O 0 7.323711059825655e-08
. O 0 1.7549403708017053e-08
29 O 0 1.7251350925562292e-07
, O 0 2.5683110749241678e-08
P O 0 4.642900421458762e-06
= O 0 7.297829256458499e-07
2 O 0 5.790405666061815e-08
. O 0 2.1804373417921852e-08
57 O 0 2.2749640038455254e-07
x O 0 2.0470274364470242e-07
10 O 0 4.4994344250426366e-08
( O 0 5.47501528558314e-08
- O 0 1.475209217005613e-07
3 O 0 2.1809157146890357e-08
) O 0 2.456249426074919e-08
; O 0 6.041821620783594e-08
SIBPAL O 0 2.446930193400476e-05
Pempirical O 0 8.909047210181598e-06
value O 0 5.1491511499079934e-08
< O 0 8.812589840090368e-06
1 O 0 1.170074526157805e-07
x O 0 8.208065196413372e-07
10 O 0 1.2100925061986345e-07
( O 0 1.4787954683015414e-07
- O 0 3.809520592312765e-07
3 O 0 4.940964970501227e-08
) O 0 1.862790810491788e-08
) O 0 9.585954252600004e-09
that O 0 1.991188902650265e-08
are O 0 2.535060517061538e-08
linked O 0 3.2907206332311034e-05
to O 0 5.9713070186262485e-06
mental O 1 0.9924219250679016
health O 1 0.5312568545341492
wellness O 0 0.24939848482608795
. O 0 9.93590583675541e-05

These O 0 1.1174776091138483e-06
findings O 0 2.7859671263286145e-06
are O 0 2.7608718866645177e-08
consistent O 0 2.1468298427862464e-07
with O 0 3.850259133741929e-08
the O 0 5.8969359173488556e-08
hypothesis O 0 7.388714493572479e-07
that O 0 2.976169177770771e-08
certain O 0 1.5789237295393832e-07
alleles O 0 3.3077094485634007e-06
could O 0 3.820959761924314e-07
prevent O 0 4.749604158860166e-06
or O 0 5.486063514581474e-07
modify O 0 8.44348414830165e-06
the O 0 6.05138325227017e-07
clinical O 0 0.00010129129805136472
manifestations O 0 6.433463568100706e-05
of O 0 1.0750122783065308e-06
BPAD B-Disease 1 0.9960786700248718
and O 0 1.6316420214934624e-06
perhaps O 0 9.585977750248276e-06
other O 0 2.073095174637274e-06
related O 0 0.009048637934029102
affective B-Disease 1 0.9975737929344177
disorders I-Disease 1 0.999525785446167
. O 0 0.001464242348447442

Segregation O 0 0.0489630252122879
distortion O 1 0.5033255815505981
in O 0 0.01085062325000763
myotonic B-Disease 1 0.9983012676239014
dystrophy I-Disease 1 0.9991648197174072
. O 0 0.005624293349683285

Myotonic B-Disease 1 0.9976615905761719
dystrophy I-Disease 1 0.9995397329330444
( O 0 0.022386960685253143
DM B-Disease 1 0.9986081719398499
) O 0 4.959289981343318e-06
is O 0 1.2727959983749315e-06
an O 0 7.509102943004109e-06
autosomal B-Disease 1 0.9961340427398682
dominant I-Disease 1 0.8230257630348206
disease I-Disease 1 0.9994679093360901
which O 0 1.6785801904006803e-07
, O 0 8.028440845464502e-08
in O 0 5.166475247619928e-08
the O 0 1.3858043246273155e-07
typical O 0 1.087709370040102e-05
pedigree O 0 3.956683212891221e-05
, O 0 1.0384005832975163e-07
shows O 0 1.2932130744047754e-07
a O 0 1.9674472184760816e-07
three O 0 1.325196876678092e-07
generation O 0 2.2735986931365915e-05
anticipation O 0 8.472987974528223e-05
cascade O 0 0.0021180242765694857
. O 0 3.1078725442057475e-05

This O 0 2.0076035070815124e-05
results O 0 0.0001368577213725075
in O 0 0.00029964145505800843
infertility B-Disease 1 0.9970241189002991
and O 0 0.21442736685276031
congenital B-Disease 1 0.9999325275421143
myotonic I-Disease 1 0.9998871088027954
dystrophy I-Disease 1 0.9998701810836792
( O 0 0.0005461741238832474
CDM B-Disease 0 0.07677400857210159
) O 0 3.553397789346491e-07
with O 0 4.685727006403795e-08
the O 0 1.9842060794417193e-07
disappearance O 0 1.076005537470337e-05
of O 0 2.463602868374437e-06
DM B-Disease 1 0.9981315732002258
in O 0 2.073482619380229e-06
that O 0 2.968716444229358e-06
pedigree O 0 0.0010857520392164588
. O 0 2.968964327010326e-05

The O 0 1.0552838602961856e-06
concept O 0 9.928216968546622e-07
of O 0 3.67519788824211e-07
segregation O 0 0.0003868101630359888
distortion O 0 0.0001034052693285048
, O 0 1.1874026739633337e-07
where O 0 4.992832458583507e-08
there O 0 1.5342054737743638e-08
is O 0 1.3779835050797828e-08
preferential O 0 2.3997355924620933e-07
transmission O 0 3.605130700634618e-07
of O 0 3.835260997675505e-09
the O 0 2.022329503859055e-08
larger O 0 2.579470503860648e-07
allele O 0 1.4395981224879506e-06
at O 0 5.084184522274882e-07
the O 0 2.4627572656754637e-06
DM B-Disease 1 0.9970507621765137
locus O 0 1.3445300282910466e-05
, O 0 1.9743227142043906e-07
has O 0 6.147065079176173e-08
been O 0 2.4025791134363317e-08
put O 0 2.0321662574929178e-08
forward O 0 1.325638709914756e-08
to O 0 1.4065830278298108e-08
explain O 0 6.21251842858328e-07
partially O 0 4.197910129732918e-06
the O 0 2.4838175249897176e-07
maintenance O 0 8.393454481847584e-05
of O 0 9.727750693855342e-07
DM B-Disease 1 0.9975852966308594
in O 0 6.669725394203851e-07
the O 0 1.2951237522429437e-06
population O 0 1.8980335880769417e-06
. O 0 1.2719181540887803e-05

In O 0 1.1782402680182713e-06
a O 0 1.6338873365384643e-06
survey O 0 4.82986888528103e-06
of O 0 8.402681714869686e-07
DM B-Disease 1 0.9941343665122986
in O 0 4.752504310090444e-07
Northern O 0 5.026658413953555e-07
Ireland O 0 7.011336720097461e-07
, O 0 3.645415063147084e-07
59 O 0 6.4365203797933646e-06
pedigrees O 0 4.484434975893237e-05
were O 0 1.3512479881683248e-06
ascertained O 0 0.00018971905228681862
. O 0 1.972105383174494e-05

Sibships O 0 0.0013851355761289597
where O 0 7.131563393159013e-07
the O 0 1.442859343114833e-07
status O 0 1.204804789267655e-07
of O 0 4.722646274046838e-09
all O 0 4.519748575404492e-09
the O 0 3.533236991870581e-08
members O 0 4.788490670648571e-08
had O 0 2.4683575361450494e-07
been O 0 7.127946588525447e-08
identified O 0 1.6298537275361014e-07
were O 0 1.2775660529484867e-08
examined O 0 1.9018771979517624e-07
to O 0 1.898729395932719e-09
determine O 0 8.993463751494346e-09
the O 0 1.6002337233089747e-08
transmission O 0 1.472747953812359e-06
of O 0 5.3244001207986e-08
the O 0 2.8777001261914847e-06
DM B-Disease 1 0.997908353805542
expansion O 0 1.2980411156604532e-05
from O 0 1.2883668887297972e-06
affected O 0 2.9764300961687695e-06
parents O 0 3.523408622641e-07
to O 0 3.1185106053044365e-08
their O 0 1.1885605033512547e-07
offspring O 0 4.169447493040934e-05
. O 0 9.197557119478006e-06

Where O 0 3.538602868502494e-06
the O 0 2.573700840002857e-06
transmitting O 0 0.00014922388072591275
parent O 0 4.530233491095714e-05
was O 0 5.841606252943166e-06
male O 0 7.553108389402041e-06
, O 0 1.5701739357609767e-06
58 O 0 3.372583523741923e-05
. O 0 1.5673040252295323e-05

3 O 0 1.949849320226349e-06
% O 0 2.916771961736231e-07
of O 0 3.856726848994185e-08
the O 0 3.4482314958950155e-07
offspring O 0 6.932059022801695e-06
were O 0 1.1719495063289287e-07
affected O 0 4.123530743527226e-07
, O 0 1.9508032522708163e-08
and O 0 3.858520170041402e-09
in O 0 4.369458572739404e-09
the O 0 8.096545656144372e-09
case O 0 6.722203949038885e-08
of O 0 7.784203504002107e-09
a O 0 3.9168568832792516e-07
female O 0 2.5399810965609504e-06
transmitting O 0 0.00014236831339076161
parent O 0 2.795434011204634e-05
, O 0 9.621785466151778e-07
68 O 0 3.5611188650364056e-05
. O 0 1.2877359949925449e-05

7 O 0 5.799605787615292e-05
% O 0 1.8993672711076215e-05
were O 0 6.6301417973591015e-06
affected O 0 0.00011827031994471326
. O 0 3.7647718272637576e-05

Studies O 0 1.582193908689078e-05
on O 0 3.6157189242658205e-06
meiotic O 0 0.0017452443717047572
drive O 0 3.4890807000920177e-05
in O 0 4.729752618004568e-06
DM B-Disease 1 0.9974773526191711
have O 0 1.026265650239111e-07
shown O 0 1.8854827033010224e-07
increased O 0 1.5880175396887353e-07
transmission O 0 4.2681205059125205e-07
of O 0 6.5749912181445325e-09
the O 0 2.7181618733607138e-08
larger O 0 3.171731748352613e-07
allele O 0 2.1422742975119036e-06
at O 0 8.795057624411129e-07
the O 0 3.2346385978598846e-06
DM B-Disease 1 0.990624725818634
locus O 0 8.19356573629193e-05
in O 0 3.8376856537070125e-06
non O 0 0.00016137213970068842
- O 0 0.0037855077534914017
DM O 1 0.9920782446861267
heterozygotes O 0 0.0010698267724364996
for O 0 7.939718670968432e-06
CTGn O 0 0.011385648511350155
. O 0 8.294552389997989e-05

This O 0 1.7027485910148243e-06
study O 0 1.0922350384134916e-06
provides O 0 5.628955364045396e-07
further O 0 2.2775647323669546e-07
evidence O 0 6.658565325778909e-07
that O 0 3.1681463497079676e-07
the O 0 2.87844932245207e-06
DM B-Disease 1 0.9969213008880615
expansion O 0 2.1983134502079338e-05
tends O 0 9.227165719494224e-06
to O 0 9.565884795392776e-08
be O 0 4.4451832081904286e-07
transmitted O 0 6.202181248227134e-05
preferentially O 0 6.99753945809789e-05
. O 0 2.331706309632864e-05

Diagnosis O 1 0.9797138571739197
of O 0 0.000666657870169729
hemochromatosis B-Disease 1 0.9986526966094971
. O 0 0.001446363516151905

If O 0 0.007252820301800966
untreated O 1 0.9970049262046814
, O 0 0.007652269210666418
hemochromatosis B-Disease 1 0.9997619986534119
can O 0 0.0017777144676074386
cause O 1 0.9886801242828369
serious O 1 0.994945228099823
illness O 1 0.9988061189651489
and O 0 2.462104475853266e-06
early B-Disease 0 1.4900548194418661e-05
death I-Disease 0 8.217156573664397e-05
, O 0 6.802065399824642e-07
but O 0 8.981105565908365e-07
the O 0 1.550309571030084e-05
disease O 1 0.9981694221496582
is O 0 1.8643565908860182e-06
still O 0 1.1070001164625864e-05
substantially O 0 0.0017964404541999102
under O 0 0.0016108250711113214
- O 1 0.5638433694839478
diagnosed O 1 0.9982590079307556
. O 0 8.923702262109146e-05

The O 0 4.440506927494425e-06
cornerstone O 0 2.1425486920634285e-05
of O 0 2.0538873002351465e-07
screening O 0 6.408113222278189e-06
and O 0 1.173848858115889e-07
case O 0 7.610610737174284e-07
detection O 0 1.170825044027879e-06
is O 0 2.3241067736989862e-08
the O 0 1.8788480105058625e-08
measurement O 0 3.1619944707017567e-07
of O 0 1.2565033102873713e-07
serum O 0 0.002505280775949359
transferrin O 0 0.0013379240408539772
saturation O 0 1.2374077414278872e-05
and O 0 2.0881479656509327e-07
the O 0 1.333451450591383e-06
serum O 0 0.004643562249839306
ferritin O 0 0.009057370014488697
level O 0 8.857219654601067e-05
. O 0 2.7120693630422466e-05

Once O 0 9.917967690853402e-05
the O 0 1.4892422768753022e-05
diagnosis O 1 0.835605800151825
is O 0 5.132558271725429e-06
suspected O 0 5.0362399633741006e-05
, O 0 1.109844674829219e-06
physicians O 0 1.9363555111340247e-05
must O 0 4.1419841068091046e-07
use O 0 2.3630861960555194e-06
serum O 0 0.02052859403192997
ferritin O 0 0.11864600330591202
levels O 0 0.00021748157450929284
and O 0 7.541109880548902e-06
hepatic O 1 0.9955808520317078
iron O 1 0.7491804361343384
stores O 0 4.453133442439139e-05
on O 0 4.30824002251029e-05
liver O 1 0.9985590577125549
biopsy O 0 0.4256630539894104
specimens O 0 5.646695717587136e-05
to O 0 9.406330150341091e-07
assess O 0 7.73888168623671e-05
patients O 0 0.000255784165346995
for O 0 7.733417817235022e-08
the O 0 1.698276150818856e-07
presence O 0 2.5187227947753854e-06
of O 0 2.4221953935921192e-06
iron B-Disease 1 0.995053768157959
overload I-Disease 1 0.9918388724327087
. O 0 8.949309994932264e-05

Liver O 1 0.9977486729621887
biopsy O 0 0.26571834087371826
is O 0 8.229329750975012e-07
also O 0 1.0461676680506571e-07
used O 0 4.275754861282621e-08
to O 0 9.72315916669686e-09
establish O 0 7.281562375283102e-08
the O 0 3.157136774234459e-08
presence O 0 1.9080648883118556e-07
or O 0 2.160968222142401e-07
absence O 0 5.364417575037805e-06
of O 0 1.1563339512576931e-06
cirrhosis B-Disease 1 0.9997209906578064
, O 0 5.443142185868055e-07
which O 0 2.2554783640771348e-07
can O 0 1.286798806177103e-06
affect O 0 8.326386159751564e-05
prognosis O 1 0.9909636974334717
and O 0 4.5692891035287175e-06
management O 0 0.0005078086396679282
. O 0 5.155929102329537e-05

A O 0 1.2152162526035681e-05
DNA O 0 1.5345573046943173e-05
- O 0 3.045183348149294e-06
based O 0 1.0279445916694385e-07
test O 0 2.4778719875939714e-07
for O 0 4.832633493379035e-08
the O 0 4.1399266592634376e-07
HFE O 0 0.004800000227987766
gene O 0 1.5317849602070055e-06
is O 0 6.038745681280488e-08
commercially O 0 2.0483045659602794e-07
available O 0 2.0286575974637344e-08
, O 0 7.789105360700432e-09
but O 0 3.672679937949397e-09
its O 0 4.1571772690929265e-09
place O 0 8.537119455809261e-09
in O 0 2.3336525600825553e-08
the O 0 5.354882546271256e-07
diagnosis O 0 0.37238579988479614
of O 0 9.043434147315565e-06
hemochromatosis B-Disease 1 0.9998106360435486
is O 0 4.822256414627191e-06
still O 0 3.5274370020488277e-06
being O 0 2.9994314445502823e-06
evaluated O 0 5.172131204744801e-05
. O 0 2.38296743191313e-05

Currently O 0 5.32151352672372e-06
, O 0 2.0772220921116968e-07
the O 0 4.3476049427226826e-08
most O 0 1.6136091574026068e-08
useful O 0 3.336713305657213e-08
role O 0 2.2496390528203847e-08
for O 0 4.072115089570616e-09
this O 0 9.691516034138203e-09
test O 0 4.8520377049499075e-08
is O 0 8.533407758193334e-09
in O 0 6.83318113203768e-09
the O 0 3.7790162110695746e-08
detection O 0 3.4089403015968855e-06
of O 0 4.190368088075047e-07
hemochromatosis B-Disease 1 0.9994708895683289
in O 0 2.134039362999829e-07
the O 0 1.2182327679965965e-07
family O 0 4.973301201971481e-07
members O 0 3.265012082920293e-08
of O 0 8.597731948611909e-08
patients O 0 0.00029880195506848395
with O 0 1.1743728833835121e-07
a O 0 2.8893541639263276e-06
proven O 0 2.905937253672164e-05
case O 0 1.6965001350399689e-06
of O 0 5.377419256547e-07
the O 0 0.00011313767754472792
disease O 1 0.9977704286575317
. O 0 6.233654130483046e-05

It O 0 2.646976781761623e-06
is O 0 1.3645332046507974e-06
crucial O 0 1.037134188663913e-05
to O 0 4.9063404730986804e-05
diagnose O 1 0.9983477592468262
hemochromatosis B-Disease 1 0.9996858835220337
before O 1 0.7916220426559448
hepatic B-Disease 1 0.9995145797729492
cirrhosis I-Disease 1 0.9997001886367798
develops O 1 0.9792773127555847
because O 0 0.006069853436201811
phlebotomy O 1 0.9937120676040649
therapy O 1 0.9885480403900146
can O 0 0.0022538730408996344
avert O 1 0.9971058964729309
serious O 1 0.9995278120040894
chronic O 1 0.9999852180480957
disease O 1 0.9998296499252319
and O 0 1.9811666334135225e-06
can O 0 2.6862542767958075e-07
even O 0 2.170388313516014e-07
lead O 0 3.9156469711087993e-07
to O 0 7.334376306289414e-08
normal O 0 3.373424078745302e-06
life O 0 7.565594387415331e-06
expectancy O 0 0.0003938184236176312
. O 0 1.455563619856548e-06
. O 0 9.145350304606836e-06

Prevalence O 0 0.0006095358985476196
of O 0 6.65042989567155e-07
the O 0 2.9198965876275906e-06
I1307K O 0 0.00036153383553028107
APC B-Disease 0 0.0010482515208423138
gene O 0 1.3653070709551685e-05
variant O 0 4.0960418118629605e-05
in O 0 8.204357015983987e-08
Israeli O 0 3.380659734375513e-07
Jews O 0 6.441614885943636e-08
of O 0 6.8449472756526575e-09
differing O 0 1.7832948628893064e-07
ethnic O 0 2.3029311080335901e-07
origin O 0 1.0485183565833722e-06
and O 0 7.5175798883719835e-06
risk O 0 0.4676377475261688
for O 0 0.017112398520112038
colorectal B-Disease 1 0.9999697208404541
cancer I-Disease 1 0.9997983574867249
. O 0 0.0008964317385107279

BACKGROUND O 0 0.00036095958785153925
& O 0 0.00013514887541532516
AIMS O 0 1.3072364708932582e-05
Israeli O 0 2.0198640413582325e-06
Jews O 0 2.367493010524413e-07
of O 0 7.931183887421867e-08
European O 0 1.321774220741645e-06
birth O 0 1.4656829080195166e-05
, O 0 1.5707369982465025e-07
i O 0 2.47013787202377e-07
. O 0 3.4977993834672816e-08
e O 0 2.2906824881374632e-07
. O 0 1.3221010952690904e-08
, O 0 4.859660407419142e-08
Ashkenazim O 0 4.680845904658781e-06
, O 0 5.843272177230574e-08
have O 0 5.6664759995328495e-08
the O 0 2.2350284325511893e-06
highest O 0 0.3893081545829773
colorectal B-Disease 1 0.999974250793457
cancer I-Disease 1 0.9998791217803955
incidence O 0 0.1185852512717247
of O 0 8.084990810175441e-08
any O 0 1.7905730942402442e-07
Israeli O 0 1.463994635741983e-06
ethnic O 0 1.10885764570412e-06
group O 0 4.6217746785259806e-06
. O 0 1.0800910786201712e-05

The O 0 1.571500615682453e-05
I1307K O 0 0.0008372798329219222
APC B-Disease 0 0.0032552736811339855
gene O 0 7.424751674989238e-05
variant O 0 0.0009495929698459804
was O 0 6.734152520948555e-06
found O 0 2.379113766437513e-06
in O 0 1.2003026768070413e-06
6 O 0 1.744852852425538e-05
. O 0 1.1540322702785488e-05

1 O 0 3.747674099940923e-06
% O 0 3.49595921989021e-07
of O 0 6.766545368463994e-08
American O 0 3.154524961246352e-07
Jews O 0 2.3600945553425845e-07
, O 0 5.495018129408891e-08
28 O 0 1.6993664075926063e-07
% O 0 6.105199190642452e-08
of O 0 1.2132539950471255e-07
their O 0 2.127709194610361e-05
familial O 1 0.9995136260986328
colorectal B-Disease 1 0.9999916553497314
cancer I-Disease 1 0.9999415874481201
cases O 0 0.0002243457711301744
, O 0 6.988372547311883e-07
but O 0 1.1963116719471145e-07
not O 0 5.3799336541260345e-08
in O 0 1.6286138304622e-07
non O 0 3.7608854199788766e-06
- O 0 1.6010379113140516e-05
Jews O 0 2.2429394448408857e-06
. O 0 5.4043462114350405e-06

We O 0 4.266429186827736e-06
assessed O 0 2.6112755222129636e-05
the O 0 2.0705147107946686e-06
I1307K O 0 0.001031922409310937
prevalence O 0 0.0012272846652194858
in O 0 8.930971517884245e-08
Israeli O 0 3.2267956839859835e-07
Jews O 0 3.812638382783007e-08
of O 0 5.840572914195263e-09
differing O 0 1.8243868282752373e-07
ethnic O 0 1.1582715586655468e-07
origin O 0 7.9993503732112e-07
and O 0 7.813800948497374e-06
risk O 1 0.6160892844200134
for O 0 0.014840353280305862
colorectal B-Disease 1 0.9999657869338989
cancer I-Disease 1 0.9997660517692566
. O 0 0.000794026767835021

METHODS O 0 7.78143930801889e-06
DNA O 0 7.959157301229425e-06
samples O 0 7.921211704342568e-07
from O 0 4.0959542957352824e-07
500 O 0 1.3843634860677412e-06
unrelated O 0 3.3437581805628724e-06
Jews O 0 1.0501540970153656e-07
of O 0 2.6133974984077213e-08
European O 0 4.5994812580829603e-07
or O 0 3.589384220958891e-07
non O 0 1.2036349517074996e-06
- O 0 7.705390316914418e-07
European O 0 4.726226165985281e-08
origin O 0 1.7299056409569857e-08
, O 0 1.5978640632852148e-08
with O 0 1.2010231920100978e-08
or O 0 5.1606548367999494e-08
without O 0 3.547471294496063e-08
a O 0 1.54778803107547e-07
personal O 0 7.614792139065685e-07
and O 0 2.2287845524715522e-07
/ O 0 3.125030343653634e-05
or O 0 1.0250899151742487e-07
family O 0 2.720094585129118e-07
history O 0 1.2041546426644345e-07
of O 0 1.3418873834325495e-07
neoplasia B-Disease 1 0.9843348860740662
, O 0 1.3654778285854263e-07
were O 0 3.062489284388903e-08
examined O 0 6.518777695418976e-07
for O 0 2.8201567303653974e-08
the O 0 1.4115340718490188e-07
I1307K O 0 2.8920037948410027e-05
variant O 0 8.793784218141809e-06
by O 0 5.700851701817555e-08
the O 0 7.819027558753078e-08
allele O 0 1.987185896723531e-06
- O 0 1.2267133797649876e-06
specific O 0 1.3599131420960475e-07
oligonucleotide O 0 6.251739978324622e-05
( O 0 5.166153187019518e-06
ASO O 0 0.014933724887669086
) O 0 8.54179518228193e-07
method O 0 4.111434463993646e-06
. O 0 1.0623243724694476e-05

RESULTS O 0 2.6971309125656262e-05
In O 0 9.062860044650733e-07
persons O 0 1.4773733028050628e-06
at O 0 9.122475603362545e-06
average O 0 0.0003661920491140336
risk O 0 0.043891388922929764
for O 0 0.0006709647132083774
colorectal B-Disease 1 0.9999618530273438
cancer I-Disease 1 0.9998059868812561
, O 0 4.534725576377241e-06
I1307K O 0 0.000248934724368155
was O 0 3.5614757507573813e-06
found O 0 8.276655307781766e-07
in O 0 4.2329514826633385e-07
5 O 0 6.993125225562835e-06
. O 0 5.069701273896499e-06

0 O 0 2.3383679490507348e-06
% O 0 3.6359713817546435e-07
of O 0 6.289671006243225e-08
120 O 0 7.107120723048865e-07
European O 0 5.160841851648001e-07
and O 0 2.8263016815799347e-07
1 O 0 3.1390418371302076e-06
. O 0 4.46322974312352e-06

6 O 0 1.1080288459197618e-05
% O 0 7.735984013379493e-07
of O 0 1.580930586442264e-07
188 O 0 1.2626763236767147e-05
non O 0 2.7139894882566296e-06
- O 0 2.3919290015328443e-06
European O 0 1.7960613263312553e-07
Jews O 0 1.454248064192143e-07
( O 0 3.258641925185657e-07
P O 0 2.2127482225187123e-05
= O 0 3.265117129558348e-06
0 O 0 2.519582551485655e-07
. O 0 3.03134584100917e-07
08 O 0 1.7527012460050173e-05
) O 0 1.0302436521669733e-06
. O 0 3.4602660434757126e-06

It O 0 3.0701651212439174e-06
occurred O 0 2.8364724130369723e-05
in O 0 1.9640742721094284e-06
15 O 0 1.6708831026335247e-05
. O 0 1.4542145436280407e-05

4 O 0 4.762699518323643e-06
% O 0 6.60035027522099e-07
of O 0 2.0179028581424063e-07
52 O 0 1.1485578397696372e-05
Ashkenazi O 0 9.107868390856311e-05
Israelis O 0 2.5422034468647325e-06
with O 0 3.1576121273246827e-06
familial O 1 0.9864609241485596
cancer B-Disease 1 0.9974486231803894
( O 0 4.319006166042527e-06
P O 0 0.00033842207631096244
= O 0 9.276132004742976e-06
0 O 0 3.421736778363993e-07
. O 0 1.8316495697945356e-07
02 O 0 3.6990833905292675e-05
) O 0 5.0188212696866685e-08
and O 0 1.2149603101363482e-08
was O 0 1.393405710814477e-07
not O 0 1.706542285262458e-08
detected O 0 1.0182534424529877e-06
in O 0 2.822906886024157e-08
51 O 0 4.979242476110812e-07
non O 0 7.78393768996466e-07
- O 0 2.305502903254819e-06
European O 0 2.7729447538149543e-07
Jews O 0 7.04517162830598e-07
at O 0 1.3743969248025678e-05
increased O 0 0.0015823548892512918
cancer B-Disease 1 0.9983463287353516
risk O 0 0.014887315221130848
. O 0 3.637651025201194e-05

Colorectal B-Disease 1 0.9973708391189575
neoplasia I-Disease 1 0.9948177933692932
occurred O 0 0.0007108742720447481
personally O 0 7.149649172788486e-05
or O 0 4.418345440626581e-07
in O 0 5.385960477610752e-08
the O 0 3.192068120938529e-08
families O 0 2.5949747239906173e-08
of O 0 6.05353944749254e-09
13 O 0 1.5271174902409257e-07
of O 0 3.034775986066052e-08
20 O 0 1.05937976968562e-06
Ashkenazi O 0 3.7018955481471494e-05
I1307K O 0 4.2569412471493706e-05
carriers O 0 2.960514393635094e-06
, O 0 2.8876296909174926e-08
8 O 0 6.120811235632573e-08
of O 0 1.2306073493562053e-08
whom O 0 5.160566161066527e-07
also O 0 7.074230268244719e-08
had O 0 1.445083341877762e-07
a O 0 1.8961958403451717e-07
personal O 0 3.279473901329766e-07
or O 0 3.823941767677752e-07
family O 0 1.1904986649824423e-06
history O 0 9.53670621584024e-07
of O 0 2.5187998744513607e-06
noncolonic O 1 0.9351040720939636
neoplasia B-Disease 1 0.9939588308334351
. O 0 0.00018781925609800965

CONCLUSIONS O 0 5.124440212966874e-05
The O 0 9.097307156480383e-06
I1307K O 0 0.001569847110658884
APC O 0 0.014695740304887295
variant O 0 0.0013718341942876577
may O 0 2.156425807697815e-06
represent O 0 8.799271711268375e-08
a O 0 8.326437637151685e-07
susceptibility O 0 0.00021308106079231948
gene O 0 1.729983887344133e-05
for O 0 2.748638053162722e-06
colorectal B-Disease 1 0.9997162222862244
, I-Disease 0 4.286043235879333e-07
or I-Disease 0 2.0172372217075463e-07
other I-Disease 0 1.198966117499367e-07
, I-Disease 0 2.022165517701069e-06
cancers I-Disease 0 0.4995638132095337
in O 0 8.742006798456714e-07
Ashkenazi O 0 0.00010167393338633701
Jews O 0 6.796968818889582e-07
, O 0 1.5566581623716047e-07
and O 0 2.2651570930065645e-07
partially O 0 2.696017145353835e-05
explains O 0 5.158837666385807e-06
the O 0 9.359503678751935e-07
higher O 0 8.806233381619677e-05
incidence O 1 0.9749607443809509
of O 0 0.002018352970480919
colorectal B-Disease 1 0.9999836683273315
cancer I-Disease 1 0.9997413754463196
in O 0 7.092583018675214e-06
European O 0 1.2000602509942837e-05
Israelis O 0 3.9423859561793506e-05
. O 0 2.12722643482266e-05

Systematic O 0 1.9871515178238042e-05
analysis O 0 2.697634499781998e-06
of O 0 1.5799599850652157e-06
coproporphyrinogen O 0 0.01883242465555668
oxidase O 0 0.00909510813653469
gene O 0 0.003275109687820077
defects O 1 0.995570719242096
in O 0 2.1737432689405978e-05
hereditary B-Disease 1 0.873493492603302
coproporphyria I-Disease 0 0.11106204986572266
and O 0 9.058263458427973e-06
mutation O 0 0.00098363496363163
update O 0 0.001126025803387165
. O 0 3.640972499852069e-05

Hereditary B-Disease 1 0.8869835734367371
coproporphyria I-Disease 0 0.36355239152908325
( O 0 0.00039316798211075366
HC B-Disease 1 0.990228533744812
) O 0 2.6717892978922464e-05
is O 0 1.3783897884422913e-05
an O 0 0.000336284952936694
acute O 1 0.999405026435852
hepatic B-Disease 1 0.9995676875114441
porphyria I-Disease 1 0.9992226362228394
with O 0 0.0005289100809022784
autosomal O 1 0.9968451261520386
dominant O 0 0.15171654522418976
inheritance O 1 0.9103877544403076
caused O 1 0.922615647315979
by O 0 2.923276406363584e-05
deficient B-Disease 1 0.7898695468902588
activity I-Disease 0 3.563575319276424e-06
of I-Disease 0 1.5005440445747809e-06
coproporphyrinogen I-Disease 0 0.007927389815449715
III I-Disease 0 0.018261775374412537
oxidase I-Disease 0 0.0005140018183737993
( O 0 1.2014275853289291e-05
CPO O 0 0.0002756480826064944
) O 0 5.170752501726383e-06
. O 0 8.590242032369133e-06

Clinical O 0 0.0037214402109384537
manifestations O 0 0.0002897920203395188
of O 0 5.126595169713255e-06
the O 0 0.0007512251031585038
disease O 1 0.9991456270217896
are O 0 1.4526945051329676e-06
characterized O 0 0.08664862811565399
by O 0 0.00018293452740181237
acute O 1 0.9991236329078674
attacks O 0 0.0008349951822310686
of O 0 0.0003158555191475898
neurological B-Disease 1 0.9998525381088257
dysfunction I-Disease 1 0.9996682405471802
often O 0 0.0010202990379184484
precipitated O 1 0.6583892107009888
by O 0 5.305768809193978e-06
drugs O 0 0.0003546098596416414
, O 0 1.59572505253891e-06
fasting O 0 6.515093991765752e-05
, O 0 6.374760687322123e-06
cyclical O 0 0.04129207506775856
hormonal O 0 0.09937922656536102
changes O 0 4.6976212615845725e-05
, O 0 3.3129352232208475e-05
or O 0 0.0029932144097983837
infectious B-Disease 1 0.998818576335907
diseases I-Disease 1 0.9989271759986877
. O 0 0.0002411488676443696

Skin O 1 0.9982471466064453
photosensitivity O 1 0.9959992170333862
may O 0 0.0002446327416691929
also O 0 2.6250586415699217e-06
be O 0 6.22148263573763e-07
present O 0 9.614863301976584e-06
. O 0 2.5078099497477524e-05

The O 0 5.787115355815331e-07
seven O 0 4.218769333874661e-07
exons O 0 2.9859886581107276e-06
, O 0 2.137106491773011e-07
the O 0 2.894310853207571e-07
exon O 0 4.918492049910128e-05
/ O 0 2.1861358618480153e-05
intron O 0 2.1563111658906564e-05
boundaries O 0 2.540152088670311e-08
and O 0 9.80072645262453e-09
part O 0 1.528728432731441e-08
of O 0 4.272907361269063e-09
3 O 0 1.1976312919159682e-07
noncoding O 0 2.786472123261774e-06
sequence O 0 4.0189991779016054e-08
of O 0 1.2877039878844698e-08
the O 0 3.3959571510422393e-07
CPO O 0 2.911302181018982e-05
gene O 0 1.0506224725759239e-06
were O 0 5.130465652314342e-08
systematically O 0 4.171135401520587e-07
analyzed O 0 1.7826675957621774e-07
by O 0 3.593486752606623e-08
an O 0 2.210508114330878e-07
exon O 0 4.037312828586437e-05
- O 0 4.926115707348799e-06
by O 0 2.2127692034246138e-07
- O 0 4.901540705759544e-06
exon O 0 3.510906390147284e-05
denaturing O 0 0.0005318717448972166
gradient O 0 0.0002147044287994504
gel O 0 0.0026794662699103355
electrophoresis O 0 0.00038456678157672286
( O 0 6.556999323947821e-06
DGGE O 0 0.0002886697475332767
) O 0 2.1244994741209666e-07
strategy O 0 2.5953514182219806e-07
followed O 0 4.517906404544192e-08
by O 0 7.316977690408066e-09
direct O 0 2.0309920856220742e-08
sequencing O 0 1.2447671338122746e-07
in O 0 3.5024523725724066e-08
seven O 0 3.1241012266036705e-07
unrelated O 0 0.0001820422476157546
heterozygous O 0 0.001401968882419169
HC B-Disease 1 0.9989798665046692
patients O 0 0.3827923536300659
from O 0 4.738203642773442e-06
France O 0 7.503326287405798e-06
, O 0 4.997043561161263e-07
Holland O 0 8.297865861095488e-06
, O 0 1.1632729979282885e-07
and O 0 2.2395657595097873e-07
Czech O 0 1.0893495527852792e-05
Republic O 0 4.940521648677532e-06
. O 0 1.2408348084136378e-05

Seven O 0 7.811780960764736e-06
novel O 0 1.727662493067328e-05
mutations O 0 7.949007340357639e-06
and O 0 8.596764189405803e-08
two O 0 1.1180240022667931e-07
new O 0 1.4307727269624593e-06
polymorphisms O 0 3.984726936323568e-05
were O 0 2.432417659292696e-06
detected O 0 0.00028960921918042004
. O 0 1.3930504792369902e-05

Among O 0 1.0257056146656396e-06
these O 0 8.727248967943524e-08
mutations O 0 1.2499780268626637e-06
two O 0 6.77565097362276e-08
are O 0 6.450392930901216e-08
missense O 0 3.984069553553127e-05
( O 0 1.4759368696104502e-06
G197W O 0 3.297830335213803e-05
, O 0 2.2496288920592633e-07
W427R O 0 1.5328065273934044e-05
) O 0 1.42415771620108e-07
, O 0 2.1062096067225866e-08
two O 0 1.198730092966116e-08
are O 0 2.3105553026425696e-08
nonsense O 0 7.512670435971813e-06
( O 0 4.734671108508337e-07
Q306X O 0 1.8586721125757322e-05
, O 0 1.0127492799938409e-07
Q385X O 0 6.342669166770065e-06
) O 0 5.710221628874024e-08
, O 0 9.015876933915479e-09
two O 0 3.6037053341431147e-09
are O 0 2.262353193671629e-09
small O 0 1.1288901902162252e-07
deletions O 0 4.838794211536879e-06
( O 0 7.390293035314244e-07
662de14bp O 0 2.6308794986107387e-05
; O 0 3.4888981303993205e-07
1168del3bp O 0 5.774854798801243e-05
removing O 0 4.48410855824477e-06
a O 0 1.750618423557171e-07
glycine O 0 4.104586878383998e-06
at O 0 2.1890866719331825e-07
position O 0 1.4704602335768868e-07
390 O 0 1.4661671912108432e-06
) O 0 3.591992836504687e-08
, O 0 5.113717893578951e-09
and O 0 1.5866838953826345e-09
one O 0 4.048186230676265e-09
is O 0 9.759892449778818e-09
a O 0 1.0629506164150371e-07
splicing O 0 3.1120364383241395e-06
mutation O 0 1.140404765465064e-05
( O 0 2.0697011677839328e-06
IVS1 O 0 0.0019133513560518622
- O 0 4.465001984499395e-05
15c O 0 0.00019911247363779694
- O 0 1.3824866982758977e-05
- O 0 3.5358298191567883e-06
> O 0 6.003643193253083e-06
g O 0 1.1273704103587079e-06
) O 0 2.0930739808022736e-08
which O 0 1.529685000889458e-08
creates O 0 4.4667368115369754e-07
a O 0 1.646584451009403e-07
new O 0 3.992617223502748e-07
acceptor O 0 3.542476406437345e-05
splice O 0 0.00011362830991856754
site O 0 4.614939462044276e-05
. O 0 1.294647609029198e-05

The O 0 6.183234745549271e-06
pathological O 0 0.0002032079064520076
significance O 0 2.668600131983112e-07
of O 0 2.120932052207536e-08
the O 0 1.5339135472913767e-07
point O 0 9.327646921519772e-07
mutations O 0 7.639015166205354e-06
G197W O 0 2.718564064707607e-05
, O 0 2.2985210534898215e-07
W427R O 0 6.463549198088003e-06
, O 0 3.2723125542588605e-08
and O 0 1.0310230891263927e-08
the O 0 4.6858342983568946e-08
in O 0 1.6885637421637512e-07
- O 0 6.0243814914429095e-06
frame O 0 1.8258111595059745e-05
deletion O 0 7.44758581276983e-05
390delGly O 0 6.368814501911402e-05
were O 0 9.586999283328623e-08
assessed O 0 3.196187208232004e-07
by O 0 1.0087697788208061e-08
their O 0 2.2247310660361563e-09
respective O 0 2.3326069964468843e-08
expression O 0 8.216211710987409e-08
in O 0 2.692840261886431e-08
a O 0 2.3007974903066497e-07
prokaryotic O 0 7.145484232751187e-06
system O 0 1.6269308389382786e-06
using O 0 6.162914587548585e-07
site O 0 7.240033028210746e-06
- O 0 6.849848432466388e-06
directed O 0 2.787338644338888e-06
mutagenesis O 0 0.00025409850059077144
. O 0 2.4401138944085687e-05

These O 0 1.7475838376412867e-06
mutations O 0 1.6664702343405224e-05
resulted O 0 6.089208000048529e-06
in O 0 1.0936112460058212e-07
the O 0 1.2578256303186208e-07
absence O 0 1.5773659924889216e-06
or O 0 2.4340045001736144e-07
a O 0 6.463052955041348e-07
dramatic O 0 7.954550710564945e-06
decrease O 0 1.1743940376618411e-05
of O 0 4.023409871933836e-07
CPO O 0 0.0006315711070783436
activity O 0 1.2244855497556273e-05
. O 0 1.381016136292601e-05

The O 0 9.769465805220534e-07
two O 0 3.3268605648117955e-07
polymorphisms O 0 1.2185805644548964e-05
were O 0 2.554636751028738e-07
localized O 0 1.4698276572744362e-05
in O 0 1.4256090707931435e-07
noncoding O 0 1.032704585668398e-05
part O 0 3.877283205611093e-08
of O 0 4.5260200032259945e-09
the O 0 2.422351386144328e-08
gene O 0 2.6543813191892696e-07
1 O 0 8.988322264258386e-08
) O 0 2.9191948414108992e-08
a O 0 1.863619161213137e-07
C O 0 1.639533365960233e-05
/ O 0 7.75604166847188e-06
G O 0 3.2602629289613105e-06
polymorphism O 0 6.436106900764571e-07
in O 0 3.8004696278903793e-08
the O 0 2.853362559562811e-07
promotor O 0 0.0005041220574639738
region O 0 1.111455731006572e-06
, O 0 1.4738887443854765e-07
142 O 0 2.098193817801075e-06
bp O 0 6.503243184852181e-06
upstream O 0 4.3703278151951963e-07
from O 0 3.19306678875364e-08
the O 0 2.3616475886001354e-08
transcriptional O 0 1.8544245676821447e-06
initiation O 0 4.194253051537089e-06
site O 0 3.2781279060145607e-06
( O 0 1.2032012364215916e-06
- O 0 5.594753474724712e-06
142C O 0 2.160988333343994e-05
/ O 0 1.113114740292076e-05
G O 0 6.937269972695503e-06
) O 0 7.009451508110942e-08
, O 0 1.3654591235479074e-08
and O 0 8.132204243338492e-09
2 O 0 7.554720582447771e-08
) O 0 2.6332164893005938e-08
a O 0 8.513253391129183e-08
6 O 0 4.35183693525687e-07
bp O 0 6.547882549057249e-06
deletion O 0 2.551598527134047e-06
polymorphism O 0 5.260783950689074e-07
in O 0 1.8259772360806892e-08
the O 0 1.7751224490325512e-08
3 O 0 1.0235797276436642e-07
noncoding O 0 4.719146545539843e-06
part O 0 2.150197886408023e-08
of O 0 1.3742590176946123e-08
the O 0 1.9720155819413776e-07
CPO O 0 3.425862450967543e-05
gene O 0 1.38357415835344e-06
, O 0 1.751570266605995e-07
574 O 0 2.1978084987495095e-05
bp O 0 4.21596860178397e-06
downstream O 0 2.793651390220475e-07
of O 0 5.820543602652606e-09
the O 0 2.5095195255175895e-08
last O 0 6.531895024863843e-08
base O 0 1.8942666102361727e-08
of O 0 2.7052249329528877e-09
the O 0 4.0458569827706015e-08
normal O 0 1.0044807368103648e-06
termination O 0 3.511623071972281e-05
codon O 0 1.2860105016443413e-05
( O 0 3.2904179079196183e-06
+ O 0 6.686893902951851e-05
574 O 0 0.0003025456389877945
delATTCTT O 0 0.000560103275347501
) O 0 1.0130029295396525e-05
. O 0 1.0823141565197147e-05

Five O 0 6.443747406592593e-05
intragenic O 0 0.022152816876769066
dimorphisms O 0 0.0031353572849184275
are O 0 2.4747191673668567e-07
now O 0 5.92084006711957e-07
well O 0 1.0568130903720885e-07
characterized O 0 4.109184828848811e-06
and O 0 2.847924562843218e-08
the O 0 2.824037714788119e-08
high O 0 4.493748235745443e-07
degree O 0 2.88374451429263e-07
of O 0 5.416123372015136e-08
allelic O 0 0.00012968684313818812
heterogeneity O 0 8.894121128832921e-05
in O 0 2.1931689389020903e-06
HC B-Disease 1 0.9887771010398865
is O 0 2.948731889773626e-07
demonstrated O 0 2.784615560358361e-07
with O 0 1.0816246565070742e-08
seven O 0 1.731106991087472e-08
new O 0 1.0465544875160049e-08
different O 0 2.9643496546327697e-09
mutations O 0 1.0778192915950058e-07
making O 0 1.0676784789609428e-08
a O 0 1.4569738304714974e-08
total O 0 1.2434757223900306e-08
of O 0 2.5974062012323884e-08
nineteen O 0 1.6651007172185928e-05
CPO O 0 0.005126082804054022
gene B-Disease 0 0.000952324247919023
defects I-Disease 1 0.9953113198280334
reported O 0 0.00010567474237177521
so O 0 8.571187777306477e-07
far O 0 1.307520506088622e-06
. O 0 9.558294777889387e-07
. O 0 4.658112629840616e-06

Coincidence O 0 1.3993272659718059e-05
of O 0 1.588705202948404e-07
two O 0 1.248647834017902e-07
novel O 0 5.610221705865115e-06
arylsulfatase O 0 0.0001444646914023906
A O 0 1.7308713040620205e-06
alleles O 0 1.6313993000949267e-06
and O 0 4.1970633901655674e-07
mutation O 0 1.890090607048478e-05
459 O 0 0.00014650251250714064
+ O 0 9.751462494023144e-05
1G O 0 0.0008452381589449942
> O 0 1.5943796825013123e-05
A O 0 4.419938477440155e-07
within O 0 6.468109603474659e-08
a O 0 4.0524841438127623e-07
family O 0 3.2228515465249075e-06
with O 0 3.2877171634027036e-06
metachromatic B-Disease 1 0.9624698162078857
leukodystrophy I-Disease 1 0.9970632195472717
: O 0 6.203814564287313e-07
molecular O 0 9.146772868007247e-07
basis O 0 5.7233606298723316e-08
of O 0 2.2434413438077172e-07
phenotypic O 0 0.0002481780538801104
heterogeneity O 0 0.004462487064301968
. O 0 0.0001623103889869526

In O 0 2.3727218376734527e-06
a O 0 2.4031348857533885e-06
family O 0 1.5532148154306924e-06
with O 0 1.4529229019899503e-07
three O 0 2.444290601033572e-07
siblings O 0 1.004956902761478e-05
, O 0 2.247767412200119e-07
one O 0 2.022353129405019e-07
developed O 0 6.446201950893737e-06
classical O 0 2.7681182473315857e-05
late O 0 0.003040678333491087
infantile O 1 0.9968484044075012
metachromatic B-Disease 1 0.9966838955879211
leukodystrophy I-Disease 1 0.9990041851997375
( O 0 0.0011239948216825724
MLD B-Disease 1 0.9956177473068237
) O 0 9.239069186151028e-06
, O 0 3.3564228942850605e-06
fatal O 0 0.023704247549176216
at O 0 1.5645923667761963e-06
age O 0 4.626670033758273e-06
5 O 0 7.394579597530537e-07
years O 0 5.09451297148189e-07
, O 0 1.2556623119053256e-07
with O 0 7.25035874893365e-07
deficient O 0 0.32716870307922363
arylsulfatase O 0 0.00037222259561531246
A O 0 6.034265879861778e-06
( O 0 2.089991994580487e-06
ARSA O 0 0.0027177922893315554
) O 0 2.2751810035970266e-07
activity O 0 2.3969931817191537e-07
and O 0 5.426753801884843e-08
increased O 0 2.564474016253371e-06
galactosylsulfatide O 0 0.00023920902458485216
( O 0 6.558756922458997e-06
GS O 0 0.17374174296855927
) O 0 1.636419824535551e-06
excretion O 0 0.00017710041720420122
. O 0 1.543411963211838e-05

The O 0 1.2066944918842637e-06
two O 0 1.497376160841668e-07
other O 0 2.2152309497869282e-07
siblings O 0 2.5104081942117773e-05
, O 0 7.304834070964716e-07
apparently O 0 5.175591923034517e-06
healthy O 0 4.008265477750683e-06
at O 0 2.2021924905857304e-07
12 O 0 1.5629920824267174e-07
( O 0 8.676840934640495e-08
1 O 0 1.5321765545195376e-07
/ O 0 9.6593225862307e-07
2 O 0 2.9138323753841178e-08
) O 0 1.0113551773827112e-08
and O 0 7.690493575296387e-09
15 O 0 3.7793189022750084e-08
years O 0 5.202320707553554e-08
, O 0 1.8075839491871193e-08
respectively O 0 1.326448568761407e-07
, O 0 2.020760092591445e-08
and O 0 7.761313369769596e-09
their O 0 1.605528865411543e-08
father O 0 3.4476768178137718e-06
, O 0 3.186028720847389e-07
apparently O 0 1.164176228485303e-05
healthy O 0 7.5848615779250395e-06
as O 0 5.649080137004603e-08
well O 0 4.7251262458303245e-08
, O 0 1.9134569129164447e-07
presented O 0 4.612101292877924e-06
ARSA O 0 0.03640054166316986
and O 0 3.516678077630786e-07
GS O 0 0.0019625516142696142
values O 0 3.59031488983419e-08
within O 0 3.4114655989014864e-08
the O 0 1.8865296169678913e-07
range O 0 1.9692729438247625e-06
of O 0 6.963451596675441e-06
MLD B-Disease 1 0.9984337687492371
patients O 1 0.8765027523040771
. O 0 8.313240687130019e-05

Mutation O 0 0.00011845066910609603
screening O 0 8.373695891350508e-06
and O 0 1.54679057118301e-07
sequence O 0 6.463139357038017e-07
analysis O 0 5.987068902868486e-07
disclosed O 0 1.7426493286620826e-05
the O 0 1.2097878254735406e-07
involvement O 0 7.534199539804831e-07
of O 0 1.4058535668937111e-08
three O 0 6.786062556329853e-08
different O 0 1.5221506544094154e-07
ARSA O 0 0.12547871470451355
mutations O 0 2.3610948574059876e-06
being O 0 6.565019106119507e-08
the O 0 2.3118028380508804e-08
molecular O 0 3.5790270658253576e-07
basis O 0 4.4258094078486465e-08
of O 0 2.7943761438109505e-07
intrafamilial O 0 0.001042255898937583
phenotypic O 0 0.00022396449639927596
heterogeneity O 0 0.002814497798681259
. O 0 0.00010622131958371028

The O 0 8.315237937495112e-05
late O 0 0.009950120002031326
infantile O 1 0.9975680708885193
patient O 1 0.9866097569465637
inherited O 1 0.7229485511779785
from O 0 4.163439371041022e-06
his O 0 3.213159970982815e-06
mother O 0 1.2911656085634604e-05
the O 0 3.14265832912497e-07
frequent O 0 3.7819906992808683e-06
0 O 0 2.6541076749708736e-06
- O 0 1.1408506907173432e-05
type O 0 9.36943160922965e-06
mutation O 0 1.8573873603600077e-05
459 O 0 0.00016780963051132858
+ O 0 0.00010665755689842626
1G O 0 0.0007418758468702435
> O 0 2.168748869735282e-05
A O 0 4.0043852322924067e-07
, O 0 2.4279806609683874e-08
and O 0 1.0516610693400708e-08
from O 0 3.784259661188116e-08
his O 0 1.3904814011311828e-07
father O 0 6.940757089068939e-07
a O 0 1.2178122688055737e-07
novel O 0 5.08517359776306e-07
, O 0 4.654319241126359e-08
single O 0 2.230800646429998e-07
basepair O 0 1.5225428796838969e-05
microdeletion O 0 4.507922767515993e-06
of O 0 1.4884926180513958e-08
guanine O 0 9.446036415283743e-07
at O 0 1.1493609264334737e-07
nucleotide O 0 2.943124002285913e-07
7 O 0 2.944808557003853e-07
in O 0 1.2049012809711712e-07
exon O 0 1.3209664757596329e-05
1 O 0 7.81688584083895e-07
( O 0 1.5655311926821014e-06
7delG O 0 9.435134415980428e-05
) O 0 2.6175089260505047e-06
. O 0 4.519045432971325e-06

The O 0 1.438334038539324e-05
two O 0 4.764993718708865e-06
clinically O 0 0.007621025666594505
unaffected O 0 0.0005026489961892366
siblings O 0 1.1484001333883498e-05
carried O 0 7.123053364921361e-07
the O 0 4.492471532557829e-07
maternal O 0 8.191651431843638e-05
mutation O 0 4.73756663268432e-05
459 O 0 0.0002517823886591941
+ O 0 0.000154617489897646
1G O 0 0.0008157572592608631
> O 0 1.3147667232260574e-05
A O 0 2.929092772774311e-07
and O 0 1.8009936653129444e-08
, O 0 8.41088976244464e-09
on O 0 9.340955564596243e-09
their O 0 9.219811580862824e-09
paternal O 0 3.1651006793254055e-06
allele O 0 1.0184700158788473e-06
, O 0 3.266537973445338e-08
a O 0 4.408798659483182e-08
novel O 0 1.2543816296783916e-07
cytosine O 0 2.6795200369633676e-07
to O 0 8.43493896951486e-09
thymidine O 0 1.4228560303308768e-06
transition O 0 3.6560200555868505e-07
at O 0 2.0725205729377194e-07
nucleotide O 0 1.5776035979797598e-06
2435 O 0 0.00014654500409960747
in O 0 7.316701555737382e-08
exon O 0 5.190845513425302e-06
8 O 0 2.497570505965996e-07
, O 0 1.5064234304418278e-08
resulting O 0 1.463971983639567e-07
in O 0 1.0749364953710483e-08
substitution O 0 1.4808402681865118e-07
of O 0 6.635870875015826e-08
alanine O 0 5.8948033256456256e-05
464 O 0 6.066105925128795e-05
by O 0 2.2027650175004965e-06
valine O 0 0.0003813362563960254
( O 0 1.075608452083543e-05
A464V O 0 0.00036578677827492356
) O 0 9.12876748770941e-06
. O 0 1.6998110368149355e-05

The O 0 1.0947295777441468e-05
fathers O 0 3.8473564927699044e-05
genotype O 0 0.00016044235962908715
thus O 0 5.532268460228806e-06
was O 0 5.028733721701428e-05
7delG O 0 0.005296654533594847
/ O 0 0.002549683442339301
A464V O 0 0.0010328389471396804
. O 0 4.130607339902781e-05

Mutation O 0 0.0004607016744557768
A464V O 0 0.0005339591880328953
was O 0 5.745975158788497e-06
not O 0 1.5422214971749781e-07
found O 0 3.357897355726891e-07
in O 0 4.319955735354597e-07
18 O 0 2.0140811102464795e-05
unrelated O 0 0.06312212347984314
MLD B-Disease 1 0.9993002414703369
patients O 0 0.046149611473083496
and O 0 1.0215566135229892e-06
50 O 0 4.9125569603347685e-06
controls O 0 2.0682235117419623e-05
. O 0 7.896284841990564e-06

A464V O 0 0.0021912469528615475
, O 0 7.983703653735574e-06
although O 0 6.907825536472956e-06
clearly O 0 1.551620152895339e-05
modifying O 0 0.00038340961327776313
ARSA O 1 0.6790233254432678
and O 0 1.1471348443592433e-05
GS O 1 0.9864230751991272
levels O 0 5.334644811227918e-05
, O 0 1.0570505537543795e-06
apparently O 0 9.38974608288845e-06
bears O 0 1.1883992556249723e-05
little O 0 2.0042102732986677e-06
significance O 0 1.0807234502863139e-06
for O 0 3.179642078521283e-07
clinical O 0 0.00014235243725124747
manifestation O 0 0.0004503018280956894
of O 0 4.983089638699312e-06
MLD B-Disease 1 0.9977026581764221
, O 0 8.016052561288234e-06
mimicking O 0 0.00047679731505922973
the O 0 4.716671810456319e-06
frequent O 0 0.00034283261629752815
ARSA O 1 0.9624137282371521
pseudodeficiency O 0 0.020787913352251053
allele O 0 0.0007721131551079452
. O 0 0.00012970168609172106

Our O 0 3.47565173797193e-06
results O 0 2.176695033995202e-06
demonstrate O 0 1.3137012047081953e-06
that O 0 1.2524594694696134e-07
in O 0 2.5682552973194106e-07
certain O 0 1.9527280983311357e-06
genetic O 0 0.00037706358125433326
conditions O 0 0.0345495343208313
MLD B-Disease 1 0.998040497303009
- O 0 0.0007587278378196061
like O 0 1.1136201464978512e-05
ARSA O 0 0.22196725010871887
and O 0 1.7835496919360594e-06
GS O 0 0.0769977942109108
values O 0 2.0852070292676217e-07
need O 0 2.5123196678578097e-07
not O 0 4.930148023163383e-08
be O 0 8.358485814596861e-08
paralleled O 0 2.3888787836767733e-05
by O 0 8.962385436461773e-06
clinical O 1 0.7225812673568726
disease O 1 0.9990590214729309
, O 0 4.904215984424809e-07
a O 0 8.919037099985871e-07
finding O 0 3.1510392091149697e-06
with O 0 5.437142135633621e-06
serious O 0 0.024007277563214302
diagnostic O 0 0.01358777191489935
and O 0 1.2319139386818279e-05
prognostic O 0 0.25096595287323
implications O 0 0.0026457463391125202
. O 0 9.381967538502067e-05

Moreover O 0 9.657221380621195e-05
, O 0 2.7267562927590916e-06
further O 0 1.1400741641409695e-05
ARSA O 0 0.3366612195968628
alleles O 0 3.4487093216739595e-05
functionally O 0 0.00010476102033862844
similar O 0 2.049926024483284e-06
to O 0 7.550944474132848e-07
A464V O 0 0.00022877786250319332
might O 0 4.886298938799882e-07
exist O 0 7.340478447304122e-08
which O 0 5.906456213011779e-09
, O 0 4.173137835294938e-09
together O 0 5.39106537189582e-09
with O 0 6.297281629485951e-08
0 O 0 1.3476523008648655e-06
- O 0 1.915398024721071e-05
type O 0 2.0147919713053852e-05
mutations O 0 1.265830360352993e-05
, O 0 7.758133051538607e-07
may O 0 2.18730783672072e-05
cause O 0 0.003271304303780198
pathological O 1 0.5864511728286743
ARSA O 1 0.9884238839149475
and O 0 9.359411706100218e-06
GS O 1 0.961068332195282
levels O 0 1.8946204363601282e-05
, O 0 2.3443783447874011e-07
but O 0 1.1385029097255028e-07
not O 0 2.658835285274108e-07
clinical O 0 0.00023986517044249922
outbreak O 0 0.0074357036501169205
of O 0 1.4545174735758337e-06
the O 0 0.00030034908559173346
disease O 1 0.9988911747932434
. O 0 1.5992556654964574e-05
. O 0 4.2089417547686026e-05

Human O 0 0.04660433903336525
MLH1 O 1 0.9940555095672607
deficiency O 1 0.9993969202041626
predisposes O 1 0.9767358303070068
to O 0 0.00028714307700283825
hematological B-Disease 1 0.9975710511207581
malignancy I-Disease 1 0.9991344809532166
and O 0 0.0007794381235726178
neurofibromatosis B-Disease 1 0.9992468357086182
type I-Disease 0 0.014815688133239746
1 I-Disease 0 7.890948472777382e-05
. O 0 3.304422352812253e-05

Heterozygous O 0 0.0014876504428684711
germ O 0 0.29732608795166016
- O 0 6.537536683026701e-05
line O 0 5.137955668033101e-06
mutations O 0 1.8646411490408354e-06
in O 0 7.57872058443354e-08
the O 0 5.324055223354662e-07
DNA O 0 4.101772719877772e-05
mismatch O 0 0.10266266018152237
repair O 0 0.06089851260185242
genes O 0 7.552208444394637e-06
lead O 0 1.8033410015050322e-05
to O 0 1.4613519851991441e-05
hereditary B-Disease 1 0.9973903298377991
nonpolyposis I-Disease 1 0.9987064599990845
colorectal I-Disease 1 0.9999696016311646
cancer I-Disease 1 0.9997645020484924
. O 0 0.001109229400753975

The O 0 0.0021251977887004614
disease O 1 0.9980720281600952
susceptibility O 0 0.0010101905791088939
of O 0 2.751011436430417e-07
individuals O 0 8.756867941883684e-07
who O 0 1.6082680076578981e-06
constitutionally O 0 8.053943929553498e-06
lack O 0 4.325296231399989e-06
both O 0 2.788264055197942e-07
wild O 0 9.030541150423232e-06
- O 0 2.9725451895501465e-05
type O 0 1.587670158187393e-05
alleles O 0 6.183653567859437e-06
is O 0 1.267606535293453e-06
unknown O 0 1.3897968528908677e-05
. O 0 1.3515377759176772e-05

We O 0 1.067120592779247e-06
have O 0 1.3891890660033823e-07
identified O 0 3.5036794088227907e-07
three O 0 7.44737604918555e-08
offspring O 0 6.325508365989663e-06
in O 0 2.0139666503382614e-06
a O 0 0.00029988298774696887
hereditary B-Disease 1 0.9970566034317017
nonpolyposis I-Disease 1 0.9991368651390076
colorectal I-Disease 1 0.9999843835830688
cancer I-Disease 1 0.9999022483825684
family O 0 0.0029247466009110212
who O 0 8.409773727180436e-05
developed O 0 0.004953595343977213
hematological B-Disease 1 0.9978489875793457
malignancy I-Disease 1 0.9974809288978577
at O 0 2.509319529053755e-06
a O 0 7.122462193365209e-07
very O 0 1.0000191252856894e-07
early O 0 2.4389234454247344e-07
age O 0 7.570333195872081e-07
, O 0 2.2696369228469848e-08
and O 0 5.1209601004131855e-09
at O 0 2.2747117967014674e-08
least O 0 2.2096169338681193e-09
two O 0 6.511489125671233e-10
of O 0 1.6196951557745365e-09
them O 0 2.00531378169444e-08
displayed O 0 1.5554456922473037e-06
signs O 0 4.467659891815856e-05
of O 0 2.2897702365298755e-06
neurofibromatosis B-Disease 1 0.9986730813980103
type I-Disease 0 0.0006610422278754413
1 I-Disease 0 1.4043256669538096e-05
( O 0 1.1568686204554979e-05
NF1 B-Disease 0 0.028546663001179695
) O 0 8.425394298683386e-06
. O 0 1.1096552952949423e-05

DNA O 0 4.054837063449668e-06
sequence O 0 6.181055027809634e-07
analysis O 0 3.1751542906022223e-07
and O 0 8.18041883121623e-08
allele O 0 2.6395987333671656e-06
- O 0 8.211039812522358e-07
specific O 0 2.491981199170823e-08
amplification O 0 1.503147814219119e-06
in O 0 3.742862375588629e-08
two O 0 5.1856677174555443e-08
siblings O 0 1.0064530215458944e-05
revealed O 0 1.2996365512663033e-05
a O 0 3.5091072732029716e-06
homozygous O 0 0.00015067958156578243
MLH1 O 0 0.0497114434838295
mutation O 0 6.455162656493485e-05
( O 0 7.234746590256691e-06
C676T O 0 0.001061232527717948
- O 0 0.0002743095101322979
- O 0 5.8515048294793814e-05
> O 0 0.0001967299758689478
Arg226Stop O 0 0.0005127825425006449
) O 0 5.505495209945366e-06
. O 0 7.264122814376606e-06

Thus O 0 1.213107771036448e-05
, O 0 1.9988960957562085e-06
a O 0 9.51108813751489e-06
homozygous O 0 0.0005932858330197632
germ O 1 0.8129756450653076
- O 0 0.00023037291248328984
line O 0 5.233784395386465e-05
MLH1 O 0 0.043095123022794724
mutation O 0 0.0001580161915626377
and O 0 1.2520966265583411e-05
consequent O 1 0.911688506603241
mismatch O 1 0.9979544878005981
repair O 1 0.9993869066238403
deficiency O 1 0.9997586607933044
results O 0 3.1947391107678413e-05
in O 0 2.824899638653733e-06
a O 0 6.294883496593684e-05
mutator O 1 0.9204509258270264
phenotype O 0 0.13261954486370087
characterized O 0 0.06188032031059265
by O 0 0.0009845823515206575
leukemia B-Disease 1 0.9998195767402649
and O 0 0.00027916781255044043
/ O 1 0.9531314373016357
or O 0 0.0035695284605026245
lymphoma B-Disease 1 0.9999523162841797
associated O 0 0.0008352315635420382
with O 0 0.0002452981425449252
neurofibromatosis B-Disease 1 0.9996433258056641
type I-Disease 0 0.0018717857310548425
1 I-Disease 0 1.4253876543079969e-05
. O 0 3.0551377676601987e-06
. O 0 7.597022886329796e-06

Missense O 0 0.0005653784028254449
mutations O 0 1.5766134310979396e-05
in O 0 8.238510673663768e-08
the O 0 5.9417693876184785e-08
most O 0 2.1736980215791846e-08
ancient O 0 1.9770018866438477e-07
residues O 0 9.748461025083088e-07
of O 0 1.3654154429332266e-07
the O 0 1.4930185443517985e-06
PAX6 O 0 0.018217850476503372
paired O 0 2.4100057999021374e-05
domain O 0 9.54127790464554e-06
underlie O 0 0.00011071332119172439
a O 0 4.207405254419427e-06
spectrum O 0 6.665325781796128e-05
of O 0 2.9037379135843366e-05
human O 1 0.7688736915588379
congenital B-Disease 1 0.9999372959136963
eye I-Disease 1 0.9987887740135193
malformations I-Disease 1 0.9988207221031189
. O 0 0.002447988837957382

Mutations O 0 4.7601100959582254e-05
of O 0 5.454449478747847e-07
the O 0 4.594037363858661e-06
human O 0 4.2153766116825864e-05
PAX6 O 1 0.8154491782188416
gene O 0 0.000854683865327388
underlie O 0 0.45781421661376953
aniridia B-Disease 1 0.9968808889389038
( O 0 0.008543433621525764
congenital B-Disease 1 0.9996377229690552
absence I-Disease 0 5.445191345643252e-05
of I-Disease 0 2.586205027910182e-07
the I-Disease 0 1.5344211306000943e-06
iris I-Disease 0 0.0009076024289242923
) O 0 2.645346626195533e-07
, O 0 1.3846140234363702e-07
a O 0 9.440794315196399e-07
rare O 0 9.317825606558472e-05
dominant O 0 0.0004646765592042357
malformation B-Disease 1 0.9971407651901245
of I-Disease 0 3.249721203246736e-06
the I-Disease 0 0.0001508295099483803
eye I-Disease 0 0.4435062110424042
. O 0 6.803431460866705e-05

The O 0 1.628501763661916e-06
spectrum O 0 1.20291570055997e-05
of O 0 2.8249321530893212e-06
PAX6 O 1 0.898258626461029
mutations O 0 0.0008662269101478159
in O 0 5.722124842577614e-05
aniridia B-Disease 1 0.9976776242256165
patients O 0 0.06930028647184372
is O 0 6.058867256797384e-07
highly O 0 1.4688667988593807e-06
biased O 0 1.240999608853599e-06
, O 0 3.495478395620921e-08
with O 0 2.9593289596618888e-08
92 O 0 6.004646024848626e-07
% O 0 1.336775046212324e-08
of O 0 4.153000610074287e-09
all O 0 2.5015674864903303e-08
reported O 0 3.4605634482431924e-06
mutations O 0 1.7537761323183076e-06
leading O 0 2.5919430868270865e-07
to O 0 5.407071768104288e-08
premature O 0 5.975272870273329e-05
truncation O 0 3.8112716538307723e-06
of O 0 1.3251331587582627e-08
the O 0 8.728480338504596e-08
protein O 0 1.3026453871134436e-06
( O 0 2.546303790040838e-07
nonsense O 0 1.543791540825623e-06
, O 0 1.8422197101131133e-08
splicing O 0 1.9870122969223303e-07
, O 0 1.757147671810344e-08
insertions O 0 7.802087225172727e-07
and O 0 1.9630759240385487e-08
deletions O 0 6.904808742547175e-07
) O 0 2.9953039160091066e-08
and O 0 4.0390002453705165e-09
just O 0 9.457861160910852e-09
2 O 0 1.6701866556445566e-08
% O 0 6.267586005748171e-09
leading O 0 5.524671831125261e-09
to O 0 2.984397173833031e-10
substitution O 0 4.343044590626732e-09
of O 0 5.741515596291435e-10
one O 0 3.3491449613620716e-09
amino O 0 1.172016652617458e-07
acid O 0 7.870745321270078e-06
by O 0 1.7018787445977068e-07
another O 0 7.333495091188524e-07
( O 0 1.7127205182987382e-06
missense O 0 8.572169463150203e-05
) O 0 2.0886170659650816e-06
. O 0 6.312942332442617e-06

The O 0 1.3493421420207596e-06
extraordinary O 0 2.322854243175243e-06
conservation O 0 5.074380169389769e-07
of O 0 2.3914465074881264e-08
the O 0 4.049238953029999e-07
PAX6 O 0 0.00037064304342493415
protein O 0 9.612319900043076e-07
at O 0 2.1884834211505222e-07
the O 0 5.289317428491813e-08
amino O 0 8.751766813475115e-07
acid O 0 5.139087443239987e-05
level O 0 2.9766968054900644e-06
amongst O 0 2.9299833386176033e-06
vertebrates O 0 3.785966691793874e-05
predicts O 0 0.00018440632265992463
that O 0 8.949999710239354e-07
pathological O 0 0.002399238059297204
missense O 0 0.0006072158575989306
mutations O 0 1.7894524717121385e-05
should O 0 1.523860078123107e-07
in O 0 9.167244741092873e-08
fact O 0 3.6714425277750706e-07
be O 0 3.9141379915008656e-08
common O 0 6.500463314296212e-07
even O 0 1.2431704021764745e-07
though O 0 1.1987259540546802e-07
they O 0 1.3451027847111163e-08
are O 0 1.633776136600318e-08
hardly O 0 6.170716460474068e-06
ever O 0 2.0798177047254285e-06
seen O 0 1.0594287232379429e-05
in O 0 7.05980619386537e-06
aniridia B-Disease 1 0.9910598397254944
patients O 0 0.41487669944763184
. O 0 6.85000341036357e-05

This O 0 1.9025388837690116e-06
indicates O 0 7.515952802350512e-06
that O 0 6.594448365149219e-08
there O 0 4.448584078886597e-08
is O 0 4.211650050933713e-08
a O 0 3.886864874402818e-07
heavy O 0 8.695980795891955e-05
ascertainment O 0 0.0007398297893814743
bias O 0 3.2701718737371266e-06
in O 0 2.6089601590228995e-08
the O 0 3.7856747070463825e-08
selection O 0 1.0817034734600384e-07
of O 0 1.0801777250435407e-07
patients O 0 0.0004748590290546417
for O 0 7.83483415034425e-07
PAX6 O 0 0.015483268536627293
mutation O 0 4.760633146361215e-06
analysis O 0 1.1564084445581102e-07
and O 0 4.255179675283216e-08
that O 0 5.101445665900428e-08
the O 0 6.143444011286192e-07
missing O 0 5.161971057532355e-05
PAX6 O 0 0.08525638282299042
missense O 0 0.002005351474508643
mutations O 0 0.00036257310421206057
frequently O 0 4.677090691984631e-05
may O 0 7.339797593886033e-05
underlie O 0 0.001951561076566577
phenotypes O 0 0.0010206763399764895
distinct O 0 2.2878450181451626e-05
from O 0 6.116578879300505e-05
textbook O 0 0.0366339385509491
aniridia B-Disease 1 0.9730076193809509
. O 0 0.00011653799447230995

Here O 0 3.8913890421099495e-06
we O 0 1.20911423096004e-07
present O 0 2.3676849991716153e-07
four O 0 2.546116775192786e-07
novel O 0 1.0599097549857106e-05
PAX6 O 0 0.04586600139737129
missense O 0 0.0003614351444412023
mutations O 0 8.332448487635702e-06
, O 0 1.6466253782709828e-07
two O 0 9.501005848733257e-08
in O 0 8.363691108570492e-07
association O 0 4.1540846723364666e-05
with O 0 7.416059361275984e-06
atypical O 1 0.7983279824256897
phenotypes O 0 0.11534874141216278
ectopia B-Disease 1 0.5030520558357239
pupillae I-Disease 0 0.0433938205242157
( O 0 1.7790798665373586e-05
displaced B-Disease 0 6.826878961874172e-05
pupils I-Disease 0 2.4447772375424393e-05
) O 0 6.1453579291992355e-06
and O 0 5.512716234079562e-05
congenital B-Disease 1 0.9997767806053162
nystagmus I-Disease 1 0.6132277846336365
( O 0 8.22639231046196e-06
searching B-Disease 0 7.664526492590085e-06
gaze I-Disease 0 4.31751468568109e-05
) O 0 2.0526633193185262e-07
, O 0 2.3594592946096782e-08
and O 0 6.499655036407148e-09
two O 0 7.053545747481849e-09
in O 0 6.393631224455021e-08
association O 0 2.22602830035612e-06
with O 0 1.0674182959746759e-07
more O 0 2.2233881225020014e-07
recognizable O 0 0.00038338699960149825
aniridia B-Disease 1 0.9065758585929871
phenotypes O 0 0.011957532726228237
. O 0 5.127442273078486e-05

Strikingly O 0 8.684139174874872e-05
, O 0 1.716241087024173e-07
all O 0 1.3243549368269214e-08
four O 0 7.162111614889e-08
mutations O 0 7.597796525260492e-07
are O 0 7.722713135649428e-09
located O 0 8.633868731067196e-08
within O 0 3.2998400456563104e-08
the O 0 4.709650340828375e-07
PAX6 O 0 0.0023648589849472046
paired O 0 4.399795216158964e-06
domain O 0 5.418044679572631e-07
and O 0 6.350958159373477e-08
affect O 0 3.3872692029035534e-07
amino O 0 3.186812875810574e-07
acids O 0 3.5332442394064856e-07
which O 0 2.0279882662066484e-08
are O 0 3.957827843237283e-09
highly O 0 7.070952534604658e-08
conserved O 0 1.5356961569068517e-07
in O 0 2.806719834325122e-08
all O 0 1.0105761560907922e-08
known O 0 7.72461589804152e-07
paired O 0 5.637687536363956e-06
domain O 0 2.8948759336344665e-06
proteins O 0 6.1885912145953625e-06
. O 0 1.148724459199002e-05

Our O 0 1.183226345347066e-06
results O 0 9.70988025983388e-07
support O 0 1.8579051186407014e-07
the O 0 5.3711875835915635e-08
hypothesis O 0 5.467135792969202e-07
that O 0 1.7382104644525498e-08
the O 0 2.6299538546936674e-08
under O 0 1.2950222583185678e-07
- O 0 2.0813585877021978e-07
representation O 0 8.645697491260762e-09
of O 0 3.321575192671844e-08
missense O 0 7.826954242773354e-05
mutations O 0 2.4277353077195585e-05
is O 0 1.546152020637237e-06
caused O 0 0.0002775700995698571
by O 0 1.2106620488339104e-06
ascertainment O 0 0.003495824057608843
bias O 0 1.74152464751387e-05
and O 0 1.2299670970605803e-07
suggest O 0 4.681465952671715e-07
that O 0 4.986142343454958e-08
a O 0 6.497773483715719e-07
substantial O 0 5.535155196412234e-06
burden O 0 0.00014887026918586344
of O 0 2.890079258577316e-06
PAX6 B-Disease 1 0.9970513582229614
- I-Disease 1 0.6910960078239441
related I-Disease 0 0.00921426061540842
disease I-Disease 1 0.9992202520370483
remains O 0 2.7166021027369425e-05
to O 0 1.9278041918369127e-07
be O 0 2.800592255880474e-07
uncovered O 0 6.908183422638103e-05
. O 0 1.3668789051735075e-06
. O 0 7.681299393880181e-06

The O 0 4.7672438086010516e-06
chromosomal O 0 6.20622668066062e-05
order O 0 2.799033040901122e-07
of O 0 8.317058330931104e-08
genes O 0 1.8593211734696524e-06
controlling O 0 1.1810858268290758e-05
the O 0 2.5636131795181427e-06
major O 0 6.112222763476893e-05
histocompatibility O 1 0.8390074372291565
complex O 0 2.335266981390305e-05
, O 0 9.398312954544963e-07
properdin O 0 0.00043571190326474607
factor O 0 5.0414482757332735e-06
B O 0 5.467873052111827e-05
, O 0 3.055738773127814e-07
and O 0 4.941596216667676e-07
deficiency B-Disease 1 0.9931952953338623
of I-Disease 0 9.222098640293552e-09
the I-Disease 0 5.998499119641565e-08
second I-Disease 0 1.5840198841488018e-07
component I-Disease 0 8.953311976256373e-07
of I-Disease 0 1.681736847558568e-07
complement I-Disease 0 2.2585751139558852e-05
. O 0 1.610719846212305e-05

The O 0 1.0464286788192112e-06
relationship O 0 8.84802432210563e-07
of O 0 3.125155600969265e-08
the O 0 1.1676722522224736e-07
genes O 0 3.752620330033096e-07
coding O 0 3.7781876471854048e-06
for O 0 1.4124660197012417e-07
HLA O 0 0.0005008564330637455
to O 0 1.126861004507873e-08
those O 0 2.423654521521712e-08
coding O 0 1.8502114471630193e-06
for O 0 1.0736643929476486e-07
properdin O 0 0.00019651382172014564
Factor O 0 3.5262801247881725e-06
B O 0 3.494838529150002e-05
allotypes O 0 7.858119352022186e-05
and O 0 1.608128599173142e-07
for O 0 3.691158951824036e-07
deficiency B-Disease 1 0.9809396266937256
of I-Disease 0 6.886301306963105e-09
the I-Disease 0 2.381291785980011e-08
second I-Disease 0 5.309837192157829e-08
component I-Disease 0 1.1420097933978468e-07
of I-Disease 0 1.3304819468373807e-08
complement I-Disease 0 8.257505328401749e-07
( O 0 1.2452354667402687e-06
C2 O 0 0.0040688104927539825
) O 0 1.593533625054988e-07
was O 0 1.9329718270455487e-07
studied O 0 2.1817129436385585e-07
in O 0 8.516208538367209e-08
families O 0 2.3464494347535947e-07
of O 0 1.0930498319794424e-06
patients O 1 0.815541684627533
with O 0 0.001062986208125949
connective O 1 0.9990971088409424
tissue O 1 0.9993768334388733
disorders O 1 0.9995821118354797
. O 0 0.0027442583814263344

Patients O 0 0.007611990440636873
were O 0 4.884295208285039e-07
selected O 0 1.8086001318806666e-07
because O 0 2.3009597782674973e-07
they O 0 2.0047668414235886e-08
were O 0 4.639243655901737e-08
heterozygous O 0 5.549960405915044e-06
or O 0 3.79195125788101e-06
homozygous O 0 0.0007920974167063832
for O 0 0.0007016169256530702
C2 B-Disease 1 0.9995033740997314
deficiency I-Disease 1 0.999794065952301
. O 0 0.0006469698273576796

12 O 0 5.1291967793076765e-06
families O 0 1.0528661960051977e-06
with O 0 6.642012522206642e-07
15 O 0 3.925423243344994e-06
matings O 0 0.00016058179608080536
informative O 0 7.17410584911704e-05
for O 0 0.00033680041087791324
C2 B-Disease 1 0.9996949434280396
deficiency I-Disease 1 0.9998784065246582
were O 0 6.858266260678647e-06
found O 0 3.7857971619814634e-05
. O 0 1.633619649510365e-05

Of O 0 8.693238555679272e-07
57 O 0 1.9048255126108415e-05
informative O 0 9.602647878637072e-06
meioses O 0 0.00017458610818721354
, O 0 1.0903703895337458e-07
two O 0 1.929396375999204e-08
crossovers O 0 6.43624218810146e-07
were O 0 5.89507997972305e-08
noted O 0 5.526750896933663e-07
between O 0 4.4256577780288353e-07
the O 0 5.2997285820310935e-05
C2 B-Disease 1 0.9994775652885437
deficiency I-Disease 1 0.9998044371604919
gene O 0 3.8339248931151815e-06
and O 0 8.360112246919016e-08
the O 0 9.71413214756467e-07
HLA O 0 0.0595054030418396
- O 0 9.405707714904565e-06
B O 0 2.961884092655964e-06
gene O 0 2.2210674899270089e-07
, O 0 8.660848038744007e-09
with O 0 1.0340717615520134e-08
a O 0 6.652408757190642e-08
recombinant O 0 7.88320676292642e-07
fraction O 0 2.4798174536044826e-07
of O 0 1.009495775861069e-07
0 O 0 4.3039531192334834e-06
. O 0 5.328455699782353e-06

035 O 1 0.6266486048698425
. O 0 0.0010165771236643195

A O 0 1.373716804664582e-05
lod O 0 4.0285518480231985e-05
score O 0 6.504382810135212e-08
of O 0 2.0323678739941897e-08
13 O 0 3.8065277863097435e-07
was O 0 2.1650340897849674e-07
calculated O 0 2.253465964940915e-07
for O 0 2.708288775465917e-07
linkage O 0 0.00013703660806640983
between O 0 0.00021132164692971855
C2 B-Disease 1 0.9996090531349182
deficiency I-Disease 1 0.9998923540115356
and O 0 1.178242928290274e-05
HLA O 1 0.6593101024627686
- O 0 1.0865781405300368e-05
B O 0 1.8718998262556852e-06
at O 0 3.3392346665550576e-08
a O 0 1.3981893864922768e-08
maximum O 0 2.1301184816024943e-08
likelihood O 0 8.737642076539487e-08
value O 0 1.4154042382585885e-09
of O 0 1.0060062782812906e-09
the O 0 2.279576172270481e-08
recombinant O 0 1.3206893072492676e-06
fraction O 0 1.9468748746476194e-07
of O 0 1.068298089990094e-07
0 O 0 4.076565801369725e-06
. O 0 6.584672064491315e-06

04 O 0 0.07226927578449249
. O 0 0.0005769130075350404

18 O 0 1.7399775970261544e-05
families O 0 8.401142963521124e-07
with O 0 1.8284872282947617e-07
21 O 0 1.1171898677275749e-06
informative O 0 1.5286269672287744e-06
matings O 0 8.107626854325645e-06
for O 0 7.955910774626318e-08
both O 0 1.7589557899100328e-07
properdin O 0 0.000291616830509156
Factor O 0 5.5313985285465606e-06
B O 0 8.459278615191579e-05
allotype O 0 0.0005055146175436676
and O 0 2.8022750484524295e-06
HLA O 0 0.37857508659362793
- O 0 7.408895180560648e-05
B O 0 2.3863307433202863e-05
were O 0 2.3982531160982035e-07
found O 0 3.885163096128963e-06
. O 0 5.215433247940382e-06

Of O 0 1.5750450756968348e-06
72 O 0 3.711237877723761e-05
informative O 0 1.3951776963949669e-05
meioses O 0 0.0002260437177028507
, O 0 1.6880677833341906e-07
three O 0 1.5550735099623125e-07
recombinants O 0 3.666778138722293e-05
were O 0 2.232430063031643e-08
found O 0 7.264264212381022e-08
, O 0 9.254590871421442e-09
giving O 0 1.7645398031618242e-08
a O 0 6.112726680385094e-08
recombinant O 0 9.559415730109322e-07
fraction O 0 2.329655188759716e-07
of O 0 7.969686066644499e-08
0 O 0 9.586598935129587e-06
. O 0 1.1576366887311451e-05

042 O 0 0.04167081415653229
. O 0 0.0004534171021077782

A O 0 1.1096849448222201e-05
lod O 0 7.541184459114447e-05
score O 0 1.205846160701185e-07
of O 0 3.819276273020478e-08
16 O 0 8.49555419790704e-07
between O 0 1.2491485676946468e-06
HLA O 0 0.061744574457407
- O 0 7.309333796001738e-06
B O 0 2.2015026388544356e-06
and O 0 3.066276832441872e-08
Factor O 0 4.2528432686594897e-07
B O 0 4.4325274757284205e-06
allotypes O 0 9.582331585988868e-06
was O 0 6.353781145662651e-08
calculated O 0 2.815797905952877e-08
at O 0 3.4940118354143124e-08
a O 0 2.5336682085708162e-08
maximum O 0 4.127826613853358e-08
likelihood O 0 1.194918297642289e-07
value O 0 3.099840384379604e-09
of O 0 1.638550184424048e-09
the O 0 2.0897353181226208e-08
recombinant O 0 1.2191896985314088e-06
fraction O 0 5.594906724581961e-07
of O 0 1.2311313923873968e-07
0 O 0 6.681728336843662e-06
. O 0 7.33125489205122e-06

04 O 0 0.05039793252944946
. O 0 0.0006202398799359798

A O 0 1.2786791558028199e-05
crossover O 0 1.3870864677301142e-05
was O 0 2.6234267807012657e-06
shown O 0 3.061240079205163e-07
to O 0 1.3182485325557991e-08
have O 0 6.983853051423239e-09
occurred O 0 1.2053438069870026e-07
between O 0 1.3512122976067076e-08
genes O 0 2.5037440565256475e-08
for O 0 1.2320729325665525e-08
Factor O 0 3.777496146994963e-07
B O 0 6.408333319996018e-06
and O 0 1.9974544329670607e-07
HLA O 0 0.03225070983171463
- O 0 2.276451778016053e-05
D O 0 3.640465729404241e-05
, O 0 3.8805307411848844e-08
in O 0 5.055262519704229e-08
which O 0 4.7162663463495846e-07
HLA O 0 0.01725931651890278
- O 0 3.716337596415542e-05
D O 0 0.00020330441475380212
segregared O 0 7.863470818847418e-05
with O 0 1.324281242887082e-06
HLA O 0 0.06885918974876404
- O 0 9.182763278658967e-06
A O 0 1.065379706233216e-06
and O 0 5.410970516095404e-07
B O 0 7.661947893211618e-05
. O 0 6.19678257862688e-06

These O 0 8.926346026782994e-07
studies O 0 6.990105703152949e-07
suggest O 0 6.638402396674792e-07
that O 0 1.5339040260187176e-08
the O 0 3.036321771787698e-08
genes O 0 1.184909450557825e-07
for O 0 5.15068343531766e-08
Factor O 0 4.553168764687143e-06
B O 0 0.0003601666248869151
and O 0 4.978768993169069e-05
C2 B-Disease 1 0.9996793270111084
deficiency I-Disease 1 0.9998231530189514
are O 0 3.12648538169924e-08
located O 0 1.2039227215154824e-07
outside O 0 4.8629519966425505e-08
those O 0 1.7174224709037844e-08
for O 0 1.1866713833796894e-07
HLA O 0 0.005568517372012138
, O 0 2.383495534274971e-08
that O 0 3.27115023956992e-09
the O 0 4.757299443269858e-09
order O 0 1.1422882195688544e-08
of O 0 1.5591862023711656e-08
genese O 0 5.029980093240738e-05
is O 0 5.91574348618451e-07
HLA O 0 0.0011926935985684395
- O 0 1.388410623803793e-06
A O 0 1.8079258268244303e-07
, O 0 5.92774398455731e-08
- O 0 1.3574115200754022e-06
B O 0 1.3292894891492324e-06
, O 0 7.784875322158769e-08
- O 0 2.2296294446277898e-06
D O 0 1.791445174603723e-05
, O 0 4.0487361019359014e-08
Factor O 0 1.0048581771116005e-06
B O 0 4.129950684728101e-05
allotype O 0 0.002254084451124072
, O 0 6.646473775617778e-05
C2 B-Disease 1 0.9993945360183716
deficiency I-Disease 1 0.9998359680175781
, O 0 8.306547982783741e-08
that O 0 1.80011792139112e-08
the O 0 5.891629584198199e-08
genes O 0 7.205313181657402e-07
coding O 0 5.5619726481381804e-05
for O 0 2.180287083319854e-05
C2 B-Disease 1 0.9995137453079224
deficiency I-Disease 1 0.9998056292533875
and O 0 1.4862181387798046e-06
Factor O 0 5.872024757991312e-06
B O 0 2.6939480449073017e-05
allotypes O 0 1.7137896065833047e-05
are O 0 1.2021485140678578e-08
approximately O 0 7.377548172371462e-08
3 O 0 4.949774847773369e-07
- O 0 8.819818617666897e-07
- O 0 2.534398788611725e-07
5 O 0 6.796554430366086e-08
centimorgans O 0 1.378440401822445e-06
from O 0 4.105503492723983e-08
the O 0 1.582719875159455e-07
HLA O 0 0.0015356591902673244
- O 0 2.1348994323489023e-06
A O 0 4.0010485236052773e-07
and O 0 4.870034331361239e-07
HLA O 0 0.015718750655651093
- O 0 1.0080341780849267e-05
B O 0 3.1258882700058166e-06
loci O 0 7.348259032369242e-07
, O 0 2.8275140451228253e-08
and O 0 9.160792124873751e-09
that O 0 7.265092527575234e-09
the O 0 3.012262439483493e-08
apparent O 0 3.2491634556208737e-06
lack O 0 3.4963025541401294e-07
of O 0 3.0121185545795015e-08
recombinants O 0 1.7713193301460706e-05
between O 0 7.955440395335245e-08
the O 0 1.221916363647324e-07
Factor O 0 1.7363685174132115e-06
B O 0 7.096808985807002e-05
gene O 0 2.967899854411371e-05
and O 0 3.1782055884832516e-05
C2 B-Disease 1 0.9996029734611511
deficiency I-Disease 1 0.9998666048049927
gene O 0 2.253076308988966e-05
suggests O 0 2.1670598471246194e-06
that O 0 2.109401719962989e-08
these O 0 5.833058036586181e-09
two O 0 7.771179255655625e-09
genes O 0 1.9051591948482383e-07
lie O 0 4.7086851395761187e-07
in O 0 2.490156703061075e-08
close O 0 1.974367904722385e-07
proximity O 0 2.2194646476236812e-07
to O 0 2.2532546495313e-08
one O 0 1.1199982452581025e-07
another O 0 2.1418329652078683e-06
. O 0 9.223364941135515e-06

Distribution O 0 7.62423405831214e-06
of O 0 3.4031486393359955e-06
emerin O 0 0.002910129725933075
and O 0 4.892033302894561e-06
lamins O 0 0.00532922986894846
in O 0 1.2423993211996276e-06
the O 0 4.726419774669921e-06
heart O 0 0.025769606232643127
and O 0 1.3439457688946277e-06
implications O 0 7.719187124166638e-05
for O 0 1.1283824278507382e-05
Emery B-Disease 0 0.3658735752105713
- I-Disease 1 0.7805213332176208
Dreifuss I-Disease 1 0.9925057291984558
muscular I-Disease 1 0.9987394213676453
dystrophy I-Disease 1 0.998598039150238
. O 0 0.0007438361644744873

Emerin O 0 0.001422242377884686
is O 0 1.3332073649507947e-06
a O 0 1.4084938584346673e-06
nuclear O 0 1.065512333298102e-05
membrane O 0 4.72003785034758e-06
protein O 0 1.2506267239587032e-06
which O 0 8.472981249951772e-08
is O 0 2.2081863448875083e-07
missing O 0 6.780422154406551e-06
or O 0 4.2731157918751705e-06
defective O 0 0.053609997034072876
in O 0 2.806551674439106e-05
Emery B-Disease 0 0.3617139458656311
- I-Disease 1 0.7364360690116882
Dreifuss I-Disease 1 0.9936380982398987
muscular I-Disease 1 0.9984924793243408
dystrophy I-Disease 1 0.9990743398666382
( O 0 0.002135327784344554
EDMD B-Disease 1 0.994215190410614
) O 0 4.578577500069514e-05
. O 0 4.666580935008824e-05

It O 0 3.985685737006861e-07
is O 0 6.710239119911421e-08
one O 0 1.2749297617631328e-08
member O 0 2.721943914707481e-08
of O 0 5.3424131785106965e-09
a O 0 2.4692383249202976e-07
family O 0 1.3709545783058275e-06
of O 0 3.070069283239718e-07
lamina O 1 0.742049515247345
- O 0 2.524272167647723e-05
associated O 0 5.024855909141479e-07
proteins O 0 1.5108814466202602e-07
which O 0 5.4949655492464444e-08
includes O 0 5.793487503069628e-07
LAP1 O 0 0.002477202331647277
, O 0 2.0367024262668565e-06
LAP2 O 0 0.0008477119263261557
and O 0 2.166289050364867e-06
lamin O 0 0.009853308089077473
B O 0 0.0009551046532578766
receptor O 0 0.0006938215810805559
( O 0 8.502531272824854e-05
LBR O 1 0.9668645858764648
) O 0 1.0376209502283018e-05
. O 0 1.7901214960147627e-05

A O 0 1.663104194449261e-05
panel O 0 1.2055019396939315e-05
of O 0 4.4734935045198654e-07
16 O 0 1.5543038898613304e-05
monoclonal O 0 0.0001599750539753586
antibodies O 0 0.00018813597853295505
( O 0 4.826001713809092e-06
mAbs O 0 0.0004903691005893052
) O 0 5.001935505788424e-07
has O 0 9.474313600321693e-08
been O 0 2.162115997350611e-08
mapped O 0 8.940653373201712e-08
to O 0 3.629836653473717e-09
six O 0 1.2959953110680544e-08
specific O 0 1.5907117401070536e-08
sites O 0 2.9109548549399733e-08
throughout O 0 3.24198978773893e-08
the O 0 9.384370969200972e-08
emerin O 0 2.1764542907476425e-05
molecule O 0 3.030570724149584e-06
using O 0 1.0675867088139057e-06
phage O 0 0.00028721315902657807
- O 0 5.1538854677346535e-06
displayed O 0 1.5008001810201677e-06
peptide O 0 5.325097845343407e-06
libraries O 0 3.3745848782018584e-07
and O 0 4.011279841620308e-08
has O 0 7.607396668163346e-08
been O 0 2.007410770943352e-08
used O 0 3.088982225563086e-08
to O 0 4.820049070985988e-08
localize O 0 6.816379755036905e-05
emerin O 0 0.0003518187440931797
in O 0 1.2948977428095532e-06
human O 0 5.092709216114599e-06
and O 0 1.0346761882829014e-05
rabbit O 0 0.33695653080940247
heart O 1 0.8869428634643555
. O 0 6.254434993024915e-05

Several O 0 1.1385747711756267e-05
mAbs O 0 0.0011130085913464427
against O 0 2.2420199456973933e-06
different O 0 6.640086667175638e-07
emerin O 0 0.003547206288203597
epitopes O 0 0.0011143507435917854
did O 0 3.957274657295784e-06
not O 0 3.0072624213062227e-07
recognize O 0 4.7928219828463625e-06
intercalated O 0 0.0005971450009383261
discs O 0 2.6436282496433705e-05
in O 0 4.0065276607492706e-07
the O 0 2.246921894766274e-06
heart O 0 0.29728665947914124
, O 0 3.2566165941716463e-07
though O 0 2.5417182314413367e-07
they O 0 2.1620911283548594e-08
recognized O 0 3.05217128016011e-07
cardiomyocyte O 0 7.936423207866028e-05
nuclei O 0 6.4606524574628565e-06
strongly O 0 6.772723395442881e-07
, O 0 3.138536541769099e-08
both O 0 1.0544187745153977e-08
at O 0 1.0150777285389267e-07
the O 0 9.661325606202809e-08
rim O 0 1.5232224541250616e-05
and O 0 9.227732533645394e-08
in O 0 3.0181229249137687e-07
intranuclear O 0 0.00020758558821398765
spots O 0 3.015046786458697e-06
or O 0 9.792795481189387e-07
channels O 0 7.296664989553392e-06
. O 0 9.58591317612445e-06

A O 0 0.0010365601629018784
polyclonal O 0 0.08365148305892944
rabbit O 0 0.02050880156457424
antiserum O 0 0.008960478939116001
against O 0 3.2750704122008756e-05
emerin O 0 0.0027346783317625523
did O 0 2.0550778572214767e-06
recognize O 0 1.4165736956783803e-06
both O 0 1.0028231400838195e-07
nuclear O 0 8.862822141963989e-06
membrane O 0 1.0914832273556385e-05
and O 0 3.442921467922133e-07
intercalated O 0 0.0002330845018150285
discs O 0 2.256826701341197e-05
but O 0 1.7814727470977232e-07
, O 0 7.227612286442309e-08
after O 0 2.8355458425721736e-07
affinity O 0 7.472517040696403e-07
purification O 0 3.360468099344871e-06
against O 0 2.005784836001112e-07
a O 0 3.4220110478599963e-07
pure O 0 3.4868967304646503e-06
- O 0 5.800807684863685e-06
emerin O 0 1.645391239435412e-05
band O 0 1.0320816272724187e-06
on O 0 7.071653840284853e-08
a O 0 2.374595595711071e-07
western O 0 1.3827562952428707e-06
blot O 0 9.578749450156465e-05
, O 0 2.3323805464769976e-07
it O 0 1.4744188092663535e-07
stained O 0 0.00019585220434237272
only O 0 3.285521543716641e-08
the O 0 2.812261357121315e-07
nuclear O 0 3.624154123826884e-05
membrane O 0 6.982194463489577e-05
. O 0 1.1693427040881943e-05

These O 0 1.3735209449805552e-06
results O 0 2.673261406016536e-06
would O 0 1.7747898084508051e-07
not O 0 3.5050387481305734e-08
be O 0 1.465650445453548e-08
expected O 0 2.0020505075990513e-07
if O 0 2.56724888458848e-07
immunostaining O 0 4.886961687589064e-05
at O 0 1.1309489309496712e-06
intercalated O 0 0.00021482525335159153
discs O 0 9.295507879869547e-06
were O 0 2.4607183846114822e-08
due O 0 1.6102586641864036e-07
to O 0 6.194684321059185e-09
a O 0 4.769421835248977e-08
product O 0 8.974446785714463e-08
of O 0 9.277991708245281e-09
the O 0 1.2556861861412472e-07
emerin O 0 0.00013489330012816936
gene O 0 1.6552863826291286e-06
and O 0 4.146211551869783e-08
, O 0 5.7456187363413846e-08
therefore O 0 5.12620097481431e-08
, O 0 2.3224982825809093e-08
cast O 0 6.77203289001227e-08
some O 0 1.39005260635372e-08
doubt O 0 4.6247191676229704e-07
upon O 0 1.6232937127824698e-07
the O 0 4.5667437120755494e-07
hypothesis O 0 6.481785385403782e-05
that O 0 2.8444006602512673e-05
cardiac B-Disease 1 0.9985113739967346
defects I-Disease 1 0.9981781244277954
in O 0 2.6280637030140497e-05
EDMD B-Disease 1 0.9966739416122437
are O 0 7.230630671983818e-07
caused O 0 0.00023549029720015824
by O 0 4.411364500356285e-07
absence O 0 4.6066547838563565e-06
of O 0 6.18415640474268e-07
emerin O 0 0.003616997739300132
from O 0 1.785501081030816e-05
intercalated O 0 0.015815600752830505
discs O 0 0.0012760307872667909
. O 0 2.9003063900745474e-05

Although O 0 3.830377681879327e-05
emerin O 0 0.0006189873092807829
was O 0 2.3753912046231562e-06
abundant O 0 6.77702018947457e-07
in O 0 4.718975077366849e-08
the O 0 9.192475403096978e-08
membranes O 0 1.6209497744057444e-06
of O 0 6.114311901228575e-08
cardiomyocyte O 0 0.0001866750098997727
nuclei O 0 5.454842266772175e-06
, O 0 8.572531129402705e-08
it O 0 4.7476660824941064e-08
was O 0 4.3382121361901227e-07
absent O 0 1.5213016695270198e-06
from O 0 9.46616793839894e-08
many O 0 1.0889612411801863e-07
non O 0 4.498195721680531e-06
- O 0 0.00011847981659229845
myocyte O 0 0.0051196059212088585
cells O 0 7.0745800258009695e-06
in O 0 4.703752551904472e-07
the O 0 4.165953214396723e-06
heart O 0 0.17327405512332916
. O 0 2.278078318340704e-05

This O 0 2.0943885203905666e-07
distribution O 0 4.5569899498332234e-07
of O 0 4.318687274462718e-07
emerin O 0 0.0005017368821427226
was O 0 1.3502252613761812e-06
similar O 0 1.3232622109171643e-07
to O 0 7.0444441391259716e-09
that O 0 6.232347526946569e-09
of O 0 1.5053464252900994e-08
lamin O 0 9.593879076419398e-05
A O 0 2.947253108231962e-07
, O 0 2.657855802112863e-08
a O 0 8.64355769181202e-08
candidate O 0 1.0897258562181378e-07
gene O 0 3.4199490528408205e-07
for O 0 3.714641749752445e-08
an O 0 5.36095342340559e-07
autosomal O 0 0.004282844252884388
form O 0 1.0465230843692552e-05
of O 0 1.2098900697310455e-05
EDMD B-Disease 1 0.9917687177658081
. O 0 0.00015126173093449324

In O 0 2.1712217858294025e-05
contrast O 0 0.00014275572902988642
, O 0 4.270965655450709e-05
lamin O 1 0.6036327481269836
B1 O 1 0.9901673793792725
was O 0 2.1809608369949274e-05
absent O 0 3.276651113992557e-05
from O 0 1.5267403341567842e-06
cardiomyocyte O 0 0.00022148290008772165
nuclei O 0 2.1386334992712364e-05
, O 0 1.1121470606667572e-06
showing O 0 6.491446129075484e-06
that O 0 1.8020541574514937e-06
lamin O 0 0.14563629031181335
B1 O 1 0.972139835357666
is O 0 9.101510300979498e-08
not O 0 6.846174294139473e-09
essential O 0 2.9464876760698644e-08
for O 0 1.1521149367865746e-08
localization O 0 7.995224109436094e-07
of O 0 6.04454228891882e-08
emerin O 0 7.360601011896506e-05
to O 0 9.88666499779356e-08
the O 0 1.8174612250732025e-06
nuclear O 0 0.0002226781944045797
lamina O 0 0.08044823259115219
. O 0 4.012080898974091e-05

Lamin O 1 0.9509207010269165
B1 O 1 0.9902966618537903
is O 0 3.7278123272699304e-06
also O 0 1.2404019571476965e-06
almost O 0 2.148264684365131e-06
completely O 0 3.62361861334648e-05
absent O 0 0.00018493949028197676
from O 0 3.1311243219533935e-05
skeletal O 1 0.9920588731765747
muscle O 1 0.8707528114318848
nuclei O 0 0.0021770140156149864
. O 0 0.00011519319377839565

In O 0 1.9746363250305876e-05
EDMD B-Disease 0 0.052437249571084976
, O 0 2.7644875899568433e-07
the O 0 8.868234147030307e-08
additional O 0 3.6466460073825147e-07
absence O 0 7.329884283535648e-06
of O 0 1.522430807199271e-06
lamin O 1 0.9728705883026123
B1 O 1 0.9967116117477417
from O 0 7.236763485707343e-05
heart O 1 0.9333620071411133
and O 0 1.8120224922313355e-05
skeletal O 1 0.9956589937210083
muscle O 0 0.32868343591690063
nuclei O 0 0.00014656160783488303
which O 0 2.629277560117771e-06
already O 0 2.3666632841923274e-05
lack O 0 3.7114823498995975e-05
emerin O 0 0.0013295465614646673
may O 0 1.493119611950533e-06
offer O 0 1.3058291870038374e-07
an O 0 4.194838254534261e-08
alternative O 0 2.515678545478295e-07
explanation O 0 3.8261231338765356e-07
of O 0 4.024690980486412e-08
why O 0 1.9577123566705268e-06
these O 0 3.2558213547417836e-07
tissues O 0 0.00018555522547103465
are O 0 2.5877048415168247e-07
particularly O 0 1.4320000445877668e-05
affected O 0 3.6016830563312396e-05
. O 0 3.1212057365337387e-06
. O 0 1.7222932001459412e-05

Genetic O 0 4.909335621050559e-05
mapping O 0 5.517615591088543e-06
of O 0 4.2127990695917106e-07
the O 0 5.973990027996479e-06
copper B-Disease 0 0.11448953300714493
toxicosis I-Disease 1 0.9564871788024902
locus O 0 5.964666706859134e-05
in O 0 4.617386821337277e-06
Bedlington O 0 0.005818056408315897
terriers O 0 0.00015232569421641529
to O 0 3.8009994796084356e-07
dog O 0 3.58331308234483e-05
chromosome O 0 3.7265610899339663e-06
10 O 0 1.2062923815392423e-07
, O 0 2.795494857821268e-08
in O 0 3.065481379849189e-08
a O 0 2.4178604007829563e-07
region O 0 6.479994567598624e-07
syntenic O 0 3.558112075552344e-05
to O 0 1.0999728772276285e-07
human O 0 2.2375088519765995e-06
chromosome O 0 7.610509055666625e-05
region O 0 1.5027613699203357e-05
2p13 O 0 0.0016638949746266007
- O 0 0.0002994860988110304
p16 O 0 0.0010161646641790867
. O 0 2.9513996196328662e-05

Abnormal O 1 0.9809207916259766
hepatic B-Disease 1 0.9950127005577087
copper I-Disease 1 0.8669788241386414
accumulation I-Disease 0 0.05318361148238182
is O 0 2.273390236950945e-06
recognized O 0 2.7760670491261408e-06
as O 0 2.5508832095511025e-06
an O 0 0.0001819124590838328
inherited B-Disease 1 0.9996140599250793
disorder I-Disease 1 0.9998589754104614
in O 0 6.053275228623534e-06
man O 0 0.00018075642583426088
, O 0 2.4509552076779073e-06
mouse O 0 0.00015725442790426314
, O 0 2.8902995836688206e-06
rat O 0 0.0036400435492396355
and O 0 2.0723043689940823e-06
dog O 0 0.0017762171337381005
. O 0 2.4322080207639374e-05

The O 0 1.43336628752877e-05
major O 0 4.975750562152825e-05
cause O 0 0.00029444292886182666
of O 0 7.63805383030558e-06
hepatic B-Disease 1 0.9982137680053711
copper I-Disease 1 0.7396726012229919
accumulation I-Disease 0 0.005564473569393158
in O 0 2.044246684818063e-06
man O 0 1.5795149010955356e-05
is O 0 5.611119036075252e-07
a O 0 3.7594509194605052e-06
dysfunctional O 0 0.006409442517906427
ATP7B O 0 0.044764719903469086
gene O 0 0.00022712044301442802
, O 0 3.6261419154470786e-05
causing O 1 0.7556647062301636
Wilson B-Disease 1 0.8440237641334534
disease I-Disease 1 0.9989107847213745
( O 0 0.000345224398188293
WD B-Disease 1 0.9893400073051453
) O 0 2.7348916773917153e-05
. O 0 4.249919584253803e-05

Mutations O 0 4.976723721483722e-05
in O 0 7.489539939342649e-07
the O 0 1.8416667444398627e-06
ATP7B O 0 0.0013134654145687819
genes O 0 8.7074431576184e-07
have O 0 4.5138495607943696e-08
also O 0 5.406132785878981e-08
been O 0 1.2727787179755978e-07
demonstrated O 0 1.6068224795162678e-06
in O 0 3.681420821521897e-07
mouse O 0 8.329173579113558e-05
and O 0 2.457300297464826e-06
rat O 0 0.006679631769657135
. O 0 2.33111950365128e-05

The O 0 2.8378899514791556e-05
ATP7B O 0 0.012427120469510555
gene O 0 2.7726307962439023e-05
has O 0 1.1194231319677783e-06
been O 0 3.2713211339796544e-07
excluded O 0 1.4667782579635968e-06
in O 0 1.0133540229162463e-07
the O 0 3.3205878935405053e-07
much O 0 3.942609964724397e-06
rarer O 0 0.004456758964806795
human O 0 0.00035206618485972285
copper B-Disease 1 0.9973397850990295
overload I-Disease 1 0.9994235038757324
disease O 1 0.9991637468338013
non B-Disease 0 0.0003461753949522972
- I-Disease 0 0.0006599550251848996
Indian I-Disease 0 8.838673238642514e-05
childhood I-Disease 1 0.7558491826057434
cirrhosis I-Disease 1 0.999116837978363
, O 0 1.612179767107591e-05
indicating O 0 0.0007693736115470529
genetic O 0 0.0014052470214664936
heterogeneity O 0 0.0031293598003685474
. O 0 0.00012452909140847623

By O 0 6.231105999177089e-06
investigating O 0 5.4938860557740554e-05
the O 0 7.935971552797128e-06
common O 0 0.000293490884359926
autosomal O 1 0.9932136535644531
recessive O 1 0.9965208768844604
copper B-Disease 1 0.9970224499702454
toxicosis I-Disease 1 0.998187243938446
( O 0 0.00023443871759809554
CT B-Disease 0 0.40528976917266846
) O 0 1.1678008604576462e-06
in O 0 1.205849002872128e-06
Bedlington O 0 0.0023585911840200424
terriers O 0 7.826954242773354e-05
, O 0 4.9857142414566624e-08
we O 0 1.4504689005434557e-08
have O 0 5.785545820202742e-09
identified O 0 4.5431391981765046e-08
a O 0 4.143563714364973e-08
new O 0 1.3164749645966367e-07
locus O 0 1.149704257841222e-05
involved O 0 7.0798505475977436e-06
in O 0 0.00011012294999090955
progressive O 1 0.9972466230392456
liver B-Disease 1 0.9999207258224487
disease I-Disease 1 0.9997603297233582
. O 0 0.0010578513611108065

We O 0 3.5734547054744326e-06
examined O 0 2.4607134037069045e-05
whether O 0 1.103865997720277e-06
the O 0 1.9899378003174206e-06
WD B-Disease 0 0.1893930286169052
gene O 0 2.4222872525569983e-05
ATP7B O 0 0.002841497305780649
was O 0 3.078077725149342e-06
also O 0 3.3212526773240825e-07
causative O 0 1.693952981440816e-05
for O 0 2.7875276487066003e-07
CT B-Disease 0 0.003074568696320057
by O 0 5.928704922553152e-07
investigating O 0 4.752912445837865e-06
the O 0 9.69913571680081e-07
chromosomal O 0 0.0006522854091599584
co O 0 8.350471034646034e-05
- O 0 3.729021273102262e-06
localization O 0 3.7790380247315625e-06
of O 0 1.0933108995914154e-07
ATP7B O 0 0.0005634645349346101
and O 0 1.878042326097784e-07
C04107 O 0 1.2362448615022004e-05
, O 0 4.648340024004938e-08
using O 0 6.3520971593789e-08
fluorescence O 0 2.7455387225927552e-06
in O 0 2.882696890083025e-07
situ O 0 4.3112155253766105e-05
hybridization O 0 9.364589459437411e-06
( O 0 2.706522082007723e-06
FISH O 0 1.5176879060163628e-05
) O 0 3.0179237455740804e-06
. O 0 7.950205144879874e-06

C04107 O 0 0.0005157997948117554
is O 0 1.9225124106014846e-06
an O 0 1.128320263887872e-06
anonymous O 0 2.2559037461178377e-05
microsatellite O 0 0.0012633961159735918
marker O 0 0.00016328149649780244
closely O 0 1.702050940366462e-05
linked O 0 0.0003430460928939283
to O 0 8.406597771681845e-06
CT B-Disease 1 0.8895233273506165
. O 0 4.563625407172367e-05

However O 0 3.062201722059399e-05
, O 0 1.663061266299337e-05
BAC O 0 0.0028138633351773024
clones O 0 0.000149823390529491
containing O 0 1.0881523849093355e-05
ATP7B O 0 0.0018801008118316531
and O 0 4.1345327872477355e-07
C04107 O 0 3.370043486938812e-05
mapped O 0 1.3737029576077475e-06
to O 0 7.662998058322046e-08
the O 0 8.744124784243468e-07
canine O 0 0.0007420830079354346
chromosome O 0 3.6555986298481e-05
regions O 0 1.627905476198066e-06
CFA22q11 O 0 0.0003976874868385494
and O 0 6.903425742166291e-07
CFA10q26 O 0 0.00038128497544676065
, O 0 2.596970887225325e-07
respectively O 0 8.534841526852688e-07
, O 0 1.451576565614232e-07
demonstrating O 0 2.635116516103153e-06
that O 0 9.46064119489165e-07
WD B-Disease 0 0.13371214270591736
cannot O 0 6.918689905432984e-07
be O 0 9.811054724195856e-08
homologous O 0 1.7120253687608056e-05
to O 0 4.403552338771988e-06
CT B-Disease 0 0.4089406430721283
. O 0 2.4743188987486064e-05

The O 0 2.3846314434194937e-05
copper O 0 0.006028271280229092
transport O 0 0.000218031374970451
genes O 0 2.4929973733378574e-05
CTR1 O 0 0.004297602456063032
and O 0 1.4031230648470228e-06
CTR2 O 0 0.0015062333550304174
were O 0 1.987808389003476e-07
also O 0 8.766053127828854e-08
excluded O 0 5.824644517815614e-07
as O 0 3.697732964269562e-08
candidate O 0 2.0448655391192005e-07
genes O 0 4.7583819196006516e-07
for O 0 2.8891454917356896e-07
CT B-Disease 0 0.03755875304341316
since O 0 2.589494556559657e-07
they O 0 7.592666051436936e-09
both O 0 1.9454153843412314e-08
mapped O 0 2.0242957816662965e-06
to O 0 6.072855285310652e-07
canine O 0 0.003568862099200487
chromosome O 0 0.00028940054471604526
region O 0 5.3611489420291036e-05
CFA11q22 O 0 0.011553192511200905
. O 0 7.079882925609127e-05

2 O 0 0.00019897340098395944
- O 0 0.00022133892343845218
22 O 0 2.7409332687966526e-05
. O 0 2.5494226065347902e-05

5 O 0 0.000849375850521028
. O 0 0.0003103346098214388

A O 0 5.055159817857202e-06
transcribed O 0 6.374432359734783e-06
sequence O 0 1.0452666856508586e-06
identified O 0 1.0533633485465543e-06
from O 0 1.2212547062517842e-07
the O 0 3.677771474031033e-07
C04107 O 0 5.5566924856975675e-05
- O 0 2.752176214926294e-06
containing O 0 9.446018793823896e-07
BAC O 0 0.00022331136278808117
was O 0 3.2277313266604324e-07
found O 0 4.6578360723970036e-08
to O 0 2.735923265717588e-09
be O 0 3.5582035096126674e-09
homologous O 0 1.1602947580513501e-07
to O 0 1.1247309750217482e-08
a O 0 1.3779342111774895e-07
gene O 0 5.381770051826607e-07
expressed O 0 1.7952426389911125e-07
from O 0 2.23098766127805e-07
human O 0 1.4441633311434998e-06
chromosome O 0 5.307355968398042e-05
2p13 O 0 0.0003337725647725165
- O 0 1.7696951545076445e-05
p16 O 0 1.7219957953784615e-05
, O 0 6.242677130785523e-08
a O 0 1.6305175165598484e-07
region O 0 2.1381950432441954e-07
devoid O 0 6.9829627591389e-07
of O 0 1.811681116237196e-08
any O 0 1.0270979799997804e-07
positional O 0 1.1136563443869818e-05
candidate O 0 6.935179499123478e-06
genes O 0 2.5274181098211557e-05
. O 0 2.0244875486241654e-05

Molecular O 0 6.6343732214591e-06
analysis O 0 2.6173913170168817e-07
of O 0 5.2179721876655094e-08
the O 0 5.46896615105652e-07
APC B-Disease 0 0.00013866668450646102
gene O 0 1.5118860119400779e-06
in O 0 1.0192702148970056e-07
205 O 0 2.3656700705032563e-06
families O 0 2.711369120333984e-07
: O 0 2.3739140431189298e-07
extended O 0 2.6295183488400653e-06
genotype O 0 0.00010365129128331318
- O 0 2.9514894777094014e-05
phenotype O 0 4.350865492597222e-05
correlations O 0 8.722672646399587e-06
in O 0 8.40925508782675e-07
FAP B-Disease 0 0.01608635112643242
and O 0 4.206439641052384e-08
evidence O 0 7.630720944007408e-08
for O 0 6.324495149812037e-09
the O 0 1.581635800107506e-08
role O 0 5.448430329124676e-08
of O 0 4.0038880655401954e-08
APC B-Disease 0 0.00010352209937991574
amino O 0 6.89013995724963e-06
acid O 0 0.0016966760158538818
changes O 0 0.00018686288967728615
in O 0 0.009271626360714436
colorectal B-Disease 1 0.9999572038650513
cancer I-Disease 1 0.9998748302459717
predisposition O 1 0.993251383304596
. O 0 0.00034130687708966434

BACKGROUND O 0 0.0003551053232513368
/ O 0 0.00023739748576190323
AIMS O 0 1.2543745469884016e-05
The O 0 8.253655323642306e-07
development O 0 9.529182534606662e-06
of O 0 0.00014638967695645988
colorectal B-Disease 1 0.9999535083770752
cancer I-Disease 1 0.9995040893554688
and O 0 1.769832351783407e-07
a O 0 3.939912289752101e-07
variable O 0 1.0507376373425359e-06
range O 0 8.026157161111769e-07
of O 0 5.480384857037279e-07
extracolonic O 0 0.026945438235998154
manifestations O 0 0.001864684745669365
in O 0 0.00019977941701654345
familial B-Disease 1 0.9992719292640686
adenomatous I-Disease 1 0.9996895790100098
polyposis I-Disease 1 0.9997289776802063
( O 0 0.0011673031840473413
FAP B-Disease 1 0.8458672165870667
) O 0 6.367023388520465e-07
is O 0 7.704003479602761e-08
the O 0 4.8581686229454135e-08
result O 0 9.514661059029095e-08
of O 0 1.0784645176897811e-08
the O 0 1.992614215851063e-07
dominant O 0 1.5229915334202815e-05
inheritance O 0 0.00045429772580973804
of O 0 0.00011882671242346987
adenomatous B-Disease 1 0.9993849992752075
polyposis I-Disease 1 0.9992614388465881
coli I-Disease 1 0.9978494644165039
( O 0 0.00014343495422508568
APC B-Disease 0 0.007203591987490654
) O 0 9.176985258818604e-06
gene O 0 0.00011965697194682434
mutations O 0 0.0001811439433367923
. O 0 2.2590122171095572e-05

In O 0 5.131267926117289e-07
this O 0 7.740280238976993e-08
study O 0 1.3900266537802963e-07
, O 0 1.7534180329903393e-08
direct O 0 2.3021136996703717e-08
mutation O 0 2.2893131301771064e-07
analysis O 0 1.6590613327593928e-08
of O 0 1.144676442521586e-08
the O 0 3.679658675537212e-07
APC B-Disease 0 0.00017747364472597837
gene O 0 2.2651493054581806e-06
was O 0 3.201788558726548e-07
performed O 0 1.6197353147617832e-07
to O 0 2.5876696341242678e-08
determine O 0 4.477091124499566e-07
genotype O 0 4.1359566239407286e-05
- O 0 7.887652827776037e-06
phenotype O 0 6.690917416563025e-06
correlations O 0 8.91441061412479e-07
for O 0 7.488912245889878e-08
nine O 0 1.8379645325694582e-06
extracolonic O 0 0.0009873920353129506
manifestations O 0 9.48752676777076e-06
and O 0 4.544387266491867e-08
to O 0 3.18682431554862e-08
investigate O 0 7.668728585485951e-07
the O 0 2.8295164611336077e-07
incidence O 0 0.0002122488949680701
of O 0 4.6284080212899426e-07
APC B-Disease 0 0.002435204340144992
mutations O 0 7.093729800544679e-05
in O 0 8.081927262537647e-06
non O 0 0.0012118857121095061
- O 1 0.8938748836517334
FAP O 1 0.9966480135917664
colorectal B-Disease 1 0.9999221563339233
cancer I-Disease 1 0.9996077418327332
. O 0 0.0003783647553063929

METHODS O 0 1.4527120583807118e-05
The O 0 7.698428817093372e-06
APC B-Disease 0 0.000629532674793154
gene O 0 7.585664206999354e-06
was O 0 2.0133561520196963e-06
analysed O 0 4.8977653932524845e-06
in O 0 5.464081596073811e-07
190 O 0 1.1215925042051822e-05
unrelated O 0 0.00014062997070141137
FAP B-Disease 0 0.01735331304371357
and O 0 1.351813921246503e-06
15 O 0 2.9167154934839346e-05
non O 0 0.0008614791440777481
- O 1 0.8214107751846313
FAP O 1 0.9979967474937439
colorectal B-Disease 1 0.9999507665634155
cancer I-Disease 1 0.9998575448989868
patients O 0 0.06405697017908096
using O 0 3.120131168543594e-06
denaturing O 0 0.008051039651036263
gradient O 0 0.0004933368763886392
gel O 0 0.0013694844674319029
electrophoresis O 0 4.53191896667704e-05
, O 0 1.446151856043798e-07
the O 0 6.450184031336903e-08
protein O 0 1.3590448588729487e-06
truncation O 0 1.471622999815736e-05
test O 0 6.127014557932853e-07
, O 0 3.9048913436090515e-08
and O 0 1.8084254094219432e-08
direct O 0 3.018244001395942e-07
sequencing O 0 1.0656048289092723e-05
. O 0 1.1136648026877083e-05

RESULTS O 0 0.00016226861043833196
Chain O 0 0.0001103282265830785
terminating O 0 8.303083450300619e-05
signals O 0 2.3796517325536115e-06
were O 0 1.0232889025019176e-07
only O 0 6.817197117925389e-08
identified O 0 1.0718734984038747e-06
in O 0 4.377293691959494e-07
patients O 0 0.00015199721383396536
belonging O 0 7.939279385027476e-07
to O 0 6.356811610430668e-08
the O 0 8.885993452167895e-07
FAP B-Disease 0 0.01729964092373848
group O 0 1.3974209878142574e-06
( O 0 2.398166770944954e-06
105 O 0 2.442097320454195e-05
patients O 0 0.0012383866123855114
) O 0 5.348265403881669e-06
. O 0 1.0375992133049294e-05

Amino O 0 5.7419394579483196e-05
acid O 0 0.00044872023863717914
changes O 0 2.747062808339251e-06
were O 0 1.87711492571907e-07
identified O 0 1.2118241556891007e-06
in O 0 1.4108880463936657e-07
four O 0 4.22488540152699e-07
patients O 0 0.00014224578626453876
, O 0 1.3929693842840152e-08
three O 0 7.800403878377438e-09
of O 0 1.5925545326922474e-08
whom O 0 5.128401312504138e-07
belonged O 0 9.272533816329087e-07
to O 0 3.431526707231569e-08
the O 0 2.3881628408162214e-07
non O 0 8.53753044793848e-06
- O 0 0.0001631826744414866
FAP O 0 0.011751342564821243
group O 0 1.3351590496313293e-05
of O 0 0.0005446491413749754
colorectal B-Disease 1 0.9999479055404663
cancer I-Disease 1 0.9999139308929443
patients O 1 0.9961138963699341
. O 0 0.00042576866690069437

Genotype O 0 0.007219470106065273
- O 0 0.0008487270679324865
phenotype O 0 0.0004731195222120732
correlations O 0 3.784148066188209e-05
identified O 0 5.515153588930843e-06
significant O 0 7.698324679950019e-07
differences O 0 1.4399194014913519e-06
in O 0 8.789860572733232e-08
the O 0 7.524879919174055e-08
nature O 0 2.7994494189442776e-07
of O 0 6.995187362690558e-08
certain O 0 1.5274335964932106e-06
extracolonic O 0 0.019294487312436104
manifestations O 0 0.003558345604687929
in O 0 5.830304871778935e-05
FAP B-Disease 1 0.9963681697845459
patients O 0 0.006701688282191753
belonging O 0 2.216174380009761e-06
to O 0 6.787693251908422e-08
three O 0 4.4076892891098396e-07
mutation O 0 5.843569670105353e-05
subgroups O 0 5.2674015023512766e-05
. O 0 2.3498976588598453e-05

CONCLUSIONS O 0 8.998798875836655e-05
Extended O 0 4.183247801847756e-05
genotype O 0 0.0011375064495950937
- O 0 0.00011451710452092811
phenotype O 0 4.013282523374073e-05
correlations O 0 3.0658084142487496e-06
made O 0 1.8546019475706998e-07
in O 0 4.447023016496132e-08
this O 0 4.386813401424661e-08
study O 0 5.523305048882321e-07
may O 0 2.768592821666971e-07
have O 0 3.968993578240543e-09
the O 0 6.1062102041375965e-09
potential O 0 1.6118557155664348e-08
to O 0 2.3950512684223213e-09
determine O 0 1.1417568224203478e-08
the O 0 8.037062571020215e-09
most O 0 1.845229924413161e-08
appropriate O 0 1.5532354780134483e-07
surveillance O 0 5.285754923534114e-06
and O 0 9.184105351778271e-07
prophylactic O 0 0.06996658444404602
treatment O 0 0.1377801150083542
regimens O 0 0.009094486013054848
for O 0 6.238273044800735e-07
those O 0 1.1737407703549252e-06
patients O 0 0.0023864873219281435
with O 0 1.7706979633658193e-06
mutations O 0 0.00011250036914134398
associated O 0 2.5336150429211557e-05
with O 0 9.868454981187824e-06
life O 0 0.00034208837314508855
threatening O 1 0.645876944065094
conditions O 0 0.012638323940336704
. O 0 0.00012341600086074322

This O 0 1.7608216467124294e-06
study O 0 2.2730130240233848e-06
also O 0 1.983789701398564e-07
provided O 0 2.0978386316983233e-07
evidence O 0 2.401599203949445e-07
for O 0 2.9711156201983613e-08
the O 0 1.270347382842374e-07
pathological O 0 0.0001061438670149073
nature O 0 2.8751824743267207e-07
of O 0 1.8562397841037637e-08
amino O 0 1.6866803207449266e-06
acid O 0 6.614134326810017e-05
changes O 0 1.5325374533858849e-06
in O 0 6.906323051225627e-07
APC O 0 0.0002984901366289705
associated O 0 1.9143635654472746e-06
with O 0 2.630004871662095e-07
both O 0 2.1402647689683363e-06
FAP B-Disease 0 0.23039159178733826
and O 0 1.2540037459984887e-05
non O 0 0.0038782597985118628
- O 1 0.9851014614105225
FAP O 1 0.9980601668357849
colorectal B-Disease 1 0.9999700784683228
cancer I-Disease 1 0.9999278783798218
patients O 1 0.9956152439117432
. O 0 4.3147279939148575e-05
. O 0 6.300108361756429e-05

Inherited B-Disease 1 0.9974086880683899
colorectal I-Disease 1 0.9998205304145813
polyposis I-Disease 1 0.9991649389266968
and O 0 0.01242715585976839
cancer B-Disease 1 0.9992807507514954
risk O 0 0.0002124774910043925
of O 0 2.70911243660521e-07
the O 0 5.305465492710937e-06
APC O 0 0.0074366494081914425
I1307K O 0 0.0008101426647044718
polymorphism O 0 0.00016779554425738752
. O 0 2.945776031992864e-05

Germ O 0 0.3734828531742096
- O 0 5.510204209713265e-05
line O 0 2.4359580947930226e-06
and O 0 1.981097454972769e-07
somatic O 0 1.1748779797926545e-05
truncating O 0 3.683496106532402e-05
mutations O 0 1.32895479509898e-06
of O 0 7.021575498811217e-08
the O 0 1.0260323506372515e-06
APC B-Disease 0 0.0004647403839044273
gene O 0 1.9680694549606415e-06
are O 0 3.5209794191359833e-08
thought O 0 1.119472244681674e-06
to O 0 1.1210406682948815e-06
initiate O 0 0.0014021978713572025
colorectal B-Disease 1 0.9996721744537354
tumor I-Disease 1 0.9986957907676697
formation O 0 0.20223332941532135
in O 0 0.0037244167178869247
familial B-Disease 1 0.9996116757392883
adenomatous I-Disease 1 0.9998144507408142
polyposis I-Disease 1 0.9999483823776245
syndrome I-Disease 1 0.9999221563339233
and O 0 0.0016602021642029285
sporadic O 1 0.986809492111206
colorectal O 1 0.9998288154602051
carcinogenesis O 1 0.9963416457176208
, O 0 2.3807706384104677e-05
respectively O 0 9.70435721683316e-05
. O 0 7.538602949352935e-05

Recently O 0 7.865046063670889e-05
, O 0 1.9294793673907407e-06
an O 0 3.170457148371497e-06
isoleucine O 0 0.002091378904879093
- O 0 0.00014059456589166075
- O 0 1.8864207959268242e-05
> O 0 1.9801900634774938e-05
lysine O 0 2.138796480721794e-05
polymorphism O 0 2.226750211775652e-06
at O 0 1.0230659199805814e-06
codon O 0 1.5021138096926734e-05
1307 O 0 0.00015857194375712425
( O 0 1.1515830919961445e-06
I1307K O 0 8.330048331117723e-06
) O 0 6.041533850975611e-08
of O 0 2.0355644281266905e-08
the O 0 2.2778253594424314e-07
APC B-Disease 0 0.0001350532693322748
gene O 0 1.9021106254513143e-06
has O 0 1.277737027294279e-07
been O 0 3.516831625915984e-08
identified O 0 5.918276713146042e-08
in O 0 1.1363015417487077e-08
6 O 0 1.1266509147844772e-07
% O 0 5.728570329210925e-08
- O 0 2.6033933409053134e-07
7 O 0 2.926369546685237e-08
% O 0 1.262566318160907e-08
of O 0 5.9537912378004876e-09
the O 0 2.394509692749125e-07
Ashkenazi O 0 2.510650119802449e-05
Jewish O 0 1.2171437901997706e-06
population O 0 1.0047106115962379e-06
. O 0 5.724988113797735e-06

To O 0 1.5581492789351614e-06
assess O 0 1.004368550638901e-05
the O 0 7.740810019640776e-07
risk O 0 7.143746188376099e-06
of O 0 3.6046007068080144e-08
this O 0 3.294828445632447e-07
common O 0 1.0582281902316026e-05
APC B-Disease 0 0.012657188810408115
allelic O 0 0.006961494218558073
variant O 0 0.28623199462890625
in O 0 0.0005610922817140818
colorectal O 1 0.9998273253440857
carcinogenesis O 1 0.9868987798690796
, O 0 5.142692884874123e-07
we O 0 3.1718883519715746e-08
have O 0 8.178465016328573e-09
analyzed O 0 1.2905024959763978e-07
a O 0 9.112922327858541e-08
large O 0 2.2670630528409674e-07
cohort O 0 8.902116860554088e-06
of O 0 2.2885468808908627e-07
unselected O 0 0.0027606491930782795
Ashkenazi O 0 0.00014223290781956166
Jewish O 0 3.327925014673383e-06
subjects O 0 8.334609447047114e-06
with O 0 4.5431086618918926e-05
adenomatous B-Disease 1 0.9976325035095215
polyps I-Disease 1 0.9941359758377075
and O 0 1.240723577211611e-05
. O 0 4.102292950847186e-05
or O 0 0.11599389463663101
colorectal B-Disease 1 0.9999802112579346
cancer I-Disease 1 0.9997867941856384
, I-Disease 0 4.3639059299493965e-07
for O 0 1.2535421944903646e-07
the O 0 1.6366960835512145e-06
APC O 0 0.0015182362403720617
I1307K O 0 0.0006291538593359292
polymorphism O 0 0.00014687962539028376
. O 0 2.951498026959598e-05

The O 0 2.1624251530738547e-05
APC O 0 0.0018931175582110882
I1307K O 0 0.00032191589707508683
allele O 0 3.225262480555102e-05
was O 0 2.0985460196243366e-06
identified O 0 7.413390221699956e-07
in O 0 5.3845841563315844e-08
48 O 0 3.664775078959792e-07
( O 0 5.717272699712339e-08
10 O 0 1.0693619323376424e-08
. O 0 4.894681548961444e-09
1 O 0 4.0337518214528245e-08
% O 0 4.851686341567074e-08
) O 0 8.340601453937779e-08
of O 0 6.041822757651971e-07
476 O 0 0.012562747113406658
patients O 0 0.06675372272729874
. O 0 3.910786108463071e-05

Compared O 0 9.80644290393684e-06
with O 0 1.2856318676313094e-07
the O 0 4.9990450889936255e-08
frequency O 0 7.149896674718548e-08
in O 0 9.264375044892859e-09
two O 0 5.188721452498157e-09
separate O 0 4.2547579681695424e-08
population O 0 1.721466347248679e-08
control O 0 9.536645961816248e-08
groups O 0 1.5348872395293256e-08
, O 0 2.002011711965679e-08
the O 0 1.0686670748327742e-07
APC O 0 0.00020382362708915025
I1307K O 0 2.295820195286069e-05
allele O 0 1.7336831206193892e-06
is O 0 7.800139201208367e-08
associated O 0 1.8433343029755633e-07
with O 0 2.441876212344596e-08
an O 0 1.1869701666000765e-07
estimated O 0 1.0077257002194528e-06
relative O 0 3.5021300845983205e-06
risk O 0 1.4313828614831436e-05
of O 0 2.5116895585597376e-07
1 O 0 7.99913686932996e-06
. O 0 1.1776890460168943e-05

5 O 0 0.00010759551514638588
- O 0 0.00016842567129060626
1 O 0 1.549824810354039e-05
. O 0 1.2816664821002632e-05

7 O 0 0.00017279645544476807
for O 0 0.00011331019049976021
colorectal B-Disease 1 0.9991546869277954
neoplasia I-Disease 1 0.9931821227073669
( O 0 5.1035849537584e-06
both O 0 1.1185352377651725e-06
P O 0 0.0018345359712839127
= O 0 0.00010658516839612275
. O 0 2.353249328734819e-06
01 O 0 0.000800649868324399
) O 0 2.6858724595513195e-06
. O 0 6.351385763991857e-06

Furthermore O 0 4.589164745993912e-05
, O 0 1.8373195871390635e-06
compared O 0 5.150342985871248e-06
with O 0 1.5030963140816311e-06
noncarriers O 0 0.0021376600489020348
, O 0 4.262135007593315e-06
APC O 0 0.001707771560177207
I1307K O 0 0.00035816404852084816
carriers O 0 2.7658039471134543e-05
had O 0 6.340997060760856e-07
increased O 0 7.093415774761525e-07
numbers O 0 2.2836110247226316e-07
of O 0 3.906218069005263e-07
adenomas B-Disease 1 0.9829949736595154
and O 0 0.0002106569882016629
colorectal B-Disease 1 0.999823272228241
cancers I-Disease 1 0.9980908036231995
per O 0 6.3810066421865486e-06
patient O 0 0.001115436665713787
( O 0 5.027995030104648e-06
P O 0 0.0005344897508621216
= O 0 2.1128736989339814e-05
. O 0 3.0281213980742905e-07
03 O 0 4.374917989480309e-05
) O 0 7.609486374349217e-08
, O 0 8.696934727936423e-09
as O 0 5.293240512571629e-09
well O 0 5.8785047940546065e-09
as O 0 9.509777854077583e-09
a O 0 2.5069033426916576e-07
younger O 0 6.477204351540422e-06
age O 0 2.325397690583486e-05
at O 0 4.716905823443085e-05
diagnosis O 1 0.9317851066589355
. O 0 6.554965511895716e-05

We O 0 2.1354674117901595e-06
conclude O 0 9.553734344081022e-06
that O 0 2.1880390477235778e-07
the O 0 1.0738083346950589e-06
APC O 0 0.000687453371938318
I1307K O 0 0.0003851514193229377
variant O 0 0.000379660603357479
leads O 0 1.7035628843586892e-05
to O 0 1.1382926459191367e-06
increased O 0 0.00017786263197194785
adenoma B-Disease 1 0.9981932044029236
formation O 0 5.4919844842515886e-05
and O 0 8.314536614761892e-08
directly O 0 1.5212306436751533e-07
contributes O 0 5.693483444701997e-07
to O 0 9.355398233878987e-09
3 O 0 4.8079474623818896e-08
% O 0 6.52841976034324e-08
- O 0 1.6258344714970008e-07
4 O 0 2.0253905219647095e-08
% O 0 1.2165139118280877e-08
of O 0 1.1249648323996553e-08
all O 0 2.0767288333445322e-07
Ashkenazi O 0 0.0028992772568017244
Jewish O 0 0.008338436484336853
colorectal B-Disease 1 0.9999300241470337
cancer I-Disease 1 0.9995689988136292
. O 0 0.0002809712605085224

The O 0 5.314240752340993e-06
estimated O 0 1.9054687072639354e-05
relative O 0 5.040823089075275e-05
risk O 0 0.000305009976727888
for O 0 1.5407175624204683e-06
carriers O 0 0.0002746473182924092
may O 0 4.41522934124805e-06
justify O 0 6.322227363853017e-06
specific O 0 2.618187977532216e-07
clinical O 0 1.0179487617278937e-05
screening O 0 1.3335505855138763e-06
for O 0 1.3628832284950931e-08
the O 0 5.787027390624644e-08
360 O 0 3.3471869187451375e-07
, O 0 5.67764040226848e-08
000 O 0 4.157842283802893e-07
Americans O 0 9.019079527661233e-08
expected O 0 4.3398092230972907e-08
to O 0 1.039238384237251e-08
harbor O 0 3.923585609300062e-06
this O 0 1.8139250101967264e-08
allele O 0 4.881296149505943e-07
, O 0 1.557940620955378e-08
and O 0 1.668594507009402e-08
genetic O 0 6.880513296891877e-07
testing O 0 9.849755144841765e-08
in O 0 6.805450869507013e-09
the O 0 7.009329117124707e-09
setting O 0 5.340246289620154e-08
of O 0 3.4902353007737474e-08
long O 0 1.4369109521794599e-05
- O 0 1.060558861354366e-05
term O 0 2.24877180698968e-06
- O 0 2.4364412638533395e-06
outcome O 0 9.859355714070261e-07
studies O 0 1.255529809895961e-06
may O 0 4.8547640290053096e-06
impact O 0 5.357939880923368e-05
significantly O 0 0.002620948478579521
on O 0 0.004104357212781906
colorectal B-Disease 1 0.9999743700027466
cancer I-Disease 1 0.999901294708252
prevention O 0 0.16019612550735474
in O 0 9.972588941309368e-07
this O 0 7.026464459158888e-07
population O 0 2.1356936485972255e-06
. O 0 9.026520274346694e-06

Localization O 0 3.275420385762118e-05
of O 0 8.747969673095213e-07
human O 0 7.036307579255663e-06
BRCA1 O 0 0.00039235473377630115
and O 0 2.460728296682646e-07
its O 0 5.005103389521537e-07
loss O 0 2.4673254301887937e-05
in O 0 4.3855840203832486e-07
high O 0 2.2160256776260212e-05
- O 0 1.7833433958003297e-05
grade O 0 4.529378202278167e-05
, O 0 1.2995593579034903e-06
non B-Disease 0 0.0001608136371942237
- I-Disease 0 0.02430836297571659
inherited I-Disease 1 0.9940967559814453
breast I-Disease 1 0.9985989928245544
carcinomas I-Disease 1 0.997863233089447
. O 0 0.00038927100831642747

Although O 0 4.563288712233771e-06
the O 0 1.1387269296392333e-06
link O 0 6.489075531135313e-06
between O 0 9.024842029248248e-07
the O 0 1.3878790923627093e-05
BRCA1 O 1 0.7925422787666321
tumour B-Disease 1 0.9980288147926331
- O 0 0.0006301110261119902
suppressor O 0 0.0004928992711938918
gene O 0 2.8071941414964385e-05
and O 0 8.679456186655443e-06
hereditary B-Disease 1 0.9970466494560242
breast I-Disease 1 0.9996633529663086
and I-Disease 0 0.23587313294410706
ovarian I-Disease 1 0.9999808073043823
cancer I-Disease 1 0.9998457431793213
is O 0 6.861066026431217e-07
established O 0 3.566951534139662e-07
, O 0 2.320058634097677e-08
the O 0 2.5661858416015093e-08
role O 0 8.491489467132851e-08
, O 0 2.0694741920124216e-08
if O 0 1.4776613710409947e-08
any O 0 7.607132701537012e-09
, O 0 2.5071466680515186e-08
of O 0 6.5749816258176e-08
BRCA1 O 0 0.0007145463605411351
in O 0 2.2522208382724784e-06
non B-Disease 0 0.00023953744675964117
- I-Disease 0 0.013418668881058693
familial I-Disease 1 0.9913330674171448
cancers I-Disease 1 0.9964560866355896
is O 0 1.75111235876102e-05
unclear O 0 7.024965452728793e-05
. O 0 3.889129584422335e-05

BRCA1 O 0 0.020219141617417336
mutations O 0 5.141416113474406e-05
are O 0 4.1161678154821857e-07
rare O 0 3.987752279499546e-05
in O 0 3.859277057927102e-06
sporadic B-Disease 0 0.021078480407595634
cancers I-Disease 1 0.9957133531570435
, O 0 5.10567019773589e-07
but O 0 2.741849414178432e-07
loss O 0 9.69748361967504e-06
of O 0 1.371996773968931e-07
BRCA1 O 0 0.000959819124545902
resulting O 0 6.859796940261731e-06
from O 0 2.932382301423786e-07
reduced O 0 3.415708988541155e-06
expression O 0 4.0982831706060097e-07
or O 0 2.583995808436157e-07
incorrect O 0 2.6905818231170997e-06
subcellular O 0 9.242665328201838e-06
localization O 0 8.176351911970414e-06
is O 0 1.2968934015589184e-07
postulated O 0 1.6438606280644308e-06
to O 0 2.0917211074333864e-08
be O 0 1.0656318494284278e-08
important O 0 3.943076620771535e-08
in O 0 8.108315228128049e-07
non B-Disease 0 8.083810826065019e-05
- I-Disease 0 0.013566996902227402
familial I-Disease 1 0.992119312286377
breast I-Disease 1 0.9990412592887878
and I-Disease 0 0.098783478140831
ovarian I-Disease 1 0.9999358654022217
cancers I-Disease 1 0.9995044469833374
. O 0 0.0010793678229674697

Epigenetic O 0 0.003364279167726636
loss O 0 0.006399995647370815
, O 0 4.659818841901142e-06
however O 0 1.30626915506582e-06
, O 0 1.2983883834749577e-07
has O 0 6.005871711067812e-08
not O 0 2.215458749788013e-08
received O 0 2.76833389989406e-07
general O 0 3.8781860212111496e-07
acceptance O 0 3.0198268632375402e-06
due O 0 1.1905157180081005e-06
to O 0 2.3773706558927188e-08
controversy O 0 8.805060929262254e-07
regarding O 0 7.202085328117391e-08
the O 0 5.71177913855081e-08
subcellular O 0 3.8459365896414965e-06
localization O 0 3.3467572393419687e-06
of O 0 1.7917875538842054e-07
BRCA1 O 0 0.00025292864302173257
proteins O 0 4.7098123445721285e-07
, O 0 6.334420987741396e-08
reports O 0 1.1340869576770274e-07
of O 0 9.257520972028033e-09
which O 0 3.421566319161684e-08
have O 0 2.8467082913152808e-08
ranged O 0 1.5519769931415794e-06
from O 0 7.18567392254954e-08
exclusively O 0 1.1073342420786503e-07
nuclear O 0 2.0519737518043257e-06
, O 0 3.2767847102377345e-08
to O 0 2.1030341912364747e-08
conditionally O 0 7.674781954847276e-06
nuclear O 0 1.5885128732406884e-06
, O 0 4.0387249100604095e-08
to O 0 2.5434538031277043e-08
the O 0 7.605894438711402e-07
ER O 0 0.007541446480900049
/ O 0 7.471039134543389e-05
golgi O 0 0.00021695448958780617
, O 0 4.447387524919577e-08
to O 0 2.0322554306062557e-08
cytoplasmic O 0 5.657308065565303e-06
invaginations O 0 1.4224533515516669e-05
into O 0 8.006526996950925e-08
the O 0 3.4526476611063117e-07
nucleus O 0 5.4538231779588386e-05
. O 0 1.430312931915978e-05

In O 0 9.571484724801849e-07
an O 0 3.380485793513799e-07
attempt O 0 1.1375828989912407e-06
to O 0 9.153092861424739e-08
resolve O 0 1.979123226192314e-06
this O 0 5.700786687157233e-08
issue O 0 1.7776915228751022e-07
, O 0 3.068699072628078e-08
we O 0 1.2850565056510277e-08
have O 0 3.9576864452328664e-08
comprehensively O 0 3.578805262804963e-05
characterized O 0 0.00032322993502020836
19 O 0 5.2445713663473725e-05
anti O 0 0.0035274503752589226
- O 0 0.0016732517397031188
BRCA1 O 0 0.007748802658170462
antibodies O 0 0.00027108920039609075
. O 0 1.8149419702240266e-05

These O 0 2.56914950114151e-06
reagents O 0 7.008237298578024e-05
detect O 0 3.938147710869089e-05
a O 0 2.3066818357619923e-06
220 O 0 6.5668054958223365e-06
- O 0 1.0994534932251554e-05
kD O 0 8.008249278645962e-05
protein O 0 1.1844026630569715e-06
localized O 0 5.144525857758708e-06
in O 0 3.31377307816183e-08
discrete O 0 6.953530373721151e-07
nuclear O 0 1.159225394076202e-05
foci O 0 2.2795062250224873e-05
in O 0 1.209573241567341e-07
all O 0 1.2216543154863757e-07
epithelial O 0 0.010600143112242222
cell O 0 6.312286132015288e-05
lines O 0 1.4727366988154245e-06
, O 0 5.628784904843087e-08
including O 0 3.088540623252811e-08
those O 0 1.1808462119233809e-07
derived O 0 4.550121502688853e-06
from O 0 6.815925007686019e-05
breast B-Disease 1 0.9974901676177979
malignancies I-Disease 1 0.9713989496231079
. O 0 8.800123032415286e-05

Immunohistochemical O 0 0.016385678201913834
staining O 0 0.0011062960838899016
of O 0 8.288153367175255e-06
human O 0 0.0007701162830926478
breast O 1 0.9946730732917786
specimens O 0 0.0001761915482347831
also O 0 7.923236807982903e-06
revealed O 0 0.0007724771276116371
BRCA1 O 0 0.010078106075525284
nuclear O 0 0.00030521504231728613
foci O 0 0.002000768668949604
in O 0 0.00021972173999529332
benign O 1 0.9986078143119812
breast O 1 0.9991934895515442
, O 0 0.0006461591692641377
invasive B-Disease 1 0.9953136444091797
lobular I-Disease 1 0.9991446733474731
cancers I-Disease 1 0.9979352951049805
and O 0 4.949868161929771e-05
low B-Disease 0 0.037615783512592316
- I-Disease 0 0.10122296214103699
grade I-Disease 1 0.7046594023704529
ductal I-Disease 1 0.9963167905807495
carcinomas I-Disease 1 0.9963672161102295
. O 0 0.00019784663163591176

Conversely O 0 0.0003166164387948811
, O 0 8.153901944751851e-06
BRCA1 O 0 0.0007335029076784849
expression O 0 2.5671142793726176e-06
was O 0 3.6546364299283596e-06
reduced O 0 8.090048140729778e-06
or O 0 1.1578766816455754e-06
undetectable O 0 0.0001548988657305017
in O 0 1.4486193578022721e-08
the O 0 1.614458966514576e-08
majority O 0 4.026518496402787e-08
of O 0 5.199731845095812e-08
high O 0 3.139346881653182e-05
- O 0 7.142882532207295e-05
grade O 0 0.00027243836666457355
, O 0 1.2069963304384146e-05
ductal B-Disease 1 0.9977090358734131
carcinomas I-Disease 1 0.9979491829872131
, O 0 8.542113505427551e-07
suggesting O 0 4.5625401980942115e-06
that O 0 6.87808707766635e-08
absence O 0 2.3101733859220985e-06
of O 0 1.9199221412691259e-07
BRCA1 O 0 0.009192277677357197
may O 0 1.8500862779546878e-06
contribute O 0 2.537825878334843e-07
to O 0 1.2920339464983499e-08
the O 0 5.03787873640249e-08
pathogenesis O 0 3.347941310494207e-05
of O 0 2.005784160985513e-08
a O 0 2.6692416099649563e-07
significant O 0 7.082438173711125e-07
percentage O 0 2.7759319891629275e-06
of O 0 1.831125473472639e-06
sporadic B-Disease 1 0.5957995057106018
breast I-Disease 1 0.9996194839477539
cancers I-Disease 1 0.9981963038444519
. O 0 1.1905465726158582e-05
. O 0 4.024984082207084e-05

